{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2022 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014April3, 2022and January2, 2022 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the FiscalFirstQuartersEndedApril3, 2022andApril4, 2021 |  |  | 2\n |  |  | \n |  |  | \n |  |  | \nConsolidated Statements of Comprehensive Income for the FiscalFirstQuartersEndedApril3, 2022andApril4, 2021 |  |  | 3\n |  |  | \nConsolidated Statements of Equity for the FiscalFirstQuarters EndedApril3, 2022andApril4, 2021 |  |  | 4\n |  |  | \nConsolidated Statements of Cash Flows for the FiscalThreeMonths EndedApril3, 2022andApril4, 2021 |  |  | 5\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 6\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 42\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 53\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 54\n |  |  | \nPart II \u2014 Other Information |  |  | 54\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 54\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 55\n |  |  | \nItem\u00a06 - Exhibits |  |  | 56\n |  |  | \nSignatures |  |  | 57\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 3, 2022 |  | January 2, 2022\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 10,463 |  |  | 14,487 | \nMarketable securities |  | 19,925 |  |  | 17,121 | \nAccounts receivable, trade, less allowances for doubtful accounts and credit losses $234(2021, $230) |  | 15,594 |  |  | 15,283 | \nInventories (Note 2) |  | 10,990 |  |  | 10,387 | \nPrepaid expenses and other |  | 3,452 |  |  | 3,701 | \n |  |  |  | \nTotal current assets |  | 60,424 |  |  | 60,979 | \nProperty, plant and equipment at cost |  | 47,702 |  |  | 47,679 | \nLess: accumulated depreciation |  | (29,001) |  |  | (28,717) | \nProperty, plant and equipment, net |  | 18,701 |  |  | 18,962 | \nIntangible assets, net (Note 3) |  | 44,420 |  |  | 46,392 | \nGoodwill (Note 3) |  | 34,935 |  |  | 35,246 | \nDeferred taxes on income (Note 5) |  | 9,936 |  |  | 10,223 | \nOther assets |  | 9,939 |  |  | 10,216 | \nTotal assets |  | $ | 178,355 |  |  | 182,018 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 4,297 |  |  | 3,766 | \nAccounts payable |  | 9,309 |  |  | 11,055 | \nAccrued liabilities |  | 13,006 |  |  | 13,612 | \nAccrued rebates, returns and promotions |  | 12,972 |  |  | 12,095 | \nAccrued compensation and employee related obligations |  | 2,098 |  |  | 3,586 | \nAccrued taxes on income (Note 5) |  | 1,708 |  |  | 1,112 | \nTotal current liabilities |  | 43,390 |  |  | 45,226 | \nLong-term debt (Note 4) |  | 28,851 |  |  | 29,985 | \nDeferred taxes on income (Note 5) |  | 6,424 |  |  | 7,487 | \nEmployee related obligations (Note 6) |  | 8,739 |  |  | 8,898 | \nLong-term taxes payable (Note 5) |  | 5,745 |  |  | 5,713 | \nOther liabilities |  | 10,497 |  |  | 10,686 | \nTotal liabilities |  | $ | 103,646 |  |  | 107,995 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (13,757) |  |  | (13,058) | \nRetained earnings |  | 124,380 |  |  | 123,060 | \nLess: common stock held in treasury, at cost (490,459,000and490,878,000shares) |  | 39,034 |  |  | 39,099 | \nTotal shareholders\u2019 equity |  | 74,709 |  |  | 74,023 | \nTotal liabilities and shareholders' equity |  | $ | 178,355 |  |  | 182,018 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended\n |  | April 3,2022 |  | Percentto Sales |  | April 4,2021 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 23,426 |  |  | 100.0 | % |  | $ | 22,321 |  |  | 100.0 | %\nCost of products sold |  | 7,598 |  |  | 32.4 |  |  | 7,063 |  |  | 31.7 | \nGross profit |  | 15,828 |  |  | 67.6 |  |  | 15,258 |  |  | 68.3 | \nSelling, marketing and administrative expenses |  | 5,938 |  |  | 25.4 |  |  | 5,432 |  |  | 24.3 | \nResearch and development expense |  | 3,462 |  |  | 14.8 |  |  | 3,178 |  |  | 14.2 | \nIn-process research and development |  | 610 |  |  | 2.6 |  |  | \u2014 |  |  | \u2014 | \nInterest income |  | (22) |  |  | (0.1) |  |  | (15) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 10 |  |  | 0.0 |  |  | 63 |  |  | 0.3 | \nOther (income) expense, net |  | (102) |  |  | (0.4) |  |  | (882) |  |  | (3.9) | \nRestructuring (Note 12) |  | 70 |  |  | 0.3 |  |  | 53 |  |  | 0.2 | \nEarnings before provision for taxes on income |  | 5,862 |  |  | 25.0 |  |  | 7,429 |  |  | 33.3 | \nProvision for taxes on income (Note 5) |  | 713 |  |  | 3.0 |  |  | 1,232 |  |  | 5.5 | \nNET EARNINGS |  | $ | 5,149 |  |  | 22.0 | % |  | $ | 6,197 |  |  | 27.8 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.96 |  |  |  |  | $ | 2.35 |  |  | \nDiluted |  | $ | 1.93 |  |  |  |  | $ | 2.32 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,629.2 |  |  |  |  | 2,631.6 |  |  | \nDiluted |  | 2,666.5 |  |  |  |  | 2,672.7 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal First Quarter Ended |  | \n | April 3, 2022 |  | April 4, 2021 |  |  |  | \n |  |  |  |  |  |  | \nNet earnings | $ | 5,149 |  |  | 6,197 |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (554) |  |  | 276 |  |  |  |  | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | (13) |  |  | \u2014 |  |  |  |  | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | (13) |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (53) |  |  | (41) |  |  |  |  | \nGain (loss) amortization during period | 217 |  |  | 274 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | 164 |  |  | 233 |  |  |  |  | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (195) |  |  | (522) |  |  |  |  | \nReclassifications to earnings | (101) |  |  | (73) |  |  |  |  | \nNet change | (296) |  |  | (595) |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (699) |  |  | (86) |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 4,450 |  |  | 6,111 |  |  |  |  | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income for the fiscal first quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $145million and $319million; Securities: $3million in 2022; Employee Benefit Plans: $19million and $66million; Derivatives & Hedges: $78million and $157million.\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \nNet earnings | 5,149 |  |  | 5,149 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.06per share) | (2,787) |  |  | (2,787) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 600 |  |  | (1,042) |  |  | \u2014 |  |  | \u2014 |  |  | 1,642 | \nRepurchase of common stock | (1,577) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,577) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (699) |  |  | \u2014 |  |  | (699) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 3, 2022 | $ | 74,709 |  |  | 124,380 |  |  | (13,757) |  |  | 3,120 |  |  | (39,034) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 3, 2021 | $ | 63,278 |  |  | 113,890 |  |  | (15,242) |  |  | 3,120 |  |  | (38,490) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 6,197 |  |  | 6,197 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.01per share) | (2,659) |  |  | (2,659) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 542 |  |  | (920) |  |  | \u2014 |  |  | \u2014 |  |  | 1,462 | \nRepurchase of common stock | (1,438) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,438) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (86) |  |  | \u2014 |  |  | (86) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 4, 2021 | $ | 65,834 |  |  | 116,508 |  |  | (15,328) |  |  | 3,120 |  |  | (38,466) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Three Months Ended\n |  | April 3,2022 |  | April 4,2021\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 5,149 |  |  | 6,197 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 1,769 |  |  | 1,894 | \nStock based compensation |  | 278 |  |  | 307 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 610 |  |  | 14 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (168) |  |  | (580) | \n |  |  |  | \nDeferred tax provision |  | (926) |  |  | (730) | \nCredit losses and accounts receivable allowances |  | 6 |  |  | (13) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (427) |  |  | (1,604) | \nIncrease in inventories |  | (600) |  |  | (695) | \nDecrease in accounts payable and accrued liabilities |  | (2,817) |  |  | (2,336) | \nDecrease in other current and non-current assets |  | 995 |  |  | 2,522 | \nIncrease/(Decrease) in other current and non-current liabilities |  | 110 |  |  | (902) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 3,979 |  |  | 4,074 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (607) |  |  | (677) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 248 |  |  | 603 | \nAcquisitions, net of cash acquired (Note 10) |  | (252) |  |  | \u2014 | \nPurchases of investments |  | (9,018) |  |  | (5,994) | \nSales of investments |  | 6,303 |  |  | 5,233 | \nCredit support agreements activity, net |  | (249) |  |  | 751 | \nOther (primarily licenses and milestones) |  | (59) |  |  | (101) | \n |  |  |  | \nNET CASH USED BY INVESTING ACTIVITIES |  | (3,634) |  |  | (185) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (2,787) |  |  | (2,659) | \nRepurchase of common stock |  | (1,577) |  |  | (1,438) | \nProceeds from short-term debt |  | 3,019 |  |  | 23 | \nRepayment of short-term debt |  | (856) |  |  | (475) | \nProceeds from long-term debt, net of issuance costs |  | \u2014 |  |  | 1 | \nRepayment of long-term debt |  | (2,132) |  |  | (1,001) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 321 |  |  | 236 | \nCredit support agreements activity, net |  | (235) |  |  | 212 | \nOther |  | (138) |  |  | (24) | \n |  |  |  | \nNET CASH USED BY FINANCING ACTIVITIES |  | (4,385) |  |  | (5,125) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 16 |  |  | (78) | \nDecrease in cash and cash equivalents |  | (4,024) |  |  | (1,314) | \nCash and Cash equivalents, beginning of period |  | 14,487 |  |  | 13,985 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 10,463 |  |  | 12,671 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | 255 |  |  | \u2014 | \nFair value of liabilities assumed and noncontrolling interests |  | (3) |  |  | \u2014 | \nNet cash paid for acquisitions |  | $ | 252 |  |  | \u2014 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022\nRaw materials and supplies |  | $ | 1,679 |  |  | 1,592 | \nGoods in process |  | 2,629 |  |  | 2,287 | \nFinished goods |  | 6,682 |  |  | 6,508 | \nTotal inventories |  | $ | 10,990 |  |  | 10,387 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 37,960 |  |  | 38,572 | \nLess accumulated amortization |  | (20,492) |  |  | (20,088) | \nPatents and trademarks \u2014 net |  | 17,468 |  |  | 18,484 | \nCustomer relationships and other intangibles \u2014 gross |  | 22,910 |  |  | 23,011 | \nLess accumulated amortization |  | (12,147) |  |  | (11,925) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 10,763 |  |  | 11,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,947 |  |  | 6,985 | \nPurchased in-process research and development(2) |  | 9,242 |  |  | 9,837 | \nTotal intangible assets with indefinite lives |  | 16,189 |  |  | 16,822 | \nTotal intangible assets \u2014 net |  | $ | 44,420 |  |  | 46,392 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January 2, 2022 |  | $ | 9,810 |  |  | 10,580 |  |  | 14,856 |  |  | 35,246 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | 73 |  |  | 73 | \n |  |  |  |  |  |  |  | \nCurrency translation/Other |  | (195) |  |  | (170) |  |  | (19) |  |  | (384) | \nGoodwill at April 3, 2022 |  | $ | 9,615 |  |  | 10,410 |  |  | 14,910 |  |  | 34,935 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026\n$4,600 |  | 4,600 |  | 4,400 |  | 3,600 |  | 3,000  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n | April 3, 2022 | April 4, 2021\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (531) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 531 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 40 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 40 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (17) |  | (52) |  | 23 |  | \u2014 |  | (18) |  | 17 |  | 34 |  | (113) |  | \u2014 |  | 3 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | 22 |  | (94) |  | 33 |  | \u2014 |  | (73) |  | (3) |  | (193) |  | (76) |  | \u2014 |  | 17 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 |  | \u2014 |  |  | \u2014 |  | 92 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (128) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (307) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022 |  | April 3, 2022 |  | January 2, 2022\n |  |  |  |  |  |  |  | \nLong-term Debt |  | 9,313 |  |  | 9,793 |  |  | (694) |  |  | (142) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative |  | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal First Quarter Ended |  | \nDerivatives Not Designated as Hedging Instruments |  |  |  | April 3, 2022 |  | April 4, 2021 |  |  |  | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | 29 |  |  | (16) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  |  |  | April 3, 2022 |  | April 4, 2021\nDebt |  | $ | 68 |  |  | 209 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 560 |  |  | 361 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 2, 2022 |  |  |  |  |  | April 3, 2022 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 1,884 |  |  | (402) |  |  | (30) |  |  | 1,452 |  |  | 1,452 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 500 |  |  | (5) |  |  | 10 |  |  | 505 |  |  | 505 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 3, 2022 |  |  |  | January 2, 2022\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 742 |  |  | \u2014 |  |  | 742 |  |  | 540 | \nInterest rate contracts(2) |  | \u2014 |  |  | 975 |  |  | \u2014 |  |  | 975 |  |  | 796 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 1,717 |  |  | \u2014 |  |  | 1,717 |  |  | 1,336 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 1,058 |  |  | \u2014 |  |  | 1,058 |  |  | 881 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,652 |  |  | \u2014 |  |  | 1,652 |  |  | 979 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,710 |  |  | \u2014 |  |  | 2,710 |  |  | 1,860 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 36 |  |  | \u2014 |  |  | 36 |  |  | 24 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 68 |  |  | \u2014 |  |  | 68 |  |  | 28 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 1,452 |  |  | \u2014 |  |  | \u2014 |  |  | 1,452 |  |  | 1,884 | \nDebt securities(4) |  | \u2014 |  |  | 19,583 |  |  | \u2014 |  |  | 19,583 |  |  | 19,727 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 486 |  |  | 486 |  |  | 533 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | April 3, 2022 |  | January 2, 2022\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 1,753 |  |  | 1,360 | \nCredit Support Agreement (CSA) |  | (1,655) |  |  | (1,285) | \nTotal Net Asset |  | 98 |  |  | 75 | \n |  |  |  | \nTotal Gross Liabilities |  | 2,778 |  |  | 1,888 | \nCredit Support Agreement (CSA) |  | (2,709) |  |  | (1,855) | \nTotal Net Liabilities |  | $ | 69 |  |  | 33 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | April 3, 2022 |  | April 4, 2021\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 533 |  |  | $ | 633 | \nChanges in estimated fair value(6) |  | (47) |  |  | 15 | \nAdditions |  | \u2014 |  |  | \u2014 | \nPayments |  | \u2014 |  |  | (48) | \nEnding Balance |  | $ | 486 |  |  | $ | 600 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/( Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 3,128 |  |  |  |  | \u2014 |  |  | 3,128 |  |  | 3,128 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities(1) | 329 |  |  |  |  | \u2014 |  |  | 329 |  |  | \u2014 |  |  | 329 | \nU.S. reverse repurchase agreements | 1,449 |  |  |  |  | \u2014 |  |  | 1,449 |  |  | 1,449 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 3,557 |  |  |  |  | (6) |  |  | 3,551 |  |  | 540 |  |  | 3,017 | \nMoney market funds | 1,579 |  |  |  |  | \u2014 |  |  | 1,579 |  |  | 1,579 |  |  | \u2014 | \nTime deposits(1) | 763 |  |  |  |  | \u2014 |  |  | 763 |  |  | 763 |  |  | \u2014 | \nSubtotal | 10,805 |  |  |  |  | (6) |  |  | 10,799 |  |  | 7,459 |  |  | 3,346 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov't securities | 19,354 |  |  |  |  | (19) |  |  | 19,335 |  |  | 2,968 |  |  | 16,367 | \nOther sovereign securities | 3 |  |  |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 | \nCorporate debt securities | 246 |  |  |  |  | (1) |  |  | 245 |  |  | 36 |  |  | 209 | \nSubtotal available for sale debt(2) | $ | 19,603 |  |  |  |  | (20) |  |  | 19,583 |  |  | 3,004 |  |  | 16,579 | \nTotal cash, cash equivalents and current marketable securities | $ | 30,408 |  |  |  |  | (26) |  |  | 30,382 |  |  | 10,463 |  |  | 19,925 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 19,585 |  |  | 19,564 | \nDue after one year through five years |  | 19 |  |  | 19 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 19,604 |  |  | 19,583 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 4,297 |  |  | 4,298 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n6.73% Debentures due 2023 |  | 250 |  |  | 266 | \n3.375% Notes due 2023 |  | 802 |  |  | 820 | \n |  |  |  | \n0.650% Notes due 2024 (750MM Euro 1.1311) |  | 824 |  |  | 829 | \n5.50% Notes due 2024 (500 MM GBP 1.3485) |  | 654 |  |  | 713 | \n2.625% Notes due 2025 |  | 749 |  |  | 762 | \n |  |  |  | \n0.55% Notes due 2025 |  | 950 |  |  | 886 | \n2.45% Notes due 2026 |  | 1,995 |  |  | 1,981 | \n2.95% Notes due 2027 |  | 930 |  |  | 934 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,436 |  |  | 1,307 | \n2.90%\u00a0Notes due 2028 |  | 1,496 |  |  | 1,489 | \n1.150% Notes due 2028 (750MM Euro 1.1311) |  | 826 |  |  | 829 | \n6.95% Notes due 2029 |  | 298 |  |  | 379 | \n |  |  |  | \n1.30% Notes due 2030 |  | 1,672 |  |  | 1,486 | \n4.95% Debentures due 2033 |  | 498 |  |  | 590 | \n4.375% Notes due 2033 |  | 855 |  |  | 959 | \n1.650% Notes due 2035 (1.5B Euro 1.1311) |  | 1,654 |  |  | 1,687 | \n3.55% Notes due 2036 |  | 917 |  |  | 947 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,288 | \n3.625% Notes due 2037 |  | 1,416 |  |  | 1,463 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 999 | \n5.85% Debentures due 2038 |  | 697 |  |  | 901 | \n4.50% Debentures due 2040 |  | 540 |  |  | 617 | \n |  |  |  | \n2.10% Notes due 2040 |  | 914 |  |  | 777 | \n4.85% Notes due 2041 |  | 297 |  |  | 342 | \n4.50% Notes due 2043 |  | 496 |  |  | 565 | \n3.70% Notes due 2046 |  | 1,975 |  |  | 2,097 | \n3.75% Notes due 2047 |  | 906 |  |  | 969 | \n3.50% Notes due 2048 |  | 743 |  |  | 766 | \n2.25% Notes due 2050 |  | 914 |  |  | 759 | \n2.45% Notes due 2060 |  | 1,155 |  |  | 942 | \nOther |  | 7 |  |  | 7 | \nTotal Non-Current Debt |  | $ | 28,851 |  |  | 29,356 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n |  | Retirement Plans |  | Other Benefit Plans |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021 |  |  |  |  |  |  |  | \nService cost |  | $ | 321 |  |  | 353 |  |  | 80 |  |  | 77 |  |  |  |  |  |  |  |  | \nInterest cost |  | 230 |  |  | 193 |  |  | 26 |  |  | 20 |  |  |  |  |  |  |  |  | \nExpected return on plan assets |  | (699) |  |  | (680) |  |  | (2) |  |  | (2) |  |  |  |  |  |  |  |  | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (45) |  |  | (1) |  |  | (8) |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial losses |  | 162 |  |  | 314 |  |  | 30 |  |  | 38 |  |  |  |  |  |  |  |  | \nCurtailments and settlements |  | 1 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nNet periodic benefit cost/(credit) |  | $ | (31) |  |  | 136 |  |  | 133 |  |  | 125 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 2, 2022 |  | $ | (10,017) |  |  | (3) |  |  | (2,702) |  |  | (336) |  |  | (13,058) | \nNet change |  | (554) |  |  | (13) |  |  | 164 |  |  | (296) |  |  | (699) | \n |  |  |  |  |  |  |  |  |  | \nApril 3, 2022 |  | $ | (10,571) |  |  | (16) |  |  | (2,538) |  |  | (632) |  |  | (13,757) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Shares in Millions) |  | April 3, 2022 |  | April 4, 2021 |  |  |  | \nBasic net earnings per share |  | $ | 1.96 |  |  | 2.35 |  |  |  |  | \nAverage shares outstanding \u2014 basic |  | 2,629.2 |  |  | 2,631.6 |  |  |  |  | \nPotential shares exercisable under stock option plans |  | 140.1 |  |  | 128.4 |  |  |  |  | \nLess: shares which could be repurchased under treasury stock method |  | (102.8) |  |  | (87.3) |  |  |  |  | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,666.5 |  |  | 2,672.7 |  |  |  |  | \nDiluted net earnings per share |  | $ | 1.93 |  |  | 2.32 |  |  |  |  |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 3,2022 |  | April 4,2021 |  | PercentChange |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nOTC(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 670 |  |  | 599 |  |  | 11.8 | % |  |  |  |  |  | \nInternational |  | 791 |  |  | 673 |  |  | 17.5 |  |  |  |  |  |  | \nWorldwide |  | 1,461 |  |  | 1,273 |  |  | 14.8 |  |  |  |  |  |  | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 544 |  |  | 634 |  |  | (14.2) |  |  |  |  |  |  | \nInternational |  | 468 |  |  | 529 |  |  | (11.6) |  |  |  |  |  |  | \nWorldwide |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  |  |  |  |  | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 143 |  |  | 163 |  |  | (12.6) |  |  |  |  |  |  | \nInternational |  | 223 |  |  | 254 |  |  | (12.0) |  |  |  |  |  |  | \nWorldwide |  | 366 |  |  | 417 |  |  | (12.2) |  |  |  |  |  |  | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 85 |  |  | 96 |  |  | (11.5) |  |  |  |  |  |  | \nInternational |  | 270 |  |  | 293 |  |  | (7.7) |  |  |  |  |  |  | \nWorldwide |  | 355 |  |  | 389 |  |  | (8.6) |  |  |  |  |  |  | \nWomen's Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3 |  |  | 3 |  |  | 7.2 |  |  |  |  |  |  | \nInternational |  | 224 |  |  | 219 |  |  | 2.5 |  |  |  |  |  |  | \nWorldwide |  | 228 |  |  | 222 |  |  | 2.6 |  |  |  |  |  |  | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 112 |  |  | 115 |  |  | (3.3) |  |  |  |  |  |  | \nInternational |  | 52 |  |  | 61 |  |  | (15.3) |  |  |  |  |  |  | \nWorldwide |  | 164 |  |  | 177 |  |  | (7.4) |  |  |  |  |  |  | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,557 |  |  | 1,611 |  |  | (3.4) |  |  |  |  |  |  | \nInternational |  | 2,029 |  |  | 2,030 |  |  | 0.0 |  |  |  |  |  | \nWorldwide |  | 3,586 |  |  | 3,641 |  |  | (1.5) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,501 |  |  | 2,413 |  |  | 3.7 |  |  |  |  |  |  | \nInternational |  | 1,617 |  |  | 1,501 |  |  | 7.7 |  |  |  |  |  |  | \nWorldwide |  | 4,119 |  |  | 3,914 |  |  | 5.2 |  |  |  |  |  |  | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 358 |  |  | 489 |  |  | (26.8) |  |  |  |  |  |  | \nU.S. Exports |  | 80 |  |  | 57 |  |  | 40.5 |  |  |  |  |  |  | \nInternational |  | 225 |  |  | 232 |  |  | (2.6) |  |  |  |  |  |  | \nWorldwide |  | 663 |  |  | 777 |  |  | (14.7) |  |  |  |  |  |  | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 287 |  |  | 255 |  |  | 12.5 |  |  |  |  |  |  | \nInternational |  | 283 |  |  | 307 |  |  | (7.6) |  |  |  |  |  |  | \nWorldwide |  | 571 |  |  | 562 |  |  | 1.5 |  |  |  |  |  |  | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,379 |  |  | 1,331 |  |  | 3.6 |  |  |  |  |  |  | \nInternational |  | 909 |  |  | 817 |  |  | 11.2 |  |  |  |  |  |  | \nWorldwide |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  |  |  |  |  | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 391 |  |  | 274 |  |  | 42.7 |  |  |  |  |  |  | \nInternational |  | 199 |  |  | 143 |  |  | 38.8 |  |  |  |  |  |  | \nWorldwide |  | 590 |  |  | 418 |  |  | 41.3 |  |  |  |  |  |  | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 6 |  |  | 7 |  |  | (3.2) |  |  |  |  |  |  | \nInternational |  | 0 |  |  | 2 |  |  | * |  |  |  |  |  | \nWorldwide |  | 6 |  |  | 8 |  |  | (22.0) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 461 |  |  | 512 |  |  | (10.0) |  |  |  |  |  |  | \nInternational |  | 836 |  |  | 485 |  |  | 72.3 |  |  |  |  |  |  | \nWorldwide |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  |  |  |  |  | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 75 |  |  | 100 |  |  | (24.9) |  |  |  |  |  |  | \nInternational |  | 382 |  |  | 0 |  | * |  |  |  |  |  | \nWorldwide |  | 457 |  |  | 100 |  |  | * |  |  |  |  |  | \nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 10 |  |  | (12.6) |  |  |  |  |  |  | \nInternational |  | 239 |  |  | 233 |  |  | 2.5 |  |  |  |  |  |  | \nWorldwide |  | 248 |  |  | 243 |  |  | 1.8 |  |  |  |  |  |  | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 369 |  |  | 380 |  |  | (3.1) |  |  |  |  |  |  | \nInternational |  | 132 |  |  | 166 |  |  | (20.3) |  |  |  |  |  |  | \nWorldwide |  | 501 |  |  | 546 |  |  | (8.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 8 |  |  | 21 |  |  | (62.5) |  |  |  |  |  |  | \nInternational |  | 83 |  |  | 87 |  |  | (3.8) |  |  |  |  |  |  | \nWorldwide |  | 91 |  |  | 108 |  |  | (15.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 843 |  |  | 771 |  |  | 9.3 |  |  |  |  |  |  | \nInternational |  | 898 |  |  | 943 |  |  | (4.8) |  |  |  |  |  |  | \nWorldwide |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  |  |  |  |  | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 35 |  |  | 47 |  |  | (26.5) |  |  |  |  |  |  | \nInternational |  | 122 |  |  | 123 |  |  | (1.3) |  |  |  |  |  |  | \nWorldwide |  | 157 |  |  | 171 |  |  | (8.3) |  |  |  |  |  |  | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 661 |  |  | 589 |  |  | 12.2 |  |  |  |  |  |  | \nInternational |  | 387 |  |  | 376 |  |  | 3.0 |  |  |  |  |  |  | \nWorldwide |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  |  |  |  |  | \nRISPERDAL CONSTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 63 |  |  | 67 |  |  | (6.4) |  |  |  |  |  |  | \nInternational |  | 66 |  |  | 89 |  |  | (26.1) |  |  |  |  |  |  | \nWorldwide |  | 129 |  |  | 157 |  |  | (17.6) |  |  |  |  |  |  | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 84 |  |  | 67 |  |  | 25.5 |  |  |  |  |  |  | \nInternational |  | 323 |  |  | 355 |  |  | (8.9) |  |  |  |  |  |  | \nWorldwide |  | 408 |  |  | 422 |  |  | (3.5) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,582 |  |  | 1,377 |  |  | 14.9 |  |  |  |  |  |  | \nInternational |  | 2,369 |  |  | 2,193 |  |  | 8.0 |  |  |  |  |  |  | \nWorldwide |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  |  |  |  |  | \nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 953 |  |  | 691 |  |  | 37.9 |  |  |  |  |  |  | \nInternational |  | 903 |  |  | 674 |  |  | 34.0 |  |  |  |  |  |  | \nWorldwide |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  |  |  |  |  | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 206 |  |  | 171 |  |  | 20.3 |  |  |  |  |  |  | \nInternational |  | 194 |  |  | 90 |  |  | * |  |  |  |  |  | \nWorldwide |  | 400 |  |  | 261 |  |  | 53.0 |  |  |  |  |  |  | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 370 |  |  | 444 |  |  | (16.7) |  |  |  |  |  |  | \nInternational |  | 668 |  |  | 680 |  |  | (1.8) |  |  |  |  |  |  | \nWorldwide |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  |  |  |  |  | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 19 |  |  | 50 |  |  | (62.1) |  |  |  |  |  |  | \nInternational |  | 520 |  |  | 588 |  |  | (11.6) |  |  |  |  |  |  | \nWorldwide |  | 539 |  |  | 638 |  |  | (15.6) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 34 |  |  | 21 |  |  | 63.1 |  |  |  |  |  |  | \nInternational |  | 84 |  |  | 161 |  |  | (47.7) |  |  |  |  |  |  | \nWorldwide |  | 118 |  |  | 182 |  |  | (35.1) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 572 |  |  | 573 |  |  | (0.2) |  |  |  |  |  |  | \nInternational |  | 279 |  |  | 288 |  |  | (2.9) |  |  |  |  |  |  | \nWorldwide |  | 852 |  |  | 861 |  |  | (1.1) |  |  |  |  |  |  | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 273 |  |  | 272 |  |  | 0.5 |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 179 |  |  | (4.8) |  |  |  |  |  |  | \nWorldwide |  | 443 |  |  | 450 |  |  | (1.6) |  |  |  |  |  |  | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 269 |  |  | 259 |  |  | 3.9 |  |  |  |  |  |  | \nInternational |  | 56 |  |  | 46 |  |  | 20.9 |  |  |  |  |  |  | \nWorldwide |  | 325 |  |  | 305 |  |  | 6.5 |  |  |  |  |  |  | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 30 |  |  | 42 |  |  | (29.0) |  |  |  |  |  |  | \nInternational |  | 53 |  |  | 63 |  |  | (15.2) |  |  |  |  |  |  | \nWorldwide |  | 83 |  |  | 105 |  |  | (20.8) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 672 |  |  | 799 |  |  | (15.8) |  |  |  |  |  |  | \nInternational |  | 238 |  |  | 245 |  |  | (3.0) |  |  |  |  |  |  | \nWorldwide |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  |  |  |  |  | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  | \nWorldwide |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  | \nINVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 60 |  |  | 87 |  |  | (30.7) |  |  |  |  |  |  | \nInternational |  | 68 |  |  | 63 |  |  | 7.5 |  |  |  |  |  |  | \nWorldwide |  | 128 |  |  | 150 |  |  | (14.6) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(1,2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 104 |  |  | 122 |  |  | (14.9) |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 182 |  |  | (6.6) |  |  |  |  |  |  | \nWorldwide |  | 274 |  |  | 305 |  |  | (10.0) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 6,632 |  |  | 6,446 |  |  | 2.9 |  |  |  |  |  |  | \nInternational |  | 6,237 |  |  | 5,655 |  |  | 10.3 |  |  |  |  |  |  | \nWorldwide |  | 12,869 |  |  | 12,101 |  |  | 6.3 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH(3) |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 494 |  |  | 434 |  |  | 13.8 |  |  |  |  |  |  | \nInternational |  | 597 |  |  | 514 |  |  | 16.2 |  |  |  |  |  |  | \nWorldwide |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  |  |  |  |  | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,289 |  |  | 1,249 |  |  | 3.2 |  |  |  |  |  |  | \nInternational |  | 899 |  |  | 864 |  |  | 4.1 |  |  |  |  |  |  | \nWorldwide |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  |  |  |  |  | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 225 |  |  | 209 |  |  | 7.3 |  |  |  |  |  |  | \nInternational |  | 164 |  |  | 146 |  |  | 12.2 |  |  |  |  |  |  | \nWorldwide |  | 389 |  |  | 356 |  |  | 9.3 |  |  |  |  |  |  | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 201 |  |  | 185 |  |  | 8.6 |  |  |  |  |  |  | \nInternational |  | 138 |  |  | 132 |  |  | 4.1 |  |  |  |  |  |  | \nWorldwide |  | 339 |  |  | 317 |  |  | 6.7 |  |  |  |  |  |  | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 475 |  |  | 450 |  |  | 5.5 |  |  |  |  |  |  | \nInternational |  | 273 |  |  | 282 |  |  | (3.3) |  |  |  |  |  |  | \nWorldwide |  | 748 |  |  | 733 |  |  | 2.1 |  |  |  |  |  |  | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 387 |  |  | 404 |  |  | (4.1) |  |  |  |  |  |  | \nInternational |  | 324 |  |  | 303 |  |  | 7.0 |  |  |  |  |  |  | \nWorldwide |  | 712 |  |  | 707 |  |  | 0.6 |  |  |  |  |  |  | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 921 |  |  | 898 |  |  | 2.5 |  |  |  |  |  |  | \nInternational |  | 1,513 |  |  | 1,474 |  |  | 2.7 |  |  |  |  |  |  | \nWorldwide |  | 2,434 |  |  | 2,372 |  |  | 2.6 |  |  |  |  |  |  | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 417 |  |  | 405 |  |  | 3.0 |  |  |  |  |  |  | \nInternational |  | 729 |  |  | 713 |  |  | 2.2 |  |  |  |  |  |  | \nWorldwide |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  |  |  |  |  | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 504 |  |  | 493 |  |  | 2.1 |  |  |  |  |  |  | \nInternational |  | 784 |  |  | 761 |  |  | 3.1 |  |  |  |  |  |  | \nWorldwide |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  |  |  |  |  | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 521 |  |  | 472 |  |  | 10.4 |  |  |  |  |  |  | \nInternational |  | 736 |  |  | 673 |  |  | 9.4 |  |  |  |  |  |  | \nWorldwide |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  |  |  |  |  | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 400 |  |  | 371 |  |  | 7.7 |  |  |  |  |  |  | \nInternational |  | 511 |  |  | 486 |  |  | 5.1 |  |  |  |  |  |  | \nWorldwide |  | 910 |  |  | 857 |  |  | 6.2 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 121 |  |  | 101 |  |  | 20.2 |  |  |  |  |  |  | \nInternational |  | 226 |  |  | 187 |  |  | 20.5 |  |  |  |  |  |  | \nWorldwide |  | 347 |  |  | 288 |  |  | 20.4 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,225 |  |  | 3,054 |  |  | 5.6 |  |  |  |  |  |  | \nInternational |  | 3,746 |  |  | 3,525 |  |  | 6.3 |  |  |  |  |  |  | \nWorldwide |  | 6,971 |  |  | 6,579 |  |  | 5.9 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 11,414 |  |  | 11,111 |  |  | 2.7 |  |  |  |  |  |  | \nInternational |  | 12,012 |  |  | 11,210 |  |  | 7.2 |  |  |  |  |  |  | \nWorldwide |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  |  | \n(Dollars in Millions) |  | April 3,2022 |  | April 4,2021 |  | PercentChange |  |  |  |  |  |  |  |  |  |  | \nConsumer Health(1) |  | $ | 686 |  |  | 842 |  |  | (18.5)% |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical(2) |  | 3,924 |  |  | 5,169 |  |  | (24.1) |  |  |  |  |  |  |  |  |  |  | \nMedTech(3) |  | 1,477 |  |  | 1,629 |  |  | (9.3) |  |  |  |  |  |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 6,087 |  |  | 7,640 |  |  | (20.3) |  |  |  |  |  |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 102 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,862 |  |  | 7,429 |  |  | (21.1)% |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | PercentChange |  |  |  |  |  | \nUnited States |  | $ | 11,414 |  |  | 11,111 |  |  | 2.7 | % |  |  |  |  |  | \nEurope |  | 6,024 |  |  | 5,414 |  |  | 11.3 |  |  |  |  |  |  | \nWestern Hemisphere, excluding U.S. |  | 1,482 |  |  | 1,424 |  |  | 4.1 |  |  |  |  |  |  | \nAsia-Pacific, Africa |  | 4,506 |  |  | 4,372 |  |  | 3.1 |  |  |  |  |  |  | \nTotal |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Severance | Asset Write-offs/Sales |  | Other(2) | Total\nReserve balance, January 2, 2022 | $ | 112 |  | \u2014 |  |  | 25 |  | 137 | \n |  |  |  |  | \nCurrent year activity: |  |  |  |  | \nCharges | \u2014 |  | (23) |  |  | 95 |  | 72 | \nCash settlements | (10) |  | 35 |  | (3) |  | (107) |  | (82) | \nSettled non cash | \u2014 |  | (12) |  |  | \u2014 |  | (12) | \n |  |  |  |  | \n |  |  |  |  | \nReserve balance, April 3, 2022(1) | $ | 102 |  | \u2014 |  |  | 13 |  | 115 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 1,461 |  |  | $ | 1,273 |  |  | 14.8 | % |  | 17.1 | % |  | (2.3) | %\nSkin Health/Beauty |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  | (11.0) |  |  | (2.0) | \nOral Care |  | 366 |  |  | 417 |  |  | (12.2) |  |  | (10.2) |  |  | (2.0) | \nBaby Care |  | 355 |  |  | 389 |  |  | (8.6) |  |  | (6.4) |  |  | (2.2) | \nWomen\u2019s Health |  | 228 |  |  | 222 |  |  | 2.6 |  |  | 8.3 |  |  | (5.7) | \nWound Care/Other |  | 164 |  |  | 177 |  |  | (7.4) |  |  | (7.2) |  |  | (0.2) | \nTotal Consumer Health Sales |  | $ | 3,586 |  |  | $ | 3,641 |  |  | (1.5) | % |  | 0.8 | % |  | (2.3) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,119 |  |  | $ | 3,914 |  |  | 5.2 | % |  | 7.5 | % |  | (2.3) | %\nREMICADE |  | 663 |  |  | 777 |  |  | (14.7) |  |  | (14.2) |  |  | (0.5) | \nSIMPONI/ SIMPONI ARIA |  | 571 |  |  | 562 |  |  | 1.5 |  |  | 4.7 |  |  | (3.2) | \nSTELARA |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  | 9.0 |  |  | (2.5) | \nTREMFYA |  | 590 |  |  | 418 |  |  | 41.3 |  |  | 44.5 |  |  | (3.2) | \nOther Immunology |  | 6 |  |  | 8 |  |  | (22.0) |  |  | (22.0) |  |  | 0.0\nInfectious Diseases |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  | 33.1 |  |  | (3.1) | \nCOVID-19 VACCINE |  | 457 |  |  | 100 |  |  | * |  | * |  | *\nEDURANT/rilpivirine |  | 248 |  |  | 243 |  |  | 1.8 |  |  | 9.6 |  |  | (7.8) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 501 |  |  | 546 |  |  | (8.3) |  |  | (6.9) |  |  | (1.4) | \nOther Infectious Diseases(2) |  | 91 |  |  | 108 |  |  | (15.3) |  |  | (11.0) |  |  | (4.3) | \nNeuroscience |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  | 5.0 |  |  | (3.5) | \nCONCERTA/ methylphenidate |  | 157 |  |  | 171 |  |  | (8.3) |  |  | (4.8) |  |  | (3.5) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  | 11.3 |  |  | (2.7) | \nRISPERDAL CONSTA |  | 129 |  |  | 157 |  |  | (17.6) |  |  | (13.9) |  |  | (3.7) | \nOther Neuroscience(2) |  | 408 |  |  | 422 |  |  | (3.5) |  |  | 1.7 |  |  | (5.2) | \nOncology |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  | 14.9 |  |  | (4.3) | \nDARZALEX |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  | 40.3 |  |  | (4.3) | \nERLEADA |  | 400 |  |  | 261 |  |  | 53.0 |  |  | 57.5 |  |  | (4.5) | \nIMBRUVICA |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  | (3.9) |  |  | (3.8) | \nZYTIGA/ abiraterone acetate |  | 539 |  |  | 638 |  |  | (15.6) |  |  | (10.1) |  |  | (5.5) | \nOther Oncology |  | 118 |  |  | 182 |  |  | (35.1) |  |  | (32.3) |  |  | (2.8) | \nPulmonary Hypertension |  | 852 |  |  | 861 |  |  | (1.1) |  |  | 1.2 |  |  | (2.3) | \nOPSUMIT |  | 443 |  |  | 450 |  |  | (1.6) |  |  | 1.1 |  |  | (2.7) | \nUPTRAVI |  | 325 |  |  | 305 |  |  | 6.5 |  |  | 7.7 |  |  | (1.2) | \nOther Pulmonary Hypertension |  | 83 |  |  | 105 |  |  | (20.8) |  |  | (16.8) |  |  | (4.0) | \nCardiovascular / Metabolism / Other |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  | (11.9) |  |  | (0.9) | \nXARELTO |  | 508 |  |  | 589 |  |  | (13.8) |  |  | (13.8) |  |  | \u2014 | \nINVOKANA/ INVOKAMET |  | 128 |  |  | 150 |  |  | (14.6) |  |  | (13.1) |  |  | (1.5) | \nOther(1,2) |  | 274 |  |  | 305 |  |  | (10.0) |  |  | (7.5) |  |  | (2.5) | \nTotal Pharmaceutical Sales |  | $ | 12,869 |  |  | $ | 12,101 |  |  | 6.3 | % |  | 9.3 | % |  | (3.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,434 |  |  | $ | 2,372 |  |  | 2.6 | % |  | 5.0 | % |  | (2.4) | %\nAdvanced |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  | 4.5 |  |  | (2.0) | \nGeneral |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  | 5.5 |  |  | (2.8) | \nOrthopaedics |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  | 5.6 |  |  | (2.1) | \nHips |  | 389 |  |  | 356 |  |  | 9.3 |  |  | 11.3 |  |  | (2.0) | \nKnees |  | 339 |  |  | 317 |  |  | 6.7 |  |  | 8.8 |  |  | (2.1) | \nTrauma |  | 748 |  |  | 733 |  |  | 2.1 |  |  | 4.2 |  |  | (2.1) | \nSpine, Sports & Other |  | 712 |  |  | 707 |  |  | 0.6 |  |  | 2.7 |  |  | (2.1) | \nVision |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  | 13.9 |  |  | (4.1) | \nContact Lenses/Other |  | 910 |  |  | 857 |  |  | 6.2 |  |  | 10.6 |  |  | (4.4) | \nSurgical |  | 347 |  |  | 288 |  |  | 20.4 |  |  | 23.8 |  |  | (3.4) | \nInterventional Solutions |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  | 17.4 |  |  | (2.3) | \n |  |  |  |  |  |  |  |  |  | \nTotal MedTech Sales |  | $ | 6,971 |  |  | $ | 6,579 |  |  | 5.9 | % |  | 8.5 | % |  | (2.6) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal First Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2022 |  | 2021 |  | Change\nChanges in the fair value of securities |  | $ | 0.4 |  |  | 0.0 |  |  | 0.4 | \nAcquisition, integration and divestiture related(1) |  | 0.0 |  |  | (0.5) |  |  | 0.5 | \nConsumer Health separation costs |  | 0.1 |  |  | 0.0 |  |  | 0.1 | \nEmployee benefit plan related |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \nOther |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | (0.1) |  |  | $ | (0.9) |  |  | $ | 0.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021\nConsumer Health |  | $ | 686 |  |  | $ | 842 |  |  | $ | 3,586 |  |  | $ | 3,641 |  |  | 19.1 | % |  | 23.1 | %\nPharmaceutical |  | 3,924 |  |  | 5,169 |  |  | 12,869 |  |  | 12,101 |  |  | 30.5 |  |  | 42.7 | \nMedTech |  | 1,477 |  |  | 1,629 |  |  | 6,971 |  |  | 6,579 |  |  | 21.2 |  |  | 24.8 | \nSegment earnings before tax |  | 6,087 |  |  | 7,640 |  |  | 23,426 |  |  | 22,321 |  |  | 26.0 |  |  | 34.2 | \nLess: Expenses not allocated to segments(1) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 102 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,862 |  |  | $ | 7,429 |  |  | $ | 23,426 |  |  | $ | 22,321 |  |  | 25.0 | % |  | 33.3 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.5 |  | Q4 2021 Cash and cash equivalents balance\n4.0 |  | cash generated from operating activities\n(3.6) |  | net cash used by investing activities\n(4.4) |  | net cash used by financing activities\n | \n$ | 10.5 |  | Q1 2022 Cash and cash equivalents balance  |  |  |  |  | \n(Dollars In Billions) | \n$ | 5.1 |  | Net Earnings\n1.6 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses\n | \n(1.0) |  | an increase in accounts receivable and inventories\n | \n(2.8) |  | a decrease in accounts payable and accrued liabilities\n1.0 |  | a decrease in other current and non-current assets\n0.1 |  | an increase in other current and non-current liabilities\n$ | 4.0 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n$ | (0.6) |  | additions to property, plant and equipment\n0.2 |  | proceeds from the disposal of assets/businesses, net\n(0.3) |  | acquisitions, net of cash acquired and other\n(2.7) |  | net purchases of investments\n | \n(0.2) |  | credit support agreements activity, net\n | \n$ | (3.6) |  | Net cash used for investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (2.8) |  | dividends to shareholders\n(1.6) |  | repurchase of common stock\n0.0 | net repayment of short and long term debt\n0.3 |  | proceeds from stock options exercised/employee withholding tax on stock awards, net\n(0.2) |  | credit support agreements activity, net\n(0.1) |  | other and rounding\n$ | (4.4) |  | Net cash used for financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nJanuary 3, 2022 through January 30, 2022 |  | 918,500 |  |  | 170.99 |  |  |  |  | \u2014\nJanuary 31, 2022 through February 27, 2022 |  | 4,728,073 |  |  | 168.98 |  |  |  |  | \u2014\nFebruary 28, 2022 through April 3, 2022 |  | 3,596,956 |  |  | 172.58 |  |  |  |  | \u2014\nTotal |  | 9,243,529 |  |  |  |  |  |  |   |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: April 29, 2022 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: April 29, 2022 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2022 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014April3, 2022and January2, 2022 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the FiscalFirstQuartersEndedApril3, 2022andApril4, 2021 |  |  | 2\n |  |  | \n |  |  | \n |  |  | \nConsolidated Statements of Comprehensive Income for the FiscalFirstQuartersEndedApril3, 2022andApril4, 2021 |  |  | 3\n |  |  | \nConsolidated Statements of Equity for the FiscalFirstQuarters EndedApril3, 2022andApril4, 2021 |  |  | 4\n |  |  | \nConsolidated Statements of Cash Flows for the FiscalThreeMonths EndedApril3, 2022andApril4, 2021 |  |  | 5\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 6\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 42\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 53\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 54\n |  |  | \nPart II \u2014 Other Information |  |  | 54\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 54\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 55\n |  |  | \nItem\u00a06 - Exhibits |  |  | 56\n |  |  | \nSignatures |  |  | 57\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 3, 2022 |  | January 2, 2022\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 10,463 |  |  | 14,487 | \nMarketable securities |  | 19,925 |  |  | 17,121 | \nAccounts receivable, trade, less allowances for doubtful accounts and credit losses $234(2021, $230) |  | 15,594 |  |  | 15,283 | \nInventories (Note 2) |  | 10,990 |  |  | 10,387 | \nPrepaid expenses and other |  | 3,452 |  |  | 3,701 | \n |  |  |  | \nTotal current assets |  | 60,424 |  |  | 60,979 | \nProperty, plant and equipment at cost |  | 47,702 |  |  | 47,679 | \nLess: accumulated depreciation |  | (29,001) |  |  | (28,717) | \nProperty, plant and equipment, net |  | 18,701 |  |  | 18,962 | \nIntangible assets, net (Note 3) |  | 44,420 |  |  | 46,392 | \nGoodwill (Note 3) |  | 34,935 |  |  | 35,246 | \nDeferred taxes on income (Note 5) |  | 9,936 |  |  | 10,223 | \nOther assets |  | 9,939 |  |  | 10,216 | \nTotal assets |  | $ | 178,355 |  |  | 182,018 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 4,297 |  |  | 3,766 | \nAccounts payable |  | 9,309 |  |  | 11,055 | \nAccrued liabilities |  | 13,006 |  |  | 13,612 | \nAccrued rebates, returns and promotions |  | 12,972 |  |  | 12,095 | \nAccrued compensation and employee related obligations |  | 2,098 |  |  | 3,586 | \nAccrued taxes on income (Note 5) |  | 1,708 |  |  | 1,112 | \nTotal current liabilities |  | 43,390 |  |  | 45,226 | \nLong-term debt (Note 4) |  | 28,851 |  |  | 29,985 | \nDeferred taxes on income (Note 5) |  | 6,424 |  |  | 7,487 | \nEmployee related obligations (Note 6) |  | 8,739 |  |  | 8,898 | \nLong-term taxes payable (Note 5) |  | 5,745 |  |  | 5,713 | \nOther liabilities |  | 10,497 |  |  | 10,686 | \nTotal liabilities |  | $ | 103,646 |  |  | 107,995 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (13,757) |  |  | (13,058) | \nRetained earnings |  | 124,380 |  |  | 123,060 | \nLess: common stock held in treasury, at cost (490,459,000and490,878,000shares) |  | 39,034 |  |  | 39,099 | \nTotal shareholders\u2019 equity |  | 74,709 |  |  | 74,023 | \nTotal liabilities and shareholders' equity |  | $ | 178,355 |  |  | 182,018 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended\n |  | April 3,2022 |  | Percentto Sales |  | April 4,2021 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 23,426 |  |  | 100.0 | % |  | $ | 22,321 |  |  | 100.0 | %\nCost of products sold |  | 7,598 |  |  | 32.4 |  |  | 7,063 |  |  | 31.7 | \nGross profit |  | 15,828 |  |  | 67.6 |  |  | 15,258 |  |  | 68.3 | \nSelling, marketing and administrative expenses |  | 5,938 |  |  | 25.4 |  |  | 5,432 |  |  | 24.3 | \nResearch and development expense |  | 3,462 |  |  | 14.8 |  |  | 3,178 |  |  | 14.2 | \nIn-process research and development |  | 610 |  |  | 2.6 |  |  | \u2014 |  |  | \u2014 | \nInterest income |  | (22) |  |  | (0.1) |  |  | (15) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 10 |  |  | 0.0 |  |  | 63 |  |  | 0.3 | \nOther (income) expense, net |  | (102) |  |  | (0.4) |  |  | (882) |  |  | (3.9) | \nRestructuring (Note 12) |  | 70 |  |  | 0.3 |  |  | 53 |  |  | 0.2 | \nEarnings before provision for taxes on income |  | 5,862 |  |  | 25.0 |  |  | 7,429 |  |  | 33.3 | \nProvision for taxes on income (Note 5) |  | 713 |  |  | 3.0 |  |  | 1,232 |  |  | 5.5 | \nNET EARNINGS |  | $ | 5,149 |  |  | 22.0 | % |  | $ | 6,197 |  |  | 27.8 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.96 |  |  |  |  | $ | 2.35 |  |  | \nDiluted |  | $ | 1.93 |  |  |  |  | $ | 2.32 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,629.2 |  |  |  |  | 2,631.6 |  |  | \nDiluted |  | 2,666.5 |  |  |  |  | 2,672.7 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal First Quarter Ended |  | \n | April 3, 2022 |  | April 4, 2021 |  |  |  | \n |  |  |  |  |  |  | \nNet earnings | $ | 5,149 |  |  | 6,197 |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (554) |  |  | 276 |  |  |  |  | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | (13) |  |  | \u2014 |  |  |  |  | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | (13) |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (53) |  |  | (41) |  |  |  |  | \nGain (loss) amortization during period | 217 |  |  | 274 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | 164 |  |  | 233 |  |  |  |  | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (195) |  |  | (522) |  |  |  |  | \nReclassifications to earnings | (101) |  |  | (73) |  |  |  |  | \nNet change | (296) |  |  | (595) |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (699) |  |  | (86) |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 4,450 |  |  | 6,111 |  |  |  |  | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income for the fiscal first quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $145million and $319million; Securities: $3million in 2022; Employee Benefit Plans: $19million and $66million; Derivatives & Hedges: $78million and $157million.\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \nNet earnings | 5,149 |  |  | 5,149 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.06per share) | (2,787) |  |  | (2,787) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 600 |  |  | (1,042) |  |  | \u2014 |  |  | \u2014 |  |  | 1,642 | \nRepurchase of common stock | (1,577) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,577) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (699) |  |  | \u2014 |  |  | (699) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 3, 2022 | $ | 74,709 |  |  | 124,380 |  |  | (13,757) |  |  | 3,120 |  |  | (39,034) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 3, 2021 | $ | 63,278 |  |  | 113,890 |  |  | (15,242) |  |  | 3,120 |  |  | (38,490) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 6,197 |  |  | 6,197 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.01per share) | (2,659) |  |  | (2,659) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 542 |  |  | (920) |  |  | \u2014 |  |  | \u2014 |  |  | 1,462 | \nRepurchase of common stock | (1,438) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,438) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (86) |  |  | \u2014 |  |  | (86) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 4, 2021 | $ | 65,834 |  |  | 116,508 |  |  | (15,328) |  |  | 3,120 |  |  | (38,466) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Three Months Ended\n |  | April 3,2022 |  | April 4,2021\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 5,149 |  |  | 6,197 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 1,769 |  |  | 1,894 | \nStock based compensation |  | 278 |  |  | 307 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 610 |  |  | 14 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (168) |  |  | (580) | \n |  |  |  | \nDeferred tax provision |  | (926) |  |  | (730) | \nCredit losses and accounts receivable allowances |  | 6 |  |  | (13) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (427) |  |  | (1,604) | \nIncrease in inventories |  | (600) |  |  | (695) | \nDecrease in accounts payable and accrued liabilities |  | (2,817) |  |  | (2,336) | \nDecrease in other current and non-current assets |  | 995 |  |  | 2,522 | \nIncrease/(Decrease) in other current and non-current liabilities |  | 110 |  |  | (902) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 3,979 |  |  | 4,074 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (607) |  |  | (677) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 248 |  |  | 603 | \nAcquisitions, net of cash acquired (Note 10) |  | (252) |  |  | \u2014 | \nPurchases of investments |  | (9,018) |  |  | (5,994) | \nSales of investments |  | 6,303 |  |  | 5,233 | \nCredit support agreements activity, net |  | (249) |  |  | 751 | \nOther (primarily licenses and milestones) |  | (59) |  |  | (101) | \n |  |  |  | \nNET CASH USED BY INVESTING ACTIVITIES |  | (3,634) |  |  | (185) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (2,787) |  |  | (2,659) | \nRepurchase of common stock |  | (1,577) |  |  | (1,438) | \nProceeds from short-term debt |  | 3,019 |  |  | 23 | \nRepayment of short-term debt |  | (856) |  |  | (475) | \nProceeds from long-term debt, net of issuance costs |  | \u2014 |  |  | 1 | \nRepayment of long-term debt |  | (2,132) |  |  | (1,001) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 321 |  |  | 236 | \nCredit support agreements activity, net |  | (235) |  |  | 212 | \nOther |  | (138) |  |  | (24) | \n |  |  |  | \nNET CASH USED BY FINANCING ACTIVITIES |  | (4,385) |  |  | (5,125) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 16 |  |  | (78) | \nDecrease in cash and cash equivalents |  | (4,024) |  |  | (1,314) | \nCash and Cash equivalents, beginning of period |  | 14,487 |  |  | 13,985 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 10,463 |  |  | 12,671 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | 255 |  |  | \u2014 | \nFair value of liabilities assumed and noncontrolling interests |  | (3) |  |  | \u2014 | \nNet cash paid for acquisitions |  | $ | 252 |  |  | \u2014 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022\nRaw materials and supplies |  | $ | 1,679 |  |  | 1,592 | \nGoods in process |  | 2,629 |  |  | 2,287 | \nFinished goods |  | 6,682 |  |  | 6,508 | \nTotal inventories |  | $ | 10,990 |  |  | 10,387 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 37,960 |  |  | 38,572 | \nLess accumulated amortization |  | (20,492) |  |  | (20,088) | \nPatents and trademarks \u2014 net |  | 17,468 |  |  | 18,484 | \nCustomer relationships and other intangibles \u2014 gross |  | 22,910 |  |  | 23,011 | \nLess accumulated amortization |  | (12,147) |  |  | (11,925) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 10,763 |  |  | 11,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,947 |  |  | 6,985 | \nPurchased in-process research and development(2) |  | 9,242 |  |  | 9,837 | \nTotal intangible assets with indefinite lives |  | 16,189 |  |  | 16,822 | \nTotal intangible assets \u2014 net |  | $ | 44,420 |  |  | 46,392 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January 2, 2022 |  | $ | 9,810 |  |  | 10,580 |  |  | 14,856 |  |  | 35,246 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | 73 |  |  | 73 | \n |  |  |  |  |  |  |  | \nCurrency translation/Other |  | (195) |  |  | (170) |  |  | (19) |  |  | (384) | \nGoodwill at April 3, 2022 |  | $ | 9,615 |  |  | 10,410 |  |  | 14,910 |  |  | 34,935 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026\n$4,600 |  | 4,600 |  | 4,400 |  | 3,600 |  | 3,000  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n | April 3, 2022 | April 4, 2021\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (531) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 531 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 40 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 40 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (17) |  | (52) |  | 23 |  | \u2014 |  | (18) |  | 17 |  | 34 |  | (113) |  | \u2014 |  | 3 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | 22 |  | (94) |  | 33 |  | \u2014 |  | (73) |  | (3) |  | (193) |  | (76) |  | \u2014 |  | 17 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 |  | \u2014 |  |  | \u2014 |  | 92 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (128) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (307) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | April 3, 2022 |  | January 2, 2022 |  | April 3, 2022 |  | January 2, 2022\n |  |  |  |  |  |  |  | \nLong-term Debt |  | 9,313 |  |  | 9,793 |  |  | (694) |  |  | (142) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative |  | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal First Quarter Ended |  | \nDerivatives Not Designated as Hedging Instruments |  |  |  | April 3, 2022 |  | April 4, 2021 |  |  |  | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | 29 |  |  | (16) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  |  |  | April 3, 2022 |  | April 4, 2021\nDebt |  | $ | 68 |  |  | 209 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 560 |  |  | 361 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 2, 2022 |  |  |  |  |  | April 3, 2022 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 1,884 |  |  | (402) |  |  | (30) |  |  | 1,452 |  |  | 1,452 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 500 |  |  | (5) |  |  | 10 |  |  | 505 |  |  | 505 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 3, 2022 |  |  |  | January 2, 2022\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 742 |  |  | \u2014 |  |  | 742 |  |  | 540 | \nInterest rate contracts(2) |  | \u2014 |  |  | 975 |  |  | \u2014 |  |  | 975 |  |  | 796 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 1,717 |  |  | \u2014 |  |  | 1,717 |  |  | 1,336 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 1,058 |  |  | \u2014 |  |  | 1,058 |  |  | 881 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,652 |  |  | \u2014 |  |  | 1,652 |  |  | 979 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,710 |  |  | \u2014 |  |  | 2,710 |  |  | 1,860 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 36 |  |  | \u2014 |  |  | 36 |  |  | 24 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 68 |  |  | \u2014 |  |  | 68 |  |  | 28 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 1,452 |  |  | \u2014 |  |  | \u2014 |  |  | 1,452 |  |  | 1,884 | \nDebt securities(4) |  | \u2014 |  |  | 19,583 |  |  | \u2014 |  |  | 19,583 |  |  | 19,727 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 486 |  |  | 486 |  |  | 533 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | April 3, 2022 |  | January 2, 2022\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 1,753 |  |  | 1,360 | \nCredit Support Agreement (CSA) |  | (1,655) |  |  | (1,285) | \nTotal Net Asset |  | 98 |  |  | 75 | \n |  |  |  | \nTotal Gross Liabilities |  | 2,778 |  |  | 1,888 | \nCredit Support Agreement (CSA) |  | (2,709) |  |  | (1,855) | \nTotal Net Liabilities |  | $ | 69 |  |  | 33 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | April 3, 2022 |  | April 4, 2021\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 533 |  |  | $ | 633 | \nChanges in estimated fair value(6) |  | (47) |  |  | 15 | \nAdditions |  | \u2014 |  |  | \u2014 | \nPayments |  | \u2014 |  |  | (48) | \nEnding Balance |  | $ | 486 |  |  | $ | 600 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/( Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 3,128 |  |  |  |  | \u2014 |  |  | 3,128 |  |  | 3,128 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities(1) | 329 |  |  |  |  | \u2014 |  |  | 329 |  |  | \u2014 |  |  | 329 | \nU.S. reverse repurchase agreements | 1,449 |  |  |  |  | \u2014 |  |  | 1,449 |  |  | 1,449 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 3,557 |  |  |  |  | (6) |  |  | 3,551 |  |  | 540 |  |  | 3,017 | \nMoney market funds | 1,579 |  |  |  |  | \u2014 |  |  | 1,579 |  |  | 1,579 |  |  | \u2014 | \nTime deposits(1) | 763 |  |  |  |  | \u2014 |  |  | 763 |  |  | 763 |  |  | \u2014 | \nSubtotal | 10,805 |  |  |  |  | (6) |  |  | 10,799 |  |  | 7,459 |  |  | 3,346 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov't securities | 19,354 |  |  |  |  | (19) |  |  | 19,335 |  |  | 2,968 |  |  | 16,367 | \nOther sovereign securities | 3 |  |  |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 | \nCorporate debt securities | 246 |  |  |  |  | (1) |  |  | 245 |  |  | 36 |  |  | 209 | \nSubtotal available for sale debt(2) | $ | 19,603 |  |  |  |  | (20) |  |  | 19,583 |  |  | 3,004 |  |  | 16,579 | \nTotal cash, cash equivalents and current marketable securities | $ | 30,408 |  |  |  |  | (26) |  |  | 30,382 |  |  | 10,463 |  |  | 19,925 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 19,585 |  |  | 19,564 | \nDue after one year through five years |  | 19 |  |  | 19 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 19,604 |  |  | 19,583 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 4,297 |  |  | 4,298 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n6.73% Debentures due 2023 |  | 250 |  |  | 266 | \n3.375% Notes due 2023 |  | 802 |  |  | 820 | \n |  |  |  | \n0.650% Notes due 2024 (750MM Euro 1.1311) |  | 824 |  |  | 829 | \n5.50% Notes due 2024 (500 MM GBP 1.3485) |  | 654 |  |  | 713 | \n2.625% Notes due 2025 |  | 749 |  |  | 762 | \n |  |  |  | \n0.55% Notes due 2025 |  | 950 |  |  | 886 | \n2.45% Notes due 2026 |  | 1,995 |  |  | 1,981 | \n2.95% Notes due 2027 |  | 930 |  |  | 934 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,436 |  |  | 1,307 | \n2.90%\u00a0Notes due 2028 |  | 1,496 |  |  | 1,489 | \n1.150% Notes due 2028 (750MM Euro 1.1311) |  | 826 |  |  | 829 | \n6.95% Notes due 2029 |  | 298 |  |  | 379 | \n |  |  |  | \n1.30% Notes due 2030 |  | 1,672 |  |  | 1,486 | \n4.95% Debentures due 2033 |  | 498 |  |  | 590 | \n4.375% Notes due 2033 |  | 855 |  |  | 959 | \n1.650% Notes due 2035 (1.5B Euro 1.1311) |  | 1,654 |  |  | 1,687 | \n3.55% Notes due 2036 |  | 917 |  |  | 947 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,288 | \n3.625% Notes due 2037 |  | 1,416 |  |  | 1,463 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 999 | \n5.85% Debentures due 2038 |  | 697 |  |  | 901 | \n4.50% Debentures due 2040 |  | 540 |  |  | 617 | \n |  |  |  | \n2.10% Notes due 2040 |  | 914 |  |  | 777 | \n4.85% Notes due 2041 |  | 297 |  |  | 342 | \n4.50% Notes due 2043 |  | 496 |  |  | 565 | \n3.70% Notes due 2046 |  | 1,975 |  |  | 2,097 | \n3.75% Notes due 2047 |  | 906 |  |  | 969 | \n3.50% Notes due 2048 |  | 743 |  |  | 766 | \n2.25% Notes due 2050 |  | 914 |  |  | 759 | \n2.45% Notes due 2060 |  | 1,155 |  |  | 942 | \nOther |  | 7 |  |  | 7 | \nTotal Non-Current Debt |  | $ | 28,851 |  |  | 29,356 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n |  | Retirement Plans |  | Other Benefit Plans |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021 |  |  |  |  |  |  |  | \nService cost |  | $ | 321 |  |  | 353 |  |  | 80 |  |  | 77 |  |  |  |  |  |  |  |  | \nInterest cost |  | 230 |  |  | 193 |  |  | 26 |  |  | 20 |  |  |  |  |  |  |  |  | \nExpected return on plan assets |  | (699) |  |  | (680) |  |  | (2) |  |  | (2) |  |  |  |  |  |  |  |  | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (45) |  |  | (1) |  |  | (8) |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial losses |  | 162 |  |  | 314 |  |  | 30 |  |  | 38 |  |  |  |  |  |  |  |  | \nCurtailments and settlements |  | 1 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nNet periodic benefit cost/(credit) |  | $ | (31) |  |  | 136 |  |  | 133 |  |  | 125 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 2, 2022 |  | $ | (10,017) |  |  | (3) |  |  | (2,702) |  |  | (336) |  |  | (13,058) | \nNet change |  | (554) |  |  | (13) |  |  | 164 |  |  | (296) |  |  | (699) | \n |  |  |  |  |  |  |  |  |  | \nApril 3, 2022 |  | $ | (10,571) |  |  | (16) |  |  | (2,538) |  |  | (632) |  |  | (13,757) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Shares in Millions) |  | April 3, 2022 |  | April 4, 2021 |  |  |  | \nBasic net earnings per share |  | $ | 1.96 |  |  | 2.35 |  |  |  |  | \nAverage shares outstanding \u2014 basic |  | 2,629.2 |  |  | 2,631.6 |  |  |  |  | \nPotential shares exercisable under stock option plans |  | 140.1 |  |  | 128.4 |  |  |  |  | \nLess: shares which could be repurchased under treasury stock method |  | (102.8) |  |  | (87.3) |  |  |  |  | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,666.5 |  |  | 2,672.7 |  |  |  |  | \nDiluted net earnings per share |  | $ | 1.93 |  |  | 2.32 |  |  |  |  |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 3,2022 |  | April 4,2021 |  | PercentChange |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nOTC(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 670 |  |  | 599 |  |  | 11.8 | % |  |  |  |  |  | \nInternational |  | 791 |  |  | 673 |  |  | 17.5 |  |  |  |  |  |  | \nWorldwide |  | 1,461 |  |  | 1,273 |  |  | 14.8 |  |  |  |  |  |  | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 544 |  |  | 634 |  |  | (14.2) |  |  |  |  |  |  | \nInternational |  | 468 |  |  | 529 |  |  | (11.6) |  |  |  |  |  |  | \nWorldwide |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  |  |  |  |  | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 143 |  |  | 163 |  |  | (12.6) |  |  |  |  |  |  | \nInternational |  | 223 |  |  | 254 |  |  | (12.0) |  |  |  |  |  |  | \nWorldwide |  | 366 |  |  | 417 |  |  | (12.2) |  |  |  |  |  |  | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 85 |  |  | 96 |  |  | (11.5) |  |  |  |  |  |  | \nInternational |  | 270 |  |  | 293 |  |  | (7.7) |  |  |  |  |  |  | \nWorldwide |  | 355 |  |  | 389 |  |  | (8.6) |  |  |  |  |  |  | \nWomen's Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3 |  |  | 3 |  |  | 7.2 |  |  |  |  |  |  | \nInternational |  | 224 |  |  | 219 |  |  | 2.5 |  |  |  |  |  |  | \nWorldwide |  | 228 |  |  | 222 |  |  | 2.6 |  |  |  |  |  |  | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 112 |  |  | 115 |  |  | (3.3) |  |  |  |  |  |  | \nInternational |  | 52 |  |  | 61 |  |  | (15.3) |  |  |  |  |  |  | \nWorldwide |  | 164 |  |  | 177 |  |  | (7.4) |  |  |  |  |  |  | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,557 |  |  | 1,611 |  |  | (3.4) |  |  |  |  |  |  | \nInternational |  | 2,029 |  |  | 2,030 |  |  | 0.0 |  |  |  |  |  | \nWorldwide |  | 3,586 |  |  | 3,641 |  |  | (1.5) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,501 |  |  | 2,413 |  |  | 3.7 |  |  |  |  |  |  | \nInternational |  | 1,617 |  |  | 1,501 |  |  | 7.7 |  |  |  |  |  |  | \nWorldwide |  | 4,119 |  |  | 3,914 |  |  | 5.2 |  |  |  |  |  |  | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 358 |  |  | 489 |  |  | (26.8) |  |  |  |  |  |  | \nU.S. Exports |  | 80 |  |  | 57 |  |  | 40.5 |  |  |  |  |  |  | \nInternational |  | 225 |  |  | 232 |  |  | (2.6) |  |  |  |  |  |  | \nWorldwide |  | 663 |  |  | 777 |  |  | (14.7) |  |  |  |  |  |  | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 287 |  |  | 255 |  |  | 12.5 |  |  |  |  |  |  | \nInternational |  | 283 |  |  | 307 |  |  | (7.6) |  |  |  |  |  |  | \nWorldwide |  | 571 |  |  | 562 |  |  | 1.5 |  |  |  |  |  |  | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,379 |  |  | 1,331 |  |  | 3.6 |  |  |  |  |  |  | \nInternational |  | 909 |  |  | 817 |  |  | 11.2 |  |  |  |  |  |  | \nWorldwide |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  |  |  |  |  | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 391 |  |  | 274 |  |  | 42.7 |  |  |  |  |  |  | \nInternational |  | 199 |  |  | 143 |  |  | 38.8 |  |  |  |  |  |  | \nWorldwide |  | 590 |  |  | 418 |  |  | 41.3 |  |  |  |  |  |  | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 6 |  |  | 7 |  |  | (3.2) |  |  |  |  |  |  | \nInternational |  | 0 |  |  | 2 |  |  | * |  |  |  |  |  | \nWorldwide |  | 6 |  |  | 8 |  |  | (22.0) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 461 |  |  | 512 |  |  | (10.0) |  |  |  |  |  |  | \nInternational |  | 836 |  |  | 485 |  |  | 72.3 |  |  |  |  |  |  | \nWorldwide |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  |  |  |  |  | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 75 |  |  | 100 |  |  | (24.9) |  |  |  |  |  |  | \nInternational |  | 382 |  |  | 0 |  | * |  |  |  |  |  | \nWorldwide |  | 457 |  |  | 100 |  |  | * |  |  |  |  |  | \nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 10 |  |  | (12.6) |  |  |  |  |  |  | \nInternational |  | 239 |  |  | 233 |  |  | 2.5 |  |  |  |  |  |  | \nWorldwide |  | 248 |  |  | 243 |  |  | 1.8 |  |  |  |  |  |  | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 369 |  |  | 380 |  |  | (3.1) |  |  |  |  |  |  | \nInternational |  | 132 |  |  | 166 |  |  | (20.3) |  |  |  |  |  |  | \nWorldwide |  | 501 |  |  | 546 |  |  | (8.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 8 |  |  | 21 |  |  | (62.5) |  |  |  |  |  |  | \nInternational |  | 83 |  |  | 87 |  |  | (3.8) |  |  |  |  |  |  | \nWorldwide |  | 91 |  |  | 108 |  |  | (15.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 843 |  |  | 771 |  |  | 9.3 |  |  |  |  |  |  | \nInternational |  | 898 |  |  | 943 |  |  | (4.8) |  |  |  |  |  |  | \nWorldwide |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  |  |  |  |  | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 35 |  |  | 47 |  |  | (26.5) |  |  |  |  |  |  | \nInternational |  | 122 |  |  | 123 |  |  | (1.3) |  |  |  |  |  |  | \nWorldwide |  | 157 |  |  | 171 |  |  | (8.3) |  |  |  |  |  |  | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 661 |  |  | 589 |  |  | 12.2 |  |  |  |  |  |  | \nInternational |  | 387 |  |  | 376 |  |  | 3.0 |  |  |  |  |  |  | \nWorldwide |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  |  |  |  |  | \nRISPERDAL CONSTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 63 |  |  | 67 |  |  | (6.4) |  |  |  |  |  |  | \nInternational |  | 66 |  |  | 89 |  |  | (26.1) |  |  |  |  |  |  | \nWorldwide |  | 129 |  |  | 157 |  |  | (17.6) |  |  |  |  |  |  | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 84 |  |  | 67 |  |  | 25.5 |  |  |  |  |  |  | \nInternational |  | 323 |  |  | 355 |  |  | (8.9) |  |  |  |  |  |  | \nWorldwide |  | 408 |  |  | 422 |  |  | (3.5) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,582 |  |  | 1,377 |  |  | 14.9 |  |  |  |  |  |  | \nInternational |  | 2,369 |  |  | 2,193 |  |  | 8.0 |  |  |  |  |  |  | \nWorldwide |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  |  |  |  |  | \nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 953 |  |  | 691 |  |  | 37.9 |  |  |  |  |  |  | \nInternational |  | 903 |  |  | 674 |  |  | 34.0 |  |  |  |  |  |  | \nWorldwide |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  |  |  |  |  | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 206 |  |  | 171 |  |  | 20.3 |  |  |  |  |  |  | \nInternational |  | 194 |  |  | 90 |  |  | * |  |  |  |  |  | \nWorldwide |  | 400 |  |  | 261 |  |  | 53.0 |  |  |  |  |  |  | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 370 |  |  | 444 |  |  | (16.7) |  |  |  |  |  |  | \nInternational |  | 668 |  |  | 680 |  |  | (1.8) |  |  |  |  |  |  | \nWorldwide |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  |  |  |  |  | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 19 |  |  | 50 |  |  | (62.1) |  |  |  |  |  |  | \nInternational |  | 520 |  |  | 588 |  |  | (11.6) |  |  |  |  |  |  | \nWorldwide |  | 539 |  |  | 638 |  |  | (15.6) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 34 |  |  | 21 |  |  | 63.1 |  |  |  |  |  |  | \nInternational |  | 84 |  |  | 161 |  |  | (47.7) |  |  |  |  |  |  | \nWorldwide |  | 118 |  |  | 182 |  |  | (35.1) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 572 |  |  | 573 |  |  | (0.2) |  |  |  |  |  |  | \nInternational |  | 279 |  |  | 288 |  |  | (2.9) |  |  |  |  |  |  | \nWorldwide |  | 852 |  |  | 861 |  |  | (1.1) |  |  |  |  |  |  | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 273 |  |  | 272 |  |  | 0.5 |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 179 |  |  | (4.8) |  |  |  |  |  |  | \nWorldwide |  | 443 |  |  | 450 |  |  | (1.6) |  |  |  |  |  |  | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 269 |  |  | 259 |  |  | 3.9 |  |  |  |  |  |  | \nInternational |  | 56 |  |  | 46 |  |  | 20.9 |  |  |  |  |  |  | \nWorldwide |  | 325 |  |  | 305 |  |  | 6.5 |  |  |  |  |  |  | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 30 |  |  | 42 |  |  | (29.0) |  |  |  |  |  |  | \nInternational |  | 53 |  |  | 63 |  |  | (15.2) |  |  |  |  |  |  | \nWorldwide |  | 83 |  |  | 105 |  |  | (20.8) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 672 |  |  | 799 |  |  | (15.8) |  |  |  |  |  |  | \nInternational |  | 238 |  |  | 245 |  |  | (3.0) |  |  |  |  |  |  | \nWorldwide |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  |  |  |  |  | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  | \nWorldwide |  | 508 |  |  | 589 |  |  | (13.8) |  |  |  |  |  |  | \nINVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 60 |  |  | 87 |  |  | (30.7) |  |  |  |  |  |  | \nInternational |  | 68 |  |  | 63 |  |  | 7.5 |  |  |  |  |  |  | \nWorldwide |  | 128 |  |  | 150 |  |  | (14.6) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(1,2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 104 |  |  | 122 |  |  | (14.9) |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 182 |  |  | (6.6) |  |  |  |  |  |  | \nWorldwide |  | 274 |  |  | 305 |  |  | (10.0) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 6,632 |  |  | 6,446 |  |  | 2.9 |  |  |  |  |  |  | \nInternational |  | 6,237 |  |  | 5,655 |  |  | 10.3 |  |  |  |  |  |  | \nWorldwide |  | 12,869 |  |  | 12,101 |  |  | 6.3 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH(3) |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 494 |  |  | 434 |  |  | 13.8 |  |  |  |  |  |  | \nInternational |  | 597 |  |  | 514 |  |  | 16.2 |  |  |  |  |  |  | \nWorldwide |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  |  |  |  |  | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,289 |  |  | 1,249 |  |  | 3.2 |  |  |  |  |  |  | \nInternational |  | 899 |  |  | 864 |  |  | 4.1 |  |  |  |  |  |  | \nWorldwide |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  |  |  |  |  | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 225 |  |  | 209 |  |  | 7.3 |  |  |  |  |  |  | \nInternational |  | 164 |  |  | 146 |  |  | 12.2 |  |  |  |  |  |  | \nWorldwide |  | 389 |  |  | 356 |  |  | 9.3 |  |  |  |  |  |  | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 201 |  |  | 185 |  |  | 8.6 |  |  |  |  |  |  | \nInternational |  | 138 |  |  | 132 |  |  | 4.1 |  |  |  |  |  |  | \nWorldwide |  | 339 |  |  | 317 |  |  | 6.7 |  |  |  |  |  |  | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 475 |  |  | 450 |  |  | 5.5 |  |  |  |  |  |  | \nInternational |  | 273 |  |  | 282 |  |  | (3.3) |  |  |  |  |  |  | \nWorldwide |  | 748 |  |  | 733 |  |  | 2.1 |  |  |  |  |  |  | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 387 |  |  | 404 |  |  | (4.1) |  |  |  |  |  |  | \nInternational |  | 324 |  |  | 303 |  |  | 7.0 |  |  |  |  |  |  | \nWorldwide |  | 712 |  |  | 707 |  |  | 0.6 |  |  |  |  |  |  | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 921 |  |  | 898 |  |  | 2.5 |  |  |  |  |  |  | \nInternational |  | 1,513 |  |  | 1,474 |  |  | 2.7 |  |  |  |  |  |  | \nWorldwide |  | 2,434 |  |  | 2,372 |  |  | 2.6 |  |  |  |  |  |  | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 417 |  |  | 405 |  |  | 3.0 |  |  |  |  |  |  | \nInternational |  | 729 |  |  | 713 |  |  | 2.2 |  |  |  |  |  |  | \nWorldwide |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  |  |  |  |  | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 504 |  |  | 493 |  |  | 2.1 |  |  |  |  |  |  | \nInternational |  | 784 |  |  | 761 |  |  | 3.1 |  |  |  |  |  |  | \nWorldwide |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  |  |  |  |  | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 521 |  |  | 472 |  |  | 10.4 |  |  |  |  |  |  | \nInternational |  | 736 |  |  | 673 |  |  | 9.4 |  |  |  |  |  |  | \nWorldwide |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  |  |  |  |  | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 400 |  |  | 371 |  |  | 7.7 |  |  |  |  |  |  | \nInternational |  | 511 |  |  | 486 |  |  | 5.1 |  |  |  |  |  |  | \nWorldwide |  | 910 |  |  | 857 |  |  | 6.2 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 121 |  |  | 101 |  |  | 20.2 |  |  |  |  |  |  | \nInternational |  | 226 |  |  | 187 |  |  | 20.5 |  |  |  |  |  |  | \nWorldwide |  | 347 |  |  | 288 |  |  | 20.4 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,225 |  |  | 3,054 |  |  | 5.6 |  |  |  |  |  |  | \nInternational |  | 3,746 |  |  | 3,525 |  |  | 6.3 |  |  |  |  |  |  | \nWorldwide |  | 6,971 |  |  | 6,579 |  |  | 5.9 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 11,414 |  |  | 11,111 |  |  | 2.7 |  |  |  |  |  |  | \nInternational |  | 12,012 |  |  | 11,210 |  |  | 7.2 |  |  |  |  |  |  | \nWorldwide |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  |  | \n(Dollars in Millions) |  | April 3,2022 |  | April 4,2021 |  | PercentChange |  |  |  |  |  |  |  |  |  |  | \nConsumer Health(1) |  | $ | 686 |  |  | 842 |  |  | (18.5)% |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical(2) |  | 3,924 |  |  | 5,169 |  |  | (24.1) |  |  |  |  |  |  |  |  |  |  | \nMedTech(3) |  | 1,477 |  |  | 1,629 |  |  | (9.3) |  |  |  |  |  |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 6,087 |  |  | 7,640 |  |  | (20.3) |  |  |  |  |  |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 102 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,862 |  |  | 7,429 |  |  | (21.1)% |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | PercentChange |  |  |  |  |  | \nUnited States |  | $ | 11,414 |  |  | 11,111 |  |  | 2.7 | % |  |  |  |  |  | \nEurope |  | 6,024 |  |  | 5,414 |  |  | 11.3 |  |  |  |  |  |  | \nWestern Hemisphere, excluding U.S. |  | 1,482 |  |  | 1,424 |  |  | 4.1 |  |  |  |  |  |  | \nAsia-Pacific, Africa |  | 4,506 |  |  | 4,372 |  |  | 3.1 |  |  |  |  |  |  | \nTotal |  | $ | 23,426 |  |  | 22,321 |  |  | 5.0 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Severance | Asset Write-offs/Sales |  | Other(2) | Total\nReserve balance, January 2, 2022 | $ | 112 |  | \u2014 |  |  | 25 |  | 137 | \n |  |  |  |  | \nCurrent year activity: |  |  |  |  | \nCharges | \u2014 |  | (23) |  |  | 95 |  | 72 | \nCash settlements | (10) |  | 35 |  | (3) |  | (107) |  | (82) | \nSettled non cash | \u2014 |  | (12) |  |  | \u2014 |  | (12) | \n |  |  |  |  | \n |  |  |  |  | \nReserve balance, April 3, 2022(1) | $ | 102 |  | \u2014 |  |  | 13 |  | 115 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 1,461 |  |  | $ | 1,273 |  |  | 14.8 | % |  | 17.1 | % |  | (2.3) | %\nSkin Health/Beauty |  | 1,012 |  |  | 1,163 |  |  | (13.0) |  |  | (11.0) |  |  | (2.0) | \nOral Care |  | 366 |  |  | 417 |  |  | (12.2) |  |  | (10.2) |  |  | (2.0) | \nBaby Care |  | 355 |  |  | 389 |  |  | (8.6) |  |  | (6.4) |  |  | (2.2) | \nWomen\u2019s Health |  | 228 |  |  | 222 |  |  | 2.6 |  |  | 8.3 |  |  | (5.7) | \nWound Care/Other |  | 164 |  |  | 177 |  |  | (7.4) |  |  | (7.2) |  |  | (0.2) | \nTotal Consumer Health Sales |  | $ | 3,586 |  |  | $ | 3,641 |  |  | (1.5) | % |  | 0.8 | % |  | (2.3) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,119 |  |  | $ | 3,914 |  |  | 5.2 | % |  | 7.5 | % |  | (2.3) | %\nREMICADE |  | 663 |  |  | 777 |  |  | (14.7) |  |  | (14.2) |  |  | (0.5) | \nSIMPONI/ SIMPONI ARIA |  | 571 |  |  | 562 |  |  | 1.5 |  |  | 4.7 |  |  | (3.2) | \nSTELARA |  | 2,288 |  |  | 2,148 |  |  | 6.5 |  |  | 9.0 |  |  | (2.5) | \nTREMFYA |  | 590 |  |  | 418 |  |  | 41.3 |  |  | 44.5 |  |  | (3.2) | \nOther Immunology |  | 6 |  |  | 8 |  |  | (22.0) |  |  | (22.0) |  |  | 0.0\nInfectious Diseases |  | 1,297 |  |  | 998 |  |  | 30.0 |  |  | 33.1 |  |  | (3.1) | \nCOVID-19 VACCINE |  | 457 |  |  | 100 |  |  | * |  | * |  | *\nEDURANT/rilpivirine |  | 248 |  |  | 243 |  |  | 1.8 |  |  | 9.6 |  |  | (7.8) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 501 |  |  | 546 |  |  | (8.3) |  |  | (6.9) |  |  | (1.4) | \nOther Infectious Diseases(2) |  | 91 |  |  | 108 |  |  | (15.3) |  |  | (11.0) |  |  | (4.3) | \nNeuroscience |  | 1,741 |  |  | 1,715 |  |  | 1.5 |  |  | 5.0 |  |  | (3.5) | \nCONCERTA/ methylphenidate |  | 157 |  |  | 171 |  |  | (8.3) |  |  | (4.8) |  |  | (3.5) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,048 |  |  | 965 |  |  | 8.6 |  |  | 11.3 |  |  | (2.7) | \nRISPERDAL CONSTA |  | 129 |  |  | 157 |  |  | (17.6) |  |  | (13.9) |  |  | (3.7) | \nOther Neuroscience(2) |  | 408 |  |  | 422 |  |  | (3.5) |  |  | 1.7 |  |  | (5.2) | \nOncology |  | 3,950 |  |  | 3,570 |  |  | 10.6 |  |  | 14.9 |  |  | (4.3) | \nDARZALEX |  | 1,856 |  |  | 1,365 |  |  | 36.0 |  |  | 40.3 |  |  | (4.3) | \nERLEADA |  | 400 |  |  | 261 |  |  | 53.0 |  |  | 57.5 |  |  | (4.5) | \nIMBRUVICA |  | 1,038 |  |  | 1,125 |  |  | (7.7) |  |  | (3.9) |  |  | (3.8) | \nZYTIGA/ abiraterone acetate |  | 539 |  |  | 638 |  |  | (15.6) |  |  | (10.1) |  |  | (5.5) | \nOther Oncology |  | 118 |  |  | 182 |  |  | (35.1) |  |  | (32.3) |  |  | (2.8) | \nPulmonary Hypertension |  | 852 |  |  | 861 |  |  | (1.1) |  |  | 1.2 |  |  | (2.3) | \nOPSUMIT |  | 443 |  |  | 450 |  |  | (1.6) |  |  | 1.1 |  |  | (2.7) | \nUPTRAVI |  | 325 |  |  | 305 |  |  | 6.5 |  |  | 7.7 |  |  | (1.2) | \nOther Pulmonary Hypertension |  | 83 |  |  | 105 |  |  | (20.8) |  |  | (16.8) |  |  | (4.0) | \nCardiovascular / Metabolism / Other |  | 910 |  |  | 1,044 |  |  | (12.8) |  |  | (11.9) |  |  | (0.9) | \nXARELTO |  | 508 |  |  | 589 |  |  | (13.8) |  |  | (13.8) |  |  | \u2014 | \nINVOKANA/ INVOKAMET |  | 128 |  |  | 150 |  |  | (14.6) |  |  | (13.1) |  |  | (1.5) | \nOther(1,2) |  | 274 |  |  | 305 |  |  | (10.0) |  |  | (7.5) |  |  | (2.5) | \nTotal Pharmaceutical Sales |  | $ | 12,869 |  |  | $ | 12,101 |  |  | 6.3 | % |  | 9.3 | % |  | (3.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,434 |  |  | $ | 2,372 |  |  | 2.6 | % |  | 5.0 | % |  | (2.4) | %\nAdvanced |  | 1,146 |  |  | 1,118 |  |  | 2.5 |  |  | 4.5 |  |  | (2.0) | \nGeneral |  | 1,288 |  |  | 1,254 |  |  | 2.7 |  |  | 5.5 |  |  | (2.8) | \nOrthopaedics |  | 2,188 |  |  | 2,113 |  |  | 3.5 |  |  | 5.6 |  |  | (2.1) | \nHips |  | 389 |  |  | 356 |  |  | 9.3 |  |  | 11.3 |  |  | (2.0) | \nKnees |  | 339 |  |  | 317 |  |  | 6.7 |  |  | 8.8 |  |  | (2.1) | \nTrauma |  | 748 |  |  | 733 |  |  | 2.1 |  |  | 4.2 |  |  | (2.1) | \nSpine, Sports & Other |  | 712 |  |  | 707 |  |  | 0.6 |  |  | 2.7 |  |  | (2.1) | \nVision |  | 1,257 |  |  | 1,145 |  |  | 9.8 |  |  | 13.9 |  |  | (4.1) | \nContact Lenses/Other |  | 910 |  |  | 857 |  |  | 6.2 |  |  | 10.6 |  |  | (4.4) | \nSurgical |  | 347 |  |  | 288 |  |  | 20.4 |  |  | 23.8 |  |  | (3.4) | \nInterventional Solutions |  | 1,092 |  |  | 949 |  |  | 15.1 |  |  | 17.4 |  |  | (2.3) | \n |  |  |  |  |  |  |  |  |  | \nTotal MedTech Sales |  | $ | 6,971 |  |  | $ | 6,579 |  |  | 5.9 | % |  | 8.5 | % |  | (2.6) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal First Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2022 |  | 2021 |  | Change\nChanges in the fair value of securities |  | $ | 0.4 |  |  | 0.0 |  |  | 0.4 | \nAcquisition, integration and divestiture related(1) |  | 0.0 |  |  | (0.5) |  |  | 0.5 | \nConsumer Health separation costs |  | 0.1 |  |  | 0.0 |  |  | 0.1 | \nEmployee benefit plan related |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \nOther |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | (0.1) |  |  | $ | (0.9) |  |  | $ | 0.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021 |  | April 3, 2022 |  | April 4, 2021\nConsumer Health |  | $ | 686 |  |  | $ | 842 |  |  | $ | 3,586 |  |  | $ | 3,641 |  |  | 19.1 | % |  | 23.1 | %\nPharmaceutical |  | 3,924 |  |  | 5,169 |  |  | 12,869 |  |  | 12,101 |  |  | 30.5 |  |  | 42.7 | \nMedTech |  | 1,477 |  |  | 1,629 |  |  | 6,971 |  |  | 6,579 |  |  | 21.2 |  |  | 24.8 | \nSegment earnings before tax |  | 6,087 |  |  | 7,640 |  |  | 23,426 |  |  | 22,321 |  |  | 26.0 |  |  | 34.2 | \nLess: Expenses not allocated to segments(1) |  | 123 |  |  | 211 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 102 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,862 |  |  | $ | 7,429 |  |  | $ | 23,426 |  |  | $ | 22,321 |  |  | 25.0 | % |  | 33.3 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.5 |  | Q4 2021 Cash and cash equivalents balance\n4.0 |  | cash generated from operating activities\n(3.6) |  | net cash used by investing activities\n(4.4) |  | net cash used by financing activities\n | \n$ | 10.5 |  | Q1 2022 Cash and cash equivalents balance  |  |  |  |  | \n(Dollars In Billions) | \n$ | 5.1 |  | Net Earnings\n1.6 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses\n | \n(1.0) |  | an increase in accounts receivable and inventories\n | \n(2.8) |  | a decrease in accounts payable and accrued liabilities\n1.0 |  | a decrease in other current and non-current assets\n0.1 |  | an increase in other current and non-current liabilities\n$ | 4.0 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n$ | (0.6) |  | additions to property, plant and equipment\n0.2 |  | proceeds from the disposal of assets/businesses, net\n(0.3) |  | acquisitions, net of cash acquired and other\n(2.7) |  | net purchases of investments\n | \n(0.2) |  | credit support agreements activity, net\n | \n$ | (3.6) |  | Net cash used for investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (2.8) |  | dividends to shareholders\n(1.6) |  | repurchase of common stock\n0.0 | net repayment of short and long term debt\n0.3 |  | proceeds from stock options exercised/employee withholding tax on stock awards, net\n(0.2) |  | credit support agreements activity, net\n(0.1) |  | other and rounding\n$ | (4.4) |  | Net cash used for financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nJanuary 3, 2022 through January 30, 2022 |  | 918,500 |  |  | 170.99 |  |  |  |  | \u2014\nJanuary 31, 2022 through February 27, 2022 |  | 4,728,073 |  |  | 168.98 |  |  |  |  | \u2014\nFebruary 28, 2022 through April 3, 2022 |  | 3,596,956 |  |  | 172.58 |  |  |  |  | \u2014\nTotal |  | 9,243,529 |  |  |  |  |  |  |   |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: April 29, 2022 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: April 29, 2022 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2022 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014October2, 2022 and January 2, 2022 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the FiscalThirdQuarters EndedOctober2, 2022 andOctober3, 2021 |  |  | 2\n |  |  | \nConsolidated Statements of Earnings for the FiscalNineMonths EndedOctober2, 2022 andOctober3, 2021 |  |  | 3\n |  |  | \nConsolidated Statements of Comprehensive Income for the FiscalThirdQuarters and FiscalNineMonths EndedOctober2, 2022 andOctober3, 2021 |  |  | 4\n |  |  | \nConsolidated Statements of Equity for the FiscalThirdQuarters and FiscalNineMonths EndedOctober2, 2022 andOctober3, 2021 |  |  | 5\n |  |  | \nConsolidated Statements of Cash Flows for the FiscalNineMonths EndedOctober2, 2022 andOctober3, 2021 |  |  | 7\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 8\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 47\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 65\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 65\n |  |  | \nPart II \u2014 Other Information |  |  | 65\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 65\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 66\n |  |  | \nItem\u00a06 - Exhibits |  |  | 67\n |  |  | \nSignatures |  |  | 68\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | October 2, 2022 |  | January 2, 2022\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 11,355 |  |  | 14,487 | \nMarketable securities |  | 22,724 |  |  | 17,121 | \nAccounts receivable, trade, less allowances $201(2021, $230) |  | 15,890 |  |  | 15,283 | \nInventories (Note 2) |  | 11,675 |  |  | 10,387 | \nPrepaid expenses and other |  | 3,592 |  |  | 3,701 | \n |  |  |  | \nTotal current assets |  | 65,236 |  |  | 60,979 | \nProperty, plant and equipment at cost |  | 46,681 |  |  | 47,679 | \nLess: accumulated depreciation |  | (28,529) |  |  | (28,717) | \nProperty, plant and equipment, net |  | 18,152 |  |  | 18,962 | \nIntangible assets, net (Note 3) |  | 40,336 |  |  | 46,392 | \nGoodwill (Note 3) |  | 33,383 |  |  | 35,246 | \nDeferred taxes on income (Note 5) |  | 9,392 |  |  | 10,223 | \nOther assets |  | 8,625 |  |  | 10,216 | \nTotal assets |  | $ | 175,124 |  |  | 182,018 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 4,424 |  |  | 3,766 | \nAccounts payable |  | 10,153 |  |  | 11,055 | \nAccrued liabilities |  | 11,953 |  |  | 13,612 | \nAccrued rebates, returns and promotions |  | 14,021 |  |  | 12,095 | \nAccrued compensation and employee related obligations |  | 3,006 |  |  | 3,586 | \nAccrued taxes on income (Note 5) |  | 1,986 |  |  | 1,112 | \nTotal current liabilities |  | 45,543 |  |  | 45,226 | \nLong-term debt (Note 4) |  | 27,603 |  |  | 29,985 | \nDeferred taxes on income (Note 5) |  | 4,946 |  |  | 7,487 | \nEmployee related obligations (Note 6) |  | 8,353 |  |  | 8,898 | \nLong-term taxes payable (Note 5) |  | 4,162 |  |  | 5,713 | \nOther liabilities |  | 9,918 |  |  | 10,686 | \nTotal liabilities |  | $ | 100,525 |  |  | 107,995 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (15,292) |  |  | (13,058) | \nRetained earnings |  | 127,917 |  |  | 123,060 | \nLess: common stock held in treasury, at cost (502,961,000and490,878,000shares) |  | 41,146 |  |  | 39,099 | \nTotal shareholders\u2019 equity |  | 74,599 |  |  | 74,023 | \nTotal liabilities and shareholders' equity |  | $ | 175,124 |  |  | 182,018 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended\n |  | October 2,2022 |  | Percentto Sales |  | October 3,2021 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 23,791 |  |  | 100.0 | % |  | $ | 23,338 |  |  | 100.0 | %\nCost of products sold |  | 7,807 |  |  | 32.8 |  |  | 7,250 |  |  | 31.1 | \nGross profit |  | 15,984 |  |  | 67.2 |  |  | 16,088 |  |  | 68.9 | \nSelling, marketing and administrative expenses |  | 6,089 |  |  | 25.6 |  |  | 6,000 |  |  | 25.7 | \nResearch and development expense |  | 3,597 |  |  | 15.1 |  |  | 3,422 |  |  | 14.7 | \nIn-process research and development |  | \u2014 |  |  | \u2014 |  |  | 900 |  |  | 3.9 | \nInterest income |  | (150) |  |  | (0.6) |  |  | (13) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 51 |  |  | 0.2 |  |  | 20 |  |  | 0.1 | \nOther (income) expense, net |  | 493 |  |  | 2.1 |  |  | 1,850 |  |  | 7.9 | \nRestructuring (Note 12) |  | 82 |  |  | 0.3 |  |  | 60 |  |  | 0.2 | \nEarnings before provision for taxes on income |  | 5,822 |  |  | 24.5 |  |  | 3,849 |  |  | 16.5 | \nProvision for taxes on income (Note 5) |  | 1,364 |  |  | 5.8 |  |  | 182 |  |  | 0.8 | \nNET EARNINGS |  | $ | 4,458 |  |  | 18.7 | % |  | $ | 3,667 |  |  | 15.7 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.70 |  |  |  |  | $ | 1.39 |  |  | \nDiluted |  | $ | 1.68 |  |  |  |  | $ | 1.37 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,627.9 |  |  |  |  | 2,632.6 |  |  | \nDiluted |  | 2,661.3 |  |  |  |  | 2,674.9 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 2,2022 |  | Percentto Sales |  | October 3,2021 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 71,237 |  |  | 100.0 | % |  | $ | 68,971 |  |  | 100.0 | %\nCost of products sold |  | 23,324 |  |  | 32.7 |  |  | 21,900 |  |  | 31.8 | \nGross profit |  | 47,913 |  |  | 67.3 |  |  | 47,071 |  |  | 68.2 | \nSelling, marketing and administrative expenses |  | 18,253 |  |  | 25.7 |  |  | 17,505 |  |  | 25.4 | \nResearch and development expense |  | 10,762 |  |  | 15.1 |  |  | 9,994 |  |  | 14.5 | \nIn-process research and development |  | 610 |  |  | 0.9 |  |  | 900 |  | 1.3\nInterest income |  | (236) |  |  | (0.3) |  |  | (40) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 99 |  |  | 0.1 |  |  | 123 |  |  | 0.2 | \nOther (income) expense, net |  | 664 |  |  | 0.9 |  |  | 480 |  |  | 0.7 | \nRestructuring (Note 12) |  | 237 |  |  | 0.3 |  |  | 169 |  |  | 0.2 | \nEarnings before provision for taxes on income |  | 17,524 |  |  | 24.6 |  |  | 17,940 |  |  | 26.0 | \nProvision for taxes on income (Note 5) |  | 3,103 |  |  | 4.4 |  |  | 1,798 |  |  | 2.6 | \nNET EARNINGS |  | $ | 14,421 |  |  | 20.2 | % |  | $ | 16,142 |  |  | 23.4 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 5.49 |  |  |  |  | $ | 6.13 |  |  | \nDiluted |  | $ | 5.41 |  |  |  |  | $ | 6.04 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,628.9 |  |  |  |  | 2,632.2 |  |  | \nDiluted |  | 2,667.5 |  |  |  |  | 2,674.6 |  |  | \n |  |  |  |  |  |  |  | \nSee Notes to Consolidated Financial Statements  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\n |  |  |  |  |  |  | \nNet earnings | $ | 4,458 |  |  | 3,667 |  |  | $ | 14,421 |  |  | 16,142 | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (1,252) |  |  | (382) |  |  | (1,957) |  |  | (241) | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | (2) |  |  | \u2014 |  |  | (35) |  |  | (1) | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  | \nNet change | (2) |  |  | \u2014 |  |  | (35) |  |  | (1) | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (37) |  |  | (40) |  |  | (110) |  |  | (122) | \nGain (loss) amortization during period | 151 |  |  | 273 |  |  | 454 |  |  | 822 | \n |  |  |  |  |  |  | \nNet change | 114 |  |  | 233 |  |  | 344 |  |  | 700 | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (204) |  |  | 67 |  |  | (254) |  |  | (55) | \nReclassifications to earnings | (105) |  |  | (233) |  |  | (332) |  |  | (576) | \nNet change | (309) |  |  | (166) |  |  | (586) |  |  | (631) | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (1,449) |  |  | (315) |  |  | (2,234) |  |  | (173) | \n |  |  |  |  |  |  | \nComprehensive income | $ | 3,009 |  |  | 3,352 |  |  | $ | 12,187 |  |  | 15,969 | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income for the fiscal third quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $181million and $86million; Employee Benefit Plans: $33million and $65million; Derivatives & Hedges: $82million and $43million.\n\nThe tax effects in other comprehensive income for the fiscal nine months were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $859million and $315million; Securities: $9million in 2022; Employee Benefit Plans: $98million and $197million; Derivatives & Hedges: $155million and $167million.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, July 3, 2022 | $ | 76,357 |  |  | 126,216 |  |  | (13,843) |  |  | 3,120 |  |  | (39,136) | \nNet earnings | 4,458 |  |  | 4,458 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.13per share) | (2,970) |  |  | (2,970) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 368 |  |  | 213 |  |  | \u2014 |  |  | \u2014 |  |  | 155 | \nRepurchase of common stock | (2,165) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,165) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (1,449) |  |  | \u2014 |  |  | (1,449) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 2, 2022 | $ | 74,599 |  |  | 127,917 |  |  | (15,292) |  |  | 3,120 |  |  | (41,146) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \nNet earnings | 14,421 |  |  | 14,421 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($3.32per share) | (8,728) |  |  | (8,728) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 1,832 |  |  | (836) |  |  | \u2014 |  |  | \u2014 |  |  | 2,668 | \nRepurchase of common stock | (4,715) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,715) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (2,234) |  |  | \u2014 |  |  | (2,234) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 2, 2022 | $ | 74,599 |  |  | 127,917 |  |  | (15,292) |  |  | 3,120 |  |  | (41,146) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, July 4, 2021 | $ | 69,580 |  |  | 120,154 |  |  | (15,100) |  |  | 3,120 |  |  | (38,594) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 3,667 |  |  | 3,667 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.06per share) | (2,791) |  |  | (2,791) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 522 |  |  | 62 |  |  | \u2014 |  |  | \u2014 |  |  | 460 | \nRepurchase of common stock | (391) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (391) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (315) |  |  | \u2014 |  |  | (315) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 3, 2021 | $ | 70,272 |  |  | 121,092 |  |  | (15,415) |  |  | 3,120 |  |  | (38,525) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 3, 2021 | $ | 63,278 |  |  | 113,890 |  |  | (15,242) |  |  | 3,120 |  |  | (38,490) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 16,142 |  |  | 16,142 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($3.13per share) | (8,241) |  |  | (8,241) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 1,726 |  |  | (699) |  |  | \u2014 |  |  | \u2014 |  |  | 2,425 | \nRepurchase of common stock | (2,460) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,460) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (173) |  |  | \u2014 |  |  | (173) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 3, 2021 | $ | 70,272 |  |  | 121,092 |  |  | (15,415) |  |  | 3,120 |  |  | (38,525) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 2,2022 |  | October 3,2021\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 14,421 |  |  | 16,142 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 5,198 |  |  | 5,547 | \nStock based compensation |  | 925 |  |  | 920 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 787 |  |  | 964 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (213) |  |  | (601) | \n |  |  |  | \nDeferred tax provision |  | (2,488) |  |  | (2,564) | \nCredit losses and accounts receivable allowances |  | (14) |  |  | (60) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (1,591) |  |  | (1,818) | \nIncrease in inventories |  | (1,877) |  |  | (1,178) | \nIncrease in accounts payable and accrued liabilities |  | 141 |  |  | 182 | \nDecrease in other current and non-current assets |  | 4,563 |  |  | 2,082 | \nDecrease in other current and non-current liabilities |  | (4,008) |  |  | (1,938) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 15,844 |  |  | 17,678 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (2,422) |  |  | (2,237) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 322 |  |  | 666 | \nAcquisitions, net of cash acquired (Note 10) |  | (522) |  |  | \u2014 | \nPurchases of investments |  | (31,163) |  |  | (18,843) | \nSales of investments |  | 26,324 |  |  | 16,809 | \nCredit support agreements activity, net |  | (305) |  |  | 696 | \nOther (primarily licenses and milestones) |  | (208) |  |  | (414) | \n |  |  |  | \nNET CASH USED BY INVESTING ACTIVITIES |  | (7,974) |  |  | (3,323) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (8,728) |  |  | (8,241) | \nRepurchase of common stock |  | (4,715) |  |  | (2,460) | \nProceeds from short-term debt |  | 7,099 |  |  | 1,283 | \nRepayment of short-term debt |  | (4,808) |  |  | (821) | \nProceeds from long-term debt, net of issuance costs |  | 1 |  |  | 3 | \nRepayment of long-term debt |  | (2,133) |  |  | (1,452) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 907 |  |  | 808 | \nCredit support agreements activity, net |  | 1,678 |  |  | 168 | \nOther |  | 128 |  |  | 101 | \n |  |  |  | \nNET CASH USED BY FINANCING ACTIVITIES |  | (10,571) |  |  | (10,611) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | (431) |  |  | (125) | \n(Decrease)/Increase in cash and cash equivalents |  | (3,132) |  |  | 3,619 | \nCash and Cash equivalents, beginning of period |  | 14,487 |  |  | 13,985 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 11,355 |  |  | 17,604 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | 620 |  |  | \u2014 | \nFair value of liabilities assumed and noncontrolling interests |  | (98) |  |  | \u2014 | \nNet cash paid for acquisitions |  | $ | 522 |  |  | \u2014 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | January 2, 2022\nRaw materials and supplies |  | $ | 1,730 |  |  | 1,592 | \nGoods in process |  | 2,106 |  |  | 2,287 | \nFinished goods |  | 7,839 |  |  | 6,508 | \nTotal inventories |  | $ | 11,675 |  |  | 10,387 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | January 2, 2022\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross(1) |  | $ | 35,132 |  |  | 38,572 | \nLess accumulated amortization |  | (20,116) |  |  | (20,088) | \nPatents and trademarks \u2014 net |  | 15,016 |  |  | 18,484 | \nCustomer relationships and other intangibles \u2014 gross |  | 22,302 |  |  | 23,011 | \nLess accumulated amortization |  | (12,406) |  |  | (11,925) | \nCustomer relationships and other intangibles\u00a0\u2014 net(2) |  | 9,896 |  |  | 11,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,648 |  |  | 6,985 | \nPurchased in-process research and development(3) |  | 8,776 |  |  | 9,837 | \nTotal intangible assets with indefinite lives |  | 15,424 |  |  | 16,822 | \nTotal intangible assets \u2014 net |  | $ | 40,336 |  |  | 46,392 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January 2, 2022 |  | $ | 9,810 |  |  | 10,580 |  |  | 14,856 |  |  | 35,246 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | 195 |  |  | 195 | \n |  |  |  |  |  |  |  | \nCurrency translation/Other |  | (1,037) |  |  | (920) |  |  | (101) |  |  | (2,058) | \nGoodwill at October 2, 2022 |  | $ | 8,773 |  |  | 9,660 |  |  | 14,950 |  |  | 33,383 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2022 |  | 2023 |  | 2024 |  | 2025 |  | 2026\n$4,300 |  | 4,300 |  | 4,100 |  | 3,400 |  | 2,800  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | October 2, 2022 | October 3, 2021\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (322) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (62) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 322 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 62 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 13 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 34 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 13 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 34 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (20) |  | (83) |  | 53 |  | \u2014 |  | 22 |  | (3) |  | 58 |  | 8 |  | \u2014 |  | 19 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (45) |  | (94) |  | 91 |  | \u2014 |  | 36 |  | (35) |  | (155) |  | 37 |  | \u2014 |  | 42 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 |  | \u2014 |  |  | \u2014 |  | 117 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (205) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 144 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | October 2, 2022 | October 3, 2021\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (1,094) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (56) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 1,094 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 56 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 115 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 115 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (54) |  | (141) |  | 118 |  | \u2014 |  | (35) |  | 25 |  | 106 |  | (1) |  | \u2014 |  | 24 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (48) |  | (153) |  | 193 |  | \u2014 |  | (75) |  | (41) |  | (398) |  | 80 |  | \u2014 |  | 67 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 342 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 307 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (273) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 122 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | October 2, 2022 |  | January 2, 2022 |  | October 2, 2022 |  | January 2, 2022\n |  |  |  |  |  |  |  | \nLong-term Debt |  | $ | 8,668 |  |  | 9,793 |  |  | (1,430) |  |  | (142) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative | Gain/(Loss)Recognized InIncome on Derivative | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal Third Quarter Ended | Fiscal Nine Months Ended | \nDerivatives Not Designated as Hedging Instruments |  |  |  | October 2, 2022 |  | October 3, 2021 | October 2, 2022 |  | October 3, 2021 | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | 109 |  |  | (13) |  | 211 |  |  | (50) |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  |  |  | October 2, 2022 |  | October 3, 2021\nDebt |  | $ | 208 |  |  | 115 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 261 |  |  | 141 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulated OCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  |  |  | October 2, 2022 |  | October 3, 2021\nDebt |  | $ | 478 |  |  | 279 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 1,134 |  |  | 432 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 2, 2022 |  |  |  |  |  | October 2, 2022 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 1,884 |  |  | (607) |  |  | (755) |  |  | 522 |  |  | 522 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 500 |  |  | (29) |  |  | 60 |  |  | 531 |  |  | 531 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | October 2, 2022 |  |  |  | January 2, 2022\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 1,942 |  |  | \u2014 |  |  | 1,942 |  |  | 540 | \nInterest rate contracts(2) |  | \u2014 |  |  | 2,533 |  |  | \u2014 |  |  | 2,533 |  |  | 796 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 4,475 |  |  | \u2014 |  |  | 4,475 |  |  | 1,336 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 1,881 |  |  | \u2014 |  |  | 1,881 |  |  | 881 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,884 |  |  | \u2014 |  |  | 1,884 |  |  | 979 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 3,765 |  |  | \u2014 |  |  | 3,765 |  |  | 1,860 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 178 |  |  | \u2014 |  |  | 178 |  |  | 24 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 68 |  |  | \u2014 |  |  | 68 |  |  | 28 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 522 |  |  | \u2014 |  |  | \u2014 |  |  | 522 |  |  | 1,884 | \nDebt securities(4) |  | \u2014 |  |  | 22,124 |  |  | \u2014 |  |  | 22,124 |  |  | 19,727 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 525 |  |  | 525 |  |  | 533 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | October 2, 2022 |  | January 2, 2022\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 4,653 |  |  | 1,360 | \nCredit Support Agreement (CSA) |  | (4,440) |  |  | (1,285) | \nTotal Net Asset |  | 213 |  |  | 75 | \n |  |  |  | \nTotal Gross Liabilities |  | 3,833 |  |  | 1,888 | \nCredit Support Agreement (CSA) |  | (3,636) |  |  | (1,855) | \nTotal Net Liabilities |  | $ | 197 |  |  | 33 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | October 2, 2022 |  | October 3, 2021\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 533 |  |  | $ | 633 | \nChanges in estimated fair value(6) |  | (85) |  |  | 28 | \nAdditions |  | 89 |  |  | \u2014 | \nPayments |  | (12) |  |  | (48) | \nEnding Balance |  | $ | 525 |  |  | $ | 613 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/( Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 4,037 |  |  |  |  | \u2014 |  |  | 4,037 |  |  | 4,037 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities(1) | 389 |  |  |  |  |  |  | 389 |  |  | 89 |  |  | 300 | \nU.S. reverse repurchase agreements | 2,541 |  |  |  |  | \u2014 |  |  | 2,541 |  |  | 2,541 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 2,544 |  |  |  |  | (5) |  |  | 2,539 |  |  |  |  | 2,544 | \nMoney market funds | 1,516 |  |  |  |  | \u2014 |  |  | 1,516 |  |  | 1,516 |  |  | \u2014 | \nTime deposits(1) | 928 |  |  |  |  | \u2014 |  |  | 928 |  |  | 928 |  |  | \u2014 | \nSubtotal | 11,955 |  |  |  |  | (5) |  |  | 11,950 |  |  | 9,111 |  |  | 2,844 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov't securities | 21,930 |  |  |  |  | (48) |  |  | 21,882 |  |  | 2,189 |  |  | 19,693 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities | 243 |  |  |  |  | (1) |  |  | 242 |  |  | 55 |  |  | 187 | \nSubtotal available for sale debt(2) | $ | 22,173 |  |  |  |  | (49) |  |  | 22,124 |  |  | 2,244 |  |  | 19,880 | \nTotal cash, cash equivalents and current marketable securities | $ | 34,128 |  |  |  |  | (54) |  |  | 34,074 |  |  | 11,355 |  |  | 22,724 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 22,153 |  |  | 22,104 | \nDue after one year through five years |  | 20 |  |  | 20 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 22,173 |  |  | 22,124 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 4,424 |  |  | 4,422 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n6.73% Debentures due 2023 |  | 250 |  |  | 256 | \n3.375% Notes due 2023 |  | 802 |  |  | 797 | \n |  |  |  | \n0.650% Notes due 2024 (750MM Euro0.9712) |  | 722 |  |  | 702 | \n5.50% Notes due 2024 (500MM GBP1.0908) |  | 544 |  |  | 548 | \n2.625% Notes due 2025 |  | 749 |  |  | 721 | \n0.550% Notes due 2025 |  | 922 |  |  | 826 | \n |  |  |  | \n2.45% Notes due 2026 |  | 1,996 |  |  | 1,868 | \n2.95% Notes due 2027 |  | 877 |  |  | 829 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,396 |  |  | 1,185 | \n2.90%\u00a0Notes due 2028 |  | 1,496 |  |  | 1,379 | \n1.150% Notes due 2028 (750MM Euro0.9712) |  | 724 |  |  | 649 | \n6.95% Notes due 2029 |  | 298 |  |  | 342 | \n1.30% Notes due 2030 |  | 1,606 |  |  | 1,276 | \n4.95% Debentures due 2033 |  | 498 |  |  | 507 | \n4.375% Notes due 2033 |  | 855 |  |  | 820 | \n1.650% Notes due 2035 (1.5B Euro0.9712) |  | 1,450 |  |  | 1,181 | \n3.55% Notes due 2036 |  | 841 |  |  | 726 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,074 | \n3.625% Notes due 2037 |  | 1,334 |  |  | 1,154 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 822 | \n5.85% Debentures due 2038 |  | 697 |  |  | 747 | \n4.50% Debentures due 2040 |  | 540 |  |  | 506 | \n2.10% Notes due 2040 |  | 827 |  |  | 551 | \n4.85% Notes due 2041 |  | 297 |  |  | 291 | \n4.50% Notes due 2043 |  | 496 |  |  | 457 | \n3.70% Notes due 2046 |  | 1,976 |  |  | 1,626 | \n3.75% Notes due 2047 |  | 811 |  |  | 668 | \n3.50% Notes due 2048 |  | 743 |  |  | 593 | \n2.25% Notes due 2050 |  | 809 |  |  | 500 | \n2.45% Notes due 2060 |  | 1,054 |  |  | 619 | \nOther |  | 8 |  |  | 12 | \nTotal Non-Current Debt |  | $ | 27,603 |  |  | 24,232 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n |  | Retirement Plans |  | Other Benefit Plans |  | Retirement Plans |  | Other Benefit Plans\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\nService cost |  | $ | 313 |  |  | 339 |  |  | 80 |  |  | 78 |  |  | 953 |  |  | 1,019 |  |  | 240 |  |  | 232 | \nInterest cost |  | 226 |  |  | 192 |  |  | 26 |  |  | 20 |  |  | 685 |  |  | 578 |  |  | 79 |  |  | 61 | \nExpected return on plan assets |  | (683) |  |  | (661) |  |  | (2) |  |  | (1) |  |  | (2,075) |  |  | (1,988) |  |  | (6) |  |  | (5) | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (46) |  |  | (1) |  |  | (8) |  |  | (138) |  |  | (136) |  |  | (4) |  |  | (23) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial losses |  | 163 |  |  | 314 |  |  | 30 |  |  | 38 |  |  | 492 |  |  | 944 |  |  | 91 |  |  | 113 | \nCurtailments and settlements |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  | \u2014 |  |  | \u2014 | \nNet periodic benefit cost/(credit) |  | $ | (27) |  |  | 138 |  |  | 133 |  |  | 127 |  |  | (82) |  |  | 418 |  |  | 400 |  |  | 378 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 2, 2022 |  | $ | (10,017) |  |  | (3) |  |  | (2,702) |  |  | (336) |  |  | (13,058) | \nNet change |  | (1,957) |  |  | (35) |  |  | 344 |  |  | (586) |  |  | (2,234) | \n |  |  |  |  |  |  |  |  |  | \nOctober 2, 2022 |  | $ | (11,974) |  |  | (38) |  |  | (2,358) |  |  | (922) |  |  | (15,292) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Shares in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\nBasic net earnings per share |  | $ | 1.70 |  |  | 1.39 |  |  | 5.49 |  |  | 6.13 | \nAverage shares outstanding \u2014 basic |  | 2,627.9 |  |  | 2,632.6 |  |  | 2,628.9 |  |  | 2,632.2 | \nPotential shares exercisable under stock option plans |  | 140.1 |  |  | 138.3 |  |  | 141.1 |  |  | 139.1 | \nLess: shares which could be repurchased under treasury stock method |  | (106.7) |  |  | (96.0) |  |  | (102.5) |  |  | (96.7) | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,661.3 |  |  | 2,674.9 |  |  | 2,667.5 |  |  | 2,674.6 | \nDiluted net earnings per share |  | $ | 1.68 |  |  | 1.37 |  |  | 5.41 |  |  | 6.04 |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 2,2022 |  | October 3,2021 |  | PercentChange |  | October 2,2022 |  | October 3,2021 |  | Percent Change\n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH(1) |  |  |  |  |  |  |  |  |  |  |  | \nOTC |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 695 |  |  | 686 |  |  | 1.4 | % |  | $ | 2,028 |  |  | 1,960 |  |  | 3.5 | %\nInternational |  | 825 |  |  | 798 |  |  | 3.4 |  |  | 2,434 |  |  | 2,223 |  |  | 9.5 | \nWorldwide |  | 1,519 |  |  | 1,484 |  |  | 2.5 |  |  | 4,462 |  |  | 4,183 |  |  | 6.7 | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 591 |  |  | 569 |  |  | 3.7 |  |  | 1,764 |  |  | 1,862 |  |  | (5.3) | \nInternational |  | 535 |  |  | 555 |  |  | (3.6) |  |  | 1,500 |  |  | 1,595 |  |  | (6.0) | \nWorldwide |  | 1,126 |  |  | 1,124 |  |  | 0.1 |  |  | 3,264 |  |  | 3,457 |  |  | (5.6) | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 158 |  |  | 150 |  |  | 5.2 |  |  | 471 |  |  | 478 |  |  | (1.5) | \nInternational |  | 217 |  |  | 248 |  |  | (12.4) |  |  | 664 |  |  | 762 |  |  | (12.8) | \nWorldwide |  | 375 |  |  | 398 |  |  | (5.8) |  |  | 1,135 |  |  | 1,240 |  |  | (8.5) | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 91 |  |  | 95 |  |  | (4.0) |  |  | 264 |  |  | 288 |  |  | (8.2) | \nInternational |  | 283 |  |  | 296 |  |  | (4.5) |  |  | 840 |  |  | 879 |  |  | (4.4) | \nWorldwide |  | 375 |  |  | 391 |  |  | (4.3) |  |  | 1,105 |  |  | 1,167 |  |  | (5.4) | \nWomen's Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2 |  |  | 3 |  |  | (22.0) |  |  | 9 |  |  | 9 |  |  | (2.8) | \nInternational |  | 222 |  |  | 229 |  |  | (2.7) |  |  | 674 |  |  | 675 |  |  | (0.1) | \nWorldwide |  | 225 |  |  | 232 |  |  | (3.0) |  |  | 684 |  |  | 684 |  |  | (0.1) | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 122 |  |  | 122 |  |  | (0.2) |  |  | 366 |  |  | 390 |  |  | (6.0) | \nInternational |  | 53 |  |  | 61 |  |  | (11.4) |  |  | 170 |  |  | 186 |  |  | (8.2) | \nWorldwide |  | 176 |  |  | 182 |  |  | (3.9) |  |  | 537 |  |  | 575 |  |  | (6.7) | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,659 |  |  | 1,625 |  |  | 2.1 |  |  | 4,903 |  |  | 4,987 |  |  | (1.7) | \nInternational |  | 2,136 |  |  | 2,187 |  |  | (2.3) |  |  | 6,283 |  |  | 6,320 |  |  | (0.6) | \nWorldwide |  | 3,795 |  |  | 3,812 |  |  | (0.4) |  |  | 11,186 |  |  | 11,307 |  |  | (1.1) | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL(1) |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,876 |  |  | 2,771 |  |  | 3.8 |  |  | 8,230 |  |  | 7,932 |  |  | 3.8 | \nInternational |  | 1,411 |  |  | 1,480 |  |  | (4.7) |  |  | 4,587 |  |  | 4,464 |  |  | 2.8 | \nWorldwide |  | 4,287 |  |  | 4,250 |  |  | 0.9 |  |  | 12,817 |  |  | 12,395 |  |  | 3.4 | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 350 |  |  | 480 |  |  | (27.0) |  |  | 1,099 |  |  | 1,508 |  |  | (27.1) | \nU.S. Exports |  | 39 |  |  | 47 |  |  | (16.9) |  |  | 163 |  |  | 197 |  |  | (17.2) | \nInternational |  | 169 |  |  | 234 |  |  | (27.8) |  |  | 606 |  |  | 721 |  |  | (16.0) | \nWorldwide |  | 558 |  |  | 761 |  |  | (26.6) |  |  | 1,868 |  |  | 2,426 |  |  | (23.0) | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 298 |  |  | 295 |  |  | 0.9 |  |  | 886 |  |  | 840 |  |  | 5.4 | \nInternational |  | 248 |  |  | 276 |  |  | (10.4) |  |  | 797 |  |  | 877 |  |  | (9.2) | \nWorldwide |  | 545 |  |  | 571 |  |  | (4.6) |  |  | 1,682 |  |  | 1,717 |  |  | (2.0) | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,655 |  |  | 1,569 |  |  | 5.5 |  |  | 4,766 |  |  | 4,396 |  |  | 8.4 | \nInternational |  | 794 |  |  | 809 |  |  | (1.9) |  |  | 2,571 |  |  | 2,404 |  |  | 6.9 | \nWorldwide |  | 2,449 |  |  | 2,378 |  |  | 3.0 |  |  | 7,336 |  |  | 6,800 |  |  | 7.9 | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 530 |  |  | 376 |  |  | 40.7 |  |  | 1,303 |  |  | 975 |  |  | 33.6 | \nInternational |  | 200 |  |  | 161 |  |  | 24.6 |  |  | 613 |  |  | 459 |  |  | 33.7 | \nWorldwide |  | 729 |  |  | 537 |  |  | 35.9 |  |  | 1,916 |  |  | 1,434 |  |  | 33.6 | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 5 |  |  | 3 |  |  | * |  | 14 |  |  | 15 |  |  | (3.5) | \nInternational |  | 0 |  | 0 |  | * |  | 0 |  | 3 |  |  | *\nWorldwide |  | 5 |  |  | 3 |  |  | * |  | 14 |  |  | 18 |  |  | (19.3) | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 390 |  |  | 679 |  |  | (42.7) |  |  | 1,266 |  |  | 1,635 |  |  | (22.6) | \nInternational |  | 905 |  |  | 698 |  |  | 29.7 |  |  | 2,642 |  |  | 1,758 |  |  | 50.3 | \nWorldwide |  | 1,295 |  |  | 1,378 |  |  | (6.0) |  |  | 3,908 |  |  | 3,394 |  |  | 15.2 | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 0 |  | 270 |  |  | * |  | 120 |  |  | 421 |  |  | (71.5) | \nInternational |  | 489 |  |  | 233 |  |  | * |  | 1,370 |  |  | 346 |  |  | *\nWorldwide |  | 489 |  |  | 502 |  |  | (2.7) |  | 1,490 |  |  | 766 |  |  | *\nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 12 |  |  | (27.1) |  |  | 27 |  |  | 31 |  |  | (14.5) | \nInternational |  | 237 |  |  | 247 |  |  | (4.2) |  |  | 691 |  |  | 733 |  |  | (5.7) | \nWorldwide |  | 245 |  |  | 259 |  |  | (5.2) |  |  | 718 |  |  | 764 |  |  | (6.1) | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 372 |  |  | 380 |  |  | (2.2) |  |  | 1,096 |  |  | 1,128 |  |  | (2.9) | \nInternational |  | 112 |  |  | 137 |  |  | (17.9) |  |  | 354 |  |  | 440 |  |  | (19.5) | \nWorldwide |  | 485 |  |  | 517 |  |  | (6.4) |  |  | 1,450 |  |  | 1,568 |  |  | (7.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 10 |  |  | 18 |  |  | (46.4) |  |  | 24 |  |  | 55 |  |  | (57.2) | \nInternational |  | 68 |  |  | 82 |  |  | (17.1) |  |  | 228 |  |  | 240 |  |  | (5.0) | \nWorldwide |  | 77 |  |  | 99 |  |  | (22.4) |  |  | 251 |  |  | 295 |  |  | (14.8) | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 919 |  |  | 835 |  |  | 10.0 |  |  | 2,658 |  |  | 2,448 |  |  | 8.6 | \nInternational |  | 763 |  |  | 845 |  |  | (9.9) |  |  | 2,498 |  |  | 2,751 |  |  | (9.2) | \nWorldwide |  | 1,681 |  |  | 1,680 |  |  | 0.0 |  | 5,156 |  |  | 5,199 |  |  | (0.8) | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 41 |  |  | 35 |  |  | 19.3 |  |  | 114 |  |  | 117 |  |  | (2.2) | \nInternational |  | 117 |  |  | 122 |  |  | (4.4) |  |  | 362 |  |  | 372 |  |  | (2.6) | \nWorldwide |  | 158 |  |  | 157 |  |  | 0.8 |  |  | 476 |  |  | 489 |  |  | (2.5) | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 684 |  |  | 648 |  |  | 5.3 |  |  | 2,036 |  |  | 1,882 |  |  | 8.1 | \nInternational |  | 348 |  |  | 355 |  |  | (2.3) |  |  | 1,097 |  |  | 1,111 |  |  | (1.3) | \nWorldwide |  | 1,031 |  |  | 1,004 |  |  | 2.6 |  |  | 3,132 |  |  | 2,994 |  |  | 4.6 | \nRISPERDAL CONSTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 67 |  |  | 71 |  |  | (6.1) |  |  | 195 |  |  | 210 |  |  | (7.1) | \nInternational |  | 52 |  |  | 69 |  |  | (24.2) |  |  | 178 |  |  | 242 |  |  | (26.3) | \nWorldwide |  | 119 |  |  | 140 |  |  | (14.9) |  |  | 373 |  |  | 452 |  |  | (17.4) | \nOTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 127 |  |  | 81 |  |  | 57.2 |  |  | 313 |  |  | 239 |  |  | 31.1 | \nInternational |  | 246 |  |  | 298 |  |  | (17.9) |  |  | 861 |  |  | 1,026 |  |  | (16.2) | \nWorldwide |  | 374 |  |  | 379 |  |  | (1.9) |  |  | 1,174 |  |  | 1,265 |  |  | (7.3) | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,812 |  |  | 1,525 |  |  | 18.8 |  |  | 5,073 |  |  | 4,364 |  |  | 16.2 | \nInternational |  | 2,252 |  |  | 2,140 |  |  | 5.2 |  |  | 6,983 |  |  | 6,406 |  |  | 9.0 | \nWorldwide |  | 4,064 |  |  | 3,665 |  |  | 10.9 |  |  | 12,056 |  |  | 10,770 |  |  | 11.9 | \nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,097 |  |  | 841 |  |  | 30.3 |  |  | 3,071 |  |  | 2,302 |  |  | 33.4 | \nInternational |  | 955 |  |  | 739 |  |  | 29.3 |  |  | 2,823 |  |  | 2,076 |  |  | 36.0 | \nWorldwide |  | 2,052 |  |  | 1,580 |  |  | 29.8 |  |  | 5,894 |  |  | 4,378 |  |  | 34.6 | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 254 |  |  | 214 |  |  | 19.1 |  |  | 693 |  | 578 |  | 20.0 | \nInternational |  | 235 |  |  | 130 |  |  | * |  | 647 |  | 329 |  | *\nWorldwide |  | 490 |  |  | 344 |  |  | 42.2 |  |  | 1,340 |  |  | 907 |  | 47.7 | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 353 |  |  | 413 |  |  | (14.6) |  |  | 1,072 |  |  | 1,311 |  |  | (18.3) | \nInternational |  | 559 |  |  | 654 |  |  | (14.6) |  |  | 1,847 |  |  | 1,996 |  |  | (7.5) | \nWorldwide |  | 911 |  |  | 1,066 |  |  | (14.6) |  |  | 2,918 |  |  | 3,307 |  |  | (11.8) | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 16 |  |  | 25 |  |  | (33.1) |  |  | 54 |  |  | 96 |  |  | (43.4) | \nInternational |  | 440 |  |  | 523 |  |  | (15.9) |  |  | 1,446 |  |  | 1,653 |  |  | (12.5) | \nWorldwide |  | 456 |  |  | 548 |  |  | (16.7) |  |  | 1,500 |  |  | 1,749 |  |  | (14.2) | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 92 |  |  | 32 |  |  | * |  | 183 |  |  | 76 |  |  | *\nInternational |  | 64 |  |  | 94 |  |  | (32.1) |  |  | 220 |  |  | 352 |  |  | (37.5) | \nWorldwide |  | 155 |  |  | 126 |  |  | 23.1 |  |  | 403 |  |  | 428 |  |  | (5.9) | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 604 |  |  | 610 |  |  | (1.1) |  |  | 1,736 |  |  | 1,778 |  |  | (2.4) | \nInternational |  | 247 |  |  | 258 |  |  | (3.8) |  |  | 810 |  |  | 821 |  |  | (1.3) | \nWorldwide |  | 852 |  |  | 868 |  |  | (1.9) |  |  | 2,547 |  |  | 2,599 |  |  | (2.0) | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 289 |  |  | 299 |  |  | (3.4) |  |  | 827 |  |  | 861 |  |  | (4.0) | \nInternational |  | 152 |  |  | 159 |  |  | (4.7) |  |  | 495 |  |  | 510 |  |  | (3.0) | \nWorldwide |  | 441 |  |  | 458 |  |  | (3.9) |  |  | 1,322 |  |  | 1,371 |  |  | (3.6) | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 283 |  |  | 265 |  |  | 6.6 |  |  | 824 |  |  | 792 |  |  | 3.9 | \nInternational |  | 50 |  |  | 44 |  |  | 14.2 |  |  | 162 |  |  | 135 |  |  | 20.4 | \nWorldwide |  | 333 |  |  | 309 |  |  | 7.7 |  |  | 986 |  |  | 927 |  |  | 6.3 | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 33 |  |  | 47 |  |  | (29.5) |  |  | 86 |  |  | 125 |  |  | (31.3) | \nInternational |  | 46 |  |  | 54 |  |  | (15.7) |  |  | 154 |  |  | 176 |  |  | (13.0) | \nWorldwide |  | 78 |  |  | 101 |  |  | (22.1) |  |  | 239 |  |  | 301 |  |  | (20.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 837 |  |  | 800 |  |  | 4.5 |  |  | 2,266 |  |  | 2,379 |  |  | (4.8) | \nInternational |  | 198 |  |  | 241 |  |  | (17.5) |  |  | 651 |  |  | 727 |  |  | (10.4) | \nWorldwide |  | 1,034 |  |  | 1,041 |  |  | (0.6) |  |  | 2,916 |  |  | 3,106 |  |  | (6.1) | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 689 |  |  | 636 |  |  | 8.4 |  |  | 1,806 |  |  | 1,794 |  |  | 0.7 | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nWorldwide |  | 689 |  |  | 636 |  |  | 8.4 |  |  | 1,806 |  |  | 1,794 |  |  | 0.7 | \nINVOKANA / INVOKAMET |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 49 |  |  | 66 |  |  | (25.8) |  |  | 164 |  |  | 249 |  |  | (34.1) | \nInternational |  | 60 |  |  | 67 |  |  | (11.0) |  |  | 193 |  |  | 194 |  |  | (0.6) | \nWorldwide |  | 109 |  |  | 133 |  |  | (18.4) |  |  | 357 |  |  | 443 |  |  | (19.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 98 |  |  | 98 |  |  | (0.1) |  |  | 295 |  |  | 336 |  |  | (12.2) | \nInternational |  | 138 |  |  | 173 |  |  | (20.0) |  |  | 458 |  |  | 533 |  |  | (14.0) | \nWorldwide |  | 236 |  |  | 271 |  |  | (12.8) |  |  | 753 |  |  | 869 |  |  | (13.3) | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 7,438 |  |  | 7,221 |  |  | 3.0 |  |  | 21,229 |  |  | 20,536 |  |  | 3.4 | \nInternational |  | 5,776 |  |  | 5,661 |  |  | 2.0 |  |  | 18,171 |  |  | 16,927 |  |  | 7.3 | \nWorldwide |  | 13,214 |  |  | 12,882 |  |  | 2.6 |  |  | 39,400 |  |  | 37,463 |  |  | 5.2 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH(3) |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 547 |  |  | 444 |  |  | 23.2 |  |  | 1,566 |  |  | 1,353 |  |  | 15.7 | \nInternational |  | 513 |  |  | 513 |  |  | 0.0 |  | 1,636 |  |  | 1,599 |  |  | 2.3 | \nWorldwide |  | 1,060 |  |  | 957 |  |  | 10.8 |  |  | 3,202 |  |  | 2,952 |  |  | 8.5 | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,309 |  |  | 1,249 |  |  | 4.8 |  |  | 3,936 |  |  | 3,821 |  |  | 3.0 | \nInternational |  | 785 |  |  | 843 |  |  | (6.9) |  |  | 2,504 |  |  | 2,611 |  |  | (4.1) | \nWorldwide |  | 2,095 |  |  | 2,093 |  |  | 0.1 |  |  | 6,440 |  |  | 6,433 |  |  | 0.1 | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 228 |  |  | 209 |  |  | 9.1 |  |  | 693 |  |  | 651 |  |  | 6.5 | \nInternational |  | 124 |  |  | 146 |  |  | (15.1) |  |  | 437 |  |  | 451 |  |  | (3.3) | \nWorldwide |  | 352 |  |  | 355 |  |  | (0.9) |  |  | 1,129 |  |  | 1,102 |  |  | 2.5 | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 203 |  |  | 184 |  |  | 9.8 |  |  | 620 |  |  | 579 |  |  | 6.9 | \nInternational |  | 115 |  |  | 131 |  |  | (12.8) |  |  | 386 |  |  | 403 |  |  | (4.4) | \nWorldwide |  | 317 |  |  | 316 |  |  | 0.4 |  |  | 1,005 |  |  | 983 |  |  | 2.3 | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 473 |  |  | 455 |  |  | 3.8 |  |  | 1,412 |  |  | 1,352 |  |  | 4.4 | \nInternational |  | 244 |  |  | 260 |  |  | (6.0) |  |  | 749 |  |  | 805 |  |  | (7.0) | \nWorldwide |  | 717 |  |  | 715 |  |  | 0.2 |  |  | 2,161 |  |  | 2,157 |  |  | 0.2 | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 406 |  |  | 401 |  |  | 1.3 |  |  | 1,211 |  |  | 1,239 |  |  | (2.2) | \nInternational |  | 303 |  |  | 306 |  |  | (1.1) |  |  | 933 |  |  | 952 |  |  | (2.0) | \nWorldwide |  | 708 |  |  | 706 |  |  | 0.3 |  |  | 2,144 |  |  | 2,190 |  |  | (2.1) | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 984 |  |  | 948 |  |  | 3.7 |  |  | 2,897 |  |  | 2,881 |  |  | 0.5 | \nInternational |  | 1,439 |  |  | 1,457 |  |  | (1.2) |  |  | 4,410 |  |  | 4,418 |  |  | (0.2) | \nWorldwide |  | 2,422 |  |  | 2,405 |  |  | 0.7 |  |  | 7,306 |  |  | 7,299 |  |  | 0.1 | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 457 |  |  | 440 |  |  | 3.8 |  |  | 1,328 |  |  | 1,304 |  |  | 1.8 | \nInternational |  | 701 |  |  | 705 |  |  | (0.4) |  |  | 2,132 |  |  | 2,126 |  |  | 0.3 | \nWorldwide |  | 1,158 |  |  | 1,144 |  |  | 1.2 |  |  | 3,460 |  |  | 3,430 |  |  | 0.9 | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 527 |  |  | 508 |  |  | 3.6 |  |  | 1,569 |  |  | 1,577 |  |  | (0.5) | \nInternational |  | 737 |  |  | 752 |  |  | (2.0) |  |  | 2,277 |  |  | 2,292 |  |  | (0.6) | \nWorldwide |  | 1,264 |  |  | 1,261 |  |  | 0.3 |  |  | 3,846 |  |  | 3,869 |  |  | (0.6) | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 517 |  |  | 475 |  |  | 8.8 |  |  | 1,534 |  |  | 1,414 |  |  | 8.5 | \nInternational |  | 689 |  |  | 714 |  |  | (3.5) |  |  | 2,170 |  |  | 2,103 |  |  | 3.2 | \nWorldwide |  | 1,206 |  |  | 1,189 |  |  | 1.4 |  |  | 3,704 |  |  | 3,517 |  |  | 5.3 | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 405 |  |  | 359 |  |  | 12.6 |  |  | 1,179 |  |  | 1,082 |  |  | 9.0 | \nInternational |  | 503 |  |  | 522 |  |  | (3.6) |  |  | 1,533 |  |  | 1,525 |  |  | 0.5 | \nWorldwide |  | 908 |  |  | 882 |  |  | 3.0 |  |  | 2,712 |  |  | 2,607 |  |  | 4.0 | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 112 |  |  | 117 |  |  | (3.2) |  |  | 355 |  |  | 333 |  |  | 6.8 | \nInternational |  | 186 |  |  | 191 |  |  | (3.3) |  |  | 637 |  |  | 577 |  |  | 10.3 | \nWorldwide |  | 298 |  |  | 308 |  |  | (3.2) |  |  | 992 |  |  | 910 |  |  | 9.0 | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,356 |  |  | 3,117 |  |  | 7.7 |  |  | 9,932 |  |  | 9,470 |  |  | 4.9 | \nInternational |  | 3,426 |  |  | 3,527 |  |  | (2.9) |  |  | 10,719 |  |  | 10,731 |  |  | (0.1) | \nWorldwide |  | 6,782 |  |  | 6,644 |  |  | 2.1 |  |  | 20,651 |  |  | 20,201 |  |  | 2.2 | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 12,453 |  |  | 11,963 |  |  | 4.1 |  |  | 36,064 |  |  | 34,993 |  |  | 3.1 | \nInternational |  | 11,338 |  |  | 11,375 |  |  | (0.3) |  |  | 35,173 |  |  | 33,978 |  |  | 3.5 | \nWorldwide |  | $ | 23,791 |  |  | 23,338 |  |  | 1.9 | % |  | $ | 71,237 |  |  | 68,971 |  |  | 3.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended | \n(Dollars in Millions) |  | October 2,2022 |  | October 3,2021 |  | PercentChange |  | October 2,2022 |  | October 3,2021 |  | PercentChange |  |  |  |  | \nConsumer Health(1) |  | $ | 809 |  |  | (577) |  |  | ** |  | $ | 2,279 |  |  | 1,131 |  |  | ** |  |  |  |  | \nPharmaceutical(2) |  | 4,249 |  |  | 4,200 |  |  | 1.2 |  |  | 12,593 |  |  | 13,663 |  |  | (7.8) |  |  |  |  |  | \nMedTech(3) |  | 1,124 |  |  | 423 |  |  | ** |  | 3,742 |  |  | 3,798 |  |  | (1.5) |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 6,182 |  |  | 4,046 |  |  | 52.8 |  |  | 18,614 |  |  | 18,592 |  |  | 0.1 |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 111 |  |  | 197 |  |  |  |  | 471 |  |  | 652 |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 249 |  |  | \u2014 |  |  |  |  | 619 |  |  | \u2014 |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,822 |  |  | 3,849 |  |  | 51.3 | % |  | $ | 17,524 |  |  | 17,940 |  |  | (2.3) | % |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | PercentChange |  | October 2, 2022 |  | October 3, 2021 |  | Percent Change\nUnited States |  | $ | 12,453 |  |  | 11,963 |  |  | 4.1 | % |  | $ | 36,064 |  |  | 34,993 |  |  | 3.1 | %\nEurope |  | 5,524 |  |  | 5,587 |  |  | (1.1) |  |  | 17,633 |  |  | 16,669 |  |  | 5.8 | \nWestern Hemisphere, excluding U.S. |  | 1,562 |  |  | 1,500 |  |  | 4.1 |  |  | 4,580 |  |  | 4,291 |  |  | 6.7 | \nAsia-Pacific, Africa |  | 4,252 |  |  | 4,288 |  |  | (0.9) |  |  | 12,960 |  |  | 13,018 |  |  | (0.4) | \nTotal |  | $ | 23,791 |  |  | 23,338 |  |  | 1.9 | % |  | $ | 71,237 |  |  | 68,971 |  |  | 3.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Severance | Asset Write-offs/Sales |  | Other(2) | Total\nReserve balance, January 2, 2022 | $ | 112 |  | \u2014 |  |  | 25 |  | 137 | \n |  |  |  |  | \nCurrent year activity: |  |  |  |  | \nCharges | \u2014 |  | (4) |  |  | 327 |  | 323 | \nCash settlements | (28) |  | 35 |  | (3) |  | (317) |  | (310) | \nSettled non cash | \u2014 |  | (31) |  |  | \u2014 |  | (31) | \n |  |  |  |  | \n |  |  |  |  | \nReserve balance, October 2, 2022(1) | $ | 84 |  | \u2014 |  |  | 35 |  | 119 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 4,462 |  |  | $ | 4,183 |  |  | 6.7 | % |  | 10.3 | % |  | (3.6) | %\nSkin Health/Beauty |  | 3,264 |  |  | 3,457 |  |  | (5.6) |  |  | (2.2) |  |  | (3.4) | \nOral Care |  | 1,135 |  |  | 1,240 |  |  | (8.5) |  |  | (5.0) |  |  | (3.5) | \nBaby Care |  | 1,105 |  |  | 1,167 |  |  | (5.4) |  |  | (1.5) |  |  | (3.9) | \nWomen\u2019s Health |  | 684 |  |  | 684 |  |  | (0.1) |  |  | 7.8 |  |  | (7.9) | \nWound Care/Other |  | 537 |  |  | 575 |  |  | (6.7) |  |  | (5.8) |  |  | (0.9) | \nTotal Consumer Health Sales |  | $ | 11,186 |  |  | $ | 11,307 |  |  | (1.1) | % |  | 2.6 | % |  | (3.7) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 1,519 |  |  | $ | 1,484 |  |  | 2.5 | % |  | 7.2 | % |  | (4.7) | %\nSkin Health/Beauty |  | 1,126 |  |  | 1,124 |  |  | 0.1 |  |  | 5.0 |  |  | (4.9) | \nOral Care |  | 375 |  |  | 398 |  |  | (5.8) |  |  | (0.7) |  |  | (5.1) | \nBaby Care |  | 375 |  |  | 391 |  |  | (4.3) |  |  | 1.6 |  |  | (5.9) | \nWomen\u2019s Health |  | 225 |  |  | 232 |  |  | (3.0) |  |  | 7.9 |  |  | (10.9) | \nWound Care/Other |  | 176 |  |  | 182 |  |  | (3.9) |  |  | (2.5) |  |  | (1.4) | \nTotal Consumer Health Sales |  | $ | 3,795 |  |  | $ | 3,812 |  |  | (0.4) | % |  | 4.7 | % |  | (5.1) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 12,817 |  |  | $ | 12,395 |  |  | 3.4 | % |  | 7.1 | % |  | (3.7) | %\nREMICADE |  | 1,868 |  |  | 2,426 |  |  | (23.0) |  |  | (21.8) |  |  | (1.2) | \nSIMPONI/ SIMPONI ARIA |  | 1,682 |  |  | 1,717 |  |  | (2.0) |  |  | 2.9 |  |  | (4.9) | \nSTELARA |  | 7,336 |  |  | 6,800 |  |  | 7.9 |  |  | 11.9 |  |  | (4.0) | \nTREMFYA |  | 1,916 |  |  | 1,434 |  |  | 33.6 |  |  | 38.5 |  |  | (4.9) | \nOther Immunology |  | 14 |  |  | 18 |  |  | (19.3) |  |  | (19.3) |  |  | 0.0\nInfectious Diseases |  | 3,908 |  |  | 3,394 |  |  | 15.2 |  |  | 23.9 |  |  | (8.7) | \nCOVID-19 VACCINE |  | 1,490 |  |  | 766 |  |  | * |  | * |  | *\nEDURANT/rilpivirine |  | 718 |  |  | 764 |  |  | (6.1) |  |  | 4.0 |  |  | (10.1) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA |  | 1,450 |  |  | 1,568 |  |  | (7.5) |  |  | (5.2) |  |  | (2.3) | \nOther Infectious Diseases(2) |  | 251 |  |  | 295 |  |  | (14.8) |  |  | (10.6) |  |  | (4.2) | \nNeuroscience |  | 5,156 |  |  | 5,199 |  |  | (0.8) |  |  | 3.7 |  |  | (4.5) | \nCONCERTA/methylphenidate |  | 476 |  |  | 489 |  |  | (2.5) |  |  | 4.4 |  |  | (6.9) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA |  | 3,132 |  |  | 2,994 |  |  | 4.6 |  |  | 8.6 |  |  | (4.0) | \nRISPERDAL CONSTA |  | 373 |  |  | 452 |  |  | (17.4) |  |  | (12.4) |  |  | (5.0) | \nOther Neuroscience(2) |  | 1,174 |  |  | 1,265 |  |  | (7.3) |  |  | (2.4) |  |  | (4.9) | \nOncology |  | 12,056 |  |  | 10,770 |  |  | 11.9 |  |  | 19.0 |  |  | (7.1) | \nDARZALEX |  | 5,894 |  |  | 4,378 |  |  | 34.6 |  |  | 41.6 |  |  | (7.0) | \nERLEADA |  | 1,340 |  |  | 907 |  | 47.7 |  |  | 54.9 |  |  | (7.2) | \nIMBRUVICA |  | 2,918 |  |  | 3,307 |  |  | (11.8) |  |  | (6.1) |  |  | (5.7) | \nZYTIGA/ abiraterone acetate |  | 1,500 |  |  | 1,749 |  |  | (14.2) |  |  | (4.2) |  |  | (10.0) | \nOther Oncology |  | 403 |  |  | 428 |  |  | (5.9) |  |  | (0.8) |  |  | (5.1) | \nPulmonary Hypertension |  | 2,547 |  |  | 2,599 |  |  | (2.0) |  |  | 1.7 |  |  | (3.7) | \nOPSUMIT |  | 1,322 |  |  | 1,371 |  |  | (3.6) |  |  | 0.7 |  |  | (4.3) | \nUPTRAVI |  | 986 |  |  | 927 |  |  | 6.3 |  |  | 8.0 |  |  | (1.7) | \nOther Pulmonary Hypertension |  | 239 |  |  | 301 |  |  | (20.5) |  |  | (13.5) |  |  | (7.0) | \nCardiovascular / Metabolism / Other |  | 2,916 |  |  | 3,106 |  |  | (6.1) |  |  | (4.5) |  |  | (1.6) | \nXARELTO |  | 1,806 |  |  | 1,794 |  |  | 0.7 |  |  | 0.7 |  |  | \u2014 | \nINVOKANA/ INVOKAMET |  | 357 |  |  | 443 |  |  | (19.5) |  |  | (16.6) |  |  | (2.9) | \n |  |  |  |  |  |  |  |  |  | \nOther(1,2) |  | 753 |  |  | 869 |  |  | (13.3) |  |  | (9.2) |  |  | (4.1) | \nTotal Pharmaceutical Sales |  | $ | 39,400 |  |  | $ | 37,463 |  |  | 5.2 | % |  | 10.2 | % |  | (5.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,287 |  |  | $ | 4,250 |  |  | 0.9 | % |  | 5.6 | % |  | (4.7) | %\nREMICADE |  | 558 |  |  | 761 |  |  | (26.6) |  |  | (25.1) |  |  | (1.5) | \nSIMPONI/ SIMPONI ARIA |  | 545 |  |  | 571 |  |  | (4.6) |  |  | 1.9 |  |  | (6.5) | \nSTELARA |  | 2,449 |  |  | 2,378 |  |  | 3.0 |  |  | 8.0 |  |  | (5.0) | \nTREMFYA |  | 729 |  |  | 537 |  |  | 35.9 |  |  | 41.9 |  |  | (6.0) | \nOther Immunology |  | 5 |  |  | 3 |  |  | * |  | * |  | *\nInfectious Diseases |  | 1,295 |  |  | 1,378 |  |  | (6.0) |  |  | 3.8 |  |  | (9.8) | \nCOVID-19 VACCINE |  | 489 |  |  | 502 |  |  | (2.7) |  |  | 13.1 |  |  | (15.8) | \nEDURANT/rilpivirine |  | 245 |  |  | 259 |  |  | (5.2) |  |  | 8.2 |  |  | (13.4) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 485 |  |  | 517 |  |  | (6.4) |  |  | (3.3) |  |  | (3.1) | \nOther Infectious Diseases(2) |  | 77 |  |  | 99 |  |  | (22.4) |  |  | (17.2) |  |  | (5.2) | \nNeuroscience |  | 1,681 |  |  | 1,680 |  |  | 0.0 |  | 5.9 |  |  | (5.9) | \nCONCERTA/ methylphenidate |  | 158 |  |  | 157 |  |  | 0.8 |  |  | 10.5 |  |  | (9.7) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,031 |  |  | 1,004 |  |  | 2.6 |  |  | 7.8 |  |  | (5.2) | \nRISPERDAL CONSTA |  | 119 |  |  | 140 |  |  | (14.9) |  |  | (8.6) |  |  | (6.3) | \nOther Neuroscience(2) |  | 374 |  |  | 379 |  |  | (1.9) |  |  | 4.3 |  |  | (6.2) | \nOncology |  | 4,064 |  |  | 3,665 |  |  | 10.9 |  |  | 20.0 |  |  | (9.1) | \nDARZALEX |  | 2,052 |  |  | 1,580 |  |  | 29.8 |  |  | 38.7 |  |  | (8.9) | \nERLEADA |  | 490 |  |  | 344 |  |  | 42.2 |  |  | 51.2 |  |  | (9.0) | \nIMBRUVICA |  | 911 |  |  | 1,066 |  |  | (14.6) |  |  | (7.2) |  |  | (7.4) | \nZYTIGA/ abiraterone acetate |  | 456 |  |  | 548 |  |  | (16.7) |  |  | (2.6) |  |  | (14.1) | \nOther Oncology |  | 155 |  |  | 126 |  |  | 23.1 |  |  | 30.2 |  |  | (7.1) | \nPulmonary Hypertension |  | 852 |  |  | 868 |  |  | (1.9) |  |  | 3.0 |  |  | (4.9) | \nOPSUMIT |  | 441 |  |  | 458 |  |  | (3.9) |  |  | 1.8 |  |  | (5.7) | \nUPTRAVI |  | 333 |  |  | 309 |  |  | 7.7 |  |  | 9.9 |  |  | (2.2) | \nOther Pulmonary Hypertension |  | 78 |  |  | 101 |  |  | (22.1) |  |  | (12.9) |  |  | (9.2) | \nCardiovascular / Metabolism / Other |  | 1,034 |  |  | 1,041 |  |  | (0.6) |  |  | 1.4 |  |  | (2.0) | \nXARELTO |  | 689 |  |  | 636 |  |  | 8.4 |  |  | 8.4 |  |  | \u2014 | \nINVOKANA/ INVOKAMET |  | 109 |  |  | 133 |  |  | (18.4) |  |  | (14.1) |  |  | (4.3) | \nOther(1,2) |  | 236 |  |  | 271 |  |  | (12.8) |  |  | (7.3) |  |  | (5.5) | \nTotal Pharmaceutical Sales |  | $ | 13,214 |  |  | $ | 12,882 |  |  | 2.6 | % |  | 9.0 | % |  | (6.4) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 7,306 |  |  | $ | 7,299 |  |  | 0.1 | % |  | 4.6 | % |  | (4.5) | %\nAdvanced |  | 3,460 |  |  | 3,430 |  |  | 0.9 |  |  | 5.2 |  |  | (4.3) | \nGeneral |  | 3,846 |  |  | 3,869 |  |  | (0.6) |  |  | 4.1 |  |  | (4.7) | \nOrthopaedics |  | 6,440 |  |  | 6,433 |  |  | 0.1 |  |  | 3.5 |  |  | (3.4) | \nHips |  | 1,129 |  |  | 1,102 |  |  | 2.5 |  |  | 5.7 |  |  | (3.2) | \nKnees |  | 1,005 |  |  | 983 |  |  | 2.3 |  |  | 5.6 |  |  | (3.3) | \nTrauma |  | 2,161 |  |  | 2,157 |  |  | 0.2 |  |  | 3.6 |  |  | (3.4) | \nSpine, Sports & Other |  | 2,144 |  |  | 2,190 |  |  | (2.1) |  |  | 1.4 |  |  | (3.5) | \nVision |  | 3,704 |  |  | 3,517 |  |  | 5.3 |  |  | 11.1 |  |  | (5.8) | \nContact Lenses/Other |  | 2,712 |  |  | 2,607 |  |  | 4.0 |  |  | 10.2 |  |  | (6.2) | \nSurgical |  | 992 |  |  | 910 |  |  | 9.0 |  |  | 13.6 |  |  | (4.6) | \nInterventional Solutions |  | 3,202 |  |  | 2,952 |  |  | 8.5 |  |  | 13.2 |  |  | (4.7) | \nTotal MedTech Sales |  | $ | 20,651 |  |  | $ | 20,201 |  |  | 2.2 | % |  | 6.6 | % |  | (4.4) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,422 |  |  | $ | 2,405 |  |  | 0.7 | % |  | 7.1 | % |  | (6.4) | %\nAdvanced |  | 1,158 |  |  | 1,144 |  |  | 1.2 |  |  | 7.5 |  |  | (6.3) | \nGeneral |  | 1,264 |  |  | 1,261 |  |  | 0.3 |  |  | 6.7 |  |  | (6.4) | \nOrthopaedics |  | 2,095 |  |  | 2,093 |  |  | 0.1 |  |  | 4.7 |  |  | (4.6) | \nHips |  | 352 |  |  | 355 |  |  | (0.9) |  |  | 3.5 |  |  | (4.4) | \nKnees |  | 317 |  |  | 316 |  |  | 0.4 |  |  | 4.9 |  |  | (4.5) | \nTrauma |  | 717 |  |  | 715 |  |  | 0.2 |  |  | 4.8 |  |  | (4.6) | \nSpine, Sports & Other |  | 708 |  |  | 706 |  |  | 0.3 |  |  | 5.2 |  |  | (4.9) | \nVision |  | 1,206 |  |  | 1,189 |  |  | 1.4 |  |  | 8.6 |  |  | (7.2) | \nContact Lenses/Other |  | 908 |  |  | 882 |  |  | 3.0 |  |  | 10.8 |  |  | (7.8) | \nSurgical |  | 298 |  |  | 308 |  |  | (3.2) |  |  | 2.3 |  |  | (5.5) | \nInterventional Solutions |  | 1,060 |  |  | 957 |  |  | 10.8 |  |  | 17.7 |  |  | (6.9) | \n |  |  |  |  |  |  |  |  |  | \nTotal MedTech Sales |  | $ | 6,782 |  |  | $ | 6,644 |  |  | 2.1 | % |  | 8.1 | % |  | (6.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Nine Months |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2022 |  | 2021 |  | Change\nChanges in the fair value of securities |  | $ | 0.7 |  |  | (0.3) |  |  | 1.0 | \nConsumer Health separation costs |  | 0.6 |  |  | 0.0 |  |  | 0.6 | \nLitigation related(1) |  | 0.6 |  |  | 2.1 |  |  | (1.5) | \nCOVID-19 Vaccine related costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nAcquisition, integration and divestiture related(2) |  | 0.0 |  |  | (0.5) |  |  | 0.5 | \nEmployee benefit plan related |  | (0.9) |  |  | (0.5) |  |  | (0.4) | \nOther |  | (0.5) |  |  | (0.3) |  |  | (0.2) | \nTotal Other (Income) Expense, Net |  | $ | 0.7 |  |  | 0.5 |  |  | 0.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Third Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2022 |  | 2021 |  | Change\nLitigation related(1) |  | $ | 0.2 |  |  | 2.1 |  |  | (1.9) | \n |  |  |  |  |  | \nConsumer Health separation costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nChanges in the fair value of securities |  | 0.2 |  |  | (0.1) |  |  | 0.3 | \nCOVID-19 Vaccine related costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nEmployee benefit plan related |  | (0.3) |  |  | (0.2) |  |  | (0.1) | \nOther |  | 0.0 |  |  | 0.1 |  |  | (0.1) | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 0.5 |  |  | 1.9 |  |  | (1.4) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\nConsumer Health(1) |  | $ | 2,279 |  |  | $ | 1,131 |  |  | $ | 11,186 |  |  | $ | 11,307 |  |  | 20.4 | % |  | 10.0 | %\nPharmaceutical(1) |  | 12,593 |  |  | 13,663 |  |  | 39,400 |  |  | 37,463 |  |  | 32.0 |  |  | 36.5 | \nMedTech |  | 3,742 |  |  | 3,798 |  |  | 20,651 |  |  | 20,201 |  |  | 18.1 |  |  | 18.8 | \nSegment earnings before tax |  | 18,614 |  |  | 18,592 |  |  | 71,237 |  |  | 68,971 |  |  | 26.1 |  |  | 27.0 | \nLess: Expenses not allocated to segments(2) |  | 471 |  |  | 652 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 619 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 17,524 |  |  | $ | 17,940 |  |  | $ | 71,237 |  |  | $ | 68,971 |  |  | 24.6 | % |  | 26.0 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021 |  | October 2, 2022 |  | October 3, 2021\nConsumer Health(1) |  | $ | 809 |  |  | $ | (577) |  |  | $ | 3,795 |  |  | $ | 3,812 |  |  | 21.3 | % |  | (15.1) | %\nPharmaceutical(1) |  | 4,249 |  |  | 4,200 |  |  | 13,214 |  |  | 12,882 |  |  | 32.2 |  |  | 32.6 | \nMedTech |  | 1,124 |  |  | 423 |  |  | 6,782 |  |  | 6,644 |  |  | 16.6 |  |  | 6.4 | \nSegment earnings before tax |  | 6,182 |  |  | 4,046 |  |  | 23,791 |  |  | 23,338 |  |  | 26.0 |  |  | 17.3 | \nLess: Expenses not allocated to segments(2) |  | 111 |  |  | 197 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 249 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,822 |  |  | $ | 3,849 |  |  | $ | 23,791 |  |  | $ | 23,338 |  |  | 24.5 | % |  | 16.5 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.5 |  | Q4 2021 Cash and cash equivalents balance\n15.8 |  | cash generated from operating activities\n(8.0) |  | net cash used by investing activities\n(10.6) |  | net cash used by financing activities\n | \n(0.3) |  | effect of exchange rate and rounding\n$ | 11.4 |  | Q3 2022 Cash and cash equivalents balance  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.4 |  | Net Earnings\n4.2 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision, net gain on sale of assets/businesses and credit losses and accounts receivable allowances\n | \n(3.5) |  | an increase in accounts receivable and inventories\n | \n0.1 |  | an increase in accounts payable and accrued liabilities\n4.6 |  | a decrease in other current and non-current assets\n(4.0) |  | a decrease in other current and non-current liabilities\n$ | 15.8 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n$ | (2.4) |  | additions to property, plant and equipment\n0.3 |  | proceeds from the disposal of assets/businesses, net\n(0.5) |  | acquisitions, net of cash acquired and other\n(4.8) |  | net purchases of investments\n(0.3) |  | credit support agreements activity, net\n$ | (0.3) |  | Other and rounding\n | \n$ | (8.0) |  | Net cash used for investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (8.7) |  | dividends to shareholders\n(4.7) |  | repurchase of common stock\n0.2 | net proceeds from short and long term debt\n0.9 |  | proceeds from stock options exercised/employee withholding tax on stock awards, net\n1.7 |  | credit support agreements activity, net\n0.0 | other and rounding\n$ | (10.6) |  | Net cash used for financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs(3)\nJuly 4, 2022 through July 31, 2022 |  |  |  |  |  |  |  | \u2014\nAugust 1, 2022 through August 28, 2022 |  | 660,000 |  |  | 172.83 |  |  |  |  | \u2014\nAugust 29, 2022 through October 2, 2022 |  | 12,382,285 |  |  | 165.58 |  |  | 12,232,285 |  |  | \u2014\nTotal |  | 13,042,285 |  |  | 165.94 |  |  | 12,232,285 |  |  | 18,207,721 |   |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: October 27, 2022 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: October 27, 2022 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2023 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014 April 2, 2023 and January 1, 2023 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the Fiscal First Quarters Ended April 2, 2023 and April 3, 2022 |  |  | 2\n |  |  | \n |  |  | \n |  |  | \nConsolidated Statements of Comprehensive Income for the Fiscal First Quarters Ended April 2, 2023 and April 3, 2022 |  |  | 3\n |  |  | \nConsolidated Statements of Equity for the Fiscal First Quarters Ended April 2, 2023 and April 3, 2022 |  |  | 4\n |  |  | \nConsolidated Statements of Cash Flows for the Fiscal Three Months Ended April 2, 2023 and April 3, 2022 |  |  | 5\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 6\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 38\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 49\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 49\n |  |  | \nPart II \u2014 Other Information |  |  | 50\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 50\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 50\n |  |  | \nItem\u00a06 - Exhibits |  |  | 51\n |  |  | \nSignatures |  |  | 52\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 2, 2023 |  | January 1, 2023\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents (Note 4) |  | $ | 19,170 |  |  | 14,127 | \nRestricted cash (Note 4) |  | 7,695 |  |  | \u2014 | \nMarketable securities |  | 5,443 |  |  | 9,392 | \nAccounts receivable, trade, less allowances $207(2022, $203) |  | 16,350 |  |  | 16,160 | \nInventories (Note 2) |  | 12,809 |  |  | 12,483 | \nPrepaid expenses and other |  | 2,921 |  |  | 3,132 | \n |  |  |  | \nTotal current assets |  | 64,388 |  |  | 55,294 | \nProperty, plant and equipment at cost |  | 50,367 |  |  | 49,253 | \nLess: accumulated depreciation |  | (30,193) |  |  | (29,450) | \nProperty, plant and equipment, net |  | 20,174 |  |  | 19,803 | \nIntangible assets, net (Note 3) |  | 47,448 |  |  | 48,325 | \nGoodwill (Note 3) |  | 45,575 |  |  | 45,231 | \nDeferred taxes on income (Note 5) |  | 8,817 |  |  | 9,123 | \nOther assets |  | 9,567 |  |  | 9,602 | \nTotal assets |  | $ | 195,969 |  |  | 187,378 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 17,979 |  |  | 12,771 | \nAccounts payable |  | 9,909 |  |  | 11,703 | \nAccrued liabilities |  | 11,204 |  |  | 11,456 | \nAccrued rebates, returns and promotions |  | 14,784 |  |  | 14,417 | \nAccrued compensation and employee related obligations |  | 2,231 |  |  | 3,328 | \nAccrued taxes on income (Note 5) |  | 4,266 |  |  | 2,127 | \nTotal current liabilities |  | 60,373 |  |  | 55,802 | \nLong-term debt (Note 4) |  | 34,928 |  |  | 26,888 | \nDeferred taxes on income (Note 5) |  | 4,417 |  |  | 6,374 | \nEmployee related obligations (Note 6) |  | 6,665 |  |  | 6,767 | \nLong-term taxes payable (Note 5) |  | 4,296 |  |  | 4,306 | \nOther liabilities |  | 14,421 |  |  | 10,437 | \nTotal liabilities |  | $ | 125,100 |  |  | 110,574 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (12,626) |  |  | (12,967) | \nRetained earnings and Additional paid-in capital |  | 124,558 |  |  | 128,345 | \nLess: common stock held in treasury, at cost (521,519,000and506,246,000shares) |  | 44,183 |  |  | 41,694 | \nTotal shareholders\u2019 equity |  | 70,869 |  |  | 76,804 | \nTotal liabilities and shareholders\u2019 equity |  | $ | 195,969 |  |  | 187,378 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended\n |  | April 2,2023 |  | Percentto Sales |  | April 3,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 24,746 |  |  | 100.0 | % |  | $ | 23,426 |  |  | 100.0 | %\nCost of products sold |  | 8,395 |  |  | 33.9 |  |  | 7,598 |  |  | 32.4 | \nGross profit |  | 16,351 |  |  | 66.1 |  |  | 15,828 |  |  | 67.6 | \nSelling, marketing and administrative expenses |  | 6,138 |  |  | 24.8 |  |  | 5,938 |  |  | 25.4 | \nResearch and development expense |  | 3,563 |  |  | 14.4 |  |  | 3,462 |  |  | 14.8 | \nIn-process research and development |  | 49 |  |  | 0.2 |  |  | 610 |  |  | 2.6 | \nInterest income |  | (235) |  |  | (1.0) |  |  | (22) |  |  | (0.1) | \nInterest expense, net of portion capitalized |  | 215 |  |  | 0.9 |  |  | 10 |  |  | 0.0 | \nOther (income) expense, net |  | 7,228 |  |  | 29.2 |  |  | (102) |  |  | (0.4) | \nRestructuring |  | 130 |  |  | 0.6 |  |  | 70 |  |  | 0.3 | \nEarnings/(Loss) before provision for taxes on income |  | (737) |  |  | (3.0) |  |  | 5,862 |  |  | 25.0 | \nProvision for/(Benefit from) taxes on income (Note 5) |  | (669) |  |  | (2.7) |  |  | 713 |  |  | 3.0 | \nNET EARNINGS/(LOSS) |  | $ | (68) |  |  | (0.3) | % |  | $ | 5,149 |  |  | 22.0 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS/(LOSS) PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | (0.03) |  |  |  |  | $ | 1.96 |  |  | \nDiluted |  | $ | (0.03) |  |  |  |  | $ | 1.93 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,605.5 |  |  |  |  | 2,629.2 |  |  | \nDiluted |  | 2,605.5 |  |  |  |  | 2,666.5 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal First Quarter Ended |  | \n | April 2, 2023 |  | April 3, 2022 |  |  |  | \n |  |  |  |  |  |  | \nNet earnings/(loss) | $ | (68) |  |  | 5,149 |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (181) |  |  | (554) |  |  |  |  | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | 17 |  |  | (13) |  |  |  |  | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | 17 |  |  | (13) |  |  |  |  | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (35) |  |  | (53) |  |  |  |  | \nGain (loss) amortization during period | (33) |  |  | 217 |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | (68) |  |  | 164 |  |  |  |  | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | 570 |  |  | (195) |  |  |  |  | \nReclassifications to earnings | 3 |  |  | (101) |  |  |  |  | \nNet change | 573 |  |  | (296) |  |  |  |  | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | 341 |  |  | (699) |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 273 |  |  | 4,450 |  |  |  |  | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income/(loss) for the fiscal first quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $234million and $145million; Securities: $5million and $3million; Employee Benefit Plans: $22million and $19million; Derivatives & Hedges: $154million and $78million.\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 1, 2023 | $ | 76,804 |  |  | 128,345 |  |  | (12,967) |  |  | 3,120 |  |  | (41,694) | \nNet earnings/(loss) | (68) |  |  | (68) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.13per share) | (2,942) |  |  | (2,942) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 295 |  |  | (777) |  |  | \u2014 |  |  | \u2014 |  |  | 1,072 | \nRepurchase of common stock | (3,537) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3,537) | \nOther | (24) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (24) | \nOther comprehensive income (loss), net of tax | 341 |  |  | \u2014 |  |  | 341 |  |  | \u2014 |  |  | \u2014 | \nBalance, April 2, 2023 | $ | 70,869 |  |  | 124,558 |  |  | (12,626) |  |  | 3,120 |  |  | (44,183) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 5,149 |  |  | 5,149 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.06per share) | (2,787) |  |  | (2,787) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 600 |  |  | (1,042) |  |  | \u2014 |  |  | \u2014 |  |  | 1,642 | \nRepurchase of common stock | (1,577) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,577) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (699) |  |  | \u2014 |  |  | (699) |  |  | \u2014 |  |  | \u2014 | \nBalance, April 3, 2022 | $ | 74,709 |  |  | 124,380 |  |  | (13,757) |  |  | 3,120 |  |  | (39,034) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Three Months Ended\n |  | April 2,2023 |  | April 3,2022\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet (loss)/earnings |  | $ | (68) |  |  | 5,149 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 1,880 |  |  | 1,769 | \nStock based compensation |  | 306 |  |  | 278 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 426 |  |  | 610 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (8) |  |  | (168) | \n |  |  |  | \nDeferred tax provision |  | (1,543) |  |  | (926) | \nCredit losses and accounts receivable allowances |  | 1 |  |  | 6 | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (54) |  |  | (427) | \nIncrease in inventories |  | (524) |  |  | (600) | \nDecrease in accounts payable and accrued liabilities |  | (2,572) |  |  | (2,817) | \n(Increase)/Decrease in other current and non-current assets |  | (915) |  |  | 995 | \nIncrease in other current and non-current liabilities |  | 6,328 |  |  | 110 | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 3,257 |  |  | 3,979 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (863) |  |  | (607) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 40 |  |  | 248 | \nAcquisitions, net of cash acquired (Note 10) |  | \u2014 |  |  | (252) | \nPurchases of investments |  | (3,774) |  |  | (9,018) | \nSales of investments |  | 7,766 |  |  | 6,303 | \nCredit support agreements activity, net |  | 158 |  |  | (249) | \nOther (primarily licenses and milestones) |  | (12) |  |  | (59) | \n |  |  |  | \nNET CASH FROM/(USED BY) INVESTING ACTIVITIES |  | 3,315 |  |  | (3,634) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (2,942) |  |  | (2,787) | \nRepurchase of common stock |  | (3,537) |  |  | (1,577) | \nProceeds from short-term debt |  | 11,094 |  |  | 3,019 | \nRepayment of short-term debt |  | (5,388) |  |  | (856) | \nProceeds from long-term debt, net of issuance costs (Note 4) |  | 7,674 |  |  | \u2014 | \nRepayment of long-term debt |  | (500) |  |  | (2,132) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | (11) |  |  | 321 | \nCredit support agreements activity, net |  | (13) |  |  | (235) | \nOther |  | (239) |  |  | (138) | \n |  |  |  | \nNET CASH FROM/(USED BY) FINANCING ACTIVITIES |  | 6,138 |  |  | (4,385) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | 28 |  |  | 16 | \nIncrease/(Decrease) in cash, cash equivalents and restricted cash |  | 12,738 |  |  | (4,024) | \nCash and Cash equivalents beginning of period |  | 14,127 |  |  | 14,487 | \nCASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD |  | $ | 26,865 |  |  | 10,463 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | \u2014 |  |  | 255 | \nFair value of liabilities assumed |  | \u2014 |  |  | (3) | \nNet cash paid for acquisitions |  | $ | \u2014 |  |  | 252 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | January 1, 2023\nRaw materials and supplies |  | $ | 2,267 |  |  | 2,070 | \nGoods in process |  | 1,866 |  |  | 1,700 | \nFinished goods |  | 8,676 |  |  | 8,713 | \nTotal inventories |  | $ | 12,809 |  |  | 12,483 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | January 1, 2023\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 44,636 |  |  | 44,012 | \nLess accumulated amortization |  | (23,512) |  |  | (22,266) | \nPatents and trademarks \u2014 net |  | 21,124 |  |  | 21,746 | \nCustomer relationships and other intangibles \u2014 gross |  | 23,008 |  |  | 22,987 | \nLess accumulated amortization |  | (13,211) |  |  | (12,901) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 9,797 |  |  | 10,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,843 |  |  | 6,807 | \nPurchased in-process research and development |  | 9,684 |  |  | 9,686 | \nTotal intangible assets with indefinite lives |  | 16,527 |  |  | 16,493 | \nTotal intangible assets \u2014 net |  | $ | 47,448 |  |  | 48,325 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January\u00a01, 2023 |  | $ | 9,184 |  |  | 10,184 |  |  | 25,863 |  |  | 45,231 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nCurrency translation/Other |  | 49 |  |  | 124 |  |  | 171 |  | * | 344 | \nGoodwill at April\u00a02, 2023 |  | $ | 9,233 |  |  | 10,308 |  |  | 26,034 |  |  | 45,575 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2023 |  | 2024 |  | 2025 |  | 2026 |  | 2027\n$4,800 |  | 4,600 |  | 3,800 |  | 3,200 |  | 2,600  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | April 2, 2023 | April 3, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (929) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (531) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 929 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 531 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 34 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 34 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 45 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | 12 |  | (146) |  | (13) |  | \u2014 |  | 2 |  | (17) |  | (52) |  | 23 |  | \u2014 |  | (18) | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | 24 |  | 145 |  | (36) |  | \u2014 |  | (14) |  | 22 |  | (94) |  | 33 |  | \u2014 |  | (73) | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 108 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | 417 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (128) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | April 2, 2023 |  | January 1, 2023 |  | April 2, 2023 |  | January 1, 2023\n |  |  |  |  |  |  |  | \nLong-term Debt |  | $ | 8,860 |  |  | 8,665 |  |  | (1,214) |  |  | (1,435) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative |  | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal First Quarter Ended |  | \nDerivatives Not Designated as Hedging Instruments |  |  |  | April 2, 2023 |  | April 3, 2022 |  |  |  | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | (31) |  |  | 29 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  |  |  | April 2, 2023 |  | April 3, 2022\nDebt |  | $ | (77) |  |  | 68 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 690 |  |  | 560 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 1, 2023 |  |  |  |  |  | April 2, 2023 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 576 |  |  | (73) |  |  | 2 |  |  | 505 |  |  | 505 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 698 |  |  | (1) |  |  | 27 |  |  | 724 |  |  | 724 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | April 2, 2023 |  |  |  | January 1, 2023\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 661 |  |  | \u2014 |  |  | 661 |  |  | 629 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,399 |  |  | \u2014 |  |  | 1,399 |  |  | 1,534 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,060 |  |  | \u2014 |  |  | 2,060 |  |  | 2,163 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 349 |  |  | \u2014 |  |  | 349 |  |  | 511 | \nInterest rate contracts(2) |  | \u2014 |  |  | 2,553 |  |  | \u2014 |  |  | 2,553 |  |  | 2,778 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,902 |  |  | \u2014 |  |  | 2,902 |  |  | 3,289 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 32 |  |  | \u2014 |  |  | 32 |  |  | 38 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 56 |  |  | \u2014 |  |  | 56 |  |  | 68 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 505 |  |  | \u2014 |  |  | \u2014 |  |  | 505 |  |  | 576 | \nDebt securities(4) |  | \u2014 |  |  | 8,942 |  |  | \u2014 |  |  | 8,942 |  |  | 10,487 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 1,142 |  |  | 1,142 |  |  | 1,120 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | April 2, 2023 |  | January 1, 2023\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 2,092 |  |  | 2,201 | \nCredit Support Agreement (CSA) |  | (2,028) |  |  | (2,176) | \nTotal Net Asset |  | 64 |  |  | 25 | \n |  |  |  | \nTotal Gross Liabilities |  | 2,958 |  |  | 3,357 | \nCredit Support Agreement (CSA) |  | (2,729) |  |  | (3,023) | \nTotal Net Liabilities |  | $ | 229 |  |  | 334 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | April 2, 2023 |  | April 3, 2022\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 1,120 |  |  | 533 | \nChanges in estimated fair value(6) |  | 23 |  |  | (47) | \nAdditions |  | \u2014 |  |  | \u2014 | \nPayments |  | (1) |  |  | \u2014 | \nEnding Balance |  | $ | 1,142 |  |  | 486 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/(Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 4,674 |  |  |  |  | \u2014 |  |  | 4,674 |  |  | 4,674 |  |  | \u2014 | \nRestricted cash(1) | 7,695 |  |  |  |  | \u2014 |  |  | 7,695 |  |  | 7,695 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nU.S. reverse repurchase agreements | 6,286 |  |  |  |  | \u2014 |  |  | 6,286 |  |  | 6,286 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(2) | 672 |  |  |  |  | \u2014 |  |  | 672 |  |  | 300 |  |  | 372 | \nMoney market funds | 3,364 |  |  |  |  | \u2014 |  |  | 3,364 |  |  | 3,364 |  |  | \u2014 | \nTime deposits(2) | 675 |  |  |  |  | \u2014 |  |  | 675 |  |  | 675 |  |  | \u2014 | \nSubtotal | 23,366 |  |  |  |  | \u2014 |  |  | 23,366 |  |  | 22,994 |  |  | 372 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov\u2019t securities | 8,462 |  |  |  |  | (9) |  |  | 8,453 |  |  | 3,804 |  |  | 4,649 | \nU.S. Gov\u2019t Agencies | 185 |  |  |  |  | (3) |  |  | 182 |  |  | \u2014 |  |  | 182 | \nCorporate debt securities | 308 |  |  |  |  | (1) |  |  | 307 |  |  | 67 |  |  | 240 | \nSubtotal available for sale debt(3) | $ | 8,955 |  |  |  |  | (13) |  |  | 8,942 |  |  | 3,871 |  |  | 5,071 | \nTotal cash, cash equivalents, restricted cash and current marketable securities | $ | 32,321 |  |  |  |  | (13) |  |  | 32,308 |  |  | 26,865 |  |  | 5,443 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 8,901 |  |  | 8,889 | \nDue after one year through five years |  | 54 |  |  | 53 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 8,955 |  |  | 8,942 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 17,979 |  |  | 17,982 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n |  |  |  | \n0.650% Notes due 2024 (750MM Euro1.0909) |  | 812 |  |  | 796 | \n5.50% Notes due 2024 (500MM GBP1.2359) |  | 617 |  |  | 626 | \n2.625% Notes due 2025 |  | 749 |  |  | 732 | \n0.55% Notes due 2025 |  | 936 |  |  | 920 | \n |  |  |  | \n2.45% Notes due 2026 |  | 1,997 |  |  | 1,924 | \n2.95% Notes due 2027 |  | 896 |  |  | 968 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,412 |  |  | 1,329 | \n2.90%\u00a0Notes due 2028 |  | 1,496 |  |  | 1,438 | \n1.150% Notes due 2028 (750MM Euro1.0909) |  | 814 |  |  | 737 | \n6.95% Notes due 2029 |  | 298 |  |  | 368 | \n1.30% Notes due 2030 |  | 1,628 |  |  | 1,469 | \n4.95% Debentures due 2033 |  | 498 |  |  | 543 | \n4.375% Notes due 2033 |  | 854 |  |  | 879 | \n1.650% Notes due 2035 (1.5B Euro1.0909) |  | 1,629 |  |  | 1,369 | \n3.55% Notes due 2036 |  | 864 |  |  | 933 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,161 | \n3.625% Notes due 2037 |  | 1,359 |  |  | 1,389 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 896 | \n5.85% Debentures due 2038 |  | 697 |  |  | 806 | \n4.50% Debentures due 2040 |  | 540 |  |  | 551 | \n2.10% Notes due 2040 |  | 852 |  |  | 726 | \n4.85% Notes due 2041 |  | 297 |  |  | 311 | \n4.50% Notes due 2043 |  | 496 |  |  | 501 | \n3.70% Notes due 2046 |  | 1,976 |  |  | 1,785 | \n3.75% Notes due 2047 |  | 837 |  |  | 899 | \n3.50% Notes due 2048 |  | 743 |  |  | 651 | \n2.25% Notes due 2050 |  | 834 |  |  | 667 | \n2.45% Notes due 2060 |  | 1,080 |  |  | 819 | \n5.50% Debentures due 2025* |  | 748 |  |  | 775 | \n5.35% Debentures due 2026* |  | 747 |  |  | 776 | \n5.05% Debentures due 2028* |  | 993 |  |  | 1,038 | \n5.00% Debentures due 2030* |  | 992 |  |  | 1,033 | \n4.90% Debentures due 2033* |  | 1,240 |  |  | 1,271 | \n5.10% Debentures due 2043* |  | 741 |  |  | 774 | \n5.05% Debentures due 2053* |  | 1,476 |  |  | 1,540 | \n5.20% Debentures due 2063* |  | 738 |  |  | 776 | \nOther |  | 57 |  |  | 56 | \nTotal Non-Current Debt |  | $ | 34,928 |  |  | 34,232 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n |  | Retirement Plans |  | Other Benefit Plans |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | April 2, 2023 |  | April 3, 2022 |  |  |  |  |  |  |  | \nService cost |  | $ | 212 |  |  | 321 |  |  | 68 |  |  | 80 |  |  |  |  |  |  |  |  | \nInterest cost |  | 354 |  |  | 230 |  |  | 54 |  |  | 26 |  |  |  |  |  |  |  |  | \nExpected return on plan assets |  | (668) |  |  | (699) |  |  | (1) |  |  | (2) |  |  |  |  |  |  |  |  | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (46) |  |  | \u2014 |  |  | (1) |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial (gains) losses |  | (50) |  |  | 162 |  |  | 6 |  |  | 30 |  |  |  |  |  |  |  |  | \nCurtailments and settlements |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nNet periodic benefit cost/(credit) |  | $ | (198) |  |  | (31) |  |  | 127 |  |  | 133 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 1, 2023 |  | $ | (11,813) |  |  | (27) |  |  | (897) |  |  | (230) |  |  | (12,967) | \nNet change |  | (181) |  |  | 17 |  |  | (68) |  |  | 573 |  |  | 341 | \n |  |  |  |  |  |  |  |  |  | \nApril 2, 2023 |  | $ | (11,994) |  |  | (10) |  |  | (965) |  |  | 343 |  |  | (12,626) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Shares in Millions) |  | April 2, 2023 |  | April 3, 2022 |  |  |  | \nBasic net earnings/(loss) per share |  | $ | (0.03) |  |  | 1.96 |  |  |  |  | \nAverage shares outstanding \u2014 basic |  | 2,605.5 |  |  | 2,629.2 |  |  |  |  | \nPotential shares exercisable under stock option plans |  | \u2014 |  |  | 140.1 |  |  |  |  | \nLess: shares which could be repurchased under treasury stock method |  | \u2014 |  |  | (102.8) |  |  |  |  | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 basic/diluted* |  | 2,605.5 |  |  | 2,666.5 |  |  |  |  | \nNet earnings/(loss) per share (basic/diluted)* |  | $ | (0.03) |  |  | 1.93 |  |  |  |  |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 2,2023 |  | April 3,2022 |  | PercentChange |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nOTC |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 745 |  |  | 670 |  |  | 11.0 | % |  |  |  |  |  | \nInternational |  | 897 |  |  | 791 |  |  | 13.5 |  |  |  |  |  |  | \nWorldwide |  | 1,642 |  |  | 1,461 |  |  | 12.4 |  |  |  |  |  |  | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 617 |  |  | 544 |  |  | 13.4 |  |  |  |  |  |  | \nInternational |  | 493 |  |  | 468 |  |  | 5.3 |  |  |  |  |  |  | \nWorldwide |  | 1,110 |  |  | 1,012 |  |  | 9.7 |  |  |  |  |  |  | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 159 |  |  | 143 |  |  | 11.6 |  |  |  |  |  |  | \nInternational |  | 202 |  |  | 223 |  |  | (9.6) |  |  |  |  |  |  | \nWorldwide |  | 361 |  |  | 366 |  |  | (1.3) |  |  |  |  |  |  | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 96 |  |  | 85 |  |  | 13.0 |  |  |  |  |  |  | \nInternational |  | 263 |  |  | 270 |  |  | (2.8) |  |  |  |  |  |  | \nWorldwide |  | 359 |  |  | 355 |  |  | 1.0 |  |  |  |  |  |  | \nWomen\u2019s Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3 |  |  | 3 |  |  | 1.8 |  |  |  |  |  |  | \nInternational |  | 214 |  |  | 224 |  |  | (4.9) |  |  |  |  |  |  | \nWorldwide |  | 217 |  |  | 228 |  |  | (4.8) |  |  |  |  |  |  | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 115 |  |  | 112 |  |  | 2.6 |  |  |  |  |  |  | \nInternational |  | 49 |  |  | 52 |  |  | (6.0) |  |  |  |  |  |  | \nWorldwide |  | 164 |  |  | 164 |  |  | (0.1) |  |  |  |  |  |  | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,735 |  |  | 1,557 |  |  | 11.4 |  |  |  |  |  |  | \nInternational |  | 2,117 |  |  | 2,029 |  |  | 4.4 |  |  |  |  |  |  | \nWorldwide |  | 3,852 |  |  | 3,586 |  |  | 7.4 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,448 |  |  | 2,501 |  |  | (2.1) |  |  |  |  |  |  | \nInternational |  | 1,664 |  |  | 1,617 |  |  | 2.9 |  |  |  |  |  |  | \nWorldwide |  | 4,112 |  |  | 4,119 |  |  | (0.2) |  |  |  |  |  |  | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 276 |  |  | 358 |  |  | (22.8) |  |  |  |  |  |  | \nU.S. Exports |  | 41 |  |  | 80 |  |  | (48.8) |  |  |  |  |  |  | \nInternational |  | 170 |  |  | 225 |  |  | (24.4) |  |  |  |  |  |  | \nWorldwide |  | 487 |  |  | 663 |  |  | (26.5) |  |  |  |  |  |  | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 271 |  |  | 287 |  |  | (5.6) |  |  |  |  |  |  | \nInternational |  | 266 |  |  | 283 |  |  | (6.1) |  |  |  |  |  |  | \nWorldwide |  | 537 |  |  | 571 |  |  | (5.8) |  |  |  |  |  |  | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,451 |  |  | 1,379 |  |  | 5.2 |  |  |  |  |  |  | \nInternational |  | 993 |  |  | 909 |  |  | 9.3 |  |  |  |  |  |  | \nWorldwide |  | 2,444 |  |  | 2,288 |  |  | 6.8 |  |  |  |  |  |  | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 406 |  |  | 391 |  |  | 3.9 |  |  |  |  |  |  | \nInternational |  | 234 |  |  | 199 |  |  | 17.3 |  |  |  |  |  |  | \nWorldwide |  | 640 |  |  | 590 |  |  | 8.4 |  |  |  |  |  |  | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3 |  |  | 6 |  |  | (51.2) |  |  |  |  |  |  | \nInternational |  | 0 |  | 0 |  | \u2014 |  |  |  |  |  |  | \nWorldwide |  | 3 |  |  | 6 |  |  | (51.3) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 392 |  |  | 461 |  |  | (14.9) |  |  |  |  |  |  | \nInternational |  | 1,193 |  |  | 836 |  |  | 42.8 |  |  |  |  |  |  | \nWorldwide |  | 1,586 |  |  | 1,297 |  |  | 22.3 |  |  |  |  |  |  | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 0 |  | 75 |  |  | * |  |  |  |  |  | \nInternational |  | 747 |  |  | 382 |  |  | 95.6 |  |  |  |  |  |  | \nWorldwide |  | 747 |  |  | 457 |  |  | 63.4 |  |  |  |  |  |  | \nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 9 |  |  | (1.4) |  |  |  |  |  |  | \nInternational |  | 271 |  |  | 239 |  |  | 13.4 |  |  |  |  |  |  | \nWorldwide |  | 280 |  |  | 248 |  |  | 12.8 |  |  |  |  |  |  | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 378 |  |  | 369 |  |  | 2.5 |  |  |  |  |  |  | \nInternational |  | 99 |  |  | 132 |  |  | (25.2) |  |  |  |  |  |  | \nWorldwide |  | 477 |  |  | 501 |  |  | (4.8) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 5 |  |  | 8 |  |  | (33.1) |  |  |  |  |  |  | \nInternational |  | 77 |  |  | 83 |  |  | (7.6) |  |  |  |  |  |  | \nWorldwide |  | 82 |  |  | 91 |  |  | (9.8) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 978 |  |  | 843 |  |  | 16.0 |  |  |  |  |  |  | \nInternational |  | 826 |  |  | 898 |  |  | (8.1) |  |  |  |  |  |  | \nWorldwide |  | 1,804 |  |  | 1,741 |  |  | 3.6 |  |  |  |  |  |  | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 70 |  |  | 35 |  |  | * |  |  |  |  |  | \nInternational |  | 136 |  |  | 122 |  |  | 11.4 |  |  |  |  |  |  | \nWorldwide |  | 206 |  |  | 157 |  |  | 31.4 |  |  |  |  |  |  | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 713 |  |  | 661 |  |  | 7.9 |  |  |  |  |  |  | \nInternational |  | 331 |  |  | 387 |  |  | (14.6) |  |  |  |  |  |  | \nWorldwide |  | 1,044 |  |  | 1,048 |  |  | (0.4) |  |  |  |  |  |  | \nSPRAVATO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 111 |  |  | 61 |  |  | 82.4 |  |  |  |  |  |  | \nInternational |  | 20 |  |  | 9 |  |  | * |  |  |  |  |  | \nWorldwide |  | 131 |  |  | 70 |  |  | 86.9 |  |  |  |  |  |  | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 84 |  |  | 86 |  |  | (3.5) |  |  |  |  |  |  | \nInternational |  | 339 |  |  | 380 |  |  | (10.7) |  |  |  |  |  |  | \nWorldwide |  | 423 |  |  | 467 |  |  | (9.4) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,889 |  |  | 1,582 |  |  | 19.4 |  |  |  |  |  |  | \nInternational |  | 2,223 |  |  | 2,369 |  |  | (6.1) |  |  |  |  |  |  | \nWorldwide |  | 4,112 |  |  | 3,950 |  |  | 4.1 |  |  |  |  |  |  | \nCARVYKTI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 70 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nInternational |  | 2 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nWorldwide |  | 72 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,191 |  |  | 953 |  |  | 25.0 |  |  |  |  |  |  | \nInternational |  | 1,072 |  |  | 903 |  |  | 18.8 |  |  |  |  |  |  | \nWorldwide |  | 2,264 |  |  | 1,856 |  |  | 22.0 |  |  |  |  |  |  | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 249 |  |  | 206 |  |  | 21.2 |  |  |  |  |  |  | \nInternational |  | 293 |  |  | 194 |  |  | 50.9 |  |  |  |  |  |  | \nWorldwide |  | 542 |  |  | 400 |  |  | 35.6 |  |  |  |  |  |  | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 270 |  |  | 370 |  |  | (27.1) |  |  |  |  |  |  | \nInternational |  | 557 |  |  | 668 |  |  | (16.6) |  |  |  |  |  |  | \nWorldwide |  | 827 |  |  | 1,038 |  |  | (20.3) |  |  |  |  |  |  | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 16 |  |  | 19 |  |  | (14.0) |  |  |  |  |  |  | \nInternational |  | 229 |  |  | 520 |  |  | (56.0) |  |  |  |  |  |  | \nWorldwide |  | 245 |  |  | 539 |  |  | (54.5) |  |  |  |  |  |  | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 92 |  |  | 34 |  |  | * |  |  |  |  |  | \nInternational |  | 70 |  |  | 84 |  |  | (17.2) |  |  |  |  |  |  | \nWorldwide |  | 162 |  |  | 118 |  |  | 37.4 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 600 |  |  | 572 |  |  | 4.9 |  |  |  |  |  |  | \nInternational |  | 272 |  |  | 279 |  |  | (2.7) |  |  |  |  |  |  | \nWorldwide |  | 872 |  |  | 852 |  |  | 2.4 |  |  |  |  |  |  | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 273 |  |  | 273 |  |  | (0.1) |  |  |  |  |  |  | \nInternational |  | 167 |  |  | 170 |  |  | (1.6) |  |  |  |  |  |  | \nWorldwide |  | 440 |  |  | 443 |  |  | (0.7) |  |  |  |  |  |  | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 304 |  |  | 269 |  |  | 13.1 |  |  |  |  |  |  | \nInternational |  | 58 |  |  | 56 |  |  | 3.3 |  |  |  |  |  |  | \nWorldwide |  | 362 |  |  | 325 |  |  | 11.4 |  |  |  |  |  |  | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 23 |  |  | 30 |  |  | (22.4) |  |  |  |  |  |  | \nInternational |  | 47 |  |  | 53 |  |  | (12.6) |  |  |  |  |  |  | \nWorldwide |  | 70 |  |  | 83 |  |  | (16.1) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 715 |  |  | 672 |  |  | 6.3 |  |  |  |  |  |  | \nInternational |  | 212 |  |  | 238 |  |  | (10.8) |  |  |  |  |  |  | \nWorldwide |  | 927 |  |  | 910 |  |  | 1.8 |  |  |  |  |  |  | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 578 |  |  | 508 |  |  | 13.7 |  |  |  |  |  |  | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  | \nWorldwide |  | 578 |  |  | 508 |  |  | 13.7 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 137 |  |  | 164 |  |  | (16.7) |  |  |  |  |  |  | \nInternational |  | 212 |  |  | 238 |  |  | (10.8) |  |  |  |  |  |  | \nWorldwide |  | 349 |  |  | 402 |  |  | (13.2) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 7,023 |  |  | 6,632 |  |  | 5.9 |  |  |  |  |  |  | \nInternational |  | 6,390 |  |  | 6,237 |  |  | 2.4 |  |  |  |  |  |  | \nWorldwide |  | 13,413 |  |  | 12,869 |  |  | 4.2 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 863 |  |  | 494 |  |  | 74.5 |  |  |  |  |  |  | \nInternational |  | 640 |  |  | 597 |  |  | 7.1 |  |  |  |  |  |  | \nWorldwide |  | 1,503 |  |  | 1,092 |  |  | 37.6 |  |  |  |  |  |  | \nELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 571 |  |  | 470 |  |  | 21.4 |  |  |  |  |  |  | \nInternational |  | 522 |  |  | 532 |  |  | (1.8) |  |  |  |  |  |  | \nWorldwide |  | 1,092 |  |  | 1,002 |  |  | 9.1 |  |  |  |  |  |  | \nABIOMED(3) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 264 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nInternational |  | 60 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nWorldwide |  | 324 |  |  | \u2014 |  |  | * |  |  |  |  |  | \nOTHER INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 28 |  |  | 24 |  |  | 17.4 |  |  |  |  |  |  | \nInternational |  | 58 |  |  | 65 |  |  | (11.7) |  |  |  |  |  |  | \nWorldwide |  | 87 |  |  | 90 |  |  | (3.9) |  |  |  |  |  |  | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,363 |  |  | 1,289 |  |  | 5.8 |  |  |  |  |  |  | \nInternational |  | 881 |  |  | 899 |  |  | (2.0) |  |  |  |  |  |  | \nWorldwide |  | 2,245 |  |  | 2,188 |  |  | 2.6 |  |  |  |  |  |  | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 241 |  |  | 225 |  |  | 7.3 |  |  |  |  |  |  | \nInternational |  | 149 |  |  | 164 |  |  | (9.0) |  |  |  |  |  |  | \nWorldwide |  | 390 |  |  | 389 |  |  | 0.4 |  |  |  |  |  |  | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 226 |  |  | 201 |  |  | 12.4 |  |  |  |  |  |  | \nInternational |  | 142 |  |  | 138 |  |  | 3.4 |  |  |  |  |  |  | \nWorldwide |  | 368 |  |  | 339 |  |  | 8.7 |  |  |  |  |  |  | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 491 |  |  | 475 |  |  | 3.2 |  |  |  |  |  |  | \nInternational |  | 267 |  |  | 273 |  |  | (2.4) |  |  |  |  |  |  | \nWorldwide |  | 757 |  |  | 748 |  |  | 1.2 |  |  |  |  |  |  | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 406 |  |  | 387 |  |  | 4.7 |  |  |  |  |  |  | \nInternational |  | 323 |  |  | 324 |  |  | (0.3) |  |  |  |  |  |  | \nWorldwide |  | 729 |  |  | 712 |  |  | 2.4 |  |  |  |  |  |  | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 975 |  |  | 921 |  |  | 5.9 |  |  |  |  |  |  | \nInternational |  | 1,459 |  |  | 1,513 |  |  | (3.6) |  |  |  |  |  |  | \nWorldwide |  | 2,434 |  |  | 2,434 |  |  | 0.0 |  |  |  |  |  |  | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 444 |  |  | 417 |  |  | 6.5 |  |  |  |  |  |  | \nInternational |  | 673 |  |  | 729 |  |  | (7.6) |  |  |  |  |  |  | \nWorldwide |  | 1,118 |  |  | 1,146 |  |  | (2.5) |  |  |  |  |  |  | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 531 |  |  | 504 |  |  | 5.4 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInternational |  | 785 |  |  | 784 |  |  | 0.2 |  |  |  |  |  |  | \nWorldwide |  | 1,316 |  |  | 1,288 |  |  | 2.2 |  |  |  |  |  |  | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 558 |  |  | 521 |  |  | 7.1 |  |  |  |  |  |  | \nInternational |  | 743 |  |  | 736 |  |  | 0.8 |  |  |  |  |  |  | \nWorldwide |  | 1,300 |  |  | 1,257 |  |  | 3.4 |  |  |  |  |  |  | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 444 |  |  | 400 |  |  | 11.1 |  |  |  |  |  |  | \nInternational |  | 509 |  |  | 511 |  |  | (0.3) |  |  |  |  |  |  | \nWorldwide |  | 953 |  |  | 910 |  |  | 4.7 |  |  |  |  |  |  | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 114 |  |  | 121 |  |  | (6.0) |  |  |  |  |  |  | \nInternational |  | 233 |  |  | 226 |  |  | 3.3 |  |  |  |  |  |  | \nWorldwide |  | 347 |  |  | 347 |  |  | 0.1 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,759 |  |  | 3,225 |  |  | 16.6 |  |  |  |  |  |  | \nInternational |  | 3,722 |  |  | 3,746 |  |  | (0.6) |  |  |  |  |  |  | \nWorldwide |  | 7,481 |  |  | 6,971 |  |  | 7.3 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 12,517 |  |  | 11,414 |  |  | 9.7 |  |  |  |  |  |  | \nInternational |  | 12,229 |  |  | 12,012 |  |  | 1.8 |  |  |  |  |  |  | \nWorldwide |  | $ | 24,746 |  |  | 23,426 |  |  | 5.6 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  |  | \n(Dollars in Millions) |  | April 2,2023 |  | April 3,2022 |  | PercentChange |  |  |  |  |  |  |  |  |  |  | \nConsumer Health(1) |  | $ | 776 |  |  | 686 |  |  | 13.1 | % |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical(2) |  | 4,444 |  |  | 3,924 |  |  | 13.3 |  |  |  |  |  |  |  |  |  |  |  | \nMedTech(3) |  | 1,445 |  |  | 1,477 |  |  | (2.2) |  |  |  |  |  |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 6,665 |  |  | 6,087 |  |  | 9.5 |  |  |  |  |  |  |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 7,102 |  |  | 123 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 300 |  |  | 102 |  |  |  |  |  |  |  |  |  |  |  |  |  | \nWorldwide income/(loss) before tax |  | $ | (737) |  |  | 5,862 |  |  | * |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal First Quarter Ended |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | PercentChange |  |  |  |  |  | \nUnited States |  | $ | 12,517 |  |  | 11,414 |  |  | 9.7 | % |  |  |  |  |  | \nEurope |  | 6,332 |  |  | 6,024 |  |  | 5.1 |  |  |  |  |  |  | \nWestern Hemisphere, excluding U.S. |  | 1,587 |  |  | 1,482 |  |  | 7.1 |  |  |  |  |  |  | \nAsia-Pacific, Africa |  | 4,310 |  |  | 4,506 |  |  | (4.3) |  |  |  |  |  |  | \nTotal |  | $ | 24,746 |  |  | 23,426 |  |  | 5.6 | % |  |  |  |  |  |   |  |  |  |  |  |  |  | \nProduct or product category |  | Number of Plaintiffs\nBody powders containing talc, primarily JOHNSON\u2019S Baby Powder |  | 40,330 | \nDePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System |  | 160 | \nPINNACLE Acetabular Cup System |  | 940 | \nPelvic meshes |  | 8,780 | \nETHICON PHYSIOMESH Flexible Composite Mesh |  | 2,070 | \nRISPERDAL |  | 520 | \nELMIRON |  | 2,070 | \nTYLENOL |  | 200 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC(1) |  | $ | 1,642 |  |  | $ | 1,461 |  |  | 12.4 | % |  | 15.8 | % |  | (3.4) | %\nSkin Health/Beauty |  | 1,110 |  |  | 1,012 |  |  | 9.7 |  |  | 13.1 |  |  | (3.4) | \nOral Care |  | 361 |  |  | 366 |  |  | (1.3) |  |  | 2.1 |  |  | (3.4) | \nBaby Care |  | 359 |  |  | 355 |  |  | 1.0 |  |  | 6.5 |  |  | (5.5) | \nWomen\u2019s Health |  | 217 |  |  | 228 |  |  | (4.8) |  |  | 4.1 |  |  | (8.9) | \nWound Care/Other |  | 164 |  |  | 164 |  |  | (0.1) |  |  | 2.5 |  |  | (2.6) | \nTotal Consumer Health Sales |  | $ | 3,852 |  |  | $ | 3,586 |  |  | 7.4 | % |  | 11.3 | % |  | (3.9) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,112 |  |  | $ | 4,119 |  |  | (0.2) | % |  | 2.5 | % |  | (2.7) | %\nREMICADE |  | 487 |  |  | 663 |  |  | (26.5) |  |  | (25.0) |  |  | (1.5) | \nSIMPONI/ SIMPONI ARIA |  | 537 |  |  | 571 |  |  | (5.8) |  |  | (1.9) |  |  | (3.9) | \nSTELARA |  | 2,444 |  |  | 2,288 |  |  | 6.8 |  |  | 9.6 |  |  | (2.8) | \nTREMFYA |  | 640 |  |  | 590 |  |  | 8.4 |  |  | 11.0 |  |  | (2.6) | \nOther Immunology |  | 3 |  |  | 6 |  |  | (51.3) |  | (51.3) |  | 0.0\nInfectious Diseases |  | 1,586 |  |  | 1,297 |  |  | 22.3 |  |  | 26.4 |  |  | (4.1) | \nCOVID-19 VACCINE |  | 747 |  |  | 457 |  |  | 63.4 |  |  | 70.8 |  |  | (7.4) | \nEDURANT/rilpivirine |  | 280 |  |  | 248 |  |  | 12.8 |  |  | 18.0 |  |  | (5.2) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 477 |  |  | 501 |  |  | (4.8) |  |  | (3.7) |  |  | (1.1) | \nOther Infectious Diseases |  | 82 |  |  | 91 |  |  | (9.8) |  |  | (8.0) |  |  | (1.8) | \nNeuroscience |  | 1,804 |  |  | 1,741 |  |  | 3.6 |  | 6.1 |  |  | (2.5) | \nCONCERTA/ methylphenidate |  | 206 |  |  | 157 |  |  | 31.4 |  |  | 38.2 |  |  | (6.8) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,044 |  |  | 1,048 |  |  | (0.4) |  |  | 1.7 |  |  | (2.1) | \nSPRAVATO |  | 131 |  |  | 70 |  |  | 86.9 |  |  | 88.0 |  |  | (1.1) | \nOther Neuroscience(1) |  | 423 |  |  | 467 |  |  | (9.4) |  |  | (6.9) |  |  | (2.5) | \nOncology |  | 4,112 |  |  | 3,950 |  |  | 4.1 |  |  | 7.7 |  |  | (3.6) | \nCARVYKTI |  | 72 |  |  | \u2014 |  |  | * |  | * |  | \u2014 | \nDARZALEX |  | 2,264 |  |  | 1,856 |  |  | 22.0 |  |  | 25.7 |  |  | (3.7) | \nERLEADA |  | 542 |  |  | 400 |  |  | 35.6 |  |  | 40.3 |  |  | (4.7) | \nIMBRUVICA |  | 827 |  |  | 1,038 |  |  | (20.3) |  |  | (17.2) |  |  | (3.1) | \nZYTIGA/ abiraterone acetate |  | 245 |  |  | 539 |  |  | (54.5) |  |  | (50.9) |  |  | (3.6) | \nOther Oncology |  | 162 |  |  | 118 |  |  | 37.4 |  |  | 41.0 |  |  | (3.6) | \nPulmonary Hypertension |  | 872 |  |  | 852 |  |  | 2.4 |  |  | 5.0 |  |  | (2.6) | \nOPSUMIT |  | 440 |  |  | 443 |  |  | (0.7) |  |  | 2.3 |  |  | (3.0) | \nUPTRAVI |  | 362 |  |  | 325 |  |  | 11.4 |  |  | 12.4 |  |  | (1.0) | \nOther Pulmonary Hypertension |  | 70 |  |  | 83 |  |  | (16.1) |  |  | (9.3) |  |  | (6.8) | \nCardiovascular / Metabolism / Other |  | 927 |  |  | 910 |  |  | 1.8 |  |  | 3.0 |  |  | (1.2) | \nXARELTO |  | 578 |  |  | 508 |  |  | 13.7 |  |  | 13.7 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 349 |  |  | 402 |  |  | (13.2) |  |  | (10.5) |  |  | (2.7) | \nTotal Pharmaceutical Sales |  | $ | 13,413 |  |  | $ | 12,869 |  |  | 4.2 | % |  | 7.2 | % |  | (3.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,434 |  |  | $ | 2,434 |  |  | 0.0 | % |  | 4.1 | % |  | (4.1) | %\nAdvanced |  | 1,118 |  |  | 1,146 |  |  | (2.5) |  |  | 1.6 |  |  | (4.1) | \nGeneral |  | 1,316 |  |  | 1,288 |  |  | 2.2 |  |  | 6.4 |  |  | (4.2) | \nOrthopaedics |  | 2,245 |  |  | 2,188 |  |  | 2.6 |  |  | 5.1 |  |  | (2.5) | \nHips |  | 390 |  |  | 389 |  |  | 0.4 |  |  | 2.7 |  |  | (2.3) | \nKnees |  | 368 |  |  | 339 |  |  | 8.7 |  |  | 11.3 |  |  | (2.6) | \nTrauma |  | 757 |  |  | 748 |  |  | 1.2 |  |  | 3.4 |  |  | (2.2) | \nSpine, Sports & Other |  | 729 |  |  | 712 |  |  | 2.4 |  |  | 5.2 |  |  | (2.8) | \nInterventional Solutions |  | 1,503 |  |  | 1,092 |  |  | 37.6 |  |  | 41.9 |  |  | (4.3) | \nElectrophysiology |  | 1,092 |  |  | 1,002 |  |  | 9.1 |  |  | 13.3 |  |  | (4.2) | \nAbiomed |  | 324 |  |  | \u2014 |  |  | * |  | * |  | \u2014 | \nOther Interventional Solutions |  | 87 |  |  | 90 |  |  | (3.9) |  |  | 1.1 |  |  | (5.0) | \nVision |  | 1,300 |  |  | 1,257 |  |  | 3.4 |  |  | 7.6 |  |  | (4.2) | \nContact Lenses/Other |  | 953 |  |  | 910 |  |  | 4.7 |  |  | 9.3 |  |  | (4.6) | \nSurgical |  | 347 |  |  | 347 |  |  | 0.1 |  |  | 3.1 |  |  | (3.0) | \nTotal MedTech Sales |  | $ | 7,481 |  |  | $ | 6,971 |  |  | 7.3 | % |  | 11.0 | % |  | (3.7) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal First Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\nLitigation related(1) |  | $ | 6.9 |  |  | 0.0 |  |  | 6.9 | \n |  |  |  |  |  | \nConsumer Health separation costs |  | 0.3 |  |  | 0.1 |  |  | 0.2 | \nCOVID-19 Vaccine related exit costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nChanges in the fair value of securities |  | 0.1 |  |  | 0.4 |  |  | (0.3) | \nEmployee benefit plan related |  | (0.4) |  |  | (0.3) |  |  | (0.1) | \nOther |  | 0.1 |  |  | (0.3) |  |  | 0.4 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 7.2 |  |  | (0.1) |  |  | 7.3 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | April 2, 2023 |  | April 3, 2022 |  | April 2, 2023 |  | April 3, 2022\nConsumer Health |  | $ | 776 |  |  | $ | 686 |  |  | $ | 3,852 |  |  | $ | 3,586 |  |  | 20.1 | % |  | 19.1 | %\nPharmaceutical |  | 4,444 |  |  | 3,924 |  |  | 13,413 |  |  | 12,869 |  |  | 33.1 |  |  | 30.5 | \nMedTech |  | 1,445 |  |  | 1,477 |  |  | 7,481 |  |  | 6,971 |  |  | 19.3 |  |  | 21.2 | \nSegment earnings before tax |  | 6,665 |  |  | 6,087 |  |  | 24,746 |  |  | 23,426 |  |  | 26.9 |  |  | 26.0 | \nLess: Expenses not allocated to segments(1) |  | 7,102 |  |  | 123 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 300 |  |  | 102 |  |  |  |  |  |  |  |  | \nWorldwide income/(loss) before tax |  | $ | (737) |  |  | $ | 5,862 |  |  | $ | 24,746 |  |  | $ | 23,426 |  |  | (3.0) | % |  | 25.0 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.1 |  | Q4 2022 Cash and cash equivalents balance\n3.3 |  | net cash generated from operating activities\n3.3 |  | net cash generated from investing activities\n6.1 |  | net cash generated from financing activities\n0.1 |  | rounding\n | \n | \n$ | 26.9 |  | Q1 2023 Cash, cash equivalents and restricted cash balance  |  |  |  |  | \n(Dollars In Billions) | \n$ | (0.1) |  | Net Loss\n1.1 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses\n | \n(0.6) |  | an increase in accounts receivable and inventories\n | \n(2.6) |  | a decrease in accounts payable and accrued liabilities\n(0.9) |  | an increase in other current and non-current assets\n6.3 |  | an increase in other current and non-current liabilities\n0.1 |  | Rounding\n$ | 3.3 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n(0.9) |  | additions to property, plant and equipment\n | \n | \n4.0 |  | net sales of investments\n0.2 |  | credit support agreements activity, net\n | \n | \n$ | 3.3 |  | Net cash from investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (2.9) |  | dividends to shareholders\n(3.5) |  | repurchase of common stock\n5.2 | net proceeds from short term debt and repayment of long term debt\n7.7 |  | proceeds from Kenvue long term debt, net of issuance cost\n | \n | \n$ | (0.4) |  | other and rounding\n$ | 6.1 |  | Net cash from financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nJanuary 2, 2023 through January 29, 2023 |  | 2,507,585 |  |  | 176.23 |  |  | 635,911 |  |  | \u2014\nJanuary 30, 2023 through February 26, 2023 |  | 18,143,502 |  |  | 162.00 |  |  | 13,852,301 |  |  | \u2014\nFebruary 27, 2023 through April 2, 2023 |  | 996,230 |  |  | 156.52 |  |  | 646,230 |  |  | \u2014\nTotal |  | 21,647,317 |  |  | 163.39 |  |  | 15,134,442 |  |  | \u2014  |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: April\u00a028, 2023 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: April\u00a028, 2023 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2023 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014 July 2, 2023 and January 1, 2023 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the Fiscal Second Quarters Ended July 2, 2023 and July 3, 2022 |  |  | 2\n |  |  | \nConsolidated Statements of Earnings for the Fiscal Six Months Ended July 2, 2023 and July 3, 2022 |  |  | 3\n |  |  | \nConsolidated Statements of Comprehensive Income for the Fiscal Second Quartersand Fiscal Six MonthsEnded July 2, 2023 and July 3, 2022 |  |  | 4\n |  |  | \nConsolidated Statements of Equity for the Fiscal Second Quarters and Fiscal Six Months Ended July 2, 2023 and July 3, 2022 |  |  | 5\n |  |  | \nConsolidated Statements of Cash Flows for the Fiscal Six Months Ended July 2, 2023 and July 3, 2022 |  |  | 7\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 8\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 43\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 61\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 61\n |  |  | \nPart II \u2014 Other Information |  |  | 61\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 61\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 61\n |  |  | \nItem\u00a06 - Exhibits |  |  | 62\n |  |  | \nSignatures |  |  | 63\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | July 2, 2023 |  | January 1, 2023\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents (Note 4) |  | $ | 21,183 |  |  | 14,127 | \n |  |  |  | \nMarketable securities |  | 7,322 |  |  | 9,392 | \nAccounts receivable, trade, less allowances $205(2022, $203) |  | 16,777 |  |  | 16,160 | \nInventories (Note 2) |  | 12,888 |  |  | 12,483 | \nPrepaid expenses and other |  | 2,397 |  |  | 3,132 | \n |  |  |  | \nTotal current assets |  | 60,567 |  |  | 55,294 | \nProperty, plant and equipment at cost |  | 51,218 |  |  | 49,253 | \nLess: accumulated depreciation |  | (30,642) |  |  | (29,450) | \nProperty, plant and equipment, net |  | 20,576 |  |  | 19,803 | \nIntangible assets, net (Note 3) |  | 46,246 |  |  | 48,325 | \nGoodwill (Note 3) |  | 45,440 |  |  | 45,231 | \nDeferred taxes on income (Note 5) |  | 8,779 |  |  | 9,123 | \nOther assets |  | 10,078 |  |  | 9,602 | \nTotal assets |  | $ | 191,686 |  |  | 187,378 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 11,701 |  |  | 12,771 | \nAccounts payable |  | 10,443 |  |  | 11,703 | \nAccrued liabilities |  | 10,605 |  |  | 11,456 | \nAccrued rebates, returns and promotions |  | 15,672 |  |  | 14,417 | \nAccrued compensation and employee related obligations |  | 3,062 |  |  | 3,328 | \nAccrued taxes on income (Note 5) |  | 2,687 |  |  | 2,127 | \nTotal current liabilities |  | 54,170 |  |  | 55,802 | \nLong-term debt (Note 4) |  | 33,901 |  |  | 26,888 | \nDeferred taxes on income (Note 5) |  | 3,627 |  |  | 6,374 | \nEmployee related obligations (Note 6) |  | 6,461 |  |  | 6,767 | \nLong-term taxes payable (Note 5) |  | 2,536 |  |  | 4,306 | \nOther liabilities |  | 14,582 |  |  | 10,437 | \nTotal liabilities |  | $ | 115,277 |  |  | 110,574 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (13,135) |  |  | (12,967) | \nRetained earnings and Additional paid-in capital |  | 129,381 |  |  | 128,345 | \nLess: common stock held in treasury, at cost (521,700,000and506,246,000shares) |  | 44,217 |  |  | 41,694 | \nTotal Johnson & Johnson shareholders\u2019 equity |  | 75,149 |  |  | 76,804 | \nEquity attributable to non-controlling interest (Note 12) |  | 1,260 |  |  | \u2014 | \nTotal equity |  | $ | 76,409 |  |  | 76,804 | \nTotal liabilities and shareholders\u2019 equity |  | $ | 191,686 |  |  | 187,378 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended\n |  | July 2,2023 |  | Percentto Sales |  | July 3,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 25,530 |  |  | 100.0 | % |  | $ | 24,020 |  |  | 100.0 | %\nCost of products sold |  | 8,212 |  |  | 32.2 |  |  | 7,919 |  |  | 33.0 | \nGross profit |  | 17,318 |  |  | 67.8 |  |  | 16,101 |  |  | 67.0 | \nSelling, marketing and administrative expenses |  | 6,665 |  |  | 26.1 |  |  | 6,226 |  |  | 25.9 | \nResearch and development expense |  | 3,829 |  |  | 15.0 |  |  | 3,703 |  |  | 15.4 | \n |  |  |  |  |  |  |  | \nInterest income |  | (369) |  |  | (1.5) |  |  | (64) |  |  | (0.3) | \nInterest expense, net of portion capitalized |  | 346 |  |  | 1.4 |  |  | 38 |  |  | 0.2 | \nOther (income) expense, net* |  | (60) |  |  | (0.2) |  |  | 273 |  |  | 1.1 | \nRestructuring |  | 145 |  |  | 0.5 |  |  | 85 |  |  | 0.4 | \nEarnings before provision for taxes on income |  | 6,762 |  |  | 26.5 |  |  | 5,840 |  |  | 24.3 | \nProvision for taxes on income (Note 5) |  | 1,618 |  |  | 6.4 |  |  | 1,026 |  |  | 4.3 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nNET EARNINGS |  | $ | 5,144 |  |  | 20.1 | % |  | $ | 4,814 |  |  | 20.0 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.98 |  |  |  |  | $ | 1.83 |  |  | \nDiluted |  | $ | 1.96 |  |  |  |  | $ | 1.80 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,598.4 |  |  |  |  | 2,629.6 |  |  | \nDiluted |  | 2,625.7 |  |  |  |  | 2,667.9 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Six Months Ended\n |  | July 2,2023 |  | Percentto Sales |  | July 3,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 50,276 |  |  | 100.0 | % |  | $ | 47,446 |  |  | 100.0 | %\nCost of products sold |  | 16,607 |  |  | 33.0 |  |  | 15,517 |  |  | 32.7 | \nGross profit |  | 33,669 |  |  | 67.0 |  |  | 31,929 |  |  | 67.3 | \nSelling, marketing and administrative expenses |  | 12,803 |  |  | 25.5 |  |  | 12,164 |  |  | 25.6 | \nResearch and development expense |  | 7,392 |  |  | 14.7 |  |  | 7,165 |  |  | 15.1 | \nIn-process research and development impairments |  | 49 |  |  | 0.1 |  |  | 610 |  | 1.3 | \nInterest income |  | (604) |  |  | (1.2) |  |  | (86) |  |  | (0.2) | \nInterest expense, net of portion capitalized |  | 561 |  |  | 1.1 |  |  | 48 |  |  | 0.1 | \nOther (income) expense, net* |  | 7,168 |  |  | 14.3 |  |  | 171 |  |  | 0.4 | \nRestructuring |  | 275 |  |  | 0.5 |  |  | 155 |  |  | 0.3 | \nEarnings before provision for taxes on income |  | 6,025 |  |  | 12.0 |  |  | 11,702 |  |  | 24.7 | \nProvision for taxes on income (Note 5) |  | 949 |  |  | 1.9 |  |  | 1,739 |  |  | 3.7 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nNET EARNINGS |  | $ | 5,076 |  |  | 10.1 | % |  | $ | 9,963 |  |  | 21.0 | %\n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \nBasic |  | $ | 1.95 |  |  |  |  | $ | 3.79 |  |  | \nDiluted |  | $ | 1.93 |  |  |  |  | $ | 3.73 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,601.9 |  |  |  |  | 2,629.4 |  |  | \nDiluted |  | 2,630.7 |  |  |  |  | 2,669.2 |  |  | \n |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\n |  |  |  |  |  |  | \nNet earnings | $ | 5,144 |  |  | 4,814 |  |  | $ | 5,076 |  |  | 9,963 | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | (715) |  |  | (151) |  |  | (896) |  |  | (705) | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | 4 |  |  | (20) |  |  | 21 |  |  | (33) | \nReclassifications to earnings | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  | \nNet change | 4 |  |  | (20) |  |  | 21 |  |  | (33) | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (36) |  |  | (20) |  |  | (71) |  |  | (73) | \nGain (loss) amortization during period | (34) |  |  | 86 |  |  | (67) |  |  | 303 | \n |  |  |  |  |  |  | \nNet change | (70) |  |  | 66 |  |  | (138) |  |  | 230 | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (137) |  |  | 145 |  |  | 433 |  |  | (50) | \nReclassifications to earnings | (139) |  |  | (126) |  |  | (136) |  |  | (227) | \nNet change | (276) |  |  | 19 |  |  | 297 |  |  | (277) | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (1,057) |  |  | (86) |  |  | (716) |  |  | (785) | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 4,087 |  |  | 4,728 |  |  | $ | 4,360 |  |  | 9,178 | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income/(loss) for the fiscal second quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $32million and $533million; Securities: $1million and $6million; Employee Benefit Plans: $21million and $84million; Derivatives & Hedges: $74million and $5million.\n\nThe tax effects in other comprehensive income/(loss) for the fiscal six months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $266million and $678million; Securities: $6million and $9million; Employee Benefit Plans: $43million and $65million; Derivatives & Hedges: $80million and $73million.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount |  | Non-controlling interest (NCI) | \nBalance, April 2, 2023 | $ | 70,869 |  |  | 124,558 |  |  | (12,626) |  |  | 3,120 |  |  | (44,183) |  |  | \u2014 |  | \nNet earnings | 5,144 |  |  | 5,144 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nCash dividends paid                   ($1.19per share) | (3,092) |  |  | (3,092) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nEmployee compensation and stock option plans | 649 |  |  | 301 |  |  | \u2014 |  |  | \u2014 |  |  | 348 |  |  |  | \nRepurchase of common stock | (381) |  |  |  |  | \u2014 |  |  | \u2014 |  |  | (381) |  |  |  | \nOther | (1) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  | \nKenvue IPO | 4,278 |  |  | 2,470 |  |  | 548 |  |  |  |  |  |  | 1,260 |  | *\nOther comprehensive income (loss), net of tax | (1,057) |  |  | \u2014 |  |  | (1,057) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nBalance, July 2, 2023 | $ | 76,409 |  |  | 129,381 |  |  | (13,135) |  |  | 3,120 |  |  | (44,217) |  |  | 1,260 |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount |  | Non-controlling interest (NCI) | \nBalance, January 1, 2023 | $ | 76,804 |  |  | 128,345 |  |  | (12,967) |  |  | 3,120 |  |  | (41,694) |  |  | \u2014 |  | \nNet earnings | 5,076 |  |  | 5,076 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nCash dividends paid ($2.32per share) | (6,034) |  |  | (6,034) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nEmployee compensation and stock option plans | 944 |  |  | (476) |  |  | \u2014 |  |  | \u2014 |  |  | 1,420 |  |  | \u2014 |  | \nRepurchase of common stock | (3,918) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3,918) |  |  | \u2014 |  | \nOther | (25) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (25) |  |  | \u2014 |  | \nKenvue IPO | 4,278 |  |  | 2,470 |  |  | 548 |  |  | \u2014 |  |  | \u2014 |  |  | 1,260 |  | *\nOther comprehensive income (loss), net of tax | (716) |  |  | \u2014 |  |  | (716) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nBalance, July 2, 2023 | $ | 76,409 |  |  | 129,381 |  |  | (13,135) |  |  | 3,120 |  |  | (44,217) |  |  | 1,260 |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, April 3, 2022 | $ | 74,709 |  |  | 124,380 |  |  | (13,757) |  |  | 3,120 |  |  | (39,034) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 4,814 |  |  | 4,814 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.13per share) | (2,971) |  |  | (2,971) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 864 |  |  | (7) |  |  | \u2014 |  |  | \u2014 |  |  | 871 | \nRepurchase of common stock | (973) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (973) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (86) |  |  | \u2014 |  |  | (86) |  |  | \u2014 |  |  | \u2014 | \nBalance, July 3, 2022 | $ | 76,357 |  |  | 126,216 |  |  | (13,843) |  |  | 3,120 |  |  | (39,136) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \nFiscal Six Months Ended July\u00a03, 2022\n | Total |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 9,963 |  |  | 9,963 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($2.19per share) | (5,758) |  |  | (5,758) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 1,464 |  |  | (1,049) |  |  | \u2014 |  |  | \u2014 |  |  | 2,513 | \nRepurchase of common stock | (2,550) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,550) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (785) |  |  | \u2014 |  |  | (785) |  |  | \u2014 |  |  | \u2014 | \nBalance, July 3, 2022 | $ | 76,357 |  |  | 126,216 |  |  | (13,843) |  |  | 3,120 |  |  | (39,136) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Six Months Ended\n |  | July 2,2023 |  | July 3,2022\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 5,076 |  |  | 9,963 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 3,814 |  |  | 3,513 | \nStock based compensation |  | 688 |  |  | 644 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 388 |  |  | 747 | \n |  |  |  | \nNet gain on sale of assets/businesses |  | (47) |  |  | (213) | \n |  |  |  | \nDeferred tax provision |  | (2,342) |  |  | (2,349) | \nCredit losses and accounts receivable allowances |  | \u2014 |  |  | (3) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (599) |  |  | (1,386) | \nIncrease in inventories |  | (741) |  |  | (1,257) | \nDecrease in accounts payable and accrued liabilities |  | (1,061) |  |  | (1,170) | \n(Increase)/Decrease in other current and non-current assets |  | (1,144) |  |  | 3,527 | \nIncrease/(Decrease) in other current and non-current liabilities |  | 3,407 |  |  | (2,456) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 7,439 |  |  | 9,560 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (1,987) |  |  | (1,470) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 116 |  |  | 314 | \nAcquisitions, net of cash acquired (Note 10) |  | \u2014 |  |  | (523) | \nPurchases of investments |  | (9,688) |  |  | (22,048) | \nSales of investments |  | 11,877 |  |  | 17,634 | \nCredit support agreements activity, net |  | (798) |  |  | (10) | \nOther (primarily licenses and milestones) |  | 19 |  |  | (170) | \n |  |  |  | \nNET CASH USED BY INVESTING ACTIVITIES |  | (461) |  |  | (6,273) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (6,034) |  |  | (5,758) | \nRepurchase of common stock |  | (3,918) |  |  | (2,550) | \nProceeds from short-term debt (Note 4) |  | 12,221 |  |  | 4,371 | \nRepayment of short-term debt |  | (13,611) |  |  | (2,201) | \nProceeds from long-term debt, net of issuance costs (Note 4) |  | 7,674 |  |  | 2 | \nRepayment of long-term debt |  | (501) |  |  | (2,132) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 254 |  |  | 820 | \nCredit support agreements activity, net |  | (126) |  |  | 813 | \nProceeds from Kenvue initial public offering (Note 12) |  | 4,241 |  |  | \u2014 | \nOther |  | (53) |  |  | (11) | \n |  |  |  | \nNET CASH FROM/(USED BY) FINANCING ACTIVITIES |  | 147 |  |  | (6,646) | \n |  |  |  | \nEffect of exchange rate changes on cash and cash equivalents |  | (69) |  |  | (145) | \nIncrease/(Decrease) in cash and cash equivalents |  | 7,056 |  |  | (3,504) | \nCash and Cash equivalents beginning of period |  | 14,127 |  |  | 14,487 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 21,183 |  |  | 10,983 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | \u2014 |  |  | 621 | \nFair value of liabilities assumed |  | \u2014 |  |  | (98) | \nNet cash paid for acquisitions |  | $ | \u2014 |  |  | 523 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | January 1, 2023\nRaw materials and supplies |  | $ | 2,419 |  |  | 2,070 | \nGoods in process |  | 1,944 |  |  | 1,700 | \nFinished goods |  | 8,525 |  |  | 8,713 | \nTotal inventories |  | $ | 12,888 |  |  | 12,483 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | January 1, 2023\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 44,637 |  |  | 44,012 | \nLess accumulated amortization |  | (24,460) |  |  | (22,266) | \nPatents and trademarks \u2014 net |  | 20,177 |  |  | 21,746 | \nCustomer relationships and other intangibles \u2014 gross |  | 23,055 |  |  | 22,987 | \nLess accumulated amortization |  | (13,516) |  |  | (12,901) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 9,539 |  |  | 10,086 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 6,834 |  |  | 6,807 | \nPurchased in-process research and development |  | 9,696 |  |  | 9,686 | \nTotal intangible assets with indefinite lives |  | 16,530 |  |  | 16,493 | \nTotal intangible assets \u2014 net |  | $ | 46,246 |  |  | 48,325 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Consumer Health |  | Pharmaceutical |  | MedTech |  | Total\nGoodwill at January\u00a01, 2023 |  | $ | 9,184 |  |  | 10,184 |  |  | 25,863 |  |  | 45,231 | \nGoodwill, related to acquisitions |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nGoodwill, related to divestitures |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCurrency translation/Other |  | (103) |  |  | 137 |  |  | 175 |  | * | 209 | \nGoodwill at July\u00a02, 2023 |  | $ | 9,081 |  |  | 10,321 |  |  | 26,038 |  |  | 45,440 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2023 |  | 2024 |  | 2025 |  | 2026 |  | 2027\n$4,800 |  | 4,600 |  | 3,800 |  | 3,200 |  | 2,600  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | July 2, 2023 | July 3, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (175) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (241) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 175 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 241 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 33 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 44 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 33 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 44 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (15) |  | 56 |  | (12) |  | \u2014 |  | 3 |  | (17) |  | (6) |  | 42 |  | \u2014 |  | (39) | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (14) |  | 251 |  | 7 |  | \u2014 |  | 18 |  | (25) |  | 35 |  | 69 |  | \u2014 |  | (38) | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 74 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (432) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | July 2, 2023 | July 3, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (1,104) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (772) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 1,104 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 772 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 67 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 89 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 67 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 89 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | (3) |  | (90) |  | (25) |  | \u2014 |  | 5 |  | (34) |  | (58) |  | 65 |  | \u2014 |  | (57) | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | 10 |  | 396 |  | (29) |  | \u2014 |  | 4 |  | (3) |  | (59) |  | 102 |  | \u2014 |  | (111) | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 182 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 222 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (15) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (68) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | July 2, 2023 |  | January 1, 2023 |  | July 2, 2023 |  | January 1, 2023\n |  |  |  |  |  |  |  | \nLong-term Debt |  | $ | 8,662 |  |  | 8,665 |  |  | (1,443) |  |  | (1,435) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative | Gain/(Loss)Recognized InIncome on Derivative | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal Second Quarter Ended | Fiscal Six Months Ended | \nDerivatives Not Designated as Hedging Instruments |  |  |  | July 2, 2023 |  | July 3, 2022 | July 2, 2023 |  | July 3, 2022 | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | 33 |  |  | 73 |  | 2 |  |  | 102 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  |  |  | July 2, 2023 |  | July 3, 2022\nDebt |  | $ | 11 |  |  | 202 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | (24) |  |  | 313 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulated OCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  |  |  | July 2, 2023 |  | July 3, 2022\nDebt |  | $ | (66) |  |  | 270 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 666 |  |  | 873 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 1, 2023 |  |  |  |  |  | July 2, 2023 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value |  | $ | 576 |  |  | (30) |  |  | (53) |  |  | 493 |  |  | 493 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 698 |  |  | (26) |  |  | 75 |  |  | 747 |  |  | 747 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | July 2, 2023 |  |  |  | January 1, 2023\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 893 |  |  | \u2014 |  |  | 893 |  |  | 629 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,310 |  |  | \u2014 |  |  | 1,310 |  |  | 1,534 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,203 |  |  | \u2014 |  |  | 2,203 |  |  | 2,163 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 446 |  |  | \u2014 |  |  | 446 |  |  | 511 | \nInterest rate contracts(2) |  | \u2014 |  |  | 3,691 |  |  | \u2014 |  |  | 3,691 |  |  | 2,778 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 4,137 |  |  | \u2014 |  |  | 4,137 |  |  | 3,289 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 55 |  |  | \u2014 |  |  | 55 |  |  | 38 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 22 |  |  | 68 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 493 |  |  | \u2014 |  |  | \u2014 |  |  | 493 |  |  | 576 | \nDebt securities(4) |  | \u2014 |  |  | 9,831 |  |  | \u2014 |  |  | 9,831 |  |  | 10,487 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 1,142 |  |  | 1,142 |  |  | 1,120 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | July 2, 2023 |  | January 1, 2023\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 2,258 |  |  | 2,201 | \nCredit Support Agreement (CSA) |  | (2,119) |  |  | (2,176) | \nTotal Net Asset |  | 139 |  |  | 25 | \n |  |  |  | \nTotal Gross Liabilities |  | 4,159 |  |  | 3,357 | \nCredit Support Agreement (CSA) |  | (3,890) |  |  | (3,023) | \nTotal Net Liabilities |  | $ | 269 |  |  | 334 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | July 2, 2023 |  | July 3, 2022\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 1,120 |  |  | 533 | \nChanges in estimated fair value(6) |  | 25 |  |  | (88) | \nAdditions |  | \u2014 |  |  | 91 | \nPayments |  | (3) |  |  | \u2014 | \nEnding Balance |  | $ | 1,142 |  |  | 536 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/(Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 4,430 |  |  |  |  | \u2014 |  |  | 4,430 |  |  | 4,430 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities | 423 |  |  |  |  | \u2014 |  |  | 423 |  |  | 423 |  |  | \u2014 | \nU.S. reverse repurchase agreements | 8,991 |  |  |  |  | \u2014 |  |  | 8,991 |  |  | 8,991 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 641 |  |  |  |  | \u2014 |  |  | 641 |  |  | 368 |  |  | 273 | \nMoney market funds | 3,570 |  |  |  |  | \u2014 |  |  | 3,570 |  |  | 3,570 |  |  | \u2014 | \nTime deposits(1) | 619 |  |  |  |  | \u2014 |  |  | 619 |  |  | 619 |  |  | \u2014 | \nSubtotal | 18,674 |  |  |  |  | \u2014 |  |  | 18,674 |  |  | 18,401 |  |  | 273 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov\u2019t securities | 9,416 |  |  |  |  | (5) |  |  | 9,411 |  |  | 2,729 |  |  | 6,682 | \nU.S. Gov\u2019t Agencies | 123 |  |  |  |  | (2) |  |  | 121 |  |  | \u2014 |  |  | 121 | \nOther sovereign securities | 9 |  |  |  |  | \u2014 |  |  | 9 |  |  | 7 |  |  | 2 | \nCorporate debt securities | 291 |  |  |  |  | (1) |  |  | 290 |  |  | 46 |  |  | 244 | \nSubtotal available for sale debt(2) | $ | 9,839 |  |  |  |  | (8) |  |  | 9,831 |  |  | 2,782 |  |  | 7,049 | \nTotal cash, cash equivalents and current marketable securities | $ | 28,513 |  |  |  |  | (8) |  |  | 28,505 |  |  | 21,183 |  |  | 7,322 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 9,823 |  |  | 9,815 | \nDue after one year through five years |  | 16 |  |  | 16 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 9,839 |  |  | 9,831 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 11,701 |  |  | 11,676 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n |  |  |  | \n |  |  |  | \n5.50% Notes due 2024 (500MM GBP1.2605) |  | 629 |  |  | 627 | \n2.625% Notes due 2025 |  | 749 |  |  | 726 | \n0.55% Notes due 2025 |  | 926 |  |  | 914 | \n |  |  |  | \n2.45% Notes due 2026 |  | 1,997 |  |  | 1,890 | \n2.95% Notes due 2027 |  | 875 |  |  | 954 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,394 |  |  | 1,313 | \n2.90%\u00a0Notes due 2028 |  | 1,497 |  |  | 1,411 | \n1.150% Notes due 2028 (750MM Euro1.0873) |  | 811 |  |  | 728 | \n6.95% Notes due 2029 |  | 298 |  |  | 347 | \n1.30% Notes due 2030 |  | 1,605 |  |  | 1,435 | \n4.95% Debentures due 2033 |  | 498 |  |  | 525 | \n4.375% Notes due 2033 |  | 854 |  |  | 857 | \n1.650% Notes due 2035 (1.5B Euro1.0873) |  | 1,619 |  |  | 1,400 | \n3.55% Notes due 2036 |  | 840 |  |  | 901 | \n5.95% Notes due 2037 |  | 993 |  |  | 1,126 | \n3.625% Notes due 2037 |  | 1,334 |  |  | 1,355 | \n3.40%\u00a0Notes due 2038 |  | 992 |  |  | 889 | \n5.85% Debentures due 2038 |  | 697 |  |  | 783 | \n4.50% Debentures due 2040 |  | 541 |  |  | 539 | \n2.10% Notes due 2040 |  | 826 |  |  | 704 | \n4.85% Notes due 2041 |  | 297 |  |  | 299 | \n4.50% Notes due 2043 |  | 496 |  |  | 499 | \n3.70% Notes due 2046 |  | 1,977 |  |  | 1,758 | \n3.75% Notes due 2047 |  | 811 |  |  | 871 | \n3.50% Notes due 2048 |  | 743 |  |  | 640 | \n2.25% Notes due 2050 |  | 807 |  |  | 666 | \n2.45% Notes due 2060 |  | 1,053 |  |  | 811 | \n5.50% Debentures due 2025* |  | 748 |  |  | 752 | \n5.35% Debentures due 2026* |  | 747 |  |  | 756 | \n5.05% Debentures due 2028* |  | 994 |  |  | 1,006 | \n5.00% Debentures due 2030* |  | 992 |  |  | 1,006 | \n4.90% Debentures due 2033* |  | 1,240 |  |  | 1,264 | \n5.10% Debentures due 2043* |  | 741 |  |  | 763 | \n5.05% Debentures due 2053* |  | 1,476 |  |  | 1,531 | \n5.20% Debentures due 2063* |  | 738 |  |  | 765 | \nOther |  | 66 |  |  | 66 | \nTotal Non-Current Debt |  | $ | 33,901 |  |  | 32,877 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n |  | Retirement Plans |  | Other Benefit Plans |  | Retirement Plans |  | Other Benefit Plans\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\nService cost |  | $ | 216 |  |  | 319 |  |  | 69 |  |  | 80 |  |  | 428 |  |  | 640 |  |  | 137 |  |  | 160 | \nInterest cost |  | 373 |  |  | 229 |  |  | 55 |  |  | 27 |  |  | 727 |  |  | 459 |  |  | 109 |  |  | 53 | \nExpected return on plan assets |  | (694) |  |  | (693) |  |  | (2) |  |  | (2) |  |  | (1,362) |  |  | (1,392) |  |  | (3) |  |  | (4) | \nAmortization of prior service cost/(credit) |  | (46) |  |  | (46) |  |  | (1) |  |  | (2) |  |  | (92) |  |  | (92) |  |  | (1) |  |  | (3) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial (gains) losses |  | (50) |  |  | 167 |  |  | 7 |  |  | 31 |  |  | (100) |  |  | 329 |  |  | 13 |  |  | 61 | \nCurtailments and settlements |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 | \nNet periodic benefit cost/(credit) |  | $ | (201) |  |  | (24) |  |  | 128 |  |  | 134 |  |  | (399) |  |  | (55) |  |  | 255 |  |  | 267 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign |  | Gain/(Loss) |  | Employee |  | Gain/(Loss) |  | Total Accumulated\n |  | Currency |  | On |  | Benefit |  | On Derivatives |  | Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 1, 2023 |  | $ | (11,813) |  |  | (27) |  |  | (897) |  |  | (230) |  |  | (12,967) | \nNet change |  | (896) |  |  | 21 |  |  | (138) |  |  | 297 |  |  | (716) | \nAmount attributable to non-controlling interest |  | 548 |  |  |  |  |  |  |  |  | 548 | \nJuly 2, 2023 |  | $ | (12,161) |  |  | (6) |  |  | (1,035) |  |  | 67 |  |  | (13,135) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n(Shares in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\nBasic net earnings per share |  | $ | 1.98 |  |  | 1.83 |  |  | 1.95 |  |  | 3.79 | \nAverage shares outstanding \u2014 basic |  | 2,598.4 |  |  | 2,629.6 |  |  | 2,601.9 |  |  | 2,629.4 | \nPotential shares exercisable under stock option plans |  | 95.2 |  |  | 143.7 |  |  | 96.9 |  |  | 141.8 | \nLess: shares which could be repurchased under treasury stock method |  | (67.9) |  |  | (105.4) |  |  | (68.1) |  |  | (102.0) | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,625.7 |  |  | 2,667.9 |  |  | 2,630.7 |  |  | 2,669.2 | \nDiluted net earnings per share |  | $ | 1.96 |  |  | 1.80 |  |  | 1.93 |  |  | 3.73 |   |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n(Dollars in Millions) |  | July 2,2023 |  | July 3,2022 |  | PercentChange |  | July 2,2023 |  | July 3,2022 |  | Percent Change\n |  |  |  |  |  |  |  |  |  |  |  | \nCONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nOTC |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | $ | 712 |  |  | 663 |  |  | 7.5 | % |  | $ | 1,457 |  |  | 1,333 |  |  | 9.3 | %\nInternational |  | 947 |  |  | 818 |  |  | 15.7 |  |  | 1,844 |  |  | 1,609 |  |  | 14.6 | \nWorldwide |  | 1,659 |  |  | 1,482 |  |  | 12.0 |  |  | 3,301 |  |  | 2,943 |  |  | 12.2 | \nSkin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 650 |  |  | 629 |  |  | 3.4 |  |  | 1,267 |  |  | 1,173 |  |  | 8.0 | \nInternational |  | 498 |  |  | 497 |  |  | 0.3 |  |  | 991 |  |  | 965 |  |  | 2.7 | \nWorldwide |  | 1,148 |  |  | 1,126 |  |  | 2.0 |  |  | 2,258 |  |  | 2,138 |  |  | 5.6 | \nOral Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 173 |  |  | 170 |  |  | 1.7 |  |  | 332 |  |  | 313 |  |  | 6.2 | \nInternational |  | 225 |  |  | 224 |  |  | 0.3 |  |  | 427 |  |  | 447 |  |  | (4.7) | \nWorldwide |  | 398 |  |  | 394 |  |  | 0.9 |  |  | 759 |  |  | 760 |  |  | (0.2) | \nBaby Care |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 99 |  |  | 88 |  |  | 12.5 |  |  | 195 |  |  | 173 |  |  | 12.7 | \nInternational |  | 261 |  |  | 287 |  |  | (9.1) |  |  | 524 |  |  | 557 |  |  | (6.0) | \nWorldwide |  | 360 |  |  | 375 |  |  | (4.0) |  |  | 719 |  |  | 730 |  |  | (1.6) | \nWomen\u2019s Health |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 4 |  |  | 3 |  |  | (2.1) |  |  | 7 |  |  | 7 |  |  | (0.1) | \nInternational |  | 235 |  |  | 228 |  |  | 3.5 |  |  | 449 |  |  | 452 |  |  | (0.7) | \nWorldwide |  | 238 |  |  | 230 |  |  | 3.4 |  |  | 455 |  |  | 458 |  |  | (0.6) | \nWound Care/Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 149 |  |  | 133 |  |  | 12.3 |  |  | 264 |  |  | 245 |  |  | 7.9 | \nInternational |  | 58 |  |  | 65 |  |  | (10.3) |  |  | 107 |  |  | 117 |  |  | (8.4) | \nWorldwide |  | 207 |  |  | 197 |  |  | 4.9 |  |  | 371 |  |  | 361 |  |  | 2.6 | \nTOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,787 |  |  | 1,687 |  |  | 6.0 |  |  | 3,522 |  |  | 3,244 |  |  | 8.6 | \nInternational |  | 2,224 |  |  | 2,118 |  |  | 5.0 |  |  | 4,341 |  |  | 4,147 |  |  | 4.7 | \nWorldwide |  | 4,011 |  |  | 3,805 |  |  | 5.4 |  |  | 7,863 |  |  | 7,391 |  |  | 6.4 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,865 |  |  | 2,853 |  |  | 0.4 |  |  | 5,313 |  |  | 5,354 |  |  | (0.8) | \nInternational |  | 1,631 |  |  | 1,559 |  |  | 4.7 |  |  | 3,295 |  |  | 3,176 |  |  | 3.8 | \nWorldwide |  | 4,496 |  |  | 4,411 |  |  | 1.9 |  |  | 8,608 |  |  | 8,530 |  |  | 0.9 | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 277 |  |  | 391 |  |  | (29.3) |  |  | 553 |  |  | 749 |  |  | (26.2) | \nU.S. Exports |  | 33 |  |  | 44 |  |  | (24.9) |  |  | 74 |  |  | 124 |  |  | (40.3) | \nInternational |  | 152 |  |  | 212 |  |  | (28.2) |  |  | 322 |  |  | 437 |  |  | (26.2) | \nWorldwide |  | 462 |  |  | 647 |  |  | (28.6) |  |  | 949 |  |  | 1,310 |  |  | (27.5) | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 285 |  |  | 301 |  |  | (5.1) |  |  | 556 |  |  | 588 |  |  | (5.4) | \nInternational |  | 244 |  |  | 266 |  |  | (8.2) |  |  | 510 |  |  | 549 |  |  | (7.1) | \nWorldwide |  | 529 |  |  | 566 |  |  | (6.6) |  |  | 1,066 |  |  | 1,137 |  |  | (6.2) | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,817 |  |  | 1,731 |  |  | 4.9 |  |  | 3,268 |  |  | 3,110 |  |  | 5.1 | \nInternational |  | 981 |  |  | 868 |  |  | 13.0 |  |  | 1,974 |  |  | 1,777 |  |  | 11.1 | \nWorldwide |  | 2,797 |  |  | 2,599 |  |  | 7.6 |  |  | 5,241 |  |  | 4,887 |  |  | 7.2 | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 450 |  |  | 382 |  |  | 17.8 |  |  | 856 |  |  | 773 |  |  | 10.7 | \nInternational |  | 255 |  |  | 214 |  |  | 19.4 |  |  | 489 |  |  | 413 |  |  | 18.4 | \nWorldwide |  | 706 |  |  | 597 |  |  | 18.3 |  |  | 1,346 |  |  | 1,187 |  |  | 13.4 | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 4 |  |  | 3 |  |  | 17.8 |  |  | 7 |  |  | 9 |  |  | (30.2) | \nInternational |  | 0 |  | 0 |  | \u2014 |  |  | 0 |  | 0 |  | \u2014\nWorldwide |  | 4 |  |  | 3 |  |  | 17.8 |  |  | 7 |  |  | 9 |  |  | (30.2) | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 395 |  |  | 415 |  |  | (4.9) |  |  | 787 |  |  | 876 |  |  | (10.2) | \nInternational |  | 727 |  |  | 901 |  |  | (19.4) |  |  | 1,920 |  |  | 1,737 |  |  | 10.5 | \nWorldwide |  | 1,121 |  |  | 1,316 |  |  | (14.8) |  |  | 2,707 |  |  | 2,613 |  |  | 3.6 | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | \u2014 |  |  | 45 |  |  | * |  | \u2014 |  |  | 120 |  |  | *\nInternational |  | 285 |  |  | 499 |  |  | (43.0) |  |  | 1,032 |  |  | 881 |  |  | 17.1\nWorldwide |  | 285 |  |  | 544 |  |  | (47.7) |  |  | 1,032 |  |  | 1,001 |  |  | 3.0\nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 8 |  |  | 9 |  |  | (9.0) |  |  | 17 |  |  | 18 |  |  | (5.3) | \nInternational |  | 258 |  |  | 215 |  |  | 19.9 |  |  | 529 |  |  | 454 |  |  | 16.4 | \nWorldwide |  | 266 |  |  | 225 |  |  | 18.6 |  |  | 546 |  |  | 473 |  |  | 15.6 | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 382 |  |  | 355 |  |  | 7.6 |  |  | 760 |  |  | 724 |  |  | 5.0 | \nInternational |  | 109 |  |  | 110 |  |  | (0.2) |  |  | 208 |  |  | 242 |  |  | (13.9) | \nWorldwide |  | 491 |  |  | 464 |  |  | 5.8 |  |  | 968 |  |  | 965 |  |  | 0.3 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 5 |  |  | 6 |  |  | (27.2) |  |  | 10 |  |  | 14 |  |  | (30.6) | \nInternational |  | 74 |  |  | 77 |  |  | (3.5) |  |  | 151 |  |  | 160 |  |  | (5.6) | \nWorldwide |  | 79 |  |  | 83 |  |  | (5.2) |  |  | 161 |  |  | 174 |  |  | (7.6) | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,029 |  |  | 896 |  |  | 14.9 |  |  | 2,007 |  |  | 1,739 |  |  | 15.4 | \nInternational |  | 764 |  |  | 837 |  |  | (8.8) |  |  | 1,590 |  |  | 1,735 |  |  | (8.4) | \nWorldwide |  | 1,793 |  |  | 1,734 |  |  | 3.5 |  |  | 3,597 |  |  | 3,475 |  |  | 3.5 | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 64 |  |  | 38 |  |  | 68.2 |  |  | 134 |  |  | 73 |  |  | 84.0 | \nInternational |  | 143 |  |  | 123 |  |  | 16.3 |  |  | 279 |  |  | 245 |  |  | 13.9 | \nWorldwide |  | 208 |  |  | 161 |  |  | 28.6 |  |  | 414 |  |  | 318 |  |  | 30.0 | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 721 |  |  | 691 |  |  | 4.3 |  |  | 1,434 |  |  | 1,352 |  |  | 6.0 | \nInternational |  | 310 |  |  | 362 |  |  | (14.4) |  |  | 641 |  |  | 749 |  |  | (14.5) | \nWorldwide |  | 1,031 |  |  | 1,054 |  |  | (2.1) |  |  | 2,075 |  |  | 2,102 |  |  | (1.3) | \nSPRAVATO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 144 |  |  | 74 |  |  | 93.2 |  |  | 255 |  |  | 135 |  |  | 88.3 | \nInternational |  | 25 |  |  | 11 |  |  | * |  | 45 |  |  | 20 |  |  | *\nWorldwide |  | 169 |  |  | 85 |  |  | 98.2 |  |  | 300 |  |  | 155 |  |  | 93.1 | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 100 |  |  | 93 |  |  | 9.3 |  |  | 184 |  |  | 179 |  |  | 3.1 | \nInternational |  | 286 |  |  | 341 |  |  | (16.4) |  |  | 625 |  |  | 721 |  |  | (13.4) | \nWorldwide |  | 386 |  |  | 433 |  |  | (10.9) |  |  | 809 |  |  | 900 |  |  | (10.1) | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,069 |  |  | 1,679 |  |  | 23.2 |  |  | 3,958 |  |  | 3,261 |  |  | 21.4 | \nInternational |  | 2,329 |  |  | 2,362 |  |  | (1.4) |  |  | 4,552 |  |  | 4,731 |  |  | (3.8) | \nWorldwide |  | 4,398 |  |  | 4,042 |  |  | 8.8 |  |  | 8,510 |  |  | 7,992 |  |  | 6.5 | \nCARVYKTI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 114 |  |  | 24 |  |  | * |  | 184 |  |  | 24 |  |  | *\nInternational |  | 3 |  |  | \u2014 |  |  | * |  | 5 |  |  | \u2014 |  |  | *\nWorldwide |  | 117 |  |  | 24 |  |  | * |  | 189 |  |  | 24 |  |  | *\nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,322 |  |  | 1,021 |  |  | 29.5 |  |  | 2,513 |  |  | 1,974 |  |  | 27.3 | \nInternational |  | 1,110 |  |  | 965 |  |  | 15.0 |  |  | 2,182 |  |  | 1,868 |  |  | 16.8 | \nWorldwide |  | 2,431 |  |  | 1,986 |  |  | 22.4 |  |  | 4,695 |  |  | 3,842 |  |  | 22.2 | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 241 |  |  | 233 |  |  | 3.6 |  |  | 490 |  | 439 |  | 11.8 | \nInternational |  | 326 |  |  | 218 |  |  | 49.7 |  |  | 619 |  | 412 |  | 50.3 | \nWorldwide |  | 567 |  |  | 450 |  |  | 25.9 |  |  | 1,109 |  |  | 850 |  | 30.4 | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 262 |  |  | 349 |  |  | (24.9) |  |  | 532 |  |  | 719 |  |  | (26.0) | \nInternational |  | 579 |  |  | 620 |  |  | (6.7) |  |  | 1,136 |  |  | 1,288 |  |  | (11.8) | \nWorldwide |  | 841 |  |  | 970 |  |  | (13.2) |  |  | 1,668 |  |  | 2,008 |  |  | (16.9) | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 19 |  |  | (55.2) |  |  | 25 |  |  | 38 |  |  | (34.7) | \nInternational |  | 218 |  |  | 486 |  |  | (55.1) |  |  | 447 |  |  | 1,006 |  |  | (55.6) | \nWorldwide |  | 227 |  |  | 505 |  |  | (55.1) |  |  | 472 |  |  | 1,044 |  |  | (54.8) | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 122 |  |  | 33 |  |  | * |  | 214 |  |  | 67 |  |  | *\nInternational |  | 92 |  |  | 72 |  |  | 27.8 |  |  | 162 |  |  | 156 |  |  | 3.6 | \nWorldwide |  | 214 |  |  | 106 |  |  | * |  | 376 |  |  | 224 |  |  | 68.0 | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 684 |  |  | 560 |  |  | 22.0 |  |  | 1,284 |  |  | 1,132 |  |  | 13.4 | \nInternational |  | 289 |  |  | 284 |  |  | 2.0 |  |  | 561 |  |  | 563 |  |  | (0.4) | \nWorldwide |  | 972 |  |  | 843 |  |  | 15.3 |  |  | 1,844 |  |  | 1,695 |  |  | 8.8 | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 328 |  |  | 265 |  |  | 23.7 |  |  | 601 |  |  | 538 |  |  | 11.6 | \nInternational |  | 179 |  |  | 173 |  |  | 3.4 |  |  | 346 |  |  | 343 |  |  | 0.9 | \nWorldwide |  | 507 |  |  | 438 |  |  | 15.7 |  |  | 947 |  |  | 881 |  |  | 7.5 | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 338 |  |  | 272 |  |  | 24.2 |  |  | 642 |  |  | 541 |  |  | 18.7 | \nInternational |  | 61 |  |  | 56 |  |  | 10.0 |  |  | 119 |  |  | 112 |  |  | 6.6 | \nWorldwide |  | 399 |  |  | 328 |  |  | 21.8 |  |  | 761 |  |  | 653 |  |  | 16.6 | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 18 |  |  | 23 |  |  | (23.8) |  |  | 41 |  |  | 53 |  |  | (23.0) | \nInternational |  | 48 |  |  | 55 |  |  | (10.9) |  |  | 95 |  |  | 108 |  |  | (11.7) | \nWorldwide |  | 66 |  |  | 78 |  |  | (14.7) |  |  | 136 |  |  | 161 |  |  | (15.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 776 |  |  | 757 |  |  | 2.6 |  |  | 1,491 |  |  | 1,429 |  |  | 4.3 | \nInternational |  | 174 |  |  | 215 |  |  | (19.0) |  |  | 386 |  |  | 453 |  |  | (14.7) | \nWorldwide |  | 950 |  |  | 972 |  |  | (2.2) |  |  | 1,877 |  |  | 1,882 |  |  | (0.3) | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 637 |  |  | 609 |  |  | 4.7 |  |  | 1,215 |  |  | 1,117 |  |  | 8.8 | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nWorldwide |  | 637 |  |  | 609 |  |  | 4.7 |  |  | 1,215 |  |  | 1,117 |  |  | 8.8 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 138 |  |  | 148 |  |  | (6.3) |  |  | 275 |  |  | 312 |  |  | (11.8) | \nInternational |  | 174 |  |  | 215 |  |  | (19.0) |  |  | 386 |  |  | 453 |  |  | (14.7) | \nWorldwide |  | 313 |  |  | 363 |  |  | (13.8) |  |  | 662 |  |  | 765 |  |  | (13.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 7,818 |  |  | 7,159 |  |  | 9.2 |  |  | 14,841 |  |  | 13,791 |  |  | 7.6 | \nInternational |  | 5,913 |  |  | 6,158 |  |  | (4.0) |  |  | 12,303 |  |  | 12,395 |  |  | (0.7) | \nWorldwide |  | 13,731 |  |  | 13,317 |  |  | 3.1 |  |  | 27,144 |  |  | 26,186 |  |  | 3.7 | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 908 |  |  | 525 |  |  | 73.1 |  |  | 1,771 |  |  | 1,019 |  |  | 73.8 | \nInternational |  | 712 |  |  | 525 |  |  | 35.7 |  |  | 1,352 |  |  | 1,123 |  |  | 20.5 | \nWorldwide |  | 1,620 |  |  | 1,049 |  |  | 54.4 |  |  | 3,123 |  |  | 2,141 |  |  | 45.8 | \nELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 609 |  |  | 499 |  |  | 22.0 |  |  | 1,180 |  |  | 969 |  |  | 21.7 | \nInternational |  | 587 |  |  | 469 |  |  | 25.1 |  |  | 1,109 |  |  | 1,001 |  |  | 10.8 | \nWorldwide |  | 1,196 |  |  | 968 |  |  | 23.5 |  |  | 2,288 |  |  | 1,970 |  |  | 16.2 | \nABIOMED(3) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 272 |  |  | \u2014 |  |  | * |  | 536 |  |  | \u2014 |  |  | *\nInternational |  | 59 |  |  | \u2014 |  |  | * |  | 119 |  |  | \u2014 |  |  | *\nWorldwide |  | 331 |  |  | \u2014 |  |  | * |  | 655 |  |  | \u2014 |  |  | *\nOTHER INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 27 |  |  | 26 |  |  | 4.5 |  |  | 55 |  |  | 51 |  |  | 10.8 | \nInternational |  | 67 |  |  | 56 |  |  | 20.0 |  |  | 125 |  |  | 121 |  |  | 2.8 | \nWorldwide |  | 93 |  |  | 81 |  |  | 15.1 |  |  | 180 |  |  | 171 |  |  | 5.1 | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,388 |  |  | 1,338 |  |  | 3.7 |  |  | 2,751 |  |  | 2,627 |  |  | 4.7 | \nInternational |  | 878 |  |  | 820 |  |  | 7.0 |  |  | 1,759 |  |  | 1,719 |  |  | 2.3 | \nWorldwide |  | 2,265 |  |  | 2,157 |  |  | 5.0 |  |  | 4,510 |  |  | 4,345 |  |  | 3.8 | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 250 |  |  | 240 |  |  | 4.1 |  |  | 491 |  |  | 465 |  |  | 5.6 | \nInternational |  | 147 |  |  | 148 |  |  | (0.8) |  |  | 296 |  |  | 312 |  |  | (5.1) | \nWorldwide |  | 397 |  |  | 388 |  |  | 2.2 |  |  | 787 |  |  | 777 |  |  | 1.3 | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 221 |  |  | 216 |  |  | 2.4 |  |  | 447 |  |  | 417 |  |  | 7.2 | \nInternational |  | 142 |  |  | 133 |  |  | 6.3 |  |  | 284 |  |  | 271 |  |  | 4.8 | \nWorldwide |  | 363 |  |  | 349 |  |  | 3.9 |  |  | 731 |  |  | 688 |  |  | 6.3 | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 483 |  |  | 464 |  |  | 4.3 |  |  | 974 |  |  | 939 |  |  | 3.7 | \nInternational |  | 255 |  |  | 232 |  |  | 9.9 |  |  | 522 |  |  | 505 |  |  | 3.2 | \nWorldwide |  | 739 |  |  | 696 |  |  | 6.1 |  |  | 1,496 |  |  | 1,444 |  |  | 3.6 | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 433 |  |  | 418 |  |  | 3.5 |  |  | 839 |  |  | 805 |  |  | 4.1 | \nInternational |  | 334 |  |  | 306 |  |  | 9.0 |  |  | 657 |  |  | 630 |  |  | 4.2 | \nWorldwide |  | 766 |  |  | 724 |  |  | 5.8 |  |  | 1,495 |  |  | 1,436 |  |  | 4.2 | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,015 |  |  | 992 |  |  | 2.2 |  |  | 1,990 |  |  | 1,913 |  |  | 4.0 | \nInternational |  | 1,580 |  |  | 1,458 |  |  | 8.4 |  |  | 3,039 |  |  | 2,971 |  |  | 2.3 | \nWorldwide |  | 2,594 |  |  | 2,450 |  |  | 5.9 |  |  | 5,028 |  |  | 4,884 |  |  | 3.0 | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 466 |  |  | 454 |  |  | 2.7 |  |  | 910 |  |  | 871 |  |  | 4.5 | \nInternational |  | 757 |  |  | 702 |  |  | 7.8 |  |  | 1,430 |  |  | 1,431 |  |  | 0.0\nWorldwide |  | 1,222 |  |  | 1,156 |  |  | 5.8 |  |  | 2,340 |  |  | 2,302 |  |  | 1.7 | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 548 |  |  | 538 |  |  | 1.9 |  |  | 1,079 |  |  | 1,042 |  |  | 3.6 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInternational |  | 823 |  |  | 756 |  |  | 8.9 |  |  | 1,608 |  |  | 1,540 |  |  | 4.5 | \nWorldwide |  | 1,372 |  |  | 1,294 |  |  | 6.0 |  |  | 2,688 |  |  | 2,582 |  |  | 4.1 | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 529 |  |  | 496 |  |  | 6.6 |  |  | 1,087 |  |  | 1,017 |  |  | 6.9 | \nInternational |  | 778 |  |  | 745 |  |  | 4.6 |  |  | 1,521 |  |  | 1,481 |  |  | 2.7 | \nWorldwide |  | 1,308 |  |  | 1,241 |  |  | 5.4 |  |  | 2,608 |  |  | 2,498 |  |  | 4.4 | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 409 |  |  | 374 |  |  | 9.1 |  |  | 853 |  |  | 774 |  |  | 10.1 | \nInternational |  | 530 |  |  | 519 |  |  | 2.2 |  |  | 1,039 |  |  | 1,030 |  |  | 0.9 | \nWorldwide |  | 939 |  |  | 894 |  |  | 5.1 |  |  | 1,892 |  |  | 1,804 |  |  | 4.9 | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 120 |  |  | 122 |  |  | (1.1) |  |  | 234 |  |  | 243 |  |  | (3.6) | \nInternational |  | 249 |  |  | 225 |  |  | 10.1 |  |  | 482 |  |  | 451 |  |  | 6.7 | \nWorldwide |  | 369 |  |  | 347 |  |  | 6.2 |  |  | 716 |  |  | 694 |  |  | 3.1 | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,839 |  |  | 3,351 |  |  | 14.6 |  |  | 7,598 |  |  | 6,576 |  |  | 15.5 | \nInternational |  | 3,949 |  |  | 3,547 |  |  | 11.3 |  |  | 7,671 |  |  | 7,293 |  |  | 5.2 | \nWorldwide |  | 7,788 |  |  | 6,898 |  |  | 12.9 |  |  | 15,269 |  |  | 13,869 |  |  | 10.1 | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 13,444 |  |  | 12,197 |  |  | 10.2 |  |  | 25,961 |  |  | 23,611 |  |  | 10.0 | \nInternational |  | 12,086 |  |  | 11,823 |  |  | 2.2 |  |  | 24,315 |  |  | 23,835 |  |  | 2.0 | \nWorldwide |  | $ | 25,530 |  |  | 24,020 |  |  | 6.3 | % |  | $ | 50,276 |  |  | 47,446 |  |  | 6.0 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended | \n(Dollars in Millions) |  | July 2,2023 |  | July 3,2022 |  | PercentChange |  | July 2,2023 |  | July 3,2022 |  | PercentChange |  |  |  |  | \nConsumer Health(1) |  | $ | 860 |  |  | 784 |  |  | 9.7 | % |  | $ | 1,636 |  |  | 1,470 |  |  | 11.3% |  |  |  |  | \nPharmaceutical(2) |  | 4,862 |  |  | 4,420 |  |  | 10.0 |  |  | 9,306 |  |  | 8,344 |  |  | 11.5 |  |  |  |  |  | \nMedTech(3) |  | 1,699 |  |  | 1,141 |  |  | 48.9 |  | 3,144 |  |  | 2,618 |  |  | 20.1 |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 7,421 |  |  | 6,345 |  |  | 17.0 |  |  | 14,086 |  |  | 12,432 |  |  | 13.3 |  |  |  |  |  | \nLess: Expense not allocated to segments(4) |  | 377 |  |  | 237 |  |  |  |  | 7,479 |  |  | 360 |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 282 |  |  | 268 |  |  |  |  | 582 |  |  | 370 |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 6,762 |  |  | 5,840 |  |  | 15.8% |  | $ | 6,025 |  |  | 11,702 |  |  | (48.5) | % |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | PercentChange |  | July 2, 2023 |  | July 3, 2022 |  | Percent Change\nUnited States |  | $ | 13,444 |  |  | 12,197 |  |  | 10.2 | % |  | $ | 25,961 |  |  | 23,611 |  |  | 10.0 | %\nEurope |  | 5,894 |  |  | 6,085 |  |  | (3.1) |  |  | 12,226 |  |  | 12,109 |  |  | 1.0 | \nWestern Hemisphere, excluding U.S. |  | 1,713 |  |  | 1,536 |  |  | 11.5 |  |  | 3,300 |  |  | 3,018 |  |  | 9.3 | \nAsia-Pacific, Africa |  | 4,479 |  |  | 4,202 |  |  | 6.6 |  |  | 8,789 |  |  | 8,708 |  |  | 0.9 | \nTotal |  | $ | 25,530 |  |  | 24,020 |  |  | 6.3 | % |  | $ | 50,276 |  |  | 47,446 |  |  | 6.0 | %  |  |  |  |  |  |  |  | \nProduct or product category |  | Number of Plaintiffs\nBody powders containing talc, primarily JOHNSON\u2019S Baby Powder |  | 40,480 | \nDePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System |  | 160 | \nPINNACLE Acetabular Cup System |  | 940 | \nPelvic meshes |  | 7,160 | \nETHICON PHYSIOMESH Flexible Composite Mesh |  | 910 | \nRISPERDAL |  | 240 | \nELMIRON |  | 2,130 | \nTYLENOL |  | 520 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC |  | $ | 3,301 |  |  | $ | 2,943 |  |  | 12.2 | % |  | 14.8 | % |  | (2.6) | %\nSkin Health/Beauty |  | 2,258 |  |  | 2,138 |  |  | 5.6 |  |  | 8.0 |  |  | (2.4) | \nOral Care |  | 759 |  |  | 760 |  |  | (0.2) |  |  | 2.4 |  |  | (2.6) | \nBaby Care |  | 719 |  |  | 730 |  |  | (1.6) |  |  | 3.1 |  |  | (4.7) | \nWomen\u2019s Health |  | 455 |  |  | 458 |  |  | (0.6) |  |  | 7.1 |  |  | (7.7) | \nWound Care/Other |  | 371 |  |  | 361 |  |  | 2.6 |  |  | 4.9 |  |  | (2.3) | \nTotal Consumer Health Sales |  | $ | 7,863 |  |  | $ | 7,391 |  |  | 6.4 | % |  | 9.5 | % |  | (3.1) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nOTC |  | $ | 1,659 |  |  | $ | 1,482 |  |  | 12.0 | % |  | 13.9 | % |  | (1.9) | %\nSkin Health/Beauty |  | 1,148 |  |  | 1,126 |  |  | 2.0 |  |  | 3.5 |  |  | (1.5) | \nOral Care |  | 398 |  |  | 394 |  |  | 0.9 |  |  | 2.7 |  |  | (1.8) | \nBaby Care |  | 360 |  |  | 375 |  |  | (4.0) |  |  | (0.2) |  |  | (3.8) | \nWomen\u2019s Health |  | 238 |  |  | 230 |  |  | 3.4 |  |  | 10.0 |  |  | (6.6) | \nWound Care/Other |  | 207 |  |  | 197 |  |  | 4.9 |  |  | 6.8 |  |  | (1.9) | \nTotal Consumer Health Sales |  | $ | 4,011 |  |  | $ | 3,805 |  |  | 5.4 | % |  | 7.7 | % |  | (2.3) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 8,608 |  |  | $ | 8,530 |  |  | 0.9 | % |  | 2.6 | % |  | (1.7) | %\nREMICADE |  | 949 |  |  | 1,310 |  |  | (27.5) |  |  | (26.3) |  |  | (1.2) | \nSIMPONI/ SIMPONI ARIA |  | 1,066 |  |  | 1,137 |  |  | (6.2) |  |  | (3.3) |  |  | (2.9) | \nSTELARA |  | 5,241 |  |  | 4,887 |  |  | 7.2 |  |  | 8.7 |  |  | (1.5) | \nTREMFYA |  | 1,346 |  |  | 1,187 |  |  | 13.4 |  |  | 15.0 |  |  | (1.6) | \nOther Immunology |  | 7 |  |  | 9 |  |  | (30.2) |  |  | (30.2) |  |  | \u2014 | \nInfectious Diseases |  | 2,707 |  |  | 2,613 |  |  | 3.6 |  |  | 4.7 |  |  | (1.1) | \nCOVID-19 VACCINE |  | 1,032 |  |  | 1,001 |  |  | 3.0 |  | 4.2 |  | (1.2)\nEDURANT/rilpivirine |  | 546 |  |  | 473 |  |  | 15.6 |  |  | 17.1 |  |  | (1.5) | \nPREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA |  | 968 |  |  | 965 |  |  | 0.3 |  |  | 0.7 |  |  | (0.4) | \nOther Infectious Diseases |  | 161 |  |  | 174 |  |  | (7.6) |  |  | (3.6) |  |  | (4.0) | \nNeuroscience |  | 3,597 |  |  | 3,475 |  |  | 3.5 |  |  | 5.8 |  |  | (2.3) | \nCONCERTA/methylphenidate |  | 414 |  |  | 318 |  |  | 30.0 |  |  | 35.3 |  |  | (5.3) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA |  | 2,075 |  |  | 2,102 |  |  | (1.3) |  |  | 0.1 |  |  | (1.4) | \nSPRAVATO |  | 300 |  |  | 155 |  |  | 93.1 |  |  | 93.8 |  |  | (0.7) | \nOther Neuroscience(1) |  | 809 |  |  | 900 |  |  | (10.1) |  |  | (6.4) |  |  | (3.7) | \nOncology |  | 8,510 |  |  | 7,992 |  |  | 6.5 |  |  | 8.8 |  |  | (2.3) | \nCARVYKTI |  | 189 |  |  | 24 |  |  | * |  | * |  | *\nDARZALEX |  | 4,695 |  |  | 3,842 |  |  | 22.2 |  |  | 24.5 |  |  | (2.3) | \nERLEADA |  | 1,109 |  |  | 850 |  | 30.4 |  |  | 33.2 |  |  | (2.8) | \nIMBRUVICA |  | 1,668 |  |  | 2,008 |  |  | (16.9) |  |  | (15.0) |  |  | (1.9) | \nZYTIGA/ abiraterone acetate |  | 472 |  |  | 1,044 |  |  | (54.8) |  |  | (52.3) |  |  | (2.5) | \nOther Oncology |  | 376 |  |  | 224 |  |  | 68.0 |  |  | 70.4 |  |  | (2.4) | \nPulmonary Hypertension |  | 1,844 |  |  | 1,695 |  |  | 8.8 |  |  | 10.8 |  |  | (2.0) | \nOPSUMIT |  | 947 |  |  | 881 |  |  | 7.5 |  |  | 9.5 |  |  | (2.0) | \nUPTRAVI |  | 761 |  |  | 653 |  |  | 16.6 |  |  | 17.5 |  |  | (0.9) | \nOther Pulmonary Hypertension |  | 136 |  |  | 161 |  |  | (15.5) |  |  | (9.5) |  |  | (6.0) | \nCardiovascular / Metabolism / Other |  | 1,877 |  |  | 1,882 |  |  | (0.3) |  |  | 0.4 |  |  | (0.7) | \nXARELTO |  | 1,215 |  |  | 1,117 |  |  | 8.8 |  |  | 8.8 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 662 |  |  | 765 |  |  | (13.5) |  |  | (11.9) |  |  | (1.6) | \nTotal Pharmaceutical Sales |  | $ | 27,144 |  |  | $ | 26,186 |  |  | 3.7 | % |  | 5.5 | % |  | (1.8) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,496 |  |  | $ | 4,411 |  |  | 1.9 | % |  | 2.6 | % |  | (0.7) | %\nREMICADE |  | 462 |  |  | 647 |  |  | (28.6) |  |  | (27.6) |  |  | (1.0) | \nSIMPONI/ SIMPONI ARIA |  | 529 |  |  | 566 |  |  | (6.6) |  |  | (4.7) |  |  | (1.9) | \nSTELARA |  | 2,797 |  |  | 2,599 |  |  | 7.6 |  |  | 8.0 |  |  | (0.4) | \nTREMFYA |  | 706 |  |  | 597 |  |  | 18.3 |  |  | 18.9 |  |  | (0.6) | \nOther Immunology |  | 4 |  |  | 3 |  |  | 17.8 |  | 17.8 |  | \u2014\nInfectious Diseases |  | 1,121 |  |  | 1,316 |  |  | (14.8) |  |  | (16.6) |  |  | 1.8 | \nCOVID-19 VACCINE |  | 285 |  |  | 544 |  |  | (47.7) |  |  | (51.8) |  |  | 4.1 | \nEDURANT/rilpivirine |  | 266 |  |  | 225 |  |  | 18.6 |  |  | 16.2 |  |  | 2.4 | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 491 |  |  | 464 |  |  | 5.8 |  |  | 5.6 |  |  | 0.2 | \nOther Infectious Diseases |  | 79 |  |  | 83 |  |  | (5.2) |  |  | 1.3 |  |  | (6.5) | \nNeuroscience |  | 1,793 |  |  | 1,734 |  |  | 3.5 |  | 5.5 |  |  | (2.0) | \nCONCERTA/ methylphenidate |  | 208 |  |  | 161 |  |  | 28.6 |  |  | 32.4 |  |  | (3.8) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,031 |  |  | 1,054 |  |  | (2.1) |  |  | (1.5) |  |  | (0.6) | \nSPRAVATO |  | 169 |  |  | 85 |  |  | 98.2 |  |  | 98.5 |  |  | (0.3) | \nOther Neuroscience(1) |  | 386 |  |  | 433 |  |  | (10.9) |  |  | (5.8) |  |  | (5.1) | \nOncology |  | 4,398 |  |  | 4,042 |  |  | 8.8 |  |  | 9.7 |  |  | (0.9) | \nCARVYKTI |  | 117 |  |  | 24 |  |  | * |  | * |  | *\nDARZALEX |  | 2,431 |  |  | 1,986 |  |  | 22.4 |  |  | 23.4 |  |  | (1.0) | \nERLEADA |  | 567 |  |  | 450 |  |  | 25.9 |  |  | 26.9 |  |  | (1.0) | \nIMBRUVICA |  | 841 |  |  | 970 |  |  | (13.2) |  |  | (12.6) |  |  | (0.6) | \nZYTIGA/ abiraterone acetate |  | 227 |  |  | 505 |  |  | (55.1) |  |  | (53.8) |  |  | (1.3) | \nOther Oncology |  | 214 |  |  | 106 |  |  | * |  | * |  | *\nPulmonary Hypertension |  | 972 |  |  | 843 |  |  | 15.3 |  |  | 16.5 |  |  | (1.2) | \nOPSUMIT |  | 507 |  |  | 438 |  |  | 15.7 |  |  | 16.7 |  |  | (1.0) | \nUPTRAVI |  | 399 |  |  | 328 |  |  | 21.8 |  |  | 22.5 |  |  | (0.7) | \nOther Pulmonary Hypertension |  | 66 |  |  | 78 |  |  | (14.7) |  |  | (9.7) |  |  | (5.0) | \nCardiovascular / Metabolism / Other |  | 950 |  |  | 972 |  |  | (2.2) |  |  | (2.0) |  |  | (0.2) | \nXARELTO |  | 637 |  |  | 609 |  |  | 4.7 |  |  | 4.7 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 313 |  |  | 363 |  |  | (13.8) |  |  | (13.4) |  |  | (0.4) | \nTotal Pharmaceutical Sales |  | $ | 13,731 |  |  | $ | 13,317 |  |  | 3.1 | % |  | 3.8 | % |  | (0.7) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 5,028 |  |  | $ | 4,884 |  |  | 3.0 | % |  | 6.3 | % |  | (3.3) | %\nAdvanced |  | 2,340 |  |  | 2,302 |  |  | 1.7 |  |  | 5.0 |  |  | (3.3) | \nGeneral |  | 2,688 |  |  | 2,582 |  |  | 4.1 |  |  | 7.4 |  |  | (3.3) | \nOrthopaedics |  | 4,510 |  |  | 4,345 |  |  | 3.8 |  |  | 5.4 |  |  | (1.6) | \nHips |  | 787 |  |  | 777 |  |  | 1.3 |  |  | 2.8 |  |  | (1.5) | \nKnees |  | 731 |  |  | 688 |  |  | 6.3 |  |  | 7.9 |  |  | (1.6) | \nTrauma |  | 1,496 |  |  | 1,444 |  |  | 3.6 |  |  | 4.9 |  |  | (1.3) | \nSpine, Sports & Other |  | 1,495 |  |  | 1,436 |  |  | 4.2 |  |  | 6.1 |  |  | (1.9) | \nInterventional Solutions |  | 3,123 |  |  | 2,141 |  |  | 45.8 |  |  | 49.3 |  |  | (3.5) | \nElectrophysiology |  | 2,288 |  |  | 1,970 |  |  | 16.2 |  |  | 19.5 |  |  | (3.3) | \nAbiomed |  | 655 |  |  | \u2014 |  |  | * |  | * |  | *\nOther Interventional Solutions |  | 180 |  |  | 171 |  |  | 5.1 |  |  | 9.5 |  |  | (4.4) | \nVision |  | 2,608 |  |  | 2,498 |  |  | 4.4 |  |  | 7.2 |  |  | (2.8) | \nContact Lenses/Other |  | 1,892 |  |  | 1,804 |  |  | 4.9 |  |  | 8.0 |  |  | (3.1) | \nSurgical |  | 716 |  |  | 694 |  |  | 3.1 |  |  | 5.4 |  |  | (2.3) | \nTotal MedTech Sales |  | $ | 15,269 |  |  | $ | 13,869 |  |  | 10.1 | % |  | 12.8 | % |  | (2.7) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,594 |  |  | $ | 2,450 |  |  | 5.9 | % |  | 8.4 | % |  | (2.5) | %\nAdvanced |  | 1,222 |  |  | 1,156 |  |  | 5.8 |  |  | 8.4 |  |  | (2.6) | \nGeneral |  | 1,372 |  |  | 1,294 |  |  | 6.0 |  |  | 8.4 |  |  | (2.4) | \nOrthopaedics |  | 2,265 |  |  | 2,157 |  |  | 5.0 |  |  | 5.7 |  |  | (0.7) | \nHips |  | 397 |  |  | 388 |  |  | 2.2 |  |  | 3.0 |  |  | (0.8) | \nKnees |  | 363 |  |  | 349 |  |  | 3.9 |  |  | 4.5 |  |  | (0.6) | \nTrauma |  | 739 |  |  | 696 |  |  | 6.1 |  |  | 6.5 |  |  | (0.4) | \nSpine, Sports & Other |  | 766 |  |  | 724 |  |  | 5.8 |  |  | 7.0 |  |  | (1.2) | \nInterventional Solutions |  | 1,620 |  |  | 1,049 |  |  | 54.4 |  |  | 56.9 |  |  | (2.5) | \nElectrophysiology |  | 1,196 |  |  | 968 |  |  | 23.5 |  |  | 25.9 |  |  | (2.4) | \nAbiomed |  | 331 |  |  | \u2014 |  |  | * |  | * |  | *\nOther Interventional Solutions |  | 93 |  |  | 81 |  |  | 15.1 |  |  | 18.8 |  |  | (3.7) | \nVision |  | 1,308 |  |  | 1,241 |  |  | 5.4 |  |  | 6.9 |  |  | (1.5) | \nContact Lenses/Other |  | 939 |  |  | 894 |  |  | 5.1 |  |  | 6.6 |  |  | (1.5) | \nSurgical |  | 369 |  |  | 347 |  |  | 6.2 |  |  | 7.6 |  |  | (1.4) | \nTotal MedTech Sales |  | $ | 7,788 |  |  | $ | 6,898 |  |  | 12.9 | % |  | 14.7 | % |  | (1.8) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Six Months |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\nLitigation related(1) |  | $ | 6.8 |  |  | 0.4 |  |  | 6.4 | \n |  |  |  |  |  | \nConsumer Health separation costs |  | 0.5 |  |  | 0.4 |  |  | 0.1 | \nCOVID-19 Vaccine related exit costs |  | 0.4 |  |  | 0.0 |  |  | 0.4 | \nChanges in the fair value of securities |  | 0.1 |  |  | 0.5 |  |  | (0.4) | \nEmployee benefit plan related |  | (0.7) |  |  | (0.6) |  |  | (0.1) | \nOther(2) |  | 0.1 |  |  | (0.5) |  |  | 0.6 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 7.2 |  |  | 0.2 |  |  | 7.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Second Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\n |  |  |  |  |  | \nConsumer Health separation costs |  | $ | 0.2 |  |  | 0.3 |  |  | (0.1) | \nCOVID-19 Vaccine related exit costs |  | 0.2 |  |  | 0.0 |  |  | 0.2 | \nEmployee benefit plan related |  | (0.4) |  |  | (0.3) |  |  | (0.1) | \nLitigation related(1) |  | (0.1) |  |  | 0.4 |  |  | (0.5) | \nChanges in the fair value of securities |  | 0.0 |  | 0.1 |  |  | (0.1) | \nOther(2) |  | 0.0 |  | (0.2) |  |  | 0.2 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | (0.1) |  |  | 0.3 |  |  | (0.4) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\nConsumer Health |  | $ | 1,636 |  |  | $ | 1,470 |  |  | $ | 7,863 |  |  | $ | 7,391 |  |  | 20.8 | % |  | 19.9 | %\nPharmaceutical |  | 9,306 |  |  | 8,344 |  |  | 27,144 |  |  | 26,186 |  |  | 34.3 |  |  | 31.9 | \nMedTech |  | 3,144 |  |  | 2,618 |  |  | 15,269 |  |  | 13,869 |  |  | 20.6 |  |  | 18.9 | \nSegment earnings before tax |  | 14,086 |  |  | 12,432 |  |  | 50,276 |  |  | 47,446 |  |  | 28.0 |  |  | 26.2 | \nLess: Expenses not allocated to segments(1) |  | 7,479 |  |  | 360 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 582 |  |  | 370 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 6,025 |  |  | $ | 11,702 |  |  | $ | 50,276 |  |  | $ | 47,446 |  |  | 12.0 | % |  | 24.7 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022 |  | July 2, 2023 |  | July 3, 2022\nConsumer Health |  | $ | 860 |  |  | $ | 784 |  |  | $ | 4,011 |  |  | $ | 3,805 |  |  | 21.4 | % |  | 20.6 | %\nPharmaceutical |  | 4,862 |  |  | 4,420 |  |  | 13,731 |  |  | 13,317 |  |  | 35.4 |  |  | 33.2 | \nMedTech |  | 1,699 |  |  | 1,141 |  |  | 7,788 |  |  | 6,898 |  |  | 21.8 |  |  | 16.5 | \nSegment earnings before tax |  | 7,421 |  |  | 6,345 |  |  | 25,530 |  |  | 24,020 |  |  | 29.1 |  |  | 26.4 | \nLess: Expenses not allocated to segments(1) |  | 377 |  |  | 237 |  |  |  |  |  |  |  |  | \nLess: Consumer Health separation costs |  | 282 |  |  | 268 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 6,762 |  |  | $ | 5,840 |  |  | $ | 25,530 |  |  | $ | 24,020 |  |  | 26.5 | % |  | 24.3 | %  |  |  |  |  | \n(Dollars In Billions) | \n$ | 14.1 |  | Q4 2022 Cash and cash equivalents balance\n7.4 |  | net cash generated from operating activities\n(0.5) |  | net cash used by investing activities\n0.1 |  | net cash generated from financing activities\n0.1 |  | rounding\n | \n | \n$ | 21.2 |  | Q2 2023 Cash and cash equivalents  |  |  |  |  | \n(Dollars In Billions) | \n$ | 5.1 |  | Net earnings\n2.5 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision and net gain on sale of assets/businesses\n | \n(1.3) |  | an increase in accounts receivable and inventories\n | \n(1.1) |  | a decrease in accounts payable and accrued liabilities\n(1.1) |  | an increase in other current and non-current assets\n3.4 |  | an increase in other current and non-current liabilities\n(0.1) |  | Rounding\n$ | 7.4 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n(2.0) |  | additions to property, plant and equipment\n0.1 |  | proceeds from the disposal of assets/businesses, net\n | \n2.2 |  | net sales of investments\n(0.8) |  | credit support agreements activity, net and other\n | \n | \n$ | (0.5) |  | Net cash used by investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (6.0) |  | dividends to shareholders\n(3.9) |  | repurchase of common stock\n(1.9) |  | net repayment of short and long term debt and other\n7.7 |  | proceeds from Kenvue long term debt, net of issuance cost\n | \n | \n4.2 |  | proceeds from Kenvue initial public offering\n | \n$ | 0.1 |  | Net cash from financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nApril 3, 2023 through April 30, 2023 |  | 1,011,500 |  |  | 162.35 |  |  | \u2014 |  |  | \u2014\nMay 1, 2023 through May 28, 2023 |  | 383,500 |  |  | 161.73 |  |  | \u2014 |  |  | \u2014\nMay 29, 2023 through July 2, 2023 |  | 962,825 |  |  | 160.35 |  |  | \u2014 |  |  | \u2014\nTotal |  | 2,357,825 |  |  | 161.44 |  |  | \u2014 |  |  | \u2014  |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: July\u00a031, 2023 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: July\u00a031, 2023 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Johnson and Johnson, in 2023 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  |  |  |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  | \n |  | \n\u2611 |  | Quarterly Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934  |  |  |  |  |  |  |  | \n |  | \n\u2610 |  | Transition Report Pursuant to Section\u00a013 or 15(d) of the Securities Exchange Act of 1934for the transition period from\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0to  |  |  |  |  |  |  |  | \nNew Jersey |  | 22-1024240\n(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. EmployerIdentification No.)  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Large accelerated filer | \u2611 | Accelerated filer | \u2610\n | Non-accelerated filer | \u2610 | Smaller reporting company | \u2610\n | Emerging growth company | \u2610 |  |   |  |  |  |  |  |  |  | \nTitle of each class | Trading Symbol | Name of each exchange on which registered\nCommon Stock, Par Value $1.00 | JNJ | New York Stock Exchange\n0.650% Notes Due May 2024 | JNJ24C | New York Stock Exchange\n5.50% Notes Due November 2024 | JNJ24BP | New York Stock Exchange\n1.150% Notes Due November 2028 | JNJ28 | New York Stock Exchange\n1.650% Notes Due May 2035 | JNJ35 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Page\n |  |  | No.\nPart I \u2014 Financial Information |  |  | 1\n |  |  | \nItem\u00a01. Financial Statements (unaudited) |  |  | 1\n |  |  | \nConsolidated Balance Sheets \u2014October1, 2023 and January 1, 2023 |  |  | 1\n |  |  | \nConsolidated Statements of Earnings for the FiscalThirdQuarters EndedOctober1, 2023 andOctober2, 2022 |  |  | 2\n |  |  | \nConsolidated Statements of Earnings for the FiscalNineMonths EndedOctober1, 2023 andOctober2, 2022 |  |  | 3\n |  |  | \nConsolidated Statements of Comprehensive Income for the FiscalThirdQuarters and FiscalNineMonths EndedOctober1, 2023 andOctober2, 2022 |  |  | 4\n |  |  | \nConsolidated Statements of Equity for the FiscalThirdQuarters and FiscalNineMonths EndedOctober1, 2023 andOctober2, 2022 |  |  | 5\n |  |  | \nConsolidated Statements of Cash Flows for the FiscalNineMonths EndedOctober1, 2023 andOctober2, 2022 |  |  | 7\n |  |  | \nNotes to Consolidated Financial Statements |  |  | 9\n |  |  | \n |  |  | \n |  |  | \nItem\u00a02. Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 43\n |  |  | \nItem\u00a03. Quantitative and Qualitative Disclosures About Market Risk |  |  | 58\n |  |  | \nItem\u00a04. Controls and Procedures |  |  | 58\n |  |  | \nPart II \u2014 Other Information |  |  | 59\n |  |  | \nItem\u00a01 - Legal Proceedings |  |  | 59\n |  |  | \nItem\u00a02 - Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 59\n |  |  | \nItem 5 - Other Information |  |  | 59\n |  |  | \nItem\u00a06 - Exhibits |  |  | 60\n |  |  | \nSignatures |  |  | 61\n\n\n\n\n\n\n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | October 1, 2023 |  | January 1, 2023\nASSETS\nCurrent assets: |  |  |  | \nCash and cash equivalents (Note 4) |  | $ | 19,728 |  |  | 12,889 | \n |  |  |  | \nMarketable securities |  | 3,783 |  |  | 9,392 | \nAccounts receivable, trade, less allowances $160(2022, $169) |  | 14,798 |  |  | 14,039 | \nInventories (Note 2) |  | 11,198 |  |  | 10,268 | \nPrepaid expenses and other |  | 4,196 |  |  | 2,876 | \nCurrent assets of discontinued operations (Note 12) |  | \u2014 |  |  | 5,830 | \nTotal current assets |  | 53,703 |  |  | 55,294 | \nProperty, plant and equipment at cost |  | 45,626 |  |  | 43,534 | \nLess: accumulated depreciation |  | (26,805) |  |  | (25,552) | \nProperty, plant and equipment, net |  | 18,821 |  |  | 17,982 | \nIntangible assets, net (Note 3) |  | 35,021 |  |  | 38,489 | \nGoodwill (Note 3) |  | 36,124 |  |  | 36,047 | \nDeferred taxes on income (Note 5) |  | 9,259 |  |  | 8,947 | \nOther assets |  | 13,133 |  |  | 9,212 | \nNoncurrent assets of discontinued operations (Note 12) |  | \u2014 |  |  | 21,407\nTotal assets |  | $ | 166,061 |  |  | 187,378 | \nLIABILITIES AND SHAREHOLDERS\u2019 EQUITY\nCurrent liabilities: |  |  |  | \nLoans and notes payable |  | $ | 3,870 |  |  | 12,756 | \nAccounts payable |  | 8,355 |  |  | 9,889 | \nAccrued liabilities |  | 10,101 |  |  | 10,719 | \nAccrued rebates, returns and promotions |  | 15,808 |  |  | 13,579 | \nAccrued compensation and employee related obligations |  | 3,337 |  |  | 3,049 | \nAccrued taxes on income (Note 5) |  | 2,899 |  |  | 2,220 | \nCurrent liabilities of discontinued operations (Note 12) |  | \u2014 |  |  | 3,590\nTotal current liabilities |  | 44,370 |  |  | 55,802 | \nLong-term debt (Note 4) |  | 26,051 |  |  | 26,886 | \nDeferred taxes on income (Note 5) |  | 2,623 |  |  | 3,991 | \nEmployee related obligations (Note 6) |  | 5,687 |  |  | 6,542 | \nLong-term taxes payable (Note 5) |  | 2,540 |  |  | 4,306 | \nOther liabilities |  | 13,562 |  |  | 10,146 | \nNoncurrent liabilities of discontinued operations (Note 12) |  | \u2014 |  |  | 2,901 | \nTotal liabilities |  | $ | 94,833 |  |  | 110,574 | \nCommitments and Contingencies (Note 11) |  |  |  | \nShareholders\u2019 equity: |  |  |  | \nCommon stock \u2014 par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |  | $ | 3,120 |  |  | 3,120 | \nAccumulated other comprehensive income (loss) (Note 7) |  | (8,780) |  |  | (12,967) | \nRetained earnings and Additional paid-in capital |  | 152,536 |  |  | 128,345 | \nLess: common stock held in treasury, at cost (712,665,000and506,246,000shares) |  | 75,648 |  |  | 41,694 | \nTotal shareholders\u2019 equity |  | $ | 71,228 |  |  | 76,804 | \nTotal liabilities and shareholders\u2019 equity |  | $ | 166,061 |  |  | 187,378 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended\n |  | October 1,2023 |  | Percentto Sales |  | October 2,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 21,351 |  |  | 100.0 | % |  | $ | 19,996 |  |  | 100.0 | %\nCost of products sold |  | 6,606 |  |  | 30.9 |  |  | 6,172 |  |  | 30.9 | \nGross profit |  | 14,745 |  |  | 69.1 |  |  | 13,824 |  |  | 69.1 | \nSelling, marketing and administrative expenses |  | 5,400 |  |  | 25.3 |  |  | 4,975 |  |  | 24.9 | \nResearch and development expense |  | 3,447 |  |  | 16.2 |  |  | 3,485 |  |  | 17.4 | \nIn-process research and development impairments |  | 206 |  |  | 1.0 |  |  | \u2014 |  |  | \u2014 | \nInterest income |  | (374) |  |  | (1.7) |  |  | (150) |  |  | (0.8) | \nInterest expense, net of portion capitalized |  | 192 |  |  | 0.9 |  |  | 51 |  |  | 0.3 | \nOther (income) expense, net |  | 499 |  |  | 2.3 |  |  | 226 |  |  | 1.1 | \nRestructuring |  | 158 |  |  | 0.7 |  |  | 65 |  |  | 0.3 | \nEarnings before provision for taxes on income |  | 5,217 |  |  | 24.4 |  |  | 5,172 |  |  | 25.9 | \nProvision for taxes on income (Note\u00a05) |  | 908 |  |  | 4.2 |  |  | 862 |  |  | 4.3 | \nNet earnings from continuing operations |  | 4,309 |  |  | 20.2 | % |  | 4,310 |  |  | 21.6 | %\nNet earnings from discontinued operations, net of tax (Note 12) |  | 21,719 |  |  |  |  | 148 |  |  | \nNET EARNINGS |  | $ | 26,028 |  |  |  |  | $ | 4,458 |  |  | \n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nContinuing operations - basic |  | $ | 1.71 |  |  |  |  | $ | 1.64 |  |  | \nDiscontinued operations - basic |  | $ | 8.61 |  |  |  |  | $ | 0.06 |  |  | \nTotal net earnings per share - basic |  | $ | 10.32 |  |  |  |  | $ | 1.70 |  |  | \n |  |  |  |  |  |  |  | \nContinuing operations - diluted |  | $ | 1.69 |  |  |  |  | $ | 1.62 |  |  | \nDiscontinued operations - diluted |  | $ | 8.52 |  |  |  |  | $ | 0.06 |  |  | \nTotal net earnings per share - diluted |  | $ | 10.21 |  |  |  |  | $ | 1.68 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,522.9 |  |  |  |  | 2,627.9 |  |  | \nDiluted |  | 2,549.7 |  |  |  |  | 2,661.3 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 1,2023 |  | Percentto Sales |  | October 2,2022 |  | Percentto Sales\nSales to customers (Note 9) |  | $ | 63,764 |  |  | 100.0 | % |  | $ | 60,051 |  |  | 100.0 | %\nCost of products sold |  | 19,755 |  |  | 31.0 |  |  | 18,512 |  |  | 30.8 | \nGross profit |  | 44,009 |  |  | 69.0 |  |  | 41,539 |  |  | 69.2 | \nSelling, marketing and administrative expenses |  | 15,702 |  |  | 24.6 |  |  | 14,907 |  |  | 24.8 | \nResearch and development expense |  | 10,605 |  |  | 16.6 |  |  | 10,425 |  |  | 17.4 | \nIn-process research and development impairments |  | 255 |  |  | 0.4 |  |  | 610 |  | 1.0 | \nInterest income |  | (898) |  |  | (1.4) |  |  | (236) |  |  | (0.4) | \nInterest expense, net of portion capitalized |  | 621 |  |  | 1.0 |  |  | 99 |  |  | 0.2 | \nOther (income) expense, net |  | 7,055 |  |  | 11.1 |  |  | 15 |  |  | 0.0 | \nRestructuring |  | 433 |  |  | 0.6 |  |  | 200 |  |  | 0.4 | \nEarnings before provision for taxes on income |  | 10,236 |  |  | 16.1 |  |  | 15,519 |  |  | 25.8 | \nProvision for taxes on income (Note\u00a05) |  | 1,042 |  |  | 1.7 |  |  | 2,376 |  |  | 3.9 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nNet earnings from continuing operations |  | 9,194 |  |  | 14.4 | % |  | 13,143 |  |  | 21.9 | %\nNet earnings from discontinued operations, net of tax (Note 12) |  | 21,910 |  |  |  |  | 1,278 |  |  | \nNET EARNINGS |  | $ | 31,104 |  |  |  |  | $ | 14,421 |  |  | \n |  |  |  |  |  |  |  | \nNET EARNINGS PER SHARE (Note 8) |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nContinuing operations - basic |  | $ | 3.57 |  |  |  |  | $ | 5.00 |  |  | \nDiscontinued operations - basic |  | $ | 8.51 |  |  |  |  | $ | 0.49 |  |  | \nTotal net earnings per share - basic |  | $ | 12.08 |  |  |  |  | $ | 5.49 |  |  | \n |  |  |  |  |  |  |  | \nContinuing operations - diluted |  | $ | 3.53 |  |  |  |  | $ | 4.93 |  |  | \nDiscontinued operations - diluted |  | $ | 8.42 |  |  |  |  | $ | 0.48 |  |  | \nTotal net earnings per share - diluted |  | $ | 11.95 |  |  |  |  | $ | 5.41 |  |  | \n |  |  |  |  |  |  |  | \nAVG. SHARES OUTSTANDING |  |  |  |  |  |  |  | \nBasic |  | 2,575.6 |  |  |  |  | 2,628.9 |  |  | \nDiluted |  | 2,603.4 |  |  |  |  | 2,667.5 |  |  | \n |  |  |  |  |  |  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\n |  |  |  |  |  |  | \nNet earnings | $ | 26,028 |  |  | 4,458 |  |  | $ | 31,104 |  |  | 14,421 | \n |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  |  |  |  |  |  | \nForeign currency translation | 448 |  |  | (1,252) |  |  | (448) |  |  | (1,957) | \n |  |  |  |  |  |  | \nSecurities: |  |  |  |  |  |  | \nUnrealized holding gain (loss) arising during period | 4 |  |  | (2) |  |  | 25 |  |  | (35) | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nNet change | 4 |  |  | (2) |  |  | 25 |  |  | (35) | \n |  |  |  |  |  |  | \nEmployee benefit plans: |  |  |  |  |  |  | \nPrior service cost amortization during period | (36) |  |  | (37) |  |  | (107) |  |  | (110) | \nGain (loss) amortization during period | (34) |  |  | 151 |  |  | (101) |  |  | 454 | \nConsumer settlement/curtailment | 33 |  |  | \u2014 |  |  | 33 |  |  | \u2014 | \nNet change | (37) |  |  | 114 |  |  | (175) |  |  | 344 | \n |  |  |  |  |  |  | \nDerivatives & hedges: |  |  |  |  |  |  | \nUnrealized gain (loss) arising during period | (513) |  |  | (204) |  |  | (80) |  |  | (254) | \nReclassifications to earnings | (180) |  |  | (105) |  |  | (316) |  |  | (332) | \nNet change | (693) |  |  | (309) |  |  | (396) |  |  | (586) | \n |  |  |  |  |  |  | \nOther comprehensive income (loss) | (278) |  |  | (1,449) |  |  | (994) |  |  | (2,234) | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nComprehensive income | $ | 25,750 |  |  | 3,009 |  |  | $ | 30,110 |  |  | 12,187 | \n |  |  |  |  |  |  |   |  | \nThe tax effects in other comprehensive income/(loss) for the fiscal third quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $335million and $181million; Securities: $1million and $0million; Employee Benefit Plans: $8million and $33million; Derivatives & Hedges: $185million and $82million.\n\nThe tax effects in other comprehensive income/(loss) for the fiscal nine months were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $69million and $859million; Securities: $7million and $9million; Employee Benefit Plans: $51million and $98million; Derivatives & Hedges: $105million and $155million.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount |  | Non-controlling interest (NCI) | \nBalance, July 2, 2023 | $ | 76,409 |  |  | 129,381 |  |  | (13,135) |  |  | 3,120 |  |  | (44,217) |  |  | 1,260 |  | \nNet earnings | 26,028 |  |  | 26,028 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nCash dividends paid                   ($1.19per share) | (2,871) |  |  | (2,871) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nEmployee compensation and stock option plans | 948 |  |  | 41 |  |  | \u2014 |  |  | \u2014 |  |  | 907 |  |  |  | \nRepurchase of common stock | (920) |  |  |  |  | \u2014 |  |  | \u2014 |  |  | (920) |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nKenvue Separation (Note 12) | (28,088) |  |  | (43) |  |  | 4,633 |  |  | \u2014 |  |  | (31,418) |  |  | (1,260) |  | \nOther comprehensive income (loss), net of tax | (278) |  |  | \u2014 |  |  | (278) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nBalance, October 1, 2023 | $ | 71,228 |  |  | 152,536 |  |  | (8,780) |  |  | 3,120 |  |  | (75,648) |  |  | \u2014 |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount |  | Non-controlling interest (NCI) | \nBalance, January 1, 2023 | $ | 76,804 |  |  | 128,345 |  |  | (12,967) |  |  | 3,120 |  |  | (41,694) |  |  | \u2014 |  | \nNet earnings | 31,104 |  |  | 31,104 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nCash dividends paid ($3.51per share) | (8,905) |  |  | (8,905) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nEmployee compensation and stock option plans | 1,892 |  |  | (435) |  |  | \u2014 |  |  | \u2014 |  |  | 2,327 |  |  | \u2014 |  | \nRepurchase of common stock | (4,838) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,838) |  |  | \u2014 |  | \nOther | (25) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (25) |  |  | \u2014 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nKenvue Separation/IPO (Note 12) | (23,810) |  |  | 2,427 |  |  | 5,181 |  |  | \u2014 |  |  | (31,418) |  |  | \u2014 |  | \nOther comprehensive income (loss), net of tax | (994) |  |  | \u2014 |  |  | (994) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \nBalance, October 1, 2023 | $ | 71,228 |  |  | 152,536 |  |  | (8,780) |  |  | 3,120 |  |  | (75,648) |  |  | \u2014 |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, July 3, 2022 | $ | 76,357 |  |  | 126,216 |  |  | (13,843) |  |  | 3,120 |  |  | (39,136) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 4,458 |  |  | 4,458 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($1.13per share) | (2,970) |  |  | (2,970) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 368 |  |  | 213 |  |  | \u2014 |  |  | \u2014 |  |  | 155 | \nRepurchase of common stock | (2,165) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,165) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (1,449) |  |  | \u2014 |  |  | (1,449) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 2, 2022 | $ | 74,599 |  |  | 127,917 |  |  | (15,292) |  |  | 3,120 |  |  | (41,146) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \nFiscal nine Months Ended October\u00a02, 2022\n | Total |  | RetainedEarnings and Additional paid-in capital |  | AccumulatedOtherComprehensiveIncome |  | Common StockIssued Amount |  | TreasuryStockAmount\nBalance, January 2, 2022 | $ | 74,023 |  |  | 123,060 |  |  | (13,058) |  |  | 3,120 |  |  | (39,099) | \n |  |  |  |  |  |  |  |  | \nNet earnings | 14,421 |  |  | 14,421 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCash dividends paid ($3.32per share) | (8,728) |  |  | (8,728) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nEmployee compensation and stock option plans | 1,832 |  |  | (836) |  |  | \u2014 |  |  | \u2014 |  |  | 2,668 | \nRepurchase of common stock | (4,715) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,715) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax | (2,234) |  |  | \u2014 |  |  | (2,234) |  |  | \u2014 |  |  | \u2014 | \nBalance, October 2, 2022 | $ | 74,599 |  |  | 127,917 |  |  | (15,292) |  |  | 3,120 |  |  | (41,146) | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 1,2023 |  | October 2,2022\nCASH FLOWS FROM OPERATING ACTIVITIES |  |  |  | \nNet earnings |  | $ | 31,104 |  |  | 14,421 | \nAdjustments to reconcile net earnings to cash flows from operating activities: |  |  |  | \nDepreciation and amortization of property and intangibles |  | 5,643 |  |  | 5,198 | \nStock based compensation |  | 984 |  |  | 925 | \n |  |  |  | \n |  |  |  | \nAsset write-downs |  | 820 |  |  | 787 | \n |  |  |  | \nGain on Kenvue separation |  | (20,984) |  |  | \u2014 | \nNet gain on sale of assets/businesses |  | (117) |  |  | (213) | \n |  |  |  | \nDeferred tax provision |  | (1,782) |  |  | (2,488) | \nCredit losses and accounts receivable allowances |  | \u2014 |  |  | (14) | \nChanges in assets and liabilities, net of effects from acquisitions and divestitures: |  |  |  | \nIncrease in accounts receivable |  | (851) |  |  | (1,591) | \nIncrease in inventories |  | (1,447) |  |  | (1,877) | \nIncrease in accounts payable and accrued liabilities |  | 664 |  |  | 141 | \n(Increase)/Decrease in other current and non-current assets |  | (1,366) |  |  | 4,563 | \nIncrease/(Decrease) in other current and non-current liabilities |  | 2,260 |  |  | (4,008) | \n |  |  |  | \nNET CASH FLOWS FROM OPERATING ACTIVITIES |  | 14,928 |  |  | 15,844 | \n |  |  |  | \nCASH FLOWS FROM INVESTING ACTIVITIES |  |  |  | \nAdditions to property, plant and equipment |  | (2,954) |  |  | (2,422) | \nProceeds from the disposal of assets/businesses, net (Note 10) |  | 237 |  |  | 322 | \nAcquisitions, net of cash acquired (Note 10) |  | \u2014 |  |  | (522) | \nPurchases of investments |  | (9,981) |  |  | (31,163) | \nSales of investments |  | 15,787 |  |  | 26,324 | \nCredit support agreements activity, net |  | (917) |  |  | (305) | \nOther (primarily licenses and milestones) |  | (92) |  |  | (208) | \n |  |  |  | \nNET CASH FROM (USED BY) INVESTING ACTIVITIES |  | 2,080 |  |  | (7,974) | \n |  |  |  | \nCASH FLOWS FROM FINANCING ACTIVITIES |  |  |  | \nDividends to shareholders |  | (8,905) |  |  | (8,728) | \nRepurchase of common stock |  | (4,838) |  |  | (4,715) | \nProceeds from short-term debt (Note 4) |  | 12,462 |  |  | 7,099 | \nRepayment of short-term debt |  | (21,645) |  |  | (4,808) | \nProceeds from long-term debt, net of issuance costs (Note 4) |  | \u2014 |  |  | 1 | \nRepayment of long-term debt |  | (502) |  |  | (2,133) | \nProceeds from the exercise of stock options/employee withholding tax on stock awards, net |  | 907 |  |  | 907 | \nCredit support agreements activity, net |  | 62 |  |  | 1,678 | \nProceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation |  | 8,047 |  |  | \u2014 | \nProceeds from Kenvue initial public offering (Note 12) |  | 4,241 |  |  | \u2014 | \nCash transferred to Kenvue at separation |  | (1,114) |  |  | \u2014 | \nOther |  | 115 |  |  | 128 | \n |  |  |  | \nNET CASH USED BY FINANCING ACTIVITIES |  | (11,170) |  |  | (10,571) | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n |  | October 1,2023 |  | October 2,2022\nEffect of exchange rate changes on cash and cash equivalents |  | (237) |  |  | (431) | \nIncrease/(Decrease) in cash and cash equivalents |  | 5,601 |  |  | (3,132) | \nCash and cash equivalents from continuing operations, beginning of period |  | 12,889 |  |  | 13,309 | \nCash and cash equivalents from discontinued operations, beginning of period |  | 1,238 |  |  | 1,178 | \nCash and Cash equivalents beginning of period |  | 14,127 |  |  | 14,487 | \n |  |  |  | \nCash and cash equivalents from continuing operations, end of period |  | 19,728 |  |  | 10,347 | \nCash and cash equivalents from discontinued operations, end of period |  | \u2014 |  |  | 1,008 | \nCASH AND CASH EQUIVALENTS, END OF PERIOD |  | $ | 19,728 |  |  | 11,355 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nAcquisitions |  |  |  | \nFair value of assets acquired |  | $ | \u2014 |  |  | 620 | \nFair value of liabilities assumed |  | \u2014 |  |  | (98) | \nNet cash paid for acquisitions |  | $ | \u2014 |  |  | 522 | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | January 1, 2023\nRaw materials and supplies |  | $ | 2,233 |  |  | 1,719 | \nGoods in process |  | 1,961 |  |  | 1,577 | \nFinished goods |  | 7,004 |  |  | 6,972 | \nTotal inventories |  | $ | 11,198 |  |  | 10,268 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | January 1, 2023\nIntangible assets with definite lives: |  |  |  | \nPatents and trademarks \u2014 gross |  | $ | 39,284 |  |  | 39,388 | \nLess accumulated amortization |  | (23,052) |  |  | (20,616) | \nPatents and trademarks \u2014 net |  | 16,232 |  |  | 18,772 | \nCustomer relationships and other intangibles \u2014 gross |  | 19,844 |  |  | 19,764 | \nLess accumulated amortization |  | (12,159) |  |  | (11,363) | \nCustomer relationships and other intangibles\u00a0\u2014 net(1) |  | 7,685 |  |  | 8,401 | \nIntangible assets with indefinite lives: |  |  |  | \nTrademarks |  | 1,640 |  |  | 1,630 | \nPurchased in-process research and development |  | 9,464 |  |  | 9,686 | \nTotal intangible assets with indefinite lives |  | 11,104 |  |  | 11,316 | \nTotal intangible assets \u2014 net |  | $ | 35,021 |  |  | 38,489 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  | Innovative Medicine |  | MedTech |  | Total\nGoodwill at January\u00a01, 2023 |  |  |  | $ | 10,184 |  |  | 25,863 |  |  | 36,047 | \nGoodwill, related to acquisitions |  |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nGoodwill, related to divestitures |  |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nCurrency translation/Other |  |  |  | (35) |  |  | 112 |  | * | 77 | \nGoodwill at October\u00a01, 2023 |  |  |  | $ | 10,149 |  |  | 25,975 |  |  | 36,124 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  |  |  |  |  | \n2023 |  | 2024 |  | 2025 |  | 2026 |  | 2027\n$4,500 |  | 4,300 |  | 3,500 |  | 2,900 |  | 2,300  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | October 1, 2023 | October 2, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (61) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (322) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 61 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 322 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 31 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 13 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 31 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 13 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | 6 |  | 102 |  | (5) |  | \u2014 |  | 4 |  | (20) |  | (83) |  | 53 |  | \u2014 |  | 22 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (11) |  | (166) |  | 49 |  | \u2014 |  | 38 |  | (45) |  | (94) |  | 91 |  | \u2014 |  | 36 | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 41 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 120 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (454) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (205) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | October 1, 2023 | October 2, 2022\n(Dollars in Millions) | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense | Sales | Cost of Products Sold | R&D Expense | Interest (Income) Expense | Other (Income)  Expense\n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nThe effects of fair value, net investment and cash flow hedging: |  |  |  |  |  |  |  |  |  | \nGain (Loss) on fair value hedging relationship: |  |  |  |  |  |  |  |  |  | \nInterest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nHedged items | $ | \u2014 |  | \u2014 |  | \u2014 |  | (1,165) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,094) |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  | \u2014 |  | \u2014 |  | 1,165 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,094 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on net investment hedging relationship: |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing | \u2014 |  | \u2014 |  | \u2014 |  | 98 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 | \nAmount of gain or (loss) recognized in AOCI | \u2014 |  | \u2014 |  | \u2014 |  | 98 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nGain (Loss) on cash flow hedging relationship: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | 3 |  | 12 |  | (30) |  | \u2014 |  | 9 |  | (54) |  | (141) |  | 118 |  | \u2014 |  | (35) | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | (1) |  | 230 |  | 20 |  | \u2014 |  | 42 |  | (48) |  | (153) |  | 193 |  | \u2014 |  | (75) | \n |  |  |  |  |  |  |  |  |  | \nCross currency interest rate swaps contracts: |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) reclassified from AOCI into income | \u2014 |  | \u2014 |  | \u2014 |  | 223 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 342 |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nAmount of gain or (loss) recognized in AOCI | $ | \u2014 |  | \u2014 |  | \u2014 |  | (469) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (273) |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLine item in the Consolidated Balance Sheet in which the hedged item is included |  | Carrying Amount of the Hedged Liability |  | Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability\n |  | \n(Dollars in Millions) |  | October 1, 2023 |  | January 1, 2023 |  | October 1, 2023 |  | January 1, 2023\n |  |  |  |  |  |  |  | \nLong-term Debt |  | $ | 8,589 |  |  | 8,665 |  |  | (1,523) |  |  | (1,435) | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  | Gain/(Loss)Recognized InIncome on Derivative | Gain/(Loss)Recognized InIncome on Derivative | \n(Dollars in Millions) |  | Location of Gain /(Loss) Recognized in Income on Derivative |  | Fiscal Third Quarter Ended | Fiscal Nine Months Ended | \nDerivatives Not Designated as Hedging Instruments |  |  |  | October 1, 2023 |  | October 2, 2022 | October 1, 2023 |  | October 2, 2022 | \nForeign Exchange Contracts |  | Other (income) expense |  | $ | \u2014 |  |  | 109 |  | 2 |  |  | 211 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulatedOCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  |  |  | October 1, 2023 |  | October 2, 2022\nDebt |  | $ | 101 |  |  | 208 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 214 |  |  | 261 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Gain/(Loss)Recognized InAccumulated OCI |  | Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income |  | Gain/(Loss)                                                                                                                                                                                                                                  Reclassified FromAccumulated OCIInto Income\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  |  |  | October 1, 2023 |  | October 2, 2022\nDebt |  | $ | 35 |  |  | 478 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 | \nCross Currency interest rate swaps |  | $ | 880 |  |  | 1,134 |  |  | Interest (income) expense |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | January 1, 2023 |  |  |  |  |  | October 1, 2023 |  | \n |  | Carrying Value |  | Changes in Fair Value Reflected in Net Income(1) |  | Sales/ Purchases/Other(2) |  | Carrying Value |  | Non Current Other Assets\nEquity Investments with readily determinable value* |  | $ | 576 |  |  | (813) |  |  | 4,260 |  |  | 4,023 |  |  | 4,023 | \n |  |  |  |  |  |  |  |  |  | \nEquity Investments without readily determinable value |  | $ | 613 |  |  | (24) |  |  | 96 |  |  | 685 |  |  | 685 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | October 1, 2023 |  |  |  | January 1, 2023\n(Dollars in Millions) |  | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Total(1)\nDerivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | $ | \u2014 |  |  | 901 |  |  | \u2014 |  |  | 901 |  |  | 629 | \nInterest rate contracts(2) |  | \u2014 |  |  | 1,534 |  |  | \u2014 |  |  | 1,534 |  |  | 1,534 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 2,435 |  |  | \u2014 |  |  | 2,435 |  |  | 2,163 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 577 |  |  | \u2014 |  |  | 577 |  |  | 511 | \nInterest rate contracts(2) |  | \u2014 |  |  | 3,669 |  |  | \u2014 |  |  | 3,669 |  |  | 2,778 | \n |  |  |  |  |  |  |  |  |  | \nTotal |  | \u2014 |  |  | 4,246 |  |  | \u2014 |  |  | 4,246 |  |  | 3,289 | \nDerivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  | \nAssets: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 58 |  |  | \u2014 |  |  | 58 |  |  | 38 | \nLiabilities: |  |  |  |  |  |  |  |  |  | \nForward foreign exchange contracts |  | \u2014 |  |  | 47 |  |  | \u2014 |  |  | 47 |  |  | 68 | \nOther Investments: |  |  |  |  |  |  |  |  |  | \nEquity investments(3) |  | 4,023 |  |  | \u2014 |  |  | \u2014 |  |  | 4,023 |  |  | 576 | \nDebt securities(4) |  | \u2014 |  |  | 8,407 |  |  | \u2014 |  |  | 8,407 |  |  | 10,487 | \nOther Liabilities |  |  |  |  |  |  |  |  |  | \nContingent consideration(5) |  | $ | \u2014 |  |  | \u2014 |  |  | 1,178 |  |  | 1,178 |  |  | 1,120 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGross to Net Derivative Reconciliation |  | October 1, 2023 |  | January 1, 2023\n(Dollars in Millions) |  |  |  | \nTotal Gross Assets |  | $ | 2,493 |  |  | 2,201 | \nCredit Support Agreement (CSA) |  | (2,472) |  |  | (2,176) | \nTotal Net Asset |  | 21 |  |  | 25 | \n |  |  |  | \nTotal Gross Liabilities |  | 4,293 |  |  | 3,357 | \nCredit Support Agreement (CSA) |  | (4,174) |  |  | (3,023) | \nTotal Net Liabilities |  | $ | 119 |  |  | 334 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | October 1, 2023 |  | October 2, 2022\n(Dollars in Millions) |  |  |  | \nBeginning Balance |  | $ | 1,120 |  |  | 533 | \nChanges in estimated fair value(6) |  | 62 |  |  | (85) | \nAdditions |  | \u2014 |  |  | 89 | \nPayments |  | (4) |  |  | (12) | \nEnding Balance |  | $ | 1,178 |  |  | 525 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) | Carrying Amount |  |  |  | Gain/(Loss) |  | Estimated Fair Value |  | Cash & Cash Equivalents |  | Current Marketable Securities\nCash | $ | 3,214 |  |  |  |  | \u2014 |  |  | 3,214 |  |  | 3,214 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nNon-U.S. sovereign securities | 150 |  |  |  |  | \u2014 |  |  | 150 |  |  | 150 |  |  | \u2014 | \nU.S. reverse repurchase agreements | 7,261 |  |  |  |  | \u2014 |  |  | 7,261 |  |  | 7,261 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities(1) | 228 |  |  |  |  | \u2014 |  |  | 228 |  |  | 78 |  |  | 150 | \nMoney market funds | 3,503 |  |  |  |  | \u2014 |  |  | 3,503 |  |  | 3,503 |  |  | \u2014 | \nTime deposits(1) | 748 |  |  |  |  | \u2014 |  |  | 748 |  |  | 748 |  |  | \u2014 | \nSubtotal | 15,104 |  |  |  |  | \u2014 |  |  | 15,104 |  |  | 14,954 |  |  | 150 | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Unrealized Loss |  |  |  |  |  | \nU.S. Gov\u2019t securities | 8,062 |  |  |  |  | (1) |  |  | 8,061 |  |  | 4,728 |  |  | 3,333 | \nU.S. Gov\u2019t Agencies | 95 |  |  |  |  | (2) |  |  | 93 |  |  | \u2014 |  |  | 93 | \nOther sovereign securities | 6 |  |  |  |  | \u2014 |  |  | 6 |  |  | 2 |  |  | 4 | \nCorporate debt securities | 247 |  |  |  |  | \u2014 |  |  | 247 |  |  | 44 |  |  | 203 | \nSubtotal available for sale debt(2) | $ | 8,410 |  |  |  |  | (3) |  |  | 8,407 |  |  | 4,774 |  |  | 3,633 | \nTotal cash, cash equivalents and current marketable securities | $ | 23,514 |  |  |  |  | (3) |  |  | 23,511 |  |  | 19,728 |  |  | 3,783 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Cost Basis |  | Fair Value\nDue within one year |  | $ | 8,400 |  |  | 8,397 | \nDue after one year through five years |  | 10 |  |  | 10 | \nDue after five years through ten years |  | \u2014 |  |  | \u2014 | \nTotal debt securities |  | $ | 8,410 |  |  | 8,407 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | Carrying Amount |  | Estimated Fair Value\n |  |  |  | \nFinancial Liabilities |  |  |  | \n |  |  |  | \nCurrent Debt |  | $ | 3,870 |  |  | 3,852 | \n |  |  |  | \nNon-Current Debt |  |  |  | \n |  |  |  | \n |  |  |  | \n5.50% Notes due 2024 (500MM GBP1.2190) |  | 609 |  |  | 609 | \n2.625% Notes due 2025 |  | 750 |  |  | 726 | \n0.55% Notes due 2025 |  | 947 |  |  | 916 | \n |  |  |  | \n2.45% Notes due 2026 |  | 1,997 |  |  | 1,879 | \n2.95% Notes due 2027 |  | 882 |  |  | 937 | \n |  |  |  | \n0.95% Notes due 2027 |  | 1,409 |  |  | 1,290 | \n2.90%\u00a0Notes due 2028 |  | 1,497 |  |  | 1,384 | \n1.150% Notes due 2028 (750MM Euro1.0534) |  | 786 |  |  | 705 | \n6.95% Notes due 2029 |  | 298 |  |  | 337 | \n1.30% Notes due 2030 |  | 1,604 |  |  | 1,377 | \n4.95% Debentures due 2033 |  | 499 |  |  | 507 | \n4.375% Notes due 2033 |  | 854 |  |  | 809 | \n1.650% Notes due 2035 (1.5B Euro1.0534) |  | 1,568 |  |  | 1,282 | \n3.55% Notes due 2036 |  | 831 |  |  | 852 | \n5.95% Notes due 2037 |  | 994 |  |  | 1,060 | \n3.625% Notes due 2037 |  | 1,321 |  |  | 1,261 | \n3.40%\u00a0Notes due 2038 |  | 993 |  |  | 823 | \n5.85% Debentures due 2038 |  | 697 |  |  | 735 | \n4.50% Debentures due 2040 |  | 541 |  |  | 502 | \n2.10% Notes due 2040 |  | 809 |  |  | 639 | \n4.85% Notes due 2041 |  | 297 |  |  | 282 | \n4.50% Notes due 2043 |  | 496 |  |  | 450 | \n3.70% Notes due 2046 |  | 1,977 |  |  | 1,555 | \n3.75% Notes due 2047 |  | 787 |  |  | 788 | \n3.50% Notes due 2048 |  | 743 |  |  | 564 | \n2.25% Notes due 2050 |  | 776 |  |  | 573 | \n2.45% Notes due 2060 |  | 1,025 |  |  | 695 | \nOther |  | 64 |  |  | 62 | \nTotal Non-Current Debt |  | $ | 26,051 |  |  | 23,599 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n |  | Retirement Plans |  | Other Benefit Plans |  | Retirement Plans |  | Other Benefit Plans\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\nService cost |  | $ | 210 |  |  | 313 |  |  | 61 |  |  | 80 |  |  | 638 |  |  | 953 |  |  | 198 |  |  | 240 | \nInterest cost |  | 363 |  |  | 226 |  |  | 51 |  |  | 26 |  |  | 1,090 |  |  | 685 |  |  | 160 |  |  | 79 | \nExpected return on plan assets |  | (680) |  |  | (683) |  |  | (1) |  |  | (2) |  |  | (2,042) |  |  | (2,075) |  |  | (4) |  |  | (6) | \nAmortization of prior service cost/(credit) |  | (47) |  |  | (46) |  |  | \u2014 |  |  | (1) |  |  | (139) |  |  | (138) |  |  | (1) |  |  | (4) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRecognized actuarial (gains) losses |  | (50) |  |  | 163 |  |  | 4 |  |  | 30 |  |  | (150) |  |  | 492 |  |  | 17 |  |  | 91 | \nCurtailments and settlements |  | 72 |  |  | \u2014 |  |  | (9) |  |  | \u2014 |  |  | 72 |  |  | 1 |  |  | (9) |  |  | \u2014 | \nNet periodic benefit cost/(credit) |  | $ | (132) |  |  | (27) |  |  | 106 |  |  | 133 |  |  | (531) |  |  | (82) |  |  | 361 |  |  | 400 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | Foreign Currency |  | Gain/(Loss) On |  | Employee Benefit |  | Gain/(Loss) On Derivatives |  | Total Accumulated Other Comprehensive\n(Dollars in Millions) |  | Translation |  | Securities |  | Plans |  | & Hedges |  | Income (Loss)\nJanuary 1, 2023 |  | $ | (11,813) |  |  | (27) |  |  | (897) |  |  | (230) |  |  | (12,967) | \nChange from continuing operations |  | (448) |  |  | 25 |  |  | (175) |  |  | (396) |  |  | (994) | \nKenvue Separation |  | 4,885 |  | ** | 0 |  | 296 | * | 0 |  | 5,181 | \n |  |  |  |  |  |  |  |  |  | \nNet change |  | 4,437 |  |  | 25 |  |  | 121 |  |  | (396) |  |  | 4,187 | \nOctober 1, 2023 |  | (7,376) |  |  | (2) |  |  | (776) |  |  | (626) |  |  | (8,780) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Shares in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\nBasic net earnings per share from continuing operations |  | $ | 1.71 |  |  | 1.64 |  |  | 3.57 |  |  | 5.00 | \nBasic net earnings per share from discontinued operations |  | 8.61 |  |  | 0.06 |  |  | 8.51 |  |  | 0.49 | \nTotal net earnings per share - basic |  | 10.32 |  |  | 1.70 |  |  | 12.08 |  |  | 5.49 | \nAverage shares outstanding \u2014 basic |  | 2,522.9 |  |  | 2,627.9 |  |  | 2,575.6 |  |  | 2,628.9 | \nPotential shares exercisable under stock option plans |  | 119.2 |  |  | 140.1 |  |  | 96.9 |  |  | 141.1 | \nLess: shares which could be repurchased under treasury stock method |  | (92.4) |  |  | (106.7) |  |  | (69.1) |  |  | (102.5) | \n |  |  |  |  |  |  |  | \nAverage shares outstanding \u2014 diluted |  | 2,549.7 |  |  | 2,661.3 |  |  | 2,603.4 |  |  | 2,667.5 | \nDiluted net earnings per share from continuing operations |  | 1.69 |  |  | 1.62 |  |  | 3.53 |  |  | 4.93 | \nDiluted net earnings per share from discontinuing operations |  | 8.52 |  |  | 0.06 |  |  | 8.42 |  |  | 0.48 | \nTotal net earnings per share - diluted |  | $ | 10.21 |  |  | 1.68 |  | 11.95 |  | 5.41  |  |  |  |  |  |  |  | \n\n  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 1,2023 |  | October 2,2022 |  | PercentChange |  | October 1,2023 |  | October 2,2022 |  | Percent Change\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nINNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,193 |  |  | 2,876 |  |  | 11.0 |  |  | 8,506 |  |  | 8,230 |  |  | 3.3 | \nInternational |  | 1,656 |  |  | 1,411 |  |  | 17.4 |  |  | 4,951 |  |  | 4,587 |  |  | 7.9 | \nWorldwide |  | 4,849 |  |  | 4,287 |  |  | 13.1 |  |  | 13,457 |  |  | 12,817 |  |  | 5.0 | \nREMICADE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 296 |  |  | 350 |  |  | (15.4) |  |  | 849 |  |  | 1,099 |  |  | (22.7) | \nU.S. Exports |  | 38 |  |  | 39 |  |  | (2.5) |  |  | 112 |  |  | 163 |  |  | (31.3) | \nInternational |  | 127 |  |  | 169 |  |  | (25.1) |  |  | 449 |  |  | 606 |  |  | (25.9) | \nWorldwide |  | 461 |  |  | 558 |  |  | (17.4) |  |  | 1,410 |  |  | 1,868 |  |  | (24.5) | \nSIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 310 |  |  | 298 |  |  | 3.9 |  |  | 866 |  |  | 886 |  |  | (2.3) | \nInternational |  | 319 |  |  | 248 |  |  | 29.1 |  |  | 829 |  |  | 797 |  |  | 4.1 | \nWorldwide |  | 629 |  |  | 545 |  |  | 15.3 |  |  | 1,695 |  |  | 1,682 |  |  | 0.8 | \nSTELARA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,912 |  |  | 1,655 |  |  | 15.5 |  |  | 5,180 |  |  | 4,766 |  |  | 8.7 | \nInternational |  | 951 |  |  | 794 |  |  | 19.9 |  |  | 2,925 |  |  | 2,571 |  |  | 13.8 | \nWorldwide |  | 2,864 |  |  | 2,449 |  |  | 16.9 |  |  | 8,105 |  |  | 7,336 |  |  | 10.5 | \nTREMFYA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 634 |  |  | 530 |  |  | 19.6 |  |  | 1,490 |  |  | 1,303 |  |  | 14.4 | \nInternational |  | 258 |  |  | 200 |  |  | 29.0 |  |  | 747 |  |  | 613 |  |  | 21.9 | \nWorldwide |  | 891 |  |  | 729 |  |  | 22.2 |  |  | 2,237 |  |  | 1,916 |  |  | 16.8 | \nOTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2 |  |  | 5 |  |  | (47.1) |  |  | 9 |  |  | 14 |  |  | (36.1) | \nInternational |  | 0 |  | 0 |  | \u2014 |  |  | 0 |  | 0 |  | \u2014\nWorldwide |  | 2 |  |  | 5 |  |  | (47.1) |  |  | 9 |  |  | 14 |  |  | (36.1) | \n |  |  |  |  |  |  |  |  |  |  |  | \nInfectious Diseases |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 360 |  |  | 390 |  |  | (7.8) |  |  | 1,147 |  |  | 1,266 |  |  | (9.4) | \nInternational |  | 500 |  |  | 905 |  |  | (44.8) |  |  | 2,420 |  |  | 2,642 |  |  | (8.4) | \nWorldwide |  | 859 |  |  | 1,295 |  |  | (33.6) |  |  | 3,566 |  |  | 3,908 |  |  | (8.7) | \nCOVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \u2014 |  |  | 120 |  |  | *\nInternational |  | 41 |  |  | 489 |  |  | (91.5) |  |  | 1,073 |  |  | 1,370 |  |  | (21.6)\nWorldwide |  | 41 |  |  | 489 |  |  | (91.5) |  |  | 1,073 |  |  | 1,490 |  |  | (27.9)\nEDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 9 |  |  | 9 |  |  | 10.2 |  |  | 26 |  |  | 27 |  |  | (0.5) | \nInternational |  | 287 |  |  | 237 |  |  | 21.4 |  |  | 816 |  |  | 691 |  |  | 18.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nWorldwide |  | 297 |  |  | 245 |  |  | 21.0 |  |  | 843 |  |  | 718 |  |  | 17.5 | \nPREZISTA / PREZCOBIX /REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 345 |  |  | 372 |  |  | (7.3) |  |  | 1,105 |  |  | 1,096 |  |  | 0.9 | \nInternational |  | 102 |  |  | 112 |  |  | (9.5) |  |  | 310 |  |  | 354 |  |  | (12.5) | \nWorldwide |  | 447 |  |  | 485 |  |  | (7.8) |  |  | 1,415 |  |  | 1,450 |  |  | (2.4) | \nOTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 5 |  |  | 10 |  |  | (42.7) |  |  | 15 |  |  | 24 |  |  | (35.5) | \nInternational |  | 69 |  |  | 68 |  |  | 2.0 |  |  | 220 |  |  | 228 |  |  | (3.4) | \nWorldwide |  | 74 |  |  | 77 |  |  | (3.6) |  |  | 235 |  |  | 251 |  |  | (6.4) | \n |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,036 |  |  | 919 |  |  | 12.7 |  |  | 3,043 |  |  | 2,658 |  |  | 14.5 | \nInternational |  | 706 |  |  | 763 |  |  | (7.4) |  |  | 2,296 |  |  | 2,498 |  |  | (8.1) | \nWorldwide |  | 1,742 |  |  | 1,681 |  |  | 3.6 |  |  | 5,339 |  |  | 5,156 |  |  | 3.5 | \nCONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 57 |  |  | 41 |  |  | 38.1 |  |  | 191 |  |  | 114 |  |  | 67.4 | \nInternational |  | 133 |  |  | 117 |  |  | 13.6 |  |  | 412 |  |  | 362 |  |  | 13.8 | \nWorldwide |  | 189 |  |  | 158 |  |  | 20.0 |  |  | 603 |  |  | 476 |  |  | 26.7 | \nINVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 730 |  |  | 684 |  |  | 6.8 |  |  | 2,164 |  |  | 2,036 |  |  | 6.3 | \nInternational |  | 299 |  |  | 348 |  |  | (14.0) |  |  | 940 |  |  | 1,097 |  |  | (14.3) | \nWorldwide |  | 1,029 |  |  | 1,031 |  |  | (0.2) |  |  | 3,104 |  |  | 3,132 |  |  | (0.9) | \nSPRAVATO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 154 |  |  | 88 |  |  | 75.1 |  |  | 409 |  |  | 223 |  |  | 83.1 | \nInternational |  | 29 |  |  | 12 |  |  | * |  | 74 |  |  | 32 |  |  | *\nWorldwide |  | 183 |  |  | 100 |  |  | 82.1 |  |  | 483 |  |  | 255 |  |  | 88.8 | \nOTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 94 |  |  | 106 |  |  | (11.3) |  |  | 278 |  |  | 285 |  |  | (2.3) | \nInternational |  | 245 |  |  | 286 |  |  | (13.9) |  |  | 870 |  |  | 1,007 |  |  | (13.5) | \nWorldwide |  | 340 |  |  | 393 |  |  | (13.2) |  |  | 1,149 |  |  | 1,293 |  |  | (11.0) | \n |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 2,219 |  |  | 1,812 |  |  | 22.5 |  |  | 6,177 |  |  | 5,073 |  |  | 21.8 | \nInternational |  | 2,313 |  |  | 2,252 |  |  | 2.7 |  |  | 6,865 |  |  | 6,983 |  |  | (1.7) | \nWorldwide |  | 4,533 |  |  | 4,064 |  |  | 11.5 |  |  | 13,043 |  |  | 12,056 |  |  | 8.2 | \nCARVYKTI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 140 |  |  | 55 |  |  | * |  | 324 |  |  | 79 |  |  | *\nInternational |  | 12 |  |  | \u2014 |  |  | * |  | 17 |  |  | \u2014 |  |  | *\nWorldwide |  | 152 |  |  | 55 |  |  | * |  | 341 |  |  | 79 |  |  | *\nDARZALEX |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,369 |  |  | 1,097 |  |  | 24.8 |  |  | 3,882 |  |  | 3,071 |  |  | 26.4 | \nInternational |  | 1,130 |  |  | 955 |  |  | 18.3 |  |  | 3,312 |  |  | 2,823 |  |  | 17.3 | \nWorldwide |  | 2,499 |  |  | 2,052 |  |  | 21.8 |  |  | 7,194 |  |  | 5,894 |  |  | 22.1 | \nERLEADA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 288 |  |  | 254 |  |  | 12.9 |  |  | 778 |  | 693 |  | 12.2 | \nInternational |  | 342 |  |  | 235 |  |  | 45.8 |  |  | 961 |  | 647 |  | 48.7 | \nWorldwide |  | 631 |  |  | 490 |  |  | 28.7 |  |  | 1,740 |  |  | 1,340 |  |  | 29.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIMBRUVICA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 264 |  |  | 353 |  |  | (25.2) |  |  | 796 |  |  | 1,072 |  |  | (25.8) | \nInternational |  | 545 |  |  | 559 |  |  | (2.5) |  |  | 1,681 |  |  | 1,847 |  |  | (9.0) | \nWorldwide |  | 808 |  |  | 911 |  |  | (11.3) |  |  | 2,476 |  |  | 2,918 |  |  | (15.2) | \nZYTIGA/abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 16 |  |  | 16 |  |  | (2.8) |  |  | 41 |  |  | 54 |  |  | (24.9) | \nInternational |  | 199 |  |  | 440 |  |  | (54.9) |  |  | 646 |  |  | 1,446 |  |  | (55.3) | \nWorldwide |  | 214 |  |  | 456 |  |  | (53.0) |  |  | 686 |  |  | 1,500 |  |  | (54.2) | \nOTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 143 |  |  | 37 |  |  | * |  | 357 |  |  | 104 |  |  | *\nInternational |  | 86 |  |  | 64 |  |  | 34.5 |  |  | 248 |  |  | 220 |  |  | 12.5 | \nWorldwide |  | 229 |  |  | 100 |  |  | * |  | 605 |  |  | 324 |  |  | 86.5 | \n |  |  |  |  |  |  |  |  |  |  |  | \nPulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 680 |  |  | 604 |  |  | 12.6 |  |  | 1,964 |  |  | 1,736 |  |  | 13.1 | \nInternational |  | 274 |  |  | 247 |  |  | 10.5 |  |  | 835 |  |  | 810 |  |  | 3.0 | \nWorldwide |  | 954 |  |  | 852 |  |  | 12.0 |  |  | 2,798 |  |  | 2,547 |  |  | 9.9 | \nOPSUMIT |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 323 |  |  | 289 |  |  | 12.2 |  |  | 924 |  |  | 827 |  |  | 11.8 | \nInternational |  | 166 |  |  | 152 |  |  | 9.3 |  |  | 512 |  |  | 495 |  |  | 3.5 | \nWorldwide |  | 490 |  |  | 441 |  |  | 11.2 |  |  | 1,437 |  |  | 1,322 |  |  | 8.7 | \nUPTRAVI |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 336 |  |  | 283 |  |  | 18.9 |  |  | 978 |  |  | 824 |  |  | 18.7 | \nInternational |  | 66 |  |  | 50 |  |  | 30.9 |  |  | 185 |  |  | 162 |  |  | 14.1 | \nWorldwide |  | 402 |  |  | 333 |  |  | 20.7 |  |  | 1,163 |  |  | 986 |  |  | 18.0 | \nOTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 20 |  |  | 33 |  |  | (37.1) |  |  | 61 |  |  | 86 |  |  | (28.4) | \nInternational |  | 42 |  |  | 46 |  |  | (7.5) |  |  | 137 |  |  | 154 |  |  | (10.5) | \nWorldwide |  | 63 |  |  | 78 |  |  | (19.8) |  |  | 199 |  |  | 239 |  |  | (16.9) | \n |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 763 |  |  | 837 |  |  | (8.8) |  |  | 2,254 |  |  | 2,266 |  |  | (0.5) | \nInternational |  | 194 |  |  | 198 |  |  | (2.1) |  |  | 580 |  |  | 651 |  |  | (10.8) | \nWorldwide |  | 957 |  |  | 1,034 |  |  | (7.5) |  |  | 2,834 |  |  | 2,916 |  |  | (2.8) | \nXARELTO |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 625 |  |  | 689 |  |  | (9.4) |  |  | 1,840 |  |  | 1,806 |  |  | 1.9 | \nInternational |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nWorldwide |  | 625 |  |  | 689 |  |  | (9.4) |  |  | 1,840 |  |  | 1,806 |  |  | 1.9 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nOTHER(2) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 139 |  |  | 147 |  |  | (6.1) |  |  | 414 |  |  | 459 |  |  | (9.9) | \nInternational |  | 194 |  |  | 198 |  |  | (2.1) |  |  | 580 |  |  | 651 |  |  | (10.8) | \nWorldwide |  | 332 |  |  | 345 |  |  | (3.8) |  |  | 994 |  |  | 1,110 |  |  | (10.5) | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 8,249 |  |  | 7,438 |  |  | 10.9 |  |  | 23,090 |  |  | 21,229 |  |  | 8.8 | \nInternational |  | 5,644 |  |  | 5,776 |  |  | (2.3) |  |  | 17,947 |  |  | 18,171 |  |  | (1.2) | \nWorldwide |  | 13,893 |  |  | 13,214 |  |  | 5.1 |  |  | 41,037 |  |  | 39,400 |  |  | 4.2 | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMEDTECH |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nInterventional Solutions |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 891 |  |  | 547 |  |  | 63.0 |  |  | 2,662 |  |  | 1,566 |  |  | 70.0 | \nInternational |  | 667 |  |  | 513 |  |  | 29.9 |  |  | 2,019 |  |  | 1,636 |  |  | 23.4 | \nWorldwide |  | 1,558 |  |  | 1,060 |  |  | 47.0 |  |  | 4,681 |  |  | 3,202 |  |  | 46.2 | \nELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 611 |  |  | 520 |  |  | 17.6 |  |  | 1,791 |  |  | 1,489 |  |  | 20.3 | \nInternational |  | 549 |  |  | 453 |  |  | 21.2 |  |  | 1,658 |  |  | 1,454 |  |  | 14.0 | \nWorldwide |  | 1,161 |  |  | 973 |  |  | 19.3 |  |  | 3,449 |  |  | 2,943 |  |  | 17.2 | \nABIOMED(3) |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 254 |  |  | \u2014 |  |  | * |  | 790 |  |  | \u2014 |  |  | *\nInternational |  | 57 |  |  | \u2014 |  |  | * |  | 176 |  |  | \u2014 |  |  | *\nWorldwide |  | 311 |  |  | \u2014 |  |  | * |  | 966 |  |  | \u2014 |  |  | *\nOTHER INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 26 |  |  | 27 |  |  | (3.2) |  |  | 81 |  |  | 77 |  |  | 5.9 | \nInternational |  | 61 |  |  | 60 |  |  | 1.0 |  |  | 186 |  |  | 181 |  |  | 2.2 | \nWorldwide |  | 87 |  |  | 87 |  |  | (0.3) |  |  | 267 |  |  | 258 |  |  | 3.3 | \nOrthopaedics |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 1,349 |  |  | 1,309 |  |  | 3.1 |  |  | 4,100 |  |  | 3,936 |  |  | 4.2 | \nInternational |  | 815 |  |  | 785 |  |  | 3.9 |  |  | 2,574 |  |  | 2,504 |  |  | 2.8 | \nWorldwide |  | 2,164 |  |  | 2,095 |  |  | 3.4 |  |  | 6,674 |  |  | 6,440 |  |  | 3.6 | \nHIPS |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 239 |  |  | 228 |  |  | 4.9 |  |  | 730 |  |  | 693 |  |  | 5.4 | \nInternational |  | 136 |  |  | 124 |  |  | 9.3 |  |  | 432 |  |  | 437 |  |  | (1.0) | \nWorldwide |  | 375 |  |  | 352 |  |  | 6.5 |  |  | 1,162 |  |  | 1,129 |  |  | 2.9 | \nKNEES |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 207 |  |  | 203 |  |  | 2.3 |  |  | 654 |  |  | 620 |  |  | 5.6 | \nInternational |  | 131 |  |  | 115 |  |  | 14.6 |  |  | 415 |  |  | 386 |  |  | 7.7 | \nWorldwide |  | 338 |  |  | 317 |  |  | 6.7 |  |  | 1,069 |  |  | 1,005 |  |  | 6.4 | \nTRAUMA |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 488 |  |  | 473 |  |  | 3.2 |  |  | 1,462 |  |  | 1,412 |  |  | 3.5 | \nInternational |  | 253 |  |  | 244 |  |  | 4.2 |  |  | 775 |  |  | 749 |  |  | 3.5 | \nWorldwide |  | 742 |  |  | 717 |  |  | 3.5 |  |  | 2,238 |  |  | 2,161 |  |  | 3.5 | \nSPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 415 |  |  | 406 |  |  | 2.3 |  |  | 1,254 |  |  | 1,211 |  |  | 3.5 | \nInternational |  | 295 |  |  | 303 |  |  | (2.6) |  |  | 952 |  |  | 933 |  |  | 2.0 | \nWorldwide |  | 710 |  |  | 708 |  |  | 0.2 |  |  | 2,205 |  |  | 2,144 |  |  | 2.8 | \nSurgery |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 994 |  |  | 984 |  |  | 1.1 |  |  | 2,984 |  |  | 2,897 |  |  | 3.0 | \nInternational |  | 1,483 |  |  | 1,439 |  |  | 3.1 |  |  | 4,522 |  |  | 4,410 |  |  | 2.6 | \nWorldwide |  | 2,479 |  |  | 2,422 |  |  | 2.3 |  |  | 7,507 |  |  | 7,306 |  |  | 2.7 | \nADVANCED |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 455 |  |  | 457 |  |  | (0.4) |  |  | 1,365 |  |  | 1,328 |  |  | 2.8 | \nInternational |  | 709 |  |  | 701 |  |  | 1.0 |  |  | 2,139 |  |  | 2,132 |  |  | 0.3 | \nWorldwide |  | 1,164 |  |  | 1,158 |  |  | 0.5 |  |  | 3,504 |  |  | 3,460 |  |  | 1.3 | \nGENERAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 540 |  |  | 527 |  |  | 2.4 |  |  | 1,619 |  |  | 1,569 |  |  | 3.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInternational |  | 775 |  |  | 737 |  |  | 5.1 |  |  | 2,383 |  |  | 2,277 |  |  | 4.7 | \nWorldwide |  | 1,314 |  |  | 1,264 |  |  | 4.0 |  |  | 4,002 |  |  | 3,846 |  |  | 4.1 | \nVision |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 512 |  |  | 517 |  |  | (1.0) |  |  | 1,599 |  |  | 1,534 |  |  | 4.2 | \nInternational |  | 744 |  |  | 689 |  |  | 8.1 |  |  | 2,265 |  |  | 2,170 |  |  | 4.4 | \nWorldwide |  | 1,256 |  |  | 1,206 |  |  | 4.2 |  |  | 3,864 |  |  | 3,704 |  |  | 4.3 | \nCONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 399 |  |  | 405 |  |  | (1.2) |  |  | 1,252 |  |  | 1,179 |  |  | 6.2 | \nInternational |  | 529 |  |  | 503 |  |  | 4.9 |  |  | 1,568 |  |  | 1,533 |  |  | 2.3 | \nWorldwide |  | 928 |  |  | 908 |  |  | 2.2 |  |  | 2,820 |  |  | 2,712 |  |  | 4.0 | \nSURGICAL |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 112 |  |  | 112 |  |  | (0.1) |  |  | 346 |  |  | 355 |  |  | (2.5) | \nInternational |  | 216 |  |  | 186 |  |  | 16.6 |  |  | 698 |  |  | 637 |  |  | 9.6 | \nWorldwide |  | 328 |  |  | 298 |  |  | 10.3 |  |  | 1,044 |  |  | 992 |  |  | 5.3 | \n |  |  |  |  |  |  |  |  |  |  |  | \nTOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 3,747 |  |  | 3,356 |  |  | 11.6 |  |  | 11,345 |  |  | 9,932 |  |  | 14.2 | \nInternational |  | 3,711 |  |  | 3,426 |  |  | 8.3 |  |  | 11,382 |  |  | 10,719 |  |  | 6.2 | \nWorldwide |  | 7,458 |  |  | 6,782 |  |  | 10.0 |  |  | 22,727 |  |  | 20,651 |  |  | 10.0 | \n |  |  |  |  |  |  |  |  |  |  |  | \nWORLDWIDE |  |  |  |  |  |  |  |  |  |  |  | \nU.S. |  | 11,996 |  |  | 10,794 |  |  | 11.1 |  |  | 34,435 |  |  | 31,161 |  |  | 10.5 | \nInternational |  | 9,355 |  |  | 9,202 |  |  | 1.6 |  |  | 29,329 |  |  | 28,890 |  |  | 1.5 | \nWorldwide |  | $ | 21,351 |  |  | 19,996 |  |  | 6.8 | % |  | $ | 63,764 |  |  | 60,051 |  |  | 6.2 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended | \n(Dollars in Millions) |  | October 1,2023 |  | October 2,2022 |  | PercentChange |  | October 1,2023 |  | October 2,2022 |  | PercentChange |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInnovative Medicine(1) |  | $ | 4,794 |  |  | 4,186 |  |  | 14.5 | % |  | $ | 14,008 |  |  | 12,424 |  |  | 12.7 | % |  |  |  |  | \nMedTech(2) |  | 1,185 |  |  | 1,090 |  |  | 8.7 |  | 4,265 |  |  | 3,641 |  |  | 17.1 |  |  |  |  |  | \nSegment earnings before provision for taxes |  | 5,979 |  |  | 5,276 |  |  | 13.3 |  |  | 18,273 |  |  | 16,065 |  |  | 13.7 |  |  |  |  |  | \nLess: Expense not allocated to segments(3) |  | 762 |  |  | 104 |  |  |  |  | 8,037 |  |  | 546 |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,217 |  |  | 5,172 |  |  | 0.9 | % |  | $ | 10,236 |  |  | 15,519 |  |  | (34.0) | % |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | PercentChange |  | October 1, 2023 |  | October 2, 2022 |  | Percent Change\nUnited States |  | $ | 11,996 |  |  | 10,794 |  |  | 11.1 | % |  | $ | 34,435 |  |  | 31,161 |  |  | 10.5 | %\nEurope |  | 4,727 |  |  | 4,844 |  |  | (2.4) |  |  | 15,448 |  |  | 15,540 |  |  | (0.6) | \nWestern Hemisphere, excluding U.S. |  | 1,171 |  |  | 1,059 |  |  | 10.5 |  |  | 3,383 |  |  | 3,084 |  |  | 9.7 | \nAsia-Pacific, Africa |  | 3,457 |  |  | 3,299 |  |  | 4.8 |  |  | 10,498 |  |  | 10,266 |  |  | 2.2 | \nTotal |  | $ | 21,351 |  |  | 19,996 |  |  | 6.8 | % |  | $ | 63,764 |  |  | 60,051 |  |  | 6.2 | %  |  |  |  |  |  |  |  | \nProduct or product category |  | Number of Plaintiffs\nBody powders containing talc, primarily JOHNSON\u2019S Baby Powder |  | 52,220 | \nDePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System |  | 160 | \nPINNACLE Acetabular Cup System |  | 930 | \nPelvic meshes |  | 6,960 | \nETHICON PHYSIOMESH Flexible Composite Mesh |  | 720 | \nRISPERDAL |  | 220 | \nELMIRON |  | 2,150 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 1, 2023(1) |  | October 2, 2022 |  | October 1, 2023(1) |  | October 2, 2022\nSales to customers |  | $ | 2,173 |  |  | 3,795 |  |  | 10,036 |  |  | 11,186 | \nCost of products sold |  | 911 |  |  | 1,635 |  |  | 4,369 |  |  | 4,812 | \nGross profit |  | 1,262 |  |  | 2,160 |  |  | 5,667 |  |  | 6,374 | \nSelling, marketing and administrative expenses |  | 584 |  |  | 1,114 |  |  | 3,085 |  |  | 3,346 | \nResearch and development expense |  | 24 |  |  | 112 |  |  | 258 |  |  | 337 | \nInterest Income |  | (37) |  |  | \u2014 |  |  | (117) |  |  | \u2014 | \nInterest expense, net of portion capitalized (Note\u00a04) |  | 67 |  |  | \u2014 |  |  | 199 |  |  | \u2014 | \nOther (income) expense, net |  | 406 |  |  | 267 |  |  | 1,018 |  |  | 649 | \nGain on separation of Kenvue |  | (20,984) |  |  | \u2014 |  |  | (20,984) |  |  | \u2014 | \nRestructuring |  | \u2014 |  |  | 17 |  |  | \u2014 |  |  | 37 | \nEarnings from Discontinued Operations Before Provision for Taxes on Income |  | 21,202 |  |  | 650 |  |  | 22,208 |  |  | 2,005 | \n(Benefit from)/Provision for taxes on income (Note\u00a05) |  | (517) |  |  | 502 |  |  | 298 |  |  | 727 | \nNet earnings from Discontinued Operations |  | 21,719 |  |  | 148 |  |  | 21,910 |  |  | 1,278 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Fiscal Nine Months Ended\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022\nDepreciation and Amortization |  | 383 |  |  | 482 | \n |  |  |  | \nCapital expenditures |  | 162 |  |  | 178 |   |  |  |  |  |  | \n | January 1, 2023 | \nAssets |  | \nCurrent assets |  | \nCash and cash equivalents | $ | 1,238 |  | \nAccounts receivable trade, less allowances for doubtful accounts | 2,121 |  | \nInventories | 2,215 |  | \n |  | \nPrepaid expenses and other receivables | 256 |  | \nTotal current assets of discontinued operations | 5,830 |  | \nProperty, plant and equipment, net | 1,821 |  | \nIntangible assets, net | 9,836 |  | \nGoodwill | 9,184 |  | \nDeferred taxes on income | 176 |  | \nOther assets | 390 |  | \nTotal noncurrent assets of discontinued operations | $ | 21,407 |  | \n |  | \nLiabilities |  | \nLoans and notes payable | $ | 15 |  | \nAccounts payable | 1,814 |  | \nAccrued liabilities | 737 |  | \nAccrued rebates, returns and promotions | 838 |  | \nAccrued compensation and employee related obligations | 279 |  | \nAccrued taxes on income | (93) |  | \nTotal current liabilities of discontinued operations | 3,590 |  | \nLong-term debt | 2 |  | \nDeferred taxes on income | 2,383 |  | \nEmployee related obligations | 225 |  | \n |  | \nOther liabilities | 291 |  | \nTotal noncurrent liabilities of discontinued operations | $ | 2,901 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Pre-tax Dollars in Millions) |  | Fiscal Third Quarter Ended |  | Fiscal Nine Months Ended\nInnovative Medicine Segment(1) |  | $ | 149 |  |  | 424 | \nMedTech Segment(2) |  | 235 |  |  | 235 | \nTotal Programs |  | $ | 384 |  |  | 659 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 13,457 |  |  | $ | 12,817 |  |  | 5.0 | % |  | 5.9 | % |  | (0.9) | %\nREMICADE |  | 1,410 |  |  | 1,868 |  |  | (24.5) |  |  | (23.6) |  |  | (0.9) | \nSIMPONI/ SIMPONI ARIA |  | 1,695 |  |  | 1,682 |  |  | 0.8 |  |  | 2.9 |  |  | (2.1) | \nSTELARA |  | 8,105 |  |  | 7,336 |  |  | 10.5 |  |  | 11.1 |  |  | (0.6) | \nTREMFYA |  | 2,237 |  |  | 1,916 |  |  | 16.8 |  |  | 17.4 |  |  | (0.6) | \nOther Immunology |  | 9 |  |  | 14 |  |  | (36.1) |  |  | (36.1) |  |  | \u2014 | \nInfectious Diseases |  | 3,566 |  |  | 3,908 |  |  | (8.7) |  |  | (9.3) |  |  | 0.6 | \nCOVID-19 VACCINE |  | 1,073 |  |  | 1,490 |  |  | (27.9) |  | (29.2) |  | 1.3\nEDURANT/rilpivirine |  | 843 |  |  | 718 |  |  | 17.5 |  |  | 15.8 |  |  | 1.7 | \nPREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA |  | 1,415 |  |  | 1,450 |  |  | (2.4) |  |  | (2.5) |  |  | 0.1 | \nOther Infectious Diseases |  | 235 |  |  | 251 |  |  | (6.4) |  |  | (2.6) |  |  | (3.8) | \nNeuroscience |  | 5,339 |  |  | 5,156 |  |  | 3.5 |  |  | 5.4 |  |  | (1.9) | \nCONCERTA/methylphenidate |  | 603 |  |  | 476 |  |  | 26.7 |  |  | 30.7 |  |  | (4.0) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA |  | 3,104 |  |  | 3,132 |  |  | (0.9) |  |  | (0.1) |  |  | (0.8) | \nSPRAVATO |  | 483 |  |  | 255 |  |  | 88.8 |  |  | 88.7 |  |  | 0.1 | \nOther Neuroscience(1) |  | 1,149 |  |  | 1,293 |  |  | (11.0) |  |  | (7.1) |  |  | (3.9) | \nOncology |  | 13,043 |  |  | 12,056 |  |  | 8.2 |  |  | 9.3 |  |  | (1.1) | \nCARVYKTI |  | 341 |  |  | 79 |  |  | * |  | * |  | \u2014\nDARZALEX |  | 7,194 |  |  | 5,894 |  |  | 22.1 |  |  | 23.2 |  |  | (1.1) | \nERLEADA |  | 1,740 |  |  | 1,340 |  |  | 29.8 |  |  | 30.9 |  |  | (1.1) | \nIMBRUVICA |  | 2,476 |  |  | 2,918 |  |  | (15.2) |  |  | (14.2) |  |  | (1.0) | \nZYTIGA/ abiraterone acetate |  | 686 |  |  | 1,500 |  |  | (54.2) |  |  | (52.6) |  |  | (1.6) | \nOther Oncology |  | 605 |  |  | 324 |  |  | 86.5 |  |  | 87.4 |  |  | (0.9) | \nPulmonary Hypertension |  | 2,798 |  |  | 2,547 |  |  | 9.9 |  |  | 11.3 |  |  | (1.4) | \nOPSUMIT |  | 1,437 |  |  | 1,322 |  |  | 8.7 |  |  | 9.9 |  |  | (1.2) | \nUPTRAVI |  | 1,163 |  |  | 986 |  |  | 18.0 |  |  | 18.7 |  |  | (0.7) | \nOther Pulmonary Hypertension |  | 199 |  |  | 239 |  |  | (16.9) |  |  | (11.8) |  |  | (5.1) | \nCardiovascular / Metabolism / Other |  | 2,834 |  |  | 2,916 |  |  | (2.8) |  |  | (2.6) |  |  | (0.2) | \nXARELTO |  | 1,840 |  |  | 1,806 |  |  | 1.9 |  |  | 1.9 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 994 |  |  | 1,110 |  |  | (10.5) |  |  | (9.8) |  |  | (0.7) | \nTotal Innovative Medicine Sales |  | $ | 41,037 |  |  | $ | 39,400 |  |  | 4.2 | % |  | 5.1 | % |  | (0.9) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nImmunology |  | $ | 4,849 |  |  | $ | 4,287 |  |  | 13.1 | % |  | 12.4 | % |  | 0.7 | %\nREMICADE |  | 461 |  |  | 558 |  |  | (17.4) |  |  | (17.1) |  |  | (0.3) | \nSIMPONI/ SIMPONI ARIA |  | 629 |  |  | 545 |  |  | 15.3 |  |  | 15.8 |  |  | (0.5) | \nSTELARA |  | 2,864 |  |  | 2,449 |  |  | 16.9 |  |  | 15.8 |  |  | 1.1 | \nTREMFYA |  | 891 |  |  | 729 |  |  | 22.2 |  |  | 21.5 |  |  | 0.7 | \nOther Immunology |  | 2 |  |  | 5 |  |  | (47.1) |  | (47.1) |  | \u2014\nInfectious Diseases |  | 859 |  |  | 1,295 |  |  | (33.6) |  |  | (37.8) |  |  | 4.2 | \nCOVID-19 VACCINE |  | 41 |  |  | 489 |  |  | (91.5) |  |  | (97.8) |  |  | 6.3 | \nEDURANT/rilpivirine |  | 297 |  |  | 245 |  |  | 21.0 |  |  | 13.3 |  |  | 7.7 | \nPREZISTA/ PREZCOBIX/ REZOLSTA/SYMTUZA |  | 447 |  |  | 485 |  |  | (7.8) |  |  | (9.0) |  |  | 1.2 | \nOther Infectious Diseases |  | 74 |  |  | 77 |  |  | (3.6) |  |  | (0.5) |  |  | (3.1) | \nNeuroscience |  | 1,742 |  |  | 1,681 |  |  | 3.6 |  | 4.6 |  |  | (1.0) | \nCONCERTA/ methylphenidate |  | 189 |  |  | 158 |  |  | 20.0 |  |  | 21.4 |  |  | (1.4) | \nINVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/TREVICTA |  | 1,029 |  |  | 1,031 |  |  | (0.2) |  |  | (0.3) |  |  | 0.1 | \nSPRAVATO |  | 183 |  |  | 100 |  |  | 82.1 |  |  | 81.0 |  |  | 1.1 | \nOther Neuroscience(1) |  | 340 |  |  | 393 |  |  | (13.2) |  |  | (8.7) |  |  | (4.5) | \nOncology |  | 4,533 |  |  | 4,064 |  |  | 11.5 |  |  | 10.4 |  |  | 1.1 | \nCARVYKTI |  | 152 |  |  | 55 |  |  | * |  | * |  | \u2014\nDARZALEX |  | 2,499 |  |  | 2,052 |  |  | 21.8 |  |  | 20.7 |  |  | 1.1 | \nERLEADA |  | 631 |  |  | 490 |  |  | 28.7 |  |  | 27.0 |  |  | 1.7 | \nIMBRUVICA |  | 808 |  |  | 911 |  |  | (11.3) |  |  | (12.6) |  |  | 1.3 | \nZYTIGA/ abiraterone acetate |  | 214 |  |  | 456 |  |  | (53.0) |  |  | (53.2) |  |  | 0.2 | \nOther Oncology |  | 229 |  |  | 100 |  |  | * |  | * |  | *\nPulmonary Hypertension |  | 954 |  |  | 852 |  |  | 12.0 |  |  | 12.4 |  |  | (0.4) | \nOPSUMIT |  | 490 |  |  | 441 |  |  | 11.2 |  |  | 10.9 |  |  | 0.3 | \nUPTRAVI |  | 402 |  |  | 333 |  |  | 20.7 |  |  | 21.1 |  |  | (0.4) | \nOther Pulmonary Hypertension |  | 63 |  |  | 78 |  |  | (19.8) |  |  | (16.6) |  |  | (3.2) | \nCardiovascular / Metabolism / Other |  | 957 |  |  | 1,034 |  |  | (7.5) |  |  | (8.0) |  |  | 0.5 | \nXARELTO |  | 625 |  |  | 689 |  |  | (9.4) |  |  | (9.4) |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  | \nOther(2) |  | 332 |  |  | 345 |  |  | (3.8) |  |  | (5.3) |  |  | 1.5 | \nTotal Innovative Medicine Sales |  | $ | 13,893 |  |  | $ | 13,214 |  |  | 5.1 | % |  | 4.3 | % |  | 0.8 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 7,507 |  |  | $ | 7,306 |  |  | 2.7 | % |  | 5.3 | % |  | (2.6) | %\nAdvanced |  | 3,504 |  |  | 3,460 |  |  | 1.3 |  |  | 3.8 |  |  | (2.5) | \nGeneral |  | 4,002 |  |  | 3,846 |  |  | 4.1 |  |  | 6.5 |  |  | (2.4) | \nOrthopaedics |  | 6,674 |  |  | 6,440 |  |  | 3.6 |  |  | 4.5 |  |  | (0.9) | \nHips |  | 1,162 |  |  | 1,129 |  |  | 2.9 |  |  | 3.8 |  |  | (0.9) | \nKnees |  | 1,069 |  |  | 1,005 |  |  | 6.4 |  |  | 7.2 |  |  | (0.8) | \nTrauma |  | 2,238 |  |  | 2,161 |  |  | 3.5 |  |  | 4.0 |  |  | (0.5) | \nSpine, Sports & Other |  | 2,205 |  |  | 2,144 |  |  | 2.8 |  |  | 4.0 |  |  | (1.2) | \nInterventional Solutions |  | 4,681 |  |  | 3,202 |  |  | 46.2 |  |  | 48.9 |  |  | (2.7) | \nElectrophysiology |  | 3,449 |  |  | 2,943 |  |  | 17.2 |  |  | 19.8 |  |  | (2.6) | \nAbiomed |  | 966 |  |  | \u2014 |  |  | * |  | * |  | \u2014\nOther Interventional Solutions |  | 267 |  |  | 258 |  |  | 3.3 |  |  | 6.8 |  |  | (3.5) | \nVision |  | 3,864 |  |  | 3,704 |  |  | 4.3 |  |  | 6.6 |  |  | (2.3) | \nContact Lenses/Other |  | 2,820 |  |  | 2,712 |  |  | 4.0 |  |  | 6.6 |  |  | (2.6) | \nSurgical |  | 1,044 |  |  | 992 |  |  | 5.3 |  |  | 6.6 |  |  | (1.3) | \nTotal MedTech Sales |  | $ | 22,727 |  |  | $ | 20,651 |  |  | 10.0 | % |  | 12.0 | % |  | (2.0) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | TotalChange |  | OperationsChange |  | CurrencyChange\nSurgery |  | $ | 2,479 |  |  | $ | 2,422 |  |  | 2.3 | % |  | 3.2 | % |  | (0.9) | %\nAdvanced |  | 1,164 |  |  | 1,158 |  |  | 0.5 |  |  | 1.5 |  |  | (1.0) | \nGeneral |  | 1,314 |  |  | 1,264 |  |  | 4.0 |  |  | 4.8 |  |  | (0.8) | \nOrthopaedics |  | 2,164 |  |  | 2,095 |  |  | 3.4 |  |  | 2.6 |  |  | 0.8 | \nHips |  | 375 |  |  | 352 |  |  | 6.5 |  |  | 5.8 |  |  | 0.7 | \nKnees |  | 338 |  |  | 317 |  |  | 6.7 |  |  | 5.7 |  |  | 1.0 | \nTrauma |  | 742 |  |  | 717 |  |  | 3.5 |  |  | 2.4 |  |  | 1.1 | \nSpine, Sports & Other |  | 710 |  |  | 708 |  |  | 0.2 |  |  | (0.2) |  |  | 0.4 | \nInterventional Solutions |  | 1,558 |  |  | 1,060 |  |  | 47.0 |  |  | 48.1 |  |  | (1.1) | \nElectrophysiology |  | 1,161 |  |  | 973 |  |  | 19.3 |  |  | 20.3 |  |  | (1.0) | \nAbiomed |  | 311 |  |  | \u2014 |  |  | * |  | * |  | \u2014\nOther Interventional Solutions |  | 87 |  |  | 87 |  |  | (0.3) |  |  | 1.6 |  |  | (1.9) | \nVision |  | 1,256 |  |  | 1,206 |  |  | 4.2 |  |  | 5.4 |  |  | (1.2) | \nContact Lenses/Other |  | 928 |  |  | 908 |  |  | 2.2 |  |  | 4.0 |  |  | (1.8) | \nSurgical |  | 328 |  |  | 298 |  |  | 10.3 |  |  | 9.5 |  |  | 0.8 | \nTotal MedTech Sales |  | $ | 7,458 |  |  | $ | 6,782 |  |  | 10.0 | % |  | 10.4 | % |  | (0.4) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Nine Months |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\nLitigation related(1) |  | $ | 6.7 |  |  | 0.6 |  |  | 6.1 | \n |  |  |  |  |  | \nChanges in the fair value of securities(2) |  | 1.1 |  |  | 0.7 |  |  | 0.4 | \nCOVID-19 Vaccine related exit costs |  | 0.4 |  |  | 0.2 |  |  | 0.2 | \nEmployee benefit plan related |  | (1.1) |  |  | (0.9) |  |  | (0.2) | \nOther |  | (0.1) |  |  | (0.6) |  |  | 0.5 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 7.0 |  |  | 0.0 |  |  | 7.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Third Quarter |  |  |  |  |  | \n(Dollars in Billions)(Income)/Expense |  | 2023 |  | 2022 |  | Change\n |  |  |  |  |  | \nChanges in the fair value of securities(1) |  | $ | 1.0 |  |  | 0.2 |  |  | 0.8 | \nEmployee benefit plan related |  | (0.3) |  |  | (0.3) |  |  | \u2014 | \nLitigation related |  | (0.1) |  |  | 0.2 |  |  | (0.3) | \nCOVID-19 Vaccine related exit costs |  | 0.0 |  |  | 0.2 |  |  | (0.2) | \nOther |  | (0.1) |  |  | (0.1) |  |  | \u2014 | \n |  |  |  |  |  | \n |  |  |  |  |  | \nTotal Other (Income) Expense, Net |  | $ | 0.5 |  |  | 0.2 |  |  | 0.3 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\nInnovative Medicine |  | $ | 14,008 |  |  | $ | 12,424 |  |  | $ | 41,037 |  |  | $ | 39,400 |  |  | 34.1 | % |  | 31.5 | %\nMedTech |  | 4,265 |  |  | 3,641 |  |  | 22,727 |  |  | 20,651 |  |  | 18.8 |  |  | 17.6 | \nSegment earnings before tax |  | 18,273 |  |  | 16,065 |  |  | 63,764 |  |  | 60,051 |  |  | 28.7 |  |  | 26.8 | \nLess: Expenses not allocated to segments(1) |  | 8,037 |  |  | 546 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 10,236 |  |  | $ | 15,519 |  |  | $ | 63,764 |  |  | $ | 60,051 |  |  | 16.1 | % |  | 25.8 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Income Before Tax |  | Segment Sales |  | Percent of Segment Sales\n(Dollars in Millions) |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022 |  | October 1, 2023 |  | October 2, 2022\nInnovative Medicine |  | $ | 4,794 |  |  | $ | 4,186 |  |  | $ | 13,893 |  |  | $ | 13,214 |  |  | 34.5 | % |  | 31.7 | %\nMedTech |  | 1,185 |  |  | 1,090 |  |  | 7,458 |  |  | 6,782 |  |  | 15.9 |  |  | 16.1 | \nSegment earnings before tax |  | 5,979 |  |  | 5,276 |  |  | 21,351 |  |  | 19,996 |  |  | 28.0 |  |  | 26.4 | \nLess: Expenses not allocated to segments(1) |  | 762 |  |  | 104 |  |  |  |  |  |  |  |  | \nWorldwide income before tax |  | $ | 5,217 |  |  | $ | 5,172 |  |  | $ | 21,351 |  |  | $ | 19,996 |  |  | 24.4 | % |  | 25.9 | %  |  |  |  |  | \n(Dollars In Billions) | \n14.1 |  | Q4 2022 Cash and cash equivalents balance\n14.9 |  | net cash generated from operating activities\n2.1 |  | net cash generated from investing activities\n(11.2) |  | net cash used by financing activities\n(0.2) |  | effect of exchange rate changes on cash and cash equivalents\n | \n | \n$ | 19.7 |  | Q3 2023 Cash and cash equivalents  |  |  |  |  | \n(Dollars In Billions) | \n$ | 31.1 |  | Net earnings\n(21.0) |  | gain on Kenvue separation\n5.5 |  | non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision and net gain on sale of assets/businesses\n(2.3) |  | an increase in accounts receivable and inventories\n2.9 |  | an increase in accounts payable and accrued liabilities and other current and non-current liabilities\n(1.4) |  | an increase in other current and non-current assets\n0.1 |  | Rounding\n$ | 14.9 |  | Cash Flow from operations  |  |  |  |  | \n(Dollars In Billions) | \n(3.0) |  | additions to property, plant and equipment\n0.2 |  | proceeds from the disposal of assets/businesses, net\n | \n5.8 |  | net sales of investments\n(0.9) |  | credit support agreements activity, net  other and rounding\n | \n | \n$ | 2.1 |  | Net cash used by investing activities  |  |  |  |  | \n(Dollars In Billions) | \n$ | (8.9) |  | dividends to shareholders\n(4.8) |  | repurchase of common stock\n(9.7) |  | net repayment of short and long term debt\n8.0 |  | Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation\n4.2 |  | proceeds from Kenvue initial public offering\n(1.1) |  | Cash transferred to Kenvue at separation\n0.9 |  | proceeds from stock options exercised/employee withholding tax on stock awards, net\n0.1 |  | credit support agreements activity, net\n0.1 |  | other and rounding\n$ | (11.2) |  | Net cash from financing activities  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nFiscal Month Period |  | Total Numberof Shares Purchased(1) |  | Avg. PricePer Share |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs\nJuly 3, 2023 through July 30, 2023 |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014\nJuly 31, 2023 through August 27, 2023 |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014\nAugust 28, 2023 through October 1, 2023 |  | 5,690,272 |  |  | 161.68 |  |  | \u2014 |  |  | \u2014\nTotal |  | 5,690,272 |  |  | 161.68 |  |  | \u2014 |  |  | \u2014  |  |  |  |  |  |  |  | \nEX-101.INS |  | Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document\nEX-101.SCH |  | Inline XBRL Taxonomy Extension Schema\nEX-101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase\nEX-101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase\nEX-101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase\nEX-101.DEF |  | Inline XBRL Taxonomy Extension Definition Document\n |  | \nExhibit 104: |  | Cover Page Interactive Data File\u2013\u2013the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n |  |   |  |  |  |  | \n | JOHNSON & JOHNSON(Registrant)\n | \nDate: October\u00a027, 2023 | By /s/ J. J. WOLK\n | J. J. WOLK\n | Executive Vice President, Chief Financial Officer (Principal Financial Officer)\n | \nDate: October\u00a027, 2023 | By /s/\u00a0R. J. DECKER Jr.\n | R. J. DECKER Jr.\n | Controller (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Mastercard, in 2022 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  | \nDelaware | 13-4172551\n(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification Number)\n |  | \n2000 Purchase Street | 10577\nPurchase, | NY | (Zip Code)\n(Address of principal executive offices) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class |  | Trading Symbol |  | Name of each exchange of which registered\nClass A Common Stock, par value $0.0001 per share |  | MA |  | New York Stock Exchange\n1.1% Notes due 2022 |  | MA22 |  | New York Stock Exchange\n2.1% Notes due 2027 |  | MA27 |  | New York Stock Exchange\n1.0% Notes due 2029 |  | MA29A |  | New York Stock Exchange\n2.5% Notes due 2030 |  | MA30 |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant (1)\u00a0has filed all reports required to be filed by Section\u00a013 or 15(d)\u00a0of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\u00a0has been subject to such filing requirements for the past 90 days. | Yes | \u2612 | No | \u2610\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files) | Yes | \u2612 | No | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of \u201clarge accelerated filer,\u201d \u201caccelerated filer,\u201d \u201csmaller reporting company,\u201d and \u201cemerging growth company\u201d in Rule 12b-2 of the Exchange Act. (Check One):\nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  |  | \nNon-accelerated filer | \u2610 |  | Smaller\u00a0reporting\u00a0company | \u2610 |  |  | \n |  |  | Emerging growth\u00a0company | \u2610 |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. | \u2610\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) | Yes | \u2610 | No | \u2612  |  | \n  |  |  |  |  |  |  |  |  |  |  | \n |  |  | \nPART I | 5 | Item 1. | Consolidated financial statements (unaudited)\n30 | Item 2. | Management\u2019s discussion and analysis of financial condition and results of operations\n44 | Item 3. | Quantitative and qualitative disclosures about market risk\n45 | Item 4. | Controls and procedures\n |  |  | \n |  |  | \nPART II | 47 | Item 1. | Legal proceedings\n47 | Item 1A. | Risk factors\n47 | Item 2. | Unregistered sales of equity securities and use of proceeds\n47 | Item 5. | Other information\n47 | Item 6. | Exhibits\n49 | - | Signatures\n |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART I |  |  | \n |  | Item 1. Consolidated financial statements (unaudited) |  | \n |  | Item 2. Management\u2019s discussion and analysis of financial condition and results of operations |  | \n |  | Item 3. Quantitative and qualitative disclosures about market risk |  | \n |  | Item 4. Controls and procedures |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  | \n |  | Page\nConsolidated Statement of Operations \u2014Three and Six Months Ended June 30, 2022and2021 |  | 6\nConsolidated Statement of Comprehensive Income \u2014Three and Six Months Ended June 30, 2022and2021 |  | 7\nConsolidated Balance Sheet \u2014June 30, 2022andDecember 31, 2021 |  | 8\nConsolidated Statement of Changes in Equity\u2014Three and Six Months Ended June 30, 2022and2021 |  | 9\nConsolidated Statement of Cash Flows \u2014Six Months Ended June 30, 2022and2021 |  | 11\nNotes to consolidated financial statements |  | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Operations (Unaudited) |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNet Revenue |  | $ | 5,497 |  |  | $ | 4,528 |  |  | $ | 10,664 |  |  | $ | 8,683 | \nOperating Expenses: |  |  |  |  |  |  |  | \nGeneral and administrative |  | 1,947 |  |  | 1,718 |  |  | 3,791 |  |  | 3,394 | \nAdvertising and marketing |  | 210 |  |  | 216 |  |  | 391 |  |  | 335 | \nDepreciation and amortization |  | 189 |  |  | 186 |  |  | 381 |  |  | 349 | \nProvision for litigation |  | 133 |  |  | 67 |  |  | 133 |  |  | 67 | \nTotal operating expenses |  | 2,479 |  |  | 2,187 |  |  | 4,696 |  |  | 4,145 | \nOperating income |  | 3,018 |  |  | 2,341 |  |  | 5,968 |  |  | 4,538 | \nOther Income (Expense): |  |  |  |  |  |  |  | \nInvestment income |  | 7 |  |  | 3 |  |  | 12 |  |  | 4 | \nGains (losses) on equity investments, net |  | (117) |  |  | 243 |  |  | (193) |  |  | 337 | \nInterest expense |  | (114) |  |  | (106) |  |  | (224) |  |  | (213) | \nOther income (expense), net |  | 4 |  |  | (3) |  |  | 8 |  |  | 2 | \nTotal other income (expense) |  | (220) |  |  | 137 |  |  | (397) |  |  | 130 | \nIncome before income taxes |  | 2,798 |  |  | 2,478 |  |  | 5,571 |  |  | 4,668 | \nIncome tax expense |  | 523 |  |  | 412 |  |  | 665 |  |  | 774 | \nNet Income |  | $ | 2,275 |  |  | $ | 2,066 |  |  | $ | 4,906 |  |  | $ | 3,894 | \nBasic Earnings per Share |  | $ | 2.34 |  |  | $ | 2.09 |  |  | $ | 5.04 |  |  | $ | 3.93 | \nBasic weighted-average shares outstanding |  | 971 |  |  | 990 |  |  | 974 |  |  | 992 | \nDiluted Earnings per Share |  | $ | 2.34 |  |  | $ | 2.08 |  |  | $ | 5.02 |  |  | $ | 3.91 | \nDiluted weighted-average shares outstanding |  | 974 |  |  | 994 |  |  | 977 |  |  | 996 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Comprehensive Income (Unaudited) |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in millions)\nNet Income |  | $ | 2,275 |  |  | $ | 2,066 |  |  | $ | 4,906 |  |  | $ | 3,894 | \nOther comprehensive income (loss): |  |  |  |  |  |  |  | \nForeign currency translation adjustments |  | (710) |  |  | 143 |  |  | (774) |  |  | (55) | \nIncome tax effect |  | 31 |  |  | (9) |  |  | 43 |  |  | 24 | \nForeign currency translation adjustments, net of income tax effect |  | (679) |  |  | 134 |  |  | (731) |  |  | (31) | \n |  |  |  |  |  |  |  | \nTranslation adjustments on net investment hedges |  | 314 |  |  | (61) |  |  | 400 |  |  | 72 | \nIncome tax effect |  | (70) |  |  | 14 |  |  | (89) |  |  | (16) | \nTranslation adjustments on net investment hedges, net of income tax effect |  | 244 |  |  | (47) |  |  | 311 |  |  | 56 | \n |  |  |  |  |  |  |  | \nCash flow hedges |  | 6 |  |  | (4) |  |  | 7 |  |  | (1) | \nIncome tax effect |  | (2) |  |  | 1 |  |  | (2) |  |  | \u2014 | \nReclassification adjustments for cash flow hedges |  | \u2014 |  |  | 3 |  |  | (5) |  |  | 4 | \nIncome tax effect |  | \u2014 |  |  | (1) |  |  | 1 |  |  | (1) | \nCash flow hedges, net of income tax effect |  | 4 |  |  | (1) |  |  | 1 |  |  | 2 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nReclassification adjustments for defined benefit pension and other postretirement plans |  | (1) |  |  | (1) |  |  | (1) |  |  | (1) | \nIncome tax effect |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nDefined benefit pension and other postretirement plans, net of income tax effect |  | (1) |  |  | (1) |  |  | (1) |  |  | (1) | \n |  |  |  |  |  |  |  | \nInvestment securities available-for-sale |  | (2) |  |  | 1 |  |  | (4) |  |  | 2 | \nIncome tax effect |  | \u2014 |  |  | (1) |  |  | 1 |  |  | (1) | \nInvestment securities available-for-sale, net of income tax effect |  | (2) |  |  | \u2014 |  |  | (3) |  |  | 1 | \n |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  | (434) |  |  | 85 |  |  | (423) |  |  | 27 | \nComprehensive Income |  | $ | 1,841 |  |  | $ | 2,151 |  |  | $ | 4,483 |  |  | $ | 3,921 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Balance Sheet (Unaudited) |  |  |  | \n |  | June 30, 2022 |  | December 31, 2021\n |  | (in\u00a0millions,\u00a0except\u00a0per share\u00a0data)\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 5,921 |  |  | $ | 7,421 | \nRestricted cash for litigation settlement |  | 584 |  |  | 586 | \nInvestments |  | 438 |  |  | 473 | \nAccounts receivable |  | 3,175 |  |  | 3,006 | \nSettlement assets |  | 1,063 |  |  | 1,319 | \nRestricted security deposits held for customers |  | 1,621 |  |  | 1,873 | \nPrepaid expenses and other current assets |  | 2,409 |  |  | 2,271 | \nTotal current assets |  | 15,211 |  |  | 16,949 | \nProperty, equipment and right-of-use assets, net of accumulated depreciation and amortizationof $1,736and $1,614, respectively |  | 1,950 |  |  | 1,907 | \nDeferred income taxes |  | 920 |  |  | 486 | \nGoodwill |  | 7,519 |  |  | 7,662 | \nOther intangible assets, net of accumulated amortization of $1,839and $1,755, respectively |  | 3,676 |  |  | 3,671 | \nOther assets |  | 6,955 |  |  | 6,994 | \nTotal Assets |  | $ | 36,231 |  |  | $ | 37,669 | \nLiabilities, Redeemable Non-controlling Interests and Equity |  |  |  | \nCurrent liabilities: |  |  |  | \nAccounts payable |  | $ | 633 |  |  | $ | 738 | \nSettlement obligations |  | 672 |  |  | 913 | \nRestricted security deposits held for customers |  | 1,621 |  |  | 1,873 | \nAccrued litigation |  | 923 |  |  | 840 | \nAccrued expenses |  | 6,111 |  |  | 6,642 | \nCurrent portion of long-term debt |  | 735 |  |  | 792 | \nOther current liabilities |  | 1,390 |  |  | 1,364 | \nTotal current liabilities |  | 12,085 |  |  | 13,162 | \nLong-term debt |  | 13,746 |  |  | 13,109 | \nDeferred income taxes |  | 371 |  |  | 395 | \nOther liabilities |  | 3,767 |  |  | 3,591 | \nTotal Liabilities |  | 29,969 |  |  | 30,257 | \nCommitments and Contingencies |  |  |  | \nRedeemable Non-controlling Interests |  | 26 |  |  | 29 | \nStockholders\u2019 Equity |  |  |  | \nClass\u00a0A common stock, $0.0001par value; authorized3,000shares,1,399and1,397shares issued and960and972shares outstanding, respectively |  | \u2014 |  |  | \u2014 | \nClass B common stock, $0.0001par value; authorized1,200shares,8shares issued and outstanding |  | \u2014 |  |  | \u2014 | \nAdditional paid-in-capital |  | 5,163 |  |  | 5,061 | \nClass\u00a0A treasury stock, at cost,439and425shares, respectively |  | (47,359) |  |  | (42,588) | \nRetained earnings |  | 49,599 |  |  | 45,648 | \nAccumulated other comprehensive income (loss) |  | (1,232) |  |  | (809) | \nMastercard Incorporated Stockholders' Equity |  | 6,171 |  |  | 7,312 | \nNon-controlling interests |  | 65 |  |  | 71 | \nTotal Equity |  | 6,236 |  |  | 7,383 | \nTotal Liabilities, Redeemable Non-controlling Interests and Equity |  | $ | 36,231 |  |  | $ | 37,669 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Changes in Equity (Unaudited)\n |  | Three Months Ended June 30, 2022\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders\u2019 Equity |  | Non-ControllingInterests |  | Total Equity\n |  | Class A |  | Class B |  |  |  | \n |  | (in millions)\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at March 31, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,026 |  |  | $ | (44,994) |  |  | $ | 47,800 |  |  | $ | (798) |  |  | $ | 7,034 |  |  | $ | 68 |  |  | $ | 7,102 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,275 |  |  | \u2014 |  |  | 2,275 |  |  | \u2014 |  |  | 2,275 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3) |  |  | (3) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (434) |  |  | (434) |  |  | \u2014 |  |  | (434) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (474) |  |  | \u2014 |  |  | (474) |  |  | \u2014 |  |  | (474) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,365) |  |  | \u2014 |  |  | \u2014 |  |  | (2,365) |  |  | \u2014 |  |  | (2,365) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 137 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 137 |  |  | \u2014 |  |  | 137 | \nBalance at June 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,163 |  |  | $ | (47,359) |  |  | $ | 49,599 |  |  | $ | (1,232) |  |  | $ | 6,171 |  |  | $ | 65 |  |  | $ | 6,236 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Six Months Ended June 30, 2022\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,061 |  |  | $ | (42,588) |  |  | $ | 45,648 |  |  | $ | (809) |  |  | $ | 7,312 |  |  | $ | 71 |  |  | $ | 7,383 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4,906 |  |  | \u2014 |  |  | 4,906 |  |  | \u2014 |  |  | 4,906 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (6) |  |  | (6) | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (4) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (423) |  |  | (423) |  |  | \u2014 |  |  | (423) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (951) |  |  | \u2014 |  |  | (951) |  |  | \u2014 |  |  | (951) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,776) |  |  | \u2014 |  |  | \u2014 |  |  | (4,776) |  |  | \u2014 |  |  | (4,776) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 102 |  |  | 5 |  |  | \u2014 |  |  | \u2014 |  |  | 107 |  |  | \u2014 |  |  | 107 | \nBalance at June 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,163 |  |  | $ | (47,359) |  |  | $ | 49,599 |  |  | $ | (1,232) |  |  | $ | 6,171 |  |  | $ | 65 |  |  | $ | 6,236 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Changes in Equity (Unaudited) - (Continued)\n |  | Three Months Ended June 30, 2021\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders\u2019 Equity |  | Non-ControllingInterests |  | Total Equity\n |  | Class A |  | Class B |  |  |  | \n |  | (in millions)\nBalance at March 31, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 4,949 |  |  | $ | (38,024) |  |  | $ | 40,140 |  |  | $ | (738) |  |  | $ | 6,327 |  |  | $ | 98 |  |  | $ | 6,425 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,066 |  |  | \u2014 |  |  | 2,066 |  |  | \u2014 |  |  | 2,066 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 85 |  |  | 85 |  |  | \u2014 |  |  | 85 | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (434) |  |  | \u2014 |  |  | (434) |  |  | \u2014 |  |  | (434) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,705) |  |  | \u2014 |  |  | \u2014 |  |  | (1,705) |  |  | \u2014 |  |  | (1,705) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 104 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 104 |  |  | \u2014 |  |  | 104 | \nBalance at June 30, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,053 |  |  | $ | (39,729) |  |  | $ | 41,771 |  |  | $ | (653) |  |  | $ | 6,442 |  |  | $ | 98 |  |  | $ | 6,540 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2021\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2020 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 4,982 |  |  | $ | (36,658) |  |  | $ | 38,747 |  |  | $ | (680) |  |  | $ | 6,391 |  |  | $ | 97 |  |  | $ | 6,488 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,894 |  |  | \u2014 |  |  | 3,894 |  |  | \u2014 |  |  | 3,894 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 27 |  |  | 27 |  |  | \u2014 |  |  | 27 | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (868) |  |  | \u2014 |  |  | (868) |  |  | \u2014 |  |  | (868) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3,075) |  |  | \u2014 |  |  | \u2014 |  |  | (3,075) |  |  | \u2014 |  |  | (3,075) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 71 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 75 |  |  | \u2014 |  |  | 75 | \nBalance at June 30, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,053 |  |  | $ | (39,729) |  |  | $ | 41,771 |  |  | $ | (653) |  |  | $ | 6,442 |  |  | $ | 98 |  |  | $ | 6,540 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Cash Flows (Unaudited) |  |  |  | \n |  | Six Months Ended June 30,\n |  | 2022 |  | 2021\n |  | (in millions)\nOperating Activities |  |  |  | \nNet income |  | $ | 4,906 |  |  | $ | 3,894 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  |  | \nAmortization of customer and merchant incentives |  | 812 |  |  | 651 | \nDepreciation and amortization |  | 381 |  |  | 349 | \n(Gains) losses on equity investments, net |  | 193 |  |  | (337) | \nShare-based compensation |  | 175 |  |  | 152 | \nDeferred income taxes |  | (466) |  |  | (15) | \nOther |  | 18 |  |  | 32 | \nChanges in operating assets and liabilities: |  |  |  | \nAccounts receivable |  | (257) |  |  | (158) | \n |  |  |  | \nSettlement assets |  | 255 |  |  | 769 | \nPrepaid expenses |  | (1,033) |  |  | (995) | \nAccrued litigation and legal settlements |  | 85 |  |  | 63 | \nRestricted security deposits held for customers |  | (252) |  |  | 110 | \nAccounts payable |  | (110) |  |  | (92) | \nSettlement obligations |  | (239) |  |  | (906) | \n |  |  |  | \nAccrued expenses |  | (282) |  |  | 27 | \nNet change in other assets and liabilities |  | 53 |  |  | 187 | \nNet cash provided by operating activities |  | 4,239 |  |  | 3,731 | \nInvesting Activities |  |  |  | \nPurchases of investment securities available-for-sale |  | (124) |  |  | (261) | \nPurchases of investments held-to-maturity |  | (139) |  |  | (173) | \nProceeds from sales of investment securities available-for-sale |  | 14 |  |  | 38 | \nProceeds from maturities of investment securities available-for-sale |  | 113 |  |  | 171 | \nProceeds from maturities of investments held-to-maturity |  | 160 |  |  | 156 | \nPurchases of property and equipment |  | (201) |  |  | (146) | \nCapitalized software |  | (280) |  |  | (191) | \nPurchases of equity investments |  | (43) |  |  | (87) | \nProceeds from sales of equity investments |  | 6 |  |  | \u2014 | \nAcquisition of businesses, net of cash acquired |  | (313) |  |  | (4,200) | \n |  |  |  | \nOther investing activities |  | (5) |  |  | (9) | \nNet cash used in investing activities |  | (812) |  |  | (4,702) | \nFinancing Activities |  |  |  | \nPurchases of treasury stock |  | (4,788) |  |  | (3,067) | \nDividends paid |  | (956) |  |  | (873) | \nProceeds from debt, net |  | 843 |  |  | 1,282 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nContingent consideration paid |  | \u2014 |  |  | (64) | \nTax withholdings related to share-based payments |  | (136) |  |  | (125) | \nCash proceeds from exercise of stock options |  | 68 |  |  | 44 | \nOther financing activities |  | (6) |  |  | 2 | \nNet cash used in financing activities |  | (4,975) |  |  | (2,801) | \nEffect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents |  | (202) |  |  | (24) | \nNet decrease in cash, cash equivalents, restricted cash and restricted cash equivalents |  | (1,750) |  |  | (3,796) | \nCash, cash equivalents, restricted cash and restricted cash equivalents - beginning of period |  | 9,902 |  |  | 12,419 | \nCash, cash equivalents, restricted cash and restricted cash equivalents - end of period |  | $ | 8,152 |  |  | $ | 8,623 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in millions)\nRevenue by source: |  |  |  |  |  |  |  | \nDomestic assessments |  | $ | 2,283 |  |  | $ | 2,056 |  |  | $ | 4,417 |  |  | $ | 3,854 | \nCross-border volume fees |  | 1,615 |  |  | 1,076 |  |  | 3,010 |  |  | 2,008 | \nTransaction processing |  | 3,061 |  |  | 2,612 |  |  | 5,973 |  |  | 4,963 | \nOther revenues |  | 1,745 |  |  | 1,475 |  |  | 3,329 |  |  | 2,822 | \nGross revenue |  | 8,704 |  |  | 7,219 |  |  | 16,729 |  |  | 13,647 | \nRebates and incentives (contra-revenue) |  | (3,207) |  |  | (2,691) |  |  | (6,065) |  |  | (4,964) | \nNet revenue |  | $ | 5,497 |  |  | $ | 4,528 |  |  | $ | 10,664 |  |  | $ | 8,683 | \nNet revenue by geographic region: |  |  |  |  |  |  |  | \nNorth American Markets |  | $ | 1,979 |  |  | $ | 1,605 |  |  | $ | 3,682 |  |  | $ | 3,096 | \nInternational Markets |  | 3,436 |  |  | 2,879 |  |  | 6,821 |  |  | 5,497 | \nOther1 |  | 82 |  |  | 44 |  |  | 161 |  |  | 90 | \nNet revenue |  | $ | 5,497 |  |  | $ | 4,528 |  |  | $ | 10,664 |  |  | $ | 8,683 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2022 |  | December 31,2021\n |  | (in millions)\nReceivables from contracts with customers |  |  |  | \nAccounts receivable |  | $ | 2,922 |  |  | $ | 2,829 | \nContract assets |  |  |  | \nPrepaid expenses and other current assets |  | 77 |  |  | 134 | \nOther assets |  | 441 |  |  | 487 | \nDeferred revenue1 |  |  |  | \nOther current liabilities |  | 528 |  |  | 482 | \nOther liabilities |  | 205 |  |  | 180 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNumerator |  |  |  |  |  |  |  | \nNet income |  | $ | 2,275 |  |  | $ | 2,066 |  |  | $ | 4,906 |  |  | $ | 3,894 | \nDenominator |  |  |  |  |  |  |  | \nBasic weighted-average shares outstanding |  | 971 |  |  | 990 |  |  | 974 |  |  | 992 | \nDilutive stock options and stock units |  | 3 |  |  | 4 |  |  | 3 |  |  | 4 | \nDiluted weighted-average shares outstanding1 |  | 974 |  |  | 994 |  |  | 977 |  |  | 996 | \nEarnings per Share |  |  |  |  |  |  |  | \nBasic |  | $ | 2.34 |  |  | $ | 2.09 |  |  | $ | 5.04 |  |  | $ | 3.93 | \nDiluted |  | $ | 2.34 |  |  | $ | 2.08 |  |  | $ | 5.02 |  |  | $ | 3.91 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2022 |  | December 31,2021\n |  | (in millions)\nCash and cash equivalents |  | $ | 5,921 |  |  | $ | 7,421 | \nRestricted cash and restricted cash equivalents |  |  |  | \nRestricted cash for litigation settlement |  | 584 |  |  | 586 | \nRestricted security deposits held for customers |  | 1,621 |  |  | 1,873 | \nPrepaid expenses and other current assets |  | 26 |  |  | 22 | \n |  |  |  | \nCash, cash equivalents, restricted cash and restricted cash equivalents |  | $ | 8,152 |  |  | $ | 9,902 | \n |  |  |  | \n |  | \n |  |  |  | \n |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2022 |  | December 31,2021\n |  | (in millions)\nAvailable-for-sale securities1 |  | $ | 290 |  |  | $ | 314 | \nHeld-to-maturity securities2 |  | 148 |  |  | 159 | \nTotal investments |  | $ | 438 |  |  | $ | 473 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2022 |  | December 31, 2021\n |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue\n |  | (in millions)\nMunicipal securities |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | 2 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 2 | \nGovernment and agency securities |  | 101 |  |  | \u2014 |  |  | (1) |  |  | 100 |  |  | 98 |  |  | \u2014 |  |  | \u2014 |  |  | 98 | \nCorporate securities |  | 192 |  |  | \u2014 |  |  | (3) |  |  | 189 |  |  | 214 |  |  | \u2014 |  |  | \u2014 |  |  | 214 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal |  | $ | 294 |  |  | $ | \u2014 |  |  | $ | (4) |  |  | $ | 290 |  |  | $ | 314 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 314 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | \n |  | Amortized Cost |  | Fair\u00a0Value\n |  | (in millions)\nDue within 1 year |  | $ | 170 |  |  | $ | 168 | \nDue after 1 year through 5 years |  | 124 |  |  | 122 | \n |  |  |  | \nTotal |  | $ | 294 |  |  | $ | 290 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Balance at December 31, 2021 |  | Purchases |  | Sales |  | Changes in Fair Value1 |  | Other2 |  | Balance at June 30, 2022\n |  | (in millions)\nMarketable securities |  | $ | 627 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | (288) |  |  | $ | (18) |  |  | $ | 321 | \nNonmarketable securities |  | 1,207 |  |  | 43 |  |  | (6) |  |  | 95 |  |  | (26) |  |  | 1,313 | \nTotal equity investments |  | $ | 1,834 |  |  | $ | 43 |  |  | $ | (6) |  |  | $ | (193) |  |  | $ | (44) |  |  | $ | 1,634 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2022 |  | December 31,2021\n |  | (in millions)\nMeasurement alternative |  | $ | 1,044 |  |  | $ | 952 | \nEquity method |  | 269 |  |  | 255 | \nTotal Nonmarketable securities |  | $ | 1,313 |  |  | $ | 1,207 |   |  |  |  |  |  |  |  | \n |  | June 30,2022\n |  | (in millions)\nInitial cost basis |  | $ | 470 | \nCumulative adjustments1: |  | \nUpward adjustments |  | 608 | \nDownward adjustments (including impairment) |  | (34) | \nCarrying amount, end of period |  | $ | 1,044 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in millions)\nMeasurement alternative investments: |  |  |  |  |  |  |  | \nUpward adjustments |  | $ | 17 |  |  | $ | 118 |  |  | $ | 103 |  |  | $ | 159 | \nDownward adjustments (including impairment) |  | (12) |  |  | (1) |  |  | (12) |  |  | (1) | \nMarketable securities: |  |  |  |  |  |  |  | \nUnrealized gains/(losses), net |  | (126) |  |  | 91 |  |  | (288) |  |  | 145 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2022 |  | December 31, 2021\n |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total\n |  | (in millions)\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestment securities available-for-sale1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMunicipal securities |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | 2 |  |  | $ | \u2014 |  |  | $ | 2 | \nGovernment and agency securities |  | 34 |  |  | 66 |  |  | \u2014 |  |  | 100 |  |  | 35 |  |  | 63 |  |  | \u2014 |  |  | 98 | \nCorporate securities |  | \u2014 |  |  | 189 |  |  | \u2014 |  |  | 189 |  |  | \u2014 |  |  | 214 |  |  | \u2014 |  |  | 214 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | \u2014 |  |  | 167 |  |  | \u2014 |  |  | 167 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 8 | \nInterest rate contracts |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 6 |  |  | \u2014 |  |  | 6 | \nMarketable securities3: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nEquity securities |  | 321 |  |  | \u2014 |  |  | \u2014 |  |  | 321 |  |  | 627 |  |  | \u2014 |  |  | \u2014 |  |  | 627 | \nDeferred compensation plan4: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation assets |  | 74 |  |  | \u2014 |  |  | \u2014 |  |  | 74 |  |  | 89 |  |  | \u2014 |  |  | \u2014 |  |  | 89 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | \u2014 |  |  | $ | 3 |  |  | $ | \u2014 |  |  | $ | 3 |  |  | $ | \u2014 |  |  | $ | 15 |  |  | $ | \u2014 |  |  | $ | 15 | \nInterest rate contracts |  | \u2014 |  |  | 73 |  |  | \u2014 |  |  | 73 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 8 | \nDeferred compensation plan5: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation liabilities |  | 73 |  |  | \u2014 |  |  | \u2014 |  |  | 73 |  |  | 89 |  |  | \u2014 |  |  | \u2014 |  |  | 89 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2022 |  | December 31,2021\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 1,314 |  |  | $ | 1,326 | \nPrepaid income taxes |  | 122 |  |  | 92 | \nOther |  | 973 |  |  | 853 | \nTotal prepaid expenses and other current assets |  | $ | 2,409 |  |  | $ | 2,271 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2022 |  | December 31,2021\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 3,964 |  |  | $ | 3,798 | \nEquity investments |  | 1,634 |  |  | 1,834 | \nIncome taxes receivable |  | 670 |  |  | 645 | \nOther |  | 687 |  |  | 717 | \nTotal other assets |  | $ | 6,955 |  |  | $ | 6,994 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2022 |  | December 31,2021\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 4,471 |  |  | $ | 4,730 | \nPersonnel costs |  | 709 |  |  | 980 | \nIncome and other taxes |  | 409 |  |  | 337 | \nOther |  | 522 |  |  | 595 | \nTotal accrued expenses |  | $ | 6,111 |  |  | $ | 6,642 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | June 30,2022 |  | December 31,2021 |  | EffectiveInterest Rate\n |  |  |  |  | (in millions) |  | \n2022 EUR Notes1 |  | 1.000 | % | Senior Notes due February 2029 |  | $ | 788 |  |  | $ | \u2014 |  |  | 1.138 | %\n |  |  |  |  |  |  |  |  | \n2021 USD Notes |  | 2.000 | % | Senior Notes due November 2031 |  | 750 |  |  | 750 |  |  | 2.112 | %\n |  | 1.900 | % | Senior Notes due March 2031 |  | 600 |  |  | 600 |  |  | 1.981 | %\n |  | 2.950 | % | Senior Notes due March 2051 |  | 700 |  |  | 700 |  |  | 3.013 | %\n |  |  |  |  |  |  |  |  | \n2020 USD Notes |  | 3.300 | % | Senior Notes due March 2027 |  | 1,000 |  |  | 1,000 |  |  | 3.420 | %\n |  | 3.350 | % | Senior Notes due March 2030 |  | 1,500 |  |  | 1,500 |  |  | 3.430 | %\n |  | 3.850 | % | Senior Notes due March 2050 |  | 1,500 |  |  | 1,500 |  |  | 3.896 | %\n |  |  |  |  |  |  |  |  | \n2019 USD Notes |  | 2.950 | % | Senior Notes due June 2029 |  | 1,000 |  |  | 1,000 |  |  | 3.030 | %\n |  | 3.650 | % | Senior Notes due June 2049 |  | 1,000 |  |  | 1,000 |  |  | 3.689 | %\n |  | 2.000 | % | Senior Notes due March 2025 |  | 750 |  |  | 750 |  |  | 2.147 | %\n |  |  |  |  |  |  |  |  | \n2018 USD Notes |  | 3.500 | % | Senior Notes due February 2028 |  | 500 |  |  | 500 |  |  | 3.598 | %\n |  | 3.950 | % | Senior Notes due February 2048 |  | 500 |  |  | 500 |  |  | 3.990 | %\n |  |  |  |  |  |  |  |  | \n2016 USD Notes |  | 2.950 | % | Senior Notes due November 2026 |  | 750 |  |  | 750 |  |  | 3.044 | %\n |  | 3.800 | % | Senior Notes due November 2046 |  | 600 |  |  | 600 |  |  | 3.893 | %\n |  |  |  |  |  |  |  |  | \n2015 EUR Notes2 |  | 1.100 | % | Senior Notes due December 2022 |  | 735 |  |  | 793 |  |  | 1.265 | %\n |  | 2.100 | % | Senior Notes due December 2027 |  | 840 |  |  | 906 |  |  | 2.189 | %\n |  | 2.500 | % | Senior Notes due December 2030 |  | 158 |  |  | 170 |  |  | 2.562 | %\n |  |  |  |  |  |  |  |  | \n2014 USD Notes |  | 3.375 | % | Senior Notes due April 2024 |  | 1,000 |  |  | 1,000 |  |  | 3.484 | %\n |  |  |  |  |  |  |  |  | \n |  |  |  |  | 14,671 |  |  | 14,019 |  |  | \nLess: Unamortized discount and debt issuance costs | (117) |  |  | (116) |  |  | \nLess: Cumulative hedge accounting fair value adjustments3 |  | (73) |  |  | (2) |  |  | \nTotal debt outstanding | 14,481 |  |  | 13,901 |  |  | \nLess: Current portion4 |  | (735) |  |  | (792) |  |  | \nLong-term debt | $ | 13,746 |  |  | $ | 13,109 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nDividends declared per share |  | $ | 0.49 |  |  | $ | 0.44 |  |  | $ | 0.98 |  |  | $ | 0.88 | \nTotal dividends declared |  | $ | 474 |  |  | $ | 434 |  |  | $ | 951 |  |  | $ | 868 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30,\n |  | 2022 |  | 2021\n |  | Outstanding Shares |  | Outstanding Shares\n |  | Class\u00a0A |  | Class\u00a0B |  | Class\u00a0A |  | Class\u00a0B\n |  | (in millions)\nBalance at beginning of period |  | 966.5 |  |  | 7.7 |  |  | 983.9 |  |  | 8.2 | \nPurchases of treasury stock |  | (6.9) |  |  | \u2014 |  |  | (4.6) |  |  | \u2014 | \nShare-based payments |  | 0.4 |  |  | \u2014 |  |  | 0.3 |  |  | \u2014 | \nConversion of Class B to Class A common stock |  | \u2014 |  |  | \u2014 |  |  | 0.2 |  |  | (0.2) | \nBalance at end of period |  | 960.0 |  |  | 7.7 |  |  | 979.8 |  |  | 8.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30,\n |  | 2022 |  | 2021\n |  | Outstanding Shares |  | Outstanding Shares\n |  | Class\u00a0A |  | Class\u00a0B |  | Class\u00a0A |  | Class\u00a0B\n |  | (in millions)\nBalance at beginning of period |  | 972.1 |  |  | 7.8 |  |  | 986.9 |  |  | 8.3 | \nPurchases of treasury stock |  | (13.7) |  |  | \u2014 |  |  | (8.5) |  |  | \u2014 | \nShare-based payments |  | 1.5 |  |  | \u2014 |  |  | 1.1 |  |  | \u2014 | \nConversion of Class B to Class A common stock |  | 0.1 |  |  | (0.1) |  |  | 0.3 |  |  | (0.3) | \nBalance at end of period |  | 960.0 |  |  | 7.7 |  |  | 979.8 |  |  | 8.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30,\n |  | 2022 |  | 2021\n |  | (In millions, except per share data)\nDollar-value of shares repurchased |  | $ | 4,788 |  |  | $ | 3,067 | \nShares repurchased |  | 13.7 |  |  | 8.5 | \nAverage price paid per share |  | $ | 350.10 |  |  | $ | 359.66 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2021 |  | Increase / (Decrease) |  | Reclassifications |  | June 30, 2022\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (739) |  |  | $ | (731) |  |  | $ | \u2014 |  |  | $ | (1,470) | \nTranslation adjustments on net investment hedges2 |  | 34 |  |  | 311 |  |  | \u2014 |  |  | 345 | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | 4 |  |  | 5 |  |  | (6) |  |  | 3 | \nInterest rate contracts |  | (128) |  |  | \u2014 |  |  | 2 |  |  | (126) | \nDefined benefit pension and other postretirement plans |  | 21 |  |  | \u2014 |  |  | (1) |  |  | 20 | \nInvestment securities available-for-sale |  | (1) |  |  | (3) |  |  | \u2014 |  |  | (4) | \nAccumulated other comprehensive income (loss) |  | $ | (809) |  |  | $ | (418) |  |  | $ | (5) |  |  | $ | (1,232) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2020 |  | Increase / (Decrease) |  | Reclassifications |  | June 30, 2021\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (352) |  |  | $ | (31) |  |  | $ | \u2014 |  |  | $ | (383) | \nTranslation adjustments on net investment hedges2 |  | (175) |  |  | 56 |  |  | \u2014 |  |  | (119) | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | \u2014 |  |  | (1) |  |  | 1 |  |  | \u2014 | \nInterest rate contracts |  | (133) |  |  | \u2014 |  |  | 2 |  |  | (131) | \nDefined benefit pension and other postretirement plans |  | (20) |  |  | \u2014 |  |  | (1) |  |  | (21) | \nInvestment securities available-for-sale |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 | \nAccumulated other comprehensive income (loss) |  | $ | (680) |  |  | $ | 25 |  |  | $ | 2 |  |  | $ | (653) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Grants in 2022 |  | Weighted-AverageGrant-DateFair Value\n |  | (in millions) |  | (per option/unit)\nNon-qualified stock options |  | 0.3 |  | $ | 87 | \nRestricted stock units |  | 0.9 |  | 342 | \nPerformance stock units |  | 0.2 |  | 335 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2022 |  | December 31,2021\n |  | (in millions)\nGross settlement exposure |  | $ | 62,299 |  |  | $ | 59,571 | \nRisk mitigation arrangements applied to settlement exposure |  | (8,554) |  |  | (7,710) | \nNet settlement exposure |  | $ | 53,745 |  |  | $ | 51,861 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2022 |  | December 31, 2021\n |  | Notional |  | Derivative assets |  | Derivative liabilities |  | Notional |  | Derivative assets |  | Derivative liabilities\n |  | (in millions)\nDerivatives designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts in a cash flow hedge1 |  | $ | 217 |  |  | $ | 5 |  |  | $ | 1 |  |  | $ | 206 |  |  | $ | 7 |  |  | $ | 3 | \nInterest rate contracts in a fair value hedge2 |  | 1,000 |  |  | \u2014 |  |  | 73 |  |  | 1,000 |  |  | 6 |  |  | 8 | \nForeign exchange contracts in a net investment hedge1 |  | 2,416 |  |  | 157 |  |  | \u2014 |  |  | 1,473 |  |  | \u2014 |  |  | 4 | \nDerivatives not designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts1 |  | 540 |  |  | 5 |  |  | 2 |  |  | 530 |  |  | 1 |  |  | 8 | \nTotal derivative assets/liabilities |  | $ | 4,173 |  |  | $ | 167 |  |  | $ | 76 |  |  | $ | 3,209 |  |  | $ | 14 |  |  | $ | 23 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Gain (Loss)Recognized in OCI |  |  |  | Gain (Loss)Reclassified from AOCI\n |  | Three Months Ended June 30, |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Three Months Ended June 30,\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021\n |  | (in millions) |  |  | (in millions)\nDerivative financial instruments in a cash flow hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 6 |  |  | $ | (4) |  |  | Net revenue |  | $ | 1 |  |  | $ | (1) | \nInterest rate contracts |  | $ | \u2014 |  |  | $ | \u2014 |  |  | Interest expense |  | $ | (1) |  |  | $ | (2) | \n |  |  |  |  |  |  |  |  |  | \nDerivative financial instruments in a net investment hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 166 |  |  | $ | (34) |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Gain (Loss)Recognized in OCI |  |  |  | Gain (Loss)Reclassified from AOCI\n |  | Six Months Ended June 30, |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Six Months Ended June 30,\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021\n |  | (in millions) |  |  | (in millions)\nDerivative financial instruments in a cash flow hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 7 |  |  | $ | (1) |  |  | Net revenue |  | $ | 8 |  |  | $ | (1) | \nInterest rate contracts |  | $ | \u2014 |  |  | $ | \u2014 |  |  | Interest expense |  | $ | (3) |  |  | $ | (3) | \n |  |  |  |  |  |  |  |  |  | \nDerivative financial instruments in a net investment hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 201 |  |  | $ | 12 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\nDerivatives not designated as hedging instruments: |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in millions)\nForeign exchange derivative contracts |  |  |  |  |  |  |  | \nGeneral and administrative |  | $ | 12 |  |  | $ | (7) |  |  | $ | 13 |  |  | $ | (3) | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/(Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease)\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \n |  | ($ in millions, except per share data)\nNet revenue |  | $ | 5,497 |  |  | $ | 4,528 |  |  | 21% |  | $ | 10,664 |  |  | $ | 8,683 |  |  | 23%\nOperating expenses |  | $ | 2,479 |  |  | $ | 2,187 |  |  | 13% |  | $ | 4,696 |  |  | $ | 4,145 |  |  | 13%\nOperating income |  | $ | 3,018 |  |  | $ | 2,341 |  |  | 29% |  | $ | 5,968 |  |  | $ | 4,538 |  |  | 32%\nOperating margin |  | 54.9 | % |  | 51.7 | % |  | 3.2 ppt |  | 56.0 | % |  | 52.3 | % |  | 3.7 ppt\nIncome tax expense |  | $ | 523 |  |  | $ | 412 |  |  | 27% |  | $ | 665 |  |  | $ | 774 |  |  | (14)%\nEffective income tax rate |  | 18.7 | % |  | 16.6 | % |  | 2.1 ppt |  | 11.9 | % |  | 16.6 | % |  | (4.6) ppt\nNet income |  | $ | 2,275 |  |  | $ | 2,066 |  |  | 10% |  | $ | 4,906 |  |  | $ | 3,894 |  |  | 26%\nDiluted earnings per share |  | $ | 2.34 |  |  | $ | 2.08 |  |  | 13% |  | $ | 5.02 |  |  | $ | 3.91 |  |  | 28%\nDiluted weighted-average shares outstanding |  | 974 |  |  | 994 |  |  | (2)% |  | 977 |  |  | 996 |  |  | (2)%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Increase/(Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease)\n | 2022 |  | 2021 |  | As adjusted |  | Currency-neutral |  | 2022 |  | 2021 |  | As adjusted |  | Currency-neutral\n | ($ in millions, except per share data)\nAdjusted net revenue | $ | 5,491 |  |  | $ | 4,528 |  |  | 21% |  | 27% |  | $ | 10,627 |  |  | $ | 8,683 |  |  | 22% |  | 27%\nAdjusted operating expenses | $ | 2,313 |  |  | $ | 2,121 |  |  | 9% |  | 12% |  | $ | 4,496 |  |  | $ | 4,079 |  |  | 10% |  | 13%\nAdjusted operating margin | 57.9 | % |  | 53.2 | % |  | 4.7 ppt |  | 5.4 ppt |  | 57.7 | % |  | 53.0 | % |  | 4.7 ppt |  | 5.3 ppt\nAdjusted effective income tax rate | 18.8 | % |  | 15.9 | % |  | 2.9 ppt |  | 3.1 ppt |  | 12.3 | % |  | 16.4 | % |  | (4.1) ppt |  | (4.0) ppt\nAdjusted net income | $ | 2,497 |  |  | $ | 1,937 |  |  | 29% |  | 37% |  | $ | 5,199 |  |  | $ | 3,678 |  |  | 41% |  | 49%\nAdjusted diluted earnings per share | $ | 2.56 |  |  | $ | 1.95 |  |  | 31% |  | 40% |  | $ | 5.32 |  |  | $ | 3.69 |  |  | 44% |  | 52%  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | Adjusted net revenue | Adjusted net revenue increased 27% on a currency-neutral basis, which includes 1 percentage point of growth from acquisitions.  Primary drivers of the increase were as follows:\nThree Months Ended June 30, 2022\nGAAP |  | Non-GAAP(currency-neutral)\nup 21% |  | up 27%\n |  |  | - Gross dollar volume growth of 14% on a local currency basis\n |  |  | - Cross-border volume growth of 58% on a local currency basis\n |  |  | - Switched transactions growth of 12%\n |  |  | \n |  |  | - Other revenues increased 18% or 23% on a currency-neutral basis, which\n |  |  | includes 3 percentage points of growth due to acquisitions. The remaining growth\n |  |  | was driven primarily by our Cyber & Intelligence and Data & Services solutions.\n |  |  | \n |  |  | These increases were partially offset by:\n |  |  | - Rebates and incentives (contra-revenue) increased 19%, or 23% on a currency-\n |  |  | neutral basis, primarily due to increased volumes and transactions and new\n |  |  | and renewed deals.\n |  |  | \nSix Months Ended June 30, 2022 | Adjusted net revenue increased 27% on a currency-neutral basis, which includes 2 percentage points of growth from acquisitions.  Primary drivers of the increase were as follows:\nGAAP |  | Non-GAAP(currency-neutral)\nup 23% |  | up 27%\n |  |  | \n |  |  | - Gross dollar volume growth of 15% on a local currency basis\n |  |  | - Cross-border volume growth of 56% on a local currency basis\n |  |  | - Switched transactions growth of 16%\n |  |  | \n |  |  | - Other revenues increased 18%, or 22% on a currency-neutral basis, which\n |  |  | includes 5 percentage points of growth due to acquisitions.  The remaining growth\n |  |  | was driven primarily by our Cyber & Intelligence and Data & Services solutions.\n |  |  | \n |  |  | These increases were partially offset by:\n |  |  | - Rebates and incentives (contra-revenue) increased 22%, or 25% on a currency-\n |  |  | neutral basis, primarily due to increased volumes and transactions and new and\n |  |  | renewed deals, which includes a 1 percentage point reduction from Special Items.  |  |  |  |  |  |  |  |  |  |  | \nOperating expenses |  | Adjustedoperating expenses | \nThree Months Ended June 30, 2022 | Adjusted operating expenses increased 12% on a currency-neutral basis, which includes 5 percentage points of growth due to acquisitions.  The remaining increase was primarily due to higher personnel costs and unfavorable foreign exchange activity.\nGAAP |  | Non-GAAP(currency-neutral)\nup 13% |  | up 12%\n |  | \nSix Months Ended June 30, 2022 | Adjusted operating expenses increased 13% on a currency-neutral basis, which includes 5 percentage points of growth due to acquisitions.  The remaining increase was primarily due to higher personnel costs, increased spending on advertising and marketing and unfavorable foreign exchange activity.\nGAAP |  | Non-GAAP(currency-neutral)\nup 13% |  | up 13%\n |  |   |  |  |  |  |  |  |  |  |  |  | \nEffective incometax rate |  | Adjusted effectiveincome tax rate | \nThree Months Ended June 30, 2022 | The adjusted effective income tax rate of 18.8% was higher than prior year due to a discrete tax benefit in 2021 related to the remeasurement of the Company's net deferred tax asset in the U.K. due to an enacted tax rate change in 2021.\nGAAP |  | Non-GAAP(currency-neutral)\n18.7% |  | 18.8%\n |  | \nSix Months Ended June 30, 2022 | The adjusted effective income tax rate of 12.3% was lower than prior year due to a discrete tax benefit related to final U.S. tax regulations published in the current year, partially offset by a discrete tax benefit in the prior year related to the remeasurement of the Company's net deferred tax asset in the U.K. due to an enacted tax rate change in 2021.  The U.S. tax regulations resulted in a valuation allowance release of $333 million associated with the U.S. foreign tax credit carryforward deferred tax asset.\nGAAP |  | Non-GAAP(currency-neutral)\n11.9% |  | 12.3%\n |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, 2022\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 5,497 |  |  | $ | 2,479 |  |  | 54.9 | % |  | $ | (220) |  |  | 18.7 | % |  | $ | 2,275 |  |  | $ | 2.34 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 117 |  |  | (0.6) | % |  | 113 |  |  | 0.12 | \nLitigation provisions |  | ** |  | (133) |  |  | 2.4 | % |  | ** |  | 0.7 | % |  | 89 |  |  | 0.09 | \nRussia-related impacts |  | (6) |  |  | (33) |  |  | 0.5 | % |  | ** |  | \u2014 | % |  | 20 |  |  | 0.02 | \nAdjusted - Non-GAAP |  | $ | 5,491 |  |  | $ | 2,313 |  |  | 57.9 | % |  | $ | (104) |  |  | 18.8 | % |  | $ | 2,497 |  |  | $ | 2.56 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2022\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 10,664 |  |  | $ | 4,696 |  |  | 56.0 | % |  | $ | (397) |  |  | 11.9 | % |  | $ | 4,906 |  |  | $ | 5.02 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 193 |  |  | (0.2) | % |  | 181 |  |  | 0.18 | \nLitigation provisions |  | ** |  | (133) |  |  | 1.2 | % |  | ** |  | 0.5 | % |  | 89 |  |  | 0.09 | \nRussia-related impacts |  | (37) |  |  | (67) |  |  | 0.5 | % |  | ** |  | 0.1 | % |  | 24 |  |  | 0.02 | \nAdjusted - Non-GAAP |  | $ | 10,627 |  |  | $ | 4,496 |  |  | 57.7 | % |  | $ | (205) |  |  | 12.3 | % |  | $ | 5,199 |  |  | $ | 5.32 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, 2021\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 4,528 |  |  | $ | 2,187 |  |  | 51.7 | % |  | $ | 137 |  |  | 16.6 | % |  | $ | 2,066 |  |  | $ | 2.08 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | (243) |  |  | (0.9) | % |  | (182) |  |  | (0.18) | \nLitigation provisions |  | ** |  | $ | (67) |  |  | 1.5 | % |  | ** |  | 0.2 | % |  | 52 |  |  | 0.05 | \nAdjusted - Non-GAAP |  | $ | 4,528 |  |  | $ | 2,121 |  |  | 53.2 | % |  | $ | (106) |  |  | 15.9 | % |  | $ | 1,937 |  |  | $ | 1.95 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2021\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 8,683 |  |  | $ | 4,145 |  |  | 52.3 | % |  | $ | 130 |  |  | 16.6 | % |  | $ | 3,894 |  |  | $ | 3.91 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | (337) |  |  | (0.3) | % |  | (269) |  |  | (0.27) | \nLitigation provisions |  | ** |  | (67) |  |  | 0.8 | % |  | ** |  | 0.1 | % |  | 52 |  |  | 0.05 | \nAdjusted - Non-GAAP |  | $ | 8,683 |  |  | $ | 4,079 |  |  | 53.0 | % |  | $ | (207) |  |  | 16.4 | % |  | $ | 3,678 |  |  | $ | 3.69 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, 2022 as compared to the Three Months Ended June 30, 2021\n |  | Increase/(Decrease)\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\nReported - GAAP |  | 21% |  | 13% |  | 3.2 ppt |  | 2.1 ppt |  | 10% |  | 13%\n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 0.3 ppt |  | 17% |  | 17%\nLitigation provisions |  | ** |  | (3)% |  | 1.0 ppt |  | 0.5 ppt |  | 1% |  | 1%\nRussia-related impacts |  | \u2014% |  | (2)% |  | 0.5 ppt |  | \u2014 ppt |  | 1% |  | 1%\nAdjusted - Non-GAAP |  | 21% |  | 9% |  | 4.7 ppt |  | 2.9 ppt |  | 29% |  | 31%\nCurrency impact1 |  | 6% |  | 3% |  | 0.8 ppt |  | 0.1 ppt |  | 8% |  | 9%\nAdjusted - Non-GAAP - currency-neutral |  | 27% |  | 12% |  | 5.4 ppt |  | 3.1 ppt |  | 37% |  | 40%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2022 as compared to the Six Months Ended June 30, 2021\n |  | Increase/(Decrease)\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\nReported - GAAP |  | 23% |  | 13% |  | 3.7 ppt |  | (4.6) ppt |  | 26% |  | 28%\n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 0.1 ppt |  | 14% |  | 15%\nLitigation provisions |  | ** |  | (1)% |  | 0.5 ppt |  | 0.4 ppt |  | \u2014% |  | 1%\nRussia-related impacts |  | \u2014% |  | (2)% |  | 0.5 ppt |  | 0.1 ppt |  | 1% |  | \u2014%\nAdjusted - Non-GAAP |  | 22% |  | 10% |  | 4.7 ppt |  | (4.1) ppt |  | 41% |  | 44%\nCurrency impact1 |  | 5% |  | 2% |  | 0.7 ppt |  | 0.1 ppt |  | 7% |  | 8%\nAdjusted - Non-GAAP - currency-neutral |  | 27% |  | 13% |  | 5.3 ppt |  | (4.0) ppt |  | 49% |  | 52%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/ (Decrease) |  |  | Six Months Ended June 30, |  | Increase/ (Decrease)\n |  | 2022 |  | 2021 |  |  |  | 2022 |  | 2021 | \n |  | ($ in millions)\nDomestic assessments |  | $ | 2,283 |  |  | $ | 2,056 |  |  | 11% |  |  | $ | 4,417 |  |  | $ | 3,854 |  |  | 15%\nCross-border volume fees |  | 1,615 |  |  | 1,076 |  |  | 50% |  |  | 3,010 |  |  | 2,008 |  |  | 50%\nTransaction processing |  | 3,061 |  |  | 2,612 |  |  | 17% |  |  | 5,973 |  |  | 4,963 |  |  | 20%\nOther revenues |  | 1,745 |  |  | 1,475 |  |  | 18% |  |  | 3,329 |  |  | 2,822 |  |  | 18%\nGross revenue |  | 8,704 |  |  | 7,219 |  |  | 21% |  |  | 16,729 |  |  | 13,647 |  |  | 23%\nRebates and incentives (contra-revenue) |  | (3,207) |  |  | (2,691) |  |  | 19% |  |  | (6,065) |  |  | (4,964) |  |  | 22%\nNet revenue |  | 5,497 |  |  | 4,528 |  |  | 21% |  |  | 10,664 |  |  | 8,683 |  |  | 23%\nSpecial Items1 |  | (6) |  |  | \u2014 |  |  | ** |  |  | (37) |  |  | \u2014 |  |  | **\nAdjusted net revenue (excluding Special Items1) |  | $ | 5,491 |  |  | $ | 4,528 |  |  | 21% |  |  | $ | 10,627 |  |  | $ | 8,683 |  |  | 22%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, 2022\n |  | Operational |  | SpecialItems3 |  |  |  | Acquisitions |  | Currency Impact4 |  |  |  | Total\nDomestic assessments |  | 13 | % | 1 |  | \u2014 | % |  |  |  |  | \u2014 | % |  | (2) | % |  |  |  |  | 11 | %\nCross-border volume fees |  | 61 | % | 1 |  | \u2014 | % |  |  |  |  | \u2014 | % |  | (11) | % |  |  |  |  | 50 | %\nTransaction processing |  | 22 | % | 1, 2 |  | \u2014 | % |  |  |  |  | \u2014 | % |  | (5) | % |  |  |  |  | 17 | %\nOther revenues |  | 20 | % | 2 |  | \u2014 | % |  |  |  |  | 3 | % |  | (5) | % |  |  |  |  | 18 | %\nRebates and incentives (contra-revenue) |  | 23 | % |  |  | \u2014 | % |  |  |  |  | \u2014 | % |  | (3) | % |  |  |  |  | 19 | %\nNet revenue |  | 26 | % |  |  | \u2014 | % |  |  |  |  | 1 | % |  | (6) | % |  |  |  |  | 21 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2022\n |  | Operational |  |  |  | SpecialItems3 |  | Acquisitions |  | Currency Impact4 |  |  |  | Total\nDomestic assessments |  | 17 | % | 1 |  |  |  |  | \u2014 | % |  | \u2014 | % |  | (2) | % |  |  |  |  | 15 | %\nCross-border volume fees |  | 59 | % | 1 |  |  |  |  | \u2014 | % |  | \u2014 | % |  | (9) | % |  |  |  |  | 50 | %\nTransaction processing |  | 24 | % | 1, 2 |  |  |  |  | \u2014 | % |  | \u2014 | % |  | (4) | % |  |  |  |  | 20 | %\nOther revenues |  | 17 | % | 2 |  |  |  |  | \u2014 | % |  | 5 | % |  | (4) | % |  |  |  |  | 18 | %\nRebates and incentives (contra-revenue) |  | 26 | % |  |  |  |  |  | (1) | % |  | \u2014 | % |  | (3) | % |  |  |  |  | 22 | %\nNet revenue |  | 25 | % |  |  |  |  |  | \u2014 | % |  | 2 | % |  | (5) | % |  |  |  |  | 23 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | Increase/(Decrease) |  | Increase/(Decrease)\n |  | USD |  | Local |  | USD |  | Local |  | USD |  | Local |  | USD |  | Local\nMastercard-branded GDV1 |  | 8% |  | 14% |  | 39% |  | 33% |  | 10% |  | 15% |  | 23% |  | 20%\nUnited States |  | 10% |  | 10% |  | 34% |  | 34% |  | 12% |  | 12% |  | 24% |  | 24%\nWorldwide less United States |  | 7% |  | 16% |  | 41% |  | 33% |  | 9% |  | 17% |  | 23% |  | 18%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCross-border volume1 |  | 46% |  | 58% |  | 70% |  | 58% |  | 45% |  | 56% |  | 18% |  | 11%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMastercard-branded GDV1adjusted for Russia2 |  | 12% |  | 19% |  | 38% |  | 32% |  | 14% |  | 20% |  | 23% |  | 19%\nWorldwide less United States adjusted for Russia2 |  | 14% |  | 25% |  | 41% |  | 32% |  | 15% |  | 24% |  | 23% |  | 17%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCross-border volume1adjusted for Russia2 |  | 50% |  | 64% |  | 69% |  | 57% |  | 48% |  | 59% |  | 17% |  | 11%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | Increase/(Decrease) |  | Increase/(Decrease)\nSwitched transactions |  | 12% |  | 41% |  | 16% |  | 24%\n |  |  |  |  |  |  |  | \nSwitched transactions adjusted for Russia2 |  | 22% |  | 39% |  | 23% |  | 23%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/ (Decrease) |  | Six Months Ended June 30, |  | Increase/ (Decrease)\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \n |  | ($ in millions)\nGeneral and administrative |  | $ | 1,947 |  |  | $ | 1,718 |  |  | 13% |  | $ | 3,791 |  |  | $ | 3,394 |  |  | 12%\nAdvertising and marketing |  | 210 |  |  | 216 |  |  | (2)% |  | 391 |  |  | 335 |  |  | 17%\nDepreciation and amortization |  | 189 |  |  | 186 |  |  | 2% |  | 381 |  |  | 349 |  |  | 9%\nProvision for litigation |  | 133 |  |  | 67 |  |  | ** |  | 133 |  |  | 67 |  |  | **\nTotal operating expenses |  | 2,479 |  |  | 2,187 |  |  | 13% |  | 4,696 |  |  | 4,145 |  |  | 13%\nSpecial Items1 |  | (166) |  |  | (67) |  |  | ** |  | (200) |  |  | (67) |  |  | **\nAdjusted total operating expenses (excluding Special Items1) |  | $ | 2,313 |  |  | $ | 2,121 |  |  | 9% |  | $ | 4,496 |  |  | $ | 4,079 |  |  | 10%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, 2022\n |  | Operational |  | SpecialItems1 |  | Acquisitions |  | Currency Impact2 |  | Total\nGeneral and administrative |  | 9% |  | 2% |  | 5% |  | (3)% |  | 13%\nAdvertising and marketing |  | 1% |  | ** |  | 1% |  | (4)% |  | (2)%\nDepreciation and amortization |  | ** |  | ** |  | 6% |  | (4)% |  | 2%\nProvision for litigation |  | ** |  | ** |  | ** |  | ** |  | **\nTotal operating expenses |  | 8% |  | 4% |  | 5% |  | (3)% |  | 13%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2022\n |  | Operational |  | SpecialItems1 |  | Acquisitions |  | Currency Impact2 |  | Total\nGeneral and administrative |  | 7% |  | 2% |  | 5% |  | (2)% |  | 12%\nAdvertising and marketing |  | 20% |  | ** |  | 1% |  | (5)% |  | 17%\nDepreciation and amortization |  | 1% |  | ** |  | 11% |  | (3)% |  | 9%\nProvision for litigation |  | ** |  | ** |  | ** |  | ** |  | **\nTotal operating expenses |  | 8% |  | 3% |  | 5% |  | (2)% |  | 13%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/ (Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease)\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \n |  | ($ in millions)\nPersonnel1 |  | $ | 1,319 |  |  | $ | 1,130 |  |  | 17% |  | $ | 2,500 |  |  | $ | 2,234 |  |  | 12%\nProfessional fees |  | 109 |  |  | 106 |  |  | 3% |  | 195 |  |  | 203 |  |  | (4)%\nData processing and telecommunications |  | 225 |  |  | 215 |  |  | 5% |  | 460 |  |  | 415 |  |  | 11%\nForeign exchange activity2 |  | 35 |  |  | 8 |  |  | ** |  | 71 |  |  | 16 |  |  | **\nOther1 |  | 259 |  |  | 259 |  |  | \u2014% |  | 565 |  |  | 526 |  |  | 7%\nTotal general and administrative expenses |  | $ | 1,947 |  |  | $ | 1,718 |  |  | 13% |  | $ | 3,791 |  |  | $ | 3,394 |  |  | 12%\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/ (Decrease) |  | Six Months Ended June 30, |  | Increase/ (Decrease)\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \n |  | ($ in millions)\nInvestment income |  | $ | 7 |  |  | $ | 3 |  |  | ** |  | $ | 12 |  |  | $ | 4 |  |  | **\nGains (losses) on equity investments, net |  | (117) |  |  | 243 |  |  | ** |  | (193) |  |  | 337 |  |  | **\nInterest expense |  | (114) |  |  | (106) |  |  | 7% |  | (224) |  |  | (213) |  |  | 5%\nOther income (expense), net |  | 4 |  |  | (3) |  |  | ** |  | 8 |  |  | 2 |  |  | **\nTotal other income (expense) |  | (220) |  |  | 137 |  |  | ** |  | (397) |  |  | 130 |  |  | **\n(Gains) losses on equity investments1 |  | 117 |  |  | (243) |  |  | ** |  | 193 |  |  | (337) |  |  | **\n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted total other income (expense)1 |  | $ | (104) |  |  | $ | (106) |  |  | (2)% |  | $ | (205) |  |  | $ | (207) |  |  | (1)%  |  |  |  |  |  |  |  |  |  |  | \n | June 30,2022 |  | December 31,2021\n | (in billions)\nCash, cash equivalents and investments1 | $ | 6.4 |  |  | $ | 7.9 | \nUnused line of credit | 6.0 |  |  | 6.0 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2022 |  | 2021\n | (in millions)\nNet cash provided by operating activities | $ | 4,239 |  |  | $ | 3,731 | \nNet cash used in investing activities | (812) |  |  | (4,702) | \nNet cash used in financing activities | (4,975) |  |  | (2,801) |   |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  | (in millions, except average price data)\nRemaining authorization at December 31, 2021 |  |  |  |  |  | $ | 11,927 | \nDollar value of shares repurchased during the six months ended June 30, 2022 |  |  |  |  |  | $ | 4,788 | \nRemaining authorization at June 30, 2022 |  |  |  |  |  | $ | 7,139 | \nShares repurchased during the six months ended June 30, 2022 |  |  |  |  |  | 13.7 | \nAverage price paid per share during the six months ended June 30, 2022 |  |  |  |  |  | $ | 350.10 | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART II |  |  | \n |  | Item 1. Legal proceedings |  |  | \n |  | Item 1A. Risk factors |  |  | \n |  | Item 2. Unregistered sales of equity securities and use of proceeds |  |  | \n |  | Item 5. Other information |  |  | \n |  | Item 6. Exhibits |  |  | \n |  | Signatures |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod |  | Total\u00a0Numberof\u00a0SharesPurchased |  | Average\u00a0PricePaid\u00a0per\u00a0Share(includingcommission\u00a0cost) |  | Total\u00a0Number\u00a0ofShares\u00a0Purchased\u00a0asPart\u00a0of\u00a0PubliclyAnnounced\u00a0Plans\u00a0orPrograms |  | Dollar\u00a0Value\u00a0ofShares\u00a0that\u00a0may\u00a0yetbe\u00a0Purchased\u00a0underthe Plans\u00a0orPrograms1, 2\nApril 1 - 30 |  | 2,105,718 |  |  | $ | 357.73 |  |  | 2,105,718 |  |  | $ | 8,765,950,568 | \nMay 1 - 31 |  | 2,481,832 |  |  | 341.59 |  |  | 2,481,832 |  |  | 7,918,182,527 | \nJune 1 - 30 |  | 2,307,755 |  |  | 337.55 |  |  | 2,307,755 |  |  | 7,139,198,823 | \nTotal |  | 6,895,305 |  |  | 345.17 |  |  | 6,895,305 |  |  |   |  |  |  |  |  |  |  | \nExhibitNumber |  | Exhibit Description\n3.1 |  | Amended and Restated Certificate of Incorporation of Mastercard Incorporated (incorporated by reference to Exhibit 3.1 of the Company\u2019s Current Report onForm 8-K filed on June 24, 2022 (File No. 001-32877)).\n3.2 |  | Amended and Restated By-Laws of Mastercard Incorporated (incorporated by reference to Exhibit 3.2of the Company\u2019s Current Report onForm 8-K filed on June 24, 2022 (File No. 001-32877)).\n10.1* |  | Form of Deferred Stock Unit Agreement for awards under 2006 Non-Employee Director Equity Compensation Plan, amended and restated effective June22, 2021(effective for awards granted on and subsequent to June 21, 2022).\n10.2* |  | Form of Restricted Stock Agreement for awards under 2006 Non-Employee Director Equity Compensation Plan, amended and restated effective June22, 2021(effective for awards granted on and subsequent to June 21, 2022).\n31.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n31.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n32.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n32.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n99.1* |  | Disclosure pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012.\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH* |  | XBRL Taxonomy Extension Schema Document\n101.CAL* |  | XBRL Taxonomy Extension Calculation Linkbase Document\n101.DEF* |  | XBRL Taxonomy Extension Definition Linkbase Document\n101.LAB* |  | XBRL Taxonomy Extension Label Linkbase Document\n101.PRE* |  | XBRL Taxonomy Extension Presentation Linkbase Document  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | MASTERCARD INCORPORATED\n |  | (Registrant)\n |  |  | \nDate: | July 28, 2022 | By: |  | /S/ MICHAEL MIEBACH\n |  |  |  | Michael Miebach\n |  |  |  | President and Chief Executive Officer\n |  |  |  | (Principal Executive Officer)\n |  |  | \nDate: | July 28, 2022 | By: |  | /S/ SACHIN MEHRA\n |  |  |  | Sachin Mehra\n |  |  |  | Chief Financial Officer\n |  |  |  | (Principal Financial Officer)\n |  |  | \nDate: | July 28, 2022 | By: |  | /S/ SANDRA ARKELL\n |  |  |  | Sandra Arkell\n |  |  |  | Corporate Controller\n |  |  |  | (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Mastercard, in 2022 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  | \nDelaware | 13-4172551\n(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification Number)\n |  | \n2000 Purchase Street | 10577\nPurchase, | NY | (Zip Code)\n(Address of principal executive offices) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class |  | Trading Symbol |  | Name of each exchange of which registered\nClass A Common Stock, par value $0.0001 per share |  | MA |  | New York Stock Exchange\n1.1% Notes due 2022 |  | MA22 |  | New York Stock Exchange\n2.1% Notes due 2027 |  | MA27 |  | New York Stock Exchange\n1.0% Notes due 2029 |  | MA29A |  | New York Stock Exchange\n2.5% Notes due 2030 |  | MA30 |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant (1)\u00a0has filed all reports required to be filed by Section\u00a013 or 15(d)\u00a0of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\u00a0has been subject to such filing requirements for the past 90 days. | Yes | \u2612 | No | \u2610\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files) | Yes | \u2612 | No | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of \u201clarge accelerated filer,\u201d \u201caccelerated filer,\u201d \u201csmaller reporting company,\u201d and \u201cemerging growth company\u201d in Rule 12b-2 of the Exchange Act. (Check One):\nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  |  | \nNon-accelerated filer | \u2610 |  | Smaller\u00a0reporting\u00a0company | \u2610 |  |  | \n |  |  | Emerging growth\u00a0company | \u2610 |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. | \u2610\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) | Yes | \u2610 | No | \u2612  |  | \n  |  |  |  |  |  |  |  |  |  |  | \n |  |  | \nPART I | 5 | Item 1. | Consolidated financial statements (unaudited)\n30 | Item 2. | Management\u2019s discussion and analysis of financial condition and results of operations\n45 | Item 3. | Quantitative and qualitative disclosures about market risk\n46 | Item 4. | Controls and procedures\n |  |  | \n |  |  | \nPART II | 48 | Item 1. | Legal proceedings\n48 | Item 1A. | Risk factors\n48 | Item 2. | Unregistered sales of equity securities and use of proceeds\n48 | Item 5. | Other information\n48 | Item 6. | Exhibits\n50 | - | Signatures\n |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART I |  |  | \n |  | Item 1. Consolidated financial statements (unaudited) |  | \n |  | Item 2. Management\u2019s discussion and analysis of financial condition and results of operations |  | \n |  | Item 3. Quantitative and qualitative disclosures about market risk |  | \n |  | Item 4. Controls and procedures |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  | \n |  | Page\nConsolidated Statement of Operations \u2014Three and Nine Months Ended September 30, 2022and2021 |  | 6\nConsolidated Statement of Comprehensive Income \u2014Three and Nine Months Ended September 30, 2022and2021 |  | 7\nConsolidated Balance Sheet \u2014September 30, 2022andDecember 31, 2021 |  | 8\nConsolidated Statement of Changes in Equity\u2014Three and Nine Months Ended September 30, 2022and2021 |  | 9\nConsolidated Statement of Cash Flows \u2014Nine Months Ended September 30, 2022and2021 |  | 11\nNotes to consolidated financial statements |  | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Operations (Unaudited) |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNet Revenue |  | $ | 5,756 |  |  | $ | 4,985 |  |  | $ | 16,420 |  |  | $ | 13,668 | \nOperating Expenses: |  |  |  |  |  |  |  | \nGeneral and administrative |  | 2,069 |  |  | 1,831 |  |  | 5,860 |  |  | 5,225 | \nAdvertising and marketing |  | 182 |  |  | 222 |  |  | 573 |  |  | 557 | \nDepreciation and amortization |  | 185 |  |  | 188 |  |  | 566 |  |  | 537 | \nProvision for litigation |  | 208 |  |  | 27 |  |  | 341 |  |  | 94 | \nTotal operating expenses |  | 2,644 |  |  | 2,268 |  |  | 7,340 |  |  | 6,413 | \nOperating income |  | 3,112 |  |  | 2,717 |  |  | 9,080 |  |  | 7,255 | \nOther Income (Expense): |  |  |  |  |  |  |  | \nInvestment income |  | 16 |  |  | 5 |  |  | 28 |  |  | 9 | \nGains (losses) on equity investments, net |  | 60 |  |  | 197 |  |  | (133) |  |  | 534 | \nInterest expense |  | (120) |  |  | (110) |  |  | (344) |  |  | (323) | \nOther income (expense), net |  | 4 |  |  | 7 |  |  | 12 |  |  | 9 | \nTotal other income (expense) |  | (40) |  |  | 99 |  |  | (437) |  |  | 229 | \nIncome before income taxes |  | 3,072 |  |  | 2,816 |  |  | 8,643 |  |  | 7,484 | \nIncome tax expense |  | 573 |  |  | 402 |  |  | 1,238 |  |  | 1,176 | \nNet Income |  | $ | 2,499 |  |  | $ | 2,414 |  |  | $ | 7,405 |  |  | $ | 6,308 | \nBasic Earnings per Share |  | $ | 2.59 |  |  | $ | 2.45 |  |  | $ | 7.63 |  |  | $ | 6.37 | \nBasic weighted-average shares outstanding |  | 965 |  |  | 986 |  |  | 971 |  |  | 990 | \nDiluted Earnings per Share |  | $ | 2.58 |  |  | $ | 2.44 |  |  | $ | 7.60 |  |  | $ | 6.35 | \nDiluted weighted-average shares outstanding |  | 968 |  |  | 990 |  |  | 974 |  |  | 994 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Comprehensive Income (Unaudited) |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in millions)\nNet Income |  | $ | 2,499 |  |  | $ | 2,414 |  |  | $ | 7,405 |  |  | $ | 6,308 | \nOther comprehensive income (loss): |  |  |  |  |  |  |  | \nForeign currency translation adjustments |  | (743) |  |  | (219) |  |  | (1,517) |  |  | (274) | \nIncome tax effect |  | 62 |  |  | 9 |  |  | 105 |  |  | 33 | \nForeign currency translation adjustments, net of income tax effect |  | (681) |  |  | (210) |  |  | (1,412) |  |  | (241) | \n |  |  |  |  |  |  |  | \nTranslation adjustments on net investment hedges |  | 372 |  |  | 90 |  |  | 772 |  |  | 162 | \nIncome tax effect |  | (82) |  |  | (20) |  |  | (171) |  |  | (36) | \nTranslation adjustments on net investment hedges, net of income tax effect |  | 290 |  |  | 70 |  |  | 601 |  |  | 126 | \n |  |  |  |  |  |  |  | \nCash flow hedges |  | 14 |  |  | 2 |  |  | 21 |  |  | 1 | \nIncome tax effect |  | (3) |  |  | \u2014 |  |  | (5) |  |  | \u2014 | \nReclassification adjustments for cash flow hedges |  | (4) |  |  | 1 |  |  | (9) |  |  | 5 | \nIncome tax effect |  | 1 |  |  | \u2014 |  |  | 2 |  |  | (1) | \nCash flow hedges, net of income tax effect |  | 8 |  |  | 3 |  |  | 9 |  |  | 5 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nReclassification adjustments for defined benefit pension and other postretirement plans |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) | \nIncome tax effect |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nDefined benefit pension and other postretirement plans, net of income tax effect |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) | \n |  |  |  |  |  |  |  | \nInvestment securities available-for-sale |  | (2) |  |  | (2) |  |  | (6) |  |  | \u2014 | \nIncome tax effect |  | \u2014 |  |  | 1 |  |  | 1 |  |  | \u2014 | \nInvestment securities available-for-sale, net of income tax effect |  | (2) |  |  | (1) |  |  | (5) |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of tax |  | (385) |  |  | (138) |  |  | (808) |  |  | (111) | \nComprehensive Income |  | $ | 2,114 |  |  | $ | 2,276 |  |  | $ | 6,597 |  |  | $ | 6,197 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Balance Sheet (Unaudited) |  |  |  | \n |  | September 30, 2022 |  | December 31, 2021\n |  | (in\u00a0millions,\u00a0except\u00a0per share\u00a0data)\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 7,633 |  |  | $ | 7,421 | \nRestricted cash for litigation settlement |  | 586 |  |  | 586 | \nInvestments |  | 412 |  |  | 473 | \nAccounts receivable |  | 3,167 |  |  | 3,006 | \nSettlement assets |  | 1,019 |  |  | 1,319 | \nRestricted security deposits held for customers |  | 1,531 |  |  | 1,873 | \nPrepaid expenses and other current assets |  | 2,475 |  |  | 2,271 | \nTotal current assets |  | 16,823 |  |  | 16,949 | \nProperty, equipment and right-of-use assets, net of accumulated depreciation and amortizationof $1,788and $1,614, respectively |  | 1,951 |  |  | 1,907 | \nDeferred income taxes |  | 1,069 |  |  | 486 | \nGoodwill |  | 7,176 |  |  | 7,662 | \nOther intangible assets, net of accumulated amortization of $1,834and $1,755, respectively |  | 3,582 |  |  | 3,671 | \nOther assets |  | 7,011 |  |  | 6,994 | \nTotal Assets |  | $ | 37,612 |  |  | $ | 37,669 | \nLiabilities, Redeemable Non-controlling Interests and Equity |  |  |  | \nCurrent liabilities: |  |  |  | \nAccounts payable |  | $ | 615 |  |  | $ | 738 | \nSettlement obligations |  | 1,054 |  |  | 913 | \nRestricted security deposits held for customers |  | 1,531 |  |  | 1,873 | \nAccrued litigation |  | 1,086 |  |  | 840 | \nAccrued expenses |  | 6,888 |  |  | 6,642 | \nShort-term debt |  | 957 |  |  | 792 | \nOther current liabilities |  | 1,345 |  |  | 1,364 | \nTotal current liabilities |  | 13,476 |  |  | 13,162 | \nLong-term debt |  | 13,577 |  |  | 13,109 | \nDeferred income taxes |  | 346 |  |  | 395 | \nOther liabilities |  | 3,770 |  |  | 3,591 | \nTotal Liabilities |  | 31,169 |  |  | 30,257 | \nCommitments and Contingencies |  |  |  | \nRedeemable Non-controlling Interests |  | 20 |  |  | 29 | \nStockholders\u2019 Equity |  |  |  | \nClass\u00a0A common stock, $0.0001par value; authorized3,000shares,1,399and1,397shares issued and955and972shares outstanding, respectively |  | \u2014 |  |  | \u2014 | \nClass B common stock, $0.0001par value; authorized1,200shares,8shares issued and outstanding |  | \u2014 |  |  | \u2014 | \nAdditional paid-in-capital |  | 5,269 |  |  | 5,061 | \nClass\u00a0A treasury stock, at cost,444and425shares, respectively |  | (48,916) |  |  | (42,588) | \nRetained earnings |  | 51,625 |  |  | 45,648 | \nAccumulated other comprehensive income (loss) |  | (1,617) |  |  | (809) | \nMastercard Incorporated Stockholders' Equity |  | 6,361 |  |  | 7,312 | \nNon-controlling interests |  | 62 |  |  | 71 | \nTotal Equity |  | 6,423 |  |  | 7,383 | \nTotal Liabilities, Redeemable Non-controlling Interests and Equity |  | $ | 37,612 |  |  | $ | 37,669 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Changes in Equity (Unaudited)\n |  | Three Months Ended September 30, 2022\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders\u2019 Equity |  | Non-ControllingInterests |  | Total Equity\n |  | Class A |  | Class B |  |  |  | \n |  | (in millions)\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,163 |  |  | $ | (47,359) |  |  | $ | 49,599 |  |  | $ | (1,232) |  |  | $ | 6,171 |  |  | $ | 65 |  |  | $ | 6,236 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,499 |  |  | \u2014 |  |  | 2,499 |  |  | \u2014 |  |  | 2,499 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3) |  |  | (3) | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (385) |  |  | (385) |  |  | \u2014 |  |  | (385) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (472) |  |  | \u2014 |  |  | (472) |  |  | \u2014 |  |  | (472) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,557) |  |  | \u2014 |  |  | \u2014 |  |  | (1,557) |  |  | \u2014 |  |  | (1,557) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 106 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 106 |  |  | \u2014 |  |  | 106 | \nBalance at September 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,269 |  |  | $ | (48,916) |  |  | $ | 51,625 |  |  | $ | (1,617) |  |  | $ | 6,361 |  |  | $ | 62 |  |  | $ | 6,423 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Nine Months Ended September 30, 2022\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,061 |  |  | $ | (42,588) |  |  | $ | 45,648 |  |  | $ | (809) |  |  | $ | 7,312 |  |  | $ | 71 |  |  | $ | 7,383 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 7,405 |  |  | \u2014 |  |  | 7,405 |  |  | \u2014 |  |  | 7,405 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (9) |  |  | (9) | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (5) |  |  | \u2014 |  |  | (5) |  |  | \u2014 |  |  | (5) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (808) |  |  | (808) |  |  | \u2014 |  |  | (808) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,423) |  |  | \u2014 |  |  | (1,423) |  |  | \u2014 |  |  | (1,423) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (6,333) |  |  | \u2014 |  |  | \u2014 |  |  | (6,333) |  |  | \u2014 |  |  | (6,333) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 208 |  |  | 5 |  |  | \u2014 |  |  | \u2014 |  |  | 213 |  |  | \u2014 |  |  | 213 | \nBalance at September 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,269 |  |  | $ | (48,916) |  |  | $ | 51,625 |  |  | $ | (1,617) |  |  | $ | 6,361 |  |  | $ | 62 |  |  | $ | 6,423 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Changes in Equity (Unaudited) - (Continued)\n |  | Three Months Ended September 30, 2021\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders\u2019 Equity |  | Non-ControllingInterests |  | Total Equity\n |  | Class A |  | Class B |  |  |  | \n |  | (in millions)\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at June 30, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,053 |  |  | $ | (39,729) |  |  | $ | 41,771 |  |  | $ | (653) |  |  | $ | 6,442 |  |  | $ | 98 |  |  | $ | 6,540 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,414 |  |  | \u2014 |  |  | 2,414 |  |  | \u2014 |  |  | 2,414 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (11) |  |  | (11) | \nAcquisition of non-controlling interest |  | \u2014 |  |  | \u2014 |  |  | (122) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (122) |  |  | (17) |  |  | (139) | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (138) |  |  | (138) |  |  | \u2014 |  |  | (138) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (433) |  |  | \u2014 |  |  | (433) |  |  |  |  | (433) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,553) |  |  | \u2014 |  |  | \u2014 |  |  | (1,553) |  |  | \u2014 |  |  | (1,553) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 95 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 95 |  |  | \u2014 |  |  | 95 | \nBalance at September 30, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,026 |  |  | $ | (41,282) |  |  | $ | 43,750 |  |  | $ | (791) |  |  | $ | 6,703 |  |  | $ | 70 |  |  | $ | 6,773 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2021\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2020 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 4,982 |  |  | $ | (36,658) |  |  | $ | 38,747 |  |  | $ | (680) |  |  | $ | 6,391 |  |  | $ | 97 |  |  | $ | 6,488 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 6,308 |  |  | \u2014 |  |  | 6,308 |  |  | \u2014 |  |  | 6,308 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (10) |  |  | (10) | \nAcquisition of non-controlling interest |  | \u2014 |  |  | \u2014 |  |  | (122) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (122) |  |  | (17) |  |  | (139) | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (4) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (111) |  |  | (111) |  |  | \u2014 |  |  | (111) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,301) |  |  | \u2014 |  |  | (1,301) |  |  | \u2014 |  |  | (1,301) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,628) |  |  | \u2014 |  |  | \u2014 |  |  | (4,628) |  |  | \u2014 |  |  | (4,628) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 166 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 170 |  |  | \u2014 |  |  | 170 | \nBalance at September 30, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,026 |  |  | $ | (41,282) |  |  | $ | 43,750 |  |  | $ | (791) |  |  | $ | 6,703 |  |  | $ | 70 |  |  | $ | 6,773 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Cash Flows (Unaudited) |  |  |  | \n |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021\n |  | (in millions)\nOperating Activities |  |  |  | \nNet income |  | $ | 7,405 |  |  | $ | 6,308 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  |  | \nAmortization of customer and merchant incentives |  | 1,197 |  |  | 995 | \nDepreciation and amortization |  | 566 |  |  | 537 | \n(Gains) losses on equity investments, net |  | 133 |  |  | (534) | \nShare-based compensation |  | 273 |  |  | 241 | \nDeferred income taxes |  | (589) |  |  | (49) | \nOther |  | 40 |  |  | 34 | \nChanges in operating assets and liabilities: |  |  |  | \nAccounts receivable |  | (326) |  |  | (234) | \n |  |  |  | \nSettlement assets |  | 298 |  |  | 845 | \nPrepaid expenses |  | (1,472) |  |  | (1,742) | \nAccrued litigation and legal settlements |  | 249 |  |  | (4) | \nRestricted security deposits held for customers |  | (342) |  |  | 136 | \nAccounts payable |  | (91) |  |  | (74) | \nSettlement obligations |  | 146 |  |  | (978) | \n |  |  |  | \nAccrued expenses |  | 638 |  |  | 692 | \nNet change in other assets and liabilities |  | (30) |  |  | 101 | \nNet cash provided by operating activities |  | 8,095 |  |  | 6,274 | \nInvesting Activities |  |  |  | \nPurchases of investment securities available-for-sale |  | (192) |  |  | (344) | \nPurchases of investments held-to-maturity |  | (174) |  |  | (214) | \nProceeds from sales of investment securities available-for-sale |  | 28 |  |  | 66 | \nProceeds from maturities of investment securities available-for-sale |  | 156 |  |  | 249 | \nProceeds from maturities of investments held-to-maturity |  | 194 |  |  | 198 | \nPurchases of property and equipment |  | (312) |  |  | (285) | \nCapitalized software |  | (446) |  |  | (301) | \nPurchases of equity investments |  | (62) |  |  | (179) | \nProceeds from sales of equity investments |  | 7 |  |  | 185 | \nAcquisition of businesses, net of cash acquired |  | (313) |  |  | (4,197) | \n |  |  |  | \nOther investing activities |  | (6) |  |  | (12) | \nNet cash used in investing activities |  | (1,120) |  |  | (4,834) | \nFinancing Activities |  |  |  | \nPurchases of treasury stock |  | (6,339) |  |  | (4,628) | \nDividends paid |  | (1,430) |  |  | (1,307) | \nProceeds from debt, net |  | 1,127 |  |  | 1,282 | \n |  |  |  | \n |  |  |  | \nAcquisition of non-controlling interest |  | \u2014 |  |  | (133) | \nContingent consideration paid |  | \u2014 |  |  | (64) | \nTax withholdings related to share-based payments |  | (137) |  |  | (130) | \nCash proceeds from exercise of stock options |  | 77 |  |  | 55 | \nOther financing activities |  | (12) |  |  | (13) | \nNet cash used in financing activities |  | (6,714) |  |  | (4,938) | \nEffect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents |  | (387) |  |  | (80) | \nNet decrease in cash, cash equivalents, restricted cash and restricted cash equivalents |  | (126) |  |  | (3,578) | \nCash, cash equivalents, restricted cash and restricted cash equivalents - beginning of period |  | 9,902 |  |  | 12,419 | \nCash, cash equivalents, restricted cash and restricted cash equivalents - end of period |  | $ | 9,776 |  |  | $ | 8,841 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  | \n |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in millions)\nRevenue by source: |  |  |  |  |  |  |  | \nDomestic assessments |  | $ | 2,252 |  |  | $ | 2,139 |  |  | $ | 6,669 |  |  | $ | 5,993 | \nCross-border volume fees |  | 1,803 |  |  | 1,276 |  |  | 4,813 |  |  | 3,284 | \nTransaction processing |  | 3,288 |  |  | 2,849 |  |  | 9,261 |  |  | 7,812 | \nOther revenues |  | 1,824 |  |  | 1,562 |  |  | 5,153 |  |  | 4,384 | \nGross revenue |  | 9,167 |  |  | 7,826 |  |  | 25,896 |  |  | 21,473 | \nRebates and incentives (contra-revenue) |  | (3,411) |  |  | (2,841) |  |  | (9,476) |  |  | (7,805) | \nNet revenue |  | $ | 5,756 |  |  | $ | 4,985 |  |  | $ | 16,420 |  |  | $ | 13,668 | \nNet revenue by geographic region: |  |  |  |  |  |  |  | \nNorth American Markets |  | $ | 1,995 |  |  | $ | 1,707 |  |  | $ | 5,677 |  |  | $ | 4,803 | \nInternational Markets |  | 3,669 |  |  | 3,218 |  |  | 10,490 |  |  | 8,715 | \nOther1 |  | 92 |  |  | 60 |  |  | 253 |  |  | 150 | \nNet revenue |  | $ | 5,756 |  |  | $ | 4,985 |  |  | $ | 16,420 |  |  | $ | 13,668 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2022 |  | December 31,2021\n |  | (in millions)\nReceivables from contracts with customers |  |  |  | \nAccounts receivable |  | $ | 2,964 |  |  | $ | 2,829 | \nContract assets |  |  |  | \nPrepaid expenses and other current assets |  | 78 |  |  | 134 | \nOther assets |  | 419 |  |  | 487 | \nDeferred revenue1 |  |  |  | \nOther current liabilities |  | 461 |  |  | 482 | \nOther liabilities |  | 224 |  |  | 180 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNumerator |  |  |  |  |  |  |  | \nNet income |  | $ | 2,499 |  |  | $ | 2,414 |  |  | $ | 7,405 |  |  | $ | 6,308 | \nDenominator |  |  |  |  |  |  |  | \nBasic weighted-average shares outstanding |  | 965 |  |  | 986 |  |  | 971 |  |  | 990 | \nDilutive stock options and stock units |  | 3 |  |  | 4 |  |  | 3 |  |  | 4 | \nDiluted weighted-average shares outstanding1 |  | 968 |  |  | 990 |  |  | 974 |  |  | 994 | \nEarnings per Share |  |  |  |  |  |  |  | \nBasic |  | $ | 2.59 |  |  | $ | 2.45 |  |  | $ | 7.63 |  |  | $ | 6.37 | \nDiluted |  | $ | 2.58 |  |  | $ | 2.44 |  |  | $ | 7.60 |  |  | $ | 6.35 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2022 |  | December 31,2021\n |  | (in millions)\nCash and cash equivalents |  | $ | 7,633 |  |  | $ | 7,421 | \nRestricted cash and restricted cash equivalents |  |  |  | \nRestricted cash for litigation settlement |  | 586 |  |  | 586 | \nRestricted security deposits held for customers |  | 1,531 |  |  | 1,873 | \nPrepaid expenses and other current assets |  | 26 |  |  | 22 | \n |  |  |  | \nCash, cash equivalents, restricted cash and restricted cash equivalents |  | $ | 9,776 |  |  | $ | 9,902 | \n |  |  |  | \n |  | \n |  |  |  | \n |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2022 |  | December 31,2021\n |  | (in millions)\nAvailable-for-sale securities1 |  | $ | 282 |  |  | $ | 314 | \nHeld-to-maturity securities2 |  | 130 |  |  | 159 | \nTotal investments |  | $ | 412 |  |  | $ | 473 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2022 |  | December 31, 2021\n |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue\n |  | (in millions)\nMunicipal securities |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | 2 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 2 | \nGovernment and agency securities |  | 115 |  |  | \u2014 |  |  | (2) |  |  | 113 |  |  | 98 |  |  | \u2014 |  |  | \u2014 |  |  | 98 | \nCorporate securities |  | 172 |  |  | \u2014 |  |  | (4) |  |  | 168 |  |  | 214 |  |  | \u2014 |  |  | \u2014 |  |  | 214 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal |  | $ | 288 |  |  | $ | \u2014 |  |  | $ | (6) |  |  | $ | 282 |  |  | $ | 314 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 314 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | \n |  | Amortized Cost |  | Fair\u00a0Value\n |  | (in millions)\nDue within 1 year |  | $ | 181 |  |  | $ | 179 | \nDue after 1 year through 5 years |  | 107 |  |  | 103 | \n |  |  |  | \nTotal |  | $ | 288 |  |  | $ | 282 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Balance at December 31, 2021 |  | Purchases |  | Sales |  | Changes in Fair Value1 |  | Other2 |  | Balance at September 30, 2022\n |  | (in millions)\nMarketable securities |  | $ | 627 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | (209) |  |  | $ | (37) |  |  | $ | 381 | \nNonmarketable securities |  | 1,207 |  |  | 62 |  |  | (7) |  |  | 76 |  |  | (41) |  |  | 1,297 | \nTotal equity investments |  | $ | 1,834 |  |  | $ | 62 |  |  | $ | (7) |  |  | $ | (133) |  |  | $ | (78) |  |  | $ | 1,678 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2022 |  | December 31,2021\n |  | (in millions)\nMeasurement alternative |  | $ | 1,048 |  |  | $ | 952 | \nEquity method |  | 249 |  |  | 255 | \nTotal Nonmarketable securities |  | $ | 1,297 |  |  | $ | 1,207 |   |  |  |  |  |  |  |  | \n |  | \n |  | (in millions)\nInitial cost basis |  | $ | 481 | \nCumulative adjustments1: |  | \nUpward adjustments |  | 612 | \nDownward adjustments (including impairment) |  | (45) | \nCarrying amount, end of period |  | $ | 1,048 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in millions)\nMeasurement alternative investments: |  |  |  |  |  |  |  | \nUpward adjustments |  | $ | 4 |  |  | $ | 162 |  |  | $ | 107 |  |  | $ | 321 | \nDownward adjustments (including impairment) |  | \u2014 |  |  | (1) |  |  | (12) |  |  | (2) | \nMarketable securities: |  |  |  |  |  |  |  | \nUnrealized gains (losses), net |  | 79 |  |  | (58) |  |  | (209) |  |  | 59 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2022 |  | December 31, 2021\n |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total\n |  | (in millions)\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestment securities available-for-sale1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMunicipal securities |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | \u2014 |  |  | $ | 2 |  |  | $ | \u2014 |  |  | $ | 2 | \nGovernment and agency securities |  | 39 |  |  | 74 |  |  | \u2014 |  |  | 113 |  |  | 35 |  |  | 63 |  |  | \u2014 |  |  | 98 | \nCorporate securities |  | \u2014 |  |  | 168 |  |  | \u2014 |  |  | 168 |  |  | \u2014 |  |  | 214 |  |  | \u2014 |  |  | 214 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | \u2014 |  |  | 323 |  |  | \u2014 |  |  | 323 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 8 | \nInterest rate contracts |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 6 |  |  | \u2014 |  |  | 6 | \nMarketable securities3: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nEquity securities |  | 381 |  |  | \u2014 |  |  | \u2014 |  |  | 381 |  |  | 627 |  |  | \u2014 |  |  | \u2014 |  |  | 627 | \nDeferred compensation plan4: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation assets |  | 73 |  |  | \u2014 |  |  | \u2014 |  |  | 73 |  |  | 89 |  |  | \u2014 |  |  | \u2014 |  |  | 89 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | \u2014 |  |  | $ | 5 |  |  | $ | \u2014 |  |  | $ | 5 |  |  | $ | \u2014 |  |  | $ | 15 |  |  | $ | \u2014 |  |  | $ | 15 | \nInterest rate contracts |  | \u2014 |  |  | 111 |  |  | \u2014 |  |  | 111 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 8 | \nDeferred compensation plan5: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation liabilities |  | 71 |  |  | \u2014 |  |  | \u2014 |  |  | 71 |  |  | 89 |  |  | \u2014 |  |  | \u2014 |  |  | 89 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2022 |  | December 31,2021\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 1,342 |  |  | $ | 1,326 | \nPrepaid income taxes |  | 66 |  |  | 92 | \nOther |  | 1,067 |  |  | 853 | \nTotal prepaid expenses and other current assets |  | $ | 2,475 |  |  | $ | 2,271 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2022 |  | December 31,2021\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 4,045 |  |  | $ | 3,798 | \nEquity investments |  | 1,678 |  |  | 1,834 | \nIncome taxes receivable |  | 597 |  |  | 645 | \nOther |  | 691 |  |  | 717 | \nTotal other assets |  | $ | 7,011 |  |  | $ | 6,994 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2022 |  | December 31,2021\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 4,966 |  |  | $ | 4,730 | \nPersonnel costs |  | 1,005 |  |  | 980 | \nIncome and other taxes |  | 383 |  |  | 337 | \nOther |  | 534 |  |  | 595 | \nTotal accrued expenses |  | $ | 6,888 |  |  | $ | 6,642 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | September 30,2022 |  | December 31,2021 |  | EffectiveInterest Rate\n |  |  |  |  | (in millions) |  | \nSenior Notes |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n2022 EUR Notes1 |  | 1.000 | % | Senior Notes due February 2029 |  | $ | 728 |  |  | $ | \u2014 |  |  | 1.138 | %\n |  |  |  |  |  |  |  |  | \n2021 USD Notes |  | 2.000 | % | Senior Notes due November 2031 |  | 750 |  |  | 750 |  |  | 2.112 | %\n |  | 1.900 | % | Senior Notes due March 2031 |  | 600 |  |  | 600 |  |  | 1.981 | %\n |  | 2.950 | % | Senior Notes due March 2051 |  | 700 |  |  | 700 |  |  | 3.013 | %\n |  |  |  |  |  |  |  |  | \n2020 USD Notes |  | 3.300 | % | Senior Notes due March 2027 |  | 1,000 |  |  | 1,000 |  |  | 3.420 | %\n |  | 3.350 | % | Senior Notes due March 2030 |  | 1,500 |  |  | 1,500 |  |  | 3.430 | %\n |  | 3.850 | % | Senior Notes due March 2050 |  | 1,500 |  |  | 1,500 |  |  | 3.896 | %\n |  |  |  |  |  |  |  |  | \n2019 USD Notes |  | 2.950 | % | Senior Notes due June 2029 |  | 1,000 |  |  | 1,000 |  |  | 3.030 | %\n |  | 3.650 | % | Senior Notes due June 2049 |  | 1,000 |  |  | 1,000 |  |  | 3.689 | %\n |  | 2.000 | % | Senior Notes due March 2025 |  | 750 |  |  | 750 |  |  | 2.147 | %\n |  |  |  |  |  |  |  |  | \n2018 USD Notes |  | 3.500 | % | Senior Notes due February 2028 |  | 500 |  |  | 500 |  |  | 3.598 | %\n |  | 3.950 | % | Senior Notes due February 2048 |  | 500 |  |  | 500 |  |  | 3.990 | %\n |  |  |  |  |  |  |  |  | \n2016 USD Notes |  | 2.950 | % | Senior Notes due November 2026 |  | 750 |  |  | 750 |  |  | 3.044 | %\n |  | 3.800 | % | Senior Notes due November 2046 |  | 600 |  |  | 600 |  |  | 3.893 | %\n |  |  |  |  |  |  |  |  | \n2015 EUR Notes2 |  | 1.100 | % | Senior Notes due December 2022 |  | 680 |  |  | 793 |  |  | 1.265 | %\n |  | 2.100 | % | Senior Notes due December 2027 |  | 777 |  |  | 906 |  |  | 2.189 | %\n |  | 2.500 | % | Senior Notes due December 2030 |  | 146 |  |  | 170 |  |  | 2.562 | %\n |  |  |  |  |  |  |  |  | \n2014 USD Notes |  | 3.375 | % | Senior Notes due April 2024 |  | 1,000 |  |  | 1,000 |  |  | 3.484 | %\n |  |  |  |  |  |  |  |  | \nOther Debt |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \nINR Term Loan3 |  | 8.640 | % | Term Loan due July 2023 |  | 278 |  |  | \u2014 |  |  | 9.090 | %\n |  |  |  |  |  |  |  |  | \n |  |  |  |  | 14,759 |  |  | 14,019 |  |  | \nLess: Unamortized discount and debt issuance costs | (114) |  |  | (116) |  |  | \nLess: Cumulative hedge accounting fair value adjustments4 |  | (111) |  |  | (2) |  |  | \nTotal debt outstanding | 14,534 |  |  | 13,901 |  |  | \nLess: Short-term debt5 |  | (957) |  |  | (792) |  |  | \nLong-term debt | $ | 13,577 |  |  | $ | 13,109 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nDividends declared per share |  | $ | 0.49 |  |  | $ | 0.44 |  |  | $ | 1.47 |  |  | $ | 1.32 | \nTotal dividends declared |  | $ | 472 |  |  | $ | 433 |  |  | $ | 1,423 |  |  | $ | 1,301 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30,\n |  | 2022 |  | 2021\n |  | Outstanding Shares |  | Outstanding Shares\n |  | Class\u00a0A |  | Class\u00a0B |  | Class\u00a0A |  | Class\u00a0B\n |  | (in millions)\nBalance at beginning of period |  | 960.0 |  |  | 7.7 |  |  | 979.8 |  |  | 8.0 | \nPurchases of treasury stock |  | (4.7) |  |  | \u2014 |  |  | (4.3) |  |  | \u2014 | \nShare-based payments |  | 0.1 |  |  | \u2014 |  |  | 0.1 |  |  | \u2014 | \nConversion of Class B to Class A common stock |  | \u2014 |  |  | \u2014 |  |  | 0.1 |  |  | (0.1) | \nBalance at end of period |  | 955.4 |  |  | 7.7 |  |  | 975.7 |  |  | 7.9 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021\n |  | Outstanding Shares |  | Outstanding Shares\n |  | Class\u00a0A |  | Class\u00a0B |  | Class\u00a0A |  | Class\u00a0B\n |  | (in millions)\nBalance at beginning of period |  | 972.1 |  |  | 7.8 |  |  | 986.9 |  |  | 8.3 | \nPurchases of treasury stock |  | (18.3) |  |  | \u2014 |  |  | (12.8) |  |  | \u2014 | \nShare-based payments |  | 1.5 |  |  | \u2014 |  |  | 1.2 |  |  | \u2014 | \nConversion of Class B to Class A common stock |  | 0.1 |  |  | (0.1) |  |  | 0.4 |  |  | (0.4) | \nBalance at end of period |  | 955.4 |  |  | 7.7 |  |  | 975.7 |  |  | 7.9 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021\n |  | (In millions, except per share data)\nDollar-value of shares repurchased |  | $ | 6,339 |  |  | $ | 4,628 | \nShares repurchased |  | 18.3 |  |  | 12.8 | \nAverage price paid per share |  | $ | 345.54 |  |  | $ | 360.87 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2021 |  | Increase / (Decrease) |  | Reclassifications |  | September 30, 2022\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (739) |  |  | $ | (1,412) |  |  | $ | \u2014 |  |  | $ | (2,151) | \nTranslation adjustments on net investment hedges2 |  | 34 |  |  | 601 |  |  | \u2014 |  |  | 635 | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | 4 |  |  | 16 |  |  | (11) |  |  | 9 | \nInterest rate contracts |  | (128) |  |  | \u2014 |  |  | 4 |  |  | (124) | \nDefined benefit pension and other postretirement plans |  | 21 |  |  | \u2014 |  |  | (1) |  |  | 20 | \nInvestment securities available-for-sale |  | (1) |  |  | (5) |  |  | \u2014 |  |  | (6) | \nAccumulated other comprehensive income (loss) |  | $ | (809) |  |  | $ | (800) |  |  | $ | (8) |  |  | $ | (1,617) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2020 |  | Increase / (Decrease) |  | Reclassifications |  | September 30, 2021\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (352) |  |  | $ | (241) |  |  | $ | \u2014 |  |  | $ | (593) | \nTranslation adjustments on net investment hedges2 |  | (175) |  |  | 126 |  |  | \u2014 |  |  | (49) | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | \u2014 |  |  | 1 |  |  | 1 |  |  | 2 | \nInterest rate contracts |  | (133) |  |  | \u2014 |  |  | 3 |  |  | (130) | \nDefined benefit pension and other postretirement plans |  | (20) |  |  | \u2014 |  |  | (1) |  |  | (21) | \nInvestment securities available-for-sale |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nAccumulated other comprehensive income (loss) |  | $ | (680) |  |  | $ | (114) |  |  | $ | 3 |  |  | $ | (791) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Grants in 2022 |  | Weighted-AverageGrant-DateFair Value\n |  | (in millions) |  | (per option/unit)\nNon-qualified stock options |  | 0.3 |  | $ | 87 | \nRestricted stock units |  | 1.0 |  | $ | 341 | \nPerformance stock units |  | 0.2 |  | $ | 335 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2022 |  | December 31,2021\n |  | (in millions)\nGross settlement exposure |  | $ | 62,045 |  |  | $ | 59,571 | \nRisk mitigation arrangements applied to settlement exposure |  | (8,724) |  |  | (7,710) | \nNet settlement exposure |  | $ | 53,321 |  |  | $ | 51,861 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2022 |  | December 31, 2021\n |  | Notional |  | Derivative assets |  | Derivative liabilities |  | Notional |  | Derivative assets |  | Derivative liabilities\n |  | (in millions)\nDerivatives designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts in a cash flow hedge1 |  | $ | 502 |  |  | $ | 16 |  |  | $ | 4 |  |  | $ | 206 |  |  | $ | 7 |  |  | $ | 3 | \nInterest rate contracts in a fair value hedge2 |  | 1,000 |  |  | \u2014 |  |  | 111 |  |  | 1,000 |  |  | 6 |  |  | 8 | \nForeign exchange contracts in a net investment hedge1 |  | 1,991 |  |  | 302 |  |  | \u2014 |  |  | 1,473 |  |  | \u2014 |  |  | 4 | \nDerivatives not designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts1 |  | 442 |  |  | 5 |  |  | 1 |  |  | 530 |  |  | 1 |  |  | 8 | \nTotal derivative assets/liabilities |  | $ | 3,935 |  |  | $ | 323 |  |  | $ | 116 |  |  | $ | 3,209 |  |  | $ | 14 |  |  | $ | 23 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Gain (Loss)Recognized in OCI |  |  |  | Gain (Loss)Reclassified from AOCI\n |  | Three Months Ended September 30, |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Three Months Ended September 30,\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021\n |  | (in millions) |  |  | (in millions)\nDerivative financial instruments in a cash flow hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 14 |  |  | $ | 2 |  |  | Net revenue |  | $ | 6 |  |  | $ | \u2014 | \nInterest rate contracts |  | $ | \u2014 |  |  | $ | \u2014 |  |  | Interest expense |  | $ | (2) |  |  | $ | (1) | \n |  |  |  |  |  |  |  |  |  | \nDerivative financial instruments in a net investment hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 183 |  |  | $ | 48 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Gain (Loss)Recognized in OCI |  |  |  | Gain (Loss)Reclassified from AOCI\n |  | Nine Months Ended September 30, |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021\n |  | (in millions) |  |  | (in millions)\nDerivative financial instruments in a cash flow hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 21 |  |  | $ | 1 |  |  | Net revenue |  | $ | 14 |  |  | $ | (1) | \nInterest rate contracts |  | $ | \u2014 |  |  | $ | \u2014 |  |  | Interest expense |  | $ | (5) |  |  | $ | (4) | \n |  |  |  |  |  |  |  |  |  | \nDerivative financial instruments in a net investment hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 384 |  |  | $ | 60 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\nDerivatives not designated as hedging instruments: |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | (in millions)\nForeign exchange derivative contracts |  |  |  |  |  |  |  | \nGeneral and administrative |  | $ | 13 |  |  | $ | (2) |  |  | $ | 25 |  |  | $ | (5) | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/(Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \n |  | ($ in millions, except per share data)\nNet revenue |  | $ | 5,756 |  |  | $ | 4,985 |  |  | 15% |  | $ | 16,420 |  |  | $ | 13,668 |  |  | 20%\nOperating expenses |  | $ | 2,644 |  |  | $ | 2,268 |  |  | 17% |  | $ | 7,340 |  |  | $ | 6,413 |  |  | 14%\nOperating income |  | $ | 3,112 |  |  | $ | 2,717 |  |  | 14% |  | $ | 9,080 |  |  | $ | 7,255 |  |  | 25%\nOperating margin |  | 54.1 | % |  | 54.5 | % |  | (0.5) ppt |  | 55.3 | % |  | 53.1 | % |  | 2.2 ppt\nIncome tax expense |  | $ | 573 |  |  | $ | 402 |  |  | 42% |  | $ | 1,238 |  |  | $ | 1,176 |  |  | 5%\nEffective income tax rate |  | 18.6 | % |  | 14.3 | % |  | 4.4 ppt |  | 14.3 | % |  | 15.7 | % |  | (1.4) ppt\nNet income |  | $ | 2,499 |  |  | $ | 2,414 |  |  | 4% |  | $ | 7,405 |  |  | $ | 6,308 |  |  | 17%\nDiluted earnings per share |  | $ | 2.58 |  |  | $ | 2.44 |  |  | 6% |  | $ | 7.60 |  |  | $ | 6.35 |  |  | 20%\nDiluted weighted-average shares outstanding |  | 968 |  |  | 990 |  |  | (2)% |  | 974 |  |  | 994 |  |  | (2)%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Increase/(Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n | 2022 |  | 2021 |  | As adjusted |  | Currency-neutral |  | 2022 |  | 2021 |  | As adjusted |  | Currency-neutral\n | ($ in millions, except per share data)\nAdjusted net revenue | $ | 5,756 |  |  | $ | 4,985 |  |  | 15% |  | 23% |  | $ | 16,383 |  |  | $ | 13,668 |  |  | 20% |  | 25%\nAdjusted operating expenses | $ | 2,437 |  |  | $ | 2,158 |  |  | 13% |  | 17% |  | $ | 6,932 |  |  | $ | 6,237 |  |  | 11% |  | 14%\nAdjusted operating margin | 57.7 | % |  | 56.7 | % |  | 1.0 ppt |  | 2.0 ppt |  | 57.7 | % |  | 54.4 | % |  | 3.3 ppt |  | 4.2 ppt\nAdjusted effective income tax rate | 19.4 | % |  | 14.4 | % |  | 5.0 ppt |  | 5.4 ppt |  | 14.8 | % |  | 15.6 | % |  | (0.8) ppt |  | (0.6) ppt\nAdjusted net income | $ | 2,595 |  |  | $ | 2,341 |  |  | 11% |  | 20% |  | $ | 7,794 |  |  | $ | 6,018 |  |  | 29% |  | 38%\nAdjusted diluted earnings per share | $ | 2.68 |  |  | $ | 2.37 |  |  | 13% |  | 22% |  | $ | 8.00 |  |  | $ | 6.06 |  |  | 32% |  | 40%  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | Adjusted net revenue | Adjusted net revenue increased 23% on a currency-neutral basis, which includes 1 percentage point of growth from acquisitions.  Primary drivers of the increase were as follows:\nThree Months Ended September 30, 2022\nGAAP |  | Non-GAAP(currency-neutral)\nup 15% |  | up 23%\n |  |  | - Gross dollar volume growth of 11% on a local currency basis\n |  |  | - Cross-border volume growth of 44% on a local currency basis\n |  |  | \n |  |  | - Switched transactions growth of 9%\n |  |  | \n |  |  | - Other revenues increase of 17% or 22% on a currency-neutral basis, which\n |  |  | includes 2 percentage points of growth due to acquisitions. The remaining growth\n |  |  | was driven primarily by our Cyber & Intelligence and Data & Services solutions.\n |  |  | \n |  |  | These increases were partially offset by:\n |  |  | - Rebates and incentives (contra-revenue) increase of 20%, or 26% on a currency-\n |  |  | neutral basis, primarily due to increased volumes and transactions and new\n |  |  | and renewed deals.\n |  |  | \nNine Months Ended September 30, 2022 | Adjusted net revenue increased 25% on a currency-neutral basis, which includes 1 percentage point of growth from acquisitions.  Primary drivers of the increase were as follows:\nGAAP |  | Non-GAAP(currency-neutral)\nup 20% |  | up 25%\n |  |  | \n |  |  | - Gross dollar volume growth of 14% on a local currency basis\n |  |  | - Cross-border volume growth of 51% on a local currency basis\n |  |  | \n |  |  | - Switched transactions growth of 14%\n |  |  | \n |  |  | - Other revenues increase of 18%, or 22% on a currency-neutral basis, which\n |  |  | includes 4 percentage points of growth due to acquisitions.  The remaining growth\n |  |  | was driven primarily by our Cyber & Intelligence and Data & Services solutions.\n |  |  | \n |  |  | These increases were partially offset by:\n |  |  | - Rebates and incentives (contra-revenue) increase of 21%, or 25% on a currency-\n |  |  | neutral basis, primarily due to increased volumes and transactions and new\n |  |  | and renewed deals.  |  |  |  |  |  |  |  |  |  |  | \nOperating expenses |  | Adjustedoperating expenses | \nThree Months Ended September 30, 2022 | Adjusted operating expenses increased 17% on a currency-neutral basis, which includes 3 percentage points of growth due to acquisitions.  The remaining increase was primarily due to higher personnel costs to support our continued investment in our strategic initiatives across payments, services and new network capabilities.\nGAAP |  | Non-GAAP(currency-neutral)\nup 17% |  | up 17%\n |  | \nNine Months Ended September 30, 2022 | Adjusted operating expenses increased 14% on a currency-neutral basis, which includes 5 percentage points of growth due to acquisitions.  The remaining increase was primarily due to higher personnel costs, unfavorable foreign exchange activity and increased spending on advertising and marketing.\nGAAP |  | Non-GAAP(currency-neutral)\nup 14% |  | up 14%\n |  |   |  |  |  |  |  |  |  |  |  |  | \nEffective incometax rate |  | Adjusted effectiveincome tax rate | \nThree Months Ended September 30, 2022 | The adjusted effective income tax rate of 19.4% was higher than prior year primarily due to the recognition of U.S. tax benefits in the third quarter of 2021, the majority of which were discrete, and a discrete tax expense related to an unfavorable court ruling in the current period. These discrete tax items were partially offset by a favorable change in our geographic mix of earnings in the current period.\nGAAP |  | Non-GAAP(currency-neutral)\n18.6% |  | 19.4%\n |  | \nNine Months Ended September 30, 2022 | The adjusted effective income tax rate of 14.8% was lower than prior year due to a discrete tax benefit in the first quarter of 2022 related to final U.S. tax regulations published in the current year and a favorable change in our geographic mix of earnings in 2022.  These tax benefits in 2022 were partially offset by the recognition of U.S. tax benefits in 2021, the majority of which were discrete, and a discrete tax expense related to an unfavorable court ruling in 2022.\nGAAP |  | Non-GAAP(currency-neutral)\n14.3% |  | 14.8%\n |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, 2022\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 5,756 |  |  | $ | 2,644 |  |  | 54.1 | % |  | $ | (40) |  |  | 18.6 | % |  | $ | 2,499 |  |  | $ | 2.58 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | (60) |  |  | 0.6 | % |  | (66) |  |  | (0.07) | \nLitigation provisions |  | ** |  | (208) |  |  | 3.6 | % |  | ** |  | 0.2 | % |  | 162 |  |  | 0.17 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | $ | 5,756 |  |  | $ | 2,437 |  |  | 57.7 | % |  | $ | (99) |  |  | 19.4 | % |  | $ | 2,595 |  |  | $ | 2.68 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2022\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 16,420 |  |  | $ | 7,340 |  |  | 55.3 | % |  | $ | (437) |  |  | 14.3 | % |  | $ | 7,405 |  |  | $ | 7.60 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 133 |  |  | \u2014 | % |  | 114 |  |  | 0.12 | \nLitigation provisions |  | ** |  | (341) |  |  | 2.1 | % |  | ** |  | 0.5 | % |  | 251 |  |  | 0.26 | \nRussia-related impacts |  | (37) |  |  | (67) |  |  | 0.3 | % |  | ** |  | \u2014 | % |  | 24 |  |  | 0.02 | \nAdjusted - Non-GAAP |  | $ | 16,383 |  |  | $ | 6,932 |  |  | 57.7 | % |  | $ | (303) |  |  | 14.8 | % |  | $ | 7,794 |  |  | $ | 8.00 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, 2021\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 4,985 |  |  | $ | 2,268 |  |  | 54.5 | % |  | $ | 99 |  |  | 14.3 | % |  | $ | 2,414 |  |  | $ | 2.44 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | (197) |  |  | (0.2) | % |  | (163) |  |  | (0.16) | \nLitigation provisions |  | ** |  | $ | (27) |  |  | 0.6 | % |  | ** |  | 0.1 | % |  | 22 |  |  | 0.02 | \nIndirect tax matter |  | ** |  | (82) |  |  | 1.6 | % |  | 6 |  |  | 0.2 | % |  | 69 |  |  | 0.07 | \nAdjusted - Non-GAAP |  | $ | 4,985 |  |  | $ | 2,158 |  |  | 56.7 | % |  | $ | (92) |  |  | 14.4 | % |  | $ | 2,341 |  |  | $ | 2.37 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2021\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 13,668 |  |  | $ | 6,413 |  |  | 53.1 | % |  | $ | 229 |  |  | 15.7 | % |  | $ | 6,308 |  |  | $ | 6.35 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | (534) |  |  | (0.3) | % |  | (432) |  |  | (0.43) | \nLitigation provisions |  | ** |  | (94) |  |  | 0.7 | % |  | ** |  | 0.1 | % |  | 74 |  |  | 0.07 | \nIndirect tax matter |  | ** |  | (82) |  |  | 0.6 | % |  | 6 |  |  | 0.1 | % |  | 69 |  |  | 0.07 | \nAdjusted - Non-GAAP |  | $ | 13,668 |  |  | $ | 6,237 |  |  | 54.4 | % |  | $ | (299) |  |  | 15.6 | % |  | $ | 6,018 |  |  | $ | 6.06 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, 2022 as compared to the Three Months Ended September 30, 2021\n |  | Increase/(Decrease)\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\nReported - GAAP |  | 15% |  | 17% |  | (0.5) ppt |  | 4.4 ppt |  | 4% |  | 6%\n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 0.8 ppt |  | 5% |  | 5%\nLitigation provisions |  | ** |  | (8)% |  | 3.0 ppt |  | 0.1 ppt |  | 6% |  | 6%\n |  |  |  |  |  |  |  |  |  |  |  | \nIndirect tax matter |  | ** |  | 4% |  | (1.6) ppt |  | (0.2) ppt |  | (3)% |  | (3)%\nAdjusted - Non-GAAP |  | 15% |  | 13% |  | 1.0 ppt |  | 5.0 ppt |  | 11% |  | 13%\nCurrency impact1 |  | 7% |  | 4% |  | 1.1 ppt |  | 0.4 ppt |  | 9% |  | 9%\nAdjusted - Non-GAAP - currency-neutral |  | 23% |  | 17% |  | 2.0 ppt |  | 5.4 ppt |  | 20% |  | 22%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2022 as compared to the Nine Months Ended September 30, 2021\n |  | Increase/(Decrease)\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\nReported - GAAP |  | 20% |  | 14% |  | 2.2 ppt |  | (1.4) ppt |  | 17% |  | 20%\n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 0.3 ppt |  | 11% |  | 11%\nLitigation provisions |  | ** |  | (4)% |  | 1.4 ppt |  | 0.4 ppt |  | 3% |  | 3%\nRussia-related impacts |  | \u2014% |  | (1)% |  | 0.3 ppt |  | \u2014 ppt |  | \u2014% |  | \u2014%\nIndirect tax matter |  | ** |  | 1% |  | (0.6) ppt |  | (0.1) ppt |  | (1)% |  | (2)%\nAdjusted - Non-GAAP |  | 20% |  | 11% |  | 3.3 ppt |  | (0.8) ppt |  | 29% |  | 32%\nCurrency impact1 |  | 6% |  | 3% |  | 0.9 ppt |  | 0.2 ppt |  | 8% |  | 8%\nAdjusted - Non-GAAP - currency-neutral |  | 25% |  | 14% |  | 4.2 ppt |  | (0.6) ppt |  | 38% |  | 40%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/ (Decrease) |  |  | Nine Months Ended September 30, |  | Increase/ (Decrease)\n |  | 2022 |  | 2021 |  |  |  | 2022 |  | 2021 | \n |  | ($ in millions)\nDomestic assessments |  | $ | 2,252 |  |  | $ | 2,139 |  |  | 5% |  |  | $ | 6,669 |  |  | $ | 5,993 |  |  | 11%\nCross-border volume fees |  | 1,803 |  |  | 1,276 |  |  | 41% |  |  | 4,813 |  |  | 3,284 |  |  | 47%\nTransaction processing |  | 3,288 |  |  | 2,849 |  |  | 15% |  |  | 9,261 |  |  | 7,812 |  |  | 19%\nOther revenues |  | 1,824 |  |  | 1,562 |  |  | 17% |  |  | 5,153 |  |  | 4,384 |  |  | 18%\nGross revenue |  | 9,167 |  |  | 7,826 |  |  | 17% |  |  | 25,896 |  |  | 21,473 |  |  | 21%\nRebates and incentives (contra-revenue) |  | (3,411) |  |  | (2,841) |  |  | 20% |  |  | (9,476) |  |  | (7,805) |  |  | 21%\nNet revenue |  | 5,756 |  |  | 4,985 |  |  | 15% |  |  | 16,420 |  |  | 13,668 |  |  | 20%\nSpecial Items1 |  | \u2014 |  |  | \u2014 |  |  | ** |  |  | (37) |  |  | \u2014 |  |  | \u2014%\nAdjusted net revenue (excluding Special Items1) |  | $ | 5,756 |  |  | $ | 4,985 |  |  | 15% |  |  | $ | 16,383 |  |  | $ | 13,668 |  |  | 20%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, 2022\n |  | Increase/(Decrease)\n |  | Operational |  | SpecialItems4 |  |  |  | Acquisitions |  | Currency Impact5 |  |  |  | Total\nDomestic assessments |  | 9 | % | 1 |  | ** |  |  |  |  | \u2014 | % |  | (3) | % |  |  |  |  | 5 | %\nCross-border volume fees |  | 57 | % | 1 |  | ** |  |  |  |  | \u2014 | % |  | (15) | % |  |  |  |  | 41 | %\nTransaction processing |  | 22 | % | 2 |  | ** |  |  |  |  | \u2014 | % |  | (7) | % |  |  |  |  | 15 | %\nOther revenues |  | 20 | % | 3 |  | ** |  |  |  |  | 2 | % |  | (5) | % |  |  |  |  | 17 | %\nRebates and incentives (contra-revenue) |  | 26 | % |  |  | ** |  |  |  |  | \u2014 | % |  | (6) | % |  |  |  |  | 20 | %\nNet revenue |  | 22 | % |  |  | ** |  |  |  |  | 1 | % |  | (7) | % |  |  |  |  | 15 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2022\n |  | Increase/(Decrease)\n |  | Operational |  |  |  | SpecialItems4 |  | Acquisitions |  | Currency Impact5 |  |  |  | Total\nDomestic assessments |  | 14 | % | 1 |  |  |  |  | \u2014 | % |  | \u2014 | % |  | (3) | % |  |  |  |  | 11 | %\nCross-border volume fees |  | 58 | % | 1 |  |  |  |  | ** |  | \u2014 | % |  | (12) | % |  |  |  |  | 47 | %\nTransaction processing |  | 23 | % | 2 |  |  |  |  | ** |  | \u2014 | % |  | (5) | % |  |  |  |  | 19 | %\nOther revenues |  | 18 | % | 3 |  |  |  |  | ** |  | 4 | % |  | (4) | % |  |  |  |  | 18 | %\nRebates and incentives (contra-revenue) |  | 26 | % |  |  |  |  |  | \u2014 | % |  | \u2014 | % |  | (5) | % |  |  |  |  | 21 | %\nNet revenue |  | 24 | % |  |  |  |  |  | \u2014 | % |  | 1 | % |  | (6) | % |  |  |  |  | 20 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | Increase/(Decrease) |  | Increase/(Decrease)\n |  | USD |  | Local |  | USD |  | Local |  | USD |  | Local |  | USD |  | Local\nMastercard-branded GDV1 |  | 4% |  | 11% |  | 21% |  | 20% |  | 8% |  | 14% |  | 22% |  | 20%\nUnited States |  | 10% |  | 10% |  | 20% |  | 20% |  | 11% |  | 11% |  | 22% |  | 22%\nWorldwide less United States |  | 1% |  | 12% |  | 21% |  | 20% |  | 6% |  | 15% |  | 22% |  | 18%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCross-border volume1 |  | 29% |  | 44% |  | 54% |  | 52% |  | 39% |  | 51% |  | 30% |  | 25%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMastercard-branded GDV1adjusted for Russia2 |  | 9% |  | 18% |  | 21% |  | 20% |  | 12% |  | 19% |  | 22% |  | 19%\nWorldwide less United States adjusted for Russia2 |  | 8% |  | 22% |  | 21% |  | 19% |  | 13% |  | 24% |  | 22% |  | 18%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCross-border volume1adjusted for Russia2 |  | 33% |  | 50% |  | 53% |  | 51% |  | 42% |  | 55% |  | 30% |  | 24%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2022 |  | 2021 |  | 2022 |  | 2021\n |  | Increase/(Decrease) |  | Increase/(Decrease)\nSwitched transactions |  | 9% |  | 25% |  | 14% |  | 24%\n |  |  |  |  |  |  |  | \nSwitched transactions adjusted for Russia2 |  | 19% |  | 24% |  | 22% |  | 23%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/ (Decrease) |  | Nine Months Ended September 30, |  | Increase/ (Decrease)\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \n |  | ($ in millions)\nGeneral and administrative |  | $ | 2,069 |  |  | $ | 1,831 |  |  | 13% |  | $ | 5,860 |  |  | $ | 5,225 |  |  | 12%\nAdvertising and marketing |  | 182 |  |  | 222 |  |  | (18)% |  | 573 |  |  | 557 |  |  | 3%\nDepreciation and amortization |  | 185 |  |  | 188 |  |  | (2)% |  | 566 |  |  | 537 |  |  | 5%\nProvision for litigation |  | 208 |  |  | 27 |  |  | ** |  | 341 |  |  | 94 |  |  | **\nTotal operating expenses |  | 2,644 |  |  | 2,268 |  |  | 17% |  | 7,340 |  |  | 6,413 |  |  | 14%\nSpecial Items1 |  | (208) |  |  | (109) |  |  | ** |  | (408) |  |  | (176) |  |  | **\nAdjusted total operating expenses (excluding Special Items1) |  | $ | 2,437 |  |  | $ | 2,158 |  |  | 13% |  | $ | 6,932 |  |  | $ | 6,237 |  |  | 11%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, 2022\n |  | Increase/(Decrease)\n |  | Operational |  | SpecialItems1 |  | Acquisitions |  | Currency Impact2 |  | Total\nGeneral and administrative |  | 19% |  | (5)% |  | 4% |  | (4)% |  | 13%\nAdvertising and marketing |  | (15)% |  | ** |  | \u2014% |  | (4)% |  | (18)%\nDepreciation and amortization |  | (1)% |  | ** |  | 5% |  | (5)% |  | (2)%\nProvision for litigation |  | ** |  | ** |  | ** |  | ** |  | **\nTotal operating expenses |  | 14% |  | 4% |  | 3% |  | (4)% |  | 17%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2022\n |  | Increase/(Decrease)\n |  | Operational |  | SpecialItems1 |  | Acquisitions |  | Currency Impact2 |  | Total\nGeneral and administrative |  | 11% |  | \u2014% |  | 5% |  | (3)% |  | 12%\nAdvertising and marketing |  | 6% |  | ** |  | 1% |  | (4)% |  | 3%\nDepreciation and amortization |  | \u2014% |  | ** |  | 9% |  | (4)% |  | 5%\nProvision for litigation |  | ** |  | ** |  | ** |  | ** |  | **\nTotal operating expenses |  | 10% |  | 3% |  | 5% |  | (3)% |  | 14%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/ (Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \n |  | ($ in millions)\nPersonnel1 |  | $ | 1,382 |  |  | $ | 1,166 |  |  | 19% |  | $ | 3,882 |  |  | $ | 3,400 |  |  | 14%\nProfessional fees |  | 118 |  |  | 95 |  |  | 24% |  | 313 |  |  | 298 |  |  | 5%\nData processing and telecommunications |  | 228 |  |  | 228 |  |  | \u2014% |  | 688 |  |  | 643 |  |  | 7%\nForeign exchange activity2 |  | 38 |  |  | 19 |  |  | ** |  | 109 |  |  | 35 |  |  | **\nOther1, 3 |  | 303 |  |  | 323 |  |  | (6)% |  | 868 |  |  | 849 |  |  | 2%\nTotal general and administrative expenses |  | $ | 2,069 |  |  | $ | 1,831 |  |  | 13% |  | $ | 5,860 |  |  | $ | 5,225 |  |  | 12%\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/ (Decrease) |  | Nine Months Ended September 30, |  | Increase/ (Decrease)\n |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 | \n |  | ($ in millions)\nInvestment income |  | $ | 16 |  |  | $ | 5 |  |  | ** |  | $ | 28 |  |  | $ | 9 |  |  | **\nGains (losses) on equity investments, net |  | 60 |  |  | 197 |  |  | ** |  | (133) |  |  | 534 |  |  | **\nInterest expense |  | (120) |  |  | (110) |  |  | 9% |  | (344) |  |  | (323) |  |  | 7%\nOther income (expense), net |  | 4 |  |  | 7 |  |  | ** |  | 12 |  |  | 9 |  |  | **\nTotal other income (expense) |  | (40) |  |  | 99 |  |  | ** |  | (437) |  |  | 229 |  |  | **\n(Gains) losses on equity investments1 |  | (60) |  |  | (197) |  |  | ** |  | 133 |  |  | (534) |  |  | **\nSpecial Items1 |  | \u2014 |  |  | 6 |  |  | ** |  | \u2014 |  |  | 6 |  |  | **\n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted total other income (expense)1 |  | $ | (99) |  |  | $ | (92) |  |  | 8% |  | $ | (303) |  |  | $ | (299) |  |  | 2%  |  |  |  |  |  |  |  |  |  |  | \n | September 30,2022 |  | December 31,2021\n | (in billions)\nCash, cash equivalents and investments1 | $ | 8.0 |  |  | $ | 7.9 | \nUnused line of credit | 6.0 |  |  | 6.0 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2022 |  | 2021\n | (in millions)\nNet cash provided by operating activities | $ | 8,095 |  |  | $ | 6,274 | \nNet cash used in investing activities | (1,120) |  |  | (4,834) | \nNet cash used in financing activities | (6,714) |  |  | (4,938) |   |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  | (in millions, except average price data)\nRemaining authorization at December 31, 2021 |  |  |  |  |  | $ | 11,927 | \nDollar value of shares repurchased during the nine months ended September 30, 2022 |  |  |  |  |  | $ | 6,339 | \nRemaining authorization at September 30, 2022 |  |  |  |  |  | $ | 5,588 | \nShares repurchased during the nine months ended September 30, 2022 |  |  |  |  |  | 18.3 | \nAverage price paid per share during the nine months ended September 30, 2022 |  |  |  |  |  | $ | 345.54 | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART II |  |  | \n |  | Item 1. Legal proceedings |  |  | \n |  | Item 1A. Risk factors |  |  | \n |  | Item 2. Unregistered sales of equity securities and use of proceeds |  |  | \n |  | Item 5. Other information |  |  | \n |  | Item 6. Exhibits |  |  | \n |  | Signatures |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod |  | Total\u00a0Numberof\u00a0SharesPurchased |  | Average\u00a0PricePaid\u00a0per\u00a0Share(includingcommission\u00a0cost) |  | Total\u00a0Number\u00a0ofShares\u00a0Purchased\u00a0asPart\u00a0of\u00a0PubliclyAnnounced\u00a0Plans\u00a0orPrograms |  | Dollar\u00a0Value\u00a0ofShares\u00a0that\u00a0may\u00a0yetbe\u00a0Purchased\u00a0underthe Plans\u00a0orPrograms1, 2\nJuly 1 - 31 |  | 1,684,604 |  |  | $ | 328.44 |  |  | 1,684,604 |  |  | $ | 6,585,901,075 | \nAugust 1 - 31 |  | 1,539,240 |  |  | $ | 349.15 |  |  | 1,539,240 |  |  | $ | 6,048,468,809 | \nSeptember 1 - 30 |  | 1,444,413 |  |  | $ | 318.47 |  |  | 1,444,413 |  |  | $ | 5,588,468,056 | \nTotal |  | 4,668,257 |  |  | $ | 332.19 |  |  | 4,668,257 |  |  |   |  |  |  |  |  |  |  | \nExhibitNumber |  | Exhibit Description\n10.1*+ |  | Mastercard Senior Executive Annual Incentive Compensation Plan, as amended and restated effective September 7, 2022.\n31.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n31.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n32.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n32.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n99.1* |  | Disclosure pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012.\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH* |  | XBRL Taxonomy Extension Schema Document\n101.CAL* |  | XBRL Taxonomy Extension Calculation Linkbase Document\n101.DEF* |  | XBRL Taxonomy Extension Definition Linkbase Document\n101.LAB* |  | XBRL Taxonomy Extension Label Linkbase Document\n101.PRE* |  | XBRL Taxonomy Extension Presentation Linkbase Document  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | MASTERCARD INCORPORATED\n |  | (Registrant)\n |  |  | \nDate: | October 27, 2022 | By: |  | /S/ MICHAEL MIEBACH\n |  |  |  | Michael Miebach\n |  |  |  | President and Chief Executive Officer\n |  |  |  | (Principal Executive Officer)\n |  |  | \nDate: | October 27, 2022 | By: |  | /S/ SACHIN MEHRA\n |  |  |  | Sachin Mehra\n |  |  |  | Chief Financial Officer\n |  |  |  | (Principal Financial Officer)\n |  |  | \nDate: | October 27, 2022 | By: |  | /S/ SANDRA ARKELL\n |  |  |  | Sandra Arkell\n |  |  |  | Corporate Controller\n |  |  |  | (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Mastercard, in 2023 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  | \nDelaware | 13-4172551\n(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification Number)\n |  | \n2000 Purchase Street | 10577\nPurchase, | NY | (Zip Code)\n(Address of principal executive offices) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class |  | Trading Symbol |  | Name of each exchange of which registered\nClass A Common Stock, par value $0.0001 per share |  | MA |  | New York Stock Exchange\n2.1% Notes due 2027 |  | MA27 |  | New York Stock Exchange\n1.0% Notes due 2029 |  | MA29A |  | New York Stock Exchange\n2.5% Notes due 2030 |  | MA30 |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant (1)\u00a0has filed all reports required to be filed by Section\u00a013 or 15(d)\u00a0of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\u00a0has been subject to such filing requirements for the past 90 days. | Yes | \u2612 | No | \u2610\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files) | Yes | \u2612 | No | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of \u201clarge accelerated filer,\u201d \u201caccelerated filer,\u201d \u201csmaller reporting company,\u201d and \u201cemerging growth company\u201d in Rule 12b-2 of the Exchange Act. (Check One):\nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  |  | \nNon-accelerated filer | \u2610 |  | Smaller\u00a0reporting\u00a0company | \u2610 |  |  | \n |  |  | Emerging growth\u00a0company | \u2610 |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. | \u2610\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) | Yes | \u2610 | No | \u2612  |  | \n  |  |  |  |  |  |  |  |  |  |  | \n |  |  | \nPART I | 5 | Item 1. | Consolidated financial statements (unaudited)\n28 | Item 2. | Management\u2019s discussion and analysis of financial condition and results of operations\n39 | Item 3. | Quantitative and qualitative disclosures about market risk\n40 | Item 4. | Controls and procedures\n |  |  | \n |  |  | \nPART II | 42 | Item 1. | Legal proceedings\n42 | Item 1A. | Risk factors\n42 | Item 2. | Unregistered sales of equity securities and use of proceeds\n42 | Item 5. | Other information\n42 | Item 6. | Exhibits\n44 | - | Signatures\n |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART I |  |  | \n |  | Item 1. Consolidated financial statements (unaudited) |  | \n |  | Item 2. Management\u2019s discussion and analysis of financial condition and results of operations |  | \n |  | Item 3. Quantitative and qualitative disclosures about market risk |  | \n |  | Item 4. Controls and procedures |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  | \n |  | Page\nConsolidated Statement of Operations \u2014Three Months Ended March 31, 2023and2022 |  | 6\nConsolidated Statement of Comprehensive Income \u2014Three Months Ended March 31, 2023and2022 |  | 7\nConsolidated Balance Sheet \u2014March 31, 2023andDecember 31, 2022 |  | 8\nConsolidated Statement of Changes in Equity\u2014Three Months Ended March 31, 2023and2022 |  | 9\nConsolidated Statement of Cash Flows \u2014Three Months Ended March 31, 2023and2022 |  | 10\nNotes to consolidated financial statements |  | 11  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Operations (Unaudited) |  |  |  |  |  |  |  | \n |  |  |  | Three Months Ended March 31,\n |  |  |  |  |  | 2023 |  | 2022\n |  |  |  |  |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNet Revenue |  |  |  |  |  | $ | 5,748 |  |  | $ | 5,167 | \nOperating Expenses: |  |  |  |  |  |  |  | \nGeneral and administrative |  |  |  |  |  | 2,043 |  |  | 1,844 | \nAdvertising and marketing |  |  |  |  |  | 167 |  |  | 181 | \nDepreciation and amortization |  |  |  |  |  | 191 |  |  | 192 | \nProvision for litigation |  |  |  |  |  | 211 |  |  | \u2014 | \nTotal operating expenses |  |  |  |  |  | 2,612 |  |  | 2,217 | \nOperating income |  |  |  |  |  | 3,136 |  |  | 2,950 | \nOther Income (Expense): |  |  |  |  |  |  |  | \nInvestment income |  |  |  |  |  | 55 |  |  | 5 | \nGains (losses) on equity investments, net |  |  |  |  |  | (212) |  |  | (76) | \nInterest expense |  |  |  |  |  | (132) |  |  | (110) | \nOther income (expense), net |  |  |  |  |  | 6 |  |  | 4 | \nTotal other income (expense) |  |  |  |  |  | (283) |  |  | (177) | \nIncome before income taxes |  |  |  |  |  | 2,853 |  |  | 2,773 | \nIncome tax expense |  |  |  |  |  | 492 |  |  | 142 | \nNet Income |  |  |  |  |  | $ | 2,361 |  |  | $ | 2,631 | \nBasic Earnings per Share |  |  |  |  |  | $ | 2.48 |  |  | $ | 2.69 | \nBasic weighted-average shares outstanding |  |  |  |  |  | 953 |  |  | 977 | \nDiluted Earnings per Share |  |  |  |  |  | $ | 2.47 |  |  | $ | 2.68 | \nDiluted weighted-average shares outstanding |  |  |  |  |  | 956 |  |  | 981 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Comprehensive Income (Unaudited) |  |  |  |  |  |  |  | \n |  |  |  | Three Months Ended March 31,\n |  |  |  |  |  | 2023 |  | 2022\n |  |  |  |  |  | (in millions)\nNet Income |  |  |  |  |  | $ | 2,361 |  |  | $ | 2,631 | \nOther comprehensive income (loss): |  |  |  |  |  |  |  | \nForeign currency translation adjustments |  |  |  |  |  | 94 |  |  | (64) | \nIncome tax effect |  |  |  |  |  | (14) |  |  | 12 | \nForeign currency translation adjustments, net of income tax effect |  |  |  |  |  | 80 |  |  | (52) | \n |  |  |  |  |  |  |  | \nTranslation adjustments on net investment hedges |  |  |  |  |  | (74) |  |  | 86 | \nIncome tax effect |  |  |  |  |  | 17 |  |  | (19) | \nTranslation adjustments on net investment hedges, net of income tax effect |  |  |  |  |  | (57) |  |  | 67 | \n |  |  |  |  |  |  |  | \nCash flow hedges |  |  |  |  |  | (10) |  |  | 1 | \nIncome tax effect |  |  |  |  |  | \u2014 |  |  | \u2014 | \nReclassification adjustments for cash flow hedges |  |  |  |  |  | 8 |  |  | (5) | \nIncome tax effect |  |  |  |  |  | 1 |  |  | 1 | \nCash flow hedges, net of income tax effect |  |  |  |  |  | (1) |  |  | (3) | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nInvestment securities available-for-sale |  |  |  |  |  | 2 |  |  | (2) | \nIncome tax effect |  |  |  |  |  | \u2014 |  |  | 1 | \nInvestment securities available-for-sale, net of income tax effect |  |  |  |  |  | 2 |  |  | (1) | \n |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of income tax effect |  |  |  |  |  | 24 |  |  | 11 | \nComprehensive Income |  |  |  |  |  | $ | 2,385 |  |  | $ | 2,642 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Balance Sheet (Unaudited) |  |  |  | \n |  | March 31, 2023 |  | December 31, 2022\n |  | (in\u00a0millions,\u00a0except\u00a0per share\u00a0data)\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 6,566 |  |  | $ | 7,008 | \nRestricted cash for litigation settlement |  | 596 |  |  | 589 | \nInvestments |  | 402 |  |  | 400 | \nAccounts receivable |  | 3,511 |  |  | 3,425 | \nSettlement assets |  | 1,236 |  |  | 1,270 | \nRestricted security deposits held for customers |  | 1,608 |  |  | 1,568 | \nPrepaid expenses and other current assets |  | 2,501 |  |  | 2,346 | \nTotal current assets |  | 16,420 |  |  | 16,606 | \nProperty, equipment and right-of-use assets, net of accumulated depreciation and amortizationof $2,002and $1,904, respectively |  | 2,006 |  |  | 2,006 | \nDeferred income taxes |  | 1,267 |  |  | 1,151 | \nGoodwill |  | 7,575 |  |  | 7,522 | \nOther intangible assets, net of accumulated amortization of $2,018and $1,960, respectively |  | 4,027 |  |  | 3,859 | \nOther assets |  | 7,641 |  |  | 7,580 | \nTotal Assets |  | $ | 38,936 |  |  | $ | 38,724 | \nLiabilities, Redeemable Non-controlling Interests and Equity |  |  |  | \nCurrent liabilities: |  |  |  | \nAccounts payable |  | $ | 735 |  |  | $ | 926 | \nSettlement obligations |  | 870 |  |  | 1,111 | \nRestricted security deposits held for customers |  | 1,608 |  |  | 1,568 | \nAccrued litigation |  | 1,107 |  |  | 1,094 | \nAccrued expenses |  | 7,310 |  |  | 7,801 | \nShort-term debt |  | 276 |  |  | 274 | \nOther current liabilities |  | 1,745 |  |  | 1,397 | \nTotal current liabilities |  | 13,651 |  |  | 14,171 | \nLong-term debt |  | 15,292 |  |  | 13,749 | \nDeferred income taxes |  | 389 |  |  | 393 | \nOther liabilities |  | 4,197 |  |  | 4,034 | \nTotal Liabilities |  | 33,529 |  |  | 32,347 | \nCommitments and Contingencies |  |  |  | \nRedeemable Non-controlling Interests |  | 21 |  |  | 21 | \nStockholders\u2019 Equity |  |  |  | \nClass\u00a0A common stock, $0.0001par value; authorized3,000shares,1,400and1,399shares issued and941and948shares outstanding, respectively |  | \u2014 |  |  | \u2014 | \nClass B common stock, $0.0001par value; authorized1,200shares,7and8shares issued and outstanding, respectively |  | \u2014 |  |  | \u2014 | \nAdditional paid-in-capital |  | 5,376 |  |  | 5,298 | \nClass\u00a0A treasury stock, at cost,459and451shares, respectively |  | (54,241) |  |  | (51,354) | \nRetained earnings |  | 55,424 |  |  | 53,607 | \nAccumulated other comprehensive income (loss) |  | (1,229) |  |  | (1,253) | \nMastercard Incorporated Stockholders' Equity |  | 5,330 |  |  | 6,298 | \nNon-controlling interests |  | 56 |  |  | 58 | \nTotal Equity |  | 5,386 |  |  | 6,356 | \nTotal Liabilities, Redeemable Non-controlling Interests and Equity |  | $ | 38,936 |  |  | $ | 38,724 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | \n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Changes in Equity (Unaudited)\n |  | Three Months Ended March 31, 2023\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,298 |  |  | $ | (51,354) |  |  | $ | 53,607 |  |  | $ | (1,253) |  |  | $ | 6,298 |  |  | $ | 58 |  |  | $ | 6,356 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,361 |  |  | \u2014 |  |  | 2,361 |  |  | \u2014 |  |  | 2,361 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2) |  |  | (2) | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3) |  |  | \u2014 |  |  | (3) |  |  | \u2014 |  |  | (3) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 24 |  |  | 24 |  |  | \u2014 |  |  | 24 | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (541) |  |  | \u2014 |  |  | (541) |  |  | \u2014 |  |  | (541) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,894) |  |  | \u2014 |  |  | \u2014 |  |  | (2,894) |  |  | \u2014 |  |  | (2,894) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 78 |  |  | 7 |  |  | \u2014 |  |  | \u2014 |  |  | 85 |  |  | \u2014 |  |  | 85 | \nBalance at March 31, 2023 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,376 |  |  | $ | (54,241) |  |  | $ | 55,424 |  |  | $ | (1,229) |  |  | $ | 5,330 |  |  | $ | 56 |  |  | $ | 5,386 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | \n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, 2022\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,061 |  |  | $ | (42,588) |  |  | $ | 45,648 |  |  | $ | (809) |  |  | $ | 7,312 |  |  | $ | 71 |  |  | $ | 7,383 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,631 |  |  | \u2014 |  |  | 2,631 |  |  | \u2014 |  |  | 2,631 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3) |  |  | (3) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 11 |  |  | 11 |  |  | \u2014 |  |  | 11 | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (477) |  |  | \u2014 |  |  | (477) |  |  | \u2014 |  |  | (477) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,411) |  |  | \u2014 |  |  | \u2014 |  |  | (2,411) |  |  | \u2014 |  |  | (2,411) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | (35) |  |  | 5 |  |  | \u2014 |  |  | \u2014 |  |  | (30) |  |  | \u2014 |  |  | (30) | \nBalance at March 31, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,026 |  |  | $ | (44,994) |  |  | $ | 47,800 |  |  | $ | (798) |  |  | $ | 7,034 |  |  | $ | 68 |  |  | $ | 7,102 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Cash Flows (Unaudited) |  |  |  | \n |  | Three Months Ended March 31,\n |  | 2023 |  | 2022\n |  | (in millions)\nOperating Activities |  |  |  | \nNet income |  | $ | 2,361 |  |  | $ | 2,631 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  |  | \nAmortization of customer and merchant incentives |  | 378 |  |  | 430 | \nDepreciation and amortization |  | 191 |  |  | 192 | \n(Gains) losses on equity investments, net |  | 212 |  |  | 76 | \nShare-based compensation |  | 108 |  |  | 74 | \nDeferred income taxes |  | (129) |  |  | (320) | \nOther |  | 2 |  |  | 5 | \nChanges in operating assets and liabilities: |  |  |  | \nAccounts receivable |  | (38) |  |  | 134 | \n |  |  |  | \nSettlement assets |  | 35 |  |  | 218 | \nPrepaid expenses |  | (761) |  |  | (441) | \nAccrued litigation and legal settlements |  | 9 |  |  | (43) | \nRestricted security deposits held for customers |  | 40 |  |  | (144) | \nAccounts payable |  | (184) |  |  | (56) | \nSettlement obligations |  | (241) |  |  | (366) | \n |  |  |  | \nAccrued expenses |  | (506) |  |  | (746) | \n |  |  |  | \nNet change in other assets and liabilities |  | 442 |  |  | 138 | \nNet cash provided by operating activities |  | 1,919 |  |  | 1,782 | \nInvesting Activities |  |  |  | \nPurchases of investment securities available-for-sale |  | (50) |  |  | (58) | \nPurchases of investments held-to-maturity |  | (26) |  |  | (37) | \nProceeds from sales of investment securities available-for-sale |  | 4 |  |  | 8 | \nProceeds from maturities of investment securities available-for-sale |  | 51 |  |  | 70 | \nProceeds from maturities of investments held-to-maturity |  | 24 |  |  | 43 | \nPurchases of property and equipment |  | (110) |  |  | (146) | \nCapitalized software |  | (242) |  |  | (148) | \nPurchases of equity investments |  | (22) |  |  | (24) | \nProceeds from sales of equity investments |  | 44 |  |  | \u2014 | \n |  |  |  | \n |  |  |  | \nOther investing activities |  | (70) |  |  | 5 | \nNet cash used in investing activities |  | (397) |  |  | (287) | \nFinancing Activities |  |  |  | \nPurchases of treasury stock |  | (2,878) |  |  | (2,408) | \nDividends paid |  | (545) |  |  | (479) | \nProceeds from debt, net |  | 1,489 |  |  | 843 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nTax withholdings related to share-based payments |  | (76) |  |  | (132) | \nCash proceeds from exercise of stock options |  | 53 |  |  | 28 | \nOther financing activities |  | 2 |  |  | (6) | \nNet cash used in financing activities |  | (1,955) |  |  | (2,154) | \nEffect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents |  | 37 |  |  | (28) | \nNet decrease in cash, cash equivalents, restricted cash and restricted cash equivalents |  | (396) |  |  | (687) | \nCash, cash equivalents, restricted cash and restricted cash equivalents - beginning of period |  | 9,196 |  |  | 9,902 | \nCash, cash equivalents, restricted cash and restricted cash equivalents - end of period |  | $ | 8,800 |  |  | $ | 9,215 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | \n |  | 2023 |  | 2022 |  |  |  | \n |  | (in millions)\nNet revenue by category: |  |  |  |  |  |  |  | \nPayment network |  | $ | 3,650 |  |  | $ | 3,399 |  |  |  |  | \nValue-added services and solutions |  | 2,098 |  |  | 1,768 |  |  |  |  | \nNet revenue |  | $ | 5,748 |  |  | $ | 5,167 |  |  |  |  | \nNet revenue by geographic region: |  |  |  |  |  |  |  | \nNorth American Markets |  | $ | 1,896 |  |  | $ | 1,730 |  |  |  |  | \nInternational Markets |  | 3,852 |  |  | 3,437 |  |  |  |  | \nNet revenue |  | $ | 5,748 |  |  | $ | 5,167 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31,2023 |  | December 31,2022\n |  | (in millions)\nReceivables from contracts with customers |  |  |  | \nAccounts receivable |  | $ | 3,271 |  |  | $ | 3,213 | \nContract assets |  |  |  | \nPrepaid expenses and other current assets |  | 142 |  |  | 118 | \nOther assets |  | 511 |  |  | 442 | \nDeferred revenue1 |  |  |  | \nOther current liabilities |  | 634 |  |  | 434 | \nOther liabilities |  | 266 |  |  | 248 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three Months Ended March 31,\n |  |  |  |  |  | 2023 |  | 2022\n |  |  |  |  |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNumerator |  |  |  |  |  |  |  | \nNet income |  |  |  |  |  | $ | 2,361 |  |  | $ | 2,631 | \nDenominator |  |  |  |  |  |  |  | \nBasic weighted-average shares outstanding |  |  |  |  |  | 953 |  |  | 977 | \nDilutive stock options and stock units |  |  |  |  |  | 3 |  |  | 4 | \nDiluted weighted-average shares outstanding1 |  |  |  |  |  | 956 |  |  | 981 | \nEarnings per Share |  |  |  |  |  |  |  | \nBasic |  |  |  |  |  | $ | 2.48 |  |  | $ | 2.69 | \nDiluted |  |  |  |  |  | $ | 2.47 |  |  | $ | 2.68 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31,2023 |  | December 31,2022\n |  | (in millions)\nCash and cash equivalents |  | $ | 6,566 |  |  | $ | 7,008 | \nRestricted cash and restricted cash equivalents |  |  |  | \nRestricted cash for litigation settlement |  | 596 |  |  | 589 | \nRestricted security deposits held for customers |  | 1,608 |  |  | 1,568 | \nPrepaid expenses and other current assets |  | 30 |  |  | 31 | \n |  |  |  | \nCash, cash equivalents, restricted cash and restricted cash equivalents |  | $ | 8,800 |  |  | $ | 9,196 | \n |  |  |  | \n |  | \n |  |  |  | \n |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31,2023 |  | December 31,2022\n |  | (in millions)\nAvailable-for-sale securities1 |  | $ | 271 |  |  | $ | 272 | \nHeld-to-maturity securities2 |  | 131 |  |  | 128 | \nTotal investments |  | $ | 402 |  |  | $ | 400 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2023 |  | December 31, 2022\n |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue\n |  | (in millions)\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGovernment and agency securities |  | $ | 96 |  |  | $ | \u2014 |  |  | $ | (1) |  |  | $ | 95 |  |  | $ | 91 |  |  | $ | \u2014 |  |  | $ | (2) |  |  | $ | 89 | \nCorporate securities |  | 179 |  |  | \u2014 |  |  | (3) |  |  | 176 |  |  | 187 |  |  | \u2014 |  |  | (4) |  |  | 183 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal |  | $ | 275 |  |  | $ | \u2014 |  |  | $ | (4) |  |  | $ | 271 |  |  | $ | 278 |  |  | $ | \u2014 |  |  | $ | (6) |  |  | $ | 272 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | \n |  | Amortized Cost |  | Fair\u00a0Value\n |  | (in millions)\nDue within 1 year |  | $ | 156 |  |  | $ | 155 | \nDue after 1 year through 5 years |  | 119 |  |  | 116 | \n |  |  |  | \nTotal |  | $ | 275 |  |  | $ | 271 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Balance at December 31, 2022 |  | Purchases |  | Sales |  | Changes in Fair Value1 |  | Other2 |  | Balance at March 31, 2023\n |  | (in millions)\nMarketable securities |  | $ | 399 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | (66) |  |  | $ | 3 |  |  | $ | 336 | \nNonmarketable securities |  | 1,331 |  |  | 22 |  |  | (44) |  |  | (146) |  |  | 4 |  |  | 1,167 | \nTotal equity investments |  | $ | 1,730 |  |  | $ | 22 |  |  | $ | (44) |  |  | $ | (212) |  |  | $ | 7 |  |  | $ | 1,503 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31,2023 |  | December 31,2022\n |  | (in millions)\nMeasurement alternative |  | $ | 958 |  |  | $ | 1,087 | \nEquity method |  | 209 |  |  | 244 | \nTotal Nonmarketable securities |  | $ | 1,167 |  |  | $ | 1,331 |   |  |  |  |  |  |  |  | \n |  | \n |  | (in millions)\nInitial cost basis |  | $ | 504 | \nCumulative adjustments1: |  | \nUpward adjustments |  | 620 | \nDownward adjustments (including impairment) |  | (166) | \nCarrying amount, end of period |  | $ | 958 | \n |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three Months Ended March 31,\n |  |  |  |  |  | 2023 |  | 2022\n |  |  |  |  |  | (in millions)\nMeasurement alternative investments: |  |  |  |  |  |  |  | \nUpward adjustments |  |  |  |  |  | $ | \u2014 |  |  | $ | 86 | \nDownward adjustments (including impairment) |  |  |  |  |  | (133) |  |  | \u2014 | \nMarketable securities: |  |  |  |  |  |  |  | \nUnrealized gains (losses), net |  |  |  |  |  | (66) |  |  | (162) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2023 |  | December 31, 2022\n |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total\n |  | (in millions)\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestment securities available-for-sale1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGovernment and agency securities |  | $ | 31 |  |  | $ | 64 |  |  | $ | \u2014 |  |  | $ | 95 |  |  | $ | 35 |  |  | $ | 54 |  |  | $ | \u2014 |  |  | $ | 89 | \nCorporate securities |  | \u2014 |  |  | 176 |  |  | \u2014 |  |  | 176 |  |  | \u2014 |  |  | 183 |  |  | \u2014 |  |  | 183 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | \u2014 |  |  | 47 |  |  | \u2014 |  |  | 47 |  |  | \u2014 |  |  | 108 |  |  | \u2014 |  |  | 108 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMarketable securities3: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nEquity securities |  | 336 |  |  | \u2014 |  |  | \u2014 |  |  | 336 |  |  | 399 |  |  | \u2014 |  |  | \u2014 |  |  | 399 | \nDeferred compensation plan4: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation assets |  | 81 |  |  | \u2014 |  |  | \u2014 |  |  | 81 |  |  | 74 |  |  | \u2014 |  |  | \u2014 |  |  | 74 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | \u2014 |  |  | $ | 43 |  |  | $ | \u2014 |  |  | $ | 43 |  |  | $ | \u2014 |  |  | $ | 21 |  |  | $ | \u2014 |  |  | $ | 21 | \nInterest rate contracts |  | \u2014 |  |  | 89 |  |  | \u2014 |  |  | 89 |  |  | \u2014 |  |  | 105 |  |  | \u2014 |  |  | 105 | \nDeferred compensation plan5: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation liabilities |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 |  |  | 73 |  |  | \u2014 |  |  | \u2014 |  |  | 73 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31,2023 |  | December 31,2022\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 1,448 |  |  | $ | 1,392 | \nPrepaid income taxes |  | 25 |  |  | 34 | \nOther |  | 1,028 |  |  | 920 | \nTotal prepaid expenses and other current assets |  | $ | 2,501 |  |  | $ | 2,346 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31,2023 |  | December 31,2022\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 4,715 |  |  | $ | 4,578 | \nEquity investments |  | 1,503 |  |  | 1,730 | \nIncome taxes receivable |  | 691 |  |  | 633 | \nOther |  | 732 |  |  | 639 | \nTotal other assets |  | $ | 7,641 |  |  | $ | 7,580 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31,2023 |  | December 31,2022\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 5,619 |  |  | $ | 5,600 | \nPersonnel costs |  | 589 |  |  | 1,322 | \nIncome and other taxes |  | 588 |  |  | 279 | \nOther |  | 514 |  |  | 600 | \nTotal accrued expenses |  | $ | 7,310 |  |  | $ | 7,801 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | March 31,2023 |  | December 31,2022 |  | EffectiveInterest Rate\n |  |  |  |  | (in millions) |  | \nSenior Notes |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n2023 USD Notes |  | 4.875 | % | Senior Notes due March 2028 |  | $ | 750 |  |  | $ | \u2014 |  |  | 5.003 | %\n |  | 4.850 | % | Senior Notes due March 2033 |  | 750 |  |  | \u2014 |  |  | 4.923 | %\n |  |  |  |  |  |  |  |  | \n2022 EUR Notes1 |  | 1.000 | % | Senior Notes due February 2029 |  | 815 |  |  | 800 |  |  | 1.138 | %\n |  |  |  |  |  |  |  |  | \n2021 USD Notes |  | 2.000 | % | Senior Notes due November 2031 |  | 750 |  |  | 750 |  |  | 2.112 | %\n |  | 1.900 | % | Senior Notes due March 2031 |  | 600 |  |  | 600 |  |  | 1.981 | %\n |  | 2.950 | % | Senior Notes due March 2051 |  | 700 |  |  | 700 |  |  | 3.013 | %\n |  |  |  |  |  |  |  |  | \n2020 USD Notes |  | 3.300 | % | Senior Notes due March 2027 |  | 1,000 |  |  | 1,000 |  |  | 3.420 | %\n |  | 3.350 | % | Senior Notes due March 2030 |  | 1,500 |  |  | 1,500 |  |  | 3.430 | %\n |  | 3.850 | % | Senior Notes due March 2050 |  | 1,500 |  |  | 1,500 |  |  | 3.896 | %\n |  |  |  |  |  |  |  |  | \n2019 USD Notes |  | 2.950 | % | Senior Notes due June 2029 |  | 1,000 |  |  | 1,000 |  |  | 3.030 | %\n |  | 3.650 | % | Senior Notes due June 2049 |  | 1,000 |  |  | 1,000 |  |  | 3.689 | %\n |  | 2.000 | % | Senior Notes due March 2025 |  | 750 |  |  | 750 |  |  | 2.147 | %\n |  |  |  |  |  |  |  |  | \n2018 USD Notes |  | 3.500 | % | Senior Notes due February 2028 |  | 500 |  |  | 500 |  |  | 3.598 | %\n |  | 3.950 | % | Senior Notes due February 2048 |  | 500 |  |  | 500 |  |  | 3.990 | %\n |  |  |  |  |  |  |  |  | \n2016 USD Notes |  | 2.950 | % | Senior Notes due November 2026 |  | 750 |  |  | 750 |  |  | 3.044 | %\n |  | 3.800 | % | Senior Notes due November 2046 |  | 600 |  |  | 600 |  |  | 3.893 | %\n |  |  |  |  |  |  |  |  | \n2015 EUR Notes2 |  | 2.100 | % | Senior Notes due December 2027 |  | 870 |  |  | 854 |  |  | 2.189 | %\n |  | 2.500 | % | Senior Notes due December 2030 |  | 163 |  |  | 160 |  |  | 2.562 | %\n |  |  |  |  |  |  |  |  | \n2014 USD Notes |  | 3.375 | % | Senior Notes due April 2024 |  | 1,000 |  |  | 1,000 |  |  | 3.484 | %\n |  |  |  |  |  |  |  |  | \nOther Debt |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n2022 INR Term Loan3 |  | 8.640 | % | Term Loan due July 2023 |  | 277 |  |  | 275 |  |  | 9.090 | %\n |  |  |  |  |  |  |  |  | \n |  |  |  |  | 15,775 |  |  | 14,239 |  |  | \nLess: Unamortized discount and debt issuance costs | (118) |  |  | (111) |  |  | \nLess: Cumulative hedge accounting fair value adjustments4 |  | (89) |  |  | (105) |  |  | \nTotal debt outstanding | 15,568 |  |  | 14,023 |  |  | \nLess: Short-term debt5 |  | (276) |  |  | (274) |  |  | \nLong-term debt | $ | 15,292 |  |  | $ | 13,749 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three Months Ended March 31,\n |  |  |  |  |  | 2023 |  | 2022\n |  |  |  |  |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nDividends declared per share |  |  |  |  |  | $ | 0.57 |  |  | $ | 0.49 | \nTotal dividends declared |  |  |  |  |  | $ | 541 |  |  | $ | 477 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |  |  |  |  | \n |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n |  | 2023 |  | 2022\n |  | Outstanding Shares |  | Outstanding Shares\n |  | Class\u00a0A |  | Class\u00a0B |  | Class\u00a0A |  | Class\u00a0B\n |  | (in millions)\nBalance at beginning of period |  | 948.4 |  |  | 7.6 |  |  | 972.1 |  |  | 7.8 | \nPurchases of treasury stock |  | (8.0) |  |  | \u2014 |  |  | (6.8) |  |  | \u2014 | \nShare-based payments |  | 0.9 |  |  | \u2014 |  |  | 1.1 |  |  | \u2014 | \nConversion of Class B to Class A common stock |  | 0.1 |  |  | (0.1) |  |  | 0.1 |  |  | (0.1) | \nBalance at end of period |  | 941.4 |  |  | 7.5 |  |  | 966.5 |  |  | 7.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n |  | 2023 |  | 2022\n |  | (in millions, except per share data)\nDollar-value of shares repurchased1 |  | $ | 2,878 |  |  | $ | 2,408 | \nShares repurchased |  | 8.0 |  |  | 6.8 | \nAverage price paid per share |  | $ | 361.70 |  |  | $ | 355.13 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2022 |  | Increase / (Decrease) |  | Reclassifications |  | March 31, 2023\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (1,414) |  |  | $ | 80 |  |  | $ | \u2014 |  |  | $ | (1,334) | \nTranslation adjustments on net investment hedges2 |  | 309 |  |  | (57) |  |  | \u2014 |  |  | 252 | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | (8) |  |  | (10) |  |  | 8 |  |  | (10) | \nInterest rate contracts |  | (123) |  |  | \u2014 |  |  | 1 |  |  | (122) | \nDefined benefit pension and other postretirement plans |  | (11) |  |  | \u2014 |  |  | \u2014 |  |  | (11) | \nInvestment securities available-for-sale |  | (6) |  |  | 2 |  |  | \u2014 |  |  | (4) | \nAccumulated other comprehensive income (loss) |  | $ | (1,253) |  |  | $ | 15 |  |  | $ | 9 |  |  | $ | (1,229) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2021 |  | Increase / (Decrease) |  | Reclassifications |  | March 31, 2022\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (739) |  |  | $ | (52) |  |  | $ | \u2014 |  |  | $ | (791) | \nTranslation adjustments on net investment hedges2 |  | 34 |  |  | 67 |  |  | \u2014 |  |  | 101 | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | 4 |  |  | 1 |  |  | (5) |  |  | \u2014 | \nInterest rate contracts |  | (128) |  |  | \u2014 |  |  | 1 |  |  | (127) | \nDefined benefit pension and other postretirement plans |  | 21 |  |  | \u2014 |  |  | \u2014 |  |  | 21 | \nInvestment securities available-for-sale |  | (1) |  |  | (1) |  |  | \u2014 |  |  | (2) | \nAccumulated other comprehensive income (loss) |  | $ | (809) |  |  | $ | 15 |  |  | $ | (4) |  |  | $ | (798) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Grants in 2023 |  | Weighted-AverageGrant-DateFair Value\n |  | (in millions) |  | (per option/unit)\nNon-qualified stock options |  | 0.3 |  | $ | 123 | \nRestricted stock units |  | 1.1 |  | $ | 349 | \nPerformance stock units |  | 0.2 |  | $ | 365 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31,2023 |  | December 31,2022\n |  | (in millions)\nGross settlement exposure |  | $ | 64,833 |  |  | $ | 64,885 | \nRisk mitigation arrangements applied to settlement exposure |  | (9,587) |  |  | (10,697) | \nNet settlement exposure |  | $ | 55,246 |  |  | $ | 54,188 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2023 |  | December 31, 2022\n |  | Notional |  | Derivative assets |  | Derivative liabilities |  | Notional |  | Derivative assets |  | Derivative liabilities\n |  | (in millions)\nDerivatives designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts in a cash flow hedge1 |  | $ | 709 |  |  | $ | 5 |  |  | $ | 19 |  |  | $ | 642 |  |  | $ | 4 |  |  | $ | 15 | \nInterest rate contracts in a fair value hedge2 |  | 1,000 |  |  | \u2014 |  |  | 89 |  |  | 1,000 |  |  | \u2014 |  |  | 105 | \nForeign exchange contracts in a net investment hedge1 |  | 2,229 |  |  | 16 |  |  | 16 |  |  | 1,814 |  |  | 103 |  |  | 4 | \nDerivatives not designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts1 |  | 1,988 |  |  | 26 |  |  | 8 |  |  | 521 |  |  | 1 |  |  | 2 | \nTotal derivative assets/liabilities |  | $ | 5,926 |  |  | $ | 47 |  |  | $ | 132 |  |  | $ | 3,977 |  |  | $ | 108 |  |  | $ | 126 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Gain (Loss)Recognized in OCI |  |  |  | Gain (Loss)Reclassified from AOCI\n |  | Three Months Ended March 31, |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Three Months Ended March 31,\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022\n |  | (in millions) |  |  | (in millions)\nDerivative financial instruments in a cash flow hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | (10) |  |  | $ | 1 |  |  | Net revenue |  | $ | (6) |  |  | $ | 7 | \nInterest rate contracts |  | $ | \u2014 |  |  | $ | \u2014 |  |  | Interest expense |  | $ | (2) |  |  | $ | (2) | \n |  |  |  |  |  |  |  |  |  | \nDerivative financial instruments in a net investment hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | (39) |  |  | $ | 35 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Three Months Ended March 31,\nDerivatives not designated as hedging instruments: |  |  |  |  |  | 2023 |  | 2022\n |  |  |  |  |  | (in millions)\nForeign exchange derivative contracts |  |  |  |  |  |  |  | \nGeneral and administrative |  |  |  |  |  | $ | 15 |  |  | $ | 1 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | Three Months Ended March 31, |  | Increase/(Decrease)\n |  |  |  |  |  |  | 2023 |  | 2022 | \n |  |  |  |  |  |  |  | ($ in millions, except per share data)\nNet revenue |  |  |  |  |  |  |  | $ | 5,748 |  |  | $ | 5,167 |  |  | 11%\nOperating expenses |  |  |  |  |  |  |  | $ | 2,612 |  |  | $ | 2,217 |  |  | 18%\nOperating income |  |  |  |  |  |  |  | $ | 3,136 |  |  | $ | 2,950 |  |  | 6%\nOperating margin |  |  |  |  |  |  |  | 54.6 | % |  | 57.1 | % |  | (2.5) ppt\nIncome tax expense |  |  |  |  |  |  |  | $ | 492 |  |  | $ | 142 |  |  | **\nEffective income tax rate |  |  |  |  |  |  |  | 17.2 | % |  | 5.1 | % |  | 12.1 ppt\nNet income |  |  |  |  |  |  |  | $ | 2,361 |  |  | $ | 2,631 |  |  | (10)%\nDiluted earnings per share |  |  |  |  |  |  |  | $ | 2.47 |  |  | $ | 2.68 |  |  | (8)%\nDiluted weighted-average shares outstanding |  |  |  |  |  |  |  | 956 |  |  | 981 |  |  | (3)%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Three Months Ended March 31, |  | Increase/(Decrease)\n |  |  |  |  |  |  |  |  | 2023 |  | 2022 |  | As adjusted |  | Currency-neutral\n |  |  |  |  |  |  |  |  | ($ in millions, except per share data)\nAdjusted net revenue |  |  |  |  |  |  |  |  | $ | 5,748 |  |  | $ | 5,136 |  |  | 12% |  | 15%\nAdjusted operating expenses |  |  |  |  |  |  |  |  | $ | 2,401 |  |  | $ | 2,182 |  |  | 10% |  | 12%\nAdjusted operating margin |  |  |  |  |  |  |  |  | 58.2 | % |  | 57.5 | % |  | 0.7 ppt |  | 1.0 ppt\nAdjusted effective income tax rate |  |  |  |  |  |  |  |  | 18.3 | % |  | 5.3 | % |  | 13.0 ppt |  | 13.3 ppt\nAdjusted net income |  |  |  |  |  |  |  |  | $ | 2,678 |  |  | $ | 2,702 |  |  | (1)% |  | 2%\nAdjusted diluted earnings per share |  |  |  |  |  |  |  |  | $ | 2.80 |  |  | $ | 2.76 |  |  | 1% |  | 4%  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | Adjusted net revenue | \nThree Months Ended March 31, 2023 | Adjusted net revenue increased 15% on a currency-neutral basis.  The increase was attributable to growth in both our payment network and value-added services and solutions.\nGAAP |  | Non-GAAP(currency-neutral)\nup 11% |  | up 15%\n |  |  |   |  |  |  |  |  |  |  |  |  |  | \nOperating expenses |  | Adjustedoperating expenses | \n | \n |  | \n |  | \n |  | \nThree Months Ended March 31, 2023 | Adjusted operating expenses increased 12% on a currency-neutral basis, which includes 2 percentage points of growth due to acquisitions. The remaining increase was primarily due to higher personnel costs.\nGAAP |  | Non-GAAP(currency-neutral)\nup 18% |  | up 12%  |  |  |  |  |  |  |  |  |  |  | \nEffective incometax rate |  | Adjusted effectiveincome tax rate | \n | \n |  | \n |  | \n |  | \nThree Months Ended March 31, 2023 | The adjusted effective income tax rate of 18.3% was higher than the prior year rate of 5.3% due to a prior year discrete tax benefit related to final U.S. tax regulations published in the first quarter of 2022, which resulted in a valuation allowance release of $333 million, as well as an increase in the U.K. statutory tax rate effective in 2023.\nGAAP |  | Non-GAAP\n17.2% |  | 18.3%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, 2023\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 5,748 |  |  | $ | 2,612 |  |  | 54.6 | % |  | $ | (283) |  |  | 17.2 | % |  | $ | 2,361 |  |  | $ | 2.47 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 212 |  |  | \u2014 | % |  | 176 |  |  | 0.18 | \nLitigation provisions |  | ** |  | (211) |  |  | 3.7 | % |  | ** |  | 1.1 | % |  | 140 |  |  | 0.15 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | $ | 5,748 |  |  | $ | 2,401 |  |  | 58.2 | % |  | $ | (71) |  |  | 18.3 | % |  | $ | 2,678 |  |  | $ | 2.80 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, 2022\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 5,167 |  |  | $ | 2,217 |  |  | 57.1 | % |  | $ | (177) |  |  | 5.1 | % |  | $ | 2,631 |  |  | $ | 2.68 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 76 |  |  | 0.2 | % |  | 67 |  |  | 0.07 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRussia-related impacts |  | (30) |  |  | (34) |  |  | 0.4 | % |  | ** |  | \u2014 | % |  | 3 |  |  | \u2014 | \nAdjusted - Non-GAAP |  | $ | 5,136 |  |  | $ | 2,182 |  |  | 57.5 | % |  | $ | (101) |  |  | 5.3 | % |  | $ | 2,702 |  |  | $ | 2.76 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, 2023 as compared to the Three Months Ended March 31, 2022\n |  | Increase/(Decrease)\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\nReported - GAAP |  | 11% |  | 18% |  | (2.5) ppt |  | 12.1 ppt |  | (10)% |  | (8)%\n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | (0.2) ppt |  | 4% |  | 4%\nLitigation provisions |  | ** |  | (10)% |  | 3.7 ppt |  | 1.1 ppt |  | 5% |  | 5%\nRussia-related impacts |  | 1% |  | 2% |  | (0.4) ppt |  | \u2014 ppt |  | \u2014% |  | \u2014%\n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | 12% |  | 10% |  | 0.7 ppt |  | 13.0 ppt |  | (1)% |  | 1%\nCurrency impact1 |  | 3% |  | 2% |  | 0.3 ppt |  | 0.3 ppt |  | 3% |  | 3%\nAdjusted - Non-GAAP - currency-neutral |  | 15% |  | 12% |  | 1.0 ppt |  | 13.3 ppt |  | 2% |  | 4%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n |  | 2023 |  | 2022\n |  | Increase/(Decrease)\n |  | USD |  | Local |  | USD |  | Local\nMastercard-branded GDV growth1 |  | 10% |  | 15% |  | 12% |  | 17%\nUnited States |  | 9% |  | 9% |  | 14% |  | 14%\nWorldwide less United States |  | 11% |  | 18% |  | 11% |  | 19%\n |  |  |  |  |  |  |  | \nCross-border volume growth1 |  | 29% |  | 35% |  | 45% |  | 53%\n |  |  |  |  |  |  |  | \nMastercard-branded GDV growthadjusted for Russia1,2 |  | 11% |  | 16% |  | 16% |  | 20%\nWorldwide less United States GDV growth adjusted for Russia1,2 |  | 12% |  | 20% |  | 17% |  | 24%\n |  |  |  |  |  |  |  | \nCross-border volume growthadjusted for Russia1,2 |  | 33% |  | 40% |  | 45% |  | 52%\n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n |  | 2023 |  | 2022\n |  | Increase/(Decrease)\nSwitched transactions growth |  | 12% |  | 22%\n |  |  |  | \nSwitched transactions growth adjusted for Russia2 |  | 20% |  | 24%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | \n |  | 2023 |  | 2022 |  | Increase/(Decrease) |  | Currency-neutral Increase/(Decrease)\n |  | ($ in millions)\nDomestic assessments |  | $ | 2,254 |  |  | $ | 2,108 |  |  | 7% |  | 9%\nCross-border assessments |  | 1,849 |  |  | 1,390 |  |  | 33% |  | 39%\nTransaction processing assessments |  | 2,752 |  |  | 2,457 |  |  | 12% |  | 14%\nOther network assessments |  | 212 |  |  | 168 |  |  | 26% |  | 28%\n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | Increase/(Decrease) |  | \n |  | 2023 |  | 2022 |  |  |  |  | \n |  | ($ in millions) |  |  |  | \nPayment network |  | $ | 3,650 |  |  | $ | 3,399 |  |  |  |  | 7% |  | \nValue-added services and solutions |  | 2,098 |  |  | 1,768 |  |  |  |  | 19% |  | \nTotal net revenue |  | 5,748 |  |  | 5,167 |  |  |  |  | 11% |  | \nSpecial Items1 |  | \u2014 |  |  | (30) |  |  |  |  | ** |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \nAdjusted net revenue (excluding Special Items1) |  | $ | 5,748 |  |  | $ | 5,136 |  |  |  |  | 12% |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31,\n |  | Increase/(Decrease)\n |  | Operational |  |  |  | Acquisitions |  | Currency Impact3 |  | Special Items4 |  | Total\n |  | 2023 |  | 2022 |  |  |  |  |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  |  |  |  | 2022\nPayment network |  | 11 | % | 1 | 33 | % | 1 |  |  |  |  | \u2014 | % |  | \u2014 | % |  | (3) | % |  | (6) | % |  | (1) | % |  | 1 | % |  | 7 | % |  |  |  |  | 28 | %\nValue-added services and solutions |  | 20 | % | 2 | 14 | % | 2 |  |  |  |  | 1 | % |  | 6 | % |  | (2) | % |  | (3) | % |  | ** |  | ** |  | 19 | % |  |  |  |  | 17 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | 14 | % |  | 25 | % |  |  |  |  |  | \u2014 | % |  | 2 | % |  | (3) | % |  | (3) | % |  | (1) | % |  | 1 | % |  | 11 | % |  |  |  |  | 24 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | Three Months Ended March 31, |  | Increase/ (Decrease)\n |  |  |  |  |  |  | 2023 |  | 2022 | \n |  |  |  |  |  |  |  | ($ in millions)\nGeneral and administrative |  |  |  |  |  |  |  | $ | 2,043 |  |  | $ | 1,844 |  |  | 11%\nAdvertising and marketing |  |  |  |  |  |  |  | 167 |  |  | 181 |  |  | (8)%\nDepreciation and amortization |  |  |  |  |  |  |  | 191 |  |  | 192 |  |  | \u2014%\nProvision for litigation |  |  |  |  |  |  |  | 211 |  |  | \u2014 |  |  | **\nTotal operating expenses |  |  |  |  |  |  |  | 2,612 |  |  | 2,217 |  |  | 18%\nSpecial Items1 |  |  |  |  |  |  |  | (211) |  |  | (34) |  |  | **\nAdjusted total operating expenses (excluding Special Items1) |  |  |  |  |  |  |  | $ | 2,401 |  |  | $ | 2,182 |  |  | 10%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  | \n |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, 2023\n |  | Increase/(Decrease)\n |  | Operational |  | Acquisitions |  | Currency Impact1 |  | SpecialItems2 |  | Total\nGeneral and administrative |  | 13% |  | 2% |  | (2)% |  | (2)% |  | 11%\nAdvertising and marketing |  | (6)% |  | \u2014% |  | (3)% |  | ** |  | (8)%\nDepreciation and amortization |  | \u2014% |  | 2% |  | (3)% |  | ** |  | \u2014%\nProvision for litigation |  | ** |  | ** |  | ** |  | ** |  | **\nTotal operating expenses |  | 10% |  | 2% |  | (2)% |  | 8% |  | 18%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | Three Months Ended March 31, |  | Increase/(Decrease)\n |  |  |  |  |  |  | 2023 |  | 2022 | \n |  |  |  |  |  |  |  | ($ in millions)\nPersonnel1 |  |  |  |  |  |  |  | $ | 1,426 |  |  | $ | 1,181 |  |  | 21%\nProfessional fees |  |  |  |  |  |  |  | 100 |  |  | 86 |  |  | 16%\nData processing and telecommunications |  |  |  |  |  |  |  | 235 |  |  | 235 |  |  | \u2014%\nForeign exchange activity2 |  |  |  |  |  |  |  | 16 |  |  | 36 |  |  | **\nOther1 |  |  |  |  |  |  |  | 266 |  |  | 306 |  |  | (13)%\nTotal general and administrative expenses |  |  |  |  |  |  |  | $ | 2,043 |  |  | $ | 1,844 |  |  | 11%\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | Three Months Ended March 31, |  | Increase/ (Decrease)\n |  |  |  |  |  |  | 2023 |  | 2022 | \n |  |  |  |  |  |  |  | ($ in millions)\nInvestment income |  |  |  |  |  |  |  | $ | 55 |  |  | $ | 5 |  |  | **\nGains (losses) on equity investments, net |  |  |  |  |  |  |  | (212) |  |  | (76) |  |  | **\nInterest expense |  |  |  |  |  |  |  | (132) |  |  | (110) |  |  | 20%\nOther income (expense), net |  |  |  |  |  |  |  | 6 |  |  | 4 |  |  | **\nTotal other income (expense) |  |  |  |  |  |  |  | (283) |  |  | (177) |  |  | **\n(Gains) losses on equity investments1 |  |  |  |  |  |  |  | 212 |  |  | 76 |  |  | **\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted total other income (expense)1 |  |  |  |  |  |  |  | $ | (71) |  |  | $ | (101) |  |  | (30)%  |  |  |  |  |  |  |  |  |  |  | \n | March 31,2023 |  | December 31,2022\n | (in billions)\nCash, cash equivalents and investments1 | $ | 7.0 |  |  | $ | 7.4 | \nUnused line of credit | 8.0 |  |  | 8.0 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2023 |  | 2022\n | (in millions)\nNet cash provided by operating activities | $ | 1,919 |  |  | $ | 1,782 | \nNet cash used in investing activities | (397) |  |  | (287) | \nNet cash used in financing activities | (1,955) |  |  | (2,154) |   |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  | (in millions, except average price data)\nRemaining authorization at December 31, 2022 |  |  |  |  |  | $ | 12,174 | \nDollar-value of shares repurchased during the three months ended March 31, 20231 |  |  |  |  |  | $ | 2,878 | \nRemaining authorization at March 31, 2023 |  |  |  |  |  | $ | 9,296 | \nShares repurchased during the three months ended March 31, 2023 |  |  |  |  |  | 8.0 | \nAverage price paid per share during the three months ended March 31, 2023 |  |  |  |  |  | $ | 361.70 | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART II |  |  | \n |  | Item 1. Legal proceedings |  |  | \n |  | Item 1A. Risk factors |  |  | \n |  | Item 2. Unregistered sales of equity securities and use of proceeds |  |  | \n |  | Item 5. Other information |  |  | \n |  | Item 6. Exhibits |  |  | \n |  | Signatures |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod |  | Total\u00a0Numberof\u00a0SharesPurchased |  | Average\u00a0PricePaid\u00a0per\u00a0Share(includingcommission\u00a0cost) |  | Total\u00a0Number\u00a0ofShares\u00a0Purchased\u00a0asPart\u00a0of\u00a0PubliclyAnnounced\u00a0Plans\u00a0orPrograms |  | Dollar\u00a0Value\u00a0ofShares\u00a0that\u00a0may\u00a0yetbe\u00a0Purchased\u00a0underthe Plans\u00a0orPrograms1, 2\nJanuary 1 - 31 |  | 2,258,292 |  |  | $ | 367.17 |  |  | 2,258,292 |  |  | $ | 11,344,781,381 | \nFebruary 1 - 28 |  | 2,490,299 |  |  | $ | 366.46 |  |  | 2,490,299 |  |  | $ | 10,432,174,055 | \nMarch 1 - 31 |  | 3,208,405 |  |  | $ | 354.16 |  |  | 3,208,405 |  |  | $ | 9,295,891,709 | \nTotal |  | 7,956,996 |  |  | $ | 361.70 |  |  | 7,956,996 |  |  |   |  |  |  |  |  |  |  | \nExhibitNumber |  | Exhibit Description\n4.1 |  | Officer\u2019s Certificate of the Company, dated as ofMarch 9, 2023(incorporated by reference to Exhibit 4.1of the Company\u2019s Current Report on Form 8-K filed onMarch 9, 2023(File No. 001-32877)).\n4.2 |  | Form of Global Note representing the Company\u2019s 4.875% Notes due 2028 (included in Officer\u2019s Certificate of the Company, dated as of March 9, 2023) (incorporated by reference to Exhibit 4.1 of the Company\u2019s Current Report on Form 8-K filed on March 9, 2023 (File No. 001-32877)).\n4.3 |  | Form of Global Note representing the Company\u2019s 4.850% Notes due 2033(included in Officer\u2019s Certificate of the Company, dated as of March 9, 2023) (incorporated by reference to Exhibit 4.1of the Company\u2019s Current Report on Form 8-K filed on March 9, 2023 (File No. 001-32877)).\n10.1*+ |  | Form of Restricted Stock Unit Agreement for awards under 2006 Long Term Incentive Plan (effective for awards granted on and subsequent to March 1, 2023).\n10.2*+ |  | Form of Stock Option Agreement for awards under 2006 Long Term Incentive Plan (effective for awards granted on and subsequent to March 1, 2023).\n10.3*+ |  | Form of Performance Stock Unit Agreement for awards under 2006 Long Term Incentive Plan (effective for awards granted on and subsequent to March 1, 2023).\n31.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n31.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n32.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n32.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n99.1* |  | Disclosure pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012.\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH* |  | XBRL Taxonomy Extension Schema Document\n101.CAL* |  | XBRL Taxonomy Extension Calculation Linkbase Document\n101.DEF* |  | XBRL Taxonomy Extension Definition Linkbase Document\n101.LAB* |  | XBRL Taxonomy Extension Label Linkbase Document\n101.PRE* |  | XBRL Taxonomy Extension Presentation Linkbase Document  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | MASTERCARD INCORPORATED\n |  | (Registrant)\n |  |  | \nDate: | April 27, 2023 | By: |  | /S/ MICHAEL MIEBACH\n |  |  |  | Michael Miebach\n |  |  |  | President and Chief Executive Officer\n |  |  |  | (Principal Executive Officer)\n |  |  | \nDate: | April 27, 2023 | By: |  | /S/ SACHIN MEHRA\n |  |  |  | Sachin Mehra\n |  |  |  | Chief Financial Officer\n |  |  |  | (Principal Financial Officer)\n |  |  | \nDate: | April 27, 2023 | By: |  | /S/ SANDRA ARKELL\n |  |  |  | Sandra Arkell\n |  |  |  | Corporate Controller\n |  |  |  | (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Mastercard, in 2023 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  | \nDelaware | 13-4172551\n(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification Number)\n |  | \n2000 Purchase Street | 10577\nPurchase, | NY | (Zip Code)\n(Address of principal executive offices) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class |  | Trading Symbol |  | Name of each exchange of which registered\nClass A Common Stock, par value $0.0001 per share |  | MA |  | New York Stock Exchange\n2.1% Notes due 2027 |  | MA27 |  | New York Stock Exchange\n1.0% Notes due 2029 |  | MA29A |  | New York Stock Exchange\n2.5% Notes due 2030 |  | MA30 |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant (1)\u00a0has filed all reports required to be filed by Section\u00a013 or 15(d)\u00a0of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\u00a0has been subject to such filing requirements for the past 90 days. | Yes | \u2612 | No | \u2610\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files) | Yes | \u2612 | No | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of \u201clarge accelerated filer,\u201d \u201caccelerated filer,\u201d \u201csmaller reporting company,\u201d and \u201cemerging growth company\u201d in Rule 12b-2 of the Exchange Act. (Check One):\nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  |  | \nNon-accelerated filer | \u2610 |  | Smaller\u00a0reporting\u00a0company | \u2610 |  |  | \n |  |  | Emerging growth\u00a0company | \u2610 |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. | \u2610\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) | Yes | \u2610 | No | \u2612  |  | \n  |  |  |  |  |  |  |  |  |  |  | \n |  |  | \nPART I | 5 | Item 1. | Consolidated financial statements (unaudited)\n32 | Item 2. | Management\u2019s discussion and analysis of financial condition and results of operations\n47 | Item 3. | Quantitative and qualitative disclosures about market risk\n47 | Item 4. | Controls and procedures\n |  |  | \n |  |  | \nPART II | 50 | Item 1. | Legal proceedings\n50 | Item 1A. | Risk factors\n50 | Item 2. | Unregistered sales of equity securities and use of proceeds\n51 | Item 5. | Other information\n51 | Item 6. | Exhibits\n53 | - | Signatures\n |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART I |  |  | \n |  | Item 1. Consolidated financial statements (unaudited) |  | \n |  | Item 2. Management\u2019s discussion and analysis of financial condition and results of operations |  | \n |  | Item 3. Quantitative and qualitative disclosures about market risk |  | \n |  | Item 4. Controls and procedures |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  | \n |  | Page\nConsolidated Statement of Operations \u2014Three and Six Months Ended June 30, 2023and2022 |  | 6\nConsolidated Statement of Comprehensive Income \u2014Three and Six Months Ended June 30, 2023and2022 |  | 7\nConsolidated Balance Sheet \u2014June 30, 2023andDecember 31, 2022 |  | 8\nConsolidated Statement of Changes in Equity\u2014Three and Six Months Ended June 30, 2023and2022 |  | 9\nConsolidated Statement of Cash Flows \u2014Six Months Ended June 30, 2023and2022 |  | 11\nNotes to consolidated financial statements |  | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Operations (Unaudited) |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNet Revenue |  | $ | 6,269 |  |  | $ | 5,497 |  |  | $ | 12,017 |  |  | $ | 10,664 | \nOperating Expenses: |  |  |  |  |  |  |  | \nGeneral and administrative |  | 2,200 |  |  | 1,947 |  |  | 4,243 |  |  | 3,791 | \nAdvertising and marketing |  | 201 |  |  | 210 |  |  | 368 |  |  | 391 | \nDepreciation and amortization |  | 192 |  |  | 189 |  |  | 383 |  |  | 381 | \nProvision for litigation |  | 20 |  |  | 133 |  |  | 231 |  |  | 133 | \nTotal operating expenses |  | 2,613 |  |  | 2,479 |  |  | 5,225 |  |  | 4,696 | \nOperating income |  | 3,656 |  |  | 3,018 |  |  | 6,792 |  |  | 5,968 | \nOther Income (Expense): |  |  |  |  |  |  |  | \nInvestment income |  | 59 |  |  | 7 |  |  | 114 |  |  | 12 | \nGains (losses) on equity investments, net |  | 123 |  |  | (117) |  |  | (89) |  |  | (193) | \nInterest expense |  | (144) |  |  | (114) |  |  | (276) |  |  | (224) | \nOther income (expense), net |  | 10 |  |  | 4 |  |  | 16 |  |  | 8 | \nTotal other income (expense) |  | 48 |  |  | (220) |  |  | (235) |  |  | (397) | \nIncome before income taxes |  | 3,704 |  |  | 2,798 |  |  | 6,557 |  |  | 5,571 | \nIncome tax expense |  | 859 |  |  | 523 |  |  | 1,351 |  |  | 665 | \nNet Income |  | $ | 2,845 |  |  | $ | 2,275 |  |  | $ | 5,206 |  |  | $ | 4,906 | \nBasic Earnings per Share |  | $ | 3.01 |  |  | $ | 2.34 |  |  | $ | 5.48 |  |  | $ | 5.04 | \nBasic weighted-average shares outstanding |  | 946 |  |  | 971 |  |  | 949 |  |  | 974 | \nDiluted Earnings per Share |  | $ | 3.00 |  |  | $ | 2.34 |  |  | $ | 5.47 |  |  | $ | 5.02 | \nDiluted weighted-average shares outstanding |  | 949 |  |  | 974 |  |  | 952 |  |  | 977 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Comprehensive Income (Unaudited) |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in millions)\nNet Income |  | $ | 2,845 |  |  | $ | 2,275 |  |  | $ | 5,206 |  |  | $ | 4,906 | \nOther comprehensive income (loss): |  |  |  |  |  |  |  | \nForeign currency translation adjustments |  | 53 |  |  | (710) |  |  | 147 |  |  | (774) | \nIncome tax effect |  | \u2014 |  |  | 31 |  |  | (14) |  |  | 43 | \nForeign currency translation adjustments, net of income tax effect |  | 53 |  |  | (679) |  |  | 133 |  |  | (731) | \n |  |  |  |  |  |  |  | \nTranslation adjustments on net investment hedges |  | (11) |  |  | 314 |  |  | (85) |  |  | 400 | \nIncome tax effect |  | 2 |  |  | (70) |  |  | 19 |  |  | (89) | \nTranslation adjustments on net investment hedges, net of income tax effect |  | (9) |  |  | 244 |  |  | (66) |  |  | 311 | \n |  |  |  |  |  |  |  | \nCash flow hedges |  | (14) |  |  | 6 |  |  | (24) |  |  | 7 | \nIncome tax effect |  | 6 |  |  | (2) |  |  | 6 |  |  | (2) | \nReclassification adjustments for cash flow hedges |  | 9 |  |  | \u2014 |  |  | 17 |  |  | (5) | \nIncome tax effect |  | (5) |  |  | \u2014 |  |  | (4) |  |  | 1 | \nCash flow hedges, net of income tax effect |  | (4) |  |  | 4 |  |  | (5) |  |  | 1 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nReclassification adjustments for defined benefit pension and other postretirement plans |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) | \nIncome tax effect |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nDefined benefit pension and other postretirement plans, net of income tax effect |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) | \n |  |  |  |  |  |  |  | \nInvestment securities available-for-sale |  | \u2014 |  |  | (2) |  |  | 2 |  |  | (4) | \nIncome tax effect |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 | \nInvestment securities available-for-sale, net of income tax effect |  | \u2014 |  |  | (2) |  |  | 2 |  |  | (3) | \n |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of income tax effect |  | 40 |  |  | (434) |  |  | 64 |  |  | (423) | \nComprehensive Income |  | $ | 2,885 |  |  | $ | 1,841 |  |  | $ | 5,270 |  |  | $ | 4,483 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Balance Sheet (Unaudited) |  |  |  | \n |  | June 30, 2023 |  | December 31, 2022\n |  | (in\u00a0millions,\u00a0except\u00a0per share\u00a0data)\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 6,170 |  |  | $ | 7,008 | \nRestricted cash for litigation settlement |  | 598 |  |  | 589 | \nInvestments |  | 344 |  |  | 400 | \nAccounts receivable |  | 3,763 |  |  | 3,425 | \nSettlement assets |  | 1,378 |  |  | 1,270 | \nRestricted security deposits held for customers |  | 1,723 |  |  | 1,568 | \nPrepaid expenses and other current assets |  | 2,554 |  |  | 2,346 | \nTotal current assets |  | 16,530 |  |  | 16,606 | \nProperty, equipment and right-of-use assets, net of accumulated depreciation and amortizationof $2,082and $1,904, respectively |  | 1,986 |  |  | 2,006 | \nDeferred income taxes |  | 1,121 |  |  | 1,151 | \nGoodwill |  | 7,579 |  |  | 7,522 | \nOther intangible assets, net of accumulated amortization of $2,087and $1,960, respectively |  | 4,049 |  |  | 3,859 | \nOther assets |  | 7,739 |  |  | 7,580 | \nTotal Assets |  | $ | 39,004 |  |  | $ | 38,724 | \nLiabilities, Redeemable Non-controlling Interests and Equity |  |  |  | \nCurrent liabilities: |  |  |  | \nAccounts payable |  | $ | 643 |  |  | $ | 926 | \nSettlement obligations |  | 1,142 |  |  | 1,111 | \nRestricted security deposits held for customers |  | 1,723 |  |  | 1,568 | \nAccrued litigation |  | 1,079 |  |  | 1,094 | \nAccrued expenses |  | 7,117 |  |  | 7,801 | \nShort-term debt |  | 1,336 |  |  | 274 | \nOther current liabilities |  | 1,596 |  |  | 1,397 | \nTotal current liabilities |  | 14,636 |  |  | 14,171 | \nLong-term debt |  | 14,284 |  |  | 13,749 | \nDeferred income taxes |  | 395 |  |  | 393 | \nOther liabilities |  | 4,110 |  |  | 4,034 | \nTotal Liabilities |  | 33,425 |  |  | 32,347 | \nCommitments and Contingencies |  |  |  | \nRedeemable Non-controlling Interests |  | 22 |  |  | 21 | \nStockholders\u2019 Equity |  |  |  | \nClass\u00a0A common stock, $0.0001par value; authorized3,000shares,1,401and1,399shares issued and936and948shares outstanding, respectively |  | \u2014 |  |  | \u2014 | \nClass B common stock, $0.0001par value; authorized1,200shares,7and8shares issued and outstanding, respectively |  | \u2014 |  |  | \u2014 | \nAdditional paid-in-capital |  | 5,622 |  |  | 5,298 | \nClass\u00a0A treasury stock, at cost,465and451shares, respectively |  | (56,659) |  |  | (51,354) | \nRetained earnings |  | 57,730 |  |  | 53,607 | \nAccumulated other comprehensive income (loss) |  | (1,189) |  |  | (1,253) | \nMastercard Incorporated Stockholders' Equity |  | 5,504 |  |  | 6,298 | \nNon-controlling interests |  | 53 |  |  | 58 | \nTotal Equity |  | 5,557 |  |  | 6,356 | \nTotal Liabilities, Redeemable Non-controlling Interests and Equity |  | $ | 39,004 |  |  | $ | 38,724 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Changes in Equity (Unaudited)\n |  | Three Months Ended June 30, 2023\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders\u2019 Equity |  | Non-ControllingInterests |  | Total Equity\n |  | Class A |  | Class B |  |  |  | \n |  | (in millions)\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at March 31, 2023 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,376 |  |  | $ | (54,241) |  |  | $ | 55,424 |  |  | $ | (1,229) |  |  | $ | 5,330 |  |  | $ | 56 |  |  | $ | 5,386 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,845 |  |  | \u2014 |  |  | 2,845 |  |  | \u2014 |  |  | 2,845 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3) |  |  | (3) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 40 |  |  | 40 |  |  | \u2014 |  |  | 40 | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (538) |  |  | \u2014 |  |  | (538) |  |  | \u2014 |  |  | (538) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,423) |  |  | \u2014 |  |  | \u2014 |  |  | (2,423) |  |  | \u2014 |  |  | (2,423) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 246 |  |  | 5 |  |  | \u2014 |  |  | \u2014 |  |  | 251 |  |  | \u2014 |  |  | 251 | \nBalance at June 30, 2023 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,622 |  |  | $ | (56,659) |  |  | $ | 57,730 |  |  | $ | (1,189) |  |  | $ | 5,504 |  |  | $ | 53 |  |  | $ | 5,557 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Six Months Ended June 30, 2023\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,298 |  |  | $ | (51,354) |  |  | $ | 53,607 |  |  | $ | (1,253) |  |  | $ | 6,298 |  |  | $ | 58 |  |  | $ | 6,356 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 5,206 |  |  | \u2014 |  |  | 5,206 |  |  | \u2014 |  |  | 5,206 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (5) |  |  | (5) | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (4) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 64 |  |  | 64 |  |  | \u2014 |  |  | 64 | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,079) |  |  | \u2014 |  |  | (1,079) |  |  | \u2014 |  |  | (1,079) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (5,317) |  |  | \u2014 |  |  | \u2014 |  |  | (5,317) |  |  | \u2014 |  |  | (5,317) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 324 |  |  | 12 |  |  | \u2014 |  |  | \u2014 |  |  | 336 |  |  | \u2014 |  |  | 336 | \nBalance at June 30, 2023 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,622 |  |  | $ | (56,659) |  |  | $ | 57,730 |  |  | $ | (1,189) |  |  | $ | 5,504 |  |  | $ | 53 |  |  | $ | 5,557 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Changes in Equity (Unaudited) - (Continued)\n |  | Three Months Ended June 30, 2022\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders\u2019 Equity |  | Non-ControllingInterests |  | Total Equity\n |  | Class A |  | Class B |  |  |  | \n |  | (in millions)\nBalance at March 31, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,026 |  |  | $ | (44,994) |  |  | $ | 47,800 |  |  | $ | (798) |  |  | $ | 7,034 |  |  | $ | 68 |  |  | $ | 7,102 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,275 |  |  | \u2014 |  |  | 2,275 |  |  | \u2014 |  |  | 2,275 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3) |  |  | (3) | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (434) |  |  | (434) |  |  | \u2014 |  |  | (434) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (474) |  |  | \u2014 |  |  | (474) |  |  | \u2014 |  |  | (474) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,365) |  |  | \u2014 |  |  | \u2014 |  |  | (2,365) |  |  | \u2014 |  |  | (2,365) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 137 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 137 |  |  | \u2014 |  |  | 137 | \nBalance at June 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,163 |  |  | $ | (47,359) |  |  | $ | 49,599 |  |  | $ | (1,232) |  |  | $ | 6,171 |  |  | $ | 65 |  |  | $ | 6,236 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2022\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,061 |  |  | $ | (42,588) |  |  | $ | 45,648 |  |  | $ | (809) |  |  | $ | 7,312 |  |  | $ | 71 |  |  | $ | 7,383 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4,906 |  |  | \u2014 |  |  | 4,906 |  |  | \u2014 |  |  | 4,906 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (6) |  |  | (6) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (4) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (423) |  |  | (423) |  |  | \u2014 |  |  | (423) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (951) |  |  | \u2014 |  |  | (951) |  |  | \u2014 |  |  | (951) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,776) |  |  | \u2014 |  |  | \u2014 |  |  | (4,776) |  |  | \u2014 |  |  | (4,776) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 102 |  |  | 5 |  |  | \u2014 |  |  | \u2014 |  |  | 107 |  |  | \u2014 |  |  | 107 | \nBalance at June 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,163 |  |  | $ | (47,359) |  |  | $ | 49,599 |  |  | $ | (1,232) |  |  | $ | 6,171 |  |  | $ | 65 |  |  | $ | 6,236 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Cash Flows (Unaudited) |  |  |  | \n |  | Six Months Ended June 30,\n |  | 2023 |  | 2022\n |  | (in millions)\nOperating Activities |  |  |  | \nNet income |  | $ | 5,206 |  |  | $ | 4,906 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  |  | \nAmortization of customer and merchant incentives |  | 782 |  |  | 812 | \nDepreciation and amortization |  | 383 |  |  | 381 | \n(Gains) losses on equity investments, net |  | 89 |  |  | 193 | \nShare-based compensation |  | 243 |  |  | 175 | \nDeferred income taxes |  | 24 |  |  | (466) | \nOther |  | 37 |  |  | 18 | \nChanges in operating assets and liabilities: |  |  |  | \nAccounts receivable |  | (268) |  |  | (257) | \n |  |  |  | \nSettlement assets |  | (108) |  |  | 255 | \nPrepaid expenses |  | (1,286) |  |  | (1,033) | \nAccrued litigation and legal settlements |  | (20) |  |  | 85 | \nRestricted security deposits held for customers |  | 155 |  |  | (252) | \nAccounts payable |  | (287) |  |  | (110) | \nSettlement obligations |  | 31 |  |  | (239) | \n |  |  |  | \nAccrued expenses |  | (707) |  |  | (282) | \n |  |  |  | \nNet change in other assets and liabilities |  | 343 |  |  | 53 | \nNet cash provided by operating activities |  | 4,617 |  |  | 4,239 | \nInvesting Activities |  |  |  | \nPurchases of investment securities available-for-sale |  | (157) |  |  | (124) | \nPurchases of investments held-to-maturity |  | (31) |  |  | (139) | \nProceeds from sales of investment securities available-for-sale |  | 45 |  |  | 14 | \nProceeds from maturities of investment securities available-for-sale |  | 102 |  |  | 113 | \nProceeds from maturities of investments held-to-maturity |  | 91 |  |  | 160 | \nPurchases of property and equipment |  | (190) |  |  | (201) | \nCapitalized software |  | (395) |  |  | (280) | \nPurchases of equity investments |  | (53) |  |  | (43) | \nProceeds from sales of equity investments |  | 44 |  |  | 6 | \nAcquisition of businesses, net of cash acquired |  | \u2014 |  |  | (313) | \n |  |  |  | \nOther investing activities |  | (71) |  |  | (5) | \nNet cash used in investing activities |  | (615) |  |  | (812) | \nFinancing Activities |  |  |  | \nPurchases of treasury stock |  | (5,294) |  |  | (4,788) | \nDividends paid |  | (1,086) |  |  | (956) | \nProceeds from debt, net |  | 1,550 |  |  | 843 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nTax withholdings related to share-based payments |  | (79) |  |  | (136) | \nCash proceeds from exercise of stock options |  | 172 |  |  | 68 | \nOther financing activities |  | 3 |  |  | (6) | \nNet cash used in financing activities |  | (4,734) |  |  | (4,975) | \nEffect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents |  | 57 |  |  | (202) | \nNet decrease in cash, cash equivalents, restricted cash and restricted cash equivalents |  | (675) |  |  | (1,750) | \nCash, cash equivalents, restricted cash and restricted cash equivalents - beginning of period |  | 9,196 |  |  | 9,902 | \nCash, cash equivalents, restricted cash and restricted cash equivalents - end of period |  | $ | 8,521 |  |  | $ | 8,152 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in millions)\nNet revenue by category: |  |  |  |  |  |  |  | \nPayment network |  | $ | 4,073 |  |  | $ | 3,609 |  |  | $ | 7,723 |  |  | $ | 7,008 | \nValue-added services and solutions |  | 2,196 |  |  | 1,888 |  |  | 4,294 |  |  | 3,656 | \nNet revenue |  | $ | 6,269 |  |  | $ | 5,497 |  |  | $ | 12,017 |  |  | $ | 10,664 | \nNet revenue by geographic region: |  |  |  |  |  |  |  | \nNorth American Markets1 |  | $ | 2,138 |  |  | $ | 2,008 |  |  | $ | 4,034 |  |  | $ | 3,738 | \nInternational Markets |  | 4,131 |  |  | 3,489 |  |  | 7,983 |  |  | 6,926 | \nNet revenue |  | $ | 6,269 |  |  | $ | 5,497 |  |  | $ | 12,017 |  |  | $ | 10,664 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2023 |  | December 31,2022\n |  | (in millions)\nReceivables from contracts with customers |  |  |  | \nAccounts receivable |  | $ | 3,531 |  |  | $ | 3,213 | \nContract assets |  |  |  | \nPrepaid expenses and other current assets |  | 108 |  |  | 118 | \nOther assets |  | 421 |  |  | 442 | \nDeferred revenue1 |  |  |  | \nOther current liabilities |  | 567 |  |  | 434 | \nOther liabilities |  | 290 |  |  | 248 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNumerator |  |  |  |  |  |  |  | \nNet income |  | $ | 2,845 |  |  | $ | 2,275 |  |  | $ | 5,206 |  |  | $ | 4,906 | \nDenominator |  |  |  |  |  |  |  | \nBasic weighted-average shares outstanding |  | 946 |  |  | 971 |  |  | 949 |  |  | 974 | \nDilutive stock options and stock units |  | 2 |  |  | 3 |  |  | 3 |  |  | 3 | \nDiluted weighted-average shares outstanding1 |  | 949 |  |  | 974 |  |  | 952 |  |  | 977 | \nEarnings per Share |  |  |  |  |  |  |  | \nBasic |  | $ | 3.01 |  |  | $ | 2.34 |  |  | $ | 5.48 |  |  | $ | 5.04 | \nDiluted |  | $ | 3.00 |  |  | $ | 2.34 |  |  | $ | 5.47 |  |  | $ | 5.02 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2023 |  | December 31,2022\n |  | (in millions)\nCash and cash equivalents |  | $ | 6,170 |  |  | $ | 7,008 | \nRestricted cash and restricted cash equivalents |  |  |  | \nRestricted cash for litigation settlement |  | 598 |  |  | 589 | \nRestricted security deposits held for customers |  | 1,723 |  |  | 1,568 | \nPrepaid expenses and other current assets |  | 30 |  |  | 31 | \n |  |  |  | \nCash, cash equivalents, restricted cash and restricted cash equivalents |  | $ | 8,521 |  |  | $ | 9,196 | \n |  |  |  | \n |  | \n |  |  |  | \n |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2023 |  | December 31,2022\n |  | (in millions)\nAvailable-for-sale securities1 |  | $ | 279 |  |  | $ | 272 | \nHeld-to-maturity securities2 |  | 65 |  |  | 128 | \nTotal investments |  | $ | 344 |  |  | $ | 400 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2023 |  | December 31, 2022\n |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue\n |  | (in millions)\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGovernment and agency securities |  | $ | 100 |  |  | $ | \u2014 |  |  | $ | (1) |  |  | $ | 99 |  |  | $ | 91 |  |  | $ | \u2014 |  |  | $ | (2) |  |  | $ | 89 | \nCorporate securities |  | 183 |  |  | \u2014 |  |  | (3) |  |  | 180 |  |  | 187 |  |  | \u2014 |  |  | (4) |  |  | 183 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal |  | $ | 283 |  |  | $ | \u2014 |  |  | $ | (4) |  |  | $ | 279 |  |  | $ | 278 |  |  | $ | \u2014 |  |  | $ | (6) |  |  | $ | 272 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | \n |  | Amortized Cost |  | Fair\u00a0Value\n |  | (in millions)\nDue within 1 year |  | $ | 167 |  |  | $ | 166 | \nDue after 1 year through 5 years |  | 116 |  |  | 113 | \n |  |  |  | \nTotal |  | $ | 283 |  |  | $ | 279 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Balance at December 31, 2022 |  | Purchases |  | Sales |  | Changes in Fair Value1 |  | Other2 |  | Balance at June 30, 2023\n |  | (in millions)\nMarketable securities |  | $ | 399 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 55 |  |  | $ | 8 |  |  | $ | 462 | \nNonmarketable securities |  | 1,331 |  |  | 53 |  |  | (44) |  |  | (144) |  |  | 6 |  |  | 1,202 | \nTotal equity investments |  | $ | 1,730 |  |  | $ | 53 |  |  | $ | (44) |  |  | $ | (89) |  |  | $ | 14 |  |  | $ | 1,664 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2023 |  | December 31,2022\n |  | (in millions)\nMeasurement alternative |  | $ | 991 |  |  | $ | 1,087 | \nEquity method |  | 211 |  |  | 244 | \nTotal Nonmarketable securities |  | $ | 1,202 |  |  | $ | 1,331 |   |  |  |  |  |  |  |  | \n |  | \n |  | (in millions)\nInitial cost basis |  | $ | 529 | \nCumulative adjustments1: |  | \nUpward adjustments |  | 629 | \nDownward adjustments (including impairment) |  | (167) | \nCarrying amount, end of period |  | $ | 991 | \n |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in millions)\nMeasurement alternative investments: |  |  |  |  |  |  |  | \nUpward adjustments |  | $ | 6 |  |  | $ | 17 |  |  | $ | 6 |  |  | $ | 103 | \nDownward adjustments (including impairment) |  | (2) |  |  | (12) |  |  | (135) |  |  | (12) | \nMarketable securities: |  |  |  |  |  |  |  | \nUnrealized gains (losses), net |  | 121 |  |  | (126) |  |  | 55 |  |  | (288) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2023 |  | December 31, 2022\n |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total\n |  | (in millions)\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestment securities available-for-sale1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGovernment and agency securities |  | $ | 39 |  |  | $ | 60 |  |  | $ | \u2014 |  |  | $ | 99 |  |  | $ | 35 |  |  | $ | 54 |  |  | $ | \u2014 |  |  | $ | 89 | \nCorporate securities |  | \u2014 |  |  | 180 |  |  | \u2014 |  |  | 180 |  |  | \u2014 |  |  | 183 |  |  | \u2014 |  |  | 183 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | \u2014 |  |  | 49 |  |  | \u2014 |  |  | 49 |  |  | \u2014 |  |  | 108 |  |  | \u2014 |  |  | 108 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMarketable securities3: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nEquity securities |  | 462 |  |  | \u2014 |  |  | \u2014 |  |  | 462 |  |  | 399 |  |  | \u2014 |  |  | \u2014 |  |  | 399 | \nDeferred compensation plan4: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation assets |  | 86 |  |  | \u2014 |  |  | \u2014 |  |  | 86 |  |  | 74 |  |  | \u2014 |  |  | \u2014 |  |  | 74 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | \u2014 |  |  | $ | 55 |  |  | $ | \u2014 |  |  | $ | 55 |  |  | $ | \u2014 |  |  | $ | 21 |  |  | $ | \u2014 |  |  | $ | 21 | \nInterest rate contracts |  | \u2014 |  |  | 105 |  |  | \u2014 |  |  | 105 |  |  | \u2014 |  |  | 105 |  |  | \u2014 |  |  | 105 | \nDeferred compensation plan5: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation liabilities |  | 84 |  |  | \u2014 |  |  | \u2014 |  |  | 84 |  |  | 73 |  |  | \u2014 |  |  | \u2014 |  |  | 73 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2023 |  | December 31,2022\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 1,472 |  |  | $ | 1,392 | \nPrepaid income taxes |  | 65 |  |  | 34 | \nOther |  | 1,017 |  |  | 920 | \nTotal prepaid expenses and other current assets |  | $ | 2,554 |  |  | $ | 2,346 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2023 |  | December 31,2022\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 4,778 |  |  | $ | 4,578 | \nEquity investments |  | 1,664 |  |  | 1,730 | \nIncome taxes receivable |  | 656 |  |  | 633 | \nOther |  | 641 |  |  | 639 | \nTotal other assets |  | $ | 7,739 |  |  | $ | 7,580 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2023 |  | December 31,2022\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 5,397 |  |  | $ | 5,600 | \nPersonnel costs |  | 754 |  |  | 1,322 | \nIncome and other taxes |  | 449 |  |  | 279 | \nOther |  | 517 |  |  | 600 | \nTotal accrued expenses |  | $ | 7,117 |  |  | $ | 7,801 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | June 30,2023 |  | December 31,2022 |  | EffectiveInterest Rate\n |  |  |  |  | (in millions) |  | \nSenior Notes |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n2023 USD Notes |  | 4.875 | % | Senior Notes due March 2028 |  | $ | 750 |  |  | $ | \u2014 |  |  | 5.003 | %\n |  | 4.850 | % | Senior Notes due March 2033 |  | 750 |  |  | \u2014 |  |  | 4.923 | %\n |  |  |  |  |  |  |  |  | \n2022 EUR Notes1 |  | 1.000 | % | Senior Notes due February 2029 |  | 817 |  |  | 800 |  |  | 1.138 | %\n |  |  |  |  |  |  |  |  | \n2021 USD Notes |  | 2.000 | % | Senior Notes due November 2031 |  | 750 |  |  | 750 |  |  | 2.112 | %\n |  | 1.900 | % | Senior Notes due March 2031 |  | 600 |  |  | 600 |  |  | 1.981 | %\n |  | 2.950 | % | Senior Notes due March 2051 |  | 700 |  |  | 700 |  |  | 3.013 | %\n |  |  |  |  |  |  |  |  | \n2020 USD Notes |  | 3.300 | % | Senior Notes due March 2027 |  | 1,000 |  |  | 1,000 |  |  | 3.420 | %\n |  | 3.350 | % | Senior Notes due March 2030 |  | 1,500 |  |  | 1,500 |  |  | 3.430 | %\n |  | 3.850 | % | Senior Notes due March 2050 |  | 1,500 |  |  | 1,500 |  |  | 3.896 | %\n |  |  |  |  |  |  |  |  | \n2019 USD Notes |  | 2.950 | % | Senior Notes due June 2029 |  | 1,000 |  |  | 1,000 |  |  | 3.030 | %\n |  | 3.650 | % | Senior Notes due June 2049 |  | 1,000 |  |  | 1,000 |  |  | 3.689 | %\n |  | 2.000 | % | Senior Notes due March 2025 |  | 750 |  |  | 750 |  |  | 2.147 | %\n |  |  |  |  |  |  |  |  | \n2018 USD Notes |  | 3.500 | % | Senior Notes due February 2028 |  | 500 |  |  | 500 |  |  | 3.598 | %\n |  | 3.950 | % | Senior Notes due February 2048 |  | 500 |  |  | 500 |  |  | 3.990 | %\n |  |  |  |  |  |  |  |  | \n2016 USD Notes |  | 2.950 | % | Senior Notes due November 2026 |  | 750 |  |  | 750 |  |  | 3.044 | %\n |  | 3.800 | % | Senior Notes due November 2046 |  | 600 |  |  | 600 |  |  | 3.893 | %\n |  |  |  |  |  |  |  |  | \n2015 EUR Notes2 |  | 2.100 | % | Senior Notes due December 2027 |  | 872 |  |  | 854 |  |  | 2.189 | %\n |  | 2.500 | % | Senior Notes due December 2030 |  | 163 |  |  | 160 |  |  | 2.562 | %\n |  |  |  |  |  |  |  |  | \n2014 USD Notes |  | 3.375 | % | Senior Notes due April 2024 |  | 1,000 |  |  | 1,000 |  |  | 3.484 | %\n |  |  |  |  |  |  |  |  | \nOther Debt |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \nApril 2023 INR Term Loan3 |  | 9.480 | % | Term Loan due July 2023 |  | 61 |  |  | \u2014 |  |  | 9.705 | %\n |  |  |  |  |  |  |  |  | \n2022 INR Term Loan4 |  | 8.640 | % | Term Loan due July 2023 |  | 277 |  |  | 275 |  |  | 9.090 | %\n |  |  |  |  |  |  |  |  | \n |  |  |  |  | 15,840 |  |  | 14,239 |  |  | \nLess: Unamortized discount and debt issuance costs | (115) |  |  | (111) |  |  | \nLess: Cumulative hedge accounting fair value adjustments5 |  | (105) |  |  | (105) |  |  | \nTotal debt outstanding | 15,620 |  |  | 14,023 |  |  | \nLess: Short-term debt6 |  | (1,336) |  |  | (274) |  |  | \nLong-term debt | $ | 14,284 |  |  | $ | 13,749 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nDividends declared per share |  | $ | 0.57 |  |  | $ | 0.49 |  |  | $ | 1.14 |  |  | $ | 0.98 | \nTotal dividends declared |  | $ | 538 |  |  | $ | 474 |  |  | $ | 1,079 |  |  | $ | 951 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30,\n |  | 2023 |  | 2022\n |  | Outstanding Shares |  | Outstanding Shares\n |  | Class\u00a0A |  | Class\u00a0B |  | Class\u00a0A |  | Class\u00a0B\n |  | (in millions)\nBalance at beginning of period |  | 941.4 |  |  | 7.5 |  |  | 966.5 |  |  | 7.7 | \nPurchases of treasury stock |  | (6.5) |  |  | \u2014 |  |  | (6.9) |  |  | \u2014 | \nShare-based payments |  | 0.9 |  |  | \u2014 |  |  | 0.4 |  |  | \u2014 | \nConversion of Class B to Class A common stock |  | 0.1 |  |  | (0.1) |  |  | \u2014 |  |  | \u2014 | \nBalance at end of period |  | 935.9 |  |  | 7.4 |  |  | 960.0 |  |  | 7.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30,\n |  | 2023 |  | 2022\n |  | Outstanding Shares |  | Outstanding Shares\n |  | Class\u00a0A |  | Class\u00a0B |  | Class\u00a0A |  | Class\u00a0B\n |  | (in millions)\nBalance at beginning of period |  | 948.4 |  |  | 7.6 |  |  | 972.1 |  |  | 7.8 | \nPurchases of treasury stock |  | (14.4) |  |  | \u2014 |  |  | (13.7) |  |  | \u2014 | \nShare-based payments |  | 1.7 |  |  | \u2014 |  |  | 1.5 |  |  | \u2014 | \nConversion of Class B to Class A common stock |  | 0.2 |  |  | (0.2) |  |  | 0.1 |  |  | (0.1) | \nBalance at end of period |  | 935.9 |  |  | 7.4 |  |  | 960.0 |  |  | 7.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30,\n |  | 2023 |  | 2022\n |  | (in millions, except per share data)\nDollar-value of shares repurchased1 |  | $ | 5,294 |  |  | $ | 4,788 | \nShares repurchased |  | 14.4 |  |  | 13.7 | \nAverage price paid per share |  | $ | 367.00 |  |  | $ | 350.10 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2022 |  | Increase / (Decrease) |  | Reclassifications |  | June 30, 2023\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (1,414) |  |  | $ | 133 |  |  | $ | \u2014 |  |  | $ | (1,281) | \nTranslation adjustments on net investment hedges2 |  | 309 |  |  | (66) |  |  | \u2014 |  |  | 243 | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | (8) |  |  | (18) |  |  | 11 |  |  | (15) | \nInterest rate contracts |  | (123) |  |  | \u2014 |  |  | 2 |  |  | (121) | \nDefined benefit pension and other postretirement plans |  | (11) |  |  | \u2014 |  |  | \u2014 |  |  | (11) | \nInvestment securities available-for-sale |  | (6) |  |  | 2 |  |  | \u2014 |  |  | (4) | \nAccumulated other comprehensive income (loss) |  | $ | (1,253) |  |  | $ | 51 |  |  | $ | 13 |  |  | $ | (1,189) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2021 |  | Increase / (Decrease) |  | Reclassifications |  | June 30, 2022\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (739) |  |  | $ | (731) |  |  | $ | \u2014 |  |  | $ | (1,470) | \nTranslation adjustments on net investment hedges2 |  | 34 |  |  | 311 |  |  | \u2014 |  |  | 345 | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | 4 |  |  | 5 |  |  | (6) |  |  | 3 | \nInterest rate contracts |  | (128) |  |  | \u2014 |  |  | 2 |  |  | (126) | \nDefined benefit pension and other postretirement plans |  | 21 |  |  | \u2014 |  |  | (1) |  |  | 20 | \nInvestment securities available-for-sale |  | (1) |  |  | (3) |  |  | \u2014 |  |  | (4) | \nAccumulated other comprehensive income (loss) |  | $ | (809) |  |  | $ | (418) |  |  | $ | (5) |  |  | $ | (1,232) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Grants in 2023 |  | Weighted-AverageGrant-DateFair Value\n |  | (in millions) |  | (per option/unit)\nNon-qualified stock options |  | 0.3 |  | $ | 123 | \nRestricted stock units |  | 1.1 |  | $ | 349 | \nPerformance stock units |  | 0.2 |  | $ | 365 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30,2023 |  | December 31, 2022\n |  | (in millions)\nGross settlement exposure |  | $ | 70,079 |  |  | $ | 64,885 | \nRisk mitigation arrangements applied to settlement exposure1 |  | (10,568) |  |  | (9,224) | \nNet settlement exposure1 |  | $ | 59,511 |  |  | $ | 55,661 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2023 |  | December 31, 2022\n |  | Notional |  | Derivative assets |  | Derivative liabilities |  | Notional |  | Derivative assets |  | Derivative liabilities\n |  | (in millions)\nDerivatives designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts in a cash flow hedge1 |  | $ | 714 |  |  | $ | 5 |  |  | $ | 26 |  |  | $ | 642 |  |  | $ | 4 |  |  | $ | 15 | \nInterest rate contracts in a fair value hedge2 |  | 1,000 |  |  | \u2014 |  |  | 105 |  |  | 1,000 |  |  | \u2014 |  |  | 105 | \nForeign exchange contracts in a net investment hedge1 |  | 2,235 |  |  | 12 |  |  | 17 |  |  | 1,814 |  |  | 103 |  |  | 4 | \nDerivatives not designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts1 |  | 2,193 |  |  | 32 |  |  | 12 |  |  | 521 |  |  | 1 |  |  | 2 | \nTotal derivative assets/liabilities |  | $ | 6,142 |  |  | $ | 49 |  |  | $ | 160 |  |  | $ | 3,977 |  |  | $ | 108 |  |  | $ | 126 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Gain (Loss)Recognized in OCI |  |  |  | Gain (Loss)Reclassified from AOCI\n |  | Three Months Ended June 30, |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Three Months Ended June 30,\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022\n |  | (in millions) |  |  | (in millions)\nDerivative financial instruments in a cash flow hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | (14) |  |  | $ | 6 |  |  | Net revenue |  | $ | (8) |  |  | $ | 1 | \nInterest rate contracts |  | $ | \u2014 |  |  | $ | \u2014 |  |  | Interest expense |  | $ | (1) |  |  | $ | (1) | \n |  |  |  |  |  |  |  |  |  | \nDerivative financial instruments in a net investment hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | (7) |  |  | $ | 166 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Gain (Loss)Recognized in OCI |  |  |  | Gain (Loss)Reclassified from AOCI\n |  | Six Months Ended June 30, |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Six Months Ended June 30,\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022\n |  | (in millions) |  |  | (in millions)\nDerivative financial instruments in a cash flow hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | (24) |  |  | $ | 7 |  |  | Net revenue |  | $ | (14) |  |  | $ | 8 | \nInterest rate contracts |  | $ | \u2014 |  |  | $ | \u2014 |  |  | Interest expense |  | $ | (3) |  |  | $ | (3) | \n |  |  |  |  |  |  |  |  |  | \nDerivative financial instruments in a net investment hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | (46) |  |  | $ | 201 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\nDerivatives not designated as hedging instruments: |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in millions)\nForeign exchange derivative contracts |  |  |  |  |  |  |  | \nGeneral and administrative |  | $ | 10 |  |  | $ | 12 |  |  | $ | 25 |  |  | $ | 13 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/(Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease)\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  | ($ in millions, except per share data)\nNet revenue |  | $ | 6,269 |  |  | $ | 5,497 |  |  | 14% |  | $ | 12,017 |  |  | $ | 10,664 |  |  | 13%\nOperating expenses |  | $ | 2,613 |  |  | $ | 2,479 |  |  | 5% |  | $ | 5,225 |  |  | $ | 4,696 |  |  | 11%\nOperating income |  | $ | 3,656 |  |  | $ | 3,018 |  |  | 21% |  | $ | 6,792 |  |  | $ | 5,968 |  |  | 14%\nOperating margin |  | 58.3 | % |  | 54.9 | % |  | 3.4 ppt |  | 56.5 | % |  | 56.0 | % |  | 0.6 ppt\nIncome tax expense |  | $ | 859 |  |  | $ | 523 |  |  | 64% |  | $ | 1,351 |  |  | $ | 665 |  |  | **\nEffective income tax rate |  | 23.2 | % |  | 18.7 | % |  | 4.5 ppt |  | 20.6 | % |  | 11.9 | % |  | 8.7 ppt\nNet income |  | $ | 2,845 |  |  | $ | 2,275 |  |  | 25% |  | $ | 5,206 |  |  | $ | 4,906 |  |  | 6%\nDiluted earnings per share |  | $ | 3.00 |  |  | $ | 2.34 |  |  | 28% |  | $ | 5.47 |  |  | $ | 5.02 |  |  | 9%\nDiluted weighted-average shares outstanding |  | 949 |  |  | 974 |  |  | (3)% |  | 952 |  |  | 977 |  |  | (3)%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Increase/(Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease)\n | 2023 |  | 2022 |  | As adjusted |  | Currency-neutral |  | 2023 |  | 2022 |  | As adjusted |  | Currency-neutral\n | ($ in millions, except per share data)\nAdjusted net revenue | $ | 6,269 |  |  | $ | 5,491 |  |  | 14% |  | 15% |  | $ | 12,017 |  |  | $ | 10,627 |  |  | 13% |  | 15%\nAdjusted operating expenses | $ | 2,592 |  |  | $ | 2,313 |  |  | 12% |  | 13% |  | $ | 4,993 |  |  | $ | 4,496 |  |  | 11% |  | 12%\nAdjusted operating margin | 58.6 | % |  | 57.9 | % |  | 0.8 ppt |  | 0.8 ppt |  | 58.4 | % |  | 57.7 | % |  | 0.7 ppt |  | 0.9 ppt\nAdjusted effective income tax rate | 23.9 | % |  | 18.8 | % |  | 5.1 ppt |  | 5.1 ppt |  | 21.2 | % |  | 12.3 | % |  | 8.9 ppt |  | 9.0 ppt\nAdjusted net income | $ | 2,742 |  |  | $ | 2,497 |  |  | 10% |  | 11% |  | $ | 5,420 |  |  | $ | 5,199 |  |  | 4% |  | 6%\nAdjusted diluted earnings per share | $ | 2.89 |  |  | $ | 2.56 |  |  | 13% |  | 14% |  | $ | 5.69 |  |  | $ | 5.32 |  |  | 7% |  | 9%  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | Adjusted net revenue | \nThree Months Ended June 30, 2023 | \nGAAP |  | Non-GAAP(currency-neutral) | Adjusted net revenue increased 15% on a currency-neutral basis.  The increase was attributable to growth in both our payment network and value-added services and solutions.\nup 14% |  | up 15%\n |  |  | \nSix Months Ended June 30, 2023 | \nGAAP |  | Non-GAAP(currency-neutral) | Adjusted net revenue increased 15% on a currency-neutral basis.  The increase was attributable to growth in both our payment network and value-added services and solutions.\nup 13% |  | up 15%\n |  |  |   |  |  |  |  |  |  |  |  |  |  | \nOperating expenses |  | Adjustedoperating expenses | \nThree Months Ended June 30, 2023 | \nGAAP |  | Non-GAAP(currency-neutral) | Adjusted operating expenses increased 13% on a currency-neutral basis.  The increase was primarily due to higher personnel costs.\nup 5% |  | up 13%\n |  |  | \nSix Months Ended June 30, 2023 | \nGAAP |  | Non-GAAP(currency-neutral) | Adjusted operating expenses increased 12% on a currency-neutral basis, which includes 1 percentage point of growth due to acquisitions.  The remaining increase was primarily due to higher personnel costs.\nup 11% |  | up 12%  |  |  |  |  |  |  |  |  |  |  | \nEffective incometax rate |  | Adjusted effectiveincome tax rate | \nThree Months Ended June 30, 2023 | The adjusted effective income tax rate of 23.9% was higher than the prior year rate of 18.8% primarily due to the establishment of a valuation allowance in 2023 of $212 million and the U.K. statutory tax rate increase, effective in 2023.\nGAAP |  | Non-GAAP\n23.2% |  | 23.9%\n |  | \nSix Months Ended June 30, 2023 | The adjusted effective income tax rate of 21.2% was higher than the prior year rate of 12.3% primarily due to the establishment of a $212 million valuation allowance in 2023 and the release of a $333 million valuation allowance in 2022.  The U.K. statutory tax rate increase, effective in 2023, also contributed to the higher adjusted effective income tax rate in 2023.\nGAAP |  | Non-GAAP\n20.6% |  | 21.2%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, 2023\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 6,269 |  |  | $ | 2,613 |  |  | 58.3 | % |  | $ | 48 |  |  | 23.2 | % |  | $ | 2,845 |  |  | $ | 3.00 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | (123) |  |  | 0.7 | % |  | (118) |  |  | (0.12) | \nLitigation provisions |  | ** |  | (20) |  |  | 0.3 | % |  | ** |  | \u2014 | % |  | 15 |  |  | 0.02 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | $ | 6,269 |  |  | $ | 2,592 |  |  | 58.6 | % |  | $ | (75) |  |  | 23.9 | % |  | $ | 2,742 |  |  | $ | 2.89 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2023\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 12,017 |  |  | $ | 5,225 |  |  | 56.5 | % |  | $ | (235) |  |  | 20.6 | % |  | $ | 5,206 |  |  | $ | 5.47 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 89 |  |  | 0.2 | % |  | 58 |  |  | 0.06 | \nLitigation provisions |  | ** |  | (231) |  |  | 1.9 | % |  | ** |  | 0.4 | % |  | 156 |  |  | 0.16 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | $ | 12,017 |  |  | $ | 4,993 |  |  | 58.4 | % |  | $ | (146) |  |  | 21.2 | % |  | $ | 5,420 |  |  | $ | 5.69 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, 2022\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 5,497 |  |  | $ | 2,479 |  |  | 54.9 | % |  | $ | (220) |  |  | 18.7 | % |  | $ | 2,275 |  |  | $ | 2.34 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 117 |  |  | (0.6) | % |  | 113 |  |  | 0.12 | \nLitigation provisions |  | ** |  | (133) |  |  | 2.4 | % |  | ** |  | 0.7 | % |  | 89 |  |  | 0.09 | \nRussia-related impacts |  | (6) |  |  | (33) |  |  | 0.5 | % |  | ** |  | \u2014 | % |  | 20 |  |  | 0.02 | \nAdjusted - Non-GAAP |  | $ | 5,491 |  |  | $ | 2,313 |  |  | 57.9 | % |  | $ | (104) |  |  | 18.8 | % |  | $ | 2,497 |  |  | $ | 2.56 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2022\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 10,664 |  |  | $ | 4,696 |  |  | 56.0 | % |  | $ | (397) |  |  | 11.9 | % |  | $ | 4,906 |  |  | $ | 5.02 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 193 |  |  | (0.2) | % |  | 181 |  |  | 0.18 | \nLitigation provisions |  | ** |  | (133) |  |  | 1.2 | % |  | ** |  | 0.5 | % |  | 89 |  |  | 0.09 | \nRussia-related impacts |  | (37) |  |  | (67) |  |  | 0.5 | % |  | ** |  | 0.1 | % |  | 24 |  |  | 0.02 | \nAdjusted - Non-GAAP |  | $ | 10,627 |  |  | $ | 4,496 |  |  | 57.7 | % |  | $ | (205) |  |  | 12.3 | % |  | $ | 5,199 |  |  | $ | 5.32 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, 2023 as compared to the Three Months Ended June 30, 2022\n |  | Increase/(Decrease)\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\nReported - GAAP |  | 14% |  | 5% |  | 3.4 ppt |  | 4.5 ppt |  | 25% |  | 28%\n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 1.3 ppt |  | (11)% |  | (11)%\nLitigation provisions |  | ** |  | 5% |  | (2.1) ppt |  | (0.7) ppt |  | (3)% |  | (3)%\nRussia-related impacts |  | \u2014% |  | 2% |  | (0.5) ppt |  | \u2014 ppt |  | (1)% |  | (1)%\n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | 14% |  | 12% |  | 0.8 ppt |  | 5.1 ppt |  | 10% |  | 13%\nCurrency impact1 |  | 1% |  | 1% |  | \u2014 ppt |  | \u2014 ppt |  | 1% |  | 1%\nAdjusted - Non-GAAP - currency-neutral |  | 15% |  | 13% |  | 0.8 ppt |  | 5.1 ppt |  | 11% |  | 14%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2023 as compared to the Six Months Ended June 30, 2022\n |  | Increase/(Decrease)\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\nReported - GAAP |  | 13% |  | 11% |  | 0.6 ppt |  | 8.7 ppt |  | 6% |  | 9%\n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 0.4 ppt |  | (3)% |  | (3)%\nLitigation provisions |  | ** |  | (2)% |  | 0.7 ppt |  | (0.1) ppt |  | 1% |  | 1%\nRussia-related impacts |  | \u2014% |  | 2% |  | (0.3) ppt |  | (0.1) ppt |  | \u2014% |  | \u2014%\n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | 13% |  | 11% |  | 0.9 ppt |  | 8.9 ppt |  | 4% |  | 7%\nCurrency impact1 |  | 2% |  | 1% |  | \u2014 ppt |  | 0.1 ppt |  | 2% |  | 2%\nAdjusted - Non-GAAP - currency-neutral |  | 15% |  | 12% |  | 0.9 ppt |  | 9.0 ppt |  | 6% |  | 9%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | Increase/(Decrease) |  | Increase/(Decrease)\n |  | USD |  | Local |  | USD |  | Local |  | USD |  | Local |  | USD |  | Local\nMastercard-branded GDV growth1 |  | 10% |  | 12% |  | 8% |  | 14% |  | 10% |  | 14% |  | 10% |  | 15%\nUnited States |  | 6% |  | 6% |  | 10% |  | 10% |  | 7% |  | 7% |  | 12% |  | 12%\nWorldwide less United States |  | 12% |  | 16% |  | 7% |  | 16% |  | 12% |  | 17% |  | 9% |  | 17%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCross-border volume growth1 |  | 23% |  | 24% |  | 46% |  | 58% |  | 26% |  | 29% |  | 45% |  | 56%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMastercard-branded GDV growthadjusted for Russia1,2 |  | 10% |  | 12% |  | 13% |  | 20% |  | 11% |  | 14% |  | 14% |  | 20%\nWorldwide less United States GDV growth adjusted for Russia1,2 |  | 12% |  | 16% |  | 14% |  | 25% |  | 12% |  | 18% |  | 15% |  | 24%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCross-border volume growthadjusted for Russia1,2 |  | 23% |  | 24% |  | 50% |  | 64% |  | 27% |  | 31% |  | 48% |  | 59%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | Increase/(Decrease) |  | Increase/(Decrease)\nSwitched transactions growth |  | 17% |  | 12% |  | 15% |  | 16%\n |  |  |  |  |  |  |  | \nSwitched transactions growth adjusted for Russia2 |  | 17% |  | 22% |  | 18% |  | 23%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/(Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease)\n |  | 2023 |  | 2022 |  | As reported |  | Currency-neutral |  | 2023 |  | 2022 |  | As reported |  | Currency-neutral\n |  | ($ in millions) |  | ($ in millions)\nDomestic assessments |  | $ | 2,468 |  |  | $ | 2,251 |  |  | 10% |  | 11% |  | $ | 4,722 |  |  | $ | 4,359 |  |  | 8% |  | 10%\nCross-border assessments |  | 2,050 |  |  | 1,612 |  |  | 27% |  | 29% |  | 3,899 |  |  | 3,002 |  |  | 30% |  | 33%\nTransaction processing assessments |  | 2,979 |  |  | 2,572 |  |  | 16% |  | 16% |  | 5,731 |  |  | 5,029 |  |  | 14% |  | 15%\nOther network assessments |  | 270 |  |  | 213 |  |  | 28% |  | 30% |  | 483 |  |  | 381 |  |  | 27% |  | 29%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/(Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease) |  | \n |  | 2023 |  | 2022 |  | 2021 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  |  |  | 2021 |  | 2023 |  | 2022 |  | \n |  | ($ in millions) |  |  |  |  |  | ($ in millions) |  |  |  |  |  | \nPayment network |  | $ | 4,073 |  |  | $ | 3,609 |  |  | $ | 2,875 |  |  | 13% |  | 26% |  | $ | 7,723 |  |  | $ | 7,008 |  |  |  |  | $ | 5,523 |  |  | 10% |  | 27% |  | \nValue-added services and solutions |  | 2,196 |  |  | 1,888 |  |  | 1,653 |  |  | 16% |  | 14% |  | 4,294 |  |  | 3,656 |  |  |  |  | 3,160 |  |  | 17% |  | 16% |  | \nTotal net revenue |  | 6,269 |  |  | 5,497 |  |  | 4,528 |  |  | 14% |  | 21% |  | 12,017 |  |  | 10,664 |  |  |  |  | 8,683 |  |  | 13% |  | 23% |  | \nSpecial Items1 |  | \u2014 |  |  | (6) |  |  | \u2014 |  |  | ** |  | ** |  | \u2014 |  |  | (37) |  |  |  |  | \u2014 |  |  | ** |  | ** |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted net revenue(excluding Special Items1) |  | $ | 6,269 |  |  | $ | 5,491 |  |  | $ | 4,528 |  |  | 14% |  | 21% |  | $ | 12,017 |  |  | $ | 10,627 |  |  |  |  | $ | 8,683 |  |  | 13% |  | 22% |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30,\n |  | Increase/(Decrease)\n |  | Operational |  |  |  | Acquisitions |  | Currency Impact3 |  | Special Items4 |  | Total\n |  | 2023 |  | 2022 |  |  |  |  |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  |  |  |  | 2022\nPayment network |  | 14 | % | 1 | 31 | % | 1 |  |  |  |  | ** |  | ** |  | (1) | % |  | (6) | % |  | \u2014 | % |  | \u2014 | % |  | 13 | % |  |  |  |  | 26 | %\nValue-added services and solutions |  | 16 | % | 2 | 16 | % | 2 |  |  |  |  | \u2014 | % |  | 3 | % |  | \u2014 | % |  | (5) | % |  | ** |  | ** |  | 16 | % |  |  |  |  | 14 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | 15 | % |  | 26 | % |  |  |  |  |  | \u2014 | % |  | 1 | % |  | (1) | % |  | (6) | % |  | \u2014 | % |  | \u2014 | % |  | 14 | % |  |  |  |  | 21 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30,\n |  | Increase/(Decrease)\n |  | Operational |  |  |  | Acquisitions |  | Currency Impact3 |  | Special Items4 |  | Total\n |  | 2023 |  | 2022 |  |  |  |  |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  |  |  |  | 2022\nPayment network |  | 13 | % | 1 | 31 | % | 1 |  |  |  |  | ** |  | ** |  | (2) | % |  | (5) | % |  | (1) | % |  | 1 | % |  | 10 | % |  |  |  |  | 27 | %\nValue-added services and solutions |  | 18 | % | 2 | 15 | % | 2 |  |  |  |  | 1 | % |  | 5 | % |  | (1) | % |  | (4) | % |  | ** |  | ** |  | 17 | % |  |  |  |  | 16 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | 15 | % |  | 25 | % |  |  |  |  |  | \u2014 | % |  | 2 | % |  | (2) | % |  | (5) | % |  | \u2014 | % |  | \u2014 | % |  | 13 | % |  |  |  |  | 23 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/ (Decrease) |  | Six Months Ended June 30, |  | Increase/ (Decrease)\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  | ($ in millions)\nGeneral and administrative |  | $ | 2,200 |  |  | $ | 1,947 |  |  | 13% |  | $ | 4,243 |  |  | $ | 3,791 |  |  | 12%\nAdvertising and marketing |  | 201 |  |  | 210 |  |  | (4)% |  | 368 |  |  | 391 |  |  | (6)%\nDepreciation and amortization |  | 192 |  |  | 189 |  |  | 2% |  | 383 |  |  | 381 |  |  | 1%\nProvision for litigation |  | 20 |  |  | 133 |  |  | ** |  | 231 |  |  | 133 |  |  | **\nTotal operating expenses |  | 2,613 |  |  | 2,479 |  |  | 5% |  | 5,225 |  |  | 4,696 |  |  | 11%\nSpecial Items1 |  | (20) |  |  | (166) |  |  | ** |  | (231) |  |  | (200) |  |  | **\nAdjusted total operating expenses (excluding Special Items1) |  | $ | 2,592 |  |  | $ | 2,313 |  |  | 12% |  | $ | 4,993 |  |  | $ | 4,496 |  |  | 11%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, 2023\n |  | Increase/(Decrease)\n |  | Operational |  | Acquisitions |  | Currency Impact1 |  | SpecialItems2 |  | Total\nGeneral and administrative |  | 15% |  | \u2014% |  | (1)% |  | (2)% |  | 13%\nAdvertising and marketing |  | (4)% |  | \u2014% |  | \u2014% |  | ** |  | (4)%\nDepreciation and amortization |  | 1% |  | \u2014% |  | \u2014% |  | ** |  | 2%\nProvision for litigation |  | ** |  | ** |  | ** |  | ** |  | **\nTotal operating expenses |  | 12% |  | \u2014% |  | (1)% |  | (7)% |  | 5%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Six Months Ended June 30, 2023\n |  | Increase/(Decrease)\n |  | Operational |  | Acquisitions |  | Currency Impact1 |  | SpecialItems2 |  | Total\nGeneral and administrative |  | 14% |  | 1% |  | (1)% |  | (2)% |  | 12%\nAdvertising and marketing |  | (5)% |  | \u2014% |  | (1)% |  | ** |  | (6)%\nDepreciation and amortization |  | 1% |  | 1% |  | (1)% |  | ** |  | 1%\nProvision for litigation |  | ** |  | ** |  | ** |  | ** |  | **\nTotal operating expenses |  | 11% |  | 1% |  | (1)% |  | \u2014% |  | 11%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/ (Decrease) |  | Six Months Ended June 30, |  | Increase/(Decrease)\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  | ($ in millions)\nPersonnel1 |  | $ | 1,495 |  |  | $ | 1,319 |  |  | 13% |  | $ | 2,921 |  |  | $ | 2,500 |  |  | 17%\nProfessional fees |  | 114 |  |  | 109 |  |  | 5% |  | 214 |  |  | 195 |  |  | 10%\nData processing and telecommunications |  | 246 |  |  | 225 |  |  | 9% |  | 481 |  |  | 460 |  |  | 5%\nForeign exchange activity2 |  | 24 |  |  | 35 |  |  | ** |  | 40 |  |  | 71 |  |  | **\nOther1 |  | 321 |  |  | 259 |  |  | 24% |  | 587 |  |  | 565 |  |  | 4%\nTotal general and administrative expenses |  | $ | 2,200 |  |  | $ | 1,947 |  |  | 13% |  | $ | 4,243 |  |  | $ | 3,791 |  |  | 12%\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended June 30, |  | Increase/ (Decrease) |  | Six Months Ended June 30, |  | Increase/ (Decrease)\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  | ($ in millions)\nInvestment income |  | $ | 59 |  |  | $ | 7 |  |  | ** |  | $ | 114 |  |  | $ | 12 |  |  | **\nGains (losses) on equity investments, net |  | 123 |  |  | (117) |  |  | ** |  | (89) |  |  | (193) |  |  | **\nInterest expense |  | (144) |  |  | (114) |  |  | 27% |  | (276) |  |  | (224) |  |  | 23%\nOther income (expense), net |  | 10 |  |  | 4 |  |  | ** |  | 16 |  |  | 8 |  |  | **\nTotal other income (expense) |  | 48 |  |  | (220) |  |  | ** |  | (235) |  |  | (397) |  |  | **\n(Gains) losses on equity investments1 |  | (123) |  |  | 117 |  |  | ** |  | 89 |  |  | 193 |  |  | **\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted total other income (expense)1 |  | $ | (75) |  |  | $ | (104) |  |  | (28)% |  | $ | (146) |  |  | $ | (205) |  |  | (29)%  |  |  |  |  |  |  |  |  |  |  | \n | June 30,2023 |  | December 31,2022\n | (in billions)\nCash, cash equivalents and investments1 | $ | 6.5 |  |  | $ | 7.4 | \nUnused line of credit | 8.0 |  |  | 8.0 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2023 |  | 2022\n | (in millions)\nNet cash provided by operating activities | $ | 4,617 |  |  | $ | 4,239 | \nNet cash used in investing activities | (615) |  |  | (812) | \nNet cash used in financing activities | (4,734) |  |  | (4,975) |   |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  | (in millions, except average price data)\nRemaining authorization at December 31, 2022 |  |  |  |  |  | $ | 12,174 | \nDollar-value of shares repurchased during the six months ended June 30, 20231 |  |  |  |  |  | $ | 5,294 | \nRemaining authorization at June 30, 2023 |  |  |  |  |  | $ | 6,880 | \nShares repurchased during the six months ended June 30, 2023 |  |  |  |  |  | 14.4 | \nAverage price paid per share during the six months ended June 30, 2023 |  |  |  |  |  | $ | 367.00 | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART II |  |  | \n |  | Item 1. Legal proceedings |  |  | \n |  | Item 1A. Risk factors |  |  | \n |  | Item 2. Unregistered sales of equity securities and use of proceeds |  |  | \n |  | Item 5. Other information |  |  | \n |  | Item 6. Exhibits |  |  | \n |  | Signatures |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod |  | Total\u00a0Numberof\u00a0SharesPurchased |  | Average\u00a0PricePaid\u00a0per\u00a0Share(includingcommission\u00a0cost) |  | Total\u00a0Number\u00a0ofShares\u00a0Purchased\u00a0asPart\u00a0of\u00a0PubliclyAnnounced\u00a0Plans\u00a0orPrograms |  | Dollar\u00a0Value\u00a0ofShares\u00a0that\u00a0may\u00a0yetbe\u00a0Purchased\u00a0underthe Plans\u00a0orPrograms1, 2\nApril 1 - 30 |  | 2,070,540 |  |  | $ | 367.29 |  |  | 2,070,540 |  |  | $ | 8,535,407,807 | \nMay 1 - 31 |  | 2,250,153 |  |  | $ | 379.19 |  |  | 2,250,153 |  |  | $ | 7,682,181,892 | \nJune 1 - 30 |  | 2,148,089 |  |  | $ | 373.59 |  |  | 2,148,089 |  |  | $ | 6,879,666,632 | \nTotal |  | 6,468,782 |  |  | $ | 373.52 |  |  | 6,468,782 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Action |  | Date |  | Plans |  | Number of Securities to be Sold |  | Expiration\n |  |  | Rule 10b5-11 |  | Non-Rule 10b5-12 |  | \nSachin Mehra,Chief Financial Officer |  | Adoption |  | May 1, 2023 |  | X |  | - |  | 16,838 shares of Class A Common Stock underlying employee stock options |  | The earlier of (i) date when all securities under plan are exercised and sold and (ii) December 31, 2023\nTimothy Murphy,Chief Administrative Officer |  | Adoption |  | May 3, 2023 |  | X |  | - |  | 14,761 shares of Class A Common Stock underlying employee stock options and 256 shares of Class A Common Stock |  | The earlier of (i) date when all securities under plan are exercised and sold and (ii) December 31, 2023\nJulius Genachowski,Director |  | Adoption |  | May 15, 2023 |  | X |  | - |  | 622 shares of Class A Common Stock |  | The earlier of (i) date when all shares under plan are sold and (ii) February 29, 2024\nAjay Bhalla,President, Cyber and Intelligence Solutions |  | Adoption |  | June 15, 2023 |  | X |  | - |  | 13,996 shares of Class A Common Stock underlying employee stock options |  | The earlier of (i) date when all securities under plan are exercised and sold and (ii) March 1, 2024\n |  |  |  |  | 12,292 shares of Class A Common Stock underlying employee stock options |  | The earlier of (i) date when all securities under plan are exercised and sold and (ii) May 15, 2024\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  | \nExhibitNumber |  | Exhibit Description\n10.1*+ |  | Mastercard International Senior Executive AnnualIncentiveCompensation Plan, as amendedandrestated June 12, 2023.\n10.2*+ |  | Mastercard Incorporated Employee Stock Purchase Plan, effective as of June 27, 2023.\n10.3* |  | Schedule of Non-Employee Directors\u2019 Annual Compensation effective as of July 1, 2023.\n10.4* |  | Form ofDeferredStockUnitAgreement for awardsgrantedunder 2006Non-Employee Director Equity CompensationPlan (effective for awards granted on and subsequent toJune 27,2023).\n10.5* |  | Form of Restricted Stock Agreement for awardsgrantedunder2006Non-Employee Director Equity CompensationPlan (effective for awards granted on and subsequent toJune27, 2023).\n31.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n31.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n32.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n32.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n99.1* |  | Disclosure pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012.\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH* |  | XBRL Taxonomy Extension Schema Document\n101.CAL* |  | XBRL Taxonomy Extension Calculation Linkbase Document\n101.DEF* |  | XBRL Taxonomy Extension Definition Linkbase Document\n101.LAB* |  | XBRL Taxonomy Extension Label Linkbase Document\n101.PRE* |  | XBRL Taxonomy Extension Presentation Linkbase Document  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | MASTERCARD INCORPORATED\n |  | (Registrant)\n |  |  | \nDate: | July 27, 2023 | By: |  | /S/ MICHAEL MIEBACH\n |  |  |  | Michael Miebach\n |  |  |  | President and Chief Executive Officer\n |  |  |  | (Principal Executive Officer)\n |  |  | \nDate: | July 27, 2023 | By: |  | /S/ SACHIN MEHRA\n |  |  |  | Sachin Mehra\n |  |  |  | Chief Financial Officer\n |  |  |  | (Principal Financial Officer)\n |  |  | \nDate: | July 27, 2023 | By: |  | /S/ SANDRA ARKELL\n |  |  |  | Sandra Arkell\n |  |  |  | Corporate Controller\n |  |  |  | (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Mastercard, in 2023 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  |  |  |  | \nDelaware | 13-4172551\n(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification Number)\n |  | \n2000 Purchase Street | 10577\nPurchase, | NY | (Zip Code)\n(Address of principal executive offices) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class |  | Trading Symbol |  | Name of each exchange of which registered\nClass A Common Stock, par value $0.0001 per share |  | MA |  | New York Stock Exchange\n2.1% Notes due 2027 |  | MA27 |  | New York Stock Exchange\n1.0% Notes due 2029 |  | MA29A |  | New York Stock Exchange\n2.5% Notes due 2030 |  | MA30 |  | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant (1)\u00a0has filed all reports required to be filed by Section\u00a013 or 15(d)\u00a0of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\u00a0has been subject to such filing requirements for the past 90 days. | Yes | \u2612 | No | \u2610\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files) | Yes | \u2612 | No | \u2610  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of \u201clarge accelerated filer,\u201d \u201caccelerated filer,\u201d \u201csmaller reporting company,\u201d and \u201cemerging growth company\u201d in Rule 12b-2 of the Exchange Act. (Check One):\nLarge accelerated filer | \u2612 |  | Accelerated\u00a0filer | \u2610 |  |  | \nNon-accelerated filer | \u2610 |  | Smaller\u00a0reporting\u00a0company | \u2610 |  |  | \n |  |  | Emerging growth\u00a0company | \u2610 |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. | \u2610\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) | Yes | \u2610 | No | \u2612  |  | \n  |  |  |  |  |  |  |  |  |  |  | \n |  |  | \nPART I | 5 | Item 1. | Consolidated financial statements (unaudited)\n32 | Item 2. | Management\u2019s discussion and analysis of financial condition and results of operations\n48 | Item 3. | Quantitative and qualitative disclosures about market risk\n49 | Item 4. | Controls and procedures\n |  |  | \n |  |  | \nPART II | 51 | Item 1. | Legal proceedings\n51 | Item 1A. | Risk factors\n51 | Item 2. | Unregistered sales of equity securities,use of proceedsand issuer purchases of equity securities\n51 | Item 5. | Other information\n52 | Item 6. | Exhibits\n54 | - | Signatures\n |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART I |  |  | \n |  | Item 1. Consolidated financial statements (unaudited) |  | \n |  | Item 2. Management\u2019s discussion and analysis of financial condition and results of operations |  | \n |  | Item 3. Quantitative and qualitative disclosures about market risk |  | \n |  | Item 4. Controls and procedures |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  | \n |  | Page\nConsolidated Statement of Operations \u2014Three and Nine Months Ended September 30, 2023and2022 |  | 6\nConsolidated Statement of Comprehensive Income \u2014Three and Nine Months Ended September 30, 2023and2022 |  | 7\nConsolidated Balance Sheet \u2014September 30, 2023andDecember 31, 2022 |  | 8\nConsolidated Statement of Changes in Equity\u2014Three and Nine Months Ended September 30, 2023and2022 |  | 9\nConsolidated Statement of Cash Flows \u2014Nine Months Ended September 30, 2023and2022 |  | 11\nNotes to consolidated financial statements |  | 12  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Operations (Unaudited) |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNet Revenue |  | $ | 6,533 |  |  | $ | 5,756 |  |  | $ | 18,550 |  |  | $ | 16,420 | \nOperating Expenses: |  |  |  |  |  |  |  | \nGeneral and administrative |  | 2,285 |  |  | 2,069 |  |  | 6,528 |  |  | 5,860 | \nAdvertising and marketing |  | 193 |  |  | 182 |  |  | 561 |  |  | 573 | \nDepreciation and amortization |  | 211 |  |  | 185 |  |  | 594 |  |  | 566 | \nProvision for litigation |  | \u2014 |  |  | 208 |  |  | 231 |  |  | 341 | \nTotal operating expenses |  | 2,689 |  |  | 2,644 |  |  | 7,914 |  |  | 7,340 | \nOperating income |  | 3,844 |  |  | 3,112 |  |  | 10,636 |  |  | 9,080 | \nOther Income (Expense): |  |  |  |  |  |  |  | \nInvestment income |  | 71 |  |  | 16 |  |  | 185 |  |  | 28 | \nGains (losses) on equity investments, net |  | (6) |  |  | 60 |  |  | (95) |  |  | (133) | \nInterest expense |  | (151) |  |  | (120) |  |  | (427) |  |  | (344) | \nOther income (expense), net |  | 3 |  |  | 4 |  |  | 19 |  |  | 12 | \nTotal other income (expense) |  | (83) |  |  | (40) |  |  | (318) |  |  | (437) | \nIncome before income taxes |  | 3,761 |  |  | 3,072 |  |  | 10,318 |  |  | 8,643 | \nIncome tax expense |  | 563 |  |  | 573 |  |  | 1,914 |  |  | 1,238 | \nNet Income |  | $ | 3,198 |  |  | $ | 2,499 |  |  | $ | 8,404 |  |  | $ | 7,405 | \nBasic Earnings per Share |  | $ | 3.40 |  |  | $ | 2.59 |  |  | $ | 8.88 |  |  | $ | 7.63 | \nBasic weighted-average shares outstanding |  | 941 |  |  | 965 |  |  | 947 |  |  | 971 | \nDiluted Earnings per Share |  | $ | 3.39 |  |  | $ | 2.58 |  |  | $ | 8.85 |  |  | $ | 7.60 | \nDiluted weighted-average shares outstanding |  | 943 |  |  | 968 |  |  | 949 |  |  | 974 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Comprehensive Income (Unaudited) |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in millions)\nNet Income |  | $ | 3,198 |  |  | $ | 2,499 |  |  | $ | 8,404 |  |  | $ | 7,405 | \nOther comprehensive income (loss): |  |  |  |  |  |  |  | \nForeign currency translation adjustments |  | (239) |  |  | (743) |  |  | (92) |  |  | (1,517) | \nIncome tax effect |  | 1 |  |  | 62 |  |  | (13) |  |  | 105 | \nForeign currency translation adjustments, net of income tax effect |  | (238) |  |  | (681) |  |  | (105) |  |  | (1,412) | \n |  |  |  |  |  |  |  | \nTranslation adjustments on net investment hedges |  | 138 |  |  | 372 |  |  | 53 |  |  | 772 | \nIncome tax effect |  | (31) |  |  | (82) |  |  | (12) |  |  | (171) | \nTranslation adjustments on net investment hedges, net of income tax effect |  | 107 |  |  | 290 |  |  | 41 |  |  | 601 | \n |  |  |  |  |  |  |  | \nCash flow hedges |  | 17 |  |  | 14 |  |  | (7) |  |  | 21 | \nIncome tax effect |  | (4) |  |  | (3) |  |  | 2 |  |  | (5) | \nReclassification adjustments for cash flow hedges |  | 12 |  |  | (4) |  |  | 29 |  |  | (9) | \nIncome tax effect |  | (3) |  |  | 1 |  |  | (7) |  |  | 2 | \nCash flow hedges, net of income tax effect |  | 22 |  |  | 8 |  |  | 17 |  |  | 9 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | \nReclassification adjustments for defined benefit pension and other postretirement plans |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) | \nIncome tax effect |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nDefined benefit pension and other postretirement plans, net of income tax effect |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) | \n |  |  |  |  |  |  |  | \nInvestment securities available-for-sale |  | 1 |  |  | (2) |  |  | 3 |  |  | (6) | \nIncome tax effect |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 | \nInvestment securities available-for-sale, net of income tax effect |  | 1 |  |  | (2) |  |  | 3 |  |  | (5) | \n |  |  |  |  |  |  |  | \nOther comprehensive income (loss), net of income tax effect |  | (108) |  |  | (385) |  |  | (44) |  |  | (808) | \nComprehensive Income |  | $ | 3,090 |  |  | $ | 2,114 |  |  | $ | 8,360 |  |  | $ | 6,597 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Balance Sheet (Unaudited) |  |  |  | \n |  | September 30, 2023 |  | December 31, 2022\n |  | (in\u00a0millions,\u00a0except\u00a0per share\u00a0data)\nAssets |  |  |  | \nCurrent assets: |  |  |  | \nCash and cash equivalents |  | $ | 6,890 |  |  | $ | 7,008 | \nRestricted cash for litigation settlement |  | \u2014 |  |  | 589 | \nInvestments |  | 602 |  |  | 400 | \nAccounts receivable |  | 3,925 |  |  | 3,425 | \nSettlement assets |  | 1,118 |  |  | 1,270 | \nRestricted security deposits held for customers |  | 1,824 |  |  | 1,568 | \nPrepaid expenses and other current assets |  | 2,624 |  |  | 2,346 | \nTotal current assets |  | 16,983 |  |  | 16,606 | \nProperty, equipment and right-of-use assets, net of accumulated depreciation and amortization of $2,140and $1,904, respectively |  | 1,972 |  |  | 2,006 | \nDeferred income taxes |  | 1,370 |  |  | 1,151 | \nGoodwill |  | 7,488 |  |  | 7,522 | \nOther intangible assets, net of accumulated amortization of $2,137and $1,960, respectively |  | 4,022 |  |  | 3,859 | \nOther assets |  | 7,839 |  |  | 7,580 | \nTotal Assets |  | $ | 39,674 |  |  | $ | 38,724 | \nLiabilities, Redeemable Non-controlling Interests and Equity |  |  |  | \nCurrent liabilities: |  |  |  | \nAccounts payable |  | $ | 589 |  |  | $ | 926 | \nSettlement obligations |  | 992 |  |  | 1,111 | \nRestricted security deposits held for customers |  | 1,824 |  |  | 1,568 | \nAccrued litigation |  | 475 |  |  | 1,094 | \nAccrued expenses |  | 7,775 |  |  | 7,801 | \nShort-term debt |  | 1,337 |  |  | 274 | \nOther current liabilities |  | 1,527 |  |  | 1,397 | \nTotal current liabilities |  | 14,519 |  |  | 14,171 | \nLong-term debt |  | 14,229 |  |  | 13,749 | \nDeferred income taxes |  | 385 |  |  | 393 | \nOther liabilities |  | 4,160 |  |  | 4,034 | \nTotal Liabilities |  | 33,293 |  |  | 32,347 | \nCommitments and Contingencies |  |  |  | \nRedeemable Non-controlling Interests |  | 21 |  |  | 21 | \nStockholders\u2019 Equity |  |  |  | \nClass\u00a0A common stock, $0.0001par value; authorized3,000shares,1,401and1,399shares issued and932and948shares outstanding, respectively |  | \u2014 |  |  | \u2014 | \nClass B common stock, $0.0001par value; authorized1,200shares,7and8shares issued and outstanding, respectively |  | \u2014 |  |  | \u2014 | \nAdditional paid-in-capital |  | 5,791 |  |  | 5,298 | \nClass\u00a0A treasury stock, at cost,470and451shares, respectively |  | (58,573) |  |  | (51,354) | \nRetained earnings |  | 60,390 |  |  | 53,607 | \nAccumulated other comprehensive income (loss) |  | (1,297) |  |  | (1,253) | \nMastercard Incorporated Stockholders' Equity |  | 6,311 |  |  | 6,298 | \nNon-controlling interests |  | 49 |  |  | 58 | \nTotal Equity |  | 6,360 |  |  | 6,356 | \nTotal Liabilities, Redeemable Non-controlling Interests and Equity |  | $ | 39,674 |  |  | $ | 38,724 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Changes in Equity (Unaudited)\n |  | Three Months Ended September 30, 2023\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders\u2019 Equity |  | Non-ControllingInterests |  | Total Equity\n |  | Class A |  | Class B |  |  |  | \n |  | (in millions)\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at June 30, 2023 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,622 |  |  | $ | (56,659) |  |  | $ | 57,730 |  |  | $ | (1,189) |  |  | $ | 5,504 |  |  | $ | 53 |  |  | $ | 5,557 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,198 |  |  | \u2014 |  |  | 3,198 |  |  | \u2014 |  |  | 3,198 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) |  |  | (4) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) |  |  | \u2014 |  |  | (2) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (108) |  |  | (108) |  |  | \u2014 |  |  | (108) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (536) |  |  | \u2014 |  |  | (536) |  |  | \u2014 |  |  | (536) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,915) |  |  | \u2014 |  |  | \u2014 |  |  | (1,915) |  |  | \u2014 |  |  | (1,915) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 169 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | 170 |  |  | \u2014 |  |  | 170 | \nBalance at September 30, 2023 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,791 |  |  | $ | (58,573) |  |  | $ | 60,390 |  |  | $ | (1,297) |  |  | $ | 6,311 |  |  | $ | 49 |  |  | $ | 6,360 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n\n |  | Nine Months Ended September 30, 2023\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,298 |  |  | $ | (51,354) |  |  | $ | 53,607 |  |  | $ | (1,253) |  |  | $ | 6,298 |  |  | $ | 58 |  |  | $ | 6,356 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 8,404 |  |  | \u2014 |  |  | 8,404 |  |  | \u2014 |  |  | 8,404 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (9) |  |  | (9) | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (6) |  |  | \u2014 |  |  | (6) |  |  | \u2014 |  |  | (6) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (44) |  |  | (44) |  |  | \u2014 |  |  | (44) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,615) |  |  | \u2014 |  |  | (1,615) |  |  | \u2014 |  |  | (1,615) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (7,232) |  |  | \u2014 |  |  | \u2014 |  |  | (7,232) |  |  | \u2014 |  |  | (7,232) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 493 |  |  | 13 |  |  | \u2014 |  |  | \u2014 |  |  | 506 |  |  | \u2014 |  |  | 506 | \nBalance at September 30, 2023 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,791 |  |  | $ | (58,573) |  |  | $ | 60,390 |  |  | $ | (1,297) |  |  | $ | 6,311 |  |  | $ | 49 |  |  | $ | 6,360 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Changes in Equity (Unaudited) - (Continued)\n |  | Three Months Ended September 30, 2022\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders\u2019 Equity |  | Non-ControllingInterests |  | Total Equity\n |  | Class A |  | Class B |  |  |  | \n |  | (in millions)\nBalance at June 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,163 |  |  | $ | (47,359) |  |  | $ | 49,599 |  |  | $ | (1,232) |  |  | $ | 6,171 |  |  | $ | 65 |  |  | $ | 6,236 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,499 |  |  | \u2014 |  |  | 2,499 |  |  | \u2014 |  |  | 2,499 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3) |  |  | (3) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (1) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (385) |  |  | (385) |  |  | \u2014 |  |  | (385) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (472) |  |  | \u2014 |  |  | (472) |  |  |  |  | (472) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,557) |  |  | \u2014 |  |  | \u2014 |  |  | (1,557) |  |  | \u2014 |  |  | (1,557) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 106 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 106 |  |  | \u2014 |  |  | 106 | \nBalance at September 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,269 |  |  | $ | (48,916) |  |  | $ | 51,625 |  |  | $ | (1,617) |  |  | $ | 6,361 |  |  | $ | 62 |  |  | $ | 6,423 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2022\n |  | Stockholders\u2019 Equity |  |  |  | \n |  | Common Stock |  | AdditionalPaid-InCapital |  | Class ATreasuryStock |  | RetainedEarnings |  | AccumulatedOtherComprehensiveIncome (Loss) |  | Mastercard Incorporated Stockholders' Equity |  | Non-ControllingInterests |  | TotalEquity\n |  | Class\u00a0A |  | Class\u00a0B |  | \n |  | (in millions)\nBalance at December 31, 2021 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,061 |  |  | $ | (42,588) |  |  | $ | 45,648 |  |  | $ | (809) |  |  | $ | 7,312 |  |  | $ | 71 |  |  | $ | 7,383 | \nNet income |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 7,405 |  |  | \u2014 |  |  | 7,405 |  |  | \u2014 |  |  | 7,405 | \nActivity related to non-controlling interests |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (9) |  |  | (9) | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRedeemable non-controlling interest adjustments |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (5) |  |  | \u2014 |  |  | (5) |  |  | \u2014 |  |  | (5) | \nOther comprehensive income (loss) |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (808) |  |  | (808) |  |  | \u2014 |  |  | (808) | \nDividends |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,423) |  |  | \u2014 |  |  | (1,423) |  |  | \u2014 |  |  | (1,423) | \nPurchases of treasury stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (6,333) |  |  | \u2014 |  |  | \u2014 |  |  | (6,333) |  |  | \u2014 |  |  | (6,333) | \nShare-based payments |  | \u2014 |  |  | \u2014 |  |  | 208 |  |  | 5 |  |  | \u2014 |  |  | \u2014 |  |  | 213 |  |  | \u2014 |  |  | 213 | \nBalance at September 30, 2022 |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 5,269 |  |  | $ | (48,916) |  |  | $ | 51,625 |  |  | $ | (1,617) |  |  | $ | 6,361 |  |  | $ | 62 |  |  | $ | 6,423 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nConsolidated Statement of Cash Flows (Unaudited) |  |  |  | \n |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022\n |  | (in millions)\nOperating Activities |  |  |  | \nNet income |  | $ | 8,404 |  |  | $ | 7,405 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  |  | \nAmortization of customer and merchant incentives |  | 1,196 |  |  | 1,197 | \nDepreciation and amortization |  | 594 |  |  | 566 | \n(Gains) losses on equity investments, net |  | 95 |  |  | 133 | \nShare-based compensation |  | 374 |  |  | 273 | \nDeferred income taxes |  | (239) |  |  | (589) | \nOther |  | 88 |  |  | 40 | \nChanges in operating assets and liabilities: |  |  |  | \nAccounts receivable |  | (484) |  |  | (326) | \n |  |  |  | \nSettlement assets |  | 151 |  |  | 298 | \nPrepaid expenses |  | (1,837) |  |  | (1,472) | \nAccrued litigation and legal settlements |  | (621) |  |  | 249 | \nRestricted security deposits held for customers |  | 240 |  |  | (342) | \nAccounts payable |  | (319) |  |  | (91) | \nSettlement obligations |  | (119) |  |  | 146 | \n |  |  |  | \nAccrued expenses |  | 43 |  |  | 638 | \n |  |  |  | \nNet change in other assets and liabilities |  | 284 |  |  | (30) | \nNet cash provided by operating activities |  | 7,850 |  |  | 8,095 | \nInvesting Activities |  |  |  | \nPurchases of investment securities available-for-sale |  | (244) |  |  | (192) | \nPurchases of investments held-to-maturity |  | (327) |  |  | (174) | \nProceeds from sales of investment securities available-for-sale |  | 72 |  |  | 28 | \nProceeds from maturities of investment securities available-for-sale |  | 155 |  |  | 156 | \nProceeds from maturities of investments held-to-maturity |  | 116 |  |  | 194 | \nPurchases of property and equipment |  | (294) |  |  | (312) | \nCapitalized software |  | (525) |  |  | (446) | \nPurchases of equity investments |  | (61) |  |  | (62) | \nProceeds from sales of equity investments |  | 44 |  |  | 7 | \nAcquisition of businesses, net of cash acquired |  | \u2014 |  |  | (313) | \n |  |  |  | \nOther investing activities |  | (73) |  |  | (6) | \nNet cash used in investing activities |  | (1,137) |  |  | (1,120) | \nFinancing Activities |  |  |  | \nPurchases of treasury stock |  | (7,200) |  |  | (6,339) | \nDividends paid |  | (1,624) |  |  | (1,430) | \nProceeds from debt, net |  | 1,554 |  |  | 1,127 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \nTax withholdings related to share-based payments |  | (81) |  |  | (137) | \nCash proceeds from exercise of stock options |  | 213 |  |  | 77 | \nOther financing activities |  | \u2014 |  |  | (12) | \nNet cash used in financing activities |  | (7,138) |  |  | (6,714) | \nEffect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents |  | (29) |  |  | (387) | \nNet decrease in cash, cash equivalents, restricted cash and restricted cash equivalents |  | (454) |  |  | (126) | \nCash, cash equivalents, restricted cash and restricted cash equivalents - beginning of period |  | 9,196 |  |  | 9,902 | \nCash, cash equivalents, restricted cash and restricted cash equivalents - end of period |  | $ | 8,742 |  |  | $ | 9,776 | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in millions)\nNet revenue by category: |  |  |  |  |  |  |  | \nPayment network |  | $ | 4,210 |  |  | $ | 3,765 |  |  | $ | 11,933 |  |  | $ | 10,773 | \nValue-added services and solutions |  | 2,323 |  |  | 1,991 |  |  | 6,617 |  |  | 5,647 | \nNet revenue |  | $ | 6,533 |  |  | $ | 5,756 |  |  | $ | 18,550 |  |  | $ | 16,420 | \nNet revenue by geographic region: |  |  |  |  |  |  |  | \nNorth American Markets1 |  | $ | 2,109 |  |  | $ | 2,031 |  |  | $ | 6,143 |  |  | $ | 5,769 | \nInternational Markets |  | 4,424 |  |  | 3,725 |  |  | 12,407 |  |  | 10,651 | \nNet revenue |  | $ | 6,533 |  |  | $ | 5,756 |  |  | $ | 18,550 |  |  | $ | 16,420 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2023 |  | December 31,2022\n |  | (in millions)\nReceivables from contracts with customers |  |  |  | \nAccounts receivable |  | $ | 3,666 |  |  | $ | 3,213 | \nContract assets |  |  |  | \nPrepaid expenses and other current assets |  | 105 |  |  | 118 | \nOther assets |  | 390 |  |  | 442 | \nDeferred revenue1 |  |  |  | \nOther current liabilities |  | 548 |  |  | 434 | \nOther liabilities |  | 300 |  |  | 248 | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nNumerator |  |  |  |  |  |  |  | \nNet income |  | $ | 3,198 |  |  | $ | 2,499 |  |  | $ | 8,404 |  |  | $ | 7,405 | \nDenominator |  |  |  |  |  |  |  | \nBasic weighted-average shares outstanding |  | 941 |  |  | 965 |  |  | 947 |  |  | 971 | \nDilutive stock options and stock units |  | 2 |  |  | 3 |  |  | 2 |  |  | 3 | \nDiluted weighted-average shares outstanding1 |  | 943 |  |  | 968 |  |  | 949 |  |  | 974 | \nEarnings per Share |  |  |  |  |  |  |  | \nBasic |  | $ | 3.40 |  |  | $ | 2.59 |  |  | $ | 8.88 |  |  | $ | 7.63 | \nDiluted |  | $ | 3.39 |  |  | $ | 2.58 |  |  | $ | 8.85 |  |  | $ | 7.60 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2023 |  | December 31,2022\n |  | (in millions)\nCash and cash equivalents |  | $ | 6,890 |  |  | $ | 7,008 | \nRestricted cash and restricted cash equivalents |  |  |  | \nRestricted cash for litigation settlement1 |  | \u2014 |  |  | 589 | \nRestricted security deposits held for customers |  | 1,824 |  |  | 1,568 | \nPrepaid expenses and other current assets |  | 28 |  |  | 31 | \n |  |  |  | \nCash, cash equivalents, restricted cash and restricted cash equivalents |  | $ | 8,742 |  |  | $ | 9,196 | \n |  |  |  | \n |  | \n |  |  |  | \n |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2023 |  | December 31,2022\n |  | (in millions)\nAvailable-for-sale securities1 |  | $ | 276 |  |  | $ | 272 | \nHeld-to-maturity securities2 |  | 326 |  |  | 128 | \nTotal investments |  | $ | 602 |  |  | $ | 400 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2023 |  | December 31, 2022\n |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue |  | AmortizedCost |  | GrossUnrealizedGain |  | GrossUnrealizedLoss |  | FairValue\n |  | (in millions)\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGovernment and agency securities |  | $ | 93 |  |  | $ | \u2014 |  |  | $ | (1) |  |  | $ | 92 |  |  | $ | 91 |  |  | $ | \u2014 |  |  | $ | (2) |  |  | $ | 89 | \nCorporate securities |  | 186 |  |  | \u2014 |  |  | (2) |  |  | 184 |  |  | 187 |  |  | \u2014 |  |  | (4) |  |  | 183 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal |  | $ | 279 |  |  | $ | \u2014 |  |  | $ | (3) |  |  | $ | 276 |  |  | $ | 278 |  |  | $ | \u2014 |  |  | $ | (6) |  |  | $ | 272 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | \n |  | Amortized Cost |  | Fair\u00a0Value\n |  | (in millions)\nDue within 1 year |  | $ | 161 |  |  | $ | 160 | \nDue after 1 year through 5 years |  | 118 |  |  | 116 | \n |  |  |  | \nTotal |  | $ | 279 |  |  | $ | 276 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Balance at December 31, 2022 |  | Purchases |  | Sales |  | Changes in Fair Value1 |  | Other2 |  | Balance at September 30, 2023\n |  | (in millions)\nMarketable securities |  | $ | 399 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 58 |  |  | $ | \u2014 |  |  | $ | 457 | \nNonmarketable securities |  | 1,331 |  |  | 61 |  |  | (44) |  |  | (153) |  |  | (2) |  |  | 1,193 | \nTotal equity investments |  | $ | 1,730 |  |  | $ | 61 |  |  | $ | (44) |  |  | $ | (95) |  |  | $ | (2) |  |  | $ | 1,650 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2023 |  | December 31,2022\n |  | (in millions)\nMeasurement alternative |  | $ | 985 |  |  | $ | 1,087 | \nEquity method |  | 208 |  |  | 244 | \nTotal Nonmarketable securities |  | $ | 1,193 |  |  | $ | 1,331 |   |  |  |  |  |  |  |  | \n |  | \n |  | (in millions)\nInitial cost basis |  | $ | 534 | \nCumulative adjustments1: |  | \nUpward adjustments |  | 629 | \nDownward adjustments (including impairment) |  | (178) | \nCarrying amount, end of period |  | $ | 985 | \n |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in millions)\nMeasurement alternative investments: |  |  |  |  |  |  |  | \nUpward adjustments |  | $ | 1 |  |  | $ | 4 |  |  | $ | 7 |  |  | $ | 107 | \nDownward adjustments (including impairment) |  | (7) |  |  | \u2014 |  |  | (142) |  |  | (12) | \nMarketable securities: |  |  |  |  |  |  |  | \nUnrealized gains (losses), net |  | 3 |  |  | 79 |  |  | 58 |  |  | (209) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2023 |  | December 31, 2022\n |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total |  | Quoted\u00a0Pricesin ActiveMarkets(Level 1) |  | SignificantOtherObservableInputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | Total\n |  | (in millions)\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestment securities available-for-sale1: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGovernment and agency securities |  | $ | 37 |  |  | $ | 55 |  |  | $ | \u2014 |  |  | $ | 92 |  |  | $ | 35 |  |  | $ | 54 |  |  | $ | \u2014 |  |  | $ | 89 | \nCorporate securities |  | \u2014 |  |  | 184 |  |  | \u2014 |  |  | 184 |  |  | \u2014 |  |  | 183 |  |  | \u2014 |  |  | 183 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | \u2014 |  |  | 120 |  |  | \u2014 |  |  | 120 |  |  | \u2014 |  |  | 108 |  |  | \u2014 |  |  | 108 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMarketable securities3: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nEquity securities |  | 457 |  |  | \u2014 |  |  | \u2014 |  |  | 457 |  |  | 399 |  |  | \u2014 |  |  | \u2014 |  |  | 399 | \nDeferred compensation plan4: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation assets |  | 84 |  |  | \u2014 |  |  | \u2014 |  |  | 84 |  |  | 74 |  |  | \u2014 |  |  | \u2014 |  |  | 74 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivative instruments2: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | \u2014 |  |  | $ | 22 |  |  | $ | \u2014 |  |  | $ | 22 |  |  | $ | \u2014 |  |  | $ | 21 |  |  | $ | \u2014 |  |  | $ | 21 | \nInterest rate contracts |  | \u2014 |  |  | 109 |  |  | \u2014 |  |  | 109 |  |  | \u2014 |  |  | 105 |  |  | \u2014 |  |  | 105 | \nDeferred compensation plan5: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDeferred compensation liabilities |  | 83 |  |  | \u2014 |  |  | \u2014 |  |  | 83 |  |  | 73 |  |  | \u2014 |  |  | \u2014 |  |  | 73 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2023 |  | December 31,2022\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 1,533 |  |  | $ | 1,392 | \nPrepaid income taxes |  | 24 |  |  | 34 | \nOther |  | 1,067 |  |  | 920 | \nTotal prepaid expenses and other current assets |  | $ | 2,624 |  |  | $ | 2,346 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2023 |  | December 31,2022\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 4,917 |  |  | $ | 4,578 | \nEquity investments |  | 1,650 |  |  | 1,730 | \nIncome taxes receivable |  | 654 |  |  | 633 | \nOther |  | 618 |  |  | 639 | \nTotal other assets |  | $ | 7,839 |  |  | $ | 7,580 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2023 |  | December 31,2022\n |  | (in millions)\nCustomer and merchant incentives |  | $ | 5,667 |  |  | $ | 5,600 | \nPersonnel costs |  | 996 |  |  | 1,322 | \nIncome and other taxes |  | 555 |  |  | 279 | \nOther |  | 557 |  |  | 600 | \nTotal accrued expenses |  | $ | 7,775 |  |  | $ | 7,801 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | September 30,2023 |  | December 31,2022 |  | EffectiveInterest Rate\n |  |  |  |  | (in millions) |  | \nSenior Notes |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n2023 USD Notes |  | 4.875 | % | Senior Notes due March 2028 |  | $ | 750 |  |  | $ | \u2014 |  |  | 5.003 | %\n |  | 4.850 | % | Senior Notes due March 2033 |  | 750 |  |  | \u2014 |  |  | 4.923 | %\n |  |  |  |  |  |  |  |  | \n2022 EUR Notes1 |  | 1.000 | % | Senior Notes due February 2029 |  | 794 |  |  | 800 |  |  | 1.138 | %\n |  |  |  |  |  |  |  |  | \n2021 USD Notes |  | 2.000 | % | Senior Notes due November 2031 |  | 750 |  |  | 750 |  |  | 2.112 | %\n |  | 1.900 | % | Senior Notes due March 2031 |  | 600 |  |  | 600 |  |  | 1.981 | %\n |  | 2.950 | % | Senior Notes due March 2051 |  | 700 |  |  | 700 |  |  | 3.013 | %\n |  |  |  |  |  |  |  |  | \n2020 USD Notes |  | 3.300 | % | Senior Notes due March 2027 |  | 1,000 |  |  | 1,000 |  |  | 3.420 | %\n |  | 3.350 | % | Senior Notes due March 2030 |  | 1,500 |  |  | 1,500 |  |  | 3.430 | %\n |  | 3.850 | % | Senior Notes due March 2050 |  | 1,500 |  |  | 1,500 |  |  | 3.896 | %\n |  |  |  |  |  |  |  |  | \n2019 USD Notes |  | 2.950 | % | Senior Notes due June 2029 |  | 1,000 |  |  | 1,000 |  |  | 3.030 | %\n |  | 3.650 | % | Senior Notes due June 2049 |  | 1,000 |  |  | 1,000 |  |  | 3.689 | %\n |  | 2.000 | % | Senior Notes due March 2025 |  | 750 |  |  | 750 |  |  | 2.147 | %\n |  |  |  |  |  |  |  |  | \n2018 USD Notes |  | 3.500 | % | Senior Notes due February 2028 |  | 500 |  |  | 500 |  |  | 3.598 | %\n |  | 3.950 | % | Senior Notes due February 2048 |  | 500 |  |  | 500 |  |  | 3.990 | %\n |  |  |  |  |  |  |  |  | \n2016 USD Notes |  | 2.950 | % | Senior Notes due November 2026 |  | 750 |  |  | 750 |  |  | 3.044 | %\n |  | 3.800 | % | Senior Notes due November 2046 |  | 600 |  |  | 600 |  |  | 3.893 | %\n |  |  |  |  |  |  |  |  | \n2015 EUR Notes2 |  | 2.100 | % | Senior Notes due December 2027 |  | 846 |  |  | 854 |  |  | 2.189 | %\n |  | 2.500 | % | Senior Notes due December 2030 |  | 159 |  |  | 160 |  |  | 2.562 | %\n |  |  |  |  |  |  |  |  | \n2014 USD Notes |  | 3.375 | % | Senior Notes due April 2024 |  | 1,000 |  |  | 1,000 |  |  | 3.484 | %\n |  |  |  |  |  |  |  |  | \nOther Debt |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n2023 INR Term Loan3 |  | 9.430 | % | Term Loan due July 2024 |  | 338 |  |  | \u2014 |  |  | 9.780 | %\n |  |  |  |  |  |  |  |  | \n2022 INR Term Loan4 |  | 8.640 | % | Term Loan due July 2023 |  | \u2014 |  |  | 275 |  |  | 9.090 | %\n |  |  |  |  |  |  |  |  | \n |  |  |  |  | 15,787 |  |  | 14,239 |  |  | \nLess: Unamortized discount and debt issuance costs | (112) |  |  | (111) |  |  | \nLess: Cumulative hedge accounting fair value adjustments5 |  | (109) |  |  | (105) |  |  | \nTotal debt outstanding | 15,566 |  |  | 14,023 |  |  | \nLess: Short-term debt6 |  | (1,337) |  |  | (274) |  |  | \nLong-term debt | $ | 14,229 |  |  | $ | 13,749 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in\u00a0millions,\u00a0except\u00a0per\u00a0share\u00a0data)\nDividends declared per share |  | $ | 0.57 |  |  | $ | 0.49 |  |  | $ | 1.71 |  |  | $ | 1.47 | \nTotal dividends declared |  | $ | 536 |  |  | $ | 472 |  |  | $ | 1,615 |  |  | $ | 1,423 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30,\n |  | 2023 |  | 2022\n |  | Outstanding Shares |  | Outstanding Shares\n |  | Class\u00a0A |  | Class\u00a0B |  | Class\u00a0A |  | Class\u00a0B\n |  | (in millions)\nBalance at beginning of period |  | 935.9 |  |  | 7.4 |  |  | 960.0 |  |  | 7.7 | \nPurchases of treasury stock |  | (4.8) |  |  | \u2014 |  |  | (4.7) |  |  | \u2014 | \nShare-based payments |  | 0.5 |  |  | \u2014 |  |  | 0.1 |  |  | \u2014 | \nConversion of Class B to Class A common stock |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nBalance at end of period |  | 931.6 |  |  | 7.4 |  |  | 955.4 |  |  | 7.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022\n |  | Outstanding Shares |  | Outstanding Shares\n |  | Class\u00a0A |  | Class\u00a0B |  | Class\u00a0A |  | Class\u00a0B\n |  | (in millions)\nBalance at beginning of period |  | 948.4 |  |  | 7.6 |  |  | 972.1 |  |  | 7.8 | \nPurchases of treasury stock |  | (19.2) |  |  | \u2014 |  |  | (18.3) |  |  | \u2014 | \nShare-based payments |  | 2.2 |  |  | \u2014 |  |  | 1.5 |  |  | \u2014 | \nConversion of Class B to Class A common stock |  | 0.2 |  |  | (0.2) |  |  | 0.1 |  |  | (0.1) | \nBalance at end of period |  | 931.6 |  |  | 7.4 |  |  | 955.4 |  |  | 7.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022\n |  | (in millions, except per share data)\nDollar-value of shares repurchased1 |  | $ | 7,200 |  |  | $ | 6,339 | \nShares repurchased |  | 19.2 |  |  | 18.3 | \nAverage price paid per share |  | $ | 375.34 |  |  | $ | 345.54 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2022 |  | Increase / (Decrease) |  | Reclassifications |  | September 30, 2023\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (1,414) |  |  | $ | (105) |  |  | $ | \u2014 |  |  | $ | (1,519) | \nTranslation adjustments on net investment hedges2 |  | 309 |  |  | 41 |  |  | \u2014 |  |  | 350 | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | (8) |  |  | (5) |  |  | 18 |  |  | 5 | \nInterest rate contracts |  | (123) |  |  | \u2014 |  |  | 4 |  |  | (119) | \nDefined benefit pension and other postretirement plans |  | (11) |  |  | \u2014 |  |  | \u2014 |  |  | (11) | \nInvestment securities available-for-sale |  | (6) |  |  | 3 |  |  | \u2014 |  |  | (3) | \nAccumulated other comprehensive income (loss) |  | $ | (1,253) |  |  | $ | (66) |  |  | $ | 22 |  |  | $ | (1,297) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | December 31, 2021 |  | Increase / (Decrease) |  | Reclassifications |  | September 30, 2022\n |  | (in millions)\nForeign currency translation adjustments1 |  | $ | (739) |  |  | $ | (1,412) |  |  | $ | \u2014 |  |  | $ | (2,151) | \nTranslation adjustments on net investment hedges2 |  | 34 |  |  | 601 |  |  | \u2014 |  |  | 635 | \nCash flow hedges |  |  |  |  |  |  |  | \nForeign exchange contracts3 |  | 4 |  |  | 16 |  |  | (11) |  |  | 9 | \nInterest rate contracts |  | (128) |  |  | \u2014 |  |  | 4 |  |  | (124) | \nDefined benefit pension and other postretirement plans |  | 21 |  |  | \u2014 |  |  | (1) |  |  | 20 | \nInvestment securities available-for-sale |  | (1) |  |  | (5) |  |  | \u2014 |  |  | (6) | \nAccumulated other comprehensive income (loss) |  | $ | (809) |  |  | $ | (800) |  |  | $ | (8) |  |  | $ | (1,617) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Grants in 2023 |  | Weighted-AverageGrant-DateFair Value\n |  | (in millions) |  | (per option/unit)\nNon-qualified stock options |  | 0.3 |  | $ | 123 | \nRestricted stock units |  | 1.2 |  | $ | 350 | \nPerformance stock units |  | 0.2 |  | $ | 365 |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30,2023 |  | December 31,2022\n |  | (in millions)\nGross settlement exposure |  | $ | 73,134 |  |  | $ | 64,885 | \nRisk mitigation arrangements applied to settlement exposure1 |  | (11,141) |  |  | (9,224) | \nNet settlement exposure1 |  | $ | 61,993 |  |  | $ | 55,661 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2023 |  | December 31, 2022\n |  | Notional |  | Derivative assets |  | Derivative liabilities |  | Notional |  | Derivative assets |  | Derivative liabilities\n |  | (in millions)\nDerivatives designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts in a cash flow hedge1 |  | $ | 1,055 |  |  | $ | 15 |  |  | $ | 9 |  |  | $ | 642 |  |  | $ | 4 |  |  | $ | 15 | \nInterest rate contracts in a fair value hedge2 |  | 1,000 |  |  | \u2014 |  |  | 109 |  |  | 1,000 |  |  | \u2014 |  |  | 105 | \nForeign exchange contracts in a net investment hedge1 |  | 2,858 |  |  | 93 |  |  | \u2014 |  |  | 1,814 |  |  | 103 |  |  | 4 | \nDerivatives not designated as hedging instruments |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts1 |  | 2,099 |  |  | 12 |  |  | 13 |  |  | 521 |  |  | 1 |  |  | 2 | \nTotal derivative assets/liabilities |  | $ | 7,012 |  |  | $ | 120 |  |  | $ | 131 |  |  | $ | 3,977 |  |  | $ | 108 |  |  | $ | 126 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Gain (Loss)Recognized in OCI |  |  |  | Gain (Loss)Reclassified from AOCI\n |  | Three Months Ended September 30, |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Three Months Ended September 30,\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022\n |  | (in millions) |  |  | (in millions)\nDerivative financial instruments in a cash flow hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 17 |  |  | $ | 14 |  |  | Net revenue |  | $ | (10) |  |  | $ | 6 | \nInterest rate contracts |  | $ | \u2014 |  |  | $ | \u2014 |  |  | Interest expense |  | $ | (2) |  |  | $ | (2) | \n |  |  |  |  |  |  |  |  |  | \nDerivative financial instruments in a net investment hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 84 |  |  | $ | 183 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Gain (Loss)Recognized in OCI |  |  |  | Gain (Loss)Reclassified from AOCI\n |  | Nine Months Ended September 30, |  | Location of Gain (Loss) Reclassified from AOCI into Earnings |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022\n |  | (in millions) |  |  | (in millions)\nDerivative financial instruments in a cash flow hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | (7) |  |  | $ | 21 |  |  | Net revenue |  | $ | (24) |  |  | $ | 14 | \nInterest rate contracts |  | $ | \u2014 |  |  | $ | \u2014 |  |  | Interest expense |  | $ | (5) |  |  | $ | (5) | \n |  |  |  |  |  |  |  |  |  | \nDerivative financial instruments in a net investment hedge relationship: |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  | $ | 38 |  |  | $ | 384 |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\nDerivatives not designated as hedging instruments: |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | (in millions)\nForeign exchange contracts |  |  |  |  |  |  |  | \nGeneral and administrative |  | $ | (4) |  |  | $ | 13 |  |  | $ | 21 |  |  | $ | 25 | \n |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/(Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  | ($ in millions, except per share data)\nNet revenue |  | $ | 6,533 |  |  | $ | 5,756 |  |  | 14% |  | $ | 18,550 |  |  | $ | 16,420 |  |  | 13%\nOperating expenses |  | $ | 2,689 |  |  | $ | 2,644 |  |  | 2% |  | $ | 7,914 |  |  | $ | 7,340 |  |  | 8%\nOperating income |  | $ | 3,844 |  |  | $ | 3,112 |  |  | 24% |  | $ | 10,636 |  |  | $ | 9,080 |  |  | 17%\nOperating margin |  | 58.8 | % |  | 54.1 | % |  | 4.8 ppt |  | 57.3 | % |  | 55.3 | % |  | 2.0 ppt\nIncome tax expense |  | $ | 563 |  |  | $ | 573 |  |  | (2)% |  | $ | 1,914 |  |  | $ | 1,238 |  |  | 54%\nEffective income tax rate |  | 15.0 | % |  | 18.6 | % |  | (3.7) ppt |  | 18.6 | % |  | 14.3 | % |  | 4.2 ppt\nNet income |  | $ | 3,198 |  |  | $ | 2,499 |  |  | 28% |  | $ | 8,404 |  |  | $ | 7,405 |  |  | 13%\nDiluted earnings per share |  | $ | 3.39 |  |  | $ | 2.58 |  |  | 31% |  | $ | 8.85 |  |  | $ | 7.60 |  |  | 16%\nDiluted weighted-average shares outstanding |  | 943 |  |  | 968 |  |  | (3)% |  | 949 |  |  | 974 |  |  | (3)%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Increase/(Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n | 2023 |  | 2022 |  | As adjusted |  | Currency-neutral |  | 2023 |  | 2022 |  | As adjusted |  | Currency-neutral\n | ($ in millions, except per share data)\nAdjusted net revenue2 | $ | 6,533 |  |  | $ | 5,756 |  |  | 14% |  | 11% |  | $ | 18,550 |  |  | $ | 16,383 |  |  | 13% |  | 14%\nAdjusted operating expenses | $ | 2,689 |  |  | $ | 2,437 |  |  | 10% |  | 9% |  | $ | 7,683 |  |  | $ | 6,932 |  |  | 11% |  | 11%\nAdjusted operating margin | 58.8 | % |  | 57.7 | % |  | 1.2 ppt |  | 0.8 ppt |  | 58.6 | % |  | 57.7 | % |  | 0.9 ppt |  | 0.8 ppt\nAdjusted effective income tax rate | 15.0 | % |  | 19.4 | % |  | (4.4) ppt |  | (4.6) ppt |  | 19.0 | % |  | 14.8 | % |  | 4.2 ppt |  | 4.1 ppt\nAdjusted net income | $ | 3,202 |  |  | $ | 2,595 |  |  | 23% |  | 21% |  | $ | 8,622 |  |  | $ | 7,794 |  |  | 11% |  | 11%\nAdjusted diluted earnings per share | $ | 3.39 |  |  | $ | 2.68 |  |  | 26% |  | 24% |  | $ | 9.08 |  |  | $ | 8.00 |  |  | 14% |  | 14%  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | Adjusted net revenue | \nThree Months Ended September 30, 2023 | \nGAAP |  | Non-GAAP(currency-neutral) | Adjusted net revenue increased 11% on a currency-neutral basis.  The increase was attributable to growth in both our payment network and value-added services and solutions.\nup 14% |  | up 11%\n |  |  | \nNine Months Ended September 30, 2023 | \nGAAP |  | Non-GAAP(currency-neutral) | Adjusted net revenue increased 14% on a currency-neutral basis.  The increase was attributable to growth in both our payment network and value-added services and solutions.\nup 13% |  | up 14%\n |  |  |   |  |  |  |  |  |  |  |  |  |  | \nOperating expenses |  | Adjustedoperating expenses | \nThree Months Ended September 30, 2023 | \nGAAP |  | Non-GAAP(currency-neutral) | Adjusted operating expenses increased 9% on a currency-neutral basis, which includes 1 percentage point of growth due to acquisitions.  The increase was primarily due to higher personnel costs.\nup 2% |  | up 9%\n |  |  | \nNine Months Ended September 30, 2023 | \nGAAP |  | Non-GAAP(currency-neutral) | Adjusted operating expenses increased 11% on a currency-neutral basis, which includes 1 percentage point of growth due to acquisitions.  The increase was primarily due to higher personnel costs.\nup 8% |  | up 11%  |  |  |  |  |  |  |  |  |  |  | \nEffective incometax rate |  | Adjusted effectiveincome tax rate | \nThree Months Ended September 30, 2023 | The adjusted effective income tax rate of 15.0% was lower than the prior year rate of 19.4% primarily due to our ability to now claim more U.S. foreign tax credits generated in 2022 and 2023, partially offset by the establishment of a valuation allowance in 2023 of $115 million.\nGAAP |  | Non-GAAP\n15.0% |  | 15.0%\n |  | \nNine Months Ended September 30, 2023 | The adjusted effective income tax rate of 19.0% was higher than the prior year rate of 14.8% primarily due to the release of a $333 million valuation allowance in 2022 and the establishment of a $327 million valuation allowance in 2023, partially offset by the ability to now claim more U.S. foreign tax credits generated in 2022 and 2023.\nGAAP |  | Non-GAAP\n18.6% |  | 19.0%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, 2023\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 6,533 |  |  | $ | 2,689 |  |  | 58.8 | % |  | $ | (83) |  |  | 15.0 | % |  | $ | 3,198 |  |  | $ | 3.39 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 6 |  |  | \u2014 | % |  | 5 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | $ | 6,533 |  |  | $ | 2,689 |  |  | 58.8 | % |  | $ | (78) |  |  | 15.0 | % |  | $ | 3,202 |  |  | $ | 3.39 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2023\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 18,550 |  |  | $ | 7,914 |  |  | 57.3 | % |  | $ | (318) |  |  | 18.6 | % |  | $ | 8,404 |  |  | $ | 8.85 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 95 |  |  | 0.1 | % |  | 63 |  |  | 0.07 | \nLitigation provisions |  | ** |  | (231) |  |  | 1.2 | % |  | ** |  | 0.3 | % |  | 156 |  |  | 0.16 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | $ | 18,550 |  |  | $ | 7,683 |  |  | 58.6 | % |  | $ | (223) |  |  | 19.0 | % |  | $ | 8,622 |  |  | $ | 9.08 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, 2022\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 5,756 |  |  | $ | 2,644 |  |  | 54.1 | % |  | $ | (40) |  |  | 18.6 | % |  | $ | 2,499 |  |  | $ | 2.58 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | (60) |  |  | 0.6 | % |  | (66) |  |  | (0.07) | \nLitigation provisions |  | ** |  | (208) |  |  | 3.6 | % |  | ** |  | 0.2 | % |  | 162 |  |  | 0.17 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | $ | 5,756 |  |  | $ | 2,437 |  |  | 57.7 | % |  | $ | (99) |  |  | 19.4 | % |  | $ | 2,595 |  |  | $ | 2.68 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2022\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Other income (expense) |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\n |  | ($ in millions, except per share data)\nReported - GAAP |  | $ | 16,420 |  |  | $ | 7,340 |  |  | 55.3 | % |  | $ | (437) |  |  | 14.3 | % |  | $ | 7,405 |  |  | $ | 7.60 | \n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 133 |  |  | \u2014 | % |  | 114 |  |  | 0.12 | \nLitigation provisions |  | ** |  | (341) |  |  | 2.1 | % |  | ** |  | 0.5 | % |  | 251 |  |  | 0.26 | \nRussia-related impacts |  | (37) |  |  | (67) |  |  | 0.3 | % |  | ** |  | \u2014 | % |  | 24 |  |  | 0.02 | \nAdjusted - Non-GAAP |  | $ | 16,383 |  |  | $ | 6,932 |  |  | 57.7 | % |  | $ | (303) |  |  | 14.8 | % |  | $ | 7,794 |  |  | $ | 8.00 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, 2023 as compared to the Three Months Ended September 30, 2022\n |  | Increase/(Decrease)\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\nReported - GAAP |  | 14% |  | 2% |  | 4.8 ppt |  | (3.7) ppt |  | 28% |  | 31%\n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | (0.6) ppt |  | 4% |  | 4%\nLitigation provisions |  | ** |  | 9% |  | (3.6) ppt |  | (0.2) ppt |  | (8)% |  | (8)%\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | 14% |  | 10% |  | 1.2 ppt |  | (4.4) ppt |  | 23% |  | 26%\nCurrency impact |  | (2)% |  | (1)% |  | (0.4) ppt |  | (0.2) ppt |  | (3)% |  | (3)%\nAdjusted - Non-GAAP - currency-neutral |  | 11% |  | 9% |  | 0.8 ppt |  | (4.6) ppt |  | 21% |  | 24%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2023 as compared to the Nine Months Ended September 30, 2022\n |  | Increase/(Decrease)\n |  | Net revenue |  | Operating expenses |  | Operating margin |  | Effective income tax rate |  | Net income |  | Diluted earnings per share\nReported - GAAP |  | 13% |  | 8% |  | 2.0 ppt |  | 4.2 ppt |  | 13% |  | 16%\n(Gains) losses on equity investments |  | ** |  | ** |  | ** |  | 0.1 ppt |  | (1)% |  | (1)%\nLitigation provisions |  | ** |  | 2% |  | (0.8) ppt |  | (0.1) ppt |  | (2)% |  | (2)%\nRussia-related impacts |  | \u2014% |  | 1% |  | (0.2) ppt |  | \u2014 ppt |  | \u2014% |  | \u2014%\n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted - Non-GAAP |  | 13% |  | 11% |  | 0.9 ppt |  | 4.2 ppt |  | 11% |  | 14%\nCurrency impact |  | \u2014% |  | \u2014% |  | (0.1) ppt |  | (0.1) ppt |  | \u2014% |  | \u2014%\nAdjusted - Non-GAAP - currency-neutral |  | 14% |  | 11% |  | 0.8 ppt |  | 4.1 ppt |  | 11% |  | 14%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | Increase/(Decrease) |  | Increase/(Decrease)\n |  | USD |  | Local |  | USD |  | Local |  | USD |  | Local |  | USD |  | Local\nMastercard-branded GDV growth1 |  | 11% |  | 11% |  | 4% |  | 12% |  | 10% |  | 13% |  | 8% |  | 14%\nUnited States |  | 5% |  | 5% |  | 10% |  | 10% |  | 6% |  | 6% |  | 11% |  | 11%\nWorldwide less United States |  | 14% |  | 13% |  | 1% |  | 12% |  | 12% |  | 16% |  | 6% |  | 16%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCross-border volume growth1 |  | 26% |  | 21% |  | 29% |  | 44% |  | 26% |  | 26% |  | 39% |  | 51%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMastercard-branded GDV growthadjusted for Russia1,2 |  | 11% |  | 11% |  | 9% |  | 18% |  | 11% |  | 13% |  | 12% |  | 19%\nWorldwide less United States GDV growth adjusted for Russia1,2 |  | 14% |  | 13% |  | 8% |  | 23% |  | 13% |  | 16% |  | 13% |  | 24%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCross-border volume growthadjusted for Russia1,2 |  | 26% |  | 21% |  | 33% |  | 50% |  | 27% |  | 27% |  | 42% |  | 55%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n |  | 2023 |  | 2022 |  | 2023 |  | 2022\n |  | Increase/(Decrease) |  | Increase/(Decrease)\nSwitched transactions growth |  | 15% |  | 9% |  | 15% |  | 14%\n |  |  |  |  |  |  |  | \nSwitched transactions growth adjusted for Russia2 |  | 15% |  | 19% |  | 17% |  | 22%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/(Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n |  | 2023 |  | 2022 |  | As reported |  | Currency-neutral |  | 2023 |  | 2022 |  | As reported |  | Currency-neutral\n |  | ($ in millions) |  | ($ in millions)\nDomestic assessments |  | $ | 2,460 |  |  | $ | 2,220 |  |  | 11% |  | 10% |  | $ | 7,182 |  |  | $ | 6,579 |  |  | 9% |  | 10%\nCross-border assessments |  | 2,313 |  |  | 1,804 |  |  | 28% |  | 26% |  | 6,211 |  |  | 4,806 |  |  | 29% |  | 31%\nTransaction processing assessments |  | 3,172 |  |  | 2,786 |  |  | 14% |  | 11% |  | 8,902 |  |  | 7,815 |  |  | 14% |  | 14%\nOther network assessments |  | 229 |  |  | 195 |  |  | 17% |  | 17% |  | 712 |  |  | 576 |  |  | 24% |  | 24%\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/(Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease) |  | \n |  | 2023 |  | 2022 |  | 2021 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  |  |  | 2021 |  | 2023 |  | 2022 |  | \n |  | ($ in millions) |  |  |  |  |  | ($ in millions) |  |  |  |  |  | \nPayment network |  | $ | 4,210 |  |  | $ | 3,765 |  |  | $ | 3,234 |  |  | 12% |  | 16% |  | $ | 11,933 |  |  | $ | 10,773 |  |  |  |  | $ | 8,757 |  |  | 11% |  | 23% |  | \nValue-added services and solutions |  | 2,323 |  |  | 1,991 |  |  | 1,751 |  |  | 17% |  | 14% |  | 6,617 |  |  | 5,647 |  |  |  |  | 4,911 |  |  | 17% |  | 15% |  | \nTotal net revenue |  | 6,533 |  |  | 5,756 |  |  | 4,985 |  |  | 14% |  | 15% |  | 18,550 |  |  | 16,420 |  |  |  |  | 13,668 |  |  | 13% |  | 20% |  | \nSpecial Items1 |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | ** |  | ** |  | \u2014 |  |  | (37) |  |  |  |  | \u2014 |  |  | ** |  | ** |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted net revenue(excluding Special Items1) |  | $ | 6,533 |  |  | $ | 5,756 |  |  | $ | 4,985 |  |  | 14% |  | 15% |  | $ | 18,550 |  |  | $ | 16,383 |  |  |  |  | $ | 13,668 |  |  | 13% |  | 20% |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | \n |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30,\n |  | Increase/(Decrease)\n |  | Operational |  |  |  | Acquisitions |  | Currency Impact3 |  | Special Items4 |  | Total\n |  | 2023 |  | 2022 |  |  |  |  |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  |  |  |  | 2022\nPayment network |  | 10 | % | 1 | 24 | % | 1 |  |  |  |  | ** |  | ** |  | 2 | % |  | (8) | % |  | ** |  | \u2014 | % |  | 12 | % |  |  |  |  | 16 | %\nValue-added services and solutions |  | 13 | % | 2 | 19 | % | 2 |  |  |  |  | \u2014 | % |  | 2 | % |  | 3 | % |  | (7) | % |  | ** |  | ** |  | 17 | % |  |  |  |  | 14 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | 11 | % |  | 22 | % |  |  |  |  |  | \u2014 | % |  | 1 | % |  | 2 | % |  | (7) | % |  | \u2014 | % |  | \u2014 | % |  | 14 | % |  |  |  |  | 15 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30,\n |  | Increase/(Decrease)\n |  | Operational |  |  |  | Acquisitions |  | Currency Impact3 |  | Special Items4 |  | Total\n |  | 2023 |  | 2022 |  |  |  |  |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  |  |  |  | 2022\nPayment network |  | 12 | % | 1 | 29 | % | 1 |  |  |  |  | ** |  | ** |  | \u2014 | % |  | (6) | % |  | ** |  | \u2014 | % |  | 11 | % |  |  |  |  | 23 | %\nValue-added services and solutions |  | 16 | % | 2 | 16 | % | 2 |  |  |  |  | 1 | % |  | 4 | % |  | 1 | % |  | (5) | % |  | ** |  | ** |  | 17 | % |  |  |  |  | 15 | %\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet revenue |  | 13 | % |  | 24 | % |  |  |  |  |  | \u2014 | % |  | 1 | % |  | \u2014 | % |  | (6) | % |  | \u2014 | % |  | \u2014 | % |  | 13 | % |  |  |  |  | 20 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/ (Decrease) |  | Nine Months Ended September 30, |  | Increase/ (Decrease)\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  | ($ in millions)\nGeneral and administrative |  | $ | 2,285 |  |  | $ | 2,069 |  |  | 10% |  | $ | 6,528 |  |  | $ | 5,860 |  |  | 11%\nAdvertising and marketing |  | 193 |  |  | 182 |  |  | 6% |  | 561 |  |  | 573 |  |  | (2)%\nDepreciation and amortization |  | 211 |  |  | 185 |  |  | 14% |  | 594 |  |  | 566 |  |  | 5%\nProvision for litigation |  | \u2014 |  |  | 208 |  |  | ** |  | 231 |  |  | 341 |  |  | **\nTotal operating expenses |  | 2,689 |  |  | 2,644 |  |  | 2% |  | 7,914 |  |  | 7,340 |  |  | 8%\nSpecial Items1 |  | \u2014 |  |  | (208) |  |  | ** |  | (231) |  |  | (408) |  |  | **\nAdjusted total operating expenses (excluding Special Items1) |  | $ | 2,689 |  |  | $ | 2,437 |  |  | 10% |  | $ | 7,683 |  |  | $ | 6,932 |  |  | 11%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, 2023\n |  | Increase/(Decrease)\n |  | Operational |  | Acquisitions |  | Currency Impact1 |  | SpecialItems2, 3 |  | Total\nGeneral and administrative |  | 9% |  | 1% |  | 1% |  | ** |  | 10%\nAdvertising and marketing |  | 4% |  | \u2014% |  | 2% |  | ** |  | 6%\nDepreciation and amortization |  | 11% |  | \u2014% |  | 3% |  | ** |  | 14%\nProvision for litigation |  | ** |  | ** |  | ** |  | ** |  | **\nTotal operating expenses |  | 9% |  | 1% |  | 1% |  | (9)% |  | 2%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Nine Months Ended September 30, 2023\n |  | Increase/(Decrease)\n |  | Operational |  | Acquisitions |  | Currency Impact1 |  | SpecialItems2 |  | Total\nGeneral and administrative |  | 12% |  | 1% |  | (1)% |  | (1)% |  | 11%\nAdvertising and marketing |  | (2)% |  | \u2014% |  | \u2014% |  | ** |  | (2)%\nDepreciation and amortization |  | 4% |  | 1% |  | \u2014% |  | ** |  | 5%\nProvision for litigation |  | ** |  | ** |  | ** |  | ** |  | **\nTotal operating expenses |  | 10% |  | 1% |  | \u2014% |  | (3)% |  | 8%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/ (Decrease) |  | Nine Months Ended September 30, |  | Increase/(Decrease)\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  | ($ in millions)\nPersonnel1 |  | $ | 1,573 |  |  | $ | 1,382 |  |  | 14% |  | $ | 4,494 |  |  | $ | 3,882 |  |  | 16%\nProfessional fees |  | 118 |  |  | 118 |  |  | \u2014% |  | 332 |  |  | 313 |  |  | 6%\nData processing and telecommunications |  | 262 |  |  | 228 |  |  | 15% |  | 743 |  |  | 688 |  |  | 8%\nForeign exchange activity2 |  | 25 |  |  | 38 |  |  | ** |  | 65 |  |  | 109 |  |  | **\nOther1 |  | 307 |  |  | 303 |  |  | 2% |  | 894 |  |  | 868 |  |  | 3%\nTotal general and administrative expenses |  | $ | 2,285 |  |  | $ | 2,069 |  |  | 10% |  | $ | 6,528 |  |  | $ | 5,860 |  |  | 11%\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended September 30, |  | Increase/ (Decrease) |  | Nine Months Ended September 30, |  | Increase/ (Decrease)\n |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  | ($ in millions)\nInvestment income |  | $ | 71 |  |  | $ | 16 |  |  | ** |  | $ | 185 |  |  | $ | 28 |  |  | **\nGains (losses) on equity investments, net |  | (6) |  |  | 60 |  |  | ** |  | (95) |  |  | (133) |  |  | **\nInterest expense |  | (151) |  |  | (120) |  |  | 25% |  | (427) |  |  | (344) |  |  | 24%\nOther income (expense), net |  | 3 |  |  | 4 |  |  | ** |  | 19 |  |  | 12 |  |  | **\nTotal other income (expense) |  | (83) |  |  | (40) |  |  | ** |  | (318) |  |  | (437) |  |  | **\n(Gains) losses on equity investments1 |  | 6 |  |  | (60) |  |  | ** |  | 95 |  |  | 133 |  |  | **\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \nAdjusted total other income (expense)1 |  | $ | (78) |  |  | $ | (99) |  |  | (21)% |  | $ | (223) |  |  | $ | (303) |  |  | (26)%  |  |  |  |  |  |  |  |  |  |  | \n | September 30,2023 |  | December 31,2022\n | (in billions)\nCash, cash equivalents and investments1 | $ | 7.5 |  |  | $ | 7.4 | \nUnused line of credit | 8.0 |  |  | 8.0 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2023 |  | 2022\n | (in millions)\nNet cash provided by operating activities | $ | 7,850 |  |  | $ | 8,095 | \nNet cash used in investing activities | (1,137) |  |  | (1,120) | \nNet cash used in financing activities | (7,138) |  |  | (6,714) |   |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  | (in millions, except average price data)\nRemaining authorization at December 31, 2022 |  |  |  |  |  | $ | 12,174 | \nDollar-value of shares repurchased during the nine months ended September 30, 20231 |  |  |  |  |  | $ | 7,200 | \nRemaining authorization at September 30, 2023 |  |  |  |  |  | $ | 4,974 | \nShares repurchased during the nine months ended September 30, 2023 |  |  |  |  |  | 19.2 | \nAverage price paid per share during the nine months ended September 30, 2023 |  |  |  |  |  | $ | 375.34 | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  | PART II |  |  | \n |  | Item 1. Legal proceedings |  |  | \n |  | Item 1A. Risk factors |  |  | \n |  | Item 2. Unregistered sales of equity securities and use of proceeds |  |  | \n |  | Item 5. Other information |  |  | \n |  | Item 6. Exhibits |  |  | \n |  | Signatures |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod |  | Total\u00a0Numberof\u00a0SharesPurchased |  | Average\u00a0PricePaid\u00a0per\u00a0Share(includingcommission\u00a0cost) |  | Total\u00a0Number\u00a0ofShares\u00a0Purchased\u00a0asPart\u00a0of\u00a0PubliclyAnnounced\u00a0Plans\u00a0orPrograms |  | Dollar\u00a0Value\u00a0ofShares\u00a0that\u00a0may\u00a0yetbe\u00a0Purchased\u00a0underthe Plans\u00a0orPrograms1, 2\nJuly 1 - 31 |  | 1,664,589 |  |  | $ | 396.95 |  |  | 1,664,589 |  |  | $ | 6,218,906,492 | \nAugust 1 - 31 |  | 1,737,057 |  |  | $ | 396.20 |  |  | 1,737,057 |  |  | $ | 5,530,680,868 | \nSeptember 1 - 30 |  | 1,356,433 |  |  | $ | 410.74 |  |  | 1,356,433 |  |  | $ | 4,973,542,871 | \nTotal |  | 4,758,079 |  |  | $ | 400.61 |  |  | 4,758,079 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | Action |  | Date |  | Plans |  | Number of Securities to be Sold |  | Expiration\n |  |  | Rule 10b5-11 |  | Non-Rule 10b5-12 |  | \nEd McLaughlin,President & Chief Technology Officer, Mastercard Technology |  | Adoption |  | August 18, 2023 |  | X |  | - |  | 20,000 shares of Class A Common Stock underlying employee stock options |  | The earlier of (i) the date when all securities under plan are exercised and sold and (ii) December 31, 2024\n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  | \nExhibitNumber |  | Exhibit Description\n10.1*+ |  | Amended and RestatedMastercard InternationalIncorporated Executive Severance Plan,amended and restatedas ofOctober 17, 2023.\n10.2*+ |  | Amended and Restated Mastercard International IncorporatedChangein ControlSeverance Plan,amended and restatedas ofOctober 17, 2023.\n31.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n31.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n32.1* |  | Certification of Michael Miebach, President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n32.2* |  | Certification of Sachin Mehra, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n99.1* |  | Disclosure pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012.\n101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n101.SCH* |  | XBRL Taxonomy Extension Schema Document\n101.CAL* |  | XBRL Taxonomy Extension Calculation Linkbase Document\n101.DEF* |  | XBRL Taxonomy Extension Definition Linkbase Document\n101.LAB* |  | XBRL Taxonomy Extension Label Linkbase Document\n101.PRE* |  | XBRL Taxonomy Extension Presentation Linkbase Document  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | MASTERCARD INCORPORATED\n |  | (Registrant)\n |  |  | \nDate: | October 26, 2023 | By: |  | /S/ MICHAEL MIEBACH\n |  |  |  | Michael Miebach\n |  |  |  | President and Chief Executive Officer\n |  |  |  | (Principal Executive Officer)\n |  |  | \nDate: | October 26, 2023 | By: |  | /S/ SACHIN MEHRA\n |  |  |  | Sachin Mehra\n |  |  |  | Chief Financial Officer\n |  |  |  | (Principal Financial Officer)\n |  |  | \nDate: | October 26, 2023 | By: |  | /S/ SANDRA ARKELL\n |  |  |  | Sandra Arkell\n |  |  |  | Corporate Controller\n |  |  |  | (Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2022 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | 2000 Galloping Hill Road,Kenilworth,New Jersey07033 | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 30\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 42\n |  | \nItem 4. | Controls and Procedures | 42\n |  | \n | Cautionary Factors That May Affect Future Results | 43\n |  | \nPART II | OTHER INFORMATION | 43\n |  | \nItem 1. | Legal Proceedings | 43\n |  | \nItem 1A. | Risk Factors | 43\n |  |  |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 44\n |  |  |  | \nItem 6. | Exhibits | 44\n |  | \n | Signatures |  |  | 45  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \nSales | $ | 15,901 |  |  | $ | 10,627 |  |  |  |  | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 5,380 |  |  | 3,199 |  |  |  |  | \nSelling, general and administrative | 2,323 |  |  | 2,187 |  |  |  |  | \nResearch and development | 2,576 |  |  | 2,412 |  |  |  |  | \nRestructuring costs | 53 |  |  | 297 |  |  |  |  | \nOther (income) expense, net | 708 |  |  | (455) |  |  |  |  | \n | 11,040 |  |  | 7,640 |  |  |  |  | \nIncome from Continuing Operations Before Taxes | 4,861 |  |  | 2,987 |  |  |  |  | \nTaxes on Income from Continuing Operations | 554 |  |  | 238 |  |  |  |  | \nNet Income from Continuing Operations | 4,307 |  |  | 2,749 |  |  |  |  | \nLess: Net (Loss) Income Attributable to Noncontrolling Interests | (3) |  |  | 4 |  |  |  |  | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | 4,310 |  |  | 2,745 |  |  |  |  | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 434 |  |  |  |  | \nNet Income Attributable to Merck & Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.26 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.25 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nOther Comprehensive Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 63 |  |  | 230 |  |  |  |  | \nBenefit plan net gain and prior service credit, net of amortization | 32 |  |  | 81 |  |  |  |  | \nCumulative translation adjustment | (35) |  |  | (299) |  |  |  |  | \n | 60 |  |  | 12 |  |  |  |  | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,370 |  |  | $ | 3,191 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 8,556 |  |  | $ | 8,096 | \nShort-term investments | 372 |  |  | \u2014 | \nAccounts receivable (net of allowance for doubtful accounts of $95in 2022and $62in 2021) | 9,828 |  |  | 9,230 | \nInventories (excludes inventories of $2,495in 2022 and $2,194in 2021classified in Other assets - see Note\u00a07) | 5,774 |  |  | 5,953 | \nOther current assets | 6,654 |  |  | 6,987 | \nTotal current assets | 31,184 |  |  | 30,266 | \nInvestments | 316 |  |  | 370 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,498in 2022 and $18,192in 2021 | 19,747 |  |  | 19,279 | \nGoodwill | 21,258 |  |  | 21,264 | \nOther Intangibles, Net | 23,022 |  |  | 22,933 | \nOther Assets | 11,141 |  |  | 11,582 | \n | $ | 106,668 |  |  | $ | 105,694 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 1,208 |  |  | $ | 2,412 | \nTrade accounts payable | 3,715 |  |  | 4,609 | \nAccrued and other current liabilities | 14,051 |  |  | 13,859 | \nIncome taxes payable | 1,571 |  |  | 1,224 | \nDividends payable | 1,771 |  |  | 1,768 | \nTotal current liabilities | 22,316 |  |  | 23,872 | \nLong-Term Debt | 30,586 |  |  | 30,690 | \nDeferred Income Taxes | 3,071 |  |  | 3,441 | \nOther Noncurrent Liabilities | 9,742 |  |  | 9,434 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2022 and 2021 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,275 |  |  | 44,238 | \nRetained earnings | 56,252 |  |  | 53,696 | \nAccumulated other comprehensive loss | (4,369) |  |  | (4,429) | \n | 97,946 |  |  | 95,293 | \nLess treasury stock, at cost:1,048,727,225shares in 2022 and1,049,499,023shares in 2021 | 57,063 |  |  | 57,109 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 40,883 |  |  | 38,184 | \nNoncontrolling Interests | 70 |  |  | 73 | \nTotal equity | 40,953 |  |  | 38,257 | \n | $ | 106,668 |  |  | $ | 105,694 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31,\n | 2022 |  | 2021\nCash Flows from Operating Activities of Continuing Operations |  |  | \nNet income from continuing operations | $ | 4,307 |  |  | $ | 2,749 | \nAdjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: |  |  | \nAmortization | 699 |  |  | 514 | \nDepreciation | 421 |  |  | 378 | \nLoss (income) from investments in equity securities, net | 708 |  |  | (574) | \nDeferred income taxes | (338) |  |  | 18 | \nShare-based compensation | 120 |  |  | 111 | \nOther | 143 |  |  | 236 | \nNet changes in assets and liabilities | (1,299) |  |  | (2,192) | \nNet Cash Provided by Operating Activities of Continuing Operations | 4,761 |  |  | 1,240 | \nCash Flows from Investing Activities of Continuing Operations |  |  | \nCapital expenditures | (984) |  |  | (1,082) | \nPurchases of securities and other investments | (372) |  |  | (1) | \nProceeds from sales of securities and other investments | 1 |  |  | 386 | \nOther | 182 |  |  | 11 | \nNet Cash Used in Investing Activities of Continuing Operations | (1,173) |  |  | (686) | \nCash Flows from Financing Activities of Continuing Operations |  |  | \nNet change in short-term borrowings | \u2014 |  |  | 788 | \nPayments on debt | (1,250) |  |  | (1,153) | \nDividends paid to stockholders | (1,745) |  |  | (1,645) | \nProceeds from exercise of stock options | 12 |  |  | 9 | \nOther | (103) |  |  | (97) | \nNet Cash Used in Financing Activities of Continuing Operations | (3,086) |  |  | (2,098) | \nCash Flows from Discontinued Operations |  |  | \nNet cash provided by operating activities | \u2014 |  |  | 551 | \nNet cash used in investing activities | \u2014 |  |  | (52) | \nNet Cash Flows Provided by Discontinued Operations | \u2014 |  |  | 499 | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (55) |  |  | (97) | \nNet Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | 447 |  |  | (1,142) | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$71and $103at January 1, 2022 and 2021, respectively, included in Other current assets) | 8,167 |  |  | 8,165 | \nLess: Cash and cash equivalents related to discontinued operations | \u2014 |  |  | 141 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $58and $42at March\u00a031, 2022 and 2021, respectively, included in Other current assets) | $ | 8,614 |  |  | $ | 6,882 |   |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | \n($ in millions) |  | 2021\nSales |  | $ | 1,453 |  |  | \nCosts, Expenses and Other |  |  |  | \nCost of sales |  | 471 |  |  | \nSelling, general and administrative |  | 446 |  |  | \nResearch and development |  | 53 |  |  | \nRestructuring costs |  | 1 |  |  | \nOther (income) expense, net |  | 7 |  |  | \n |  | 978 |  |  | \nIncome from discontinued operations before taxes |  | 475 |  |  | \nTax provision |  | 38 |  |  | \nIncome from discontinued operations, net of taxes |  | 437 |  |  | \nLess: Income of discontinued operations attributable to noncontrolling interests |  | 3 |  |  | \n |  | $ | 434 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Lynparza | $ | 266 |  |  | $ | 228 |  |  |  |  | \nAlliance revenue - Koselugo | 9 |  |  | 5 |  |  |  |  | \nTotal alliance revenue | $ | 275 |  |  | $ | 233 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 299 |  |  | 42 |  |  |  |  | \nSelling, general and administrative | 44 |  |  | 40 |  |  |  |  | \nResearch and development | 26 |  |  | 29 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from AstraZeneca included inOther current assets | $ | 275 |  |  | $ | 271 |  |  |  |  | \nPayables to AstraZeneca included inTrade accounts payableandAccrued and other current liabilities(2) | 190 |  |  | 415 |  |  |  |  | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) | 600 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Lenvima | $ | 227 |  |  | $ | 130 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 53 |  |  | 47 |  |  |  |  | \nSelling, general and administrative | 31 |  |  | 23 |  |  |  |  | \nResearch and development | 57 |  |  | 64 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from Eisai included inOther current assets | $ | 241 |  |  | $ | 200 |  |  |  |  | \nPayables to Eisai included inAccrued and other current liabilities(2) | 325 |  |  | 625 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Adempas/Verquvo | $ | 72 |  |  | $ | 74 |  |  |  |  | \nNet sales of Adempas recorded by Merck | 61 |  |  | 55 |  |  |  |  | \nNet sales of Verquvo recorded by Merck | 3 |  |  | \u2014 |  |  |  |  | \nTotal sales | $ | 136 |  |  | $ | 129 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 50 |  |  | 208 |  |  |  |  | \nSelling, general and administrative | 23 |  |  | 17 |  |  |  |  | \nResearch and development | 17 |  |  | 7 |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from Bayer included inOther current assets | $ | 129 |  |  | $ | 114 |  |  |  |  | \nPayables to Bayer included inAccrued and other current liabilities(2) | 74 |  |  | 472 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nLagevriosales | $ | 3,247 |  |  | $ | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 1,724 |  |  | 46 |  |  |  |  | \nSelling, general and administrative | 34 |  |  | 3 |  |  |  |  | \nResearch and development | 6 |  |  | 42 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nPayables to Ridgeback included inAccrued and other current liabilities(2) | $ | 1,568 |  |  | $ | 283 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2022 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 18 |  |  | $ | 28 |  |  | $ | 46 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 4 |  |  | 17 |  |  | 21 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 26 |  |  | \u2014 |  |  | 27 |  |  | 53 |  |  |  |  |  |  |  |  | \n | $ | 26 |  |  | $ | 29 |  |  | $ | 72 |  |  | $ | 127 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2021 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 10 |  |  | $ | 17 |  |  | $ | 27 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 229 |  |  | \u2014 |  |  | 68 |  |  | 297 |  |  |  |  |  |  |  |  | \n | $ | 229 |  |  | $ | 20 |  |  | $ | 85 |  |  | $ | 334 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2022 | $ | 596 |  |  | $ | \u2014 |  |  | $ | 41 |  |  | $ | 637 | \nExpense | 26 |  |  | 29 |  |  | 72 |  |  | 127 | \n(Payments) receipts, net | (68) |  |  | \u2014 |  |  | (45) |  |  | (113) | \nNon-cash activity | \u2014 |  |  | (29) |  |  | (39) |  |  | (68) | \nRestructuring reserves March\u00a031, 2022(1) | $ | 554 |  |  | $ | \u2014 |  |  | $ | 29 |  |  | $ | 583 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended March 31, |  |  |  | Three Months Ended March 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  |  |  | 2022 |  | 2021 |  |  |  | \nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | (16) |  |  | $ | (25) |  |  |  |  |  |  | $ | (1) |  |  | $ | (4) |  |  |  |  | \nEuro-denominated notes | (53) |  |  | (166) |  |  |  |  |  |  | \u2014 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022\n($ in millions) | Par Value of Debt |  | Number of Interest Rate Swaps Held |  | Total Swap Notional Amount\n2.40% notes due 2022 | $ | 1,000 |  |  | 4 |  |  | $ | 1,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Carrying Amount of Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount\n($ in millions) | March 31, 2022 |  | December 31, 2021 |  | March 31, 2022 |  | December 31, 2021\nBalance Sheet Line Item in which Hedged Item is Included |  |  |  |  |  |  | \nLoans payable and current portion of long-term debt | $ | 1,003 |  |  | $ | 2,263 |  |  | $ | 4 |  |  | $ | 13 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2022 |  | December 31, 2021\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other current assets | $ | 4 |  |  | $ | \u2014 |  |  | $ | 1,000 |  |  | $ | 14 |  |  | $ | \u2014 |  |  | $ | 2,250 | \nForeign exchange contracts | Other current assets | 341 |  |  | \u2014 |  |  | 7,429 |  |  | 271 |  |  | \u2014 |  |  | 6,778 | \nForeign exchange contracts | Other Assets | 46 |  |  | \u2014 |  |  | 1,595 |  |  | 43 |  |  | \u2014 |  |  | 1,551 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 21 |  |  | 1,060 |  |  | \u2014 |  |  | 24 |  |  | 1,623 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 9 |  |  | \u2014 |  |  | 1 |  |  | 43 | \n |  | $ | 391 |  |  | $ | 22 |  |  | $ | 11,093 |  |  | $ | 328 |  |  | $ | 25 |  |  | $ | 12,245 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 288 |  |  | $ | \u2014 |  |  | $ | 12,466 |  |  | $ | 221 |  |  | $ | \u2014 |  |  | $ | 10,073 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 219 |  |  | 7,700 |  |  | \u2014 |  |  | 96 |  |  | 10,640 | \n |  | $ | 288 |  |  | $ | 219 |  |  | $ | 20,166 |  |  | $ | 221 |  |  | $ | 96 |  |  | $ | 20,713 | \n |  | $ | 679 |  |  | $ | 241 |  |  | $ | 31,259 |  |  | $ | 549 |  |  | $ | 121 |  |  | $ | 32,958 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 679 |  |  | $ | 241 |  |  | $ | 549 |  |  | $ | 121 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (191) |  |  | (191) |  |  | (110) |  |  | (110) | \nCash collateral received | (220) |  |  | \u2014 |  |  | (164) |  |  | \u2014 | \nNet amounts | $ | 268 |  |  | $ | 50 |  |  | $ | 275 |  |  | $ | 11 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |  |  |  |  |  |  |  |  | \nFinancial Statement Line Items in which Effects of Fair Value or Cash FlowHedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  |  |  |  |  | \n | $ | 15,901 |  |  | $ | 10,627 |  |  | $ | 708 |  |  | $ | (455) |  |  | $ | 60 |  |  | $ | 12 |  |  |  |  |  |  |  |  |  |  |  |  | \n(Gain) loss on fair value hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | (10) |  |  | (11) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nImpact of cash flow hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 148 |  |  | 180 |  |  |  |  |  |  |  |  |  |  |  |  | \nIncrease (decrease) inSalesas a result ofAOCLreclassifications | 67 |  |  | (112) |  |  | \u2014 |  |  | \u2014 |  |  | (67) |  |  | 112 |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of loss recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended March 31, |  |  |  | \n($ in millions) |  |  | 2022 |  | 2021 |  |  |  | \nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | 28 |  |  | $ | 50 |  |  |  |  | \nForeign exchange contracts(2) | Sales |  | (2) |  |  | (4) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities | 75 |  |  | \u2014 |  |  | \u2014 |  |  | 75 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nForeign government bonds | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 |  |  | 2 |  |  | \u2014 |  |  | \u2014 |  |  | 2 | \nTotal debt securities | $ | 454 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 454 |  |  | $ | 86 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 86 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,397 |  |  |  |  |  |  |  |  | 1,647 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 1,851 |  |  |  |  |  |  |  |  | $ | 1,733 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | March 31, 2022 |  | December 31, 2021\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nForeign government bonds | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 | \nPublicly traded equity securities | 313 |  |  | \u2014 |  |  | \u2014 |  |  | 313 |  |  | 368 |  |  | \u2014 |  |  | \u2014 |  |  | 368 | \n | 313 |  |  | 375 |  |  | \u2014 |  |  | 688 |  |  | 368 |  |  | 2 |  |  | \u2014 |  |  | 370 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 75 |  |  | \u2014 |  |  | \u2014 |  |  | 75 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nPublicly traded equity securities | 1,084 |  |  | \u2014 |  |  | \u2014 |  |  | 1,084 |  |  | 1,279 |  |  | \u2014 |  |  | \u2014 |  |  | 1,279 | \n | 1,163 |  |  | \u2014 |  |  | \u2014 |  |  | 1,163 |  |  | 1,363 |  |  | \u2014 |  |  | \u2014 |  |  | 1,363 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 351 |  |  | \u2014 |  |  | 351 | \nPurchased currency options | \u2014 |  |  | 242 |  |  | \u2014 |  |  | 242 |  |  | \u2014 |  |  | 184 |  |  | \u2014 |  |  | 184 | \nInterest rate swaps | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 14 |  |  | \u2014 |  |  | 14 | \n | \u2014 |  |  | 679 |  |  | \u2014 |  |  | 679 |  |  | \u2014 |  |  | 549 |  |  | \u2014 |  |  | 549 | \nTotal assets | $ | 1,476 |  |  | $ | 1,054 |  |  | $ | \u2014 |  |  | $ | 2,530 |  |  | $ | 1,731 |  |  | $ | 551 |  |  | $ | \u2014 |  |  | $ | 2,282 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 572 |  |  | $ | 572 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 777 |  |  | $ | 777 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 240 |  |  | \u2014 |  |  | 240 |  |  | \u2014 |  |  | 120 |  |  | \u2014 |  |  | 120 | \nWritten currency options | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 | \n | \u2014 |  |  | 241 |  |  | \u2014 |  |  | 241 |  |  | \u2014 |  |  | 121 |  |  | \u2014 |  |  | 121 | \nTotal liabilities | $ | \u2014 |  |  | $ | 241 |  |  | $ | 572 |  |  | $ | 813 |  |  | $ | \u2014 |  |  | $ | 121 |  |  | $ | 777 |  |  | $ | 898 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021\nFair value January 1 | $ | 777 |  |  | $ | 841 | \nChanges in estimated fair value(1) | (84) |  |  | (13) | \nPayments | (119) |  |  | \u2014 | \nOther | (2) |  |  | (12) | \nFair value March 31(2)(3) | $ | 572 |  |  | $ | 816 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021\nFinished goods | $ | 1,772 |  |  | $ | 1,747 | \nRaw materials and work in process | 6,365 |  |  | 6,220 | \nSupplies | 209 |  |  | 196 | \nTotal (approximates current cost) | 8,346 |  |  | 8,163 | \nDecrease to LIFO cost | (77) |  |  | (16) | \n | $ | 8,269 |  |  | $ | 8,147 | \nRecognized as: |  |  | \nInventories | $ | 5,774 |  |  | $ | 5,953 | \nOther assets | 2,495 |  |  | 2,194 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,588 |  | $ | 47,362 |  | $ | (6,634) |  | 1,047 |  | $ | (56,787) |  | $ | 87 |  | $ | 25,404 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,179 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,179 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 | \nCash dividends declared on common stock ($0.65per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,653) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,653) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 25 |  | \u2014 |  | \u2014 |  | (1) |  | 65 |  | \u2014 |  | 90 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 7 |  | 7 | \nBalance at March 31, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,613 |  | $ | 48,888 |  | $ | (6,622) |  | 1,046 |  | $ | (56,722) |  | $ | 94 |  | $ | 27,039 | \nBalance at January 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 37 |  | \u2014 |  | \u2014 |  | \u2014 |  | 46 |  | \u2014 |  | 83 | \nNet loss attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3) |  | (3) | \nBalance at March 31, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 |   |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \n($ in millions) | U.S. |  | International |  | U.S. |  | International |  |  |  |  |  |  |  | \nService cost | $ | 99 |  |  | $ | 75 |  |  | $ | 100 |  |  | $ | 92 |  |  |  |  |  |  |  |  | \nInterest cost | 103 |  |  | 38 |  |  | 96 |  |  | 29 |  |  |  |  |  |  |  |  | \nExpected return on plan assets | (196) |  |  | (101) |  |  | (188) |  |  | (104) |  |  |  |  |  |  |  |  | \nAmortization of unrecognized prior service credit | (8) |  |  | (4) |  |  | (10) |  |  | (4) |  |  |  |  |  |  |  |  | \nNet loss amortization | 56 |  |  | 25 |  |  | 85 |  |  | 41 |  |  |  |  |  |  |  |  | \nTermination benefits | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nCurtailments | 3 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nSettlements | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \n | $ | 58 |  |  | $ | 33 |  |  | $ | 91 |  |  | $ | 54 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nService cost | $ | 12 |  |  | $ | 13 |  |  |  |  | \nInterest cost | 11 |  |  | 11 |  |  |  |  | \nExpected return on plan assets | (21) |  |  | (20) |  |  |  |  | \nAmortization of unrecognized prior service credit | (25) |  |  | (25) |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n | $ | (23) |  |  | $ | (21) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nInterest income | $ | (7) |  |  | $ | (11) |  |  |  |  | \nInterest expense | 243 |  |  | 200 |  |  |  |  | \nExchange losses | 39 |  |  | 41 |  |  |  |  | \nLoss (income) from investments in equity securities, net(1) | 708 |  |  | (574) |  |  |  |  | \nNet periodic defined benefit plan (credit) cost other than service cost | (121) |  |  | (89) |  |  |  |  | \nOther, net | (154) |  |  | (22) |  |  |  |  | \n | $ | 708 |  |  | $ | (455) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ and shares in millions except per share amounts) | 2022 |  | 2021 |  |  |  | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 2,745 |  |  |  |  | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 434 |  |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nAverage common shares outstanding | 2,528 |  |  | 2,531 |  |  |  |  | \nCommon shares issuable(1) | 9 |  |  | 10 |  |  |  |  | \nAverage common shares outstanding assuming dilution | 2,537 |  |  | 2,541 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.26 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.25 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2021, net of taxes | $ | (266) |  |  | $ | (4,540) |  |  | $ | (1,828) |  |  | $ | (6,634) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 180 |  |  | (4) |  |  | (211) |  |  | (35) | \nTax | (38) |  |  | (1) |  |  | (88) |  |  | (127) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 142 |  |  | (5) |  |  | (299) |  |  | (162) | \nReclassification adjustments, pretax | 111 |  | (1) | 87 |  | (2) | \u2014 |  |  | 198 | \nTax | (23) |  |  | (1) |  |  | \u2014 |  |  | (24) | \nReclassification adjustments, net of taxes | 88 |  |  | 86 |  |  | \u2014 |  |  | 174 | \nOther comprehensive income (loss), net of taxes | 230 |  |  | 81 |  |  | (299) |  |  | 12 | \nBalance March 31, 2021, net of taxes | $ | (36) |  |  | $ | (4,459) |  |  | $ | (2,127) |  |  | $ | (6,622) | \nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 148 |  |  | 1 |  |  | (18) |  |  | 131 | \nTax | (31) |  |  | (2) |  |  | (17) |  |  | (50) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 117 |  |  | (1) |  |  | (35) |  |  | 81 | \nReclassification adjustments, pretax | (68) |  | (1) | 45 |  | (2) | \u2014 |  |  | (23) | \nTax | 14 |  |  | (12) |  |  | \u2014 |  |  | 2 | \nReclassification adjustments, net of taxes | (54) |  |  | 33 |  |  | \u2014 |  |  | (21) | \nOther comprehensive income (loss), net of taxes | 63 |  |  | 32 |  |  | (35) |  |  | 60 | \nBalance March 31, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) |   |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 2,779 |  |  | $ | 2,030 |  |  | $ | 4,809 |  |  | $ | 2,181 |  |  | $ | 1,718 |  |  | $ | 3,899 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Lynparza(1) | 141 |  |  | 125 |  |  | 266 |  |  | 118 |  |  | 110 |  |  | 228 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Lenvima(1) | 156 |  |  | 71 |  |  | 227 |  |  | 85 |  |  | 44 |  |  | 130 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Reblozyl(2) | 27 |  |  | 25 |  |  | 52 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 418 |  |  | 1,042 |  |  | 1,460 |  |  | 313 |  |  | 604 |  |  | 917 |  |  |  |  |  |  |  |  |  |  |  |  | \nProQuad/M-M-RII/Varivax | 371 |  |  | 99 |  |  | 470 |  |  | 333 |  |  | 117 |  |  | 449 |  |  |  |  |  |  |  |  |  |  |  |  | \nRotaTeq | 175 |  |  | 41 |  |  | 216 |  |  | 118 |  |  | 41 |  |  | 158 |  |  |  |  |  |  |  |  |  |  |  |  | \nPneumovax23 | 118 |  |  | 55 |  |  | 173 |  |  | 73 |  |  | 99 |  |  | 171 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaqta | 29 |  |  | 7 |  |  | 36 |  |  | 25 |  |  | 9 |  |  | 34 |  |  |  |  |  |  |  |  |  |  |  |  | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 195 |  |  | 199 |  |  | 395 |  |  | 167 |  |  | 173 |  |  | 340 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrevymis | 40 |  |  | 54 |  |  | 94 |  |  | 35 |  |  | 47 |  |  | 82 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrimaxin | 1 |  |  | 58 |  |  | 58 |  |  | \u2014 |  |  | 65 |  |  | 65 |  |  |  |  |  |  |  |  |  |  |  |  | \nNoxafil | 10 |  |  | 48 |  |  | 57 |  |  | 15 |  |  | 52 |  |  | 67 |  |  |  |  |  |  |  |  |  |  |  |  | \nCancidas | 1 |  |  | 52 |  |  | 53 |  |  | 3 |  |  | 55 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nDificid | 49 |  |  | 3 |  |  | 52 |  |  | 25 |  |  | 2 |  |  | 27 |  |  |  |  |  |  |  |  |  |  |  |  | \nInvanz | 1 |  |  | 52 |  |  | 52 |  |  | 4 |  |  | 52 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nZerbaxa | 18 |  |  | 12 |  |  | 30 |  |  | (2) |  |  | (6) |  |  | (8) |  |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Adempas/Verquvo(3) | 71 |  |  | 1 |  |  | 72 |  |  | 68 |  |  | 6 |  |  | 74 |  |  |  |  |  |  |  |  |  |  |  |  | \nAdempas | \u2014 |  |  | 61 |  |  | 61 |  |  | \u2014 |  |  | 55 |  |  | 55 |  |  |  |  |  |  |  |  |  |  |  |  | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | 1,523 |  |  | 1,723 |  |  | 3,247 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nIsentress/IsentressHD | 61 |  |  | 97 |  |  | 158 |  |  | 71 |  |  | 138 |  |  | 209 |  |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 20 |  |  | 48 |  |  | 69 |  |  | 18 |  |  | 61 |  |  | 79 |  |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 186 |  |  | 186 |  |  | \u2014 |  |  | 214 |  |  | 214 |  |  |  |  |  |  |  |  |  |  |  |  | \nRemicade | \u2014 |  |  | 61 |  |  | 61 |  |  | \u2014 |  |  | 85 |  |  | 85 |  |  |  |  |  |  |  |  |  |  |  |  | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 325 |  |  | 454 |  |  | 779 |  |  | 348 |  |  | 461 |  |  | 809 |  |  |  |  |  |  |  |  |  |  |  |  | \nJanumet | 63 |  |  | 391 |  |  | 454 |  |  | 84 |  |  | 401 |  |  | 486 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther pharmaceutical(4) | 181 |  |  | 339 |  |  | 520 |  |  | 212 |  |  | 341 |  |  | 554 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Pharmaceutical segment sales | 6,773 |  |  | 7,334 |  |  | 14,107 |  |  | 4,294 |  |  | 4,944 |  |  | 9,238 |  |  |  |  |  |  |  |  |  |  |  |  | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 171 |  |  | 661 |  |  | 832 |  |  | 157 |  |  | 662 |  |  | 819 |  |  |  |  |  |  |  |  |  |  |  |  | \nCompanion Animals | 302 |  |  | 348 |  |  | 650 |  |  | 280 |  |  | 319 |  |  | 599 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Animal Health segment sales | 473 |  |  | 1,009 |  |  | 1,482 |  |  | 437 |  |  | 981 |  |  | 1,418 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal segment sales | 7,246 |  |  | 8,343 |  |  | 15,589 |  |  | 4,731 |  |  | 5,925 |  |  | 10,656 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther(5) | 93 |  |  | 220 |  |  | 312 |  |  | 59 |  |  | (88) |  |  | (29) |  |  |  |  |  |  |  |  |  |  |  |  | \n | $ | 7,339 |  |  | $ | 8,563 |  |  | $ | 15,901 |  |  | $ | 4,790 |  |  | $ | 5,837 |  |  | $ | 10,627 |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nUnited States | $ | 7,339 |  |  | $ | 4,790 |  |  |  |  | \nEurope, Middle East and Africa | 4,359 |  |  | 3,237 |  |  |  |  | \nChina | 1,143 |  |  | 721 |  |  |  |  | \nJapan | 989 |  |  | 629 |  |  |  |  | \nAsia Pacific (other than China and Japan) | 930 |  |  | 575 |  |  |  |  | \nLatin America | 607 |  |  | 500 |  |  |  |  | \nOther | 534 |  |  | 175 |  |  |  |  | \n | $ | 15,901 |  |  | $ | 10,627 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,501 |  |  | $ | 6,589 |  |  |  |  | \nAnimal Health segment | 585 |  |  | 572 |  |  |  |  | \nTotal segment profits | 10,086 |  |  | 7,161 |  |  |  |  | \nOther profits | 194 |  |  | (50) |  |  |  |  | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 7 |  |  | 11 |  |  |  |  | \nInterest expense | (243) |  |  | (200) |  |  |  |  | \nAmortization | (699) |  |  | (514) |  |  |  |  | \nDepreciation | (378) |  |  | (340) |  |  |  |  | \nResearch and development | (2,446) |  |  | (2,305) |  |  |  |  | \nRestructuring costs | (53) |  |  | (297) |  |  |  |  | \nOther unallocated, net | (1,607) |  |  | (479) |  |  |  |  | \n | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nUnited States | $ | 7,339 |  |  | $ | 4,790 |  |  | 53 | % |  | 53 | % |  |  |  |  |  |  |  | \nInternational | 8,563 |  |  | 5,837 |  |  | 47 | % |  | 52 | % |  |  |  |  |  |  |  | \nTotal | $ | 15,901 |  |  | $ | 10,627 |  |  | 50 | % |  | 52 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nKeytruda | $ | 4,809 |  |  | $ | 3,899 |  |  | 23 | % |  | 27 | % |  |  |  |  |  |  |  | \nAlliance Revenue - Lynparza(1) | 266 |  |  | 228 |  |  | 17 | % |  | 20 | % |  |  |  |  |  |  |  | \nAlliance Revenue-Lenvima(1) | 227 |  |  | 130 |  |  | 75 | % |  | 77 | % |  |  |  |  |  |  |  |   |  |  |  |  | \nDate | Approval\nJanuary 2022 | European Commission (EC) approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions based on the KEYNOTE-564 trial.\nFebruary 2022 | Japan Ministry of Health, Labour and Welfare approval of the combination ofKeytrudaplus Lenvima for radically unresectable or metastatic RCC based on the CLEAR (Study 307)/KEYNOTE-581 trial.\nFebruary 2022 | Japan Pharmaceuticals and Medical Devices Agency approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.\nMarch 2022 | U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation based on the KEYNOTE-158 trial (Cohorts D & K).\nApril 2022 | EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1 based on the KEYNOTE-826 trial.\nApril 2022 | EC approval as monotherapy for the treatment of certain patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer based on data from KEYNOTE-164 and KEYNOTE-158.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | $ | 1,460 |  |  | $ | 917 |  |  | 59 | % |  | 60 | % |  |  |  |  |  |  |  | \nProQuad | 162 |  |  | 165 |  |  | (2) | % |  | (1) | % |  |  |  |  |  |  |  | \nM-M-RII | 103 |  |  | 80 |  |  | 29 | % |  | 31 | % |  |  |  |  |  |  |  | \nVarivax | 204 |  |  | 204 |  |  | \u2014 | % |  | 1 | % |  |  |  |  |  |  |  | \nRotaTeq | 216 |  |  | 158 |  |  | 36 | % |  | 38 | % |  |  |  |  |  |  |  | \nPneumovax 23 | 173 |  |  | 171 |  |  | 1 | % |  | 3 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nBridion | $ | 395 |  |  | $ | 340 |  |  | 16 | % |  | 20 | % |  |  |  |  |  |  |  | \nZerbaxa | 30 |  |  | (8) |  |  | * |  | * |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 72 |  |  | $ | 74 |  |  | (3) | % |  | (3) | % |  |  |  |  |  |  |  | \nAdempas | 61 |  |  | 55 |  |  | 11 | % |  | 20 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nLagevrio | $ | 3,247 |  |  | $ | \u2014 |  |  | \u2014 |  | \u2014 |  |  |  |  |  |  |  | \nIsentress/Isentress HD | 158 |  |  | 209 |  |  | (24) | % |  | (21) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nJanuvia/Janumet | $ | 1,233 |  |  | $ | 1,295 |  |  | (5) | % |  | (1) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nLivestock | $ | 832 |  |  | $ | 819 |  |  | 2 | % |  | 7 | % |  |  |  |  |  |  |  | \nCompanion Animal | 650 |  |  | 599 |  |  | 9 | % |  | 13 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  | \nCost of sales | $ | 5,380 |  |  | $ | 3,199 |  |  | 68 | % |  |  |  |  |  | \nSelling, general and administrative | 2,323 |  |  | 2,187 |  |  | 6 | % |  |  |  |  |  | \nResearch and development | 2,576 |  |  | 2,412 |  |  | 7 | % |  |  |  |  |  | \nRestructuring costs | 53 |  |  | 297 |  |  | (82) | % |  |  |  |  |  | \nOther (income) expense, net | 708 |  |  | (455) |  |  | * |  |  |  |  |  | \n | $ | 11,040 |  |  | $ | 7,640 |  |  | 45 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nPharmaceutical segment profits | $ | 9,501 |  |  | $ | 6,589 |  |  |  |  | \nAnimal Health segment profits | 585 |  |  | 572 |  |  |  |  | \nOther | (5,225) |  |  | (4,174) |  |  |  |  | \nIncome from Continuing Operations Before Taxes | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions except per share amounts) | 2022 |  | 2021 |  |  |  | \nIncome from continuing operations before taxes as reported under GAAP | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition and divestiture-related costs | 637 |  |  | 497 |  |  |  |  | \nRestructuring costs | 127 |  |  | 334 |  |  |  |  | \nLoss (income) from investments in equity securities, net | 684 |  |  | (561) |  |  |  |  | \nOther items: |  |  |  |  |  |  | \nCharge for the discontinuation of COVID-19 development programs | \u2014 |  |  | 188 |  |  |  |  | \nNon-GAAP income from continuing operations before taxes | 6,309 |  |  | 3,445 |  |  |  |  | \nTaxes on income from continuing operations as reported under GAAP | 554 |  |  | 238 |  |  |  |  | \nEstimated tax benefit on excluded items(1) | 329 |  |  | 48 |  |  |  |  | \nNet tax benefit from the settlement of certain federal income tax matters | \u2014 |  |  | 208 |  |  |  |  | \nNon-GAAP taxes on income from continuing operations | 883 |  |  | 494 |  |  |  |  | \nNon-GAAP net income from continuing operations | 5,426 |  |  | 2,951 |  |  |  |  | \nLess: Net (loss) income attributable to noncontrolling interests as reported under GAAP | (3) |  |  | 4 |  |  |  |  | \nNon-GAAP net income from continuing operations attributable to Merck\u00a0& Co., Inc. | $ | 5,429 |  |  | $ | 2,947 |  |  |  |  | \nEPS assuming dilution from continuing operations as reported under GAAP | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nEPS difference | 0.44 |  |  | 0.08 |  |  |  |  | \nNon-GAAP EPS assuming dilution from continuing operations | $ | 2.14 |  |  | $ | 1.16 |  |  |  |  |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(3)Non-Small-Cell LungMK-1026 (nemtabrutinib)Hematological MalignanciesMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)Advanced Solid TumorsColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BreastHematological MalignanciesNon-Small-Cell LungSolid TumorsMK-3475KeytrudaAdvanced Solid TumorsMK-4280 (favezelimab)(2)Hematological MalignanciesNon-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)Renal CellSmall-Cell LungMK-4830(2)ColorectalNon-Small-Cell LungRenal CellSmall-Cell LungMK-5890(3)Non-Small-Cell LungSmall-Cell Lung | CancerMK-6440 (ladiratuzumab vedotin)(1)(3)BreastEsophagealGastricHead and NeckMelanomaNon-Small-Cell LungProstateSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalColorectalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684 (vibostolimab)(2)MelanomaMK-7684A (vibostolimab+pembrolizumab)BiliaryBreastCervicalEndometrialEsophagealHead and NeckHematological MalignanciesHepatocellularProstate | CancerMK-7902 Lenvima(1)(2)BiliaryGlioblastomaPancreaticProstateSmall-Cell LungV937BreastCutaneous Squamous CellHead and NeckMelanomaSolid TumorsCardiovascularMK-2060Chikungunya Virus VaccineV184HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(4)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-3655MK-6024Overgrowth SyndromeMK-7075 (miransertib)Pneumococcal Vaccine AdultV116Pulmonary Arterial HypertensionMK-5475SchizophreniaMK-8189Treatment Resistant DepressionMK-1942  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(5)CancerMK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaBiliary (September 2019)Cutaneous Squamous Cell (August 2019) (EU)Gastric (May 2015) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Prostate (May 2019)Small-Cell Lung (May 2017)MK-3475 (pembrolizumab subcutaneous)Non-Small-Cell Lung (August 2021)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)MK-7339 Lynparza(1)(3)Colorectal (August 2020)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Colorectal (April 2021)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Melanoma (March 2019)Non-Small-Cell Lung (March 2019)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(4)HIV-1 PreventionMK-8591 (islatravir) (February 2021)(4)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular Entities/VaccinesAntiviral COVID-19MK-4482Lagevrio(EU)(1)CoughMK-7264 (gefapixant) (U.S.)(6)(EU)Pneumococcal Vaccine AdultV114 (JPN) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    High-Risk Early-Stage Triple-Negative Breast Cancer(KEYNOTE-522) (EU) (JPN)\u2022    Adjuvent Treatment of Stage IIB and IIC Melanoma(KEYNOTE-716) (EU)\u2022    Cervical Cancer (KEYNOTE-826) (JPN)\u2022    Adjuvent Renal Cell Cancer(KEYNOTE-564) (JPN)\u2022    Second-Line Hepatocellular Cancer(KEYNOTE-394) (U.S.)MK-7339 Lynparza(1)\u2022BRCA-Mutated HER2-Negative Adjuvant BreastCancer (OlympiA) (EU) (JPN)\u2022    First-Line Metastatic Prostate Cancer (PROpel) EU)MK-7902 Lenvima(1)(2)\u2022    First-Line Metastatic Hepatocellular Carcinoma(KEYNOTE-524) (U.S.)(7)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)Available in the U.S. under Emergency Use Authorization.(6)In January 2022, the FDA issued a CRL for this application. Merck is reviewing the CRL and considering next steps.(7)In July 2020, the FDA issued a CRL for Merck\u2019s and Eisai\u2019s applications. Merck and Eisai intend to submit additional data when available to the FDA.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021\nCash and investments | $ | 9,244 |  |  | $ | 8,466 | \nWorking capital | 8,868 |  |  | 6,394 | \nTotal debt to total liabilities and equity | 29.8 | % |  | 31.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nJanuary 1 - January 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nFebruary 1 - February 28 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nMarch 1 - March 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nTotal | \u2014 |  |  | $0.00 |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  May 5, 2022 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  May 5, 2022 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2022 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | 2000 Galloping Hill Road,Kenilworth,New Jersey07033 | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 30\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 42\n |  | \nItem 4. | Controls and Procedures | 42\n |  | \n | Cautionary Factors That May Affect Future Results | 43\n |  | \nPART II | OTHER INFORMATION | 43\n |  | \nItem 1. | Legal Proceedings | 43\n |  | \nItem 1A. | Risk Factors | 43\n |  |  |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 44\n |  |  |  | \nItem 6. | Exhibits | 44\n |  | \n | Signatures |  |  | 45  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \nSales | $ | 15,901 |  |  | $ | 10,627 |  |  |  |  | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 5,380 |  |  | 3,199 |  |  |  |  | \nSelling, general and administrative | 2,323 |  |  | 2,187 |  |  |  |  | \nResearch and development | 2,576 |  |  | 2,412 |  |  |  |  | \nRestructuring costs | 53 |  |  | 297 |  |  |  |  | \nOther (income) expense, net | 708 |  |  | (455) |  |  |  |  | \n | 11,040 |  |  | 7,640 |  |  |  |  | \nIncome from Continuing Operations Before Taxes | 4,861 |  |  | 2,987 |  |  |  |  | \nTaxes on Income from Continuing Operations | 554 |  |  | 238 |  |  |  |  | \nNet Income from Continuing Operations | 4,307 |  |  | 2,749 |  |  |  |  | \nLess: Net (Loss) Income Attributable to Noncontrolling Interests | (3) |  |  | 4 |  |  |  |  | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | 4,310 |  |  | 2,745 |  |  |  |  | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 434 |  |  |  |  | \nNet Income Attributable to Merck & Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.26 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.25 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nOther Comprehensive Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 63 |  |  | 230 |  |  |  |  | \nBenefit plan net gain and prior service credit, net of amortization | 32 |  |  | 81 |  |  |  |  | \nCumulative translation adjustment | (35) |  |  | (299) |  |  |  |  | \n | 60 |  |  | 12 |  |  |  |  | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,370 |  |  | $ | 3,191 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 8,556 |  |  | $ | 8,096 | \nShort-term investments | 372 |  |  | \u2014 | \nAccounts receivable (net of allowance for doubtful accounts of $95in 2022and $62in 2021) | 9,828 |  |  | 9,230 | \nInventories (excludes inventories of $2,495in 2022 and $2,194in 2021classified in Other assets - see Note\u00a07) | 5,774 |  |  | 5,953 | \nOther current assets | 6,654 |  |  | 6,987 | \nTotal current assets | 31,184 |  |  | 30,266 | \nInvestments | 316 |  |  | 370 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,498in 2022 and $18,192in 2021 | 19,747 |  |  | 19,279 | \nGoodwill | 21,258 |  |  | 21,264 | \nOther Intangibles, Net | 23,022 |  |  | 22,933 | \nOther Assets | 11,141 |  |  | 11,582 | \n | $ | 106,668 |  |  | $ | 105,694 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 1,208 |  |  | $ | 2,412 | \nTrade accounts payable | 3,715 |  |  | 4,609 | \nAccrued and other current liabilities | 14,051 |  |  | 13,859 | \nIncome taxes payable | 1,571 |  |  | 1,224 | \nDividends payable | 1,771 |  |  | 1,768 | \nTotal current liabilities | 22,316 |  |  | 23,872 | \nLong-Term Debt | 30,586 |  |  | 30,690 | \nDeferred Income Taxes | 3,071 |  |  | 3,441 | \nOther Noncurrent Liabilities | 9,742 |  |  | 9,434 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2022 and 2021 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,275 |  |  | 44,238 | \nRetained earnings | 56,252 |  |  | 53,696 | \nAccumulated other comprehensive loss | (4,369) |  |  | (4,429) | \n | 97,946 |  |  | 95,293 | \nLess treasury stock, at cost:1,048,727,225shares in 2022 and1,049,499,023shares in 2021 | 57,063 |  |  | 57,109 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 40,883 |  |  | 38,184 | \nNoncontrolling Interests | 70 |  |  | 73 | \nTotal equity | 40,953 |  |  | 38,257 | \n | $ | 106,668 |  |  | $ | 105,694 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31,\n | 2022 |  | 2021\nCash Flows from Operating Activities of Continuing Operations |  |  | \nNet income from continuing operations | $ | 4,307 |  |  | $ | 2,749 | \nAdjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: |  |  | \nAmortization | 699 |  |  | 514 | \nDepreciation | 421 |  |  | 378 | \nLoss (income) from investments in equity securities, net | 708 |  |  | (574) | \nDeferred income taxes | (338) |  |  | 18 | \nShare-based compensation | 120 |  |  | 111 | \nOther | 143 |  |  | 236 | \nNet changes in assets and liabilities | (1,299) |  |  | (2,192) | \nNet Cash Provided by Operating Activities of Continuing Operations | 4,761 |  |  | 1,240 | \nCash Flows from Investing Activities of Continuing Operations |  |  | \nCapital expenditures | (984) |  |  | (1,082) | \nPurchases of securities and other investments | (372) |  |  | (1) | \nProceeds from sales of securities and other investments | 1 |  |  | 386 | \nOther | 182 |  |  | 11 | \nNet Cash Used in Investing Activities of Continuing Operations | (1,173) |  |  | (686) | \nCash Flows from Financing Activities of Continuing Operations |  |  | \nNet change in short-term borrowings | \u2014 |  |  | 788 | \nPayments on debt | (1,250) |  |  | (1,153) | \nDividends paid to stockholders | (1,745) |  |  | (1,645) | \nProceeds from exercise of stock options | 12 |  |  | 9 | \nOther | (103) |  |  | (97) | \nNet Cash Used in Financing Activities of Continuing Operations | (3,086) |  |  | (2,098) | \nCash Flows from Discontinued Operations |  |  | \nNet cash provided by operating activities | \u2014 |  |  | 551 | \nNet cash used in investing activities | \u2014 |  |  | (52) | \nNet Cash Flows Provided by Discontinued Operations | \u2014 |  |  | 499 | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (55) |  |  | (97) | \nNet Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | 447 |  |  | (1,142) | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$71and $103at January 1, 2022 and 2021, respectively, included in Other current assets) | 8,167 |  |  | 8,165 | \nLess: Cash and cash equivalents related to discontinued operations | \u2014 |  |  | 141 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $58and $42at March\u00a031, 2022 and 2021, respectively, included in Other current assets) | $ | 8,614 |  |  | $ | 6,882 |   |  |  |  |  |  |  |  |  |  | \n |  | Three Months Ended March 31, |  | \n($ in millions) |  | 2021\nSales |  | $ | 1,453 |  |  | \nCosts, Expenses and Other |  |  |  | \nCost of sales |  | 471 |  |  | \nSelling, general and administrative |  | 446 |  |  | \nResearch and development |  | 53 |  |  | \nRestructuring costs |  | 1 |  |  | \nOther (income) expense, net |  | 7 |  |  | \n |  | 978 |  |  | \nIncome from discontinued operations before taxes |  | 475 |  |  | \nTax provision |  | 38 |  |  | \nIncome from discontinued operations, net of taxes |  | 437 |  |  | \nLess: Income of discontinued operations attributable to noncontrolling interests |  | 3 |  |  | \n |  | $ | 434 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Lynparza | $ | 266 |  |  | $ | 228 |  |  |  |  | \nAlliance revenue - Koselugo | 9 |  |  | 5 |  |  |  |  | \nTotal alliance revenue | $ | 275 |  |  | $ | 233 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 299 |  |  | 42 |  |  |  |  | \nSelling, general and administrative | 44 |  |  | 40 |  |  |  |  | \nResearch and development | 26 |  |  | 29 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from AstraZeneca included inOther current assets | $ | 275 |  |  | $ | 271 |  |  |  |  | \nPayables to AstraZeneca included inTrade accounts payableandAccrued and other current liabilities(2) | 190 |  |  | 415 |  |  |  |  | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) | 600 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Lenvima | $ | 227 |  |  | $ | 130 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 53 |  |  | 47 |  |  |  |  | \nSelling, general and administrative | 31 |  |  | 23 |  |  |  |  | \nResearch and development | 57 |  |  | 64 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from Eisai included inOther current assets | $ | 241 |  |  | $ | 200 |  |  |  |  | \nPayables to Eisai included inAccrued and other current liabilities(2) | 325 |  |  | 625 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nAlliance revenue - Adempas/Verquvo | $ | 72 |  |  | $ | 74 |  |  |  |  | \nNet sales of Adempas recorded by Merck | 61 |  |  | 55 |  |  |  |  | \nNet sales of Verquvo recorded by Merck | 3 |  |  | \u2014 |  |  |  |  | \nTotal sales | $ | 136 |  |  | $ | 129 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 50 |  |  | 208 |  |  |  |  | \nSelling, general and administrative | 23 |  |  | 17 |  |  |  |  | \nResearch and development | 17 |  |  | 7 |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nReceivables from Bayer included inOther current assets | $ | 129 |  |  | $ | 114 |  |  |  |  | \nPayables to Bayer included inAccrued and other current liabilities(2) | 74 |  |  | 472 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nLagevriosales | $ | 3,247 |  |  | $ | \u2014 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 1,724 |  |  | 46 |  |  |  |  | \nSelling, general and administrative | 34 |  |  | 3 |  |  |  |  | \nResearch and development | 6 |  |  | 42 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021 |  |  |  | \nPayables to Ridgeback included inAccrued and other current liabilities(2) | $ | 1,568 |  |  | $ | 283 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2022 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 18 |  |  | $ | 28 |  |  | $ | 46 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 4 |  |  | 17 |  |  | 21 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 26 |  |  | \u2014 |  |  | 27 |  |  | 53 |  |  |  |  |  |  |  |  | \n | $ | 26 |  |  | $ | 29 |  |  | $ | 72 |  |  | $ | 127 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2021 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 10 |  |  | $ | 17 |  |  | $ | 27 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 229 |  |  | \u2014 |  |  | 68 |  |  | 297 |  |  |  |  |  |  |  |  | \n | $ | 229 |  |  | $ | 20 |  |  | $ | 85 |  |  | $ | 334 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2022 | $ | 596 |  |  | $ | \u2014 |  |  | $ | 41 |  |  | $ | 637 | \nExpense | 26 |  |  | 29 |  |  | 72 |  |  | 127 | \n(Payments) receipts, net | (68) |  |  | \u2014 |  |  | (45) |  |  | (113) | \nNon-cash activity | \u2014 |  |  | (29) |  |  | (39) |  |  | (68) | \nRestructuring reserves March\u00a031, 2022(1) | $ | 554 |  |  | $ | \u2014 |  |  | $ | 29 |  |  | $ | 583 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended March 31, |  |  |  | Three Months Ended March 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  |  |  | 2022 |  | 2021 |  |  |  | \nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | (16) |  |  | $ | (25) |  |  |  |  |  |  | $ | (1) |  |  | $ | (4) |  |  |  |  | \nEuro-denominated notes | (53) |  |  | (166) |  |  |  |  |  |  | \u2014 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022\n($ in millions) | Par Value of Debt |  | Number of Interest Rate Swaps Held |  | Total Swap Notional Amount\n2.40% notes due 2022 | $ | 1,000 |  |  | 4 |  |  | $ | 1,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Carrying Amount of Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount\n($ in millions) | March 31, 2022 |  | December 31, 2021 |  | March 31, 2022 |  | December 31, 2021\nBalance Sheet Line Item in which Hedged Item is Included |  |  |  |  |  |  | \nLoans payable and current portion of long-term debt | $ | 1,003 |  |  | $ | 2,263 |  |  | $ | 4 |  |  | $ | 13 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2022 |  | December 31, 2021\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other current assets | $ | 4 |  |  | $ | \u2014 |  |  | $ | 1,000 |  |  | $ | 14 |  |  | $ | \u2014 |  |  | $ | 2,250 | \nForeign exchange contracts | Other current assets | 341 |  |  | \u2014 |  |  | 7,429 |  |  | 271 |  |  | \u2014 |  |  | 6,778 | \nForeign exchange contracts | Other Assets | 46 |  |  | \u2014 |  |  | 1,595 |  |  | 43 |  |  | \u2014 |  |  | 1,551 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 21 |  |  | 1,060 |  |  | \u2014 |  |  | 24 |  |  | 1,623 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 9 |  |  | \u2014 |  |  | 1 |  |  | 43 | \n |  | $ | 391 |  |  | $ | 22 |  |  | $ | 11,093 |  |  | $ | 328 |  |  | $ | 25 |  |  | $ | 12,245 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 288 |  |  | $ | \u2014 |  |  | $ | 12,466 |  |  | $ | 221 |  |  | $ | \u2014 |  |  | $ | 10,073 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 219 |  |  | 7,700 |  |  | \u2014 |  |  | 96 |  |  | 10,640 | \n |  | $ | 288 |  |  | $ | 219 |  |  | $ | 20,166 |  |  | $ | 221 |  |  | $ | 96 |  |  | $ | 20,713 | \n |  | $ | 679 |  |  | $ | 241 |  |  | $ | 31,259 |  |  | $ | 549 |  |  | $ | 121 |  |  | $ | 32,958 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 679 |  |  | $ | 241 |  |  | $ | 549 |  |  | $ | 121 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (191) |  |  | (191) |  |  | (110) |  |  | (110) | \nCash collateral received | (220) |  |  | \u2014 |  |  | (164) |  |  | \u2014 | \nNet amounts | $ | 268 |  |  | $ | 50 |  |  | $ | 275 |  |  | $ | 11 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  |  |  |  |  |  |  |  |  |  |  | \nFinancial Statement Line Items in which Effects of Fair Value or Cash FlowHedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  |  |  |  |  | \n | $ | 15,901 |  |  | $ | 10,627 |  |  | $ | 708 |  |  | $ | (455) |  |  | $ | 60 |  |  | $ | 12 |  |  |  |  |  |  |  |  |  |  |  |  | \n(Gain) loss on fair value hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | (10) |  |  | (11) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nImpact of cash flow hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 148 |  |  | 180 |  |  |  |  |  |  |  |  |  |  |  |  | \nIncrease (decrease) inSalesas a result ofAOCLreclassifications | 67 |  |  | (112) |  |  | \u2014 |  |  | \u2014 |  |  | (67) |  |  | 112 |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of loss recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended March 31, |  |  |  | \n($ in millions) |  |  | 2022 |  | 2021 |  |  |  | \nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | 28 |  |  | $ | 50 |  |  |  |  | \nForeign exchange contracts(2) | Sales |  | (2) |  |  | (4) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities | 75 |  |  | \u2014 |  |  | \u2014 |  |  | 75 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nForeign government bonds | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 |  |  | 2 |  |  | \u2014 |  |  | \u2014 |  |  | 2 | \nTotal debt securities | $ | 454 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 454 |  |  | $ | 86 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 86 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,397 |  |  |  |  |  |  |  |  | 1,647 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 1,851 |  |  |  |  |  |  |  |  | $ | 1,733 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | March 31, 2022 |  | December 31, 2021\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | 372 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nForeign government bonds | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 | \nPublicly traded equity securities | 313 |  |  | \u2014 |  |  | \u2014 |  |  | 313 |  |  | 368 |  |  | \u2014 |  |  | \u2014 |  |  | 368 | \n | 313 |  |  | 375 |  |  | \u2014 |  |  | 688 |  |  | 368 |  |  | 2 |  |  | \u2014 |  |  | 370 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 75 |  |  | \u2014 |  |  | \u2014 |  |  | 75 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nPublicly traded equity securities | 1,084 |  |  | \u2014 |  |  | \u2014 |  |  | 1,084 |  |  | 1,279 |  |  | \u2014 |  |  | \u2014 |  |  | 1,279 | \n | 1,163 |  |  | \u2014 |  |  | \u2014 |  |  | 1,163 |  |  | 1,363 |  |  | \u2014 |  |  | \u2014 |  |  | 1,363 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 351 |  |  | \u2014 |  |  | 351 | \nPurchased currency options | \u2014 |  |  | 242 |  |  | \u2014 |  |  | 242 |  |  | \u2014 |  |  | 184 |  |  | \u2014 |  |  | 184 | \nInterest rate swaps | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 14 |  |  | \u2014 |  |  | 14 | \n | \u2014 |  |  | 679 |  |  | \u2014 |  |  | 679 |  |  | \u2014 |  |  | 549 |  |  | \u2014 |  |  | 549 | \nTotal assets | $ | 1,476 |  |  | $ | 1,054 |  |  | $ | \u2014 |  |  | $ | 2,530 |  |  | $ | 1,731 |  |  | $ | 551 |  |  | $ | \u2014 |  |  | $ | 2,282 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 572 |  |  | $ | 572 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 777 |  |  | $ | 777 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 240 |  |  | \u2014 |  |  | 240 |  |  | \u2014 |  |  | 120 |  |  | \u2014 |  |  | 120 | \nWritten currency options | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 | \n | \u2014 |  |  | 241 |  |  | \u2014 |  |  | 241 |  |  | \u2014 |  |  | 121 |  |  | \u2014 |  |  | 121 | \nTotal liabilities | $ | \u2014 |  |  | $ | 241 |  |  | $ | 572 |  |  | $ | 813 |  |  | $ | \u2014 |  |  | $ | 121 |  |  | $ | 777 |  |  | $ | 898 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021\nFair value January 1 | $ | 777 |  |  | $ | 841 | \nChanges in estimated fair value(1) | (84) |  |  | (13) | \nPayments | (119) |  |  | \u2014 | \nOther | (2) |  |  | (12) | \nFair value March 31(2)(3) | $ | 572 |  |  | $ | 816 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021\nFinished goods | $ | 1,772 |  |  | $ | 1,747 | \nRaw materials and work in process | 6,365 |  |  | 6,220 | \nSupplies | 209 |  |  | 196 | \nTotal (approximates current cost) | 8,346 |  |  | 8,163 | \nDecrease to LIFO cost | (77) |  |  | (16) | \n | $ | 8,269 |  |  | $ | 8,147 | \nRecognized as: |  |  | \nInventories | $ | 5,774 |  |  | $ | 5,953 | \nOther assets | 2,495 |  |  | 2,194 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,588 |  | $ | 47,362 |  | $ | (6,634) |  | 1,047 |  | $ | (56,787) |  | $ | 87 |  | $ | 25,404 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,179 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,179 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 | \nCash dividends declared on common stock ($0.65per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,653) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,653) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 25 |  | \u2014 |  | \u2014 |  | (1) |  | 65 |  | \u2014 |  | 90 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 7 |  | 7 | \nBalance at March 31, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,613 |  | $ | 48,888 |  | $ | (6,622) |  | 1,046 |  | $ | (56,722) |  | $ | 94 |  | $ | 27,039 | \nBalance at January 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 37 |  | \u2014 |  | \u2014 |  | \u2014 |  | 46 |  | \u2014 |  | 83 | \nNet loss attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3) |  | (3) | \nBalance at March 31, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 |   |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2022 |  | 2021 |  |  |  | \n($ in millions) | U.S. |  | International |  | U.S. |  | International |  |  |  |  |  |  |  | \nService cost | $ | 99 |  |  | $ | 75 |  |  | $ | 100 |  |  | $ | 92 |  |  |  |  |  |  |  |  | \nInterest cost | 103 |  |  | 38 |  |  | 96 |  |  | 29 |  |  |  |  |  |  |  |  | \nExpected return on plan assets | (196) |  |  | (101) |  |  | (188) |  |  | (104) |  |  |  |  |  |  |  |  | \nAmortization of unrecognized prior service credit | (8) |  |  | (4) |  |  | (10) |  |  | (4) |  |  |  |  |  |  |  |  | \nNet loss amortization | 56 |  |  | 25 |  |  | 85 |  |  | 41 |  |  |  |  |  |  |  |  | \nTermination benefits | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nCurtailments | 3 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nSettlements | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  | \n | $ | 58 |  |  | $ | 33 |  |  | $ | 91 |  |  | $ | 54 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nService cost | $ | 12 |  |  | $ | 13 |  |  |  |  | \nInterest cost | 11 |  |  | 11 |  |  |  |  | \nExpected return on plan assets | (21) |  |  | (20) |  |  |  |  | \nAmortization of unrecognized prior service credit | (25) |  |  | (25) |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n | $ | (23) |  |  | $ | (21) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nInterest income | $ | (7) |  |  | $ | (11) |  |  |  |  | \nInterest expense | 243 |  |  | 200 |  |  |  |  | \nExchange losses | 39 |  |  | 41 |  |  |  |  | \nLoss (income) from investments in equity securities, net(1) | 708 |  |  | (574) |  |  |  |  | \nNet periodic defined benefit plan (credit) cost other than service cost | (121) |  |  | (89) |  |  |  |  | \nOther, net | (154) |  |  | (22) |  |  |  |  | \n | $ | 708 |  |  | $ | (455) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ and shares in millions except per share amounts) | 2022 |  | 2021 |  |  |  | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 2,745 |  |  |  |  | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 434 |  |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,310 |  |  | $ | 3,179 |  |  |  |  | \nAverage common shares outstanding | 2,528 |  |  | 2,531 |  |  |  |  | \nCommon shares issuable(1) | 9 |  |  | 10 |  |  |  |  | \nAverage common shares outstanding assuming dilution | 2,537 |  |  | 2,541 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.26 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nIncome from Discontinued Operations | \u2014 |  |  | 0.17 |  |  |  |  | \nNet Income | $ | 1.70 |  |  | $ | 1.25 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2021, net of taxes | $ | (266) |  |  | $ | (4,540) |  |  | $ | (1,828) |  |  | $ | (6,634) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 180 |  |  | (4) |  |  | (211) |  |  | (35) | \nTax | (38) |  |  | (1) |  |  | (88) |  |  | (127) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 142 |  |  | (5) |  |  | (299) |  |  | (162) | \nReclassification adjustments, pretax | 111 |  | (1) | 87 |  | (2) | \u2014 |  |  | 198 | \nTax | (23) |  |  | (1) |  |  | \u2014 |  |  | (24) | \nReclassification adjustments, net of taxes | 88 |  |  | 86 |  |  | \u2014 |  |  | 174 | \nOther comprehensive income (loss), net of taxes | 230 |  |  | 81 |  |  | (299) |  |  | 12 | \nBalance March 31, 2021, net of taxes | $ | (36) |  |  | $ | (4,459) |  |  | $ | (2,127) |  |  | $ | (6,622) | \nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 148 |  |  | 1 |  |  | (18) |  |  | 131 | \nTax | (31) |  |  | (2) |  |  | (17) |  |  | (50) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 117 |  |  | (1) |  |  | (35) |  |  | 81 | \nReclassification adjustments, pretax | (68) |  | (1) | 45 |  | (2) | \u2014 |  |  | (23) | \nTax | 14 |  |  | (12) |  |  | \u2014 |  |  | 2 | \nReclassification adjustments, net of taxes | (54) |  |  | 33 |  |  | \u2014 |  |  | (21) | \nOther comprehensive income (loss), net of taxes | 63 |  |  | 32 |  |  | (35) |  |  | 60 | \nBalance March 31, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) |   |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 2,779 |  |  | $ | 2,030 |  |  | $ | 4,809 |  |  | $ | 2,181 |  |  | $ | 1,718 |  |  | $ | 3,899 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Lynparza(1) | 141 |  |  | 125 |  |  | 266 |  |  | 118 |  |  | 110 |  |  | 228 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Lenvima(1) | 156 |  |  | 71 |  |  | 227 |  |  | 85 |  |  | 44 |  |  | 130 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Reblozyl(2) | 27 |  |  | 25 |  |  | 52 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 418 |  |  | 1,042 |  |  | 1,460 |  |  | 313 |  |  | 604 |  |  | 917 |  |  |  |  |  |  |  |  |  |  |  |  | \nProQuad/M-M-RII/Varivax | 371 |  |  | 99 |  |  | 470 |  |  | 333 |  |  | 117 |  |  | 449 |  |  |  |  |  |  |  |  |  |  |  |  | \nRotaTeq | 175 |  |  | 41 |  |  | 216 |  |  | 118 |  |  | 41 |  |  | 158 |  |  |  |  |  |  |  |  |  |  |  |  | \nPneumovax23 | 118 |  |  | 55 |  |  | 173 |  |  | 73 |  |  | 99 |  |  | 171 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaqta | 29 |  |  | 7 |  |  | 36 |  |  | 25 |  |  | 9 |  |  | 34 |  |  |  |  |  |  |  |  |  |  |  |  | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 195 |  |  | 199 |  |  | 395 |  |  | 167 |  |  | 173 |  |  | 340 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrevymis | 40 |  |  | 54 |  |  | 94 |  |  | 35 |  |  | 47 |  |  | 82 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrimaxin | 1 |  |  | 58 |  |  | 58 |  |  | \u2014 |  |  | 65 |  |  | 65 |  |  |  |  |  |  |  |  |  |  |  |  | \nNoxafil | 10 |  |  | 48 |  |  | 57 |  |  | 15 |  |  | 52 |  |  | 67 |  |  |  |  |  |  |  |  |  |  |  |  | \nCancidas | 1 |  |  | 52 |  |  | 53 |  |  | 3 |  |  | 55 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nDificid | 49 |  |  | 3 |  |  | 52 |  |  | 25 |  |  | 2 |  |  | 27 |  |  |  |  |  |  |  |  |  |  |  |  | \nInvanz | 1 |  |  | 52 |  |  | 52 |  |  | 4 |  |  | 52 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nZerbaxa | 18 |  |  | 12 |  |  | 30 |  |  | (2) |  |  | (6) |  |  | (8) |  |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue - Adempas/Verquvo(3) | 71 |  |  | 1 |  |  | 72 |  |  | 68 |  |  | 6 |  |  | 74 |  |  |  |  |  |  |  |  |  |  |  |  | \nAdempas | \u2014 |  |  | 61 |  |  | 61 |  |  | \u2014 |  |  | 55 |  |  | 55 |  |  |  |  |  |  |  |  |  |  |  |  | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | 1,523 |  |  | 1,723 |  |  | 3,247 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nIsentress/IsentressHD | 61 |  |  | 97 |  |  | 158 |  |  | 71 |  |  | 138 |  |  | 209 |  |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 20 |  |  | 48 |  |  | 69 |  |  | 18 |  |  | 61 |  |  | 79 |  |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 186 |  |  | 186 |  |  | \u2014 |  |  | 214 |  |  | 214 |  |  |  |  |  |  |  |  |  |  |  |  | \nRemicade | \u2014 |  |  | 61 |  |  | 61 |  |  | \u2014 |  |  | 85 |  |  | 85 |  |  |  |  |  |  |  |  |  |  |  |  | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 325 |  |  | 454 |  |  | 779 |  |  | 348 |  |  | 461 |  |  | 809 |  |  |  |  |  |  |  |  |  |  |  |  | \nJanumet | 63 |  |  | 391 |  |  | 454 |  |  | 84 |  |  | 401 |  |  | 486 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther pharmaceutical(4) | 181 |  |  | 339 |  |  | 520 |  |  | 212 |  |  | 341 |  |  | 554 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Pharmaceutical segment sales | 6,773 |  |  | 7,334 |  |  | 14,107 |  |  | 4,294 |  |  | 4,944 |  |  | 9,238 |  |  |  |  |  |  |  |  |  |  |  |  | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 171 |  |  | 661 |  |  | 832 |  |  | 157 |  |  | 662 |  |  | 819 |  |  |  |  |  |  |  |  |  |  |  |  | \nCompanion Animals | 302 |  |  | 348 |  |  | 650 |  |  | 280 |  |  | 319 |  |  | 599 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Animal Health segment sales | 473 |  |  | 1,009 |  |  | 1,482 |  |  | 437 |  |  | 981 |  |  | 1,418 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal segment sales | 7,246 |  |  | 8,343 |  |  | 15,589 |  |  | 4,731 |  |  | 5,925 |  |  | 10,656 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther(5) | 93 |  |  | 220 |  |  | 312 |  |  | 59 |  |  | (88) |  |  | (29) |  |  |  |  |  |  |  |  |  |  |  |  | \n | $ | 7,339 |  |  | $ | 8,563 |  |  | $ | 15,901 |  |  | $ | 4,790 |  |  | $ | 5,837 |  |  | $ | 10,627 |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nUnited States | $ | 7,339 |  |  | $ | 4,790 |  |  |  |  | \nEurope, Middle East and Africa | 4,359 |  |  | 3,237 |  |  |  |  | \nChina | 1,143 |  |  | 721 |  |  |  |  | \nJapan | 989 |  |  | 629 |  |  |  |  | \nAsia Pacific (other than China and Japan) | 930 |  |  | 575 |  |  |  |  | \nLatin America | 607 |  |  | 500 |  |  |  |  | \nOther | 534 |  |  | 175 |  |  |  |  | \n | $ | 15,901 |  |  | $ | 10,627 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,501 |  |  | $ | 6,589 |  |  |  |  | \nAnimal Health segment | 585 |  |  | 572 |  |  |  |  | \nTotal segment profits | 10,086 |  |  | 7,161 |  |  |  |  | \nOther profits | 194 |  |  | (50) |  |  |  |  | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 7 |  |  | 11 |  |  |  |  | \nInterest expense | (243) |  |  | (200) |  |  |  |  | \nAmortization | (699) |  |  | (514) |  |  |  |  | \nDepreciation | (378) |  |  | (340) |  |  |  |  | \nResearch and development | (2,446) |  |  | (2,305) |  |  |  |  | \nRestructuring costs | (53) |  |  | (297) |  |  |  |  | \nOther unallocated, net | (1,607) |  |  | (479) |  |  |  |  | \n | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nUnited States | $ | 7,339 |  |  | $ | 4,790 |  |  | 53 | % |  | 53 | % |  |  |  |  |  |  |  | \nInternational | 8,563 |  |  | 5,837 |  |  | 47 | % |  | 52 | % |  |  |  |  |  |  |  | \nTotal | $ | 15,901 |  |  | $ | 10,627 |  |  | 50 | % |  | 52 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nKeytruda | $ | 4,809 |  |  | $ | 3,899 |  |  | 23 | % |  | 27 | % |  |  |  |  |  |  |  | \nAlliance Revenue - Lynparza(1) | 266 |  |  | 228 |  |  | 17 | % |  | 20 | % |  |  |  |  |  |  |  | \nAlliance Revenue-Lenvima(1) | 227 |  |  | 130 |  |  | 75 | % |  | 77 | % |  |  |  |  |  |  |  |   |  |  |  |  | \nDate | Approval\nJanuary 2022 | European Commission (EC) approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions based on the KEYNOTE-564 trial.\nFebruary 2022 | Japan Ministry of Health, Labour and Welfare approval of the combination ofKeytrudaplus Lenvima for radically unresectable or metastatic RCC based on the CLEAR (Study 307)/KEYNOTE-581 trial.\nFebruary 2022 | Japan Pharmaceuticals and Medical Devices Agency approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.\nMarch 2022 | U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation based on the KEYNOTE-158 trial (Cohorts D & K).\nApril 2022 | EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1 based on the KEYNOTE-826 trial.\nApril 2022 | EC approval as monotherapy for the treatment of certain patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer based on data from KEYNOTE-164 and KEYNOTE-158.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | $ | 1,460 |  |  | $ | 917 |  |  | 59 | % |  | 60 | % |  |  |  |  |  |  |  | \nProQuad | 162 |  |  | 165 |  |  | (2) | % |  | (1) | % |  |  |  |  |  |  |  | \nM-M-RII | 103 |  |  | 80 |  |  | 29 | % |  | 31 | % |  |  |  |  |  |  |  | \nVarivax | 204 |  |  | 204 |  |  | \u2014 | % |  | 1 | % |  |  |  |  |  |  |  | \nRotaTeq | 216 |  |  | 158 |  |  | 36 | % |  | 38 | % |  |  |  |  |  |  |  | \nPneumovax 23 | 173 |  |  | 171 |  |  | 1 | % |  | 3 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nBridion | $ | 395 |  |  | $ | 340 |  |  | 16 | % |  | 20 | % |  |  |  |  |  |  |  | \nZerbaxa | 30 |  |  | (8) |  |  | * |  | * |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 72 |  |  | $ | 74 |  |  | (3) | % |  | (3) | % |  |  |  |  |  |  |  | \nAdempas | 61 |  |  | 55 |  |  | 11 | % |  | 20 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nLagevrio | $ | 3,247 |  |  | $ | \u2014 |  |  | \u2014 |  | \u2014 |  |  |  |  |  |  |  | \nIsentress/Isentress HD | 158 |  |  | 209 |  |  | (24) | % |  | (21) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nJanuvia/Janumet | $ | 1,233 |  |  | $ | 1,295 |  |  | (5) | % |  | (1) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  |  |  | \nLivestock | $ | 832 |  |  | $ | 819 |  |  | 2 | % |  | 7 | % |  |  |  |  |  |  |  | \nCompanion Animal | 650 |  |  | 599 |  |  | 9 | % |  | 13 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  |  |  |  |  | \nCost of sales | $ | 5,380 |  |  | $ | 3,199 |  |  | 68 | % |  |  |  |  |  | \nSelling, general and administrative | 2,323 |  |  | 2,187 |  |  | 6 | % |  |  |  |  |  | \nResearch and development | 2,576 |  |  | 2,412 |  |  | 7 | % |  |  |  |  |  | \nRestructuring costs | 53 |  |  | 297 |  |  | (82) | % |  |  |  |  |  | \nOther (income) expense, net | 708 |  |  | (455) |  |  | * |  |  |  |  |  | \n | $ | 11,040 |  |  | $ | 7,640 |  |  | 45 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2022 |  | 2021 |  |  |  | \nPharmaceutical segment profits | $ | 9,501 |  |  | $ | 6,589 |  |  |  |  | \nAnimal Health segment profits | 585 |  |  | 572 |  |  |  |  | \nOther | (5,225) |  |  | (4,174) |  |  |  |  | \nIncome from Continuing Operations Before Taxes | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions except per share amounts) | 2022 |  | 2021 |  |  |  | \nIncome from continuing operations before taxes as reported under GAAP | $ | 4,861 |  |  | $ | 2,987 |  |  |  |  | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition and divestiture-related costs | 637 |  |  | 497 |  |  |  |  | \nRestructuring costs | 127 |  |  | 334 |  |  |  |  | \nLoss (income) from investments in equity securities, net | 684 |  |  | (561) |  |  |  |  | \nOther items: |  |  |  |  |  |  | \nCharge for the discontinuation of COVID-19 development programs | \u2014 |  |  | 188 |  |  |  |  | \nNon-GAAP income from continuing operations before taxes | 6,309 |  |  | 3,445 |  |  |  |  | \nTaxes on income from continuing operations as reported under GAAP | 554 |  |  | 238 |  |  |  |  | \nEstimated tax benefit on excluded items(1) | 329 |  |  | 48 |  |  |  |  | \nNet tax benefit from the settlement of certain federal income tax matters | \u2014 |  |  | 208 |  |  |  |  | \nNon-GAAP taxes on income from continuing operations | 883 |  |  | 494 |  |  |  |  | \nNon-GAAP net income from continuing operations | 5,426 |  |  | 2,951 |  |  |  |  | \nLess: Net (loss) income attributable to noncontrolling interests as reported under GAAP | (3) |  |  | 4 |  |  |  |  | \nNon-GAAP net income from continuing operations attributable to Merck\u00a0& Co., Inc. | $ | 5,429 |  |  | $ | 2,947 |  |  |  |  | \nEPS assuming dilution from continuing operations as reported under GAAP | $ | 1.70 |  |  | $ | 1.08 |  |  |  |  | \nEPS difference | 0.44 |  |  | 0.08 |  |  |  |  | \nNon-GAAP EPS assuming dilution from continuing operations | $ | 2.14 |  |  | $ | 1.16 |  |  |  |  |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(3)Non-Small-Cell LungMK-1026 (nemtabrutinib)Hematological MalignanciesMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)Advanced Solid TumorsColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BreastHematological MalignanciesNon-Small-Cell LungSolid TumorsMK-3475KeytrudaAdvanced Solid TumorsMK-4280 (favezelimab)(2)Hematological MalignanciesNon-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)Renal CellSmall-Cell LungMK-4830(2)ColorectalNon-Small-Cell LungRenal CellSmall-Cell LungMK-5890(3)Non-Small-Cell LungSmall-Cell Lung | CancerMK-6440 (ladiratuzumab vedotin)(1)(3)BreastEsophagealGastricHead and NeckMelanomaNon-Small-Cell LungProstateSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalColorectalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684 (vibostolimab)(2)MelanomaMK-7684A (vibostolimab+pembrolizumab)BiliaryBreastCervicalEndometrialEsophagealHead and NeckHematological MalignanciesHepatocellularProstate | CancerMK-7902 Lenvima(1)(2)BiliaryGlioblastomaPancreaticProstateSmall-Cell LungV937BreastCutaneous Squamous CellHead and NeckMelanomaSolid TumorsCardiovascularMK-2060Chikungunya Virus VaccineV184HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(4)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-3655MK-6024Overgrowth SyndromeMK-7075 (miransertib)Pneumococcal Vaccine AdultV116Pulmonary Arterial HypertensionMK-5475SchizophreniaMK-8189Treatment Resistant DepressionMK-1942  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(5)CancerMK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaBiliary (September 2019)Cutaneous Squamous Cell (August 2019) (EU)Gastric (May 2015) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Prostate (May 2019)Small-Cell Lung (May 2017)MK-3475 (pembrolizumab subcutaneous)Non-Small-Cell Lung (August 2021)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)MK-7339 Lynparza(1)(3)Colorectal (August 2020)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Colorectal (April 2021)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Melanoma (March 2019)Non-Small-Cell Lung (March 2019)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(4)HIV-1 PreventionMK-8591 (islatravir) (February 2021)(4)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular Entities/VaccinesAntiviral COVID-19MK-4482Lagevrio(EU)(1)CoughMK-7264 (gefapixant) (U.S.)(6)(EU)Pneumococcal Vaccine AdultV114 (JPN) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    High-Risk Early-Stage Triple-Negative Breast Cancer(KEYNOTE-522) (EU) (JPN)\u2022    Adjuvent Treatment of Stage IIB and IIC Melanoma(KEYNOTE-716) (EU)\u2022    Cervical Cancer (KEYNOTE-826) (JPN)\u2022    Adjuvent Renal Cell Cancer(KEYNOTE-564) (JPN)\u2022    Second-Line Hepatocellular Cancer(KEYNOTE-394) (U.S.)MK-7339 Lynparza(1)\u2022BRCA-Mutated HER2-Negative Adjuvant BreastCancer (OlympiA) (EU) (JPN)\u2022    First-Line Metastatic Prostate Cancer (PROpel) EU)MK-7902 Lenvima(1)(2)\u2022    First-Line Metastatic Hepatocellular Carcinoma(KEYNOTE-524) (U.S.)(7)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)Available in the U.S. under Emergency Use Authorization.(6)In January 2022, the FDA issued a CRL for this application. Merck is reviewing the CRL and considering next steps.(7)In July 2020, the FDA issued a CRL for Merck\u2019s and Eisai\u2019s applications. Merck and Eisai intend to submit additional data when available to the FDA.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2022 |  | December 31, 2021\nCash and investments | $ | 9,244 |  |  | $ | 8,466 | \nWorking capital | 8,868 |  |  | 6,394 | \nTotal debt to total liabilities and equity | 29.8 | % |  | 31.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nJanuary 1 - January 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nFebruary 1 - February 28 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nMarch 1 - March 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nTotal | \u2014 |  |  | $0.00 |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  May 5, 2022 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  May 5, 2022 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2022 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | Not Applicable | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 34\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 48\n |  | \nItem 4. | Controls and Procedures | 49\n |  | \n | Cautionary Factors That May Affect Future Results | 49\n |  | \nPART II | OTHER INFORMATION | 49\n |  | \nItem 1. | Legal Proceedings | 49\n |  | \nItem 1A. | Risk Factors | 49\n |  |  |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 50\n |  |  |  | \nItem 6. | Exhibits | 50\n |  | \n | Signatures |  |  | 51  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nSales | $ | 14,593 |  |  | $ | 11,402 |  |  | $ | 30,494 |  |  | $ | 22,029 | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 4,216 |  |  | 3,104 |  |  | 9,596 |  |  | 6,303 | \nSelling, general and administrative | 2,512 |  |  | 2,281 |  |  | 4,834 |  |  | 4,468 | \nResearch and development | 2,798 |  |  | 4,321 |  |  | 5,374 |  |  | 6,732 | \nRestructuring costs | 142 |  |  | 82 |  |  | 194 |  |  | 380 | \nOther (income) expense, net | 438 |  |  | (103) |  |  | 1,148 |  |  | (558) | \n | 10,106 |  |  | 9,685 |  |  | 21,146 |  |  | 17,325 | \nIncome from Continuing Operations Before Taxes | 4,487 |  |  | 1,717 |  |  | 9,348 |  |  | 4,704 | \nTaxes on Income from Continuing Operations | 538 |  |  | 503 |  |  | 1,092 |  |  | 741 | \nNet Income from Continuing Operations | 3,949 |  |  | 1,214 |  |  | 8,256 |  |  | 3,963 | \nLess: Net Income Attributable to Noncontrolling Interests | 5 |  |  | 1 |  |  | 2 |  |  | 5 | \nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | 3,944 |  |  | 1,213 |  |  | 8,254 |  |  | 3,958 | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 332 |  |  | \u2014 |  |  | 766 | \nNet Income Attributable to Merck & Co., Inc. | $ | 3,944 |  |  | $ | 1,545 |  |  | $ | 8,254 |  |  | $ | 4,724 | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.56 |  |  | $ | 0.48 |  |  | $ | 3.26 |  |  | $ | 1.56 | \nIncome from Discontinued Operations | \u2014 |  |  | 0.13 |  |  | \u2014 |  |  | 0.30 | \nNet Income | $ | 1.56 |  |  | $ | 0.61 |  |  | $ | 3.26 |  |  | $ | 1.87 | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.55 |  |  | $ | 0.48 |  |  | $ | 3.25 |  |  | $ | 1.56 | \nIncome from Discontinued Operations | \u2014 |  |  | 0.13 |  |  | \u2014 |  |  | 0.30 | \nNet Income | $ | 1.55 |  |  | $ | 0.61 |  |  | $ | 3.25 |  |  | $ | 1.86 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 3,944 |  |  | $ | 1,545 |  |  | $ | 8,254 |  |  | $ | 4,724 | \nOther Comprehensive Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 183 |  |  | 10 |  |  | 246 |  |  | 240 | \nBenefit plan net gain and prior service credit, net of amortization | 246 |  |  | 1,403 |  |  | 278 |  |  | 1,484 | \nCumulative translation adjustment | (387) |  |  | 132 |  |  | (422) |  |  | (167) | \n | 42 |  |  | 1,545 |  |  | 102 |  |  | 1,557 | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 3,986 |  |  | $ | 3,090 |  |  | $ | 8,356 |  |  | $ | 6,281 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 9,675 |  |  | $ | 8,096 | \nShort-term investments | 453 |  |  | \u2014 | \nAccounts receivable (net of allowance for doubtful accounts of $82in 2022and $62in 2021) | 9,643 |  |  | 9,230 | \nInventories (excludes inventories of $2,764in 2022 and $2,194in 2021classified in Other assets - see Note\u00a07) | 5,535 |  |  | 5,953 | \nOther current assets | 6,810 |  |  | 6,987 | \nTotal current assets | 32,116 |  |  | 30,266 | \nInvestments | 238 |  |  | 370 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $17,798in 2022 and $18,192in 2021 | 20,059 |  |  | 19,279 | \nGoodwill | 21,213 |  |  | 21,264 | \nOther Intangibles, Net | 22,497 |  |  | 22,933 | \nOther Assets | 10,972 |  |  | 11,582 | \n | $ | 107,095 |  |  | $ | 105,694 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 2,979 |  |  | $ | 2,412 | \nTrade accounts payable | 3,482 |  |  | 4,609 | \nAccrued and other current liabilities | 13,501 |  |  | 13,859 | \nIncome taxes payable | 1,438 |  |  | 1,224 | \nDividends payable | 1,768 |  |  | 1,768 | \nTotal current liabilities | 23,168 |  |  | 23,872 | \nLong-Term Debt | 28,684 |  |  | 30,690 | \nDeferred Income Taxes | 2,974 |  |  | 3,441 | \nOther Noncurrent Liabilities | 8,951 |  |  | 9,434 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2022 and 2021 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,115 |  |  | 44,238 | \nRetained earnings | 58,437 |  |  | 53,696 | \nAccumulated other comprehensive loss | (4,327) |  |  | (4,429) | \n | 100,013 |  |  | 95,293 | \nLess treasury stock, at cost:1,043,894,068shares in 2022 and1,049,499,023shares in 2021 | 56,770 |  |  | 57,109 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 43,243 |  |  | 38,184 | \nNoncontrolling Interests | 75 |  |  | 73 | \nTotal equity | 43,318 |  |  | 38,257 | \n | $ | 107,095 |  |  | $ | 105,694 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months EndedJune 30,\n | 2022 |  | 2021\nCash Flows from Operating Activities of Continuing Operations |  |  | \nNet income from continuing operations | $ | 8,256 |  |  | $ | 3,963 | \nAdjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: |  |  | \nAmortization | 1,163 |  |  | 871 | \nDepreciation | 895 |  |  | 749 | \nIntangible asset impairment charges | 23 |  |  | \u2014 | \nLoss (income) from investments in equity securities, net | 991 |  |  | (854) | \nCharge for the acquisition of Pandion Therapeutics, Inc. | \u2014 |  |  | 1,556 | \nDeferred income taxes | (600) |  |  | 29 | \nShare-based compensation | 257 |  |  | 243 | \nOther | 776 |  |  | 328 | \nNet changes in assets and liabilities | (2,698) |  |  | (3,655) | \nNet Cash Provided by Operating Activities of Continuing Operations | 9,063 |  |  | 3,230 | \nCash Flows from Investing Activities of Continuing Operations |  |  | \nCapital expenditures | (2,113) |  |  | (2,068) | \nPurchases of securities and other investments | (705) |  |  | (1) | \nProceeds from sales of securities and other investments | 374 |  |  | 386 | \nAcquisition of Pandion Therapeutics, Inc., net of cash acquired | \u2014 |  |  | (1,554) | \nOther acquisitions, net of cash acquired | \u2014 |  |  | (90) | \nOther | 194 |  |  | 16 | \nNet Cash Used in Investing Activities of Continuing Operations | (2,250) |  |  | (3,311) | \nCash Flows from Financing Activities of Continuing Operations |  |  | \nNet change in short-term borrowings | \u2014 |  |  | (3,983) | \nPayments on debt | (1,250) |  |  | (1,153) | \nDistribution from Organon & Co. | \u2014 |  |  | 9,000 | \nPurchases of treasury stock | \u2014 |  |  | (239) | \nDividends paid to stockholders | (3,515) |  |  | (3,318) | \nProceeds from exercise of stock options | 109 |  |  | 51 | \nOther | (207) |  |  | (194) | \nNet Cash (Used in) Provided by Financing Activities of Continuing Operations | (4,863) |  |  | 164 | \nCash Flows from Discontinued Operations |  |  | \nNet cash provided by operating activities | \u2014 |  |  | 1,051 | \nNet cash used in investing activities | \u2014 |  |  | (134) | \nNet cash used in financing activities | \u2014 |  |  | (504) | \nNet Cash Flows Provided by Discontinued Operations | \u2014 |  |  | 413 | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (364) |  |  | (19) | \nNet Increase in Cash, Cash Equivalents and Restricted Cash | 1,586 |  |  | 477 | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$71and $103at January 1, 2022 and 2021, respectively, included in Other current assets) | 8,167 |  |  | 8,153 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $78and $55at June\u00a030, 2022 and 2021, respectively, included in Other current assets) | $ | 9,753 |  |  | $ | 8,630 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2021(1)\nSales | $ | 1,059 |  |  | $ | 2,512 | \nCosts, Expenses and Other |  |  | \nCost of sales | 318 |  |  | 789 | \nSelling, general and administrative | 431 |  |  | 877 | \nResearch and development | 50 |  |  | 103 | \nRestructuring costs | \u2014 |  |  | 1 | \nOther (income) expense, net | (23) |  |  | (15) | \n | 776 |  |  | 1,755 | \nIncome from discontinued operations before taxes | 283 |  |  | 757 | \nIncome tax benefit | (49) |  |  | (12) | \nIncome from discontinued operations, net of taxes | 332 |  |  | 769 | \nLess: Income of discontinued operations attributable to noncontrolling interests | \u2014 |  |  | 3 | \n | $ | 332 |  |  | $ | 766 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nAlliance revenue - Lynparza | $ | 275 |  |  | $ | 248 |  |  | $ | 541 |  |  | $ | 475 | \nAlliance revenue - Koselugo | 24 |  |  | 8 |  |  | 33 |  |  | 14 | \nTotal alliance revenue | $ | 299 |  |  | $ | 256 |  |  | $ | 574 |  |  | $ | 489 | \n |  |  |  |  |  |  | \nCost of sales(1) | 62 |  |  | 42 |  |  | 361 |  |  | 84 | \nSelling, general and administrative | 46 |  |  | 43 |  |  | 90 |  |  | 83 | \nResearch and development | 25 |  |  | 31 |  |  | 51 |  |  | 60 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2022 |  | December 31, 2021\nReceivables from AstraZeneca included inOther current assets |  |  |  |  | $ | 300 |  |  | $ | 271 | \nPayables to AstraZeneca included inTrade accounts payableandAccrued and other current liabilities(2) |  |  |  |  | 12 |  |  | 415 | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) |  |  |  |  | 600 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nAlliance revenue - Lenvima | $ | 231 |  |  | $ | 181 |  |  | $ | 459 |  |  | $ | 310 | \n |  |  |  |  |  |  | \nCost of sales(1) | 53 |  |  | 47 |  |  | 106 |  |  | 94 | \nSelling, general and administrative | 42 |  |  | 31 |  |  | 73 |  |  | 54 | \nResearch and development | 47 |  |  | 57 |  |  | 104 |  |  | 121 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2022 |  | December 31, 2021\nReceivables from Eisai included inOther current assets |  |  |  |  | $ | 247 |  |  | $ | 200 | \nPayables to Eisai included inAccrued and other current liabilities(2) |  |  |  |  | 25 |  |  | 625 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nAlliance revenue - Adempas/Verquvo | $ | 98 |  |  | $ | 74 |  |  | $ | 170 |  |  | $ | 149 | \nNet sales of Adempas recorded by Merck | 63 |  |  | 74 |  |  | 124 |  |  | 129 | \nNet sales of Verquvo recorded by Merck | 6 |  |  | 1 |  |  | 9 |  |  | 1 | \nTotal sales | $ | 167 |  |  | $ | 149 |  |  | $ | 303 |  |  | $ | 279 | \n |  |  |  |  |  |  | \nCost of sales(1) | 54 |  |  | 67 |  |  | 103 |  |  | 275 | \nSelling, general and administrative | 42 |  |  | 34 |  |  | 65 |  |  | 51 | \nResearch and development | 17 |  |  | 13 |  |  | 34 |  |  | 20 | \n($ in millions) |  |  |  |  | June 30, 2022 |  | December 31, 2021\nReceivables from Bayer included inOther current assets |  |  |  |  | $ | 144 |  |  | $ | 114 | \nPayables to Bayer included inAccrued and other current liabilities(2) |  |  |  |  | 74 |  |  | 472 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nLagevriosales | $ | 1,177 |  |  | $ | \u2014 |  |  | $ | 4,424 |  |  | $ | \u2014 | \n |  |  |  |  |  |  | \nCost of sales(1) | 622 |  |  | 6 |  |  | 2,338 |  |  | 52 | \nSelling, general and administrative | 30 |  |  | 4 |  |  | 65 |  |  | 7 | \nResearch and development | 15 |  |  | 68 |  |  | 21 |  |  | 110 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2022 |  | December 31, 2021\nPayables to Ridgeback included inAccrued and other current liabilities(2) |  |  |  |  | $ | 683 |  |  | $ | 283 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2022 |  | Six Months Ended June 30, 2022\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 17 |  |  | $ | 50 |  |  | $ | 67 |  |  | $ | \u2014 |  |  | $ | 35 |  |  | $ | 78 |  |  | $ | 113 | \nSelling, general and administrative | \u2014 |  |  | 8 |  |  | 19 |  |  | 27 |  |  | \u2014 |  |  | 12 |  |  | 36 |  |  | 48 | \nResearch and development | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 29 |  |  | \u2014 |  |  | 29 | \nRestructuring costs | 106 |  |  | \u2014 |  |  | 36 |  |  | 142 |  |  | 132 |  |  | \u2014 |  |  | 62 |  |  | 194 | \n | $ | 106 |  |  | $ | 47 |  |  | $ | 105 |  |  | $ | 258 |  |  | $ | 132 |  |  | $ | 76 |  |  | $ | 176 |  |  | $ | 384 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2021 |  | Six Months Ended June 30, 2021\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 11 |  |  | $ | 27 |  |  | $ | 38 |  |  | $ | \u2014 |  |  | $ | 21 |  |  | $ | 44 |  |  | $ | 65 | \nSelling, general and administrative | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 4 | \nResearch and development | \u2014 |  |  | 6 |  |  | \u2014 |  |  | 6 |  |  | \u2014 |  |  | 13 |  |  | \u2014 |  |  | 13 | \nRestructuring costs | 64 |  |  | \u2014 |  |  | 18 |  |  | 82 |  |  | 293 |  |  | \u2014 |  |  | 87 |  |  | 380 | \n | $ | 64 |  |  | $ | 19 |  |  | $ | 45 |  |  | $ | 128 |  |  | $ | 293 |  |  | $ | 38 |  |  | $ | 131 |  |  | $ | 462 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2022 | $ | 596 |  |  | $ | \u2014 |  |  | $ | 41 |  |  | $ | 637 | \nExpense | 132 |  |  | 76 |  |  | 176 |  |  | 384 | \n(Payments) receipts, net | (167) |  |  | \u2014 |  |  | (280) |  |  | (447) | \nNon-cash activity | \u2014 |  |  | (76) |  |  | 90 |  |  | 14 | \nRestructuring reserves June\u00a030, 2022(1) | $ | 561 |  |  | $ | \u2014 |  |  | $ | 27 |  |  | $ | 588 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended June 30, |  | Six Months Ended June 30, |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021\nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | (31) |  |  | $ | (3) |  |  | $ | (46) |  |  | $ | (28) |  |  | $ | (1) |  |  | $ | (4) |  |  | $ | (2) |  |  | $ | (8) | \nEuro-denominated notes | (128) |  |  | 45 |  |  | (181) |  |  | (122) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022\n($ in millions) | Par Value of Debt |  | Number of Interest Rate Swaps Held |  | Total Swap Notional Amount\n2.40% notes due 2022 | $ | 1,000 |  |  | 4 |  |  | $ | 1,000 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Carrying Amount of Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount\n($ in millions) | June 30, 2022 |  | December 31, 2021 |  | June 30, 2022 |  | December 31, 2021\nBalance Sheet Line Item in which Hedged Item is Included |  |  |  |  |  |  | \nLoans payable and current portion of long-term debt | $ | 999 |  |  | $ | 2,263 |  |  | $ | (1) |  |  | $ | 13 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2022 |  | December 31, 2021\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other current assets | $ | 1 |  |  | $ | \u2014 |  |  | $ | 1,000 |  |  | $ | 14 |  |  | $ | \u2014 |  |  | $ | 2,250 | \nForeign exchange contracts | Other current assets | 467 |  |  | \u2014 |  |  | 6,751 |  |  | 271 |  |  | \u2014 |  |  | 6,778 | \nForeign exchange contracts | Other Assets | 57 |  |  | \u2014 |  |  | 1,334 |  |  | 43 |  |  | \u2014 |  |  | 1,551 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 2 |  |  | 510 |  |  | \u2014 |  |  | 24 |  |  | 1,623 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 126 |  |  | \u2014 |  |  | 1 |  |  | 43 | \n |  | $ | 525 |  |  | $ | 3 |  |  | $ | 9,721 |  |  | $ | 328 |  |  | $ | 25 |  |  | $ | 12,245 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 407 |  |  | $ | \u2014 |  |  | $ | 10,931 |  |  | $ | 221 |  |  | $ | \u2014 |  |  | $ | 10,073 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 131 |  |  | 7,074 |  |  | \u2014 |  |  | 96 |  |  | 10,640 | \n |  | $ | 407 |  |  | $ | 131 |  |  | $ | 18,005 |  |  | $ | 221 |  |  | $ | 96 |  |  | $ | 20,713 | \n |  | $ | 932 |  |  | $ | 134 |  |  | $ | 27,726 |  |  | $ | 549 |  |  | $ | 121 |  |  | $ | 32,958 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 932 |  |  | $ | 134 |  |  | $ | 549 |  |  | $ | 121 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (123) |  |  | (123) |  |  | (110) |  |  | (110) | \nCash collateral received | (527) |  |  | \u2014 |  |  | (164) |  |  | \u2014 | \nNet amounts | $ | 282 |  |  | $ | 11 |  |  | $ | 275 |  |  | $ | 11 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021 |  | 2022 |  | 2021\nFinancial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss)\n | $ | 14,593 |  |  | $ | 11,402 |  |  | $ | 438 |  |  | $ | (103) |  |  | $ | 42 |  |  | $ | 1,545 |  |  | $ | 30,494 |  |  | $ | 22,029 |  |  | $ | 1,148 |  |  | $ | (558) |  |  | $ | 102 |  |  | $ | 1,557 | \n(Gain) loss on fair value hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | (4) |  |  | (9) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (14) |  |  | (19) |  |  | \u2014 |  |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | 1 |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nImpact of cash flow hedging relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain (loss) recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 403 |  |  | (58) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 551 |  |  | 121 | \nIncrease (decrease) inSalesas a result ofAOCLreclassifications | 172 |  |  | (71) |  |  | \u2014 |  |  | \u2014 |  |  | (172) |  |  | 71 |  |  | 239 |  |  | (183) |  |  | \u2014 |  |  | \u2014 |  |  | (239) |  |  | 183 | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 | \nAmount of loss recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) |  |  | 2022 |  | 2021 |  | 2022 |  | 2021\nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | (64) |  |  | $ | 167 |  |  | $ | (36) |  |  | $ | 217 | \nForeign exchange contracts(2) | Sales |  | (36) |  |  | 14 |  |  | (38) |  |  | 10 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 334 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 334 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities | 72 |  |  | \u2014 |  |  | \u2014 |  |  | 72 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nForeign government bonds | 2 |  |  | \u2014 |  |  | \u2014 |  |  | 2 |  |  | 2 |  |  | \u2014 |  |  | \u2014 |  |  | 2 | \nTotal debt securities | $ | 412 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 412 |  |  | $ | 86 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 86 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,530 |  |  |  |  |  |  |  |  | 1,647 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 1,942 |  |  |  |  |  |  |  |  | $ | 1,733 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | June 30, 2022 |  | December 31, 2021\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 334 |  |  | $ | \u2014 |  |  | $ | 334 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nForeign government bonds | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 | \nPublicly traded equity securities | 355 |  |  | \u2014 |  |  | \u2014 |  |  | 355 |  |  | 368 |  |  | \u2014 |  |  | \u2014 |  |  | 368 | \n | 355 |  |  | 336 |  |  | \u2014 |  |  | 691 |  |  | 368 |  |  | 2 |  |  | \u2014 |  |  | 370 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 72 |  |  | \u2014 |  |  | \u2014 |  |  | 72 |  |  | 80 |  |  | \u2014 |  |  | \u2014 |  |  | 80 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 | \nPublicly traded equity securities | 1,175 |  |  | \u2014 |  |  | \u2014 |  |  | 1,175 |  |  | 1,279 |  |  | \u2014 |  |  | \u2014 |  |  | 1,279 | \n | 1,251 |  |  | \u2014 |  |  | \u2014 |  |  | 1,251 |  |  | 1,363 |  |  | \u2014 |  |  | \u2014 |  |  | 1,363 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 576 |  |  | \u2014 |  |  | 576 |  |  | \u2014 |  |  | 351 |  |  | \u2014 |  |  | 351 | \nPurchased currency options | \u2014 |  |  | 355 |  |  | \u2014 |  |  | 355 |  |  | \u2014 |  |  | 184 |  |  | \u2014 |  |  | 184 | \nInterest rate swaps | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 14 |  |  | \u2014 |  |  | 14 | \n | \u2014 |  |  | 932 |  |  | \u2014 |  |  | 932 |  |  | \u2014 |  |  | 549 |  |  | \u2014 |  |  | 549 | \nTotal assets | $ | 1,606 |  |  | $ | 1,268 |  |  | $ | \u2014 |  |  | $ | 2,874 |  |  | $ | 1,731 |  |  | $ | 551 |  |  | $ | \u2014 |  |  | $ | 2,282 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 542 |  |  | $ | 542 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 777 |  |  | $ | 777 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 133 |  |  | \u2014 |  |  | 133 |  |  | \u2014 |  |  | 120 |  |  | \u2014 |  |  | 120 | \nWritten currency options | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 | \n | \u2014 |  |  | 134 |  |  | \u2014 |  |  | 134 |  |  | \u2014 |  |  | 121 |  |  | \u2014 |  |  | 121 | \nTotal liabilities | $ | \u2014 |  |  | $ | 134 |  |  | $ | 542 |  |  | $ | 676 |  |  | $ | \u2014 |  |  | $ | 121 |  |  | $ | 777 |  |  | $ | 898 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2022 |  | 2021\nFair value January 1 | $ | 777 |  |  | $ | 841 | \nChanges in estimated fair value(1) | (114) |  |  | 50 | \nPayments | (119) |  |  | \u2014 | \nOther | (2) |  |  | (12) | \nFair value June 30(2) | $ | 542 |  |  | $ | 879 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | June 30, 2022 |  | December 31, 2021\nFinished goods | $ | 1,680 |  |  | $ | 1,747 | \nRaw materials and work in process | 6,542 |  |  | 6,220 | \nSupplies | 217 |  |  | 196 | \nTotal (approximates current cost) | 8,439 |  |  | 8,163 | \nDecrease to LIFO cost | (140) |  |  | (16) | \n | $ | 8,299 |  |  | $ | 8,147 | \nRecognized as: |  |  | \nInventories | $ | 5,535 |  |  | $ | 5,953 | \nOther assets | 2,764 |  |  | 2,194 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at April 1, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,613 |  | $ | 48,888 |  | $ | (6,622) |  | 1,046 |  | $ | (56,722) |  | $ | 94 |  | $ | 27,039 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 1,545 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,545 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,545 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,545 | \nCash dividends declared on common stock ($0.65per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,656) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,656) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3 |  | (239) |  | \u2014 |  | (239) | \nSpin-off of Organon & Co. | \u2014 |  | \u2014 |  | 4,643 |  | \u2014 |  | 449 |  | \u2014 |  | \u2014 |  | (1) |  | 5,091 | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (217) |  | \u2014 |  | \u2014 |  | (5) |  | 279 |  | \u2014 |  | 62 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1 |  | 1 | \nBalance at June 30, 2021 | 3,577 |  | $ | 1,788 |  | $ | 44,039 |  | $ | 48,777 |  | $ | (4,628) |  | 1,044 |  | $ | (56,682) |  | $ | 94 |  | $ | 33,388 | \nBalance at April 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,944 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,944 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 42 |  | \u2014 |  | \u2014 |  | \u2014 |  | 42 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,759) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,759) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (160) |  | \u2014 |  | \u2014 |  | (5) |  | 293 |  | \u2014 |  | 133 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 5 |  | 5 | \nBalance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January\u00a01, 2021 | 3,577 |  | $ | 1,788 |  | $ | 39,588 |  | $ | 47,362 |  | $ | (6,634) |  | 1,047 |  | $ | (56,787) |  | $ | 87 |  | $ | 25,404 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,724 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,724 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,557 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,557 | \nCash dividends declared on common stock ($1.30per share) | \u2014 |  | \u2014 |  | \u2014 |  | (3,309) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,309) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3 |  | (239) |  | \u2014 |  | (239) | \nSpin-off of Organon & Co. | \u2014 |  | \u2014 |  | 4,643 |  | \u2014 |  | 449 |  | \u2014 |  | \u2014 |  | (1) |  | 5,091 | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (192) |  | \u2014 |  | \u2014 |  | (6) |  | 344 |  | \u2014 |  | 152 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 8 |  | 8 | \nBalance at June 30, 2021 | 3,577 |  | $ | 1,788 |  | $ | 44,039 |  | $ | 48,777 |  | $ | (4,628) |  | 1,044 |  | $ | (56,682) |  | $ | 94 |  | $ | 33,388 | \nBalance at January\u00a01, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 8,254 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 8,254 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 | \nCash dividends declared on common stock ($1.38per share) | \u2014 |  | \u2014 |  | \u2014 |  | (3,513) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,513) | \n |  |  |  |  |  |  |  |  | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (123) |  | \u2014 |  | \u2014 |  | (5) |  | 339 |  | \u2014 |  | 216 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 2 |  | 2 | \n |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\n($ in millions) | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International\nService cost | $ | 99 |  |  | $ | 72 |  |  | $ | 98 |  |  | $ | 87 |  |  | $ | 198 |  |  | $ | 147 |  |  | $ | 198 |  |  | $ | 179 | \nInterest cost | 103 |  |  | 37 |  |  | 106 |  |  | 30 |  |  | 206 |  |  | 75 |  |  | 202 |  |  | 59 | \nExpected return on plan assets | (197) |  |  | (98) |  |  | (191) |  |  | (104) |  |  | (393) |  |  | (199) |  |  | (379) |  |  | (209) | \nAmortization of unrecognized prior service credit | (8) |  |  | (3) |  |  | (11) |  |  | (4) |  |  | (16) |  |  | (7) |  |  | (20) |  |  | (9) | \nNet loss amortization | 56 |  |  | 25 |  |  | 58 |  |  | 38 |  |  | 112 |  |  | 50 |  |  | 142 |  |  | 78 | \nTermination benefits | 1 |  |  | \u2014 |  |  | 52 |  |  | 2 |  |  | 1 |  |  | \u2014 |  |  | 53 |  |  | 3 | \nCurtailments | 4 |  |  | \u2014 |  |  | 9 |  |  | (27) |  |  | 8 |  |  | \u2014 |  |  | 16 |  |  | (27) | \nSettlements | 101 |  |  | \u2014 |  |  | \u2014 |  |  | 2 |  |  | 101 |  |  | \u2014 |  |  | \u2014 |  |  | 2 | \n | $ | 159 |  |  | $ | 33 |  |  | $ | 121 |  |  | $ | 24 |  |  | $ | 217 |  |  | $ | 66 |  |  | $ | 212 |  |  | $ | 76 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nService cost | $ | 12 |  |  | $ | 13 |  |  | $ | 25 |  |  | $ | 26 | \nInterest cost | 11 |  |  | 11 |  |  | 23 |  |  | 22 | \nExpected return on plan assets | (21) |  |  | (20) |  |  | (43) |  |  | (39) | \nAmortization of unrecognized prior service credit | (25) |  |  | (25) |  |  | (50) |  |  | (50) | \n |  |  |  |  |  |  | \nTermination benefits | \u2014 |  |  | 37 |  |  | \u2014 |  |  | 37 | \nCurtailments | \u2014 |  |  | (27) |  |  | \u2014 |  |  | (28) | \n | $ | (23) |  |  | $ | (11) |  |  | $ | (45) |  |  | $ | (32) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nInterest income | $ | (15) |  |  | $ | (9) |  |  | $ | (22) |  |  | $ | (20) | \nInterest expense | 240 |  |  | 202 |  |  | 483 |  |  | 401 | \nExchange losses | 86 |  |  | 114 |  |  | 124 |  |  | 155 | \nLoss (income) from investments in equity securities, net(1) | 284 |  |  | (280) |  |  | 991 |  |  | (854) | \nNet periodic defined benefit plan (credit) cost other than service cost | (27) |  |  | (110) |  |  | (148) |  |  | (199) | \nOther, net | (130) |  |  | (20) |  |  | (280) |  |  | (41) | \n | $ | 438 |  |  | $ | (103) |  |  | $ | 1,148 |  |  | $ | (558) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ and shares in millions except per share amounts) | 2022 |  | 2021 |  | 2022 |  | 2021\nNet Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc. | $ | 3,944 |  |  | $ | 1,213 |  |  | $ | 8,254 |  |  | $ | 3,958 | \nIncome from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | \u2014 |  |  | 332 |  |  | \u2014 |  |  | 766 | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 3,944 |  |  | $ | 1,545 |  |  | $ | 8,254 |  |  | $ | 4,724 | \nAverage common shares outstanding | 2,531 |  |  | 2,533 |  |  | 2,529 |  |  | 2,532 | \nCommon shares issuable(1) | 9 |  |  | 7 |  |  | 9 |  |  | 8 | \nAverage common shares outstanding assuming dilution | 2,540 |  |  | 2,540 |  |  | 2,538 |  |  | 2,540 | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.56 |  |  | $ | 0.48 |  |  | $ | 3.26 |  |  | $ | 1.56 | \nIncome from Discontinued Operations | \u2014 |  |  | 0.13 |  |  | \u2014 |  |  | 0.30 | \nNet Income | $ | 1.56 |  |  | $ | 0.61 |  |  | $ | 3.26 |  |  | $ | 1.87 | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: |  |  |  |  |  |  | \nIncome from Continuing Operations | $ | 1.55 |  |  | $ | 0.48 |  |  | $ | 3.25 |  |  | $ | 1.56 | \nIncome from Discontinued Operations | \u2014 |  |  | 0.13 |  |  | \u2014 |  |  | 0.30 | \nNet Income | $ | 1.55 |  |  | $ | 0.61 |  |  | $ | 3.25 |  |  | $ | 1.86 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance April 1, 2021, net of taxes | $ | (36) |  |  | $ | (4,459) |  |  | $ | (2,127) |  |  | $ | (6,622) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | (59) |  |  | 1,767 |  |  | 140 |  |  | 1,848 | \nTax | 13 |  |  | (400) |  |  | (8) |  |  | (395) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | (46) |  |  | 1,367 |  |  | 132 |  |  | 1,453 | \nReclassification adjustments, pretax | 71 |  | (1) | 55 |  | (2) | \u2014 |  |  | 126 | \nTax | (15) |  |  | (19) |  |  | \u2014 |  |  | (34) | \nReclassification adjustments, net of taxes | 56 |  |  | 36 |  |  | \u2014 |  |  | 92 | \nOther comprehensive income (loss), net of taxes | 10 |  |  | 1,403 |  |  | 132 |  |  | 1,545 | \nSpin-off of Organon (see Note\u00a02) | \u2014 |  |  | 28 |  |  | 421 |  |  | 449 | \nBalance June 30, 2021, net of taxes | $ | (26) |  |  | $ | (3,028) |  |  | $ | (1,574) |  |  | $ | (4,628) | \nBalance April 1, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 403 |  |  | 168 |  |  | (365) |  |  | 206 | \nTax | (85) |  |  | (35) |  |  | (22) |  |  | (142) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 318 |  |  | 133 |  |  | (387) |  |  | 64 | \nReclassification adjustments, pretax | (171) |  | (1) | 144 |  | (2) | \u2014 |  |  | (27) | \nTax | 36 |  |  | (31) |  |  | \u2014 |  |  | 5 | \nReclassification adjustments, net of taxes | (135) |  |  | 113 |  |  | \u2014 |  |  | (22) | \nOther comprehensive income (loss), net of taxes | 183 |  |  | 246 |  |  | (387) |  |  | 42 | \nBalance June 30, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2021, net of taxes | $ | (266) |  |  | $ | (4,540) |  |  | $ | (1,828) |  |  | $ | (6,634) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 121 |  |  | 1,763 |  |  | (71) |  |  | 1,813 | \nTax | (25) |  |  | (401) |  |  | (96) |  |  | (522) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 96 |  |  | 1,362 |  |  | (167) |  |  | 1,291 | \nReclassification adjustments, pretax | 182 |  | (1) | 142 |  | (3) | \u2014 |  |  | 324 | \nTax | (38) |  |  | (20) |  |  | \u2014 |  |  | (58) | \nReclassification adjustments, net of taxes | 144 |  |  | 122 |  |  | \u2014 |  |  | 266 | \nOther comprehensive income (loss), net of taxes | 240 |  |  | 1,484 |  |  | (167) |  |  | 1,557 | \nSpin-off of Organon (see Note\u00a02) | \u2014 |  |  | 28 |  |  | 421 |  |  | 449 | \nBalance June 30, 2021, net of taxes | $ | (26) |  |  | $ | (3,028) |  |  | $ | (1,574) |  |  | $ | (4,628) | \nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 551 |  |  | 169 |  |  | (383) |  |  | 337 | \nTax | (116) |  |  | (37) |  |  | (39) |  |  | (192) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 435 |  |  | 132 |  |  | (422) |  |  | 145 | \nReclassification adjustments, pretax | (239) |  | (1) | 189 |  | (3) | \u2014 |  |  | (50) | \nTax | 50 |  |  | (43) |  |  | \u2014 |  |  | 7 | \nReclassification adjustments, net of taxes | (189) |  |  | 146 |  |  | \u2014 |  |  | (43) | \nOther comprehensive income (loss), net of taxes | 246 |  |  | 278 |  |  | (422) |  |  | 102 | \nBalance June 30, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total\nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 3,197 |  |  | $ | 2,055 |  |  | $ | 5,252 |  |  | $ | 2,347 |  |  | $ | 1,829 |  |  | $ | 4,176 |  |  | $ | 5,976 |  |  | $ | 4,085 |  |  | $ | 10,061 |  |  | $ | 4,528 |  |  | $ | 3,548 |  |  | $ | 8,076 | \nAlliance revenue-Lynparza(1) | 143 |  |  | 132 |  |  | 275 |  |  | 124 |  |  | 124 |  |  | 248 |  |  | 283 |  |  | 257 |  |  | 541 |  |  | 242 |  |  | 233 |  |  | 475 | \nAlliance revenue-Lenvima(1) | 128 |  |  | 103 |  |  | 231 |  |  | 88 |  |  | 93 |  |  | 181 |  |  | 284 |  |  | 175 |  |  | 459 |  |  | 173 |  |  | 137 |  |  | 310 | \nAlliance revenue-Reblozyl(2) | 28 |  |  | 5 |  |  | 33 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 55 |  |  | 30 |  |  | 86 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 428 |  |  | 1,245 |  |  | 1,674 |  |  | 454 |  |  | 781 |  |  | 1,234 |  |  | 846 |  |  | 2,287 |  |  | 3,133 |  |  | 766 |  |  | 1,385 |  |  | 2,151 | \nProQuad/M-M-RII/Varivax | 434 |  |  | 143 |  |  | 578 |  |  | 386 |  |  | 130 |  |  | 516 |  |  | 805 |  |  | 243 |  |  | 1,047 |  |  | 718 |  |  | 246 |  |  | 965 | \nRotaTeq | 98 |  |  | 75 |  |  | 173 |  |  | 111 |  |  | 97 |  |  | 208 |  |  | 273 |  |  | 116 |  |  | 389 |  |  | 229 |  |  | 137 |  |  | 366 | \nPneumovax23 | 94 |  |  | 59 |  |  | 153 |  |  | 100 |  |  | 52 |  |  | 152 |  |  | 212 |  |  | 114 |  |  | 325 |  |  | 173 |  |  | 150 |  |  | 323 | \nVaqta | 16 |  |  | 19 |  |  | 35 |  |  | 22 |  |  | 34 |  |  | 56 |  |  | 45 |  |  | 25 |  |  | 71 |  |  | 47 |  |  | 43 |  |  | 90 | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 237 |  |  | 190 |  |  | 426 |  |  | 197 |  |  | 190 |  |  | 387 |  |  | 432 |  |  | 389 |  |  | 821 |  |  | 364 |  |  | 363 |  |  | 727 | \nPrevymis | 47 |  |  | 56 |  |  | 103 |  |  | 37 |  |  | 56 |  |  | 93 |  |  | 87 |  |  | 110 |  |  | 197 |  |  | 72 |  |  | 103 |  |  | 174 | \nPrimaxin | \u2014 |  |  | 64 |  |  | 64 |  |  | \u2014 |  |  | 60 |  |  | 60 |  |  | 1 |  |  | 122 |  |  | 122 |  |  | \u2014 |  |  | 125 |  |  | 125 | \nDificid | 63 |  |  | 3 |  |  | 66 |  |  | 32 |  |  | 2 |  |  | 34 |  |  | 113 |  |  | 6 |  |  | 119 |  |  | 56 |  |  | 4 |  |  | 61 | \nNoxafil | 16 |  |  | 45 |  |  | 60 |  |  | 14 |  |  | 52 |  |  | 66 |  |  | 25 |  |  | 92 |  |  | 118 |  |  | 29 |  |  | 104 |  |  | 133 | \nInvanz | 2 |  |  | 45 |  |  | 46 |  |  | (4) |  |  | 52 |  |  | 48 |  |  | 2 |  |  | 96 |  |  | 99 |  |  | \u2014 |  |  | 104 |  |  | 104 | \nCancidas | 2 |  |  | 39 |  |  | 42 |  |  | 1 |  |  | 53 |  |  | 54 |  |  | 4 |  |  | 91 |  |  | 95 |  |  | 3 |  |  | 108 |  |  | 111 | \nZerbaxa | 22 |  |  | 24 |  |  | 46 |  |  | (2) |  |  | 1 |  |  | (1) |  |  | 40 |  |  | 36 |  |  | 76 |  |  | (4) |  |  | (5) |  |  | (9) | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Adempas/Verquvo(3) | 88 |  |  | 10 |  |  | 98 |  |  | 81 |  |  | (7) |  |  | 74 |  |  | 159 |  |  | 11 |  |  | 170 |  |  | 149 |  |  | \u2014 |  |  | 149 | \nAdempas | \u2014 |  |  | 63 |  |  | 63 |  |  | \u2014 |  |  | 74 |  |  | 74 |  |  | \u2014 |  |  | 124 |  |  | 124 |  |  | \u2014 |  |  | 129 |  |  | 129 | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | \u2014 |  |  | 1,177 |  |  | 1,177 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1,523 |  |  | 2,901 |  |  | 4,424 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nIsentress/IsentressHD | 67 |  |  | 80 |  |  | 147 |  |  | 74 |  |  | 118 |  |  | 192 |  |  | 128 |  |  | 177 |  |  | 305 |  |  | 145 |  |  | 256 |  |  | 401 | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 19 |  |  | 50 |  |  | 69 |  |  | 14 |  |  | 63 |  |  | 78 |  |  | 39 |  |  | 98 |  |  | 137 |  |  | 32 |  |  | 125 |  |  | 157 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 181 |  |  | 181 |  |  | \u2014 |  |  | 202 |  |  | 202 |  |  | \u2014 |  |  | 366 |  |  | 366 |  |  | \u2014 |  |  | 416 |  |  | 416 | \nRemicade | \u2014 |  |  | 53 |  |  | 53 |  |  | \u2014 |  |  | 75 |  |  | 75 |  |  | \u2014 |  |  | 114 |  |  | 114 |  |  | \u2014 |  |  | 160 |  |  | 160 | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 301 |  |  | 455 |  |  | 756 |  |  | 284 |  |  | 500 |  |  | 784 |  |  | 626 |  |  | 909 |  |  | 1,535 |  |  | 632 |  |  | 961 |  |  | 1,593 | \nJanumet | 105 |  |  | 371 |  |  | 476 |  |  | 74 |  |  | 403 |  |  | 477 |  |  | 168 |  |  | 762 |  |  | 931 |  |  | 158 |  |  | 805 |  |  | 962 | \nOther pharmaceutical(4) | 191 |  |  | 288 |  |  | 479 |  |  | 213 |  |  | 299 |  |  | 512 |  |  | 372 |  |  | 628 |  |  | 998 |  |  | 429 |  |  | 640 |  |  | 1,069 | \nTotal Pharmaceutical segment sales | 5,726 |  |  | 7,030 |  |  | 12,756 |  |  | 4,647 |  |  | 5,333 |  |  | 9,980 |  |  | 12,498 |  |  | 14,364 |  |  | 26,863 |  |  | 8,941 |  |  | 10,277 |  |  | 19,218 | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 164 |  |  | 662 |  |  | 826 |  |  | 161 |  |  | 659 |  |  | 821 |  |  | 335 |  |  | 1,322 |  |  | 1,658 |  |  | 318 |  |  | 1,322 |  |  | 1,640 | \nCompanion Animals | 313 |  |  | 328 |  |  | 641 |  |  | 298 |  |  | 353 |  |  | 651 |  |  | 616 |  |  | 676 |  |  | 1,291 |  |  | 578 |  |  | 672 |  |  | 1,250 | \nTotal Animal Health segment sales | 477 |  |  | 990 |  |  | 1,467 |  |  | 459 |  |  | 1,012 |  |  | 1,472 |  |  | 951 |  |  | 1,998 |  |  | 2,949 |  |  | 896 |  |  | 1,994 |  |  | 2,890 | \nTotal segment sales | 6,203 |  |  | 8,020 |  |  | 14,223 |  |  | 5,106 |  |  | 6,345 |  |  | 11,452 |  |  | 13,449 |  |  | 16,362 |  |  | 29,812 |  |  | 9,837 |  |  | 12,271 |  |  | 22,108 | \nOther(5) | 35 |  |  | 335 |  |  | 370 |  |  | (6) |  |  | (44) |  |  | (50) |  |  | 128 |  |  | 555 |  |  | 682 |  |  | 53 |  |  | (132) |  |  | (79) | \n | $ | 6,238 |  |  | $ | 8,355 |  |  | $ | 14,593 |  |  | $ | 5,100 |  |  | $ | 6,301 |  |  | $ | 11,402 |  |  | $ | 13,577 |  |  | $ | 16,917 |  |  | $ | 30,494 |  |  | $ | 9,890 |  |  | $ | 12,139 |  |  | $ | 22,029 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nUnited States | $ | 6,238 |  |  | $ | 5,100 |  |  | $ | 13,577 |  |  | $ | 9,890 | \nEurope, Middle East and Africa | 3,582 |  |  | 3,333 |  |  | 7,942 |  |  | 6,569 | \nChina | 1,372 |  |  | 975 |  |  | 2,515 |  |  | 1,697 | \nJapan | 1,114 |  |  | 661 |  |  | 2,103 |  |  | 1,291 | \nAsia Pacific (other than China and Japan) | 1,008 |  |  | 594 |  |  | 1,938 |  |  | 1,168 | \nLatin America | 642 |  |  | 532 |  |  | 1,249 |  |  | 1,032 | \nOther | 637 |  |  | 207 |  |  | 1,170 |  |  | 382 | \n | $ | 14,593 |  |  | $ | 11,402 |  |  | $ | 30,494 |  |  | $ | 22,029 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,173 |  |  | $ | 7,257 |  |  | $ | 18,673 |  |  | $ | 13,845 | \nAnimal Health segment | 571 |  |  | 552 |  |  | 1,156 |  |  | 1,124 | \nTotal segment profits | 9,744 |  |  | 7,809 |  |  | 19,829 |  |  | 14,969 | \nOther profits | 260 |  |  | (79) |  |  | 454 |  |  | (113) | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 15 |  |  | 9 |  |  | 22 |  |  | 20 | \nInterest expense | (240) |  |  | (202) |  |  | (483) |  |  | (401) | \nAmortization | (463) |  |  | (357) |  |  | (1,163) |  |  | (871) | \nDepreciation | (431) |  |  | (332) |  |  | (809) |  |  | (673) | \nResearch and development | (2,652) |  |  | (4,175) |  |  | (5,097) |  |  | (6,480) | \nRestructuring costs | (142) |  |  | (82) |  |  | (194) |  |  | (380) | \nOther unallocated, net | (1,604) |  |  | (874) |  |  | (3,211) |  |  | (1,367) | \n | $ | 4,487 |  |  | $ | 1,717 |  |  | $ | 9,348 |  |  | $ | 4,704 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nUnited States | $ | 6,238 |  |  | $ | 5,100 |  |  | 22 | % |  | 22 | % |  | $ | 13,577 |  |  | $ | 9,890 |  |  | 37 | % |  | 37 | %\nInternational | 8,355 |  |  | 6,301 |  |  | 33 | % |  | 38 | % |  | 16,917 |  |  | 12,139 |  |  | 39 | % |  | 45 | %\nTotal | $ | 14,593 |  |  | $ | 11,402 |  |  | 28 | % |  | 31 | % |  | $ | 30,494 |  |  | $ | 22,029 |  |  | 38 | % |  | 41 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nKeytruda | $ | 5,252 |  |  | $ | 4,176 |  |  | 26 | % |  | 30 | % |  | $ | 10,061 |  |  | $ | 8,076 |  |  | 25 | % |  | 29 | %\nAlliance Revenue - Lynparza(1) | 275 |  |  | 248 |  |  | 11 | % |  | 17 | % |  | 541 |  |  | 475 |  |  | 14 | % |  | 18 | %\nAlliance Revenue-Lenvima(1) | 231 |  |  | 181 |  |  | 28 | % |  | 33 | % |  | 459 |  |  | 310 |  |  | 48 | % |  | 51 | %  |  |  |  |  | \nDate | Approval\nJanuary 2022 | European Commission (EC) approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions based on the KEYNOTE-564 trial.\nFebruary 2022 | Japan Ministry of Health, Labour and Welfare approval of the combination ofKeytrudaplus Lenvima for radically unresectable or metastatic RCC based on the CLEAR (Study 307)/KEYNOTE-581 trial.\nFebruary 2022 | Japan Pharmaceuticals and Medical Devices Agency approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.\nMarch 2022 | U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation based on the KEYNOTE-158 trial (Cohorts D & K).\nApril 2022 | EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1 based on the KEYNOTE-826 trial.\nApril 2022 | EC approval as monotherapy for the treatment of certain adult patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer based on data from the KEYNOTE-164 and KEYNOTE-158 trials.\nMay 2022 | EC approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage TNBC at high risk of recurrence based on the KEYNOTE-522 trial.\nJune 2022 | EC approval as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection based on the KEYNOTE-716 trial. Additionally, EC approval expanding the indications in advanced (unresectable or metastatic) melanoma and stage III melanoma with lymph node involvement (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nGardasil/Gardasil9 | $ | 1,674 |  |  | $ | 1,234 |  |  | 36 | % |  | 40 | % |  | $ | 3,133 |  |  | $ | 2,151 |  |  | 46 | % |  | 48 | %\nProQuad | 214 |  |  | 189 |  |  | 13 | % |  | 15 | % |  | 376 |  |  | 354 |  |  | 6 | % |  | 8 | %\nM-M-RII | 103 |  |  | 87 |  |  | 17 | % |  | 19 | % |  | 206 |  |  | 167 |  |  | 23 | % |  | 25 | %\nVarivax | 261 |  |  | 240 |  |  | 9 | % |  | 10 | % |  | 465 |  |  | 444 |  |  | 5 | % |  | 6 | %\nRotaTeq | 173 |  |  | 208 |  |  | (17) | % |  | (14) | % |  | 389 |  |  | 366 |  |  | 6 | % |  | 8 | %\nPneumovax 23 | 153 |  |  | 152 |  |  | 1 | % |  | 4 | % |  | 325 |  |  | 323 |  |  | 1 | % |  | 3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nBridion | $ | 426 |  |  | $ | 387 |  |  | 10 | % |  | 15 | % |  | $ | 821 |  |  | $ | 727 |  |  | 13 | % |  | 17 | %\nZerbaxa | 46 |  |  | (1) |  |  | * |  | * |  | 76 |  |  | (9) |  |  | * |  | *  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 98 |  |  | $ | 74 |  |  | 33 | % |  | 33 | % |  | $ | 170 |  |  | $ | 149 |  |  | 14 | % |  | 15 | %\nAdempas | 63 |  |  | 74 |  |  | (14) | % |  | (5) | % |  | 124 |  |  | 129 |  |  | (4) | % |  | 6 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nLagevrio | $ | 1,177 |  |  | $ | \u2014 |  |  | \u2014 |  | \u2014 |  | $ | 4,424 |  |  | $ | \u2014 |  |  | \u2014 |  | \u2014\nIsentress/Isentress HD | 147 |  |  | 192 |  |  | (24) | % |  | (19) | % |  | 305 |  |  | 401 |  |  | (24) | % |  | (20) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nJanuvia/Janumet | $ | 1,233 |  |  | $ | 1,261 |  |  | (2) | % |  | 3 | % |  | $ | 2,466 |  |  | $ | 2,556 |  |  | (4) | % |  | 1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2022 |  | 2021 |  | % Change |  |  | 2022 |  | 2021 |  | % Change | \nLivestock | $ | 826 |  |  | $ | 821 |  |  | 1 | % |  | 6 | % |  | $ | 1,658 |  |  | $ | 1,640 |  |  | 1 | % |  | 7 | %\nCompanion Animal | 641 |  |  | 651 |  |  | (2) | % |  | 3 | % |  | 1,291 |  |  | 1,250 |  |  | 3 | % |  | 7 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | Six Months EndedJune 30, |  | \n($ in millions) | 2022 |  | 2021 |  | % Change |  | 2022 |  | 2021 |  | % Change\nCost of sales | $ | 4,216 |  |  | $ | 3,104 |  |  | 36 | % |  | $ | 9,596 |  |  | $ | 6,303 |  |  | 52 | %\nSelling, general and administrative | 2,512 |  |  | 2,281 |  |  | 10 | % |  | 4,834 |  |  | 4,468 |  |  | 8 | %\nResearch and development | 2,798 |  |  | 4,321 |  |  | (35) | % |  | 5,374 |  |  | 6,732 |  |  | (20) | %\nRestructuring costs | 142 |  |  | 82 |  |  | 73 | % |  | 194 |  |  | 380 |  |  | (49) | %\nOther (income) expense, net | 438 |  |  | (103) |  |  | * |  | 1,148 |  |  | (558) |  |  | *\n | $ | 10,106 |  |  | $ | 9,685 |  |  | 4 | % |  | $ | 21,146 |  |  | $ | 17,325 |  |  | 22 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2022 |  | 2021 |  | 2022 |  | 2021\nPharmaceutical segment profits | $ | 9,173 |  |  | $ | 7,257 |  |  | $ | 18,673 |  |  | $ | 13,845 | \nAnimal Health segment profits | 571 |  |  | 552 |  |  | 1,156 |  |  | 1,124 | \nOther | (5,257) |  |  | (6,092) |  |  | (10,481) |  |  | (10,265) | \nIncome from Continuing Operations Before Taxes | $ | 4,487 |  |  | $ | 1,717 |  |  | $ | 9,348 |  |  | $ | 4,704 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions except per share amounts) | 2022 |  | 2021 |  | 2022 |  | 2021\nIncome from continuing operations before taxes as reported under GAAP | $ | 4,487 |  |  | $ | 1,717 |  |  | $ | 9,348 |  |  | $ | 4,704 | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition and divestiture-related costs | 530 |  |  | 503 |  |  | 1,168 |  |  | 1,000 | \nRestructuring costs | 258 |  |  | 128 |  |  | 384 |  |  | 462 | \nLoss (income) from investments in equity securities, net | 234 |  |  | (258) |  |  | 918 |  |  | (819) | \nOther items: |  |  |  |  |  |  | \nCharges for the discontinuation of COVID-19 development programs | \u2014 |  |  | 37 |  |  | \u2014 |  |  | 225 | \nNon-GAAP income from continuing operations before taxes | 5,509 |  |  | 2,127 |  |  | 11,818 |  |  | 5,572 | \nTaxes on income from continuing operations as reported under GAAP | 538 |  |  | 503 |  |  | 1,092 |  |  | 741 | \nEstimated tax benefit on excluded items(1) | 223 |  |  | 65 |  |  | 552 |  |  | 113 | \nNet tax (expense) benefit from the settlement of certain federal income tax matters | \u2014 |  |  | (1) |  |  | \u2014 |  |  | 207 | \nNon-GAAP taxes on income from continuing operations | 761 |  |  | 567 |  |  | 1,644 |  |  | 1,061 | \nNon-GAAP net income from continuing operations | 4,748 |  |  | 1,560 |  |  | 10,174 |  |  | 4,511 | \nLess: Net income attributable to noncontrolling interests as reported under GAAP | 5 |  |  | 1 |  |  | 2 |  |  | 5 | \nNon-GAAP net income from continuing operations attributable to Merck\u00a0& Co., Inc. | $ | 4,743 |  |  | $ | 1,559 |  |  | $ | 10,172 |  |  | $ | 4,506 | \nEPS assuming dilution from continuing operations as reported under GAAP | $ | 1.55 |  |  | $ | 0.48 |  |  | $ | 3.25 |  |  | $ | 1.56 | \nEPS difference | 0.32 |  |  | 0.13 |  |  | 0.76 |  |  | 0.21 | \nNon-GAAP EPS assuming dilution from continuing operations | $ | 1.87 |  |  | $ | 0.61 |  |  | $ | 4.01 |  |  | $ | 1.77 |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(3)Non-Small-Cell LungMK-1026 (nemtabrutinib)Hematological MalignanciesMK-1200Neoplasm MalignantMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)Advanced Solid TumorsColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BreastGastricHematological MalignanciesNon-Small-Cell LungOvarianPancreaticSolid TumorsMK-2870(1)(3)Neoplasm MalignantMK-3475KeytrudaAdvanced Solid TumorsMK-4280 (favezelimab)(2)Hematological MalignanciesNon-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)Renal CellSmall-Cell LungMK-4830(2)ColorectalMelanomaNon-Small-Cell LungRenal CellSmall-Cell LungMK-5684(1)Neoplasm MalignantMK-5890(3)Non-Small-Cell LungSmall-Cell Lung | CancerMK-6440 (ladiratuzumab vedotin)(1)(3)BreastEsophagealGastricHead and NeckMelanomaNon-Small-Cell LungProstateSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalColorectalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684 (vibostolimab)(2)MelanomaMK-7684A (vibostolimab+pembrolizumab)BiliaryBreastCervicalColorectalEndometrialEsophagealHead and NeckHematological MalignanciesHepatocellularProstate | CancerMK-7902 Lenvima(1)(2)BiliaryGlioblastomaPancreaticProstateSmall-Cell LungV937BreastCutaneous Squamous CellHead and NeckMelanomaSolid TumorsCardiovascularMK-2060Chikungunya Virus VaccineV184HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(4)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-3655MK-6024Overgrowth SyndromeMK-7075 (miransertib)Pulmonary Arterial HypertensionMK-5475SchizophreniaMK-8189Treatment Resistant DepressionMK-1942  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(5)CancerMK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaBiliary (September 2019)Cutaneous Squamous Cell (August 2019) (EU)Gastric (May 2015) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Prostate (May 2019)Small-Cell Lung (May 2017)MK-3475 (pembrolizumab subcutaneous)Non-Small-Cell Lung (August 2021)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)MK-7339 Lynparza(1)(3)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Colorectal (April 2021)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Melanoma (March 2019)Non-Small-Cell Lung (March 2019)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(4)HIV-1 PreventionMK-8591 (islatravir) (February 2021)(4)Pneumococcal Vaccine AdultV116 (July 2022)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular Entities/VaccinesAntiviral COVID-19MK-4482Lagevrio(EU)(1)CoughMK-7264 (gefapixant) (U.S.)(6)(EU)Pneumococcal Vaccine Adult/PediatricV114 (JPN) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    Second-Line Hepatocellular Cancer(KEYNOTE-394) (U.S.)\u2022    Adjuvent Non-Small-Cell Lung Cancer(KEYNOTE-091) (U.S.) (EU)\u2022    High-Risk Early-Stage Triple-Negative Breast Cancer(KEYNOTE-522) (JPN)\u2022    Cervical Cancer (KEYNOTE-826) (JPN)\u2022    Adjuvent Renal Cell Cancer(KEYNOTE-564) (JPN)MK-7339 Lynparza(1)\u2022BRCA-Mutated HER2-Negative Adjuvant BreastCancer (OlympiA) (JPN)\u2022    First-Line Metastatic Prostate Cancer(PROpel) (EU) (JPN)MK-7902 Lenvima(1)(2)\u2022    First-Line Metastatic Hepatocellular Carcinoma(KEYNOTE-524) (U.S.)(7)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)Available in the U.S. under Emergency Use Authorization.(6)In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023.(7)In July 2020, the FDA issued a CRL for Merck\u2019s and Eisai\u2019s applications. Merck and Eisai intend to submit additional data when available to the FDA.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | June 30, 2022 |  | December 31, 2021\nCash and investments | $ | 10,366 |  |  | $ | 8,466 | \nWorking capital | 8,948 |  |  | 6,394 | \nTotal debt to total liabilities and equity | 29.6 | % |  | 31.3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nApril 1 - April 30 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nMay 1 - May 31 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nJune 1 - June 30 | \u2014 |  |  | $0.00 |  | \u2014 |  |  | $5,047\nTotal | \u2014 |  |  | $0.00 |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  August 4, 2022 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  August 4, 2022 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2023 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | Not Applicable | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 27\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 39\n |  | \nItem 4. | Controls and Procedures | 39\n |  | \n | Cautionary Factors That May Affect Future Results | 39\n |  | \nPART II | OTHER INFORMATION | 40\n |  | \nItem 1. | Legal Proceedings | 40\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 40\n |  |  |  | \nItem 6. | Exhibits | 41\n |  | \n | Signatures |  |  | 42  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2023 |  | 2022 |  |  |  | \nSales | $ | 14,487 |  |  | $ | 15,901 |  |  |  |  | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 3,926 |  |  | 5,380 |  |  |  |  | \nSelling, general and administrative | 2,479 |  |  | 2,323 |  |  |  |  | \nResearch and development | 4,276 |  |  | 2,576 |  |  |  |  | \nRestructuring costs | 67 |  |  | 53 |  |  |  |  | \nOther (income) expense, net | 89 |  |  | 708 |  |  |  |  | \n | 10,837 |  |  | 11,040 |  |  |  |  | \nIncome Before Taxes | 3,650 |  |  | 4,861 |  |  |  |  | \nTaxes on Income | 825 |  |  | 554 |  |  |  |  | \nNet Income | 2,825 |  |  | 4,307 |  |  |  |  | \nLess: Net Income (Loss) Attributable to Noncontrolling Interests | 4 |  |  | (3) |  |  |  |  | \nNet Income Attributable to Merck & Co., Inc. | $ | 2,821 |  |  | $ | 4,310 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2023 |  | 2022 |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 2,821 |  |  | $ | 4,310 |  |  |  |  | \nOther Comprehensive (Loss) Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized (loss) gain on derivatives, net of reclassifications | (133) |  |  | 63 |  |  |  |  | \nBenefit plan net (loss) gain and prior service (cost) credit, net of amortization | (50) |  |  | 32 |  |  |  |  | \nCumulative translation adjustment | 68 |  |  | (35) |  |  |  |  | \n | (115) |  |  | 60 |  |  |  |  | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 2,706 |  |  | $ | 4,370 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 9,707 |  |  | $ | 12,694 | \nShort-term investments | 680 |  |  | 498 | \nAccounts receivable (net of allowance for doubtful accounts of $76in 2023and $72in 2022) | 10,415 |  |  | 9,450 | \nInventories (excludes inventories of $3,284in 2023 and $2,938in 2022classified in Other assets - see Note\u00a07) | 5,863 |  |  | 5,911 | \nOther current assets | 6,737 |  |  | 7,169 | \nTotal current assets | 33,402 |  |  | 35,722 | \nInvestments | 1,290 |  |  | 1,015 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,256in 2023 and $17,985in 2022 | 21,758 |  |  | 21,422 | \nGoodwill | 21,209 |  |  | 21,204 | \nOther Intangibles, Net | 19,857 |  |  | 20,269 | \nOther Assets | 10,280 |  |  | 9,528 | \n | $ | 107,796 |  |  | $ | 109,160 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 2,672 |  |  | $ | 1,946 | \nTrade accounts payable | 3,680 |  |  | 4,264 | \nAccrued and other current liabilities | 13,000 |  |  | 14,159 | \nIncome taxes payable | 1,872 |  |  | 1,986 | \nDividends payable | 1,907 |  |  | 1,884 | \nTotal current liabilities | 23,131 |  |  | 24,239 | \nLong-Term Debt | 28,074 |  |  | 28,745 | \nDeferred Income Taxes | 1,442 |  |  | 1,795 | \nOther Noncurrent Liabilities | 8,244 |  |  | 8,323 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2023 and 2022 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,467 |  |  | 44,379 | \nRetained earnings | 62,039 |  |  | 61,081 | \nAccumulated other comprehensive loss | (4,883) |  |  | (4,768) | \n | 103,411 |  |  | 102,480 | \nLess treasury stock, at cost:1,039,651,210shares in 2023 and1,039,269,638shares in 2022 | 56,577 |  |  | 56,489 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 46,834 |  |  | 45,991 | \nNoncontrolling Interests | 71 |  |  | 67 | \nTotal equity | 46,905 |  |  | 46,058 | \n | $ | 107,796 |  |  | $ | 109,160 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31,\n | 2023 |  | 2022\nCash Flows from Operating Activities |  |  | \nNet income | $ | 2,825 |  |  | $ | 4,307 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nAmortization | 543 |  |  | 699 | \nDepreciation | 448 |  |  | 421 | \n(Income) loss from investments in equity securities, net | (450) |  |  | 708 | \nCharge for the acquisition of Imago BioSciences, Inc. | 1,192 |  |  | \u2014 | \nDeferred income taxes | (277) |  |  | (338) | \nShare-based compensation | 145 |  |  | 120 | \nOther | (197) |  |  | 143 | \nNet changes in assets and liabilities | (2,890) |  |  | (1,299) | \nNet Cash Provided by Operating Activities | 1,339 |  |  | 4,761 | \nCash Flows from Investing Activities |  |  | \nCapital expenditures | (1,007) |  |  | (984) | \nPurchases of securities and other investments | (562) |  |  | (372) | \nProceeds from sales of securities and other investments | 500 |  |  | 1 | \nAcquisition of Imago BioSciences, Inc., net of cash acquired | (1,327) |  |  | \u2014 | \nOther | 37 |  |  | 182 | \nNet Cash Used in Investing Activities | (2,359) |  |  | (1,173) | \nCash Flows from Financing Activities |  |  | \nPayments on debt | (1) |  |  | (1,250) | \nPurchases of treasury stock | (149) |  |  | \u2014 | \nDividends paid to stockholders | (1,853) |  |  | (1,745) | \nProceeds from exercise of stock options | 30 |  |  | 12 | \nOther | (81) |  |  | (103) | \nNet Cash Used in Financing Activities | (2,054) |  |  | (3,086) | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | 87 |  |  | (55) | \nNet (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash | (2,987) |  |  | 447 | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$79and $71at January 1, 2023 and 2022, respectively, included inOther current assets) | 12,773 |  |  | 8,167 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79and $58at March\u00a031, 2023 and 2022, respectively, included inOther current assets) | $ | 9,786 |  |  | $ | 8,614 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nAlliance revenue - Lynparza | $ | 275 |  |  | $ | 266 |  |  |  |  | \nAlliance revenue - Koselugo | 23 |  |  | 9 |  |  |  |  | \nTotal alliance revenue | $ | 298 |  |  | $ | 275 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 70 |  |  | 299 |  |  |  |  | \nSelling, general and administrative | 47 |  |  | 44 |  |  |  |  | \nResearch and development | 21 |  |  | 26 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022 |  |  |  | \nReceivables from AstraZeneca included inOther current assets | $ | 303 |  |  | $ | 303 |  |  |  |  | \nPayables to AstraZeneca included inAccrued and other current liabilities(2) | 21 |  |  | 123 |  |  |  |  | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) | 600 |  |  | 600 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nAlliance revenue - Lenvima | $ | 232 |  |  | $ | 227 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 126 |  |  | 53 |  |  |  |  | \nSelling, general and administrative | 51 |  |  | 31 |  |  |  |  | \nResearch and development | 39 |  |  | 57 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022 |  |  |  | \nReceivables from Eisai included inOther current assets | $ | 244 |  |  | $ | 214 |  |  |  |  | \nPayables to Eisai included inAccrued and other current liabilities(2) | 125 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nAlliance revenue - Adempas/Verquvo | $ | 99 |  |  | $ | 72 |  |  |  |  | \nNet sales of Adempas recorded by Merck | 59 |  |  | 61 |  |  |  |  | \nNet sales of Verquvo recorded by Merck | 7 |  |  | 3 |  |  |  |  | \nTotal sales | $ | 165 |  |  | $ | 136 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1) | 57 |  |  | 50 |  |  |  |  | \nSelling, general and administrative | 33 |  |  | 23 |  |  |  |  | \nResearch and development | 25 |  |  | 17 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022 |  |  |  | \nReceivables from Bayer included inOther current assets | $ | 142 |  |  | $ | 143 |  |  |  |  | \nPayables to Bayer included inAccrued and other current liabilities | 68 |  |  | 80 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nNet sales ofLagevriorecorded by Merck | $ | 392 |  |  | $ | 3,247 |  |  |  |  | \n |  |  |  |  |  |  | \nCost of sales(1)(2) | 221 |  |  | 1,726 |  |  |  |  | \nSelling, general and administrative(2) | 27 |  |  | 35 |  |  |  |  | \nResearch and development(2) | 16 |  |  | 25 |  |  |  |  | \n |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022 |  |  |  | \nPayables to Ridgeback included inAccrued and other current liabilities(3) | $ | 191 |  |  | $ | 348 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2023 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 21 |  |  | $ | 8 |  |  | $ | 29 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRestructuring costs | 41 |  |  | \u2014 |  |  | 26 |  |  | 67 |  |  |  |  |  |  |  |  | \n | $ | 41 |  |  | $ | 21 |  |  | $ | 35 |  |  | $ | 97 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2022 |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  |  |  |  |  |  |  | \nCost of sales | $ | \u2014 |  |  | $ | 18 |  |  | $ | 28 |  |  | $ | 46 |  |  |  |  |  |  |  |  | \nSelling, general and administrative | \u2014 |  |  | 4 |  |  | 17 |  |  | 21 |  |  |  |  |  |  |  |  | \nResearch and development | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  |  |  |  |  |  |  | \nRestructuring costs | 26 |  |  | \u2014 |  |  | 27 |  |  | 53 |  |  |  |  |  |  |  |  | \n | $ | 26 |  |  | $ | 29 |  |  | $ | 72 |  |  | $ | 127 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2023 | $ | 479 |  |  | $ | \u2014 |  |  | $ | 34 |  |  | $ | 513 | \nExpenses | 41 |  |  | 21 |  |  | 35 |  |  | 97 | \n(Payments) receipts, net | (47) |  |  | \u2014 |  |  | (27) |  |  | (74) | \nNon-cash activity | \u2014 |  |  | (21) |  |  | (9) |  |  | (30) | \nRestructuring reserves March\u00a031, 2023(1) | $ | 473 |  |  | $ | \u2014 |  |  | $ | 33 |  |  | $ | 506 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended March 31, |  |  |  | Three Months Ended March 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  |  |  | 2023 |  | 2022 |  |  |  | \nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | 1 |  |  | $ | (16) |  |  |  |  |  |  | $ | 1 |  |  | $ | (1) |  |  |  |  | \nEuro-denominated notes | 52 |  |  | (53) |  |  |  |  |  |  | \u2014 |  |  | \u2014 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | March 31, 2023 |  | December 31, 2022\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other Assets | $ | 1 |  |  | $ | \u2014 |  |  | $ | 300 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nInterest rate swap contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 200 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nForeign exchange contracts | Other current assets | 104 |  |  | \u2014 |  |  | 4,253 |  |  | 220 |  |  | \u2014 |  |  | 4,824 | \nForeign exchange contracts | Other Assets | 32 |  |  | \u2014 |  |  | 1,756 |  |  | 27 |  |  | \u2014 |  |  | 1,609 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 116 |  |  | 3,444 |  |  | \u2014 |  |  | 101 |  |  | 2,691 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 2 |  |  | 120 |  |  | \u2014 |  |  | 1 |  |  | 91 | \n |  | $ | 137 |  |  | $ | 119 |  |  | $ | 10,073 |  |  | $ | 247 |  |  | $ | 102 |  |  | $ | 9,215 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 121 |  |  | $ | \u2014 |  |  | $ | 9,507 |  |  | $ | 186 |  |  | $ | \u2014 |  |  | $ | 8,540 | \nForeign exchange contracts | Other Assets | 1 |  |  | \u2014 |  |  | 65 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 164 |  |  | 10,592 |  |  | \u2014 |  |  | 307 |  |  | 10,926 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 124 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  | $ | 122 |  |  | $ | 165 |  |  | $ | 20,288 |  |  | $ | 186 |  |  | $ | 307 |  |  | $ | 19,466 | \n |  | $ | 259 |  |  | $ | 284 |  |  | $ | 30,361 |  |  | $ | 433 |  |  | $ | 409 |  |  | $ | 28,681 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 259 |  |  | $ | 284 |  |  | $ | 433 |  |  | $ | 409 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (148) |  |  | (148) |  |  | (220) |  |  | (220) | \nCash collateral received/posted | (13) |  |  | \u2014 |  |  | (66) |  |  | (19) | \nNet amounts | $ | 98 |  |  | $ | 136 |  |  | $ | 147 |  |  | $ | 170 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  |  |  |  |  |  |  |  |  |  |  | \nFinancial Statement Caption in which Effects of Fair Value or Cash FlowHedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  |  |  |  |  | \n | $ | 14,487 |  |  | $ | 15,901 |  |  | $ | 89 |  |  | $ | 708 |  |  | $ | (115) |  |  | $ | 60 |  |  |  |  |  |  |  |  |  |  |  |  | \n(Gain) loss on fair value hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (10) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nImpact of cash flow hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of (loss) gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (66) |  |  | 148 |  |  |  |  |  |  |  |  |  |  |  |  | \nIncrease inSalesas a result ofAOCLreclassifications | 101 |  |  | 67 |  |  | \u2014 |  |  | \u2014 |  |  | (101) |  |  | (67) |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of loss recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended March 31, |  | \n($ in millions) |  |  | 2023 |  | 2022 |  |  |  | \nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | 13 |  |  | $ | 28 |  |  |  |  | \nForeign exchange contracts(2) | Sales |  | 2 |  |  | (2) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 663 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 663 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | 92 |  |  | \u2014 |  |  | \u2014 |  |  | 92 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \nForeign government bonds | 1 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nTotal debt securities | $ | 760 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 760 |  |  | $ | 569 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 569 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,585 |  |  |  |  |  |  |  |  | 1,284 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 2,345 |  |  |  |  |  |  |  |  | $ | 1,853 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | March 31, 2023 |  | December 31, 2022\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 663 |  |  | $ | \u2014 |  |  | $ | 663 |  |  | $ | \u2014 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 22 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nForeign government bonds | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nPublicly traded equity securities | 1,284 |  |  | \u2014 |  |  | \u2014 |  |  | 1,284 |  |  | 1,015 |  |  | \u2014 |  |  | \u2014 |  |  | 1,015 | \n | 1,284 |  |  | 686 |  |  | \u2014 |  |  | 1,970 |  |  | 1,015 |  |  | 498 |  |  | \u2014 |  |  | 1,513 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 70 |  |  | \u2014 |  |  | \u2014 |  |  | 70 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \nPublicly traded equity securities | 301 |  |  | \u2014 |  |  | \u2014 |  |  | 301 |  |  | 269 |  |  | \u2014 |  |  | \u2014 |  |  | 269 | \n | 375 |  |  | \u2014 |  |  | \u2014 |  |  | 375 |  |  | 340 |  |  | \u2014 |  |  | \u2014 |  |  | 340 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPurchased currency options | \u2014 |  |  | 139 |  |  | \u2014 |  |  | 139 |  |  | \u2014 |  |  | 215 |  |  | \u2014 |  |  | 215 | \nForward exchange contracts | \u2014 |  |  | 119 |  |  | \u2014 |  |  | 119 |  |  | \u2014 |  |  | 218 |  |  | \u2014 |  |  | 218 | \nInterest rate swap contracts | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n | \u2014 |  |  | 259 |  |  | \u2014 |  |  | 259 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 | \nTotal assets | $ | 1,659 |  |  | $ | 945 |  |  | $ | \u2014 |  |  | $ | 2,604 |  |  | $ | 1,355 |  |  | $ | 931 |  |  | $ | \u2014 |  |  | $ | 2,286 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 353 |  |  | $ | 353 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 456 |  |  | $ | 456 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 276 |  |  | \u2014 |  |  | 276 |  |  | \u2014 |  |  | 402 |  |  | \u2014 |  |  | 402 | \nWritten currency options | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 | \nInterest rate swap contracts | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n | \u2014 |  |  | 284 |  |  | \u2014 |  |  | 284 |  |  | \u2014 |  |  | 409 |  |  | \u2014 |  |  | 409 | \nTotal liabilities | $ | \u2014 |  |  | $ | 284 |  |  | $ | 353 |  |  | $ | 637 |  |  | $ | \u2014 |  |  | $ | 409 |  |  | $ | 456 |  |  | $ | 865 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022\nFair value January 1 | $ | 456 |  |  | $ | 777 | \nChanges in estimated fair value(1) | 14 |  |  | (84) | \nPayments | (117) |  |  | (119) | \nOther | \u2014 |  |  | (2) | \nFair value March 31(2) | $ | 353 |  |  | $ | 572 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022\nFinished goods | $ | 1,883 |  |  | $ | 1,841 | \nRaw materials and work in process | 7,348 |  |  | 7,063 | \nSupplies | 266 |  |  | 238 | \nTotal (approximates current cost) | 9,497 |  |  | 9,142 | \nDecrease to LIFO cost | (350) |  |  | (293) | \n | $ | 9,147 |  |  | $ | 8,849 | \nRecognized as: |  |  | \nInventories | $ | 5,863 |  |  | $ | 5,911 | \nOther Assets | 3,284 |  |  | 2,938 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,310 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 |  | \u2014 |  | \u2014 |  | \u2014 |  | 60 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,754) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 37 |  | \u2014 |  | \u2014 |  | \u2014 |  | 46 |  | \u2014 |  | 83 | \nNet loss attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3) |  | (3) | \n |  |  |  |  |  |  |  |  | \nBalance at March 31, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 | \nBalance at January 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,379 |  | $ | 61,081 |  | $ | (4,768) |  | 1,039 |  | $ | (56,489) |  | $ | 67 |  | $ | 46,058 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 2,821 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 2,821 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (115) |  | \u2014 |  | \u2014 |  | \u2014 |  | (115) | \nCash dividends declared on common stock ($0.73per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,863) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,863) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1 |  | (149) |  | \u2014 |  | (149) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 88 |  | \u2014 |  | \u2014 |  | \u2014 |  | 61 |  | \u2014 |  | 149 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4 |  | 4 | \n |  |  |  |  |  |  |  |  | \nBalance at March 31, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,467 |  | $ | 62,039 |  | $ | (4,883) |  | 1,040 |  | $ | (56,577) |  | $ | 71 |  | $ | 46,905 |   |  |  |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n | 2023 |  | 2022 |  |  |  | \n($ in millions) | U.S. |  | International |  | U.S. |  | International |  |  |  |  |  |  |  | \nService cost | $ | 76 |  |  | $ | 49 |  |  | $ | 99 |  |  | $ | 75 |  |  |  |  |  |  |  |  | \nInterest cost | 133 |  |  | 74 |  |  | 103 |  |  | 38 |  |  |  |  |  |  |  |  | \nExpected return on plan assets | (187) |  |  | (128) |  |  | (196) |  |  | (101) |  |  |  |  |  |  |  |  | \nAmortization of unrecognized prior service credit | \u2014 |  |  | (3) |  |  | (8) |  |  | (4) |  |  |  |  |  |  |  |  | \nNet (gain) loss amortization | \u2014 |  |  | (1) |  |  | 56 |  |  | 25 |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCurtailments | 2 |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nSettlements | 21 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  |  |  |  |  |  |  | \n | $ | 45 |  |  | $ | (9) |  |  | $ | 58 |  |  | $ | 33 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nService cost | $ | 8 |  |  | $ | 12 |  |  |  |  | \nInterest cost | 16 |  |  | 11 |  |  |  |  | \nExpected return on plan assets | (16) |  |  | (21) |  |  |  |  | \nAmortization of unrecognized prior service credit | (12) |  |  | (14) |  |  |  |  | \nNet gain amortization | (11) |  |  | (11) |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n | $ | (15) |  |  | $ | (23) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nInterest income | $ | (112) |  |  | $ | (7) |  |  |  |  | \nInterest expense | 242 |  |  | 243 |  |  |  |  | \nExchange losses | 61 |  |  | 39 |  |  |  |  | \n(Income) loss from investments in equity securities, net(1) | (450) |  |  | 708 |  |  |  |  | \nNet periodic defined benefit plan (credit) cost other than service cost | (115) |  |  | (121) |  |  |  |  | \nOther, net | 463 |  |  | (154) |  |  |  |  | \n | $ | 89 |  |  | $ | 708 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ and shares in millions except per share amounts) | 2023 |  | 2022 |  |  |  | \nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 2,821 |  |  | $ | 4,310 |  |  |  |  | \nAverage common shares outstanding | 2,538 |  |  | 2,528 |  |  |  |  | \nCommon shares issuable(1) | 13 |  |  | 9 |  |  |  |  | \nAverage common shares outstanding assuming dilution | 2,551 |  |  | 2,537 |  |  |  |  | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 148 |  |  | 1 |  |  | (18) |  |  | 131 | \nTax | (31) |  |  | (2) |  |  | (17) |  |  | (50) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 117 |  |  | (1) |  |  | (35) |  |  | 81 | \nReclassification adjustments, pretax | (68) |  | (1) | 45 |  | (2) | \u2014 |  |  | (23) | \nTax | 14 |  |  | (12) |  |  | \u2014 |  |  | 2 | \nReclassification adjustments, net of taxes | (54) |  |  | 33 |  |  | \u2014 |  |  | (21) | \nOther comprehensive income (loss), net of taxes | 63 |  |  | 32 |  |  | (35) |  |  | 60 | \nBalance March 31, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) | \nBalance January 1, 2023, net of taxes | $ | 73 |  |  | $ | (2,408) |  |  | $ | (2,433) |  |  | $ | (4,768) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | (66) |  |  | (47) |  |  | 79 |  |  | (34) | \nTax | 14 |  |  | 2 |  |  | (20) |  |  | (4) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | (52) |  |  | (45) |  |  | 59 |  |  | (38) | \nReclassification adjustments, pretax | (102) |  | (1) | (7) |  | (2) | 9 |  |  | (100) | \nTax | 21 |  |  | 2 |  |  | \u2014 |  |  | 23 | \nReclassification adjustments, net of taxes | (81) |  |  | (5) |  |  | 9 |  |  | (77) | \nOther comprehensive income (loss), net of taxes | (133) |  |  | (50) |  |  | 68 |  |  | (115) | \nBalance March 31, 2023, net of taxes | $ | (60) |  |  | $ | (2,458) |  |  | $ | (2,365) |  |  | $ | (4,883) |   |  |  |  |  |  |  |  |  | \n | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  |  |  |  |  |  |  |  |  |  |  | \nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 3,485 |  |  | $ | 2,310 |  |  | $ | 5,795 |  |  | $ | 2,779 |  |  | $ | 2,030 |  |  | $ | 4,809 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Lynparza(1) | 142 |  |  | 133 |  |  | 275 |  |  | 141 |  |  | 125 |  |  | 266 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Lenvima(1) | 153 |  |  | 79 |  |  | 232 |  |  | 156 |  |  | 71 |  |  | 227 |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Reblozyl(2) | 30 |  |  | 12 |  |  | 43 |  |  | 27 |  |  | 25 |  |  | 52 |  |  |  |  |  |  |  |  |  |  |  |  | \nWelireg | 41 |  |  | 1 |  |  | 42 |  |  | 18 |  |  | \u2014 |  |  | 18 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 416 |  |  | 1,556 |  |  | 1,972 |  |  | 418 |  |  | 1,042 |  |  | 1,460 |  |  |  |  |  |  |  |  |  |  |  |  | \nProQuad/M-M-RII/Varivax | 421 |  |  | 107 |  |  | 528 |  |  | 371 |  |  | 99 |  |  | 470 |  |  |  |  |  |  |  |  |  |  |  |  | \nRotaTeq | 180 |  |  | 117 |  |  | 297 |  |  | 175 |  |  | 41 |  |  | 216 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaxneuvance | 94 |  |  | 13 |  |  | 106 |  |  | 5 |  |  | \u2014 |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |  | \nPneumovax23 | 40 |  |  | 56 |  |  | 96 |  |  | 118 |  |  | 55 |  |  | 173 |  |  |  |  |  |  |  |  |  |  |  |  | \nVaqta | 30 |  |  | 10 |  |  | 40 |  |  | 29 |  |  | 7 |  |  | 36 |  |  |  |  |  |  |  |  |  |  |  |  | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 276 |  |  | 210 |  |  | 487 |  |  | 195 |  |  | 199 |  |  | 395 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrevymis | 54 |  |  | 75 |  |  | 129 |  |  | 40 |  |  | 54 |  |  | 94 |  |  |  |  |  |  |  |  |  |  |  |  | \nPrimaxin | 4 |  |  | 76 |  |  | 80 |  |  | 1 |  |  | 58 |  |  | 58 |  |  |  |  |  |  |  |  |  |  |  |  | \nDificid | 62 |  |  | 3 |  |  | 65 |  |  | 49 |  |  | 3 |  |  | 52 |  |  |  |  |  |  |  |  |  |  |  |  | \nNoxafil | 14 |  |  | 46 |  |  | 60 |  |  | 10 |  |  | 48 |  |  | 57 |  |  |  |  |  |  |  |  |  |  |  |  | \nZerbaxa | 27 |  |  | 23 |  |  | 50 |  |  | 18 |  |  | 12 |  |  | 30 |  |  |  |  |  |  |  |  |  |  |  |  | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Adempas/Verquvo(3) | 83 |  |  | 16 |  |  | 99 |  |  | 71 |  |  | 1 |  |  | 72 |  |  |  |  |  |  |  |  |  |  |  |  | \nAdempas | \u2014 |  |  | 59 |  |  | 59 |  |  | \u2014 |  |  | 61 |  |  | 61 |  |  |  |  |  |  |  |  |  |  |  |  | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | (2) |  |  | 394 |  |  | 392 |  |  | 1,523 |  |  | 1,723 |  |  | 3,247 |  |  |  |  |  |  |  |  |  |  |  |  | \nIsentress/IsentressHD | 52 |  |  | 71 |  |  | 123 |  |  | 61 |  |  | 97 |  |  | 158 |  |  |  |  |  |  |  |  |  |  |  |  | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 16 |  |  | 40 |  |  | 56 |  |  | 20 |  |  | 48 |  |  | 69 |  |  |  |  |  |  |  |  |  |  |  |  | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 180 |  |  | 180 |  |  | \u2014 |  |  | 186 |  |  | 186 |  |  |  |  |  |  |  |  |  |  |  |  | \nRemicade | \u2014 |  |  | 51 |  |  | 51 |  |  | \u2014 |  |  | 61 |  |  | 61 |  |  |  |  |  |  |  |  |  |  |  |  | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 271 |  |  | 280 |  |  | 551 |  |  | 325 |  |  | 454 |  |  | 779 |  |  |  |  |  |  |  |  |  |  |  |  | \nJanumet | 56 |  |  | 272 |  |  | 329 |  |  | 63 |  |  | 391 |  |  | 454 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther pharmaceutical(4) | 172 |  |  | 414 |  |  | 584 |  |  | 160 |  |  | 443 |  |  | 602 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Pharmaceutical segment sales | 6,117 |  |  | 6,604 |  |  | 12,721 |  |  | 6,773 |  |  | 7,334 |  |  | 14,107 |  |  |  |  |  |  |  |  |  |  |  |  | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 174 |  |  | 676 |  |  | 849 |  |  | 171 |  |  | 661 |  |  | 832 |  |  |  |  |  |  |  |  |  |  |  |  | \nCompanion Animals | 308 |  |  | 334 |  |  | 642 |  |  | 302 |  |  | 348 |  |  | 650 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal Animal Health segment sales | 482 |  |  | 1,010 |  |  | 1,491 |  |  | 473 |  |  | 1,009 |  |  | 1,482 |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal segment sales | 6,599 |  |  | 7,614 |  |  | 14,212 |  |  | 7,246 |  |  | 8,343 |  |  | 15,589 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther(5) | 60 |  |  | 214 |  |  | 275 |  |  | 93 |  |  | 220 |  |  | 312 |  |  |  |  |  |  |  |  |  |  |  |  | \n | $ | 6,659 |  |  | $ | 7,828 |  |  | $ | 14,487 |  |  | $ | 7,339 |  |  | $ | 8,563 |  |  | $ | 15,901 |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nUnited States | $ | 6,659 |  |  | $ | 7,339 |  |  |  |  | \nEurope, Middle East and Africa | 3,303 |  |  | 4,359 |  |  |  |  | \nChina | 1,715 |  |  | 1,143 |  |  |  |  | \nAsia Pacific (other than China and Japan) | 846 |  |  | 930 |  |  |  |  | \nJapan | 758 |  |  | 989 |  |  |  |  | \nLatin America | 661 |  |  | 607 |  |  |  |  | \nOther | 545 |  |  | 534 |  |  |  |  | \n | $ | 14,487 |  |  | $ | 15,901 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,140 |  |  | $ | 9,501 |  |  |  |  | \nAnimal Health segment | 566 |  |  | 585 |  |  |  |  | \nTotal segment profits | 9,706 |  |  | 10,086 |  |  |  |  | \nOther profits | 164 |  |  | 194 |  |  |  |  | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 112 |  |  | 7 |  |  |  |  | \nInterest expense | (242) |  |  | (243) |  |  |  |  | \nAmortization | (543) |  |  | (699) |  |  |  |  | \nDepreciation | (398) |  |  | (378) |  |  |  |  | \nResearch and development | (4,147) |  |  | (2,446) |  |  |  |  | \nRestructuring costs | (67) |  |  | (53) |  |  |  |  | \nCharge for Zetia antitrust litigation settlements | (573) |  |  | \u2014 |  |  |  |  | \nOther unallocated, net | (362) |  |  | (1,607) |  |  |  |  | \n | $ | 3,650 |  |  | $ | 4,861 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nUnited States | $ | 6,659 |  |  | $ | 7,339 |  |  | (9) | % |  | (9) | % |  |  |  |  |  |  |  | \nInternational | 7,828 |  |  | 8,563 |  |  | (9) | % |  | (2) | % |  |  |  |  |  |  |  | \nTotal | $ | 14,487 |  |  | $ | 15,901 |  |  | (9) | % |  | (5) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nKeytruda | $ | 5,795 |  |  | $ | 4,809 |  |  | 20 | % |  | 24 | % |  |  |  |  |  |  |  | \nAlliance Revenue - Lynparza(1) | 275 |  |  | 266 |  |  | 3 | % |  | 8 | % |  |  |  |  |  |  |  | \nAlliance Revenue-Lenvima(1) | 232 |  |  | 227 |  |  | 2 | % |  | 5 | % |  |  |  |  |  |  |  | \nAlliance Revenue-Reblozyl(2) | 43 |  |  | 52 |  |  | (19) | % |  | (19) | % |  |  |  |  |  |  |  | \nWelireg | 42 |  |  | 18 |  |  | * |  | * |  |  |  |  |  |  |  |   |  |  |  |  | \nDate | Approval\nJanuary 2023 | FDA approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a \u22654 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.\nMarch 2023 | FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on results from the Phase 2 KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials.\nApril 2023 | FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on data from the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | $ | 1,972 |  |  | $ | 1,460 |  |  | 35 | % |  | 43 | % |  |  |  |  |  |  |  | \nProQuad | 190 |  |  | 162 |  |  | 17 | % |  | 18 | % |  |  |  |  |  |  |  | \nM-M-RII | 102 |  |  | 103 |  |  | (1) | % |  | \u2014 | % |  |  |  |  |  |  |  | \nVarivax | 236 |  |  | 204 |  |  | 15 | % |  | 17 | % |  |  |  |  |  |  |  | \nRotaTeq | 297 |  |  | 216 |  |  | 38 | % |  | 42 | % |  |  |  |  |  |  |  | \nVaxneuvance | 106 |  |  | 5 |  |  | * |  | * |  |  |  |  |  |  |  | \nPneumovax 23 | 96 |  |  | 173 |  |  | (44) | % |  | (40) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nBridion | $ | 487 |  |  | $ | 395 |  |  | 23 | % |  | 27 | % |  |  |  |  |  |  |  | \nPrevymis | 129 |  |  | 94 |  |  | 38 | % |  | 44 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 99 |  |  | $ | 72 |  |  | 38 | % |  | 38 | % |  |  |  |  |  |  |  | \nAdempas | 59 |  |  | 61 |  |  | (3) | % |  | 5 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nLagevrio | $ | 392 |  |  | $ | 3,247 |  |  | (88) | % |  | (87) | % |  |  |  |  |  |  |  | \nIsentress/Isentress HD | 123 |  |  | 158 |  |  | (23) | % |  | (20) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nJanuvia/Janumet | $ | 880 |  |  | $ | 1,233 |  |  | (29) | % |  | (25) | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  | % ChangeExcludingForeignExchange |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  |  |  | \nLivestock | $ | 849 |  |  | $ | 832 |  |  | 2 | % |  | 8 | % |  |  |  |  |  |  |  | \nCompanion Animal | 642 |  |  | 650 |  |  | (1) | % |  | 2 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  |  |  |  |  | \nCost of sales | $ | 3,926 |  |  | $ | 5,380 |  |  | (27) | % |  |  |  |  |  | \nSelling, general and administrative | 2,479 |  |  | 2,323 |  |  | 7 | % |  |  |  |  |  | \nResearch and development | 4,276 |  |  | 2,576 |  |  | 66 | % |  |  |  |  |  | \nRestructuring costs | 67 |  |  | 53 |  |  | 26 | % |  |  |  |  |  | \nOther (income) expense, net | 89 |  |  | 708 |  |  | (87) | % |  |  |  |  |  | \n | $ | 10,837 |  |  | $ | 11,040 |  |  | (2) | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions) | 2023 |  | 2022 |  |  |  | \nPharmaceutical segment profits | $ | 9,140 |  |  | $ | 9,501 |  |  |  |  | \nAnimal Health segment profits | 566 |  |  | 585 |  |  |  |  | \nOther | (6,056) |  |  | (5,225) |  |  |  |  | \nIncome Before Taxes | $ | 3,650 |  |  | $ | 4,861 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedMarch 31, |  | \n($ in millions except per share amounts) | 2023 |  | 2022 |  |  |  | \nIncome before taxes as reported under GAAP | $ | 3,650 |  |  | $ | 4,861 |  |  |  |  | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition- and divestiture-related costs | 590 |  |  | 637 |  |  |  |  | \nRestructuring costs | 97 |  |  | 127 |  |  |  |  | \n(Income) loss from investments in equity securities, net | (429) |  |  | 684 |  |  |  |  | \nOther items: |  |  |  |  |  |  | \nCharge for Zetia antitrust litigation settlements | 573 |  |  | \u2014 |  |  |  |  | \nNon-GAAP income before taxes | 4,481 |  |  | 6,309 |  |  |  |  | \nTaxes on income as reported under GAAP | 825 |  |  | 554 |  |  |  |  | \nEstimated tax benefit on excluded items(1) | 88 |  |  | 329 |  |  |  |  | \nNon-GAAP taxes on income | 913 |  |  | 883 |  |  |  |  | \nNon-GAAP net income | 3,568 |  |  | 5,426 |  |  |  |  | \nLess: Net income (loss) attributable to noncontrolling interests as reported under GAAP | 4 |  |  | (3) |  |  |  |  | \nNon-GAAP net income attributable to Merck\u00a0& Co., Inc. | $ | 3,564 |  |  | $ | 5,429 |  |  |  |  | \nEPS assuming dilution as reported under GAAP | $ | 1.11 |  |  | $ | 1.70 |  |  |  |  | \nEPS difference | 0.29 |  |  | 0.44 |  |  |  |  | \nNon-GAAP EPS assuming dilution | $ | 1.40 |  |  | $ | 2.14 |  |  |  |  |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(2)Non-Small-Cell LungMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)ColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BladderBreastGastricHematological MalignanciesNon-Small-Cell LungOvarianPancreaticMK-2870(1)(3)Neoplasm MalignantMK-3475KeytrudaAdvanced Solid TumorsProstateMK-3543 (bomedemstat)Myeloproliferative DisordersMK-4280 (favezelimab)(2)Non-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)BaldderEsophagealMelanomaRenal CellSmall-Cell LungMK-4830(2)ColorectalEsophagealMelanomaNon-Small-Cell LungOvarianRenal CellSmall-Cell LungMK-5684(1)ProstateMK-5890 (boserolimab)(2)Non-Small-Cell LungSmall-Cell Lung | CancerMK-6440 (ladiratuzumab vedotin)(1)(3)BreastEsophagealGastricHead and NeckMelanomaNon-Small-Cell LungProstateSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalEndometrialEsophagealHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684A (vibostolimab+pembrolizumab)BiliaryBladderBreastCervicalColorectalEndometrialEsophagealGastricHead and NeckHematological MalignanciesHepatocellularOvarianProstate | CancerMK-7902 Lenvima(1)(2)BiliaryMelanomaPancreaticProstateSmall-Cell LungV940(1)(2)MelanomaDengue Fever Virus VaccineV181HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(5)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-6024 (efinopegdutide)Pulmonary Arterial HypertensionMK-5475Pulmonary Hypertension Due To Left Heart DiseaseMK-7962 (sotatercept)SchizophreniaMK-8189(6)ThrombosisMK-2060Treatment Resistant DepressionMK-1942  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(7)CancerMK-1026 (nemtabrutinib)Hematological Malignancies (March 2023)MK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaBiliary (September 2019)Cutaneous Squamous Cell (August 2019) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Small-Cell Lung (May 2017)MK-3475 (pembrolizumab subcutaneous)Non-Small-Cell Lung (August 2021)MK-3475A (pembrolizumab+hyaluronidase subcutaneous)Non-Small-Cell Lung (February 2023)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)Hematological Malignancies (October 2022)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)Colorectal (August 2022)MK-7339 Lynparza(1)(2)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Melanoma (January 2023)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Non-Small-Cell Lung (March 2019)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(5)Pneumococcal Vaccine AdultV116 (July 2022)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular EntitiesAntiviral COVID-19MK-4482Lagevrio(EU)(1)(8)CoughMK-7264 (gefapixant) (U.S.)(9)(EU) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    Second-Line Hepatocellular Carcinoma(KEYNOTE-394) (U.S.)\u2022    Locally Advanced or Metastatic Merkel Cell Carcinoma(KEYNOTE-913) (U.S.)\u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer(KEYNOTE-859) (U.S.) (EU)\u2022    Resectable Stage II, IIIA or IIIB NSCLC(KEYNOTE-671) (U.S.) (EU)\u2022    Adjuvant Non-Small-Cell Lung Cancer(KEYNOTE-091) (EU)\u2022    Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma(KEYNOTE-170/KEYNOTE-A33) (JPN)MK-7339 Lynparza(1)\u2022    First-Line Metastatic Prostate Cancer(PROpel) (U.S.) (JPN)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)On FDA partial clinical hold for higher doses than those used in current clinical trials.(6)Phase 2b development costs are being co-funded.(7)Available in the U.S. under Emergency Use Authorization.(8)Requested re-examination of EU MAA following CHMP recommendation for the refusal of the marketing authorization.(9)In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the second quarter of 2023.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | March 31, 2023 |  | December 31, 2022\nCash and investments | $ | 11,677 |  |  | $ | 14,207 | \nWorking capital | 10,271 |  |  | 11,483 | \nTotal debt to total liabilities and equity | 28.5 | % |  | 28.1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nJanuary 1 - January 31 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | $5,047\nFebruary 1 - February 28 | 328,800 |  |  | $108.43 |  | 328,800 |  |  | $5,012\nMarch 1 - March 31 | 1,066,937 |  |  | $106.55 |  | 1,066,937 |  |  | $4,898\nTotal | 1,395,737 |  |  | $107.00 |  | 1,395,737 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  May 5, 2023 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  May 5, 2023 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2023 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | Not Applicable | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Operations | 3\n | Condensed Consolidated Statement of Comprehensive(Loss)Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 29\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 42\n |  | \nItem 4. | Controls and Procedures | 42\n |  | \n | Cautionary Factors That May Affect Future Results | 42\n |  | \nPART II | OTHER INFORMATION | 43\n |  | \nItem 1. | Legal Proceedings | 43\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 43\n |  |  |  | \nItem 5. | Other Information | 43\n |  |  |  | \nItem 6. | Exhibits | 44\n |  | \n | Signatures |  |  | 45  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nSales | $ | 15,035 |  |  | $ | 14,593 |  |  | $ | 29,522 |  |  | $ | 30,494 | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 4,024 |  |  | 4,216 |  |  | 7,951 |  |  | 9,596 | \nSelling, general and administrative | 2,702 |  |  | 2,512 |  |  | 5,182 |  |  | 4,834 | \nResearch and development | 13,321 |  |  | 2,798 |  |  | 17,597 |  |  | 5,374 | \nRestructuring costs | 151 |  |  | 142 |  |  | 218 |  |  | 194 | \nOther (income) expense, net | 172 |  |  | 438 |  |  | 259 |  |  | 1,148 | \n | 20,370 |  |  | 10,106 |  |  | 31,207 |  |  | 21,146 | \n(Loss) Income Before Taxes | (5,335) |  |  | 4,487 |  |  | (1,685) |  |  | 9,348 | \nIncome Tax Provision | 637 |  |  | 538 |  |  | 1,462 |  |  | 1,092 | \nNet (Loss) Income | (5,972) |  |  | 3,949 |  |  | (3,147) |  |  | 8,256 | \nLess: Net Income Attributable to Noncontrolling Interests | 3 |  |  | 5 |  |  | 7 |  |  | 2 | \nNet (Loss) Income Attributable to Merck & Co., Inc. | $ | (5,975) |  |  | $ | 3,944 |  |  | $ | (3,154) |  |  | $ | 8,254 | \nBasic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | (2.35) |  |  | $ | 1.56 |  |  | $ | (1.24) |  |  | $ | 3.26 | \n(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | (2.35) |  |  | $ | 1.55 |  |  | $ | (1.24) |  |  | $ | 3.25 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet (Loss) Income Attributable to Merck\u00a0& Co., Inc. | $ | (5,975) |  |  | $ | 3,944 |  |  | $ | (3,154) |  |  | $ | 8,254 | \nOther Comprehensive (Loss) Income Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 145 |  |  | 183 |  |  | 12 |  |  | 246 | \nBenefit plan net (loss) gain and prior service (cost) credit, net of amortization | (25) |  |  | 246 |  |  | (75) |  |  | 278 | \nCumulative translation adjustment | (137) |  |  | (387) |  |  | (69) |  |  | (422) | \n | (17) |  |  | 42 |  |  | (132) |  |  | 102 | \nComprehensive (Loss) Income Attributable to Merck\u00a0& Co., Inc. | $ | (5,992) |  |  | $ | 3,986 |  |  | $ | (3,286) |  |  | $ | 8,356 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 5,660 |  |  | $ | 12,694 | \nShort-term investments | 718 |  |  | 498 | \nAccounts receivable (net of allowance for doubtful accounts of $86in 2023and $72in 2022) | 11,030 |  |  | 9,450 | \nInventories (excludes inventories of $3,220in 2023 and $2,938in 2022classified in Other assets - see Note\u00a07) | 5,930 |  |  | 5,911 | \nOther current assets | 6,639 |  |  | 7,169 | \nTotal current assets | 29,977 |  |  | 35,722 | \nInvestments | 1,214 |  |  | 1,015 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,432in 2023 and $17,985in 2022 | 22,231 |  |  | 21,422 | \nGoodwill | 21,195 |  |  | 21,204 | \nOther Intangibles, Net | 19,665 |  |  | 20,269 | \nOther Assets | 10,187 |  |  | 9,528 | \n | $ | 104,469 |  |  | $ | 109,160 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 2,839 |  |  | $ | 1,946 | \nTrade accounts payable | 3,442 |  |  | 4,264 | \nAccrued and other current liabilities | 13,747 |  |  | 14,159 | \nIncome taxes payable | 1,489 |  |  | 1,986 | \nDividends payable | 1,877 |  |  | 1,884 | \nTotal current liabilities | 23,394 |  |  | 24,239 | \nLong-Term Debt | 34,072 |  |  | 28,745 | \nDeferred Income Taxes | 996 |  |  | 1,795 | \nOther Noncurrent Liabilities | 7,265 |  |  | 8,323 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2023 and 2022 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,219 |  |  | 44,379 | \nRetained earnings | 54,198 |  |  | 61,081 | \nAccumulated other comprehensive loss | (4,900) |  |  | (4,768) | \n | 95,305 |  |  | 102,480 | \nLess treasury stock, at cost:1,037,678,033shares in 2023 and1,039,269,638shares in 2022 | 56,612 |  |  | 56,489 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 38,693 |  |  | 45,991 | \nNoncontrolling Interests | 49 |  |  | 67 | \nTotal equity | 38,742 |  |  | 46,058 | \n | $ | 104,469 |  |  | $ | 109,160 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months EndedJune 30,\n | 2023 |  | 2022\nCash Flows from Operating Activities |  |  | \nNet (loss) income | $ | (3,147) |  |  | $ | 8,256 | \nAdjustments to reconcile net (loss) income to net cash provided by operating activities: |  |  | \nAmortization | 1,020 |  |  | 1,163 | \nDepreciation | 874 |  |  | 895 | \n(Income) loss from investments in equity securities, net | (274) |  |  | 991 | \nCharge for the acquisition of Prometheus Biosciences, Inc. | 10,217 |  |  | \u2014 | \nCharge for the acquisition of Imago BioSciences, Inc. | 1,192 |  |  | \u2014 | \nDeferred income taxes | (632) |  |  | (600) | \nShare-based compensation | 314 |  |  | 257 | \nOther | 5 |  |  | 799 | \nNet changes in assets and liabilities | (4,526) |  |  | (2,698) | \nNet Cash Provided by Operating Activities | 5,043 |  |  | 9,063 | \nCash Flows from Investing Activities |  |  | \nCapital expenditures | (1,972) |  |  | (2,113) | \nPurchases of securities and other investments | (587) |  |  | (705) | \nProceeds from sales of securities and other investments | 785 |  |  | 374 | \nAcquisition of Prometheus Biosciences, Inc., net of cash acquired | (10,705) |  |  | \u2014 | \nAcquisition of Imago BioSciences, Inc., net of cash acquired | (1,327) |  |  | \u2014 | \nOther | 4 |  |  | 194 | \nNet Cash Used in Investing Activities | (13,802) |  |  | (2,250) | \nCash Flows from Financing Activities |  |  | \nNet change in short-term borrowings | 1,937 |  |  | \u2014 | \nProceeds from issuance of debt | 5,946 |  |  | \u2014 | \nPayments on debt | (1,751) |  |  | (1,250) | \nPurchases of treasury stock | (487) |  |  | \u2014 | \nDividends paid to stockholders | (3,738) |  |  | (3,515) | \nProceeds from exercise of stock options | 112 |  |  | 109 | \nOther | (315) |  |  | (207) | \nNet Cash Provided by (Used in) Financing Activities | 1,704 |  |  | (4,863) | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (6) |  |  | (364) | \nNet (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash | (7,061) |  |  | 1,586 | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$79and $71at January 1, 2023 and 2022, respectively, included inOther current assets) | 12,773 |  |  | 8,167 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $52and $78at June\u00a030, 2023 and 2022, respectively, included inOther current assets) | $ | 5,712 |  |  | $ | 9,753 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Lynparza | $ | 310 |  |  | $ | 275 |  |  | $ | 585 |  |  | $ | 541 | \nAlliance revenue - Koselugo | 25 |  |  | 24 |  |  | 48 |  |  | 33 | \nTotal alliance revenue | $ | 335 |  |  | $ | 299 |  |  | $ | 633 |  |  | $ | 574 | \n |  |  |  |  |  |  | \nCost of sales(1) | 78 |  |  | 62 |  |  | 148 |  |  | 361 | \nSelling, general and administrative | 51 |  |  | 46 |  |  | 98 |  |  | 90 | \nResearch and development | 22 |  |  | 25 |  |  | 43 |  |  | 51 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2023 |  | December 31, 2022\nReceivables from AstraZeneca included inOther current assets |  |  |  |  | $ | 332 |  |  | $ | 303 | \nPayables to AstraZeneca included inAccrued and other current liabilities(2) |  |  |  |  | 260 |  |  | 123 | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) |  |  |  |  | 600 |  |  | 600 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Lenvima | $ | 242 |  |  | $ | 231 |  |  | $ | 474 |  |  | $ | 459 | \n |  |  |  |  |  |  | \nCost of sales(1) | 57 |  |  | 53 |  |  | 183 |  |  | 106 | \nSelling, general and administrative | 48 |  |  | 42 |  |  | 99 |  |  | 73 | \nResearch and development | 17 |  |  | 47 |  |  | 56 |  |  | 104 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2023 |  | December 31, 2022\nReceivables from Eisai included inOther current assets |  |  |  |  | $ | 242 |  |  | $ | 214 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Adempas/Verquvo | $ | 68 |  |  | $ | 98 |  |  | $ | 167 |  |  | $ | 170 | \nNet sales of Adempas recorded by Merck | 65 |  |  | 63 |  |  | 125 |  |  | 124 | \nNet sales of Verquvo recorded by Merck | 9 |  |  | 6 |  |  | 16 |  |  | 9 | \nTotal sales | $ | 142 |  |  | $ | 167 |  |  | $ | 308 |  |  | $ | 303 | \n |  |  |  |  |  |  | \nCost of sales(1) | 56 |  |  | 54 |  |  | 113 |  |  | 103 | \nSelling, general and administrative | 34 |  |  | 42 |  |  | 67 |  |  | 65 | \nResearch and development | 25 |  |  | 17 |  |  | 50 |  |  | 34 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2023 |  | December 31, 2022\nReceivables from Bayer included inOther current assets |  |  |  |  | $ | 144 |  |  | $ | 143 | \nPayables to Bayer included inAccrued and other current liabilities |  |  |  |  | 82 |  |  | 80 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet sales ofLagevriorecorded by Merck | $ | 203 |  |  | $ | 1,177 |  |  | $ | 595 |  |  | $ | 4,424 | \n |  |  |  |  |  |  | \nCost of sales(1)(2) | 193 |  |  | 615 |  |  | 414 |  |  | 2,341 | \nSelling, general and administrative(2) | 24 |  |  | 34 |  |  | 51 |  |  | 69 | \nResearch and development(2) | 10 |  |  | 30 |  |  | 26 |  |  | 56 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | June 30, 2023 |  | December 31, 2022\nReceivables from Ridgeback included inOther current assets(3) |  |  |  |  | $ | 51 |  |  | $ | \u2014 | \nPayables to Ridgeback included inAccrued and other current liabilities(4) |  |  |  |  | 30 |  |  | 348 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2023 |  | Six Months Ended June 30, 2023\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 22 |  |  | $ | 10 |  |  | $ | 32 |  |  | $ | \u2014 |  |  | $ | 43 |  |  | $ | 18 |  |  | $ | 61 | \nSelling, general and administrative | \u2014 |  |  | \u2014 |  |  | 52 |  |  | 52 |  |  | \u2014 |  |  | \u2014 |  |  | 53 |  |  | 53 | \nResearch and development | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 | \nRestructuring costs | 110 |  |  | \u2014 |  |  | 41 |  |  | 151 |  |  | 151 |  |  | \u2014 |  |  | 67 |  |  | 218 | \n | $ | 110 |  |  | $ | 22 |  |  | $ | 104 |  |  | $ | 236 |  |  | $ | 151 |  |  | $ | 43 |  |  | $ | 139 |  |  | $ | 333 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2022 |  | Six Months Ended June 30, 2022\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 17 |  |  | $ | 50 |  |  | $ | 67 |  |  | $ | \u2014 |  |  | $ | 35 |  |  | $ | 78 |  |  | $ | 113 | \nSelling, general and administrative | \u2014 |  |  | 8 |  |  | 19 |  |  | 27 |  |  | \u2014 |  |  | 12 |  |  | 36 |  |  | 48 | \nResearch and development | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 22 |  |  | \u2014 |  |  | 29 |  |  | \u2014 |  |  | 29 | \nRestructuring costs | 106 |  |  | \u2014 |  |  | 36 |  |  | 142 |  |  | 132 |  |  | \u2014 |  |  | 62 |  |  | 194 | \n | $ | 106 |  |  | $ | 47 |  |  | $ | 105 |  |  | $ | 258 |  |  | $ | 132 |  |  | $ | 76 |  |  | $ | 176 |  |  | $ | 384 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2023 | $ | 479 |  |  | $ | \u2014 |  |  | $ | 34 |  |  | $ | 513 | \nExpenses | 151 |  |  | 43 |  |  | 139 |  |  | 333 | \n(Payments) receipts, net | (84) |  |  | \u2014 |  |  | (74) |  |  | (158) | \nNon-cash activity | \u2014 |  |  | (43) |  |  | (68) |  |  | (111) | \nRestructuring reserves June\u00a030, 2023(1) | $ | 546 |  |  | $ | \u2014 |  |  | $ | 31 |  |  | $ | 577 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended June 30, |  | Six Months Ended June 30, |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | \u2014 |  |  | $ | (31) |  |  | $ | 1 |  |  | $ | (46) |  |  | $ | \u2014 |  |  | $ | (1) |  |  | $ | 1 |  |  | $ | (2) | \nEuro-denominated notes | 21 |  |  | (128) |  |  | 73 |  |  | (181) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | June 30, 2023 |  | December 31, 2022\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 200 |  |  | $ | \u2014 |  |  | $ | 5,976 |  |  | $ | 220 |  |  | $ | \u2014 |  |  | $ | 4,824 | \nForeign exchange contracts | Other Assets | 43 |  |  | \u2014 |  |  | 1,750 |  |  | 27 |  |  | \u2014 |  |  | 1,609 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 62 |  |  | 2,245 |  |  | \u2014 |  |  | 101 |  |  | 2,691 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 328 |  |  | \u2014 |  |  | 1 |  |  | 91 | \n |  | $ | 243 |  |  | $ | 63 |  |  | $ | 10,299 |  |  | $ | 247 |  |  | $ | 102 |  |  | $ | 9,215 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 222 |  |  | $ | \u2014 |  |  | $ | 8,838 |  |  | $ | 186 |  |  | $ | \u2014 |  |  | $ | 8,540 | \n |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 181 |  |  | 10,112 |  |  | \u2014 |  |  | 307 |  |  | 10,926 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  | $ | 222 |  |  | $ | 181 |  |  | $ | 18,950 |  |  | $ | 186 |  |  | $ | 307 |  |  | $ | 19,466 | \n |  | $ | 465 |  |  | $ | 244 |  |  | $ | 29,249 |  |  | $ | 433 |  |  | $ | 409 |  |  | $ | 28,681 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 465 |  |  | $ | 244 |  |  | $ | 433 |  |  | $ | 409 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (180) |  |  | (180) |  |  | (220) |  |  | (220) | \nCash collateral received/posted | (102) |  |  | \u2014 |  |  | (66) |  |  | (19) | \nNet amounts | $ | 183 |  |  | $ | 64 |  |  | $ | 147 |  |  | $ | 170 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nFinancial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss)\n | $ | 15,035 |  |  | $ | 14,593 |  |  | $ | 172 |  |  | $ | 438 |  |  | $ | (17) |  |  | $ | 42 |  |  | $ | 29,522 |  |  | $ | 30,494 |  |  | $ | 259 |  |  | $ | 1,148 |  |  | $ | (132) |  |  | $ | 102 | \n(Gain) loss on fair value hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (14) |  |  | \u2014 |  |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | \u2014 | \nImpact of cash flow hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 194 |  |  | 403 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 128 |  |  | 551 | \nIncrease inSalesas a result ofAOCLreclassifications | 24 |  |  | 172 |  |  | \u2014 |  |  | \u2014 |  |  | (24) |  |  | (172) |  |  | 125 |  |  | 239 |  |  | \u2014 |  |  | \u2014 |  |  | (125) |  |  | (239) | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) |  |  | \u2014 |  |  | \u2014 | \nAmount of gain (loss) recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 13 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 13 |  |  | (1) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended June 30, |  | Six Months Ended June 30,\n($ in millions) |  |  | 2023 |  | 2022 |  | 2023 |  | 2022\nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | (41) |  |  | $ | (64) |  |  | $ | (28) |  |  | $ | (36) | \nForeign exchange contracts(2) | Sales |  | (5) |  |  | (36) |  |  | (3) |  |  | (38) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 561 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 561 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | 256 |  |  | \u2014 |  |  | \u2014 |  |  | 256 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal debt securities | $ | 821 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 821 |  |  | $ | 569 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 569 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,520 |  |  |  |  |  |  |  |  | 1,284 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 2,341 |  |  |  |  |  |  |  |  | $ | 1,853 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | June 30, 2023 |  | December 31, 2022\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 561 |  |  | $ | \u2014 |  |  | $ | 561 |  |  | $ | \u2014 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | \u2014 |  |  | 187 |  |  | \u2014 |  |  | 187 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPublicly traded equity securities | 1,184 |  |  | \u2014 |  |  | \u2014 |  |  | 1,184 |  |  | 1,015 |  |  | \u2014 |  |  | \u2014 |  |  | 1,015 | \n | 1,184 |  |  | 748 |  |  | \u2014 |  |  | 1,932 |  |  | 1,015 |  |  | 498 |  |  | \u2014 |  |  | 1,513 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 69 |  |  | \u2014 |  |  | \u2014 |  |  | 69 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 4 |  |  | \u2014 |  |  | \u2014 |  |  | 4 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \nPublicly traded equity securities | 336 |  |  | \u2014 |  |  | \u2014 |  |  | 336 |  |  | 269 |  |  | \u2014 |  |  | \u2014 |  |  | 269 | \n | 409 |  |  | \u2014 |  |  | \u2014 |  |  | 409 |  |  | 340 |  |  | \u2014 |  |  | \u2014 |  |  | 340 | \nDerivative assets(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 316 |  |  | \u2014 |  |  | 316 |  |  | \u2014 |  |  | 218 |  |  | \u2014 |  |  | 218 | \nPurchased currency options | \u2014 |  |  | 149 |  |  | \u2014 |  |  | 149 |  |  | \u2014 |  |  | 215 |  |  | \u2014 |  |  | 215 | \n | \u2014 |  |  | 465 |  |  | \u2014 |  |  | 465 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 | \nTotal assets | $ | 1,593 |  |  | $ | 1,213 |  |  | $ | \u2014 |  |  | $ | 2,806 |  |  | $ | 1,355 |  |  | $ | 931 |  |  | $ | \u2014 |  |  | $ | 2,286 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 349 |  |  | $ | 349 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 456 |  |  | $ | 456 | \nDerivative liabilities(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 235 |  |  | \u2014 |  |  | 235 |  |  | \u2014 |  |  | 402 |  |  | \u2014 |  |  | 402 | \nWritten currency options | \u2014 |  |  | 9 |  |  | \u2014 |  |  | 9 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 | \n | \u2014 |  |  | 244 |  |  | \u2014 |  |  | 244 |  |  | \u2014 |  |  | 409 |  |  | \u2014 |  |  | 409 | \nTotal liabilities | $ | \u2014 |  |  | $ | 244 |  |  | $ | 349 |  |  | $ | 593 |  |  | $ | \u2014 |  |  | $ | 409 |  |  | $ | 456 |  |  | $ | 865 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022\nFair value January 1 | $ | 456 |  |  | $ | 777 | \nChanges in estimated fair value(1) | 10 |  |  | (114) | \nPayments | (117) |  |  | (119) | \nOther | \u2014 |  |  | (2) | \nFair value June 30(2) | $ | 349 |  |  | $ | 542 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | June 30, 2023 |  | December 31, 2022\nFinished goods | $ | 1,841 |  |  | $ | 1,841 | \nRaw materials and work in process | 7,453 |  |  | 7,063 | \nSupplies | 269 |  |  | 238 | \nTotal | 9,563 |  |  | 9,142 | \nDecrease to LIFO cost | (413) |  |  | (293) | \n | $ | 9,150 |  |  | $ | 8,849 | \nRecognized as: |  |  | \nInventories | $ | 5,930 |  |  | $ | 5,911 | \nOther Assets | 3,220 |  |  | 2,938 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at April 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,275 |  | $ | 56,252 |  | $ | (4,369) |  | 1,049 |  | $ | (57,063) |  | $ | 70 |  | $ | 40,953 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,944 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,944 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 42 |  | \u2014 |  | \u2014 |  | \u2014 |  | 42 | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,759) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,759) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (160) |  | \u2014 |  | \u2014 |  | (5) |  | 293 |  | \u2014 |  | 133 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 5 |  | 5 | \n |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 | \nBalance at April 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,467 |  | $ | 62,039 |  | $ | (4,883) |  | 1,040 |  | $ | (56,577) |  | $ | 71 |  | $ | 46,905 | \nNet loss attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | (5,975) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (5,975) | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (17) |  | \u2014 |  | \u2014 |  | \u2014 |  | (17) | \nCash dividends declared on common stock ($0.73per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,866) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,866) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3 |  | (338) |  | \u2014 |  | (338) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (248) |  | \u2014 |  | \u2014 |  | (5) |  | 303 |  | \u2014 |  | 55 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3 |  | 3 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (25) |  | (25) | \nBalance at June 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,219 |  | $ | 54,198 |  | $ | (4,900) |  | 1,038 |  | $ | (56,612) |  | $ | 49 |  | $ | 38,742 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January\u00a01, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 8,254 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 8,254 | \nOther comprehensive income, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 |  | \u2014 |  | \u2014 |  | \u2014 |  | 102 | \nCash dividends declared on common stock ($1.38per share) | \u2014 |  | \u2014 |  | \u2014 |  | (3,513) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,513) | \n |  |  |  |  |  |  |  |  | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (123) |  | \u2014 |  | \u2014 |  | (5) |  | 339 |  | \u2014 |  | 216 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 2 |  | 2 | \n |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 | \nBalance at January\u00a01, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,379 |  | $ | 61,081 |  | $ | (4,768) |  | 1,039 |  | $ | (56,489) |  | $ | 67 |  | $ | 46,058 | \nNet loss attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | (3,154) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,154) | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (132) |  | \u2014 |  | \u2014 |  | \u2014 |  | (132) | \nCash dividends declared on common stock ($1.46per share) | \u2014 |  | \u2014 |  | \u2014 |  | (3,729) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (3,729) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4 |  | (487) |  | \u2014 |  | (487) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (160) |  | \u2014 |  | \u2014 |  | (5) |  | 364 |  | \u2014 |  | 204 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 7 |  | 7 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (25) |  | (25) | \nBalance at June 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,219 |  | $ | 54,198 |  | $ | (4,900) |  | 1,038 |  | $ | (56,612) |  | $ | 49 |  | $ | 38,742 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n($ in millions) | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International\nService cost | $ | 76 |  |  | $ | 50 |  |  | $ | 99 |  |  | $ | 72 |  |  | $ | 152 |  |  | $ | 99 |  |  | $ | 198 |  |  | $ | 147 | \nInterest cost | 133 |  |  | 75 |  |  | 103 |  |  | 37 |  |  | 266 |  |  | 149 |  |  | 206 |  |  | 75 | \nExpected return on plan assets | (185) |  |  | (130) |  |  | (197) |  |  | (98) |  |  | (372) |  |  | (257) |  |  | (393) |  |  | (199) | \nAmortization of unrecognized prior service cost (credit) | \u2014 |  |  | 16 |  |  | (8) |  |  | (3) |  |  | (1) |  |  | 12 |  |  | (16) |  |  | (7) | \nNet (gain) loss amortization | \u2014 |  |  | (1) |  |  | 56 |  |  | 25 |  |  | \u2014 |  |  | (2) |  |  | 112 |  |  | 50 | \nTermination benefits | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 | \nCurtailments | 2 |  |  | \u2014 |  |  | 4 |  |  | \u2014 |  |  | 5 |  |  | \u2014 |  |  | 8 |  |  | \u2014 | \nSettlements | 5 |  |  | \u2014 |  |  | 101 |  |  | \u2014 |  |  | 26 |  |  | \u2014 |  |  | 101 |  |  | \u2014 | \n | $ | 32 |  |  | $ | 10 |  |  | $ | 159 |  |  | $ | 33 |  |  | $ | 77 |  |  | $ | 1 |  |  | $ | 217 |  |  | $ | 66 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nService cost | $ | 8 |  |  | $ | 12 |  |  | $ | 17 |  |  | $ | 25 | \nInterest cost | 16 |  |  | 11 |  |  | 31 |  |  | 23 | \nExpected return on plan assets | (16) |  |  | (21) |  |  | (32) |  |  | (43) | \nAmortization of unrecognized prior service credit | (12) |  |  | (14) |  |  | (25) |  |  | (29) | \nNet gain amortization | (11) |  |  | (11) |  |  | (21) |  |  | (21) | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n | $ | (15) |  |  | $ | (23) |  |  | $ | (30) |  |  | $ | (45) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest income | $ | (109) |  |  | $ | (15) |  |  | $ | (221) |  |  | $ | (22) | \nInterest expense | 277 |  |  | 240 |  |  | 519 |  |  | 483 | \nExchange losses | 62 |  |  | 86 |  |  | 122 |  |  | 124 | \nLoss (income) from investments in equity securities, net(1) | 175 |  |  | 284 |  |  | (274) |  |  | 991 | \nNet periodic defined benefit plan (credit) cost other than service cost | (111) |  |  | (27) |  |  | (226) |  |  | (148) | \nOther, net | (122) |  |  | (130) |  |  | 339 |  |  | (280) | \n | $ | 172 |  |  | $ | 438 |  |  | $ | 259 |  |  | $ | 1,148 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ and shares in millions except per share amounts) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet (Loss) Income Attributable to Merck\u00a0& Co., Inc. | $ | (5,975) |  |  | $ | 3,944 |  |  | $ | (3,154) |  |  | $ | 8,254 | \nAverage common shares outstanding | 2,539 |  |  | 2,531 |  |  | 2,539 |  |  | 2,529 | \nCommon shares issuable(1) | \u2014 |  |  | 9 |  |  | \u2014 |  |  | 9 | \nAverage common shares outstanding assuming dilution | 2,539 |  |  | 2,540 |  |  | 2,539 |  |  | 2,538 | \nBasic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | (2.35) |  |  | $ | 1.56 |  |  | $ | (1.24) |  |  | $ | 3.26 | \n(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | (2.35) |  |  | $ | 1.55 |  |  | $ | (1.24) |  |  | $ | 3.25 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance April 1, 2022, net of taxes | $ | 207 |  |  | $ | (2,711) |  |  | $ | (1,865) |  |  | $ | (4,369) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 403 |  |  | 168 |  |  | (365) |  |  | 206 | \nTax | (85) |  |  | (35) |  |  | (22) |  |  | (142) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 318 |  |  | 133 |  |  | (387) |  |  | 64 | \nReclassification adjustments, pretax | (171) |  | (1) | 144 |  | (2) | \u2014 |  |  | (27) | \nTax | 36 |  |  | (31) |  |  | \u2014 |  |  | 5 | \nReclassification adjustments, net of taxes | (135) |  |  | 113 |  |  | \u2014 |  |  | (22) | \nOther comprehensive income (loss), net of taxes | 183 |  |  | 246 |  |  | (387) |  |  | 42 | \nBalance June 30, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) | \nBalance April 1, 2023, net of taxes | $ | (60) |  |  | $ | (2,458) |  |  | $ | (2,365) |  |  | $ | (4,883) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 194 |  |  | (6) |  |  | (115) |  |  | 73 | \nTax | (41) |  |  | 1 |  |  | (22) |  |  | (62) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 153 |  |  | (5) |  |  | (137) |  |  | 11 | \nReclassification adjustments, pretax | (11) |  | (1) | (23) |  | (2) | \u2014 |  |  | (34) | \nTax | 3 |  |  | 3 |  |  | \u2014 |  |  | 6 | \nReclassification adjustments, net of taxes | (8) |  |  | (20) |  |  | \u2014 |  |  | (28) | \nOther comprehensive income (loss), net of taxes | 145 |  |  | (25) |  |  | (137) |  |  | (17) | \nBalance June 30, 2023, net of taxes | $ | 85 |  |  | $ | (2,483) |  |  | $ | (2,502) |  |  | $ | (4,900) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 551 |  |  | 169 |  |  | (383) |  |  | 337 | \nTax | (116) |  |  | (37) |  |  | (39) |  |  | (192) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 435 |  |  | 132 |  |  | (422) |  |  | 145 | \nReclassification adjustments, pretax | (239) |  | (1) | 189 |  | (2) | \u2014 |  |  | (50) | \nTax | 50 |  |  | (43) |  |  | \u2014 |  |  | 7 | \nReclassification adjustments, net of taxes | (189) |  |  | 146 |  |  | \u2014 |  |  | (43) | \nOther comprehensive income (loss), net of taxes | 246 |  |  | 278 |  |  | (422) |  |  | 102 | \nBalance June 30, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) | \nBalance January 1, 2023, net of taxes | $ | 73 |  |  | $ | (2,408) |  |  | $ | (2,433) |  |  | $ | (4,768) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 128 |  |  | (53) |  |  | (36) |  |  | 39 | \nTax | (27) |  |  | 3 |  |  | (42) |  |  | (66) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 101 |  |  | (50) |  |  | (78) |  |  | (27) | \nReclassification adjustments, pretax | (113) |  | (1) | (30) |  | (2) | 9 |  |  | (134) | \nTax | 24 |  |  | 5 |  |  | \u2014 |  |  | 29 | \nReclassification adjustments, net of taxes | (89) |  |  | (25) |  |  | 9 |  |  | (105) | \nOther comprehensive income (loss), net of taxes | 12 |  |  | (75) |  |  | (69) |  |  | (132) | \nBalance June 30, 2023, net of taxes | $ | 85 |  |  | $ | (2,483) |  |  | $ | (2,502) |  |  | $ | (4,900) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total\nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 3,863 |  |  | $ | 2,408 |  |  | $ | 6,271 |  |  | $ | 3,197 |  |  | $ | 2,055 |  |  | $ | 5,252 |  |  | $ | 7,348 |  |  | $ | 4,718 |  |  | $ | 12,065 |  |  | $ | 5,976 |  |  | $ | 4,085 |  |  | $ | 10,061 | \nAlliance revenue-Lynparza(1) | 144 |  |  | 166 |  |  | 310 |  |  | 143 |  |  | 132 |  |  | 275 |  |  | 286 |  |  | 299 |  |  | 585 |  |  | 283 |  |  | 257 |  |  | 541 | \nAlliance revenue-Lenvima(1) | 163 |  |  | 79 |  |  | 242 |  |  | 128 |  |  | 103 |  |  | 231 |  |  | 316 |  |  | 158 |  |  | 474 |  |  | 284 |  |  | 175 |  |  | 459 | \nWelireg | 49 |  |  | 2 |  |  | 50 |  |  | 27 |  |  | \u2014 |  |  | 27 |  |  | 90 |  |  | 3 |  |  | 92 |  |  | 45 |  |  | \u2014 |  |  | 45 | \nAlliance revenue-Reblozyl(2) | 36 |  |  | 11 |  |  | 47 |  |  | 28 |  |  | 5 |  |  | 33 |  |  | 66 |  |  | 24 |  |  | 90 |  |  | 55 |  |  | 30 |  |  | 86 | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 464 |  |  | 1,994 |  |  | 2,458 |  |  | 428 |  |  | 1,245 |  |  | 1,674 |  |  | 880 |  |  | 3,550 |  |  | 4,430 |  |  | 846 |  |  | 2,287 |  |  | 3,133 | \nProQuad/M-M-RII/Varivax | 447 |  |  | 135 |  |  | 582 |  |  | 434 |  |  | 143 |  |  | 578 |  |  | 868 |  |  | 242 |  |  | 1,109 |  |  | 805 |  |  | 243 |  |  | 1,047 | \nRotaTeq | 93 |  |  | 37 |  |  | 131 |  |  | 98 |  |  | 75 |  |  | 173 |  |  | 273 |  |  | 155 |  |  | 428 |  |  | 273 |  |  | 116 |  |  | 389 | \nVaxneuvance | 147 |  |  | 20 |  |  | 168 |  |  | 11 |  |  | \u2014 |  |  | 12 |  |  | 241 |  |  | 33 |  |  | 274 |  |  | 16 |  |  | 1 |  |  | 16 | \nPneumovax23 | 23 |  |  | 69 |  |  | 92 |  |  | 94 |  |  | 59 |  |  | 153 |  |  | 63 |  |  | 125 |  |  | 188 |  |  | 212 |  |  | 114 |  |  | 325 | \nVaqta | 29 |  |  | 13 |  |  | 42 |  |  | 16 |  |  | 19 |  |  | 35 |  |  | 59 |  |  | 23 |  |  | 82 |  |  | 45 |  |  | 25 |  |  | 71 | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 299 |  |  | 203 |  |  | 502 |  |  | 237 |  |  | 190 |  |  | 426 |  |  | 576 |  |  | 413 |  |  | 989 |  |  | 432 |  |  | 389 |  |  | 821 | \nPrevymis | 61 |  |  | 82 |  |  | 143 |  |  | 47 |  |  | 56 |  |  | 103 |  |  | 116 |  |  | 157 |  |  | 273 |  |  | 87 |  |  | 110 |  |  | 197 | \nDificid | 68 |  |  | 8 |  |  | 76 |  |  | 63 |  |  | 3 |  |  | 66 |  |  | 130 |  |  | 11 |  |  | 141 |  |  | 113 |  |  | 6 |  |  | 119 | \nPrimaxin | (2) |  |  | 56 |  |  | 53 |  |  | \u2014 |  |  | 64 |  |  | 64 |  |  | 2 |  |  | 132 |  |  | 133 |  |  | 1 |  |  | 122 |  |  | 122 | \nNoxafil | 11 |  |  | 45 |  |  | 55 |  |  | 16 |  |  | 45 |  |  | 60 |  |  | 25 |  |  | 91 |  |  | 116 |  |  | 25 |  |  | 92 |  |  | 118 | \nZerbaxa | 30 |  |  | 24 |  |  | 54 |  |  | 22 |  |  | 24 |  |  | 46 |  |  | 57 |  |  | 47 |  |  | 104 |  |  | 40 |  |  | 36 |  |  | 76 | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Adempas/Verquvo(3) | 70 |  |  | (2) |  |  | 68 |  |  | 88 |  |  | 10 |  |  | 98 |  |  | 153 |  |  | 14 |  |  | 167 |  |  | 159 |  |  | 11 |  |  | 170 | \nAdempas | \u2014 |  |  | 65 |  |  | 65 |  |  | \u2014 |  |  | 63 |  |  | 63 |  |  | \u2014 |  |  | 125 |  |  | 125 |  |  | \u2014 |  |  | 124 |  |  | 124 | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | 2 |  |  | 201 |  |  | 203 |  |  | \u2014 |  |  | 1,177 |  |  | 1,177 |  |  | \u2014 |  |  | 595 |  |  | 595 |  |  | 1,523 |  |  | 2,901 |  |  | 4,424 | \nIsentress/IsentressHD | 56 |  |  | 80 |  |  | 136 |  |  | 67 |  |  | 80 |  |  | 147 |  |  | 108 |  |  | 151 |  |  | 259 |  |  | 128 |  |  | 177 |  |  | 305 | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 21 |  |  | 42 |  |  | 63 |  |  | 19 |  |  | 50 |  |  | 69 |  |  | 37 |  |  | 82 |  |  | 119 |  |  | 39 |  |  | 98 |  |  | 137 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 180 |  |  | 180 |  |  | \u2014 |  |  | 181 |  |  | 181 |  |  | \u2014 |  |  | 359 |  |  | 359 |  |  | \u2014 |  |  | 366 |  |  | 366 | \nRemicade | \u2014 |  |  | 48 |  |  | 48 |  |  | \u2014 |  |  | 53 |  |  | 53 |  |  | \u2014 |  |  | 99 |  |  | 99 |  |  | \u2014 |  |  | 114 |  |  | 114 | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 243 |  |  | 267 |  |  | 511 |  |  | 301 |  |  | 455 |  |  | 756 |  |  | 514 |  |  | 548 |  |  | 1,062 |  |  | 626 |  |  | 909 |  |  | 1,535 | \nJanumet | 82 |  |  | 272 |  |  | 354 |  |  | 105 |  |  | 371 |  |  | 476 |  |  | 138 |  |  | 544 |  |  | 683 |  |  | 168 |  |  | 762 |  |  | 931 | \nOther pharmaceutical(4) | 171 |  |  | 382 |  |  | 553 |  |  | 157 |  |  | 372 |  |  | 528 |  |  | 342 |  |  | 793 |  |  | 1,138 |  |  | 317 |  |  | 814 |  |  | 1,131 | \nTotal Pharmaceutical segment sales | 6,570 |  |  | 6,887 |  |  | 13,457 |  |  | 5,726 |  |  | 7,030 |  |  | 12,756 |  |  | 12,688 |  |  | 13,491 |  |  | 26,179 |  |  | 12,498 |  |  | 14,364 |  |  | 26,863 | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 165 |  |  | 643 |  |  | 807 |  |  | 164 |  |  | 662 |  |  | 826 |  |  | 338 |  |  | 1,318 |  |  | 1,656 |  |  | 335 |  |  | 1,322 |  |  | 1,658 | \nCompanion Animal | 310 |  |  | 339 |  |  | 649 |  |  | 313 |  |  | 328 |  |  | 641 |  |  | 618 |  |  | 673 |  |  | 1,291 |  |  | 616 |  |  | 676 |  |  | 1,291 | \nTotal Animal Health segment sales | 475 |  |  | 982 |  |  | 1,456 |  |  | 477 |  |  | 990 |  |  | 1,467 |  |  | 956 |  |  | 1,991 |  |  | 2,947 |  |  | 951 |  |  | 1,998 |  |  | 2,949 | \nTotal segment sales | 7,045 |  |  | 7,869 |  |  | 14,913 |  |  | 6,203 |  |  | 8,020 |  |  | 14,223 |  |  | 13,644 |  |  | 15,482 |  |  | 29,126 |  |  | 13,449 |  |  | 16,362 |  |  | 29,812 | \nOther(5) | (27) |  |  | 149 |  |  | 122 |  |  | 35 |  |  | 335 |  |  | 370 |  |  | 32 |  |  | 364 |  |  | 396 |  |  | 128 |  |  | 555 |  |  | 682 | \n | $ | 7,018 |  |  | $ | 8,018 |  |  | $ | 15,035 |  |  | $ | 6,238 |  |  | $ | 8,355 |  |  | $ | 14,593 |  |  | $ | 13,676 |  |  | $ | 15,846 |  |  | $ | 29,522 |  |  | $ | 13,577 |  |  | $ | 16,917 |  |  | $ | 30,494 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nUnited States | $ | 7,018 |  |  | $ | 6,238 |  |  | $ | 13,676 |  |  | $ | 13,577 | \nEurope, Middle East and Africa | 3,348 |  |  | 3,582 |  |  | 6,651 |  |  | 7,942 | \nChina | 1,913 |  |  | 1,372 |  |  | 3,628 |  |  | 2,515 | \nAsia Pacific (other than China and Japan) | 848 |  |  | 1,008 |  |  | 1,694 |  |  | 1,938 | \nJapan | 675 |  |  | 1,114 |  |  | 1,434 |  |  | 2,103 | \nLatin America | 742 |  |  | 642 |  |  | 1,403 |  |  | 1,249 | \nOther | 491 |  |  | 637 |  |  | 1,036 |  |  | 1,170 | \n | $ | 15,035 |  |  | $ | 14,593 |  |  | $ | 29,522 |  |  | $ | 30,494 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 9,854 |  |  | $ | 9,173 |  |  | $ | 18,993 |  |  | $ | 18,673 | \nAnimal Health segment | 467 |  |  | 571 |  |  | 1,032 |  |  | 1,156 | \nTotal segment profits | 10,321 |  |  | 9,744 |  |  | 20,025 |  |  | 19,829 | \nOther profits | 19 |  |  | 260 |  |  | 184 |  |  | 454 | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 109 |  |  | 15 |  |  | 221 |  |  | 22 | \nInterest expense | (277) |  |  | (240) |  |  | (519) |  |  | (483) | \nAmortization | (477) |  |  | (463) |  |  | (1,020) |  |  | (1,163) | \nDepreciation | (376) |  |  | (431) |  |  | (775) |  |  | (809) | \nResearch and development | (13,194) |  |  | (2,652) |  |  | (17,341) |  |  | (5,097) | \nRestructuring costs | (151) |  |  | (142) |  |  | (218) |  |  | (194) | \nCharge for Zetia antitrust litigation settlements | \u2014 |  |  | \u2014 |  |  | (573) |  |  | \u2014 | \nOther unallocated, net | (1,309) |  |  | (1,604) |  |  | (1,669) |  |  | (3,211) | \n | $ | (5,335) |  |  | $ | 4,487 |  |  | $ | (1,685) |  |  | $ | 9,348 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nUnited States | $ | 7,018 |  |  | $ | 6,238 |  |  | 12 | % |  | 12 | % |  | $ | 13,676 |  |  | $ | 13,577 |  |  | 1 | % |  | 1 | %\nInternational | 8,018 |  |  | 8,355 |  |  | (4) | % |  | 2 | % |  | 15,846 |  |  | 16,917 |  |  | (6) | % |  | \u2014 | %\nTotal | $ | 15,035 |  |  | $ | 14,593 |  |  | 3 | % |  | 7 | % |  | $ | 29,522 |  |  | $ | 30,494 |  |  | (3) | % |  | \u2014 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nKeytruda | $ | 6,271 |  |  | $ | 5,252 |  |  | 19 | % |  | 21 | % |  | $ | 12,065 |  |  | $ | 10,061 |  |  | 20 | % |  | 23 | %\nAlliance Revenue - Lynparza(1) | 310 |  |  | 275 |  |  | 13 | % |  | 15 | % |  | 585 |  |  | 541 |  |  | 8 | % |  | 12 | %\nAlliance Revenue-Lenvima(1) | 242 |  |  | 231 |  |  | 5 | % |  | 6 | % |  | 474 |  |  | 459 |  |  | 3 | % |  | 5 | %\nWelireg | 50 |  |  | 27 |  |  | 89 | % |  | 89 | % |  | 92 |  |  | 45 |  |  | * |  | *\nAlliance Revenue-Reblozyl(2) | 47 |  |  | 33 |  |  | 41 | % |  | 41 | % |  | 90 |  |  | 86 |  |  | 4 | % |  | 4 | %  |  |  |  |  | \nDate | Approval\nJanuary 2023 | U.S. Food and Drug Administration (FDA) approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a \u22654 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.\nMarch 2023 | FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials.\nApril 2023 | FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas.\nJune 2023 | Japan\u2019s Ministry of Health, Labor and Welfare (MHLW) approval for the treatment of patients with relapsed or refractory PMBCL, based on the KEYNOTE-170 and the KEYNOTE-A33 studies.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nGardasil/Gardasil9 | $ | 2,458 |  |  | $ | 1,674 |  |  | 47 | % |  | 53 | % |  | $ | 4,430 |  |  | $ | 3,133 |  |  | 41 | % |  | 48 | %\nProQuad | 222 |  |  | 214 |  |  | 4 | % |  | 4 | % |  | 412 |  |  | 376 |  |  | 10 | % |  | 10 | %\nM-M-RII | 104 |  |  | 103 |  |  | 2 | % |  | 2 | % |  | 207 |  |  | 206 |  |  | \u2014 | % |  | 1 | %\nVarivax | 255 |  |  | 261 |  |  | (2) | % |  | (2) | % |  | 491 |  |  | 465 |  |  | 5 | % |  | 6 | %\nRotaTeq | 131 |  |  | 173 |  |  | (25) | % |  | (24) | % |  | 428 |  |  | 389 |  |  | 10 | % |  | 13 | %\nVaxneuvance | 168 |  |  | 12 |  |  | * |  | * |  | 274 |  |  | 16 |  |  | * |  | *\nPneumovax 23 | 92 |  |  | 153 |  |  | (40) | % |  | (38) | % |  | 188 |  |  | 325 |  |  | (42) | % |  | (39) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nBridion | $ | 502 |  |  | $ | 426 |  |  | 18 | % |  | 19 | % |  | $ | 989 |  |  | $ | 821 |  |  | 21 | % |  | 23 | %\nPrevymis | 143 |  |  | 103 |  |  | 39 | % |  | 42 | % |  | 273 |  |  | 197 |  |  | 39 | % |  | 43 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 68 |  |  | $ | 98 |  |  | (31) | % |  | (31) | % |  | $ | 167 |  |  | $ | 170 |  |  | (2) | % |  | (2) | %\nAdempas | 65 |  |  | 63 |  |  | 3 | % |  | 5 | % |  | 125 |  |  | 124 |  |  | \u2014 | % |  | 5 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nLagevrio | $ | 203 |  |  | $ | 1,177 |  |  | (83) | % |  | (82) | % |  | $ | 595 |  |  | $ | 4,424 |  |  | (87) | % |  | (85) | %\nIsentress/Isentress HD | 136 |  |  | 147 |  |  | (7) | % |  | (4) | % |  | 259 |  |  | 305 |  |  | (15) | % |  | (12) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nJanuvia/Janumet | $ | 864 |  |  | $ | 1,233 |  |  | (30) | % |  | (28) | % |  | $ | 1,744 |  |  | $ | 2,466 |  |  | (29) | % |  | (26) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange |  | Six Months EndedJune 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nLivestock | $ | 807 |  |  | $ | 826 |  |  | (2) | % |  | 2 | % |  | $ | 1,656 |  |  | $ | 1,658 |  |  | \u2014 | % |  | 5 | %\nCompanion Animal | 649 |  |  | 641 |  |  | 1 | % |  | 2 | % |  | 1,291 |  |  | 1,291 |  |  | \u2014 | % |  | 2 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  |  |  | Six Months EndedJune 30, |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  | 2023 |  | 2022 |  | % Change\nCost of sales | $ | 4,024 |  |  | $ | 4,216 |  |  | (5) | % |  | $ | 7,951 |  |  | $ | 9,596 |  |  | (17) | %\nSelling, general and administrative | 2,702 |  |  | 2,512 |  |  | 8 | % |  | 5,182 |  |  | 4,834 |  |  | 7 | %\nResearch and development | 13,321 |  |  | 2,798 |  |  | * |  | 17,597 |  |  | 5,374 |  |  | *\nRestructuring costs | 151 |  |  | 142 |  |  | 6 | % |  | 218 |  |  | 194 |  |  | 12 | %\nOther (income) expense, net | 172 |  |  | 438 |  |  | (61) | % |  | 259 |  |  | 1,148 |  |  | (77) | %\n | $ | 20,370 |  |  | $ | 10,106 |  |  | * |  | $ | 31,207 |  |  | $ | 21,146 |  |  | 48 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nPharmaceutical segment profits | $ | 9,854 |  |  | $ | 9,173 |  |  | $ | 18,993 |  |  | $ | 18,673 | \nAnimal Health segment profits | 467 |  |  | 571 |  |  | 1,032 |  |  | 1,156 | \nOther | (15,656) |  |  | (5,257) |  |  | (21,710) |  |  | (10,481) | \n(Loss) Income Before Taxes | $ | (5,335) |  |  | $ | 4,487 |  |  | $ | (1,685) |  |  | $ | 9,348 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedJune 30, |  | Six Months EndedJune 30,\n($ in millions except per share amounts) | 2023 |  | 2022 |  | 2023 |  | 2022\n(Loss) income before taxes as reported under GAAP | $ | (5,335) |  |  | $ | 4,487 |  |  | $ | (1,685) |  |  | $ | 9,348 | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition- and divestiture-related costs | 498 |  |  | 530 |  |  | 1,088 |  |  | 1,168 | \nRestructuring costs | 236 |  |  | 258 |  |  | 333 |  |  | 384 | \nLoss (income) from investments in equity securities, net | 194 |  |  | 234 |  |  | (235) |  |  | 918 | \nOther items: |  |  |  |  |  |  | \nCharge for Zetia antitrust litigation settlements | \u2014 |  |  | \u2014 |  |  | 573 |  |  | \u2014 | \nNon-GAAP (loss) income before taxes | (4,407) |  |  | 5,509 |  |  | 74 |  |  | 11,818 | \nIncome tax provision as reported under GAAP | 637 |  |  | 538 |  |  | 1,462 |  |  | 1,092 | \nEstimated tax benefit on excluded items(1) | 173 |  |  | 223 |  |  | 261 |  |  | 552 | \nNon-GAAP income tax provision | 810 |  |  | 761 |  |  | 1,723 |  |  | 1,644 | \nNon-GAAP net (loss) income | (5,217) |  |  | 4,748 |  |  | (1,649) |  |  | 10,174 | \nLess: Net income attributable to noncontrolling interests as reported under GAAP | 3 |  |  | 5 |  |  | 7 |  |  | 2 | \nNon-GAAP net (loss) income attributable to Merck\u00a0& Co., Inc. | $ | (5,220) |  |  | $ | 4,743 |  |  | $ | (1,656) |  |  | $ | 10,172 | \nEPS assuming dilution as reported under GAAP(2) | $ | (2.35) |  |  | $ | 1.55 |  |  | $ | (1.24) |  |  | $ | 3.25 | \nEPS difference | 0.29 |  |  | 0.32 |  |  | 0.59 |  |  | 0.76 | \nNon-GAAP EPS assuming dilution(2) | $ | (2.06) |  |  | $ | 1.87 |  |  | $ | (0.65) |  |  | $ | 4.01 |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-0482(2)Non-Small-Cell LungMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)ColorectalHepatocellularMelanomaSmall-Cell LungMK-2140 (zilovertamab vedotin)BladderBreastGastricHematological MalignanciesNon-Small-Cell LungOvarianPancreaticMK-2870(1)(3)Neoplasm MalignantMK-3475KeytrudaAdvanced Solid TumorsProstateMK-3543 (bomedemstat)Myeloproliferative DisordersMK-4280 (favezelimab)(2)Non-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)BladderEsophagealMelanomaRenal CellSmall-Cell LungMK-4830(2)ColorectalEsophagealMelanomaNon-Small-Cell LungOvarianRenal CellSmall-Cell Lung | CancerMK-5684(1)ProstateMK-5890 (boserolimab)(2)Non-Small-Cell LungSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalEndometrialEsophagealHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684A (vibostolimab+pembrolizumab)BiliaryBladderBreastCervicalColorectalEndometrialEsophagealGastricHead and NeckHematological MalignanciesHepatocellularOvarianProstate | CancerMK-7902 Lenvima(1)(2)BiliaryPancreaticProstateSmall-Cell LungDengue Fever Virus VaccineV181HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(5)HypercholesterolemiaMK-0616Nonalcoholic Steatohepatitis (NASH)MK-6024 (efinopegdutide)Pulmonary Arterial HypertensionMK-5475Pulmonary Hypertension Due To Left Heart DiseaseMK-7962 (sotatercept)SchizophreniaMK-8189(6)ThrombosisMK-2060Treatment Resistant DepressionMK-1942Ulcerative ColitisMK-7240  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(7)CancerMK-1026 (nemtabrutinib)Hematological Malignancies (March 2023)MK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaCutaneous Squamous Cell (August 2019) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Small-Cell Lung (May 2017)MK-3475A (pembrolizumab+hyaluronidase subcutaneous)Non-Small-Cell Lung (February 2023)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)Hematological Malignancies (October 2022)MK-6482Welireg(3)Renal Cell (February 2020)MK-7119 Tukysa(1)Breast (October 2019)Colorectal (August 2022)MK-7339 Lynparza(2)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Melanoma (January 2023)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Esophageal (July 2021)Gastric (December 2020)Head and Neck (February 2020)Non-Small-Cell Lung (March 2019)V940(1)(2)Melanoma (July 2023)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(5)Pneumococcal Vaccine AdultV116 (July 2022)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021) | New Molecular EntitiesCoughMK-7264 (gefapixant) (U.S.)(8)(EU) | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    Second-Line Hepatocellular Carcinoma(KEYNOTE-394) (U.S.)\u2022    Locally Advanced or Metastatic Merkel Cell Carcinoma(KEYNOTE-913) (U.S.)\u2022    First-Line Advanced or Unresectable Biliary Tract Cancer(KEYNOTE-966) (U.S.) (EU) (JPN)\u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer(KEYNOTE-859) (U.S.) (EU) (JPN)\u2022    Resectable Stage II, IIIA or IIIB NSCLC(KEYNOTE-671) (U.S.) (EU)\u2022    Adjuvant Non-Small-Cell Lung Cancer(KEYNOTE-091) (EU)\u2022    Metastatic HER2+ Gastric Cancer(KEYNOTE-811) (EU)MK-7339 Lynparza(1)\u2022    First-Line Metastatic Prostate Cancer(PROpel) (JPN)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)On FDA partial clinical hold for higher doses than those used in current clinical trials.(6)Phase 2b development costs are being co-funded.(7)Available in the U.S. under Emergency Use Authorization.(8)In July 2023, the FDA accepted Merck\u2019s resubmission of the NDA for gefapixant following the Company\u2019s response to the CRL received in January 2022.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | June 30, 2023 |  | December 31, 2022\nCash and investments | $ | 7,592 |  |  | $ | 14,207 | \nWorking capital | 6,583 |  |  | 11,483 | \nTotal debt to total liabilities and equity | 35.3 | % |  | 28.1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nApril 1 - April 30 | 376,898 |  |  | $110.51 |  | 376,898 |  |  | $4,856\nMay 1 - May 31 | 907,404 |  |  | $114.76 |  | 907,404 |  |  | $4,752\nJune 1 - June 30 | 1,734,532 |  |  | $110.72 |  | 1,734,532 |  |  | $4,560\nTotal | 3,018,834 |  |  | $111.91 |  | 3,018,834 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  August 7, 2023 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  August 7, 2023 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Merck, in 2023 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  | \n  |  | \n  |  |  |  |  | \n\u2612 | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  |  |  |  |  | \n\u2610 | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n |   |  |  |  |  |  |  |  | \nNew Jersey | 22-1918501\n(State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.)\n | \n126 East Lincoln Avenue\nRahway | New Jersey | 07065\n(Address of principal executive offices) (zip code)  |  |  |  |  |  |  |  | \n | Not Applicable | \n(Former name, former address and former fiscal year, if changed since last report.)  |  |  |  |  |  |  |  | \nSecurities Registered pursuant to Section\u00a012(b) of the Act:\nTitle of each class | Trading Symbol(s) | Name of each exchange on which registered\nCommon Stock ($0.50\u00a0par value) | MRK | New York Stock Exchange\n0.500% Notes due 2024 | MRK 24 | New York Stock Exchange\n1.875% Notes due 2026 | MRK/26 | New York Stock Exchange\n2.500% Notes due 2034 | MRK/34 | New York Stock Exchange\n1.375% Notes due 2036 | MRK 36A | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 | Accelerated filer | \u2610\n |  |  | \nNon-accelerated filer | \u2610 | Smaller reporting company | \u2610\n |  |  | \n |  | Emerging growth company | \u2610  |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page No.\nPART I | FINANCIAL INFORMATION | 3\n |  | \nItem 1. | Financial Statements | 3\n | Condensed Consolidated Statement of Income | 3\n | Condensed Consolidated Statement of Comprehensive Income | 3\n | Condensed Consolidated Balance Sheet | 4\n | Condensed Consolidated Statement of Cash Flows | 5\n | Notes to Condensed Consolidated Financial Statements | 6\n |  | \nItem 2. | Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations | 31\n |  | \nItem 3. | Quantitative and Qualitative Disclosures about Market Risk | 45\n |  | \nItem 4. | Controls and Procedures | 45\n |  | \n | Cautionary Factors That May Affect Future Results | 45\n |  | \nPART II | OTHER INFORMATION | 46\n |  | \nItem 1. | Legal Proceedings | 46\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 46\n |  |  |  | \nItem 5. | Other Information | 46\n |  |  |  | \nItem 6. | Exhibits | 47\n |  | \n | Signatures |  |  | 48  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nSales | $ | 15,962 |  |  | $ | 14,959 |  |  | $ | 45,485 |  |  | $ | 45,453 | \nCosts, Expenses and Other |  |  |  |  |  |  | \nCost of sales | 4,264 |  |  | 3,934 |  |  | 12,214 |  |  | 13,530 | \nSelling, general and administrative | 2,519 |  |  | 2,520 |  |  | 7,700 |  |  | 7,355 | \nResearch and development | 3,307 |  |  | 4,399 |  |  | 20,904 |  |  | 9,773 | \nRestructuring costs | 126 |  |  | 94 |  |  | 344 |  |  | 288 | \nOther (income) expense, net | 126 |  |  | 429 |  |  | 388 |  |  | 1,576 | \n | 10,342 |  |  | 11,376 |  |  | 41,550 |  |  | 32,522 | \nIncome Before Taxes | 5,620 |  |  | 3,583 |  |  | 3,935 |  |  | 12,931 | \nTaxes on Income | 870 |  |  | 330 |  |  | 2,332 |  |  | 1,423 | \nNet Income | 4,750 |  |  | 3,253 |  |  | 1,603 |  |  | 11,508 | \nLess: Net Income Attributable to Noncontrolling Interests | 5 |  |  | 5 |  |  | 12 |  |  | 6 | \nNet Income Attributable to Merck & Co., Inc. | $ | 4,745 |  |  | $ | 3,248 |  |  | $ | 1,591 |  |  | $ | 11,502 | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.87 |  |  | $ | 1.28 |  |  | $ | 0.63 |  |  | $ | 4.55 | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.86 |  |  | $ | 1.28 |  |  | $ | 0.62 |  |  | $ | 4.53 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,745 |  |  | $ | 3,248 |  |  | $ | 1,591 |  |  | $ | 11,502 | \nOther Comprehensive Loss Net of Taxes: |  |  |  |  |  |  | \nNet unrealized gain on derivatives, net of reclassifications | 159 |  |  | 338 |  |  | 171 |  |  | 584 | \nBenefit plan net (loss) gain and prior service (cost) credit, net of amortization | \u2014 |  |  | (186) |  |  | (75) |  |  | 92 | \nCumulative translation adjustment | (175) |  |  | (568) |  |  | (244) |  |  | (990) | \n | (16) |  |  | (416) |  |  | (148) |  |  | (314) | \nComprehensive Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,729 |  |  | $ | 2,832 |  |  | $ | 1,443 |  |  | $ | 11,188 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nAssets |  |  | \nCurrent Assets |  |  | \nCash and cash equivalents | $ | 8,605 |  |  | $ | 12,694 | \nShort-term investments | 168 |  |  | 498 | \nAccounts receivable (net of allowance for doubtful accounts of $85in 2023and $72in 2022) | 10,394 |  |  | 9,450 | \nInventories (excludes inventories of $3,151in 2023 and $2,938in 2022classified in Other assets - see Note\u00a07) | 6,131 |  |  | 5,911 | \nOther current assets | 6,656 |  |  | 7,169 | \nTotal current assets | 31,954 |  |  | 35,722 | \nInvestments | 1,306 |  |  | 1,015 | \nProperty, Plant and Equipment, at cost, net of accumulated depreciation of $18,446in 2023 and $17,985in 2022 | 22,526 |  |  | 21,422 | \nGoodwill | 21,183 |  |  | 21,204 | \nOther Intangibles, Net | 19,199 |  |  | 20,269 | \nOther Assets | 10,559 |  |  | 9,528 | \n | $ | 106,727 |  |  | $ | 109,160 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nLoans payable and current portion of long-term debt | $ | 887 |  |  | $ | 1,946 | \nTrade accounts payable | 3,509 |  |  | 4,264 | \nAccrued and other current liabilities | 14,840 |  |  | 14,159 | \nIncome taxes payable | 1,981 |  |  | 1,986 | \nDividends payable | 1,877 |  |  | 1,884 | \nTotal current liabilities | 23,094 |  |  | 24,239 | \nLong-Term Debt | 33,972 |  |  | 28,745 | \nDeferred Income Taxes | 1,018 |  |  | 1,795 | \nOther Noncurrent Liabilities | 7,343 |  |  | 8,323 | \nMerck\u00a0& Co., Inc. Stockholders\u2019 Equity |  |  | \nCommon stock, $0.50par valueAuthorized -6,500,000,000sharesIssued -3,577,103,522shares in 2023 and 2022 | 1,788 |  |  | 1,788 | \nOther paid-in capital | 44,358 |  |  | 44,379 | \nRetained earnings | 57,082 |  |  | 61,081 | \nAccumulated other comprehensive loss | (4,916) |  |  | (4,768) | \n | 98,312 |  |  | 102,480 | \nLess treasury stock, at cost:1,041,809,729shares in 2023 and1,039,269,638shares in 2022 | 57,066 |  |  | 56,489 | \nTotal Merck\u00a0& Co., Inc. stockholders\u2019 equity | 41,246 |  |  | 45,991 | \nNoncontrolling Interests | 54 |  |  | 67 | \nTotal equity | 41,300 |  |  | 46,058 | \n | $ | 106,727 |  |  | $ | 109,160 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months EndedSeptember 30,\n | 2023 |  | 2022\nCash Flows from Operating Activities |  |  | \nNet income | $ | 1,603 |  |  | $ | 11,508 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nAmortization | 1,582 |  |  | 1,623 | \nDepreciation | 1,326 |  |  | 1,394 | \nIntangible asset impairment charges | 13 |  |  | 910 | \n(Income) loss from investments in equity securities, net | (240) |  |  | 1,361 | \nCharge for the acquisition of Prometheus Biosciences, Inc. | 10,217 |  |  | \u2014 | \nCharge for the acquisition of Imago BioSciences, Inc. | 1,192 |  |  | \u2014 | \nDeferred income taxes | (968) |  |  | (1,261) | \nShare-based compensation | 478 |  |  | 396 | \nOther | (94) |  |  | 1,169 | \nNet changes in assets and liabilities | (2,349) |  |  | (2,435) | \nNet Cash Provided by Operating Activities | 12,760 |  |  | 14,665 | \nCash Flows from Investing Activities |  |  | \nCapital expenditures | (2,874) |  |  | (3,239) | \nPurchases of securities and other investments | (704) |  |  | (710) | \nProceeds from sales of securities and other investments | 1,489 |  |  | 709 | \nAcquisition of Prometheus Biosciences, Inc., net of cash acquired | (10,705) |  |  | \u2014 | \nAcquisition of Imago BioSciences, Inc., net of cash acquired | (1,327) |  |  | \u2014 | \nOther acquisitions, net of cash acquired | \u2014 |  |  | (121) | \nOther | (15) |  |  | 149 | \nNet Cash Used in Investing Activities | (14,136) |  |  | (3,212) | \nCash Flows from Financing Activities |  |  | \n |  |  | \nProceeds from issuance of debt | 5,939 |  |  | \u2014 | \nPayments on debt | (1,752) |  |  | (2,250) | \nPurchases of treasury stock | (953) |  |  | \u2014 | \nDividends paid to stockholders | (5,593) |  |  | (5,262) | \nProceeds from exercise of stock options | 119 |  |  | 119 | \nOther | (325) |  |  | (172) | \nNet Cash Used in Financing Activities | (2,565) |  |  | (7,565) | \nEffect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (163) |  |  | (776) | \nNet (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash | (4,104) |  |  | 3,112 | \nCash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of$79and $71at January 1, 2023 and 2022, respectively, included inOther current assets) | 12,773 |  |  | 8,167 | \nCash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $64and $134at September\u00a030, 2023 and 2022, respectively, included inOther current assets) | $ | 8,669 |  |  | $ | 11,279 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Lynparza | $ | 299 |  |  | $ | 284 |  |  | $ | 884 |  |  | $ | 825 | \nAlliance revenue - Koselugo | 26 |  |  | 10 |  |  | 74 |  |  | 43 | \nTotal alliance revenue | $ | 325 |  |  | $ | 294 |  |  | $ | 958 |  |  | $ | 868 | \n |  |  |  |  |  |  | \nCost of sales(1) | 82 |  |  | 64 |  |  | 230 |  |  | 425 | \nSelling, general and administrative | 44 |  |  | 45 |  |  | 143 |  |  | 135 | \nResearch and development | 23 |  |  | 28 |  |  | 65 |  |  | 79 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | September 30, 2023 |  | December 31, 2022\nReceivables from AstraZeneca included inOther current assets |  |  |  |  | $ | 337 |  |  | $ | 303 | \nPayables to AstraZeneca included inAccrued and other current liabilities(2) |  |  |  |  | 257 |  |  | 123 | \nPayables to AstraZeneca included inOther Noncurrent Liabilities(2) |  |  |  |  | 600 |  |  | 600 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Lenvima | $ | 260 |  |  | $ | 202 |  |  | $ | 734 |  |  | $ | 660 | \n |  |  |  |  |  |  | \nCost of sales(1) | 137 |  |  | 53 |  |  | 320 |  |  | 159 | \nSelling, general and administrative | 46 |  |  | 42 |  |  | 145 |  |  | 115 | \nResearch and development | 5 |  |  | 24 |  |  | 61 |  |  | 128 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | September 30, 2023 |  | December 31, 2022\nReceivables from Eisai included inOther current assets |  |  |  |  | $ | 260 |  |  | $ | 214 | \nPayables to Eisai included inAccrued and other current liabilities(2) |  |  |  |  | 125 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nAlliance revenue - Adempas/Verquvo | $ | 92 |  |  | $ | 88 |  |  | $ | 259 |  |  | $ | 258 | \nNet sales of Adempas recorded by Merck | 65 |  |  | 57 |  |  | 189 |  |  | 181 | \nNet sales of Verquvo recorded by Merck | 8 |  |  | 6 |  |  | 24 |  |  | 15 | \nTotal sales | $ | 165 |  |  | $ | 151 |  |  | $ | 472 |  |  | $ | 454 | \n |  |  |  |  |  |  | \nCost of sales(1) | 53 |  |  | 55 |  |  | 165 |  |  | 158 | \nSelling, general and administrative | 33 |  |  | 42 |  |  | 100 |  |  | 107 | \nResearch and development | 26 |  |  | 18 |  |  | 76 |  |  | 52 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | September 30, 2023 |  | December 31, 2022\nReceivables from Bayer included inOther current assets |  |  |  |  | $ | 157 |  |  | $ | 143 | \nPayables to Bayer included inAccrued and other current liabilities |  |  |  |  | 82 |  |  | 80 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet sales ofLagevriorecorded by Merck | $ | 640 |  |  | $ | 436 |  |  | $ | 1,236 |  |  | $ | 4,859 | \n |  |  |  |  |  |  | \nCost of sales(1)(2) | 348 |  |  | 244 |  |  | 762 |  |  | 2,586 | \nSelling, general and administrative(2) | 21 |  |  | 48 |  |  | 72 |  |  | 117 | \nResearch and development(2) | 8 |  |  | 18 |  |  | 33 |  |  | 74 | \n |  |  |  |  |  |  | \n($ in millions) |  |  |  |  | September 30, 2023 |  | December 31, 2022\nPayables to Ridgeback included inAccrued and other current liabilities(3) |  |  |  |  | $ | 242 |  |  | $ | 348 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, 2023 |  | Nine Months Ended September 30, 2023\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 31 |  |  | $ | 2 |  |  | $ | 33 |  |  | $ | \u2014 |  |  | $ | 74 |  |  | $ | 20 |  |  | $ | 94 | \nSelling, general and administrative | \u2014 |  |  | 5 |  |  | 35 |  |  | 40 |  |  | \u2014 |  |  | 5 |  |  | 88 |  |  | 93 | \nResearch and development | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 | \nRestructuring costs | 95 |  |  | \u2014 |  |  | 31 |  |  | 126 |  |  | 246 |  |  | \u2014 |  |  | 98 |  |  | 344 | \n | $ | 95 |  |  | $ | 36 |  |  | $ | 68 |  |  | $ | 199 |  |  | $ | 246 |  |  | $ | 79 |  |  | $ | 207 |  |  | $ | 532 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, 2022 |  | Nine Months Ended September 30, 2022\n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total |  | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nCost of sales | $ | \u2014 |  |  | $ | 16 |  |  | $ | 38 |  |  | $ | 54 |  |  | $ | \u2014 |  |  | $ | 51 |  |  | $ | 116 |  |  | $ | 167 | \nSelling, general and administrative | \u2014 |  |  | 5 |  |  | 21 |  |  | 26 |  |  | \u2014 |  |  | 17 |  |  | 57 |  |  | 74 | \nResearch and development | \u2014 |  |  | \u2014 |  |  | 1 |  |  | 1 |  |  | \u2014 |  |  | 29 |  |  | 1 |  |  | 30 | \nRestructuring costs | 65 |  |  | \u2014 |  |  | 29 |  |  | 94 |  |  | 197 |  |  | \u2014 |  |  | 91 |  |  | 288 | \n | $ | 65 |  |  | $ | 21 |  |  | $ | 89 |  |  | $ | 175 |  |  | $ | 197 |  |  | $ | 97 |  |  | $ | 265 |  |  | $ | 559 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | SeparationCosts |  | AcceleratedDepreciation |  | Other |  | Total\nRestructuring reserves January\u00a01, 2023 | $ | 479 |  |  | $ | \u2014 |  |  | $ | 34 |  |  | $ | 513 | \nExpenses | 246 |  |  | 79 |  |  | 207 |  |  | 532 | \n(Payments) receipts, net | (191) |  |  | \u2014 |  |  | (103) |  |  | (294) | \nNon-cash activity | \u2014 |  |  | (79) |  |  | (105) |  |  | (184) | \nRestructuring reserves September\u00a030, 2023(1) | $ | 534 |  |  | $ | \u2014 |  |  | $ | 33 |  |  | $ | 567 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income(1) |  | Amount of Pretax (Gain) Loss Recognized inOther (income) expense, netfor Amounts Excluded from Effectiveness Testing\n | Three Months Ended September 30, |  | Nine Months Ended September 30, |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nNet Investment Hedging Relationships |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | $ | (1) |  |  | $ | (1) |  |  | $ | \u2014 |  |  | $ | (47) |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 1 |  |  | $ | (2) | \nEuro-denominated notes | (100) |  |  | (250) |  |  | (26) |  |  | (431) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023\n($ in millions) | Par Value of Debt |  | Number of Interest Rate Swaps Held |  | Total Swap Notional Amount\n4.50% notes due 2033 | $ | 1,500 |  |  | 3 |  |  | $ | 750 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Carrying Amount of Hedged Liabilities |  | Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount\n($ in millions) | September 30, 2023 |  | December 31, 2022 |  | September 30, 2023 |  | December 31, 2022\nBalance Sheet Line Item in which Hedged Item is Included |  |  |  |  |  |  | \nLong-Term Debt | $ | 743 |  |  | $ | \u2014 |  |  | $ | (7) |  |  | $ | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  | September 30, 2023 |  | December 31, 2022\n |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional |  | Fair\u00a0Value\u00a0of\u00a0Derivative |  | U.S.\u00a0DollarNotional\n($ in millions) |  | Asset |  | Liability |  | Asset |  | Liability | \nDerivatives Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts | Other Noncurrent Liabilities | $ | \u2014 |  |  | $ | 8 |  |  | $ | 750 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nForeign exchange contracts | Other current assets | 321 |  |  | \u2014 |  |  | 8,059 |  |  | 220 |  |  | \u2014 |  |  | 4,824 | \nForeign exchange contracts | Other Assets | 51 |  |  | \u2014 |  |  | 1,746 |  |  | 27 |  |  | \u2014 |  |  | 1,609 | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 4 |  |  | 680 |  |  | \u2014 |  |  | 101 |  |  | 2,691 | \nForeign exchange contracts | Other Noncurrent Liabilities | \u2014 |  |  | 1 |  |  | 178 |  |  | \u2014 |  |  | 1 |  |  | 91 | \n |  | $ | 372 |  |  | $ | 13 |  |  | $ | 11,413 |  |  | $ | 247 |  |  | $ | 102 |  |  | $ | 9,215 | \nDerivatives Not Designated as Hedging Instruments | Balance Sheet Caption |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Other current assets | $ | 229 |  |  | $ | \u2014 |  |  | $ | 8,485 |  |  | $ | 186 |  |  | $ | \u2014 |  |  | $ | 8,540 | \n |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts | Accrued and other current liabilities | \u2014 |  |  | 163 |  |  | 9,910 |  |  | \u2014 |  |  | 307 |  |  | 10,926 | \n |  |  |  |  |  |  |  |  |  |  |  | \n |  | $ | 229 |  |  | $ | 163 |  |  | $ | 18,395 |  |  | $ | 186 |  |  | $ | 307 |  |  | $ | 19,466 | \n |  | $ | 601 |  |  | $ | 176 |  |  | $ | 29,808 |  |  | $ | 433 |  |  | $ | 409 |  |  | $ | 28,681 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\n($ in millions) | Asset |  | Liability |  | Asset |  | Liability\nGross amounts recognized in the condensed consolidated balance sheet | $ | 601 |  |  | $ | 176 |  |  | $ | 433 |  |  | $ | 409 | \nGross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet | (138) |  |  | (138) |  |  | (220) |  |  | (220) | \nCash collateral received/posted | (143) |  |  | \u2014 |  |  | (66) |  |  | (19) | \nNet amounts | $ | 320 |  |  | $ | 38 |  |  | $ | 147 |  |  | $ | 170 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022\nFinancial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss) |  | Sales |  | Other (income) expense, net(1) |  | Other comprehensive income (loss)\n | $ | 15,962 |  |  | $ | 14,959 |  |  | $ | 126 |  |  | $ | 429 |  |  | $ | (16) |  |  | $ | (416) |  |  | $ | 45,485 |  |  | $ | 45,453 |  |  | $ | 388 |  |  | $ | 1,576 |  |  | $ | (148) |  |  | $ | (314) | \n(Gain) loss on fair value hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInterest rate swap contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nHedged items | \u2014 |  |  | \u2014 |  |  | (7) |  |  | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (7) |  |  | (13) |  |  | \u2014 |  |  | \u2014 | \nDerivatives designated as hedging instruments | \u2014 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 8 |  |  | 4 |  |  | \u2014 |  |  | \u2014 | \nImpact of cash flow hedging relationships: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 247 |  |  | 682 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 375 |  |  | 1,233 | \nIncrease inSalesas a result ofAOCLreclassifications | 45 |  |  | 253 |  |  | \u2014 |  |  | \u2014 |  |  | (45) |  |  | (253) |  |  | 170 |  |  | 491 |  |  | \u2014 |  |  | \u2014 |  |  | (170) |  |  | (491) | \nInterest rate contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAmount of gain recognized inOther (income) expense, neton derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (2) |  |  | \u2014 |  |  | \u2014 | \nAmount of (loss) gain recognized inOCIon derivatives | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 13 |  |  | (2) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Amount of Derivative Pretax (Gain) Loss Recognized in Income\n |  |  | Three Months Ended September 30, |  | Nine Months Ended September 30,\n($ in millions) |  |  | 2023 |  | 2022 |  | 2023 |  | 2022\nDerivatives Not Designated as Hedging Instruments | Income Statement Caption |  |  |  |  |  |  |  | \nForeign exchange contracts(1) | Other (income) expense, net |  | $ | 60 |  |  | $ | (41) |  |  | $ | 32 |  |  | $ | (77) | \nForeign exchange contracts(2) | Sales |  | \u2014 |  |  | (4) |  |  | (3) |  |  | (42) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\n | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue |  | AmortizedCost |  | Gross\u00a0Unrealized |  | FairValue\n($ in millions) | Gains |  | Losses |  | Gains |  | Losses | \nCommercial paper | $ | 168 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 168 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 498 | \nU.S. government and agency securities | 67 |  |  | \u2014 |  |  | \u2014 |  |  | 67 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 12 |  |  | \u2014 |  |  | \u2014 |  |  | 12 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nTotal debt securities | $ | 247 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 247 |  |  | $ | 569 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 569 | \nPublicly traded equity securities(1) |  |  |  |  |  |  | 1,746 |  |  |  |  |  |  |  |  | 1,284 | \nTotal debt and publicly traded equity securities |  |  |  |  |  |  | $ | 1,993 |  |  |  |  |  |  |  |  | $ | 1,853 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Fair Value Measurements Using |  | Fair Value Measurements Using\n | Level 1 |  | Level 2 |  | Level 3 |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |  | Total\n($ in millions) | September 30, 2023 |  | December 31, 2022\nAssets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nInvestments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCommercial paper | $ | \u2014 |  |  | $ | 168 |  |  | $ | \u2014 |  |  | $ | 168 |  |  | $ | \u2014 |  |  | $ | 498 |  |  | $ | \u2014 |  |  | $ | 498 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPublicly traded equity securities | 1,306 |  |  | \u2014 |  |  | \u2014 |  |  | 1,306 |  |  | 1,015 |  |  | \u2014 |  |  | \u2014 |  |  | 1,015 | \n | 1,306 |  |  | 168 |  |  | \u2014 |  |  | 1,474 |  |  | 1,015 |  |  | 498 |  |  | \u2014 |  |  | 1,513 | \nOther assets(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | 67 |  |  | \u2014 |  |  | \u2014 |  |  | 67 |  |  | 68 |  |  | \u2014 |  |  | \u2014 |  |  | 68 | \nCorporate notes and bonds | 12 |  |  | \u2014 |  |  | \u2014 |  |  | 12 |  |  | 3 |  |  | \u2014 |  |  | \u2014 |  |  | 3 | \nPublicly traded equity securities(2) | 440 |  |  | \u2014 |  |  | \u2014 |  |  | 440 |  |  | 269 |  |  | \u2014 |  |  | \u2014 |  |  | 269 | \n | 519 |  |  | \u2014 |  |  | \u2014 |  |  | 519 |  |  | 340 |  |  | \u2014 |  |  | \u2014 |  |  | 340 | \nDerivative assets(3) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 431 |  |  | \u2014 |  |  | 431 |  |  | \u2014 |  |  | 218 |  |  | \u2014 |  |  | 218 | \nPurchased currency options | \u2014 |  |  | 170 |  |  | \u2014 |  |  | 170 |  |  | \u2014 |  |  | 215 |  |  | \u2014 |  |  | 215 | \n | \u2014 |  |  | 601 |  |  | \u2014 |  |  | 601 |  |  | \u2014 |  |  | 433 |  |  | \u2014 |  |  | 433 | \nTotal assets | $ | 1,825 |  |  | $ | 769 |  |  | $ | \u2014 |  |  | $ | 2,594 |  |  | $ | 1,355 |  |  | $ | 931 |  |  | $ | \u2014 |  |  | $ | 2,286 | \nLiabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nContingent consideration | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 345 |  |  | $ | 345 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 456 |  |  | $ | 456 | \nDerivative liabilities(3) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nForward exchange contracts | \u2014 |  |  | 160 |  |  | \u2014 |  |  | 160 |  |  | \u2014 |  |  | 402 |  |  | \u2014 |  |  | 402 | \nWritten currency options | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 7 |  |  | \u2014 |  |  | 7 | \nInterest rate swaps | \u2014 |  |  | 8 |  |  | \u2014 |  |  | 8 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \n | \u2014 |  |  | 176 |  |  | \u2014 |  |  | 176 |  |  | \u2014 |  |  | 409 |  |  | \u2014 |  |  | 409 | \nTotal liabilities | $ | \u2014 |  |  | $ | 176 |  |  | $ | 345 |  |  | $ | 521 |  |  | $ | \u2014 |  |  | $ | 409 |  |  | $ | 456 |  |  | $ | 865 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | 2023 |  | 2022\nFair value January 1 | $ | 456 |  |  | $ | 777 | \nChanges in estimated fair value(1) | 6 |  |  | (156) | \nPayments | (117) |  |  | (119) | \nOther | \u2014 |  |  | (3) | \nFair value September 30(2) | $ | 345 |  |  | $ | 499 |   |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | September 30, 2023 |  | December 31, 2022\nFinished goods | $ | 1,840 |  |  | $ | 1,841 | \nRaw materials and work in process | 7,630 |  |  | 7,063 | \nSupplies | 281 |  |  | 238 | \nTotal | 9,751 |  |  | 9,142 | \nDecrease to LIFO cost | (469) |  |  | (293) | \n | $ | 9,282 |  |  | $ | 8,849 | \nRecognized as: |  |  | \nInventories | $ | 6,131 |  |  | $ | 5,911 | \nOther Assets | 3,151 |  |  | 2,938 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at July 1, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,115 |  | $ | 58,437 |  | $ | (4,327) |  | 1,044 |  | $ | (56,770) |  | $ | 75 |  | $ | 43,318 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 3,248 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 3,248 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (416) |  | \u2014 |  | \u2014 |  | \u2014 |  | (416) | \nCash dividends declared on common stock ($0.69per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,757) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,757) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 128 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | \u2014 |  | 140 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 5 |  | 5 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (14) |  | (14) | \nBalance at September 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,243 |  | $ | 59,928 |  | $ | (4,743) |  | 1,044 |  | $ | (56,758) |  | $ | 66 |  | $ | 44,524 | \nBalance at July 1, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,219 |  | $ | 54,198 |  | $ | (4,900) |  | 1,038 |  | $ | (56,612) |  | $ | 49 |  | $ | 38,742 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 4,745 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4,745 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (16) |  | \u2014 |  | \u2014 |  | \u2014 |  | (16) | \nCash dividends declared on common stock ($0.73per share) | \u2014 |  | \u2014 |  | \u2014 |  | (1,861) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (1,861) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 4 |  | (466) |  | \u2014 |  | (466) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 139 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | \u2014 |  | 151 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 5 |  | 5 | \n |  |  |  |  |  |  |  |  | \nBalance at September 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,358 |  | $ | 57,082 |  | $ | (4,916) |  | 1,042 |  | $ | (57,066) |  | $ | 54 |  | $ | 41,300 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | Common Stock | OtherPaid-InCapital | RetainedEarnings | AccumulatedOtherComprehensiveLoss | Treasury Stock | Non-controllingInterests | Total\n($ and shares in millions except per share amounts) | Shares | Par\u00a0Value | Shares | Cost\nBalance at January\u00a01, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,238 |  | $ | 53,696 |  | $ | (4,429) |  | 1,049 |  | $ | (57,109) |  | $ | 73 |  | $ | 38,257 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 11,502 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 11,502 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (314) |  | \u2014 |  | \u2014 |  | \u2014 |  | (314) | \nCash dividends declared on common stock ($2.07per share) | \u2014 |  | \u2014 |  | \u2014 |  | (5,270) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (5,270) | \n |  |  |  |  |  |  |  |  | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | 5 |  | \u2014 |  | \u2014 |  | (5) |  | 351 |  | \u2014 |  | 356 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 6 |  | 6 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (13) |  | (13) | \nBalance at September 30, 2022 | 3,577 |  | $ | 1,788 |  | $ | 44,243 |  | $ | 59,928 |  | $ | (4,743) |  | 1,044 |  | $ | (56,758) |  | $ | 66 |  | $ | 44,524 | \nBalance at January\u00a01, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,379 |  | $ | 61,081 |  | $ | (4,768) |  | 1,039 |  | $ | (56,489) |  | $ | 67 |  | $ | 46,058 | \nNet income attributable to Merck\u00a0& Co., Inc. | \u2014 |  | \u2014 |  | \u2014 |  | 1,591 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 1,591 | \nOther comprehensive loss, net of taxes | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (148) |  | \u2014 |  | \u2014 |  | \u2014 |  | (148) | \nCash dividends declared on common stock ($2.19per share) | \u2014 |  | \u2014 |  | \u2014 |  | (5,590) |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (5,590) | \nTreasury stock shares purchased | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 9 |  | (953) |  | \u2014 |  | (953) | \nShare-based compensation plans and other | \u2014 |  | \u2014 |  | (21) |  | \u2014 |  | \u2014 |  | (6) |  | 376 |  | \u2014 |  | 355 | \nNet income attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | 12 |  | 12 | \nDistributions attributable to noncontrolling interests | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | \u2014 |  | (25) |  | (25) | \nBalance at September 30, 2023 | 3,577 |  | $ | 1,788 |  | $ | 44,358 |  | $ | 57,082 |  | $ | (4,916) |  | 1,042 |  | $ | (57,066) |  | $ | 54 |  | $ | 41,300 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n($ in millions) | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International |  | U.S. |  | International\nService cost | $ | 88 |  |  | $ | 48 |  |  | $ | 91 |  |  | $ | 66 |  |  | $ | 239 |  |  | $ | 148 |  |  | $ | 289 |  |  | $ | 213 | \nInterest cost | 130 |  |  | 76 |  |  | 123 |  |  | 35 |  |  | 396 |  |  | 225 |  |  | 330 |  |  | 110 | \nExpected return on plan assets | (182) |  |  | (131) |  |  | (182) |  |  | (93) |  |  | (553) |  |  | (390) |  |  | (576) |  |  | (292) | \nAmortization of unrecognized prior service (credit) cost | \u2014 |  |  | (6) |  |  | (8) |  |  | (3) |  |  | (1) |  |  | 5 |  |  | (24) |  |  | (10) | \nNet (gain) loss amortization | \u2014 |  |  | (1) |  |  | 10 |  |  | 24 |  |  | \u2014 |  |  | (2) |  |  | 122 |  |  | 73 | \nTermination benefits | 1 |  |  | \u2014 |  |  | 1 |  |  | \u2014 |  |  | 2 |  |  | \u2014 |  |  | 2 |  |  | 1 | \nCurtailments | \u2014 |  |  | \u2014 |  |  | 3 |  |  | \u2014 |  |  | 5 |  |  | \u2014 |  |  | 11 |  |  | \u2014 | \nSettlements | \u2014 |  |  | \u2014 |  |  | 79 |  |  | \u2014 |  |  | 26 |  |  | \u2014 |  |  | 180 |  |  | \u2014 | \n | $ | 37 |  |  | $ | (14) |  |  | $ | 117 |  |  | $ | 29 |  |  | $ | 114 |  |  | $ | (14) |  |  | $ | 334 |  |  | $ | 95 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nService cost | $ | 8 |  |  | $ | 11 |  |  | $ | 24 |  |  | $ | 36 | \nInterest cost | 16 |  |  | 11 |  |  | 47 |  |  | 34 | \nExpected return on plan assets | (16) |  |  | (21) |  |  | (48) |  |  | (64) | \nAmortization of unrecognized prior service credit | (12) |  |  | (14) |  |  | (37) |  |  | (42) | \nNet gain amortization | (11) |  |  | (11) |  |  | (31) |  |  | (32) | \n |  |  |  |  |  |  | \nCurtailments | \u2014 |  |  | \u2014 |  |  | (1) |  |  | (1) | \n | $ | (15) |  |  | $ | (24) |  |  | $ | (46) |  |  | $ | (69) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest income | $ | (73) |  |  | $ | (40) |  |  | $ | (295) |  |  | $ | (62) | \nInterest expense | 317 |  |  | 244 |  |  | 836 |  |  | 727 | \nExchange losses | 85 |  |  | 96 |  |  | 208 |  |  | 220 | \nLoss (income) from investments in equity securities, net(1) | 33 |  |  | 371 |  |  | (240) |  |  | 1,361 | \nNet periodic defined benefit plan (credit) cost other than service cost | (138) |  |  | (60) |  |  | (364) |  |  | (208) | \nOther, net | (98) |  |  | (182) |  |  | 243 |  |  | (462) | \n | $ | 126 |  |  | $ | 429 |  |  | $ | 388 |  |  | $ | 1,576 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ and shares in millions except per share amounts) | 2023 |  | 2022 |  | 2023 |  | 2022\nNet Income Attributable to Merck\u00a0& Co., Inc. | $ | 4,745 |  |  | $ | 3,248 |  |  | $ | 1,591 |  |  | $ | 11,502 | \nAverage common shares outstanding | 2,537 |  |  | 2,533 |  |  | 2,538 |  |  | 2,531 | \nCommon shares issuable(1) | 9 |  |  | 9 |  |  | 11 |  |  | 9 | \nAverage common shares outstanding assuming dilution | 2,546 |  |  | 2,542 |  |  | 2,549 |  |  | 2,540 | \nBasic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.87 |  |  | $ | 1.28 |  |  | $ | 0.63 |  |  | $ | 4.55 | \nEarnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | 1.86 |  |  | $ | 1.28 |  |  | $ | 0.62 |  |  | $ | 4.53 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance July 1, 2022, net of taxes | $ | 390 |  |  | $ | (2,465) |  |  | $ | (2,252) |  |  | $ | (4,327) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 682 |  |  | (294) |  |  | (618) |  |  | (230) | \nTax | (143) |  |  | 62 |  |  | 50 |  |  | (31) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 539 |  |  | (232) |  |  | (568) |  |  | (261) | \nReclassification adjustments, pretax | (254) |  | (1) | 77 |  | (2) | \u2014 |  |  | (177) | \nTax | 53 |  |  | (31) |  |  | \u2014 |  |  | 22 | \nReclassification adjustments, net of taxes | (201) |  |  | 46 |  |  | \u2014 |  |  | (155) | \nOther comprehensive income (loss), net of taxes | 338 |  |  | (186) |  |  | (568) |  |  | (416) | \nBalance September 30, 2022, net of taxes | $ | 728 |  |  | $ | (2,651) |  |  | $ | (2,820) |  |  | $ | (4,743) | \nBalance July 1, 2023, net of taxes | $ | 85 |  |  | $ | (2,483) |  |  | $ | (2,502) |  |  | $ | (4,900) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 247 |  |  | 29 |  |  | (252) |  |  | 24 | \nTax | (52) |  |  | (7) |  |  | 77 |  |  | 18 | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 195 |  |  | 22 |  |  | (175) |  |  | 42 | \nReclassification adjustments, pretax | (45) |  | (1) | (27) |  | (2) | \u2014 |  |  | (72) | \nTax | 9 |  |  | 5 |  |  | \u2014 |  |  | 14 | \nReclassification adjustments, net of taxes | (36) |  |  | (22) |  |  | \u2014 |  |  | (58) | \nOther comprehensive income (loss), net of taxes | 159 |  |  | \u2014 |  |  | (175) |  |  | (16) | \nBalance September 30, 2023, net of taxes | $ | 244 |  |  | $ | (2,483) |  |  | $ | (2,677) |  |  | $ | (4,916) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n($ in millions) | Derivatives |  | EmployeeBenefitPlans |  | Foreign CurrencyTranslationAdjustment |  | Accumulated OtherComprehensiveLoss\nBalance January 1, 2022, net of taxes | $ | 144 |  |  | $ | (2,743) |  |  | $ | (1,830) |  |  | $ | (4,429) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 1,233 |  |  | (125) |  |  | (1,001) |  |  | 107 | \nTax | (259) |  |  | 25 |  |  | 11 |  |  | (223) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 974 |  |  | (100) |  |  | (990) |  |  | (116) | \nReclassification adjustments, pretax | (493) |  | (1) | 266 |  | (2) | \u2014 |  |  | (227) | \nTax | 103 |  |  | (74) |  |  | \u2014 |  |  | 29 | \nReclassification adjustments, net of taxes | (390) |  |  | 192 |  |  | \u2014 |  |  | (198) | \nOther comprehensive income (loss), net of taxes | 584 |  |  | 92 |  |  | (990) |  |  | (314) | \nBalance September 30, 2022, net of taxes | $ | 728 |  |  | $ | (2,651) |  |  | $ | (2,820) |  |  | $ | (4,743) | \nBalance January 1, 2023, net of taxes | $ | 73 |  |  | $ | (2,408) |  |  | $ | (2,433) |  |  | $ | (4,768) | \nOther comprehensive income (loss) before reclassification adjustments, pretax | 375 |  |  | (24) |  |  | (288) |  |  | 63 | \nTax | (79) |  |  | (4) |  |  | 35 |  |  | (48) | \nOther comprehensive income (loss) before reclassification adjustments, net of taxes | 296 |  |  | (28) |  |  | (253) |  |  | 15 | \nReclassification adjustments, pretax | (158) |  | (1) | (57) |  | (2) | 9 |  |  | (206) | \nTax | 33 |  |  | 10 |  |  | \u2014 |  |  | 43 | \nReclassification adjustments, net of taxes | (125) |  |  | (47) |  |  | 9 |  |  | (163) | \nOther comprehensive income (loss), net of taxes | 171 |  |  | (75) |  |  | (244) |  |  | (148) | \nBalance September 30, 2023, net of taxes | $ | 244 |  |  | $ | (2,483) |  |  | $ | (2,677) |  |  | $ | (4,916) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n($ in millions) | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total |  | U.S. |  | Int\u2019l |  | Total\nPharmaceutical: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nKeytruda | $ | 3,795 |  |  | $ | 2,543 |  |  | $ | 6,338 |  |  | $ | 3,331 |  |  | $ | 2,095 |  |  | $ | 5,426 |  |  | $ | 11,142 |  |  | $ | 7,261 |  |  | $ | 18,403 |  |  | $ | 9,307 |  |  | $ | 6,180 |  |  | $ | 15,487 | \nAlliance revenue-Lynparza(1) | 153 |  |  | 146 |  |  | 299 |  |  | 144 |  |  | 140 |  |  | 284 |  |  | 439 |  |  | 445 |  |  | 884 |  |  | 427 |  |  | 397 |  |  | 825 | \nAlliance revenue-Lenvima(1) | 160 |  |  | 100 |  |  | 260 |  |  | 142 |  |  | 60 |  |  | 202 |  |  | 476 |  |  | 258 |  |  | 734 |  |  | 426 |  |  | 235 |  |  | 660 | \nWelireg | 51 |  |  | 3 |  |  | 54 |  |  | 38 |  |  | \u2014 |  |  | 38 |  |  | 141 |  |  | 6 |  |  | 146 |  |  | 83 |  |  | \u2014 |  |  | 83 | \nAlliance revenue-Reblozyl(2) | 43 |  |  | 10 |  |  | 52 |  |  | 32 |  |  | 7 |  |  | 39 |  |  | 108 |  |  | 33 |  |  | 142 |  |  | 87 |  |  | 37 |  |  | 124 | \nVaccines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nGardasil/Gardasil9 | 838 |  |  | 1,746 |  |  | 2,585 |  |  | 957 |  |  | 1,337 |  |  | 2,294 |  |  | 1,718 |  |  | 5,297 |  |  | 7,015 |  |  | 1,803 |  |  | 3,624 |  |  | 5,428 | \nProQuad/M-M-RII/Varivax | 567 |  |  | 146 |  |  | 713 |  |  | 532 |  |  | 136 |  |  | 668 |  |  | 1,435 |  |  | 388 |  |  | 1,823 |  |  | 1,337 |  |  | 379 |  |  | 1,716 | \nRotaTeq | 108 |  |  | 48 |  |  | 156 |  |  | 154 |  |  | 102 |  |  | 256 |  |  | 381 |  |  | 203 |  |  | 584 |  |  | 427 |  |  | 218 |  |  | 644 | \nVaxneuvance | 182 |  |  | 33 |  |  | 214 |  |  | 15 |  |  | 1 |  |  | 16 |  |  | 423 |  |  | 65 |  |  | 488 |  |  | 31 |  |  | 1 |  |  | 32 | \nPneumovax23 | 42 |  |  | 98 |  |  | 140 |  |  | 68 |  |  | 63 |  |  | 131 |  |  | 105 |  |  | 223 |  |  | 327 |  |  | 280 |  |  | 177 |  |  | 457 | \nVaqta | 32 |  |  | 37 |  |  | 69 |  |  | 27 |  |  | 36 |  |  | 64 |  |  | 91 |  |  | 60 |  |  | 151 |  |  | 72 |  |  | 62 |  |  | 134 | \nHospital Acute Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBridion | 265 |  |  | 159 |  |  | 424 |  |  | 233 |  |  | 190 |  |  | 423 |  |  | 841 |  |  | 572 |  |  | 1,413 |  |  | 665 |  |  | 579 |  |  | 1,244 | \nPrevymis | 70 |  |  | 87 |  |  | 157 |  |  | 49 |  |  | 64 |  |  | 114 |  |  | 186 |  |  | 244 |  |  | 430 |  |  | 136 |  |  | 174 |  |  | 310 | \nDificid | 69 |  |  | 5 |  |  | 74 |  |  | 72 |  |  | 6 |  |  | 77 |  |  | 199 |  |  | 16 |  |  | 215 |  |  | 184 |  |  | 12 |  |  | 196 | \nPrimaxin | \u2014 |  |  | 41 |  |  | 41 |  |  | \u2014 |  |  | 63 |  |  | 63 |  |  | 2 |  |  | 173 |  |  | 174 |  |  | 1 |  |  | 185 |  |  | 185 | \nNoxafil | 4 |  |  | 47 |  |  | 51 |  |  | 13 |  |  | 49 |  |  | 62 |  |  | 29 |  |  | 138 |  |  | 167 |  |  | 39 |  |  | 141 |  |  | 180 | \nZerbaxa | 29 |  |  | 24 |  |  | 53 |  |  | 24 |  |  | 19 |  |  | 43 |  |  | 86 |  |  | 71 |  |  | 157 |  |  | 64 |  |  | 55 |  |  | 120 | \nCardiovascular |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nAlliance revenue-Adempas/Verquvo(3) | 96 |  |  | (4) |  |  | 92 |  |  | 85 |  |  | 3 |  |  | 88 |  |  | 249 |  |  | 10 |  |  | 259 |  |  | 244 |  |  | 14 |  |  | 258 | \nAdempas | \u2014 |  |  | 65 |  |  | 65 |  |  | \u2014 |  |  | 57 |  |  | 57 |  |  | \u2014 |  |  | 189 |  |  | 189 |  |  | \u2014 |  |  | 181 |  |  | 181 | \nVirology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLagevrio | \u2014 |  |  | 640 |  |  | 640 |  |  | \u2014 |  |  | 436 |  |  | 436 |  |  | \u2014 |  |  | 1,236 |  |  | 1,236 |  |  | 1,523 |  |  | 3,336 |  |  | 4,859 | \nIsentress/IsentressHD | 58 |  |  | 61 |  |  | 119 |  |  | 68 |  |  | 93 |  |  | 161 |  |  | 165 |  |  | 212 |  |  | 377 |  |  | 196 |  |  | 270 |  |  | 466 | \nNeuroscience |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBelsomra | 23 |  |  | 35 |  |  | 58 |  |  | 20 |  |  | 42 |  |  | 62 |  |  | 60 |  |  | 117 |  |  | 176 |  |  | 60 |  |  | 139 |  |  | 199 | \nImmunology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSimponi | \u2014 |  |  | 179 |  |  | 179 |  |  | \u2014 |  |  | 173 |  |  | 173 |  |  | \u2014 |  |  | 539 |  |  | 539 |  |  | \u2014 |  |  | 540 |  |  | 540 | \nRemicade | \u2014 |  |  | 45 |  |  | 45 |  |  | \u2014 |  |  | 49 |  |  | 49 |  |  | \u2014 |  |  | 144 |  |  | 144 |  |  | \u2014 |  |  | 163 |  |  | 163 | \nDiabetes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJanuvia | 328 |  |  | 252 |  |  | 581 |  |  | 332 |  |  | 385 |  |  | 717 |  |  | 842 |  |  | 800 |  |  | 1,642 |  |  | 958 |  |  | 1,294 |  |  | 2,252 | \nJanumet | 43 |  |  | 211 |  |  | 255 |  |  | 90 |  |  | 327 |  |  | 417 |  |  | 182 |  |  | 755 |  |  | 937 |  |  | 258 |  |  | 1,089 |  |  | 1,347 | \nOther pharmaceutical(4) | 197 |  |  | 353 |  |  | 549 |  |  | 194 |  |  | 410 |  |  | 603 |  |  | 540 |  |  | 1,147 |  |  | 1,690 |  |  | 511 |  |  | 1,225 |  |  | 1,736 | \nTotal Pharmaceutical segment sales | 7,153 |  |  | 7,110 |  |  | 14,263 |  |  | 6,620 |  |  | 6,343 |  |  | 12,963 |  |  | 19,840 |  |  | 20,602 |  |  | 40,442 |  |  | 19,119 |  |  | 20,707 |  |  | 39,826 | \nAnimal Health: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLivestock | 205 |  |  | 669 |  |  | 874 |  |  | 186 |  |  | 643 |  |  | 829 |  |  | 543 |  |  | 1,987 |  |  | 2,530 |  |  | 521 |  |  | 1,965 |  |  | 2,486 | \nCompanion Animal | 257 |  |  | 269 |  |  | 526 |  |  | 289 |  |  | 253 |  |  | 542 |  |  | 875 |  |  | 942 |  |  | 1,817 |  |  | 904 |  |  | 929 |  |  | 1,834 | \nTotal Animal Health segment sales | 462 |  |  | 938 |  |  | 1,400 |  |  | 475 |  |  | 896 |  |  | 1,371 |  |  | 1,418 |  |  | 2,929 |  |  | 4,347 |  |  | 1,425 |  |  | 2,894 |  |  | 4,320 | \nTotal segment sales | 7,615 |  |  | 8,048 |  |  | 15,663 |  |  | 7,095 |  |  | 7,239 |  |  | 14,334 |  |  | 21,258 |  |  | 23,531 |  |  | 44,789 |  |  | 20,544 |  |  | 23,601 |  |  | 44,146 | \nOther(5) | 100 |  |  | 199 |  |  | 299 |  |  | 227 |  |  | 398 |  |  | 625 |  |  | 135 |  |  | 561 |  |  | 696 |  |  | 383 |  |  | 925 |  |  | 1,307 | \n | $ | 7,715 |  |  | $ | 8,247 |  |  | $ | 15,962 |  |  | $ | 7,322 |  |  | $ | 7,637 |  |  | $ | 14,959 |  |  | $ | 21,393 |  |  | $ | 24,092 |  |  | $ | 45,485 |  |  | $ | 20,927 |  |  | $ | 24,526 |  |  | $ | 45,453 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nUnited States | $ | 7,715 |  |  | $ | 7,322 |  |  | $ | 21,393 |  |  | $ | 20,927 | \nEurope, Middle East and Africa | 3,327 |  |  | 3,286 |  |  | 9,978 |  |  | 11,228 | \nChina | 1,694 |  |  | 1,442 |  |  | 5,322 |  |  | 3,957 | \nJapan | 1,081 |  |  | 673 |  |  | 2,514 |  |  | 2,776 | \nAsia Pacific (other than China and Japan) | 781 |  |  | 854 |  |  | 2,475 |  |  | 2,792 | \nLatin America | 895 |  |  | 684 |  |  | 2,298 |  |  | 1,933 | \nOther | 469 |  |  | 698 |  |  | 1,505 |  |  | 1,840 | \n | $ | 15,962 |  |  | $ | 14,959 |  |  | $ | 45,485 |  |  | $ | 45,453 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nSegment profits: |  |  |  |  |  |  | \nPharmaceutical segment | $ | 10,407 |  |  | $ | 9,590 |  |  | $ | 29,400 |  |  | $ | 28,263 | \nAnimal Health segment | 421 |  |  | 515 |  |  | 1,453 |  |  | 1,672 | \nTotal segment profits | 10,828 |  |  | 10,105 |  |  | 30,853 |  |  | 29,935 | \nOther profits | 190 |  |  | 377 |  |  | 374 |  |  | 831 | \nUnallocated: |  |  |  |  |  |  | \nInterest income | 73 |  |  | 40 |  |  | 295 |  |  | 62 | \nInterest expense | (317) |  |  | (244) |  |  | (836) |  |  | (727) | \nAmortization | (562) |  |  | (460) |  |  | (1,582) |  |  | (1,623) | \nDepreciation | (401) |  |  | (448) |  |  | (1,175) |  |  | (1,257) | \nResearch and development | (3,183) |  |  | (4,277) |  |  | (20,523) |  |  | (9,374) | \nRestructuring costs | (126) |  |  | (94) |  |  | (344) |  |  | (288) | \nCharge for Zetia antitrust litigation settlements | \u2014 |  |  | \u2014 |  |  | (573) |  |  | \u2014 | \nOther unallocated, net | (882) |  |  | (1,416) |  |  | (2,554) |  |  | (4,628) | \n | $ | 5,620 |  |  | $ | 3,583 |  |  | $ | 3,935 |  |  | $ | 12,931 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nUnited States | $ | 7,715 |  |  | $ | 7,322 |  |  | 5 | % |  | 5 | % |  | $ | 21,393 |  |  | $ | 20,927 |  |  | 2 | % |  | 2 | %\nInternational | 8,247 |  |  | 7,637 |  |  | 8 | % |  | 12 | % |  | 24,092 |  |  | 24,526 |  |  | (2) | % |  | 4 | %\nTotal | $ | 15,962 |  |  | $ | 14,959 |  |  | 7 | % |  | 9 | % |  | $ | 45,485 |  |  | $ | 45,453 |  |  | \u2014 | % |  | 3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nKeytruda | $ | 6,338 |  |  | $ | 5,426 |  |  | 17 | % |  | 17 | % |  | $ | 18,403 |  |  | $ | 15,487 |  |  | 19 | % |  | 21 | %\nAlliance Revenue - Lynparza(1) | 299 |  |  | 284 |  |  | 5 | % |  | 6 | % |  | 884 |  |  | 825 |  |  | 7 | % |  | 10 | %\nAlliance Revenue-Lenvima(1) | 260 |  |  | 202 |  |  | 29 | % |  | 30 | % |  | 734 |  |  | 660 |  |  | 11 | % |  | 13 | %\nWelireg | 54 |  |  | 38 |  |  | 43 | % |  | 43 | % |  | 146 |  |  | 83 |  |  | 77 | % |  | 77 | %\nAlliance Revenue-Reblozyl(2) | 52 |  |  | 39 |  |  | 35 | % |  | 35 | % |  | 142 |  |  | 124 |  |  | 14 | % |  | 14 | %  |  |  |  |  | \nDate | Approval\nJanuary 2023 | U.S. Food and Drug Administration (FDA) approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a \u22654 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.\nMarch 2023 | FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials.\nApril 2023 | FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas.\nJune 2023 | Japan\u2019s Ministry of Health, Labor and Welfare (MHLW) approval for the treatment of patients with relapsed or refractory PMBCL, based on the KEYNOTE-170 and the KEYNOTE-A33 studies.\nAugust 2023 | European Commission (EC) approval in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or GEJ adenocarcinoma in adults whose tumors express PD-L1, based on the KEYNOTE-811 trial.\nOctober 2023 | EC approval as a monotherapy for the adjuvant treatment of adults with NSCLC who are at high risk of recurrence following complete resection and platinum-based chemotherapy, based on the KEYNOTE-091 trial.\nOctober 2023 | FDA approval for the treatment of patients with resectable (tumors >=4cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery, based on the KEYNOTE-671 trial.\nOctober 2023 | FDA full approval for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. The conversion from an accelerated to a full (regular) approval is based on the KEYNOTE-913 and KEYNOTE-017 trials.\nOctober 2023 | FDA approval in combination with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer, based on the KEYNOTE-966 trial.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nGardasil/Gardasil9 | $ | 2,585 |  |  | $ | 2,294 |  |  | 13 | % |  | 16 | % |  | $ | 7,015 |  |  | $ | 5,428 |  |  | 29 | % |  | 34 | %\nProQuad | 267 |  |  | 264 |  |  | 1 | % |  | 1 | % |  | 678 |  |  | 640 |  |  | 6 | % |  | 6 | %\nM-M-RII | 122 |  |  | 124 |  |  | (2) | % |  | (4) | % |  | 329 |  |  | 330 |  |  | \u2014 | % |  | (1) | %\nVarivax | 325 |  |  | 280 |  |  | 16 | % |  | 15 | % |  | 816 |  |  | 746 |  |  | 9 | % |  | 10 | %\nRotaTeq | 156 |  |  | 256 |  |  | (39) | % |  | (39) | % |  | 584 |  |  | 644 |  |  | (9) | % |  | (8) | %\nVaxneuvance | 214 |  |  | 16 |  |  | * |  | * |  | 488 |  |  | 32 |  |  | * |  | *\nPneumovax 23 | 140 |  |  | 131 |  |  | 6 | % |  | 4 | % |  | 327 |  |  | 457 |  |  | (28) | % |  | (27) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nBridion | $ | 424 |  |  | $ | 423 |  |  | \u2014 | % |  | \u2014 | % |  | $ | 1,413 |  |  | $ | 1,244 |  |  | 14 | % |  | 15 | %\nPrevymis | 157 |  |  | 114 |  |  | 38 | % |  | 38 | % |  | 430 |  |  | 310 |  |  | 39 | % |  | 41 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nAlliance Revenue - Adempas/Verquvo(1) | $ | 92 |  |  | $ | 88 |  |  | 5 | % |  | 5 | % |  | $ | 259 |  |  | $ | 258 |  |  | \u2014 | % |  | \u2014 | %\nAdempas | 65 |  |  | 57 |  |  | 15 | % |  | 11 | % |  | 189 |  |  | 181 |  |  | 5 | % |  | 7 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nLagevrio | $ | 640 |  |  | $ | 436 |  |  | 47 | % |  | 51 | % |  | $ | 1,236 |  |  | $ | 4,859 |  |  | (75) | % |  | (73) | %\nIsentress/Isentress HD | 119 |  |  | 161 |  |  | (27) | % |  | (27) | % |  | 377 |  |  | 466 |  |  | (19) | % |  | (17) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nJanuvia/Janumet | $ | 835 |  |  | $ | 1,133 |  |  | (26) | % |  | (25) | % |  | $ | 2,579 |  |  | $ | 3,599 |  |  | (28) | % |  | (26) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange |  | Nine Months EndedSeptember 30, |  |  |  | % ChangeExcludingForeignExchange\n($ in millions) | 2023 |  | 2022 |  | % Change |  |  | 2023 |  | 2022 |  | % Change | \nLivestock | $ | 874 |  |  | $ | 829 |  |  | 5 | % |  | 7 | % |  | $ | 2,530 |  |  | $ | 2,486 |  |  | 2 | % |  | 6 | %\nCompanion Animal | 526 |  |  | 542 |  |  | (3) | % |  | (4) | % |  | 1,817 |  |  | 1,834 |  |  | (1) | % |  | \u2014 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  |  |  | Nine Months EndedSeptember 30, |  | \n($ in millions) | 2023 |  | 2022 |  | % Change |  | 2023 |  | 2022 |  | % Change\nCost of sales | $ | 4,264 |  |  | $ | 3,934 |  |  | 8 | % |  | $ | 12,214 |  |  | $ | 13,530 |  |  | (10) | %\nSelling, general and administrative | 2,519 |  |  | 2,520 |  |  | \u2014 | % |  | 7,700 |  |  | 7,355 |  |  | 5 | %\nResearch and development | 3,307 |  |  | 4,399 |  |  | (25) | % |  | 20,904 |  |  | 9,773 |  |  | *\nRestructuring costs | 126 |  |  | 94 |  |  | 34 | % |  | 344 |  |  | 288 |  |  | 19 | %\nOther (income) expense, net | 126 |  |  | 429 |  |  | (71) | % |  | 388 |  |  | 1,576 |  |  | (75) | %\n | $ | 10,342 |  |  | $ | 11,376 |  |  | (9) | % |  | $ | 41,550 |  |  | $ | 32,522 |  |  | 28 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSegment Profits |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions) | 2023 |  | 2022 |  | 2023 |  | 2022\nPharmaceutical segment profits | $ | 10,407 |  |  | $ | 9,590 |  |  | $ | 29,400 |  |  | $ | 28,263 | \nAnimal Health segment profits | 421 |  |  | 515 |  |  | 1,453 |  |  | 1,672 | \nOther | (5,208) |  |  | (6,522) |  |  | (26,918) |  |  | (17,004) | \nIncome Before Taxes | $ | 5,620 |  |  | $ | 3,583 |  |  | $ | 3,935 |  |  | $ | 12,931 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months EndedSeptember 30, |  | Nine Months EndedSeptember 30,\n($ in millions except per share amounts) | 2023 |  | 2022 |  | 2023 |  | 2022\nIncome before taxes as reported under GAAP | $ | 5,620 |  |  | $ | 3,583 |  |  | $ | 3,935 |  |  | $ | 12,931 | \nIncrease (decrease) for excluded items: |  |  |  |  |  |  | \nAcquisition- and divestiture-related costs | 555 |  |  | 1,344 |  |  | 1,643 |  |  | 2,512 | \nRestructuring costs | 199 |  |  | 175 |  |  | 532 |  |  | 559 | \nLoss (income) from investments in equity securities, net | 17 |  |  | 350 |  |  | (218) |  |  | 1,268 | \nOther items: |  |  |  |  |  |  | \nCharge for Zetia antitrust litigation settlements | \u2014 |  |  | \u2014 |  |  | 573 |  |  | \u2014 | \nNon-GAAP income before taxes | 6,391 |  |  | 5,452 |  |  | 6,465 |  |  | 17,270 | \nIncome tax provision as reported under GAAP | 870 |  |  | 330 |  |  | 2,332 |  |  | 1,423 | \nEstimated tax benefit on excluded items(1) | 89 |  |  | 414 |  |  | 350 |  |  | 965 | \nNon-GAAP income tax provision | 959 |  |  | 744 |  |  | 2,682 |  |  | 2,388 | \nNon-GAAP net income | 5,432 |  |  | 4,708 |  |  | 3,783 |  |  | 14,882 | \nLess: Net income attributable to noncontrolling interests as reported under GAAP | 5 |  |  | 5 |  |  | 12 |  |  | 6 | \nNon-GAAP net income attributable to Merck\u00a0& Co., Inc. | $ | 5,427 |  |  | $ | 4,703 |  |  | $ | 3,771 |  |  | $ | 14,876 | \nEPS assuming dilution as reported under GAAP(2) | $ | 1.86 |  |  | $ | 1.28 |  |  | $ | 0.62 |  |  | $ | 4.53 | \nEPS difference | 0.27 |  |  | 0.57 |  |  | 0.86 |  |  | 1.33 | \nNon-GAAP EPS assuming dilution(2) | $ | 2.13 |  |  | $ | 1.85 |  |  | $ | 1.48 |  |  | $ | 5.86 |   |  |  |  |  |  |  |  | \nPhase 2\nCancerMK-1308 (quavonlimab)(2)Non-Small-Cell LungMK-1308A (quavonlimab+pembrolizumab)ColorectalSmall-Cell LungMK-2140 (zilovertamab vedotin)BladderBreastGastricHematological MalignanciesNon-Small-Cell LungOvarianPancreaticMK-2400 (ifinatamab deruxtecan)(1)Small-Cell LungMK-2870(1)(3)Neoplasm MalignantMK-3475KeytrudaAdvanced Solid TumorsProstateMK-3475A (pembrolizumab+hyaluronidase subcutaneous)Cutaneous Squamous CellMK-3543 (bomedemstat)Myeloproliferative DisordersMK-4280 (favezelimab)(2)Non-Small-Cell LungMK-4280A (favezelimab+pembrolizumab)BladderCutaneous Squamous CellEsophagealMelanomaRenal CellSmall-Cell LungMK-4830(2)ColorectalEsophagealMelanomaNon-Small-Cell LungOvarianRenal CellSmall-Cell Lung | CancerMK-5684(1)ProstateMK-5890 (boserolimab)(2)Non-Small-Cell LungSmall-Cell LungMK-6482Welireg(3)BiliaryColorectalEndometrialEsophagealHepatocellularPancreaticRare cancersVon Hippel-Lindau Disease-Associated Tumors (EU)MK-7119 Tukysa(1)Advanced Solid TumorsBiliaryBladderCervicalEndometrialGastricNon-Small-Cell LungMK-7339 Lynparza(1)(3)Advanced Solid TumorsMK-7684A (vibostolimab+pembrolizumab)BiliaryBladderBreastCervicalColorectalEndometrialEsophagealGastricHead and NeckHepatocellularOvarianProstate | CancerMK-7902 Lenvima(1)(2)BiliaryHead and NeckPancreaticProstateSmall-Cell LungDengue Fever Virus VaccineV181HIV-1 InfectionMK-8591B (islatravir+MK-8507)(4)MK-8591D (islatravir+lenacapavir)(1)(5)Nonalcoholic Steatohepatitis (NASH)MK-6024 (efinopegdutide)Pulmonary Arterial HypertensionMK-5475Pulmonary Hypertension Due To Left Heart DiseaseMK-7962 (sotatercept)SchizophreniaMK-8189(6)ThrombosisMK-2060  |  |  |  |  |  |  |  | \nPhase 3 (Phase 3 entry date) | Under Review\nAntiviral COVID-19MK-4482Lagevrio(U.S.) (May 2021)(1)(7)CancerMK-1022 (patritumab deruxtecan)(1)Non-Small-Cell Lung (May 2022)MK-1026 (nemtabrutinib)Hematological Malignancies (March 2023)MK-1308A (quavonlimab+pembrolizumab)Renal Cell (April 2021)MK-3475KeytrudaCutaneous Squamous Cell (August 2019) (EU)Hepatocellular (May 2016) (EU)Mesothelioma (May 2018)Ovarian (December 2018)Small-Cell Lung (May 2017)MK-3475A (pembrolizumab+hyaluronidase subcutaneous)Non-Small-Cell Lung (February 2023)MK-4280A (favezelimab+pembrolizumab)Colorectal (November 2021)Hematological Malignancies (October 2022)MK-6482Welireg(3)Renal Cell (EU) (February 2020)MK-7119 Tukysa(1)Breast (October 2019)Colorectal (August 2022)MK-7339 Lynparza(2)Non-Small-Cell Lung (June 2019)Small-Cell Lung (December 2020)MK-7684A (vibostolimab+pembrolizumab)Melanoma (January 2023)Non-Small-Cell Lung (April 2021)Small-Cell Lung (March 2022)MK-7902 Lenvima(1)(2)Esophageal (July 2021)Gastric (December 2020)V940(1)(2)Melanoma (July 2023)HIV-1 InfectionMK-8591A (doravirine+islatravir) (February 2020)(5)HypercholesterolemiaMK-0616 (August 2023)Pneumococcal Vaccine AdultV116 (July 2022)Pulmonary Arterial HypertensionMK-7962 (sotatercept) (EU) (January 2021)Respiratory Syncytial VirusMK-1654 (clesrovimab) (November 2021)Ulcerative ColitisMK-7240 (October 2023) | New Molecular EntitiesCoughMK-7264 (gefapixant) (U.S.)(8)Pulmonary Arterial HypertensionMK-7962 (sotatercept) U.S. | Certain Supplemental FilingsCancerMK-3475Keytruda\u2022    Second-Line Hepatocellular Carcinoma(KEYNOTE-394) (U.S.)\u2022    High-Risk Locally Advanced Cervical Cancer(KEYNOTE-A18) (U.S.)\u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer(KEYNOTE-859) (U.S.) (EU) (JPN)\u2022    First-Line Locally Advanced Unresectable or Metastatic Biliary Tract Cancer(KEYNOTE-966) (EU) (JPN)\u2022    Resectable Stage II, IIIA or IIIB NSCLC(KEYNOTE-671) (EU) (JPN)MK-6482Welireg\u2022    Previously Treated Advanced Renal Cell Carcinoma(LIGHTSPARK-005) (U.S.)\nFootnotes:(1)Being developed in a collaboration.(2)Being developed in combination withKeytruda.(3)Being developed as monotherapy and/or in combination withKeytruda.(4)On FDA clinical hold.(5)On FDA partial clinical hold for higher doses than those used in current clinical trials.(6)Phase 2b development costs are being co-funded.(7)Available in the U.S. under Emergency Use Authorization.(8)In July 2023, the FDA accepted Merck\u2019s resubmission of the NDA for gefapixant following the Company\u2019s response to the CRL received in January 2022.  |  |  |  |  |  |  |  |  |  |  | \n($ in millions) | September 30, 2023 |  | December 31, 2022\nCash and investments | $ | 10,079 |  |  | $ | 14,207 | \nWorking capital | 8,860 |  |  | 11,483 | \nTotal debt to total liabilities and equity | 32.7 | % |  | 28.1 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  | ($\u00a0in\u00a0millions)\nPeriod | Total\u00a0Numberof SharesPurchased(1) |  | Average\u00a0PricePaid PerShare |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0SharesThat May Yet Be PurchasedUnder the Plans or Programs(1)\nJuly 1 - July 31 | 1,918,488 |  |  | $108.79 |  | 1,918,488 |  |  | $4,351\nAugust 1 - August 31 | 1,450,550 |  |  | $106.99 |  | 1,450,550 |  |  | $4,196\nSeptember 1 - September 30 | 950,239 |  |  | $107.33 |  | 950,239 |  |  | $4,094\nTotal | 4,319,277 |  |  | $107.86 |  | 4,319,277 |  |  |   |  |  |  |  |  |  |  | \nNumber |  | Description\n | \n3.1 | \u2014 | Restated Certificate of Incorporation of Merck & Co., Inc. (November 3, 2009) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on November\u00a04, 2009 (No. 1-6571)\n | \n3.2 | \u2014 | By-Laws of Merck & Co., Inc. (effective March 22, 2022) \u2013 Incorporated by reference to Merck & Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)\n |  | \n31.1 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Executive Officer\n | \n31.2 |  | \u2014 | Rule 13a \u2013 14(a)/15d \u2013 14(a) Certification of Chief Financial Officer\n | \n32.1 |  | \u2014 | Section 1350 Certification of Chief Executive Officer\n | \n32.2 |  | \u2014 | Section 1350 Certification of Chief Financial Officer\n | \n101.INS | \u2014 | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.\n |  | \n101.SCH | \u2014 | XBRL Taxonomy Extension Schema Document.\n |  | \n101.CAL | \u2014 | XBRL Taxonomy Extension Calculation Linkbase Document.\n |  | \n101.DEF | \u2014 | XBRL Taxonomy Extension Definition Linkbase Document.\n |  | \n101.LAB | \u2014 | XBRL Taxonomy Extension Label Linkbase Document.\n |  | \n101.PRE | \u2014 | XBRL Taxonomy Extension Presentation Linkbase Document.\n |  | \n104 |  | \u2014 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).  |  |  |  |  |  |  |  | \n |  | MERCK & CO., INC.\n |  | \nDate:  November 3, 2023 |  | /s/ Jennifer Zachary\n |  | JENNIFER ZACHARY\n |  | Executive Vice President and General Counsel\n |  | \nDate:  November 3, 2023 |  | /s/ Rita A. Karachun\n |  | RITA A. KARACHUN\n |  | Senior Vice President Finance - Global Controller"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Meta, in 2022 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  | \nDelaware | 20-1665019\n(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number)  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class | Trading symbol(s) | Name of each exchange on which registered\nClass A Common Stock, $0.000006 par value | FB | The Nasdaq Stock Market LLC  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer |  | \u2612 | Accelerated\u00a0filer |  | \u2610\nNon-accelerated filer |  | \u2610 | Smaller\u00a0reporting\u00a0company |  | \u2610\n |  |  | Emerging growth company |  | \u2610\n |  |  |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |  | \u2610  |  |  |  |  |  |  |  |  |  |  | \nClass | Number of Shares Outstanding\nClass\u00a0A Common Stock | $0.000006 par value | 2,293,518,778 |  | shares outstanding as of April 22, 2022\nClass B Common Stock | $0.000006 par value | 412,804,609 |  | shares outstanding as of April 22, 2022  |  |  |  |  |  |  |  | \n |  | Page\n | \nNote About Forward-Looking Statements | 3\n | \nLimitations of Key Metrics and Other Data | 4\n | \nPART I\u2014FINANCIAL INFORMATION | 7\n |  | \nItem 1. | Financial Statements (unaudited) | 7\n |  | \n | Condensed Consolidated Balance Sheets\u2014March31, 2022and December\u00a031, 2021 | 7\n |  | \n | Condensed Consolidated Statements of Income\u2014for the threemonths endedMarch31, 2022and 2021 | 8\n |  | \n | Condensed Consolidated Statements of Comprehensive Income\u2014for the threemonths endedMarch31, 2022and 2021 | 9\n |  | \n | Condensed Consolidated Statements of Stockholders' Equity\u2014for the threemonths endedMarch31, 2022and 2021 | 10\n |  | \n | Condensed Consolidated Statements of Cash Flows\u2014for thethreemonths endedMarch31, 2022and 2021 | 11\n |  | \n | Notes to Condensed Consolidated Financial Statements | 13\n |  | \nItem 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 28\n |  | \nItem 3. | Quantitative and Qualitative Disclosures About Market Risk | 46\n |  | \nItem 4. | Controls and Procedures | 47\n | \nPART II\u2014OTHER INFORMATION | 48\n |  | \nItem 1. | Legal Proceedings | 48\n |  | \nItem\u00a01A. | Risk Factors | 51\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 85\n |  | \nItem 6. | Exhibits | 86\n | \nSIGNATURES | 87  |  |  |  |  |  |  |  |  |  |  | \n | March 31,2022 |  | December 31,2021\nAssets |  |  | \nCurrent assets: |  |  | \nCash and cash equivalents | $ | 14,886 |  |  | $ | 16,601 | \nMarketable securities | 29,004 |  |  | 31,397 | \nAccounts receivable, net | 11,390 |  |  | 14,039 | \nPrepaid expenses and other current assets | 3,985 |  |  | 4,629 | \nTotal current assets | 59,265 |  |  | 66,666 | \nEquity investments | 6,775 |  |  | 6,775 | \nProperty and equipment, net | 61,582 |  |  | 57,809 | \nOperating lease right-of-use assets | 12,241 |  |  | 12,155 | \nIntangible assets, net | 910 |  |  | 634 | \nGoodwill | 19,923 |  |  | 19,197 | \nOther assets | 3,522 |  |  | 2,751 | \nTotal assets | $ | 164,218 |  |  | $ | 165,987 | \n |  |  | \nLiabilities and stockholders' equity |  |  | \nCurrent liabilities: |  |  | \nAccounts payable | $ | 3,246 |  |  | $ | 4,083 | \nPartners payable | 935 |  |  | 1,052 | \nOperating lease liabilities, current | 1,159 |  |  | 1,127 | \nAccrued expenses and other current liabilities | 15,226 |  |  | 14,312 | \nDeferred revenue and deposits | 520 |  |  | 561 | \nTotal current liabilities | 21,086 |  |  | 21,135 | \nOperating lease liabilities, non-current | 12,894 |  |  | 12,746 | \nOther liabilities | 7,010 |  |  | 7,227 | \nTotal liabilities | 40,990 |  |  | 41,108 | \nCommitments and contingencies |  |  | \nStockholders' equity: |  |  | \nCommon stock, $0.000006par value;5,000million Class A shares authorized,2,301million and2,328million shares issued and outstanding, as of March 31, 2022 and December 31, 2021, respectively;4,141million Class B shares authorized,413million and413million shares issued and outstanding, as of March 31, 2022 and December 31, 2021, respectively | \u2014 |  |  | \u2014 | \nAdditional paid-in capital | 57,512 |  |  | 55,811 | \nAccumulated other comprehensive loss | (1,996) |  |  | (693) | \nRetained earnings | 67,712 |  |  | 69,761 | \nTotal stockholders' equity | 123,228 |  |  | 124,879 | \nTotal liabilities and stockholders' equity | $ | 164,218 |  |  | $ | 165,987 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nRevenue | $ | 27,908 |  |  | $ | 26,171 |  |  |  |  | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 6,005 |  |  | 5,131 |  |  |  |  | \nResearch and development | 7,707 |  |  | 5,197 |  |  |  |  | \nMarketing and sales | 3,312 |  |  | 2,843 |  |  |  |  | \nGeneral and administrative | 2,360 |  |  | 1,622 |  |  |  |  | \nTotal costs and expenses | 19,384 |  |  | 14,793 |  |  |  |  | \nIncome from operations | 8,524 |  |  | 11,378 |  |  |  |  | \nInterest and other income, net | 384 |  |  | 125 |  |  |  |  | \nIncome before provision for income taxes | 8,908 |  |  | 11,503 |  |  |  |  | \nProvision for income taxes | 1,443 |  |  | 2,006 |  |  |  |  | \nNet income | $ | 7,465 |  |  | $ | 9,497 |  |  |  |  | \nEarnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | $ | 2.74 |  |  | $ | 3.34 |  |  |  |  | \nDiluted | $ | 2.72 |  |  | $ | 3.30 |  |  |  |  | \nWeighted-average shares used to compute earnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | 2,725 |  |  | 2,847 |  |  |  |  | \nDiluted | 2,742 |  |  | 2,882 |  |  |  |  | \nShare-based compensation expense included in costs and expenses: |  |  |  |  |  |  | \nCost of revenue | $ | 160 |  |  | $ | 118 |  |  |  |  | \nResearch and development | 1,941 |  |  | 1,408 |  |  |  |  | \nMarketing and sales | 216 |  |  | 174 |  |  |  |  | \nGeneral and administrative | 181 |  |  | 130 |  |  |  |  | \nTotal share-based compensation expense | $ | 2,498 |  |  | $ | 1,830 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nNet income | $ | 7,465 |  |  | $ | 9,497 |  |  |  |  | \nOther comprehensive loss: |  |  |  |  |  |  | \nChange in foreign currency translation adjustment, net of tax | (359) |  |  | (601) |  |  |  |  | \nChange in unrealized gain (loss) on available-for-sale investments and other, net of tax | (944) |  |  | (172) |  |  |  |  | \nComprehensive income | $ | 6,162 |  |  | $ | 8,724 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2022 |  | Three Months Ended March 31, 2021\n | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity |  | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Income |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par Value |  |  | Shares |  | Par Value | \nBalances at beginning of period | 2,741 |  |  | $ | \u2014 |  |  | $ | 55,811 |  |  | $ | (693) |  |  | $ | 69,761 |  |  | $ | 124,879 |  |  | 2,849 |  |  | $ | \u2014 |  |  | $ | 50,018 |  |  | $ | 927 |  |  | $ | 77,345 |  |  | $ | 128,290 | \nIssuance of common stock | 11 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 11 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (4) |  |  | \u2014 |  |  | (797) |  |  | \u2014 |  |  | (128) |  |  | (925) |  |  | (4) |  |  | \u2014 |  |  | (688) |  |  | \u2014 |  |  | (389) |  |  | (1,077) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 2,498 |  |  | \u2014 |  |  | \u2014 |  |  | 2,498 |  |  | \u2014 |  |  | \u2014 |  |  | 1,830 |  |  | \u2014 |  |  | \u2014 |  |  | 1,830 | \nShare repurchases | (34) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (9,386) |  |  | (9,386) |  |  | (15) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,110) |  |  | (4,110) | \nOther comprehensive loss | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,303) |  |  | \u2014 |  |  | (1,303) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (773) |  |  | \u2014 |  |  | (773) | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 7,465 |  |  | 7,465 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 9,497 |  |  | 9,497 | \nBalances at end of period | 2,714 |  |  | $ | \u2014 |  |  | $ | 57,512 |  |  | $ | (1,996) |  |  | $ | 67,712 |  |  | $ | 123,228 |  |  | 2,841 |  |  | $ | \u2014 |  |  | $ | 51,160 |  |  | $ | 154 |  |  | $ | 82,343 |  |  | $ | 133,657 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2022 |  | 2021\nCash flows from operating activities |  |  | \nNet income | $ | 7,465 |  |  | $ | 9,497 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nDepreciation and amortization | 2,156 |  |  | 1,972 | \nShare-based compensation | 2,498 |  |  | 1,830 | \nDeferred income taxes | (563) |  |  | 418 | \nOther | (221) |  |  | (66) | \nChanges in assets and liabilities: |  |  | \nAccounts receivable | 2,557 |  |  | 849 | \nPrepaid expenses and other current assets | 573 |  |  | (461) | \nOther assets | (108) |  |  | (10) | \nAccounts payable | (882) |  |  | (250) | \nPartners payable | (105) |  |  | (72) | \nAccrued expenses and other current liabilities | 763 |  |  | (1,681) | \nDeferred revenue and deposits | (52) |  |  | 6 | \nOther liabilities | (5) |  |  | 210 | \nNet cash provided by operating activities | 14,076 |  |  | 12,242 | \nCash flows from investing activities |  |  | \nPurchases of property and equipment | (5,441) |  |  | (4,303) | \nProceeds relating to property and equipment | 126 |  |  | 31 | \nPurchases of marketable securities | (4,068) |  |  | (6,231) | \nSales of marketable securities | 5,065 |  |  | 1,650 | \nMaturities of marketable securities | 402 |  |  | 3,981 | \n |  |  | \nAcquisitions of businesses and intangible assets | (853) |  |  | \u2014 | \nOther investing activities | (10) |  |  | (2) | \nNet cash used in investing activities | (4,779) |  |  | (4,874) | \nCash flows from financing activities |  |  | \nTaxes paid related to net share settlement of equity awards | (925) |  |  | (1,077) | \nRepurchases of Class A common stock | (9,506) |  |  | (3,939) | \nPrincipal payments on finance leases | (233) |  |  | (151) | \nNet change in overdraft in cash pooling entities | 20 |  |  | (50) | \nOther financing activities | (16) |  |  | 32 | \nNet cash used in financing activities | (10,660) |  |  | (5,185) | \nEffect of exchange rate changes on cash, cash equivalents, and restricted cash | (149) |  |  | (246) | \nNet increase (decrease) in cash, cash equivalents, and restricted cash | (1,512) |  |  | 1,937 | \nCash, cash equivalents, and restricted cash at beginning of the period | 16,865 |  |  | 17,954 | \nCash, cash equivalents, and restricted cash at end of the period | $ | 15,353 |  |  | $ | 19,891 | \n |  |  | \nReconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets |  |  | \nCash and cash equivalents | $ | 14,886 |  |  | $ | 19,513 | \nRestricted cash, included in prepaid expenses and other current assets | 294 |  |  | 257 | \nRestricted cash, included in other assets | 173 |  |  | 121 | \nTotal cash, cash equivalents, and restricted cash | $ | 15,353 |  |  | $ | 19,891 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2022 |  | 2021\nSupplemental cash flow data |  |  | \nCash paid for income taxes, net | $ | 502 |  |  | $ | 2,907 | \nNon-cash investing and financing activities: |  |  | \nProperty and equipment in accounts payable and accrued expenses and other current liabilities | $ | 3,709 |  |  | $ | 2,198 | \nAcquisition of businesses in accrued expenses and other current liabilities and other liabilities | $ | 73 |  |  | $ | 118 | \nSettlement of convertible notes in exchange of equity securities in other current assets | $ | 131 |  |  | $ | \u2014 | \nOther current assets through financing arrangement in accrued expenses and other current liabilities | $ | 659 |  |  | $ | \u2014 | \nRepurchases of Class A common stock in accrued expenses and other current liabilities | $ | 221 |  |  | $ | 240 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nAdvertising | $ | 26,998 |  |  | $ | 25,439 |  |  |  |  | \nOther revenue | 215 |  |  | 198 |  |  |  |  | \nFamily of Apps | 27,213 |  |  | 25,637 |  |  |  |  | \nReality Labs | 695 |  |  | 534 |  |  |  |  | \nTotal revenue | $ | 27,908 |  |  | $ | 26,171 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nUnited States and Canada(1) | $ | 11,780 |  |  | $ | 11,436 |  |  |  |  | \nEurope(2) | 6,638 |  |  | 6,384 |  |  |  |  | \nAsia-Pacific | 6,722 |  |  | 6,101 |  |  |  |  | \nRest of World(2) | 2,768 |  |  | 2,250 |  |  |  |  | \nTotal revenue | $ | 27,908 |  |  | $ | 26,171 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \n | Class A |  | Class B |  | Class A |  | Class B |  |  |  |  |  |  |  | \nBasic EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 6,334 |  |  | $ | 1,131 |  |  | $ | 8,025 |  |  | $ | 1,472 |  |  |  |  |  |  |  |  | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,312 |  |  | 413 |  |  | 2,406 |  |  | 441 |  |  |  |  |  |  |  |  | \nBasic EPS | $ | 2.74 |  |  | $ | 2.74 |  |  | $ | 3.34 |  |  | $ | 3.34 |  |  |  |  |  |  |  |  | \nDiluted EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 6,334 |  |  | $ | 1,131 |  |  | $ | 8,025 |  |  | $ | 1,472 |  |  |  |  |  |  |  |  | \nReallocation of net income as a result of conversion of Class B to Class\u00a0A common stock | 1,131 |  |  | \u2014 |  |  | 1,472 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nReallocation of net income to Class B common stock | \u2014 |  |  | (7) |  |  | \u2014 |  |  | (18) |  |  |  |  |  |  |  |  | \nNet income for diluted EPS | $ | 7,465 |  |  | $ | 1,124 |  |  | $ | 9,497 |  |  | $ | 1,454 |  |  |  |  |  |  |  |  | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,312 |  |  | 413 |  |  | 2,406 |  |  | 441 |  |  |  |  |  |  |  |  | \nConversion of Class B to Class\u00a0A common stock | 413 |  |  | \u2014 |  |  | 441 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWeighted-average effect of dilutive RSUs | 17 |  |  | \u2014 |  |  | 35 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nShares used in computation of diluted earnings per share | 2,742 |  |  | 413 |  |  | 2,882 |  |  | 441 |  |  |  |  |  |  |  |  | \nDiluted EPS | $ | 2.72 |  |  | $ | 2.72 |  |  | $ | 3.30 |  |  | $ | 3.30 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nCash and cash equivalents: |  |  | \nCash | $ | 7,090 |  |  | $ | 7,308 | \nMoney market funds | 7,350 |  |  | 8,850 | \nU.S. government securities | 81 |  |  | 25 | \nU.S. government agency securities | \u2014 |  |  | 108 | \nCertificates of deposit and time deposits | 351 |  |  | 250 | \nCorporate debt securities | 14 |  |  | 60 | \nTotal cash and cash equivalents | 14,886 |  |  | 16,601 | \nMarketable securities: |  |  | \nU.S. government securities | 9,721 |  |  | 10,901 | \nU.S. government agency securities | 5,434 |  |  | 5,927 | \nCorporate debt securities | 13,849 |  |  | 14,569 | \nTotal marketable securities | 29,004 |  |  | 31,397 | \nTotal cash and cash equivalents and marketable securities | $ | 43,890 |  |  | $ | 47,998 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022\n | Less than 12 months |  | 12 months or greater |  | Total\n | Fair Value |  | Unrealized losses |  | Fair Value |  | Unrealized losses |  | Fair Value |  | Unrealized losses\nU.S. government securities | $ | 7,488 |  |  | $ | (218) |  |  | $ | 214 |  |  | $ | (11) |  |  | $ | 7,702 |  |  | $ | (229) | \nU.S. government agency securities | 3,345 |  |  | (110) |  |  | 1,736 |  |  | (111) |  |  | 5,081 |  |  | (221) | \nCorporate debt securities | 11,953 |  |  | (507) |  |  | 589 |  |  | (39) |  |  | 12,542 |  |  | (546) | \nTotal | $ | 22,786 |  |  | $ | (835) |  |  | $ | 2,539 |  |  | $ | (161) |  |  | $ | 25,325 |  |  | $ | (996) |   |  |  |  |  | \n | March 31, 2022\nDue within one year | $ | 2,452 | \nDue after one year to five years | 26,552 | \nTotal | $ | 29,004 |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nEquity investments under measurement alternative: |  |  | \nInitial cost | $ | 6,480 |  |  | $ | 6,480 | \nCumulative upward adjustments | 311 |  |  | 311 | \nCumulative impairment/downward adjustments | (50) |  |  | (50) | \nCarrying value | 6,741 |  |  | 6,741 | \nEquity investments under equity method | 34 |  |  | 34 | \nTotal equity investments | $ | 6,775 |  |  | $ | 6,775 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | March 31, 2022 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | \nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | $ | 7,350 |  |  | $ | 7,350 |  |  | $ | \u2014 |  |  | \nU.S. government securities |  | 81 |  |  | 81 |  |  | \u2014 |  |  | \n |  |  |  |  |  |  |  | \nCertificates of deposit and time deposits |  | 351 |  |  | \u2014 |  |  | 351 |  |  | \nCorporate debt securities |  | 14 |  |  | \u2014 |  |  | 14 |  |  | \nMarketable securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 9,721 |  |  | 9,721 |  |  | \u2014 |  |  | \nU.S. government agency securities |  | 5,434 |  |  | 5,434 |  |  | \u2014 |  |  | \nCorporate debt securities |  | 13,849 |  |  | \u2014 |  |  | 13,849 |  |  | \nTotal cash equivalents and marketable securities |  | $ | 36,800 |  |  | $ | 22,586 |  |  | $ | 14,214 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | December 31, 2021 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | \nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | $ | 8,850 |  |  | $ | 8,850 |  |  | $ | \u2014 |  |  | \nU.S. government securities |  | 25 |  |  | 25 |  |  | \u2014 |  |  | \nU.S. government agency securities |  | 108 |  |  | 108 |  |  | \u2014 |  |  | \nCertificates of deposit and time deposits |  | 250 |  |  | \u2014 |  |  | 250 |  |  | \nCorporate debt securities |  | 60 |  |  | \u2014 |  |  | 60 |  |  | \nMarketable securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 10,901 |  |  | 10,901 |  |  | \u2014 |  |  | \nU.S. government agency securities |  | 5,927 |  |  | 5,927 |  |  | \u2014 |  |  | \nCorporate debt securities |  | 14,569 |  |  | \u2014 |  |  | 14,569 |  |  | \nTotal cash equivalents and marketable securities |  | $ | 40,690 |  |  | $ | 25,811 |  |  | $ | 14,879 |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nLand | $ | 1,713 |  |  | $ | 1,688 | \nServers and network assets | 27,094 |  |  | 25,584 | \nBuildings | 23,154 |  |  | 22,531 | \nLeasehold improvements | 6,043 |  |  | 5,795 | \nEquipment and other | 5,045 |  |  | 4,764 | \nFinance lease right-of-use assets | 2,955 |  |  | 2,840 | \nConstruction in progress | 17,031 |  |  | 14,687 | \nProperty and equipment, gross | 83,035 |  |  | 77,889 | \nLess: Accumulated depreciation | (21,453) |  |  | (20,080) | \nProperty and equipment, net | $ | 61,582 |  |  | $ | 57,809 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nFinance lease cost |  |  |  |  |  |  | \nAmortization of right-of-use assets | $ | 98 |  |  | $ | 81 |  |  |  |  | \nInterest | 4 |  |  | 4 |  |  |  |  | \nOperating lease cost | 411 |  |  | 362 |  |  |  |  | \nVariable lease cost and other, net | 90 |  |  | 66 |  |  |  |  | \nTotal lease cost | $ | 603 |  |  | $ | 513 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nWeighted-average remaining lease term |  |  | \nFinance leases | 13.9years |  | 13.9years\nOperating leases | 12.8years |  | 13.0years\nWeighted-average discount rate |  |  | \nFinance leases | 2.7 | % |  | 2.7 | %\nOperating leases | 2.8 | % |  | 2.8 | %  |  |  |  |  |  |  |  |  |  |  | \n | Operating Leases |  | Finance Leases\nThe remainder of 2022 | $ | 1,061 |  |  | $ | 78 | \n2023 | 1,600 |  |  | 69 | \n2024 | 1,565 |  |  | 47 | \n2025 | 1,403 |  |  | 47 | \n2026 | 1,344 |  |  | 47 | \nThereafter | 10,312 |  |  | 434 | \nTotal undiscounted cash flows | 17,285 |  |  | 722 | \nLess: Imputed interest | (3,232) |  |  | (117) | \nPresent value of lease liabilities | $ | 14,053 |  |  | $ | 605 | \n |  |  | \nLease liabilities, current | $ | 1,159 |  |  | $ | 81 | \nLease liabilities, non-current | 12,894 |  |  | 524 | \nPresent value of lease liabilities | $ | 14,053 |  |  | $ | 605 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2022 |  | 2021\nCash paid for amounts included in the measurement of lease liabilities: |  |  | \nOperating cash flows for operating leases | $ | 389 |  |  | $ | 329 | \nOperating cash flows for finance leases | $ | 4 |  |  | $ | 4 | \nFinancing cash flows for finance leases | $ | 233 |  |  | $ | 151 | \nLease liabilities arising from obtaining right-of-use assets: |  |  | \nOperating leases | $ | 539 |  |  | $ | 1,282 | \nFinance leases | $ | 52 |  |  | $ | 24 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total\nGoodwill at December 31, 2021 | $ | 18,458 |  |  | $ | 739 |  |  | $ | 19,197 | \nAcquisitions | 759 |  |  | \u2014 |  |  | 759 | \nAdjustments | \u2014 |  |  | (33) |  |  | (33) | \nGoodwill at March 31, 2022 | $ | 19,217 |  |  | $ | 706 |  |  | $ | 19,923 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | March 31, 2022 |  | December 31, 2021\n | Weighted-Average Remaining Useful Lives(in years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount\nAcquired technology | 4.2 |  | $ | 1,534 |  |  | $ | (1,194) |  |  | $ | 340 |  |  | $ | 1,412 |  |  | $ | (1,169) |  |  | $ | 243 | \nAcquired patents | 3.2 |  | 827 |  |  | (731) |  |  | 96 |  |  | 827 |  |  | (722) |  |  | 105 | \nTrade names | 4.1 |  | 623 |  |  | (602) |  |  | 21 |  |  | 644 |  |  | (633) |  |  | 11 | \nOther | 9.6 |  | 188 |  |  | (99) |  |  | 89 |  |  | 176 |  |  | (167) |  |  | 9 | \nTotal finite-lived assets |  |  | 3,172 |  |  | (2,626) |  |  | 546 |  |  | 3,059 |  |  | (2,691) |  |  | 368 | \nTotal indefinite-lived assets | N/A |  | 364 |  |  | \u2014 |  |  | 364 |  |  | 266 |  |  | \u2014 |  |  | 266 | \nTotal intangible assets |  |  | $ | 3,536 |  |  | $ | (2,626) |  |  | $ | 910 |  |  | $ | 3,325 |  |  | $ | (2,691) |  |  | $ | 634 |   |  |  |  |  | \nThe remainder of 2022 | $ | 142 | \n2023 | 133 | \n2024 | 105 | \n2025 | 67 | \n2026 | 27 | \nThereafter | 72 | \nTotal | $ | 546 |   |  |  |  |  | \nThe remainder of 2022 | $ | 13,940 | \n2023 | 3,851 | \n2024 | 1,804 | \n2025 | 386 | \n2026 | 205 | \nThereafter | 2,542 | \nTotal | $ | 22,728 |   |  |  |  |  |  |  |  |  |  |  | \n | Number of Shares |  | Weighted-Average Grant Date Fair Value Per Share\n | (in thousands) |  | \nUnvested at December 31, 2021 | 98,848 |  |  | $ | 244.32 | \nGranted | 66,724 |  |  | $ | 214.17 | \nVested | (11,156) |  |  | $ | 219.55 | \nForfeited | (3,259) |  |  | $ | 230.73 | \nUnvested at March 31, 2022 | 151,157 |  |  | $ | 233.13 |   |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  | \nRevenue: |  |  |  |  | \nFamily of Apps | $ | 27,213 |  |  | $ | 25,637 |  |  | \nReality Labs | 695 |  |  | 534 |  |  | \nTotal revenue | $ | 27,908 |  |  | $ | 26,171 |  |  | \n |  |  |  |  | \nIncome (loss) from operations: |  |  |  |  | \nFamily of Apps | $ | 11,484 |  |  | $ | 13,205 |  |  | \nReality Labs | (2,960) |  |  | (1,827) |  |  | \nTotal income from operations | $ | 8,524 |  |  | $ | 11,378 |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nUnited States | $ | 59,080 |  |  | $ | 55,497 | \nRest of the world(1) | 14,743 |  |  | 14,467 | \nTotal long-lived assets | $ | 73,823 |  |  | $ | 69,964 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total |  |  |  |  |  | \n | Three Months Ended March 31, |  | Year-over-Year% Change |  | Three Months Ended March 31, |  | Year-over-Year% Change |  | Three Months Ended March 31, |  | Year-over-Year% Change |  |  |  | \n | 2022 |  | 2021 |  |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  |  |  | \nRevenue | $ | 27,213 |  |  | $ | 25,637 |  |  | 6% |  | $ | 695 |  |  | $ | 534 |  |  | 30% |  | $ | 27,908 |  |  | $ | 26,171 |  |  | 7% |  |  |  |  |  | \nCosts and expenses | $ | 15,729 |  |  | $ | 12,432 |  |  | 27% |  | $ | 3,655 |  |  | $ | 2,361 |  |  | 55% |  | $ | 19,384 |  |  | $ | 14,793 |  |  | 31% |  |  |  |  |  | \nIncome (loss) from operations | $ | 11,484 |  |  | $ | 13,205 |  |  | (13)% |  | $ | (2,960) |  |  | $ | (1,827) |  |  | (62)% |  | $ | 8,524 |  |  | $ | 11,378 |  |  | (25)% |  |  |  |  |  | \nOperating margin | 42 | % |  | 52 | % |  |  |  | (426) | % |  | (342) | % |  |  |  | 31 | % |  | 43 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAP/MAP: | 79% | 79% | 79% | 79% | 79% | 79% | 78% | 79% | 79%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPP: | $6.03 | $6.10 | $6.76 | $8.62 | $7.75 | $8.36 | $8.18 | $9.39 | $7.72\n |  |  |  |  |  |  |  |  | \n |  |  | Ad Revenue |  | Non-Ad Revenue |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAU/MAU: | 67% | 66% | 66% | 66% | 66% | 66% | 66% | 66% | 67%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAU/MAU: | 77% | 77% | 77% | 76% | 75% | 75% | 75% | 74% | 75% | DAU/MAU: | 75% | 74% | 74% | 74% | 73% | 73% | 73% | 72% | 73%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAU/MAU: | 62% | 61% | 62% | 62% | 62% | 62% | 63% | 63% | 64% | DAU/MAU: | 65% | 65% | 65% | 65% | 65% | 65% | 66% | 65% | 66%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPU: | $6.95 | $7.05 | $7.89 | $10.14 | $9.27 | $10.12 | $10.00 | $11.57 | $9.54  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPU: | $ | 34.18 |  | $ | 36.49 |  | $ | 39.63 |  | $ | 53.56 |  | $ | 48.03 |  | $ | 53.01 |  | $ | 52.34 |  | $ | 60.57 |  | $ | 48.29 |  | ARPU: | $10.64 | $11.03 | $12.41 | $16.87 | $15.49 | $17.23 | $16.50 | $19.68 | $15.35  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPU: | $3.06 | $2.99 | $3.67 | $4.05 | $3.94 | $4.16 | $4.30 | $4.89 | $4.47 | ARPU: | $1.99 | $1.78 | $2.22 | $2.77 | $2.64 | $3.05 | $3.14 | $3.43 | $3.14\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | Ad Revenue |  | Non-Ad Revenue |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nRevenue | $ | 27,908 |  |  | $ | 26,171 |  |  |  |  | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 6,005 |  |  | 5,131 |  |  |  |  | \nResearch and development | 7,707 |  |  | 5,197 |  |  |  |  | \nMarketing and sales | 3,312 |  |  | 2,843 |  |  |  |  | \nGeneral and administrative | 2,360 |  |  | 1,622 |  |  |  |  | \nTotal costs and expenses | 19,384 |  |  | 14,793 |  |  |  |  | \nIncome from operations | 8,524 |  |  | 11,378 |  |  |  |  | \nInterest and other income, net | 384 |  |  | 125 |  |  |  |  | \nIncome before provision for income taxes | 8,908 |  |  | 11,503 |  |  |  |  | \nProvision for income taxes | 1,443 |  |  | 2,006 |  |  |  |  | \nNet income | $ | 7,465 |  |  | $ | 9,497 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nRevenue | 100 | % |  | 100 | % |  |  |  | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 22 |  |  | 20 |  |  |  |  | \nResearch and development | 28 |  |  | 20 |  |  |  |  | \nMarketing and sales | 12 |  |  | 11 |  |  |  |  | \nGeneral and administrative | 8 |  |  | 6 |  |  |  |  | \nTotal costs and expenses | 69 |  |  | 57 |  |  |  |  | \nIncome from operations | 31 |  |  | 43 |  |  |  |  | \nInterest and other income, net | 1 |  |  | \u2014 |  |  |  |  | \nIncome before provision for income taxes | 32 |  |  | 44 |  |  |  |  | \nProvision for income taxes | 5 |  |  | 8 |  |  |  |  | \nNet income | 27 | % |  | 36 | % |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nCost of revenue | $ | 160 |  |  | $ | 118 |  |  |  |  | \nResearch and development | 1,941 |  |  | 1,408 |  |  |  |  | \nMarketing and sales | 216 |  |  | 174 |  |  |  |  | \nGeneral and administrative | 181 |  |  | 130 |  |  |  |  | \nTotal share-based compensation expense | $ | 2,498 |  |  | $ | 1,830 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nCost of revenue | 1 | % |  | \u2014 | % |  |  |  | \nResearch and development | 7 |  |  | 5 |  |  |  |  | \nMarketing and sales | 1 |  |  | 1 |  |  |  |  | \nGeneral and administrative | 1 |  |  | \u2014 |  |  |  |  | \nTotal share-based compensation expense | 9 | % |  | 7 | % |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2022 |  | 2021 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  |  |  |  |  | \nAdvertising | $ | 26,998 |  |  | $ | 25,439 |  |  | 6 | % |  |  |  |  |  | \nOther revenue | 215 |  |  | 198 |  |  | 9 | % |  |  |  |  |  | \nFamily of Apps | 27,213 |  |  | 25,637 |  |  | 6 | % |  |  |  |  |  | \nReality Labs | 695 |  |  | 534 |  |  | 30 | % |  |  |  |  |  | \nTotal revenue | $ | 27,908 |  |  | $ | 26,171 |  |  | 7 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2022 |  | 2021 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  |  |  |  |  | \nCost of revenue | $ | 6,005 |  |  | $ | 5,131 |  |  | 17 | % |  |  |  |  |  | \nPercentage of revenue | 22 | % |  | 20 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2022 |  | 2021 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  |  |  |  |  | \nResearch and development | $ | 7,707 |  |  | $ | 5,197 |  |  | 48 | % |  |  |  |  |  | \nPercentage of revenue | 28 | % |  | 20 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2022 |  | 2021 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  |  |  |  |  | \nMarketing and sales | $ | 3,312 |  |  | $ | 2,843 |  |  | 16 | % |  |  |  |  |  | \nPercentage of revenue | 12 | % |  | 11 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2022 |  | 2021 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nGeneral and administrative | $ | 2,360 |  |  | $ | 1,622 |  |  | 45 | % |  |  |  |  |  | \nPercentage of revenue | 8 | % |  | 6 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2022 |  | 2021 |  |  |  | % change |  | \n |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  | \nFamily of Apps | $ | 11,484 |  |  | $ | 13,205 |  |  |  |  | (13) | % |  | \nReality Labs | (2,960) |  |  | (1,827) |  |  |  |  | (62) | % |  | \nTotal income from operations | $ | 8,524 |  |  | $ | 11,378 |  |  |  |  | (25) | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2022 |  | 2021 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  |  |  |  |  | \nInterest income, net | $ | 76 |  |  | $ | 118 |  |  | (36) | % |  |  |  |  |  | \nForeign currency exchange gains (losses), net | 54 |  |  | (93) |  |  | 158 | % |  |  |  |  |  | \nOther income, net | 254 |  |  | 100 |  |  | 154 | % |  |  |  |  |  | \nInterest and other income, net | $ | 384 |  |  | $ | 125 |  |  | 207 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2022 |  | 2021 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  |  |  |  |  | \nProvision for income taxes | $ | 1,443 |  |  | $ | 2,006 |  |  | (28) | % |  |  |  |  |  | \nEffective tax rate | 16 | % |  | 17 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  | \nNet cash provided by operating activities | $ | 14,076 |  |  | $ | 12,242 |  |  | \nNet cash used in investing activities | $ | (4,779) |  |  | $ | (4,874) |  |  | \nNet cash used in financing activities | $ | (10,660) |  |  | $ | (5,185) |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  | \n |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total Number of Shares Purchased(1) |  | Average Price Paid Per Share(2) |  | Total Number of Shares Purchased as Part of Publicly Announced Programs(1) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(1)\n | (in thousands) |  |  |  | (in thousands) |  | (in millions)\nJanuary 1 - 31, 2022 | 19,687 |  |  | $ | 316.45 |  |  | 19,687 |  |  | $ | 32,563 | \nFebruary 1 - 28, 2022 | 5,918 |  |  | $ | 224.75 |  |  | 5,918 |  |  | $ | 31,233 | \nMarch 1 - 31, 2022 | 8,666 |  |  | $ | 210.79 |  |  | 8,666 |  |  | $ | 29,406 | \n | 34,271 |  |  |  |  | 34,271 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nExhibit |  |  |  | Incorporated by Reference |  | FiledHerewith\nNumber |  | Exhibit Description |  | Form |  | File No. |  | Exhibit |  | Filing\u00a0Date | \n |  |  |  |  |  | \n10.1 |  | Form of ExecutiveOfficerOffer Letter. |  | 10-Q |  | 001-35551 |  | 10.3 |  | July 25, 2019 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n10.2 |  | Amended and Restated Offer Letter, dated September 14, 2021, between Registrant and Marne L. Levine. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n10.3 |  | 2012 Equity Incentive Plan forms of award agreements (Additional Forms). |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n31.1 |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n31.2 |  | Certification of David M. Wehner, Chief Financial Officer, pursuant to Rule\u00a013a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.1# |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.2# |  | Certification of David M. Wehner, Chief Financial Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.INS |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.LAB |  | Inline XBRL Taxonomy Extension Labels Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n104 |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |  |  |  |  |  |  |  |  |  | X  |  |  |  |  |  |  |  | \n |  | META PLATFORMS, INC.\n | \nDate: April 27, 2022 |  | /s/ DAVID M. WEHNER\n |  | David M. WehnerChief Financial Officer(Principal Financial Officer)\n | \nDate: April 27, 2022 |  | /s/ SUSAN J.S. TAYLOR\n |  | Susan J.S. TaylorChief Accounting Officer(Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Meta, in 2022 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  | \nDelaware | 20-1665019\n(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number)  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class | Trading symbol(s) | Name of each exchange on which registered\nClass A Common Stock, $0.000006 par value | META | The Nasdaq Stock Market LLC  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer |  | \u2612 | Accelerated\u00a0filer |  | \u2610\nNon-accelerated filer |  | \u2610 | Smaller\u00a0reporting\u00a0company |  | \u2610\n |  |  | Emerging growth company |  | \u2610\n |  |  |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |  | \u2610  |  |  |  |  |  |  |  |  |  |  | \nClass | Number of Shares Outstanding\nClass\u00a0A Common Stock | $0.000006 par value | 2,280,672,002 |  | shares outstanding as of July 22, 2022\nClass B Common Stock | $0.000006 par value | 406,876,470 |  | shares outstanding as of July 22, 2022  |  |  |  |  |  |  |  | \n |  | Page\n | \nNote About Forward-Looking Statements | 3\n | \nLimitations of Key Metrics and Other Data | 4\n | \nPART I\u2014FINANCIAL INFORMATION | 7\n |  | \nItem 1. | Financial Statements (unaudited) | 7\n |  | \n | Condensed Consolidated Balance Sheets\u2014June30, 2022 and December\u00a031, 2021 | 7\n |  | \n | Condensed Consolidated Statements of Income\u2014for the threeand sixmonths endedJune30, 2022 and 2021 | 8\n |  | \n | Condensed Consolidated Statements of Comprehensive Income\u2014for the threeand sixmonths endedJune30, 2022 and 2021 | 9\n |  | \n | Condensed Consolidated Statements of Stockholders' Equity\u2014for the threeand sixmonths endedJune30, 2022 and 2021 | 10\n |  | \n | Condensed Consolidated Statements of Cash Flows\u2014for thesixmonths endedJune30, 2022 and 2021 | 11\n |  | \n | Notes to Condensed Consolidated Financial Statements | 13\n |  | \nItem 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 31\n |  | \nItem 3. | Quantitative and Qualitative Disclosures About Market Risk | 50\n |  | \nItem 4. | Controls and Procedures | 51\n | \nPART II\u2014OTHER INFORMATION | 52\n |  | \nItem 1. | Legal Proceedings | 52\n |  | \nItem\u00a01A. | Risk Factors | 55\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 88\n |  | \nItem 6. | Exhibits | 89\n | \nSIGNATURES | 90  |  |  |  |  |  |  |  |  |  |  | \n | June 30,2022 |  | December 31,2021\nAssets |  |  | \nCurrent assets: |  |  | \nCash and cash equivalents | $ | 12,681 |  |  | $ | 16,601 | \nMarketable securities | 27,808 |  |  | 31,397 | \nAccounts receivable, net | 11,525 |  |  | 14,039 | \nPrepaid expenses and other current assets | 3,973 |  |  | 4,629 | \nTotal current assets | 55,987 |  |  | 66,666 | \nNon-marketable equity securities | 6,536 |  |  | 6,775 | \nProperty and equipment, net | 67,588 |  |  | 57,809 | \nOperating lease right-of-use assets | 14,130 |  |  | 12,155 | \nIntangible assets, net | 965 |  |  | 634 | \nGoodwill | 20,229 |  |  | 19,197 | \nOther assets | 4,344 |  |  | 2,751 | \nTotal assets | $ | 169,779 |  |  | $ | 165,987 | \n |  |  | \nLiabilities and stockholders' equity |  |  | \nCurrent liabilities: |  |  | \nAccounts payable | $ | 4,008 |  |  | $ | 4,083 | \nPartners payable | 982 |  |  | 1,052 | \nOperating lease liabilities, current | 1,275 |  |  | 1,127 | \nAccrued expenses and other current liabilities | 15,420 |  |  | 14,312 | \nDeferred revenue and deposits | 532 |  |  | 561 | \nTotal current liabilities | 22,217 |  |  | 21,135 | \nOperating lease liabilities, non-current | 14,792 |  |  | 12,746 | \nOther liabilities | 7,003 |  |  | 7,227 | \nTotal liabilities | 44,012 |  |  | 41,108 | \nCommitments and contingencies |  |  | \nStockholders' equity: |  |  | \nCommon stock, $0.000006par value;5,000million Class A shares authorized,2,290million and2,328million shares issued and outstanding, as of June 30, 2022 and December 31, 2021, respectively;4,141million Class B shares authorized,407million and413million shares issued and outstanding, as of June 30, 2022 and December 31, 2021, respectively | \u2014 |  |  | \u2014 | \nAdditional paid-in capital | 59,929 |  |  | 55,811 | \nAccumulated other comprehensive loss | (3,411) |  |  | (693) | \nRetained earnings | 69,249 |  |  | 69,761 | \nTotal stockholders' equity | 125,767 |  |  | 124,879 | \nTotal liabilities and stockholders' equity | $ | 169,779 |  |  | $ | 165,987 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue | $ | 28,822 |  |  | $ | 29,077 |  |  | $ | 56,729 |  |  | $ | 55,248 | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 5,192 |  |  | 5,399 |  |  | 11,197 |  |  | 10,530 | \nResearch and development | 8,690 |  |  | 6,096 |  |  | 16,397 |  |  | 11,293 | \nMarketing and sales | 3,595 |  |  | 3,259 |  |  | 6,907 |  |  | 6,102 | \nGeneral and administrative | 2,987 |  |  | 1,956 |  |  | 5,347 |  |  | 3,578 | \nTotal costs and expenses | 20,464 |  |  | 16,710 |  |  | 39,848 |  |  | 31,503 | \nIncome from operations | 8,358 |  |  | 12,367 |  |  | 16,881 |  |  | 23,745 | \nInterest and other income (expense), net | (172) |  |  | 146 |  |  | 213 |  |  | 271 | \nIncome before provision for income taxes | 8,186 |  |  | 12,513 |  |  | 17,094 |  |  | 24,016 | \nProvision for income taxes | 1,499 |  |  | 2,119 |  |  | 2,942 |  |  | 4,124 | \nNet income | $ | 6,687 |  |  | $ | 10,394 |  |  | $ | 14,152 |  |  | $ | 19,892 | \nEarnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | $ | 2.47 |  |  | $ | 3.67 |  |  | $ | 5.21 |  |  | $ | 7.00 | \nDiluted | $ | 2.46 |  |  | $ | 3.61 |  |  | $ | 5.19 |  |  | $ | 6.90 | \nWeighted-average shares used to compute earnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | 2,704 |  |  | 2,834 |  |  | 2,714 |  |  | 2,841 | \nDiluted | 2,713 |  |  | 2,877 |  |  | 2,729 |  |  | 2,881 | \nShare-based compensation expense included in costs and expenses: |  |  |  |  |  |  | \nCost of revenue | $ | 213 |  |  | $ | 163 |  |  | $ | 373 |  |  | $ | 281 | \nResearch and development | 2,606 |  |  | 1,967 |  |  | 4,547 |  |  | 3,376 | \nMarketing and sales | 289 |  |  | 239 |  |  | 506 |  |  | 413 | \nGeneral and administrative | 243 |  |  | 179 |  |  | 424 |  |  | 309 | \nTotal share-based compensation expense | $ | 3,351 |  |  | $ | 2,548 |  |  | $ | 5,850 |  |  | $ | 4,379 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet income | $ | 6,687 |  |  | $ | 10,394 |  |  | $ | 14,152 |  |  | $ | 19,892 | \nOther comprehensive income (loss): |  |  |  |  |  |  | \nChange in foreign currency translation adjustment, net of tax | (1,076) |  |  | 169 |  |  | (1,435) |  |  | (432) | \nChange in unrealized gain (loss) on available-for-sale investments and other, net of tax | (339) |  |  | (38) |  |  | (1,283) |  |  | (210) | \nComprehensive income | $ | 5,272 |  |  | $ | 10,525 |  |  | $ | 11,434 |  |  | $ | 19,250 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2022 |  | Three Months Ended June 30, 2021\n | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity |  | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Income |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par Value |  |  | Shares |  | Par Value | \nBalances at beginning of period | 2,714 |  |  | $ | \u2014 |  |  | $ | 57,512 |  |  | $ | (1,996) |  |  | $ | 67,712 |  |  | $ | 123,228 |  |  | 2,841 |  |  | $ | \u2014 |  |  | $ | 51,160 |  |  | $ | 154 |  |  | $ | 82,343 |  |  | $ | 133,657 | \nIssuance of common stock | 14 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 11 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (5) |  |  | \u2014 |  |  | (934) |  |  | \u2014 |  |  | (68) |  |  | (1,002) |  |  | (4) |  |  | \u2014 |  |  | (863) |  |  | \u2014 |  |  | (491) |  |  | (1,354) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 3,351 |  |  | \u2014 |  |  | \u2014 |  |  | 3,351 |  |  | \u2014 |  |  | \u2014 |  |  | 2,548 |  |  | \u2014 |  |  | \u2014 |  |  | 2,548 | \nShare repurchases | (26) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (5,082) |  |  | (5,082) |  |  | (22) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (7,149) |  |  | (7,149) | \nOther comprehensive income (loss) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,415) |  |  | \u2014 |  |  | (1,415) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 131 |  |  | \u2014 |  |  | 131 | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 6,687 |  |  | 6,687 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 10,394 |  |  | 10,394 | \nBalances at end of period | 2,697 |  |  | $ | \u2014 |  |  | $ | 59,929 |  |  | $ | (3,411) |  |  | $ | 69,249 |  |  | $ | 125,767 |  |  | 2,826 |  |  | $ | \u2014 |  |  | $ | 52,845 |  |  | $ | 285 |  |  | $ | 85,097 |  |  | $ | 138,227 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30, 2022 |  | Six Months Ended June 30, 2021\n | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity |  | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Income |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par Value |  |  | Shares |  | Par Value | \nBalances at beginning of period | 2,741 |  |  | $ | \u2014 |  |  | $ | 55,811 |  |  | $ | (693) |  |  | $ | 69,761 |  |  | $ | 124,879 |  |  | 2,849 |  |  | $ | \u2014 |  |  | $ | 50,018 |  |  | $ | 927 |  |  | $ | 77,345 |  |  | $ | 128,290 | \nIssuance of common stock | 25 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 22 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (9) |  |  | \u2014 |  |  | (1,732) |  |  | \u2014 |  |  | (195) |  |  | (1,927) |  |  | (8) |  |  | \u2014 |  |  | (1,552) |  |  | \u2014 |  |  | (880) |  |  | (2,432) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 5,850 |  |  | \u2014 |  |  | \u2014 |  |  | 5,850 |  |  | \u2014 |  |  | \u2014 |  |  | 4,379 |  |  | \u2014 |  |  | \u2014 |  |  | 4,379 | \nShare repurchases | (60) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (14,469) |  |  | (14,469) |  |  | (37) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (11,260) |  |  | (11,260) | \nOther comprehensive loss | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,718) |  |  | \u2014 |  |  | (2,718) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (642) |  |  | \u2014 |  |  | (642) | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 14,152 |  |  | 14,152 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 19,892 |  |  | 19,892 | \nBalances at end of period | 2,697 |  |  | $ | \u2014 |  |  | $ | 59,929 |  |  | $ | (3,411) |  |  | $ | 69,249 |  |  | $ | 125,767 |  |  | 2,826 |  |  | $ | \u2014 |  |  | $ | 52,845 |  |  | $ | 285 |  |  | $ | 85,097 |  |  | $ | 138,227 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2022 |  | 2021\nCash flows from operating activities |  |  | \nNet income | $ | 14,152 |  |  | $ | 19,892 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nDepreciation and amortization | 4,135 |  |  | 3,958 | \nShare-based compensation | 5,850 |  |  | 4,379 | \nDeferred income taxes | (1,016) |  |  | 647 | \nOther | (33) |  |  | (88) | \nChanges in assets and liabilities: |  |  | \nAccounts receivable | 2,035 |  |  | (517) | \nPrepaid expenses and other current assets | 138 |  |  | (2,313) | \nOther assets | (132) |  |  | (195) | \nAccounts payable | (645) |  |  | (134) | \nPartners payable | (33) |  |  | (133) | \nAccrued expenses and other current liabilities | 1,943 |  |  | (200) | \nDeferred revenue and deposits | (28) |  |  | 9 | \nOther liabilities | (94) |  |  | 184 | \nNet cash provided by operating activities | 26,272 |  |  | 25,489 | \nCash flows from investing activities |  |  | \nPurchases of property and equipment | (13,013) |  |  | (8,944) | \nProceeds relating to property and equipment | 170 |  |  | 60 | \nPurchases of marketable debt securities | (6,288) |  |  | (16,528) | \nSales of marketable debt securities | 7,713 |  |  | 6,337 | \nMaturities of marketable debt securities | 913 |  |  | 6,327 | \n |  |  | \nAcquisitions of businesses and intangible assets | (1,216) |  |  | (259) | \nOther investing activities | (17) |  |  | (62) | \nNet cash used in investing activities | (11,738) |  |  | (13,069) | \nCash flows from financing activities |  |  | \nTaxes paid related to net share settlement of equity awards | (1,927) |  |  | (2,432) | \nRepurchases of Class A common stock | (14,739) |  |  | (11,018) | \nPrincipal payments on finance leases | (452) |  |  | (274) | \nNet change in overdraft in cash pooling entities | (59) |  |  | 3 | \nOther financing activities | (46) |  |  | (13) | \nNet cash used in financing activities | (17,223) |  |  | (13,734) | \nEffect of exchange rate changes on cash, cash equivalents, and restricted cash | (698) |  |  | (129) | \nNet decrease in cash, cash equivalents, and restricted cash | (3,387) |  |  | (1,443) | \nCash, cash equivalents, and restricted cash at beginning of the period | 16,865 |  |  | 17,954 | \nCash, cash equivalents, and restricted cash at end of the period | $ | 13,478 |  |  | $ | 16,511 | \n |  |  | \nReconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets |  |  | \nCash and cash equivalents | $ | 12,681 |  |  | $ | 16,186 | \nRestricted cash, included in prepaid expenses and other current assets | 228 |  |  | 201 | \nRestricted cash, included in other assets | 569 |  |  | 124 | \nTotal cash, cash equivalents, and restricted cash | $ | 13,478 |  |  | $ | 16,511 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2022 |  | 2021\nSupplemental cash flow data |  |  | \nCash paid for income taxes, net | $ | 2,641 |  |  | $ | 6,294 | \nNon-cash investing and financing activities: |  |  | \nProperty and equipment in accounts payable and accrued expenses and other current liabilities | $ | 4,543 |  |  | $ | 2,249 | \nSettlement of convertible notes with marketable equity securities | $ | 131 |  |  | $ | \u2014 | \nOther current assets through financing arrangement in accrued expenses and other current liabilities | $ | 214 |  |  | $ | 381 | \nRepurchases of Class A common stock in accrued expenses and other current liabilities | $ | 70 |  |  | $ | 310 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nAdvertising | $ | 28,152 |  |  | $ | 28,580 |  |  | $ | 55,150 |  |  | $ | 54,018 | \nOther revenue | 218 |  |  | 192 |  |  | 433 |  |  | 391 | \nFamily of Apps | 28,370 |  |  | 28,772 |  |  | 55,583 |  |  | 54,409 | \nReality Labs | 452 |  |  | 305 |  |  | 1,146 |  |  | 839 | \nTotal revenue | $ | 28,822 |  |  | $ | 29,077 |  |  | $ | 56,729 |  |  | $ | 55,248 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nUnited States and Canada(1) | $ | 12,186 |  |  | $ | 12,612 |  |  | $ | 23,965 |  |  | $ | 24,048 | \nEurope(2) | 6,650 |  |  | 7,220 |  |  | 13,288 |  |  | 13,604 | \nAsia-Pacific | 6,960 |  |  | 6,677 |  |  | 13,682 |  |  | 12,778 | \nRest of World(2) | 3,026 |  |  | 2,568 |  |  | 5,794 |  |  | 4,818 | \nTotal revenue | $ | 28,822 |  |  | $ | 29,077 |  |  | $ | 56,729 |  |  | $ | 55,248 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\n | Class A |  | Class B |  | Class A |  | Class B |  | Class A |  | Class B |  | Class A |  | Class B\nBasic EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 5,673 |  |  | $ | 1,014 |  |  | $ | 8,785 |  |  | $ | 1,609 |  |  | $ | 12,009 |  |  | $ | 2,143 |  |  | $ | 16,810 |  |  | $ | 3,082 | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,294 |  |  | 410 |  |  | 2,395 |  |  | 439 |  |  | 2,303 |  |  | 411 |  |  | 2,401 |  |  | 440 | \nBasic EPS | $ | 2.47 |  |  | $ | 2.47 |  |  | $ | 3.67 |  |  | $ | 3.67 |  |  | $ | 5.21 |  |  | $ | 5.21 |  |  | $ | 7.00 |  |  | $ | 7.00 | \nDiluted EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 5,673 |  |  | $ | 1,014 |  |  | $ | 8,785 |  |  | $ | 1,609 |  |  | $ | 12,009 |  |  | $ | 2,143 |  |  | $ | 16,810 |  |  | $ | 3,082 | \nReallocation of net income as a result of conversion of Class B to Class\u00a0A common stock | 1,014 |  |  | \u2014 |  |  | 1,609 |  |  | \u2014 |  |  | 2,143 |  |  | \u2014 |  |  | 3,082 |  |  | \u2014 | \nReallocation of net income to Class B common stock | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (24) |  |  | \u2014 |  |  | (11) |  |  | \u2014 |  |  | (44) | \nNet income for diluted EPS | $ | 6,687 |  |  | $ | 1,010 |  |  | $ | 10,394 |  |  | $ | 1,585 |  |  | $ | 14,152 |  |  | $ | 2,132 |  |  | $ | 19,892 |  |  | $ | 3,038 | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,294 |  |  | 410 |  |  | 2,395 |  |  | 439 |  |  | 2,303 |  |  | 411 |  |  | 2,401 |  |  | 440 | \nConversion of Class B to Class\u00a0A common stock | 410 |  |  | \u2014 |  |  | 439 |  |  | \u2014 |  |  | 411 |  |  | \u2014 |  |  | 440 |  |  | \u2014 | \nWeighted-average effect of dilutive RSUs | 9 |  |  | \u2014 |  |  | 43 |  |  | \u2014 |  |  | 15 |  |  | \u2014 |  |  | 40 |  |  | \u2014 | \nShares used in computation of diluted earnings per share | 2,713 |  |  | 410 |  |  | 2,877 |  |  | 439 |  |  | 2,729 |  |  | 411 |  |  | 2,881 |  |  | 440 | \nDiluted EPS | $ | 2.46 |  |  | $ | 2.46 |  |  | $ | 3.61 |  |  | $ | 3.61 |  |  | $ | 5.19 |  |  | $ | 5.19 |  |  | $ | 6.90 |  |  | $ | 6.90 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nCash and cash equivalents: |  |  | \nCash | $ | 6,322 |  |  | $ | 7,308 | \nMoney market funds | 3,879 |  |  | 8,850 | \nU.S. government securities | 624 |  |  | 25 | \nU.S. government agency securities | 1,122 |  |  | 108 | \nCertificates of deposit and time deposits | 356 |  |  | 250 | \nCorporate debt securities | 378 |  |  | 60 | \nTotal cash and cash equivalents | 12,681 |  |  | 16,601 | \nMarketable securities: |  |  | \nMarketable debt securities: |  |  | \nU.S. government securities | 9,252 |  |  | 10,901 | \nU.S. government agency securities | 5,095 |  |  | 5,927 | \nCorporate debt securities | 13,336 |  |  | 14,569 | \nTotal marketable debt securities | 27,683 |  |  | 31,397 | \nMarketable equity securities | 125 |  |  | \u2014 | \nTotal marketable securities | 27,808 |  |  | 31,397 | \nRestricted cash: |  |  | \nRestricted cash included in prepaid expenses and other current assets | 228 |  |  | 149 | \nRestricted cash included in other assets | 569 |  |  | 115 | \nTotal restricted cash | 797 |  |  | 264 | \nTotal cash, cash equivalents, marketable securities, and restricted cash | $ | 41,286 |  |  | $ | 48,262 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022\n | Less than 12 months |  | 12 months or greater |  | Total\n | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses\nU.S. government securities | $ | 8,599 |  |  | $ | (301) |  |  | $ | 212 |  |  | $ | (13) |  |  | $ | 8,811 |  |  | $ | (314) | \nU.S. government agency securities | 4,414 |  |  | (132) |  |  | 1,744 |  |  | (131) |  |  | 6,158 |  |  | (263) | \nCorporate debt securities | 12,200 |  |  | (700) |  |  | 666 |  |  | (53) |  |  | 12,866 |  |  | (753) | \nTotal | $ | 25,213 |  |  | $ | (1,133) |  |  | $ | 2,622 |  |  | $ | (197) |  |  | $ | 27,835 |  |  | $ | (1,330) |   |  |  |  |  | \n | June 30, 2022\nDue within one year | $ | 3,276 | \nDue after one year to five years | 24,407 | \nTotal | $ | 27,683 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nNon-marketable equity securities under measurement alternative: |  |  | \nInitial cost | $ | 6,385 |  |  | $ | 6,480 | \nCumulative upward adjustments | 293 |  |  | 311 | \nCumulative impairment/downward adjustments | (176) |  |  | (50) | \nCarrying value | 6,502 |  |  | 6,741 | \nNon-marketable equity securities under equity method | 34 |  |  | 34 | \nTotal | $ | 6,536 |  |  | $ | 6,775 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | June 30, 2022 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3)\nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | $ | 3,879 |  |  | $ | 3,879 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government securities |  | 624 |  |  | 624 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 1,122 |  |  | 1,122 |  |  | \u2014 |  |  | \u2014 | \nCertificates of deposit and time deposits |  | 356 |  |  | \u2014 |  |  | 356 |  |  | \u2014 | \nCorporate debt securities |  | 378 |  |  | \u2014 |  |  | 378 |  |  | \u2014 | \nMarketable debt securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 9,252 |  |  | 9,252 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 5,095 |  |  | 5,095 |  |  | \u2014 |  |  | \u2014 | \nCorporate debt securities |  | 13,336 |  |  | \u2014 |  |  | 13,336 |  |  | \u2014 | \nMarketable equity securities |  | 125 |  |  | 5 |  |  | \u2014 |  |  | 120 | \nRestricted cash equivalents |  | 448 |  |  | 448 |  |  | \u2014 |  |  | \u2014 | \nOther assets |  | 194 |  |  | \u2014 |  |  | \u2014 |  |  | 194 | \nTotal |  | $ | 34,809 |  |  | $ | 20,425 |  |  | $ | 14,070 |  |  | $ | 314 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | December 31, 2021 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3)\nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | $ | 8,850 |  |  | $ | 8,850 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government securities |  | 25 |  |  | 25 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 108 |  |  | 108 |  |  | \u2014 |  |  | \u2014 | \nCertificates of deposit and time deposits |  | 250 |  |  | \u2014 |  |  | 250 |  |  | \u2014 | \nCorporate debt securities |  | 60 |  |  | \u2014 |  |  | 60 |  |  | \u2014 | \nMarketable debt securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 10,901 |  |  | 10,901 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 5,927 |  |  | 5,927 |  |  | \u2014 |  |  | \u2014 | \nCorporate debt securities |  | 14,569 |  |  | \u2014 |  |  | 14,569 |  |  | \u2014 | \nRestricted cash equivalents |  | 71 |  |  | 71 |  |  | \u2014 |  |  | \u2014 | \nOther assets |  | 160 |  |  | \u2014 |  |  | \u2014 |  |  | 160 | \nTotal |  | $ | 40,921 |  |  | $ | 25,882 |  |  | $ | 14,879 |  |  | $ | 160 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nLand | $ | 1,703 |  |  | $ | 1,688 | \nServers and network assets | 28,996 |  |  | 25,584 | \nBuildings | 23,946 |  |  | 22,531 | \nLeasehold improvements | 6,126 |  |  | 5,795 | \nEquipment and other | 5,147 |  |  | 4,764 | \nFinance lease right-of-use assets | 3,004 |  |  | 2,840 | \nConstruction in progress | 21,100 |  |  | 14,687 | \nProperty and equipment, gross | 90,022 |  |  | 77,889 | \nLess: Accumulated depreciation | (22,434) |  |  | (20,080) | \nProperty and equipment, net | $ | 67,588 |  |  | $ | 57,809 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nFinance lease cost |  |  |  |  |  |  | \nAmortization of right-of-use assets | $ | 95 |  |  | $ | 83 |  |  | $ | 193 |  |  | $ | 164 | \nInterest | 4 |  |  | 4 |  |  | 8 |  |  | 7 | \nOperating lease cost | 435 |  |  | 371 |  |  | 846 |  |  | 733 | \nVariable lease cost and other, net | 86 |  |  | 59 |  |  | 176 |  |  | 126 | \nTotal lease cost | $ | 620 |  |  | $ | 517 |  |  | $ | 1,223 |  |  | $ | 1,030 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nWeighted-average remaining lease term |  |  | \nFinance leases | 13.9years |  | 13.9years\nOperating leases | 12.9years |  | 13.0years\nWeighted-average discount rate |  |  | \nFinance leases | 2.7 | % |  | 2.7 | %\nOperating leases | 2.9 | % |  | 2.8 | %  |  |  |  |  |  |  |  |  |  |  | \n | Operating Leases |  | Finance Leases\nThe remainder of 2022 | $ | 732 |  |  | $ | 60 | \n2023 | 1,752 |  |  | 70 | \n2024 | 1,843 |  |  | 52 | \n2025 | 1,606 |  |  | 48 | \n2026 | 1,551 |  |  | 49 | \nThereafter | 12,424 |  |  | 452 | \nTotal undiscounted cash flows | 19,908 |  |  | 731 | \nLess: Imputed interest | (3,841) |  |  | (119) | \nPresent value of lease liabilities | $ | 16,067 |  |  | $ | 612 | \n |  |  | \nLease liabilities, current | $ | 1,275 |  |  | $ | 78 | \nLease liabilities, non-current | 14,792 |  |  | 534 | \nPresent value of lease liabilities | $ | 16,067 |  |  | $ | 612 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2022 |  | 2021\nCash paid for amounts included in the measurement of lease liabilities: |  |  | \nOperating cash flows for operating leases | $ | 779 |  |  | $ | 682 | \nOperating cash flows for finance leases | $ | 8 |  |  | $ | 7 | \nFinancing cash flows for finance leases | $ | 452 |  |  | $ | 274 | \nLease liabilities arising from obtaining right-of-use assets: |  |  | \nOperating leases | $ | 3,073 |  |  | $ | 1,941 | \nFinance leases | $ | 103 |  |  | $ | 70 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total\nGoodwill at December 31, 2021 | $ | 18,458 |  |  | $ | 739 |  |  | $ | 19,197 | \nAcquisitions | 773 |  |  | 301 |  |  | 1,074 | \nAdjustments | \u2014 |  |  | (42) |  |  | (42) | \nGoodwill at June 30, 2022 | $ | 19,231 |  |  | $ | 998 |  |  | $ | 20,229 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | June 30, 2022 |  | December 31, 2021\n | Weighted-Average Remaining Useful Lives(in years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount\nAcquired technology | 5.3 |  | $ | 630 |  |  | $ | (225) |  |  | $ | 405 |  |  | $ | 1,412 |  |  | $ | (1,169) |  |  | $ | 243 | \nAcquired patents | 3.0 |  | 390 |  |  | (301) |  |  | 89 |  |  | 827 |  |  | (722) |  |  | 105 | \nTrade names | 3.9 |  | 23 |  |  | (3) |  |  | 20 |  |  | 644 |  |  | (633) |  |  | 11 | \nOther | 9.8 |  | 98 |  |  | (18) |  |  | 80 |  |  | 176 |  |  | (167) |  |  | 9 | \nTotal finite-lived assets |  |  | 1,141 |  |  | (547) |  |  | 594 |  |  | 3,059 |  |  | (2,691) |  |  | 368 | \nTotal indefinite-lived assets | N/A |  | 371 |  |  | \u2014 |  |  | 371 |  |  | 266 |  |  | \u2014 |  |  | 266 | \nTotal intangible assets |  |  | $ | 1,512 |  |  | $ | (547) |  |  | $ | 965 |  |  | $ | 3,325 |  |  | $ | (2,691) |  |  | $ | 634 |   |  |  |  |  | \nThe remainder of 2022 | $ | 99 | \n2023 | 146 | \n2024 | 118 | \n2025 | 76 | \n2026 | 35 | \nThereafter | 120 | \nTotal | $ | 594 |   |  |  |  |  | \nThe remainder of 2022 | $ | 11,777 | \n2023 | 7,633 | \n2024 | 1,465 | \n2025 | 425 | \n2026 | 295 | \nThereafter | 2,565 | \nTotal | $ | 24,160 |   |  |  |  |  |  |  |  |  |  |  | \n | Number of Shares |  | Weighted-Average Grant Date Fair Value Per Share\n | (in thousands) |  | \nUnvested at December 31, 2021 | 98,848 |  |  | $ | 244.32 | \nGranted | 83,867 |  |  | $ | 208.24 | \nVested | (25,014) |  |  | $ | 220.46 | \nForfeited | (8,515) |  |  | $ | 233.14 | \nUnvested at June 30, 2022 | 149,186 |  |  | $ | 228.67 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue: |  |  |  |  |  |  | \nFamily of Apps | $ | 28,370 |  |  | $ | 28,772 |  |  | $ | 55,583 |  |  | $ | 54,409 | \nReality Labs | 452 |  |  | 305 |  |  | 1,146 |  |  | 839 | \nTotal revenue | $ | 28,822 |  |  | $ | 29,077 |  |  | $ | 56,729 |  |  | $ | 55,248 | \n |  |  |  |  |  |  | \nIncome (loss) from operations: |  |  |  |  |  |  | \nFamily of Apps | $ | 11,164 |  |  | $ | 14,799 |  |  | $ | 22,647 |  |  | $ | 28,004 | \nReality Labs | (2,806) |  |  | (2,432) |  |  | (5,766) |  |  | (4,259) | \nTotal income from operations | $ | 8,358 |  |  | $ | 12,367 |  |  | $ | 16,881 |  |  | $ | 23,745 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nUnited States | $ | 67,040 |  |  | $ | 55,497 | \nRest of the world(1) | 14,678 |  |  | 14,467 | \nTotal long-lived assets | $ | 81,718 |  |  | $ | 69,964 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total |  |  |  |  |  | \n | Three Months Ended June 30, |  | % change |  | Three Months Ended June 30, |  | % change |  | Three Months Ended June 30, |  | % change |  |  |  | \n | 2022 |  | 2021 |  |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | (dollars in millions) |  |  |  |  |  | \nRevenue | $ | 28,370 |  |  | $ | 28,772 |  |  | (1)% |  | $ | 452 |  |  | $ | 305 |  |  | 48% |  | $ | 28,822 |  |  | $ | 29,077 |  |  | (1)% |  |  |  |  |  | \nCosts and expenses | $ | 17,206 |  |  | $ | 13,973 |  |  | 23% |  | $ | 3,258 |  |  | $ | 2,737 |  |  | 19% |  | $ | 20,464 |  |  | $ | 16,710 |  |  | 22% |  |  |  |  |  | \nIncome (loss) from operations | $ | 11,164 |  |  | $ | 14,799 |  |  | (25)% |  | $ | (2,806) |  |  | $ | (2,432) |  |  | (15)% |  | $ | 8,358 |  |  | $ | 12,367 |  |  | (32)% |  |  |  |  |  | \nOperating margin | 39 | % |  | 51 | % |  |  |  | (621) | % |  | (797) | % |  |  |  | 29 | % |  | 43 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAP/MAP: | 79% | 79% | 79% | 79% | 79% | 78% | 79% | 79% | 79%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPP: | $6.10 | $6.76 | $8.62 | $7.75 | $8.36 | $8.18 | $9.39 | $7.72 | $7.91\n |  |  |  |  |  |  |  |  | \n |  |  | Ad Revenue |  | Non-Ad Revenue |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAU/MAU: | 66% | 66% | 66% | 66% | 66% | 66% | 66% | 67% | 67%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAU/MAU: | 77% | 77% | 76% | 75% | 75% | 75% | 74% | 75% | 75% | DAU/MAU: | 74% | 74% | 74% | 73% | 73 | % | 73 | % | 72 | % | 73 | % | 74 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAU/MAU: | 61% | 62% | 62% | 62% | 62% | 63% | 63% | 64% | 64% | DAU/MAU: | 65 | % | 65 | % | 65 | % | 65 | % | 65 | % | 66 | % | 65 | % | 66 | % | 66 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPU: | $7.05 | $7.89 | $10.14 | $9.27 | $10.12 | $10.00 | $11.57 | $9.54 | $9.82  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPU: | $ | 36.49 |  | $ | 39.63 |  | $ | 53.56 |  | $ | 48.03 |  | $ | 53.01 |  | $ | 52.34 |  | $ | 60.57 |  | $ | 48.29 |  | $ | 50.25 |  | ARPU: | $11.03 | $12.41 | $16.87 | $15.49 | $17.23 | $16.50 | $19.68 | $15.35 | $15.64  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPU: | $2.99 | $3.67 | $4.05 | $3.94 | $4.16 | $4.30 | $4.89 | $4.47 | $4.54 | ARPU: | $1.78 | $2.22 | $2.77 | $2.64 | $3.05 | $3.14 | $3.43 | $3.14 | $3.35\n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | Ad Revenue |  | Non-Ad Revenue |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue | $ | 28,822 |  |  | $ | 29,077 |  |  | $ | 56,729 |  |  | $ | 55,248 | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 5,192 |  |  | 5,399 |  |  | 11,197 |  |  | 10,530 | \nResearch and development | 8,690 |  |  | 6,096 |  |  | 16,397 |  |  | 11,293 | \nMarketing and sales | 3,595 |  |  | 3,259 |  |  | 6,907 |  |  | 6,102 | \nGeneral and administrative | 2,987 |  |  | 1,956 |  |  | 5,347 |  |  | 3,578 | \nTotal costs and expenses | 20,464 |  |  | 16,710 |  |  | 39,848 |  |  | 31,503 | \nIncome from operations | 8,358 |  |  | 12,367 |  |  | 16,881 |  |  | 23,745 | \nInterest and other income (expense), net | (172) |  |  | 146 |  |  | 213 |  |  | 271 | \nIncome before provision for income taxes | 8,186 |  |  | 12,513 |  |  | 17,094 |  |  | 24,016 | \nProvision for income taxes | 1,499 |  |  | 2,119 |  |  | 2,942 |  |  | 4,124 | \nNet income | $ | 6,687 |  |  | $ | 10,394 |  |  | $ | 14,152 |  |  | $ | 19,892 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue | 100 | % |  | 100 | % |  | 100 | % |  | 100 | %\nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 18 |  |  | 19 |  |  | 20 |  |  | 19 | \nResearch and development | 30 |  |  | 21 |  |  | 29 |  |  | 20 | \nMarketing and sales | 12 |  |  | 11 |  |  | 12 |  |  | 11 | \nGeneral and administrative | 10 |  |  | 7 |  |  | 9 |  |  | 6 | \nTotal costs and expenses | 71 |  |  | 57 |  |  | 70 |  |  | 57 | \nIncome from operations | 29 |  |  | 43 |  |  | 30 |  |  | 43 | \nInterest and other income (expense), net | (1) |  |  | 1 |  |  | \u2014 |  |  | \u2014 | \nIncome before provision for income taxes | 28 |  |  | 43 |  |  | 30 |  |  | 43 | \nProvision for income taxes | 5 |  |  | 7 |  |  | 5 |  |  | 7 | \nNet income | 23 | % |  | 36 | % |  | 25 | % |  | 36 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nCost of revenue | $ | 213 |  |  | $ | 163 |  |  | $ | 373 |  |  | $ | 281 | \nResearch and development | 2,606 |  |  | 1,967 |  |  | 4,547 |  |  | 3,376 | \nMarketing and sales | 289 |  |  | 239 |  |  | 506 |  |  | 413 | \nGeneral and administrative | 243 |  |  | 179 |  |  | 424 |  |  | 309 | \nTotal share-based compensation expense | $ | 3,351 |  |  | $ | 2,548 |  |  | $ | 5,850 |  |  | $ | 4,379 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nCost of revenue | 1 | % |  | 1 | % |  | 1 | % |  | 1 | %\nResearch and development | 9 |  |  | 7 |  |  | 8 |  |  | 6 | \nMarketing and sales | 1 |  |  | 1 |  |  | 1 |  |  | 1 | \nGeneral and administrative | 1 |  |  | 1 |  |  | 1 |  |  | 1 | \nTotal share-based compensation expense | 12 | % |  | 9 | % |  | 10 | % |  | 8 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nAdvertising | $ | 28,152 |  |  | $ | 28,580 |  |  | (1) | % |  | $ | 55,150 |  |  | $ | 54,018 |  |  | 2 | %\nOther revenue | 218 |  |  | 192 |  |  | 14 | % |  | 433 |  |  | 391 |  |  | 11 | %\nFamily of Apps | 28,370 |  |  | 28,772 |  |  | (1) | % |  | 55,583 |  |  | 54,409 |  |  | 2 | %\nReality Labs | 452 |  |  | 305 |  |  | 48 | % |  | 1,146 |  |  | 839 |  |  | 37 | %\nTotal revenue | $ | 28,822 |  |  | $ | 29,077 |  |  | (1) | % |  | $ | 56,729 |  |  | $ | 55,248 |  |  | 3 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nCost of revenue | $ | 5,192 |  |  | $ | 5,399 |  |  | (4) | % |  | $ | 11,197 |  |  | $ | 10,530 |  |  | 6 | %\nPercentage of revenue | 18 | % |  | 19 | % |  |  |  | 20 | % |  | 19 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nResearch and development | $ | 8,690 |  |  | $ | 6,096 |  |  | 43 | % |  | $ | 16,397 |  |  | $ | 11,293 |  |  | 45 | %\nPercentage of revenue | 30 | % |  | 21 | % |  |  |  | 29 | % |  | 20 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nMarketing and sales | $ | 3,595 |  |  | $ | 3,259 |  |  | 10 | % |  | $ | 6,907 |  |  | $ | 6,102 |  |  | 13 | %\nPercentage of revenue | 12 | % |  | 11 | % |  |  |  | 12 | % |  | 11 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nGeneral and administrative | $ | 2,987 |  |  | $ | 1,956 |  |  | 53 | % |  | $ | 5,347 |  |  | $ | 3,578 |  |  | 49 | %\nPercentage of revenue | 10 | % |  | 7 | % |  |  |  | 9 | % |  | 6 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nFamily of Apps | $ | 11,164 |  |  | $ | 14,799 |  |  | (25) | % |  | $ | 22,647 |  |  | $ | 28,004 |  |  | (19) | %\nReality Labs | (2,806) |  |  | (2,432) |  |  | (15) | % |  | (5,766) |  |  | (4,259) |  |  | (35) | %\nTotal income from operations | $ | 8,358 |  |  | $ | 12,367 |  |  | (32) | % |  | $ | 16,881 |  |  | $ | 23,745 |  |  | (29) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nInterest income | $ | 91 |  |  | $ | 121 |  |  | (25) | % |  | $ | 167 |  |  | $ | 239 |  |  | (30) | %\nForeign currency exchange gains (losses), net | (60) |  |  | \u2014 |  |  | (100) | % |  | (6) |  |  | (93) |  |  | 94 | %\nOther income (expense), net | (203) |  |  | 25 |  |  | NM |  | 52 |  |  | 125 |  |  | (58) | %\nInterest and other income (expense) | $ | (172) |  |  | $ | 146 |  |  | (218) | % |  | $ | 213 |  |  | $ | 271 |  |  | (21) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nProvision for income taxes | $ | 1,499 |  |  | $ | 2,119 |  |  | (29) | % |  | $ | 2,942 |  |  | $ | 4,124 |  |  | (29) | %\nEffective tax rate | 18 | % |  | 17 | % |  |  |  | 17 | % |  | 17 | % |  |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2022 |  | 2021\nNet cash provided by operating activities | $ | 26,272 |  |  | $ | 25,489 | \nNet cash used in investing activities | $ | (11,738) |  |  | $ | (13,069) | \nNet cash used in financing activities | $ | (17,223) |  |  | $ | (13,734) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total Number of Shares Purchased(1) |  | Average Price Paid Per Share(2) |  | Total Number of Shares Purchased as Part of Publicly Announced Programs(1) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(1)\n | (in thousands) |  |  |  | (in thousands) |  | (in millions)\nApril 1 - 30, 2022 | 10,633 |  |  | $ | 207.84 |  |  | 10,633 |  |  | $ | 27,197 | \nMay 1 - 31, 2022 | 10,237 |  |  | $ | 197.06 |  |  | 10,237 |  |  | $ | 25,179 | \nJune 1 - 30, 2022 | 4,865 |  |  | $ | 175.74 |  |  | 4,865 |  |  | $ | 24,324 | \n | 25,735 |  |  |  |  | 25,735 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nExhibit |  |  |  | Incorporated by Reference |  | FiledHerewith\nNumber |  | Exhibit Description |  | Form |  | File No. |  | Exhibit |  | Filing\u00a0Date | \n |  |  |  |  |  | \n31.1 |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n31.2 |  | Certification of David M. Wehner, Chief Financial Officer, pursuant to Rule\u00a013a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.1# |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.2# |  | Certification of David M. Wehner, Chief Financial Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.INS |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.LAB |  | Inline XBRL Taxonomy Extension Labels Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n104 |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |  |  |  |  |  |  |  |  |  | X  |  |  |  |  |  |  |  | \n |  | META PLATFORMS, INC.\n | \nDate: July 27, 2022 |  | /s/ DAVID M. WEHNER\n |  | David M. WehnerChief Financial Officer(Principal Financial Officer)\n | \nDate: July 27, 2022 |  | /s/ SUSAN J.S. TAYLOR\n |  | Susan J.S. TaylorChief Accounting Officer(Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Meta, in 2022 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  | \nDelaware | 20-1665019\n(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number)  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class | Trading symbol(s) | Name of each exchange on which registered\nClass A Common Stock, $0.000006 par value | META | The Nasdaq Stock Market LLC  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer |  | \u2612 | Accelerated\u00a0filer |  | \u2610\nNon-accelerated filer |  | \u2610 | Smaller\u00a0reporting\u00a0company |  | \u2610\n |  |  | Emerging growth company |  | \u2610\n |  |  |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |  | \u2610  |  |  |  |  |  |  |  |  |  |  | \nClass | Number of Shares Outstanding\nClass\u00a0A Common Stock | $0.000006 par value | 2,248,672,204 |  | shares outstanding as of October 21, 2022\nClass B Common Stock | $0.000006 par value | 402,876,470 |  | shares outstanding as of October 21, 2022  |  |  |  |  |  |  |  | \n |  | Page\n | \nNote About Forward-Looking Statements | 3\n | \nLimitations of Key Metrics and Other Data | 4\n | \nPART I\u2014FINANCIAL INFORMATION | 7\n |  | \nItem 1. | Financial Statements (unaudited) | 7\n |  | \n | Condensed Consolidated Balance Sheets\u2014September30, 2022 and December\u00a031, 2021 | 7\n |  | \n | Condensed Consolidated Statements of Income\u2014for the three andninemonths endedSeptember30, 2022 and 2021 | 8\n |  | \n | Condensed Consolidated Statements of Comprehensive Income\u2014for the three andninemonths endedSeptember30, 2022 and 2021 | 9\n |  | \n | Condensed Consolidated Statements of Stockholders' Equity\u2014for the three andninemonths endedSeptember30, 2022 and 2021 | 10\n |  | \n | Condensed Consolidated Statements of Cash Flows\u2014for theninemonths endedSeptember30, 2022 and 2021 | 11\n |  | \n | Notes to Condensed Consolidated Financial Statements | 13\n |  | \nItem 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 32\n |  | \nItem 3. | Quantitative and Qualitative Disclosures About Market Risk | 53\n |  | \nItem 4. | Controls and Procedures | 55\n | \nPART II\u2014OTHER INFORMATION | 56\n |  | \nItem 1. | Legal Proceedings | 56\n |  | \nItem\u00a01A. | Risk Factors | 59\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 92\n |  | \nItem 6. | Exhibits | 93\n | \nSIGNATURES | 95  |  |  |  |  |  |  |  |  |  |  | \n | September 30,2022 |  | December 31,2021\nAssets |  |  | \nCurrent assets: |  |  | \nCash and cash equivalents | $ | 14,308 |  |  | $ | 16,601 | \nMarketable securities | 27,468 |  |  | 31,397 | \nAccounts receivable, net | 11,227 |  |  | 14,039 | \nPrepaid expenses and other current assets | 5,312 |  |  | 4,629 | \nTotal current assets | 58,315 |  |  | 66,666 | \nNon-marketable equity securities | 6,528 |  |  | 6,775 | \nProperty and equipment, net | 73,738 |  |  | 57,809 | \nOperating lease right-of-use assets | 13,641 |  |  | 12,155 | \nIntangible assets, net | 875 |  |  | 634 | \nGoodwill | 20,268 |  |  | 19,197 | \nOther assets | 5,529 |  |  | 2,751 | \nTotal assets | $ | 178,894 |  |  | $ | 165,987 | \n |  |  | \nLiabilities and stockholders' equity |  |  | \nCurrent liabilities: |  |  | \nAccounts payable | $ | 3,871 |  |  | $ | 4,083 | \nPartners payable | 975 |  |  | 1,052 | \nOperating lease liabilities, current | 1,291 |  |  | 1,127 | \nAccrued expenses and other current liabilities | 16,036 |  |  | 14,312 | \nDeferred revenue and deposits | 514 |  |  | 561 | \nTotal current liabilities | 22,687 |  |  | 21,135 | \nOperating lease liabilities, non-current | 14,687 |  |  | 12,746 | \nLong-term debt | 9,922 |  |  | \u2014 | \nOther liabilities | 7,504 |  |  | 7,227 | \nTotal liabilities | 54,800 |  |  | 41,108 | \nCommitments and contingencies |  |  | \nStockholders' equity: |  |  | \nCommon stock, $0.000006par value;5,000million Class A shares authorized,2,262million and2,328million shares issued and outstanding, as of September 30, 2022 and December 31, 2021, respectively;4,141million Class B shares authorized,403million and413million shares issued and outstanding, as of September 30, 2022 and December 31, 2021, respectively | \u2014 |  |  | \u2014 | \nAdditional paid-in capital | 62,092 |  |  | 55,811 | \nAccumulated other comprehensive loss | (5,054) |  |  | (693) | \nRetained earnings | 67,056 |  |  | 69,761 | \nTotal stockholders' equity | 124,094 |  |  | 124,879 | \nTotal liabilities and stockholders' equity | $ | 178,894 |  |  | $ | 165,987 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue | $ | 27,714 |  |  | $ | 29,010 |  |  | $ | 84,444 |  |  | $ | 84,258 | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 5,716 |  |  | 5,771 |  |  | 16,913 |  |  | 16,301 | \nResearch and development | 9,170 |  |  | 6,316 |  |  | 25,567 |  |  | 17,609 | \nMarketing and sales | 3,780 |  |  | 3,554 |  |  | 10,688 |  |  | 9,656 | \nGeneral and administrative | 3,384 |  |  | 2,946 |  |  | 8,731 |  |  | 6,524 | \nTotal costs and expenses | 22,050 |  |  | 18,587 |  |  | 61,899 |  |  | 50,090 | \nIncome from operations | 5,664 |  |  | 10,423 |  |  | 22,545 |  |  | 34,168 | \nInterest and other income (expense), net | (88) |  |  | 142 |  |  | 125 |  |  | 413 | \nIncome before provision for income taxes | 5,576 |  |  | 10,565 |  |  | 22,670 |  |  | 34,581 | \nProvision for income taxes | 1,181 |  |  | 1,371 |  |  | 4,123 |  |  | 5,496 | \nNet income | $ | 4,395 |  |  | $ | 9,194 |  |  | $ | 18,547 |  |  | $ | 29,085 | \nEarnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | $ | 1.64 |  |  | $ | 3.27 |  |  | $ | 6.86 |  |  | $ | 10.27 | \nDiluted | $ | 1.64 |  |  | $ | 3.22 |  |  | $ | 6.82 |  |  | $ | 10.11 | \nWeighted-average shares used to compute earnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | 2,682 |  |  | 2,814 |  |  | 2,703 |  |  | 2,832 | \nDiluted | 2,687 |  |  | 2,859 |  |  | 2,718 |  |  | 2,876 | \nShare-based compensation expense included in costs and expenses: |  |  |  |  |  |  | \nCost of revenue | $ | 209 |  |  | $ | 147 |  |  | $ | 582 |  |  | $ | 428 | \nResearch and development | 2,447 |  |  | 1,849 |  |  | 6,995 |  |  | 5,224 | \nMarketing and sales | 260 |  |  | 218 |  |  | 766 |  |  | 631 | \nGeneral and administrative | 218 |  |  | 165 |  |  | 641 |  |  | 474 | \nTotal share-based compensation expense | $ | 3,134 |  |  | $ | 2,379 |  |  | $ | 8,984 |  |  | $ | 6,757 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet income | $ | 4,395 |  |  | $ | 9,194 |  |  | $ | 18,547 |  |  | $ | 29,085 | \nOther comprehensive loss: |  |  |  |  |  |  | \nChange in foreign currency translation adjustment, net of tax | (1,037) |  |  | (424) |  |  | (2,472) |  |  | (856) | \nChange in unrealized gain (loss) on available-for-sale investments and other, net of tax | (606) |  |  | (68) |  |  | (1,889) |  |  | (278) | \nComprehensive income | $ | 2,752 |  |  | $ | 8,702 |  |  | $ | 14,186 |  |  | $ | 27,951 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, 2022 |  | Three Months Ended September 30, 2021\n | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity |  | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Income (Loss) |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par Value |  |  | Shares |  | Par Value | \nBalances at beginning of period | 2,697 |  |  | $ | \u2014 |  |  | $ | 59,929 |  |  | $ | (3,411) |  |  | $ | 69,249 |  |  | $ | 125,767 |  |  | 2,826 |  |  | $ | \u2014 |  |  | $ | 52,845 |  |  | $ | 285 |  |  | $ | 85,097 |  |  | $ | 138,227 | \nIssuance of common stock | 14 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 11 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (5) |  |  | \u2014 |  |  | (971) |  |  | \u2014 |  |  | (40) |  |  | (1,011) |  |  | (4) |  |  | \u2014 |  |  | (890) |  |  | \u2014 |  |  | (686) |  |  | (1,576) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 3,134 |  |  | \u2014 |  |  | \u2014 |  |  | 3,134 |  |  | \u2014 |  |  | \u2014 |  |  | 2,379 |  |  | \u2014 |  |  | \u2014 |  |  | 2,379 | \nShare repurchases | (41) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (6,548) |  |  | (6,548) |  |  | (40) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (14,372) |  |  | (14,372) | \nOther comprehensive loss | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,643) |  |  | \u2014 |  |  | (1,643) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (492) |  |  | \u2014 |  |  | (492) | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4,395 |  |  | 4,395 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 9,194 |  |  | 9,194 | \nBalances at end of period | 2,665 |  |  | $ | \u2014 |  |  | $ | 62,092 |  |  | $ | (5,054) |  |  | $ | 67,056 |  |  | $ | 124,094 |  |  | 2,793 |  |  | $ | \u2014 |  |  | $ | 54,334 |  |  | $ | (207) |  |  | $ | 79,233 |  |  | $ | 133,360 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30, 2022 |  | Nine Months Ended September 30, 2021\n | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity |  | Class\u00a0A and Class\u00a0B Common\u00a0Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Income (Loss) |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par Value |  |  | Shares |  | Par Value | \nBalances at beginning of period | 2,741 |  |  | $ | \u2014 |  |  | $ | 55,811 |  |  | $ | (693) |  |  | $ | 69,761 |  |  | $ | 124,879 |  |  | 2,849 |  |  | $ | \u2014 |  |  | $ | 50,018 |  |  | $ | 927 |  |  | $ | 77,345 |  |  | $ | 128,290 | \nIssuance of common stock | 39 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 33 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (14) |  |  | \u2014 |  |  | (2,703) |  |  | \u2014 |  |  | (235) |  |  | (2,938) |  |  | (12) |  |  | \u2014 |  |  | (2,441) |  |  | \u2014 |  |  | (1,566) |  |  | (4,007) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 8,984 |  |  | \u2014 |  |  | \u2014 |  |  | 8,984 |  |  | \u2014 |  |  | \u2014 |  |  | 6,757 |  |  | \u2014 |  |  | \u2014 |  |  | 6,757 | \nShare repurchases | (101) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (21,017) |  |  | (21,017) |  |  | (77) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (25,631) |  |  | (25,631) | \nOther comprehensive loss | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,361) |  |  | \u2014 |  |  | (4,361) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,134) |  |  | \u2014 |  |  | (1,134) | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 18,547 |  |  | 18,547 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 29,085 |  |  | 29,085 | \nBalances at end of period | 2,665 |  |  | $ | \u2014 |  |  | $ | 62,092 |  |  | $ | (5,054) |  |  | $ | 67,056 |  |  | $ | 124,094 |  |  | 2,793 |  |  | $ | \u2014 |  |  | $ | 54,334 |  |  | $ | (207) |  |  | $ | 79,233 |  |  | $ | 133,360 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2022 |  | 2021\nCash flows from operating activities |  |  | \nNet income | $ | 18,547 |  |  | $ | 29,085 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nDepreciation and amortization | 6,310 |  |  | 5,953 | \nShare-based compensation | 8,984 |  |  | 6,757 | \nDeferred income taxes | (2,113) |  |  | (139) | \nImpairment related to leases and leasehold improvements | 413 |  |  | \u2014 | \nOther | 71 |  |  | (161) | \nChanges in assets and liabilities: |  |  | \nAccounts receivable | 1,930 |  |  | (1,072) | \nPrepaid expenses and other current assets | (693) |  |  | (2,566) | \nOther assets | (160) |  |  | (184) | \nAccounts payable | (666) |  |  | 560 | \nPartners payable | (12) |  |  | (163) | \nAccrued expenses and other current liabilities | 2,942 |  |  | 895 | \nDeferred revenue and deposits | (35) |  |  | 87 | \nOther liabilities | 446 |  |  | 527 | \nNet cash provided by operating activities | 35,964 |  |  | 39,579 | \nCash flows from investing activities |  |  | \nPurchases of property and equipment | (22,388) |  |  | (13,290) | \nProceeds relating to property and equipment | 190 |  |  | 92 | \nPurchases of marketable debt securities | (8,885) |  |  | (24,314) | \nSales of marketable debt securities | 9,333 |  |  | 15,331 | \nMaturities of marketable debt securities | 1,562 |  |  | 9,318 | \n |  |  | \nAcquisitions of businesses and intangible assets | (1,250) |  |  | (330) | \nOther investing activities | (1) |  |  | (206) | \nNet cash used in investing activities | (21,439) |  |  | (13,399) | \nCash flows from financing activities |  |  | \nTaxes paid related to net share settlement of equity awards | (2,938) |  |  | (4,007) | \nRepurchases of Class A common stock | (21,093) |  |  | (24,476) | \nProceeds from issuance of long-term debt, net | 9,921 |  |  | \u2014 | \nPrincipal payments on finance leases | (615) |  |  | (505) | \nNet change in overdraft in cash pooling entities | (250) |  |  | 15 | \nOther financing activities | (101) |  |  | (13) | \nNet cash used in financing activities | (15,076) |  |  | (28,986) | \nEffect of exchange rate changes on cash, cash equivalents, and restricted cash | (1,063) |  |  | (344) | \nNet decrease in cash, cash equivalents, and restricted cash | (1,614) |  |  | (3,150) | \nCash, cash equivalents, and restricted cash at beginning of the period | 16,865 |  |  | 17,954 | \nCash, cash equivalents, and restricted cash at end of the period | $ | 15,251 |  |  | $ | 14,804 | \n |  |  | \nReconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets |  |  | \nCash and cash equivalents | $ | 14,308 |  |  | $ | 14,496 | \nRestricted cash, included in prepaid expenses and other current assets | 232 |  |  | 195 | \nRestricted cash, included in other assets | 711 |  |  | 113 | \nTotal cash, cash equivalents, and restricted cash | $ | 15,251 |  |  | $ | 14,804 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2022 |  | 2021\nSupplemental cash flow data |  |  | \nCash paid for income taxes, net | $ | 4,647 |  |  | $ | 7,919 | \nNon-cash investing and financing activities: |  |  | \nProperty and equipment in accounts payable and accrued expenses and other current liabilities | $ | 4,130 |  |  | $ | 2,635 | \n |  |  | \nAcquisition of businesses in accrued expenses and other current liabilities and other liabilities | $ | 294 |  |  | $ | 73 | \nOther current assets through financing arrangement in accrued expenses and other current liabilities | $ | 18 |  |  | $ | 491 | \nRepurchases of Class A common stock in accrued expenses and other current liabilities | $ | 265 |  |  | $ | 1,223 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nAdvertising | $ | 27,237 |  |  | $ | 28,276 |  |  | $ | 82,387 |  |  | $ | 82,294 | \nOther revenue | 192 |  |  | 176 |  |  | 624 |  |  | 567 | \nFamily of Apps | 27,429 |  |  | 28,452 |  |  | 83,011 |  |  | 82,861 | \nReality Labs | 285 |  |  | 558 |  |  | 1,433 |  |  | 1,397 | \nTotal revenue | $ | 27,714 |  |  | $ | 29,010 |  |  | $ | 84,444 |  |  | $ | 84,258 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nUnited States and Canada(1) | $ | 11,966 |  |  | $ | 12,668 |  |  | $ | 35,931 |  |  | $ | 36,716 | \nEurope(2) | 5,996 |  |  | 7,018 |  |  | 19,284 |  |  | 20,622 | \nAsia-Pacific | 6,797 |  |  | 6,592 |  |  | 20,480 |  |  | 19,370 | \nRest of World(2) | 2,955 |  |  | 2,732 |  |  | 8,749 |  |  | 7,550 | \nTotal revenue | $ | 27,714 |  |  | $ | 29,010 |  |  | $ | 84,444 |  |  | $ | 84,258 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\n | Class A |  | Class B |  | Class A |  | Class B |  | Class A |  | Class B |  | Class A |  | Class B\nBasic EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 3,729 |  |  | $ | 666 |  |  | $ | 7,782 |  |  | $ | 1,412 |  |  | $ | 15,736 |  |  | $ | 2,811 |  |  | $ | 24,588 |  |  | $ | 4,497 | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,276 |  |  | 406 |  |  | 2,382 |  |  | 432 |  |  | 2,293 |  |  | 410 |  |  | 2,394 |  |  | 438 | \nBasic EPS | $ | 1.64 |  |  | $ | 1.64 |  |  | $ | 3.27 |  |  | $ | 3.27 |  |  | $ | 6.86 |  |  | $ | 6.86 |  |  | $ | 10.27 |  |  | $ | 10.27 | \nDiluted EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 3,729 |  |  | $ | 666 |  |  | $ | 7,782 |  |  | $ | 1,412 |  |  | $ | 15,736 |  |  | $ | 2,811 |  |  | $ | 24,588 |  |  | $ | 4,497 | \nReallocation of net income as a result of conversion of Class B to Class\u00a0A common stock | 666 |  |  | \u2014 |  |  | 1,412 |  |  | \u2014 |  |  | 2,811 |  |  | \u2014 |  |  | 4,497 |  |  | \u2014 | \nReallocation of net income to Class B common stock | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (22) |  |  | \u2014 |  |  | (16) |  |  | \u2014 |  |  | (69) | \nNet income for diluted EPS | $ | 4,395 |  |  | $ | 665 |  |  | $ | 9,194 |  |  | $ | 1,390 |  |  | $ | 18,547 |  |  | $ | 2,795 |  |  | $ | 29,085 |  |  | $ | 4,428 | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,276 |  |  | 406 |  |  | 2,382 |  |  | 432 |  |  | 2,293 |  |  | 410 |  |  | 2,394 |  |  | 438 | \nConversion of Class B to Class\u00a0A common stock | 406 |  |  | \u2014 |  |  | 432 |  |  | \u2014 |  |  | 410 |  |  | \u2014 |  |  | 438 |  |  | \u2014 | \nWeighted-average effect of dilutive RSUs | 5 |  |  | \u2014 |  |  | 45 |  |  | \u2014 |  |  | 15 |  |  | \u2014 |  |  | 44 |  |  | \u2014 | \nShares used in computation of diluted earnings per share | 2,687 |  |  | 406 |  |  | 2,859 |  |  | 432 |  |  | 2,718 |  |  | 410 |  |  | 2,876 |  |  | 438 | \nDiluted EPS | $ | 1.64 |  |  | $ | 1.64 |  |  | $ | 3.22 |  |  | $ | 3.22 |  |  | $ | 6.82 |  |  | $ | 6.82 |  |  | $ | 10.11 |  |  | $ | 10.11 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\nCash and cash equivalents: |  |  | \nCash | $ | 6,160 |  |  | $ | 7,308 | \nMoney market funds | 6,789 |  |  | 8,850 | \nU.S. government securities | 752 |  |  | 25 | \nU.S. government agency securities | 155 |  |  | 108 | \nCertificates of deposit and time deposits | 435 |  |  | 250 | \nCorporate debt securities | 17 |  |  | 60 | \nTotal cash and cash equivalents | 14,308 |  |  | 16,601 | \nMarketable securities: |  |  | \nMarketable debt securities: |  |  | \nU.S. government securities | 9,303 |  |  | 10,901 | \nU.S. government agency securities | 5,049 |  |  | 5,927 | \nCorporate debt securities | 13,033 |  |  | 14,569 | \nTotal marketable debt securities | 27,385 |  |  | 31,397 | \nMarketable equity securities | 83 |  |  | \u2014 | \nTotal marketable securities | 27,468 |  |  | 31,397 | \nRestricted cash: |  |  | \nRestricted cash included in prepaid expenses and other current assets | 232 |  |  | 149 | \nRestricted cash included in other assets | 711 |  |  | 115 | \nTotal restricted cash | 943 |  |  | 264 | \nTotal cash, cash equivalents, marketable securities, and restricted cash | $ | 42,719 |  |  | $ | 48,262 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022\n | Less than 12 months |  | 12 months or greater |  | Total\n | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses\nU.S. government securities | $ | 7,418 |  |  | $ | (423) |  |  | $ | 1,793 |  |  | $ | (119) |  |  | $ | 9,211 |  |  | $ | (542) | \nU.S. government agency securities | 2,117 |  |  | (82) |  |  | 2,934 |  |  | (270) |  |  | 5,051 |  |  | (352) | \nCorporate debt securities | 8,861 |  |  | (653) |  |  | 3,869 |  |  | (374) |  |  | 12,730 |  |  | (1,027) | \nTotal | $ | 18,396 |  |  | $ | (1,158) |  |  | $ | 8,596 |  |  | $ | (763) |  |  | $ | 26,992 |  |  | $ | (1,921) |   |  |  |  |  | \n | September 30, 2022\nDue within one year | $ | 4,116 | \nDue after one year to five years | 23,269 | \nTotal | $ | 27,385 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\nNon-marketable equity securities under measurement alternative: |  |  | \nInitial cost | $ | 6,388 |  |  | $ | 6,480 | \nCumulative upward adjustments | 293 |  |  | 311 | \nCumulative impairment/downward adjustments | (186) |  |  | (50) | \nCarrying value | 6,495 |  |  | 6,741 | \nNon-marketable equity securities under equity method | 33 |  |  | 34 | \nTotal | $ | 6,528 |  |  | $ | 6,775 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | September 30, 2022 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3)\nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | $ | 6,789 |  |  | $ | 6,789 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government securities |  | 752 |  |  | 752 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 155 |  |  | 155 |  |  | \u2014 |  |  | \u2014 | \nCertificates of deposit and time deposits |  | 435 |  |  | \u2014 |  |  | 435 |  |  | \u2014 | \nCorporate debt securities |  | 17 |  |  | \u2014 |  |  | 17 |  |  | \u2014 | \nMarketable securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 9,303 |  |  | 9,303 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 5,049 |  |  | 5,049 |  |  | \u2014 |  |  | \u2014 | \nCorporate debt securities |  | 13,033 |  |  | \u2014 |  |  | 13,033 |  |  | \u2014 | \nMarketable equity securities |  | 83 |  |  | 4 |  |  | \u2014 |  |  | 79 | \nRestricted cash equivalents |  | 586 |  |  | 586 |  |  | \u2014 |  |  | \u2014 | \nOther assets |  | 194 |  |  | \u2014 |  |  | \u2014 |  |  | 194 | \nTotal |  | $ | 36,396 |  |  | $ | 22,638 |  |  | $ | 13,485 |  |  | $ | 273 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | December 31, 2021 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3)\nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | $ | 8,850 |  |  | $ | 8,850 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government securities |  | 25 |  |  | 25 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 108 |  |  | 108 |  |  | \u2014 |  |  | \u2014 | \nCertificates of deposit and time deposits |  | 250 |  |  | \u2014 |  |  | 250 |  |  | \u2014 | \nCorporate debt securities |  | 60 |  |  | \u2014 |  |  | 60 |  |  | \u2014 | \nMarketable securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 10,901 |  |  | 10,901 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 5,927 |  |  | 5,927 |  |  | \u2014 |  |  | \u2014 | \nCorporate debt securities |  | 14,569 |  |  | \u2014 |  |  | 14,569 |  |  | \u2014 | \nRestricted cash equivalents |  | 71 |  |  | 71 |  |  | \u2014 |  |  | \u2014 | \nOther assets |  | 160 |  |  | \u2014 |  |  | \u2014 |  |  | 160 | \nTotal |  | $ | 40,921 |  |  | $ | 25,882 |  |  | $ | 14,879 |  |  | $ | 160 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\nLand | $ | 1,762 |  |  | $ | 1,688 | \nServers and network assets | 31,438 |  |  | 25,584 | \nBuildings | 25,313 |  |  | 22,531 | \nLeasehold improvements | 6,625 |  |  | 5,795 | \nEquipment and other | 5,375 |  |  | 4,764 | \nFinance lease right-of-use assets | 2,995 |  |  | 2,840 | \nConstruction in progress | 23,623 |  |  | 14,687 | \nProperty and equipment, gross | 97,131 |  |  | 77,889 | \nLess: Accumulated depreciation | (23,393) |  |  | (20,080) | \nProperty and equipment, net | $ | 73,738 |  |  | $ | 57,809 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nFinance lease cost: |  |  |  |  |  |  | \nAmortization of right-of-use assets | $ | 92 |  |  | $ | 88 |  |  | $ | 285 |  |  | $ | 252 | \nInterest | 4 |  |  | 4 |  |  | 12 |  |  | 11 | \nOperating lease cost | 480 |  |  | 386 |  |  | 1,326 |  |  | 1,119 | \nVariable lease cost and other, net | 87 |  |  | 68 |  |  | 263 |  |  | 194 | \nTotal lease cost | $ | 663 |  |  | $ | 546 |  |  | $ | 1,886 |  |  | $ | 1,576 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\nWeighted-average remaining lease term: |  |  | \nFinance leases | 13.9years |  | 13.9years\nOperating leases | 12.7years |  | 13.0years\nWeighted-average discount rate: |  |  | \nFinance leases | 2.8 | % |  | 2.7 | %\nOperating leases | 3.0 | % |  | 2.8 | %  |  |  |  |  |  |  |  |  |  |  | \n | Operating Leases |  | Finance Leases\nThe remainder of 2022 | $ | 302 |  |  | $ | 28 | \n2023 | 1,775 |  |  | 68 | \n2024 | 1,916 |  |  | 55 | \n2025 | 1,630 |  |  | 47 | \n2026 | 1,575 |  |  | 47 | \nThereafter | 12,612 |  |  | 452 | \nTotal undiscounted cash flows | 19,810 |  |  | 697 | \nLess: Imputed interest | (3,832) |  |  | (116) | \nPresent value of lease liabilities | $ | 15,978 |  |  | $ | 581 | \n |  |  | \nLease liabilities, current | $ | 1,291 |  |  | $ | 64 | \nLease liabilities, non-current | 14,687 |  |  | 517 | \nPresent value of lease liabilities | $ | 15,978 |  |  | $ | 581 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2022 |  | 2021\nCash paid for amounts included in the measurement of lease liabilities: |  |  | \nOperating cash flows for operating leases | $ | 1,197 |  |  | $ | 1,040 | \nOperating cash flows for finance leases | $ | 11 |  |  | $ | 11 | \nFinancing cash flows for finance leases | $ | 615 |  |  | $ | 505 | \nLease liabilities arising from obtaining right-of-use assets: |  |  | \nOperating leases | $ | 3,565 |  |  | $ | 2,921 | \nFinance leases | $ | 114 |  |  | $ | 124 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total\nGoodwill at December 31, 2021 | $ | 18,458 |  |  | $ | 739 |  |  | $ | 19,197 | \nAcquisitions | 773 |  |  | 329 |  |  | 1,102 | \nAdjustments | 19 |  |  | (50) |  |  | (31) | \nGoodwill at September 30, 2022 | $ | 19,250 |  |  | $ | 1,018 |  |  | $ | 20,268 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | September 30, 2022 |  | December 31, 2021\n | Weighted-Average Remaining Useful Lives(in years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount\nAcquired technology | 5.3 |  | $ | 604 |  |  | $ | (255) |  |  | $ | 349 |  |  | $ | 1,412 |  |  | $ | (1,169) |  |  | $ | 243 | \nAcquired patents | 2.8 |  | 379 |  |  | (300) |  |  | 79 |  |  | 827 |  |  | (722) |  |  | 105 | \nTrade names | 3.9 |  | 11 |  |  | (2) |  |  | 9 |  |  | 644 |  |  | (633) |  |  | 11 | \nOther | 9.0 |  | 75 |  |  | (19) |  |  | 56 |  |  | 176 |  |  | (167) |  |  | 9 | \nTotal finite-lived assets |  |  | 1,069 |  |  | (576) |  |  | 493 |  |  | 3,059 |  |  | (2,691) |  |  | 368 | \nTotal indefinite-lived assets | N/A |  | 382 |  |  | \u2014 |  |  | 382 |  |  | 266 |  |  | \u2014 |  |  | 266 | \nTotal intangible assets |  |  | $ | 1,451 |  |  | $ | (576) |  |  | $ | 875 |  |  | $ | 3,325 |  |  | $ | (2,691) |  |  | $ | 634 |   |  |  |  |  | \nThe remainder of 2022 | $ | 45 | \n2023 | 137 | \n2024 | 110 | \n2025 | 66 | \n2026 | 32 | \nThereafter | 103 | \nTotal | $ | 493 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturity |  | Stated Interest Rate |  | Effective Interest Rate |  | September 30, 2022\n2027 Notes | 2027 |  | 3.50% |  | 3.63% |  | $ | 2,750 | \n2032 Notes | 2032 |  | 3.85% |  | 3.92% |  | 3,000 | \n2052 Notes | 2052 |  | 4.45% |  | 4.51% |  | 2,750 | \n2062 Notes | 2062 |  | 4.65% |  | 4.71% |  | 1,500 | \nTotal face amount of long-term debt |  |  |  |  |  |  | 10,000 | \nUnamortized discount and issuance costs, net |  |  |  |  |  |  | (78)\nLong-term debt |  |  |  |  |  |  | $ | 9,922 |   |  |  |  |  | \nRemainder of 2022 through 2026 | $ | \u2014 | \n2027 | 2,750 | \nThereafter | 7,250 | \nTotal outstanding debt | $ | 10,000 |   |  |  |  |  | \nThe remainder of 2022 | $ | 7,200 | \n2023 | 9,211 | \n2024 | 1,922 | \n2025 | 1,154 | \n2026 | 295 | \nThereafter | 2,565 | \nTotal | $ | 22,347 |   |  |  |  |  |  |  |  |  |  |  | \n | Number of Shares |  | Weighted-Average Grant Date Fair Value Per Share\n | (in thousands) |  | \nUnvested at December 31, 2021 | 98,848 |  |  | $ | 244.32 | \nGranted | 99,379 |  |  | $ | 201.25 | \nVested | (39,368) |  |  | $ | 219.68 | \nForfeited | (13,340) |  |  | $ | 234.21 | \nUnvested at September 30, 2022 | 145,519 |  |  | $ | 222.49 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue: |  |  |  |  |  |  | \nFamily of Apps | $ | 27,429 |  |  | $ | 28,452 |  |  | $ | 83,011 |  |  | $ | 82,861 | \nReality Labs | 285 |  |  | 558 |  |  | 1,433 |  |  | 1,397 | \nTotal revenue | $ | 27,714 |  |  | $ | 29,010 |  |  | $ | 84,444 |  |  | $ | 84,258 | \n |  |  |  |  |  |  | \nIncome (loss) from operations: |  |  |  |  |  |  | \nFamily of Apps | $ | 9,336 |  |  | $ | 13,054 |  |  | $ | 31,983 |  |  | $ | 41,058 | \nReality Labs | (3,672) |  |  | (2,631) |  |  | (9,438) |  |  | (6,890) | \nTotal income from operations | $ | 5,664 |  |  | $ | 10,423 |  |  | $ | 22,545 |  |  | $ | 34,168 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\nUnited States | $ | 73,195 |  |  | $ | 55,497 | \nRest of the world(1) | 14,184 |  |  | 14,467 | \nTotal long-lived assets | $ | 87,379 |  |  | $ | 69,964 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total |  |  |  |  |  | \n | Three Months Ended September 30, |  | % change |  | Three Months Ended September 30, |  | % change |  | Three Months Ended September 30, |  | % change |  |  |  | \n | 2022 |  | 2021 |  |  | 2022 |  | 2021 |  |  | 2022 |  | 2021 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages) |  |  |  |  |  | \nRevenue | $ | 27,429 |  |  | $ | 28,452 |  |  | (4)% |  | $ | 285 |  |  | $ | 558 |  |  | (49)% |  | $ | 27,714 |  |  | $ | 29,010 |  |  | (4)% |  |  |  |  |  | \nCosts and expenses | $ | 18,093 |  |  | $ | 15,398 |  |  | 18% |  | $ | 3,957 |  |  | $ | 3,189 |  |  | 24% |  | $ | 22,050 |  |  | $ | 18,587 |  |  | 19% |  |  |  |  |  | \nIncome (loss) from operations | $ | 9,336 |  |  | $ | 13,054 |  |  | (28)% |  | $ | (3,672) |  |  | $ | (2,631) |  |  | (40)% |  | $ | 5,664 |  |  | $ | 10,423 |  |  | (46)% |  |  |  |  |  | \nOperating margin | 34 | % |  | 46 | % |  |  |  | (1,288) | % |  | (472) | % |  |  |  | 20 | % |  | 36 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAP/MAP: | 79% | 79% | 79% | 79% | 78% | 79% | 79% | 79% | 79%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPP: | $6.76 | $8.62 | $7.75 | $8.36 | $8.18 | $9.39 | $7.72 | $7.91 | $7.53\n |  |  |  |  |  |  |  |  | \n |  |  | Ad Revenue |  | Non-Ad Revenue |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAU/MAU: | 66% | 66% | 66% | 66% | 66% | 66% | 67% | 67% | 67%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAU/MAU: | 77% | 76% | 75% | 75% | 75% | 74% | 75% | 75% | 74% | DAU/MAU: | 74% | 74% | 73% | 73% | 73% | 72% | 73% | 74% | 74%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAU/MAU: | 62% | 62% | 62% | 62% | 63% | 63% | 64% | 64% | 64% | DAU/MAU: | 65% | 65% | 65% | 65% | 66% | 65% | 66% | 66% | 66%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPU: | $7.89 | $10.14 | $9.27 | $10.12 | $10.00 | $11.57 | $9.54 | $9.82 | $9.41  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPU: | $39.63 | $53.56 | $48.03 | $53.01 | $52.34 | $60.57 | $48.29 | $50.25 | $49.13 | ARPU: | $12.41 | $16.87 | $15.49 | $17.23 | $16.50 | $19.68 | $15.35 | $15.64 | $14.23  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPU: | $ | 3.67 |  | $ | 4.05 |  | $ | 3.94 |  | $ | 4.16 |  | $ | 4.30 |  | $ | 4.89 |  | $ | 4.47 |  | $ | 4.54 |  | $ | 4.42 |  | ARPU: | $ | 2.22 |  | $ | 2.77 |  | $ | 2.64 |  | $ | 3.05 |  | $ | 3.14 |  | $ | 3.43 |  | $ | 3.14 |  | $ | 3.35 |  | $ | 3.21 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | Ad Revenue |  | Non-Ad Revenue |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue | $ | 27,714 |  |  | $ | 29,010 |  |  | $ | 84,444 |  |  | $ | 84,258 | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 5,716 |  |  | 5,771 |  |  | 16,913 |  |  | 16,301 | \nResearch and development | 9,170 |  |  | 6,316 |  |  | 25,567 |  |  | 17,609 | \nMarketing and sales | 3,780 |  |  | 3,554 |  |  | 10,688 |  |  | 9,656 | \nGeneral and administrative | 3,384 |  |  | 2,946 |  |  | 8,731 |  |  | 6,524 | \nTotal costs and expenses | 22,050 |  |  | 18,587 |  |  | 61,899 |  |  | 50,090 | \nIncome from operations | 5,664 |  |  | 10,423 |  |  | 22,545 |  |  | 34,168 | \nInterest and other income (expense), net | (88) |  |  | 142 |  |  | 125 |  |  | 413 | \nIncome before provision for income taxes | 5,576 |  |  | 10,565 |  |  | 22,670 |  |  | 34,581 | \nProvision for income taxes | 1,181 |  |  | 1,371 |  |  | 4,123 |  |  | 5,496 | \nNet income | $ | 4,395 |  |  | $ | 9,194 |  |  | $ | 18,547 |  |  | $ | 29,085 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue | 100 | % |  | 100 | % |  | 100 | % |  | 100 | %\nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 21 |  |  | 20 |  |  | 20 |  |  | 19 | \nResearch and development | 33 |  |  | 22 |  |  | 30 |  |  | 21 | \nMarketing and sales | 14 |  |  | 12 |  |  | 13 |  |  | 11 | \nGeneral and administrative | 12 |  |  | 10 |  |  | 10 |  |  | 8 | \nTotal costs and expenses | 80 |  |  | 64 |  |  | 73 |  |  | 59 | \nIncome from operations | 20 |  |  | 36 |  |  | 27 |  |  | 41 | \nInterest and other income (expense), net | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nIncome before provision for income taxes | 20 |  |  | 36 |  |  | 27 |  |  | 41 | \nProvision for income taxes | 4 |  |  | 5 |  |  | 5 |  |  | 7 | \nNet income | 16 | % |  | 32 | % |  | 22 | % |  | 35 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nCost of revenue | $ | 209 |  |  | $ | 147 |  |  | $ | 582 |  |  | $ | 428 | \nResearch and development | 2,447 |  |  | 1,849 |  |  | 6,995 |  |  | 5,224 | \nMarketing and sales | 260 |  |  | 218 |  |  | 766 |  |  | 631 | \nGeneral and administrative | 218 |  |  | 165 |  |  | 641 |  |  | 474 | \nTotal share-based compensation expense | $ | 3,134 |  |  | $ | 2,379 |  |  | $ | 8,984 |  |  | $ | 6,757 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nCost of revenue | 1 | % |  | 1 | % |  | 1 | % |  | 1 | %\nResearch and development | 9 |  |  | 6 |  |  | 8 |  |  | 6 | \nMarketing and sales | 1 |  |  | 1 |  |  | 1 |  |  | 1 | \nGeneral and administrative | 1 |  |  | 1 |  |  | 1 |  |  | 1 | \nTotal share-based compensation expense | 11 | % |  | 8 | % |  | 11 | % |  | 8 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nAdvertising | $ | 27,237 |  |  | $ | 28,276 |  |  | (4) | % |  | $ | 82,387 |  |  | $ | 82,294 |  |  | \u2014 | %\nOther revenue | 192 |  |  | 176 |  |  | 9 | % |  | 624 |  |  | 567 |  |  | 10 | %\nFamily of Apps | 27,429 |  |  | 28,452 |  |  | (4) | % |  | 83,011 |  |  | 82,861 |  |  | \u2014 | %\nReality Labs | 285 |  |  | 558 |  |  | (49) | % |  | 1,433 |  |  | 1,397 |  |  | 3 | %\nTotal revenue | $ | 27,714 |  |  | $ | 29,010 |  |  | (4) | % |  | $ | 84,444 |  |  | $ | 84,258 |  |  | \u2014 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nCost of revenue | $ | 5,716 |  |  | $ | 5,771 |  |  | (1) | % |  | $ | 16,913 |  |  | $ | 16,301 |  |  | 4 | %\nPercentage of revenue | 21 | % |  | 20 | % |  |  |  | 20 | % |  | 19 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nResearch and development | $ | 9,170 |  |  | $ | 6,316 |  |  | 45 | % |  | $ | 25,567 |  |  | $ | 17,609 |  |  | 45 | %\nPercentage of revenue | 33 | % |  | 22 | % |  |  |  | 30 | % |  | 21 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nMarketing and sales | $ | 3,780 |  |  | $ | 3,554 |  |  | 6 | % |  | $ | 10,688 |  |  | $ | 9,656 |  |  | 11 | %\nPercentage of revenue | 14 | % |  | 12 | % |  |  |  | 13 | % |  | 11 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nGeneral and administrative | $ | 3,384 |  |  | $ | 2,946 |  |  | 15 | % |  | $ | 8,731 |  |  | $ | 6,524 |  |  | 34 | %\nPercentage of revenue | 12 | % |  | 10 | % |  |  |  | 10 | % |  | 8 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nFamily of Apps | $ | 9,336 |  |  | $ | 13,054 |  |  | (28) | % |  | $ | 31,983 |  |  | $ | 41,058 |  |  | (22) | %\nReality Labs | (3,672) |  |  | (2,631) |  |  | (40) | % |  | (9,438) |  |  | (6,890) |  |  | (37) | %\nTotal income from operations | $ | 5,664 |  |  | $ | 10,423 |  |  | (46) | % |  | $ | 22,545 |  |  | $ | 34,168 |  |  | (34) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nInterest income (expense), net | $ | 77 |  |  | $ | 120 |  |  | (36) | % |  | $ | 244 |  |  | $ | 359 |  |  | (32) | %\nForeign currency exchange gains (losses), net | (131) |  |  | (48) |  |  | (173) | % |  | (138) |  |  | (141) |  |  | 2 | %\nOther income (expense), net | (34) |  |  | 70 |  |  | (149) | % |  | 19 |  |  | 195 |  |  | (90) | %\nInterest and other income (expense) | $ | (88) |  |  | $ | 142 |  |  | (162) | % |  | $ | 125 |  |  | $ | 413 |  |  | (70) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2022 |  | 2021 |  | % change |  | 2022 |  | 2021 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nProvision for income taxes | $ | 1,181 |  |  | $ | 1,371 |  |  | (14) | % |  | $ | 4,123 |  |  | $ | 5,496 |  |  | (25) | %\nEffective tax rate | 21 | % |  | 13 | % |  |  |  | 18 | % |  | 16 | % |  |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2022 |  | 2021\nNet cash provided by operating activities | $ | 35,964 |  |  | $ | 39,579 | \nNet cash used in investing activities | $ | (21,439) |  |  | $ | (13,399) | \nNet cash used in financing activities | $ | (15,076) |  |  | $ | (28,986) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total Number of Shares Purchased(1) |  | Average Price Paid Per Share(2) |  | Total Number of Shares Purchased as Part of Publicly Announced Programs(1) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(1)\n | (in thousands) |  |  |  | (in thousands) |  | (in millions)\nJuly 1 - 31, 2022 | 13,004 |  |  | $ | 166.26 |  |  | 13,004 |  |  | $ | 22,162 | \nAugust 1 - 31, 2022 | 12,814 |  |  | $ | 169.58 |  |  | 12,814 |  |  | $ | 19,989 | \nSeptember 1 - 30, 2022 | 15,088 |  |  | $ | 146.69 |  |  | 15,088 |  |  | $ | 17,776 | \n | 40,906 |  |  |  |  | 40,906 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nExhibitNumber |  |  |  | Incorporated by Reference |  | FiledHerewith\n | Exhibit Description |  | Form |  | File No. |  | Exhibit |  | Filing\u00a0Date | \n |  |  |  |  |  |  |  |  |  |  |  | \n4.1 |  | Indenture, dated as of August 9, 2022, between Meta Platforms, Inc. and U.S. Bank Trust Company, National Association, as trustee. |  | 8-K |  | 001-35551 |  | 4.1 |  | August 9, 2022 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n4.2 |  | First Supplemental Indenture, dated as of August 9, 2022, between Meta Platforms, Inc. and U.S. Bank Trust Company, National Association, as trustee, including forms of global notes representing the 3.500% Notes due 2027, 3.850% Notes due 2032, 4.450% Notes due 2052 and 4.650% Notes due 2062. |  | 8-K |  | 001-35551 |  | 4.2 |  | August 9, 2022 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n4.3 |  | Registration Rights Agreement, dated as of August 9, 2022, by and among Meta Platforms, Inc., Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and Barclays Capital Inc. |  | 8-K |  | 001-35551 |  | 4.7 |  | August 9, 2022 |  | \n |  |  |  |  |  |  |  |  |  |  |  | \n31.1 |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n31.2 |  | Certification of David M. Wehner, Chief Financial Officer, pursuant to Rule\u00a013a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.1# |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.2# |  | Certification of David M. Wehner, Chief Financial Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.INS |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.LAB |  | Inline XBRL Taxonomy Extension Labels Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n104 |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |  |  |  |  |  |  |  |  |  | X  |  |  |  |  |  |  |  | \n |  | META PLATFORMS, INC.\n | \nDate: October 26, 2022 |  | /s/ DAVID M. WEHNER\n |  | David M. WehnerChief Financial Officer(Principal Financial Officer)\n | \nDate: October 26, 2022 |  | /s/ SUSAN J.S. TAYLOR\n |  | Susan J.S. TaylorChief Accounting Officer(Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Meta, in 2023 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  | \nDelaware | 20-1665019\n(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number)  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class | Trading symbol(s) | Name of each exchange on which registered\nClass A Common Stock, $0.000006 par value | META | The Nasdaq Stock Market LLC  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer |  | \u2612 | Accelerated\u00a0filer |  | \u2610\nNon-accelerated filer |  | \u2610 | Smaller\u00a0reporting\u00a0company |  | \u2610\n |  |  | Emerging growth company |  | \u2610\n |  |  |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |  | \u2610  |  |  |  |  |  |  |  |  |  |  | \nClass | Number of Shares Outstanding\nClass\u00a0A Common Stock | $0.000006 par value | 2,212,153,203 |  | shares outstanding as of April 21, 2023\nClass B Common Stock | $0.000006 par value | 350,578,831 |  | shares outstanding as of April 21, 2023  |  |  |  |  |  |  |  | \n |  | Page\n | \nNote About Forward-Looking Statements | 3\n | \nLimitations of Key Metrics and Other Data | 4\n | \nPART I\u2014FINANCIAL INFORMATION | 7\n |  | \nItem 1. | Financial Statements (unaudited) | 7\n |  | \n | Condensed Consolidated Balance Sheets\u2014March31, 2023and December\u00a031, 2022 | 7\n |  | \n | Condensed Consolidated Statements of Income\u2014for the threemonthsendedMarch31, 2023and 2022 | 8\n |  | \n | Condensed Consolidated Statements of Comprehensive Income\u2014for the threemonths endedMarch31, 2023and 2022 | 9\n |  | \n | Condensed Consolidated Statements of Stockholders' Equity\u2014for the threemonths endedMarch31, 2023and 2022 | 10\n |  | \n | Condensed Consolidated Statements of Cash Flows\u2014for thethreemonths endedMarch31, 2023and 2022 | 11\n |  | \n | Notes to Condensed Consolidated Financial Statements | 13\n |  | \nItem 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 33\n |  | \nItem 3. | Quantitative and Qualitative Disclosures About Market Risk | 53\n |  | \nItem 4. | Controls and Procedures | 53\n | \nPART II\u2014OTHER INFORMATION | 54\n |  | \nItem 1. | Legal Proceedings | 54\n |  | \nItem\u00a01A. | Risk Factors | 58\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 91\n |  | \nItem 6. | Exhibits | 92\n | \nSIGNATURES | 93  |  |  |  |  |  |  |  |  |  |  | \n | March 31,2023 |  | December 31,2022\nAssets |  |  | \nCurrent assets: |  |  | \nCash and cash equivalents | $ | 11,551 |  |  | $ | 14,681 | \nMarketable securities | 25,888 |  |  | 26,057 | \nAccounts receivable, net | 11,044 |  |  | 13,466 | \nPrepaid expenses and other current assets | 4,000 |  |  | 5,345 | \nTotal current assets | 52,483 |  |  | 59,549 | \nNon-marketable equity securities | 6,167 |  |  | 6,201 | \nProperty and equipment, net | 84,156 |  |  | 79,518 | \nOperating lease right-of-use assets | 12,899 |  |  | 12,673 | \nIntangible assets, net | 949 |  |  | 897 | \nGoodwill | 20,649 |  |  | 20,306 | \nOther assets | 7,188 |  |  | 6,583 | \nTotal assets | $ | 184,491 |  |  | $ | 185,727 | \n |  |  | \nLiabilities and stockholders' equity |  |  | \nCurrent liabilities: |  |  | \nAccounts payable | $ | 3,672 |  |  | $ | 4,990 | \nPartners payable | 885 |  |  | 1,117 | \nOperating lease liabilities, current | 1,479 |  |  | 1,367 | \nAccrued expenses and other current liabilities | 19,345 |  |  | 19,552 | \nTotal current liabilities | 25,381 |  |  | 27,026 | \nOperating lease liabilities, non-current | 16,171 |  |  | 15,301 | \nLong-term debt | 9,925 |  |  | 9,923 | \nOther liabilities | 8,219 |  |  | 7,764 | \nTotal liabilities | 59,696 |  |  | 60,014 | \nCommitments and contingencies |  |  | \nStockholders' equity: |  |  | \nCommon stock, $0.000006par value;5,000million Class A shares authorized,2,215million and2,247million shares issued and outstanding, as of March\u00a031, 2023 and December\u00a031, 2022, respectively;4,141million Class B shares authorized,351million and367million shares issued and outstanding, as of March\u00a031, 2023 and December\u00a031, 2022, respectively | \u2014 |  |  | \u2014 | \nAdditional paid-in capital | 66,535 |  |  | 64,444 | \nAccumulated other comprehensive loss | (2,981) |  |  | (3,530) | \nRetained earnings | 61,241 |  |  | 64,799 | \nTotal stockholders' equity | 124,795 |  |  | 125,713 | \nTotal liabilities and stockholders' equity | $ | 184,491 |  |  | $ | 185,727 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nRevenue | $ | 28,645 |  |  | $ | 27,908 |  |  |  |  | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 6,108 |  |  | 6,005 |  |  |  |  | \nResearch and development | 9,381 |  |  | 7,707 |  |  |  |  | \nMarketing and sales | 3,044 |  |  | 3,312 |  |  |  |  | \nGeneral and administrative | 2,885 |  |  | 2,360 |  |  |  |  | \nTotal costs and expenses | 21,418 |  |  | 19,384 |  |  |  |  | \nIncome from operations | 7,227 |  |  | 8,524 |  |  |  |  | \nInterest and other income, net | 80 |  |  | 384 |  |  |  |  | \nIncome before provision for income taxes | 7,307 |  |  | 8,908 |  |  |  |  | \nProvision for income taxes | 1,598 |  |  | 1,443 |  |  |  |  | \nNet income | $ | 5,709 |  |  | $ | 7,465 |  |  |  |  | \nEarnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | $ | 2.21 |  |  | $ | 2.74 |  |  |  |  | \nDiluted | $ | 2.20 |  |  | $ | 2.72 |  |  |  |  | \nWeighted-average shares used to compute earnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | 2,587 |  |  | 2,725 |  |  |  |  | \nDiluted | 2,596 |  |  | 2,742 |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nNet income | $ | 5,709 |  |  | $ | 7,465 |  |  |  |  | \nOther comprehensive income (loss): |  |  |  |  |  |  | \nChange in foreign currency translation adjustment, net of tax | 248 |  |  | (359) |  |  |  |  | \nChange in unrealized gain (loss) on available-for-sale investments and other, net of tax | 301 |  |  | (944) |  |  |  |  | \nComprehensive income | $ | 6,258 |  |  | $ | 6,162 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2023 |  | Three Months Ended March 31, 2022\n | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Income (Loss) |  | Retained Earnings |  | Total Stockholders' Equity |  | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par  Value |  |  | Shares |  | Par  Value | \nBalances at beginning of period | 2,614 |  |  | $ | \u2014 |  |  | $ | 64,444 |  |  | $ | (3,530) |  |  | $ | 64,799 |  |  | $ | 125,713 |  |  | 2,741 |  |  | $ | \u2014 |  |  | $ | 55,811 |  |  | $ | (693) |  |  | $ | 69,761 |  |  | $ | 124,879 | \nIssuance of common stock | 14 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 11 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (6) |  |  | \u2014 |  |  | (960) |  |  | \u2014 |  |  | (49) |  |  | (1,009) |  |  | (4) |  |  | \u2014 |  |  | (797) |  |  | \u2014 |  |  | (128) |  |  | (925) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 3,051 |  |  | \u2014 |  |  | \u2014 |  |  | 3,051 |  |  | \u2014 |  |  | \u2014 |  |  | 2,498 |  |  | \u2014 |  |  | \u2014 |  |  | 2,498 | \nShare repurchases | (56) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (9,218) |  |  | (9,218) |  |  | (34) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (9,386) |  |  | (9,386) | \nOther comprehensive income (loss) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 549 |  |  | \u2014 |  |  | 549 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,303) |  |  | \u2014 |  |  | (1,303) | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 5,709 |  |  | 5,709 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 7,465 |  |  | 7,465 | \nBalances at end of period | 2,566 |  |  | $ | \u2014 |  |  | $ | 66,535 |  |  | $ | (2,981) |  |  | $ | 61,241 |  |  | $ | 124,795 |  |  | 2,714 |  |  | $ | \u2014 |  |  | $ | 57,512 |  |  | $ | (1,996) |  |  | $ | 67,712 |  |  | $ | 123,228 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2023 |  | 2022\nCash flows from operating activities |  |  | \nNet income | $ | 5,709 |  |  | $ | 7,465 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nDepreciation and amortization | 2,524 |  |  | 2,156 | \nShare-based compensation | 3,051 |  |  | 2,498 | \nDeferred income taxes | (620) |  |  | (563) | \nImpairment charges for facilities consolidation | 770 |  |  | \u2014 | \n |  |  | \n |  |  | \nOther | (7) |  |  | (221) | \nChanges in assets and liabilities: |  |  | \nAccounts receivable | 2,546 |  |  | 2,557 | \nPrepaid expenses and other current assets | 821 |  |  | 573 | \nOther assets | 30 |  |  | (108) | \nAccounts payable | (1,104) |  |  | (882) | \nPartners payable | (240) |  |  | (105) | \nAccrued expenses and other current liabilities | 334 |  |  | 763 | \nOther liabilities | 184 |  |  | (57) | \nNet cash provided by operating activities | 13,998 |  |  | 14,076 | \nCash flows from investing activities |  |  | \nPurchases of property and equipment | (6,842) |  |  | (5,441) | \nProceeds relating to property and equipment | 19 |  |  | 126 | \nPurchases of marketable debt securities | (85) |  |  | (4,068) | \n |  |  | \nMaturities and sales of marketable debt securities | 534 |  |  | 5,467 | \n |  |  | \nAcquisitions of businesses and intangible assets | (444) |  |  | (853) | \nOther investing activities | 75 |  |  | (10) | \nNet cash used in investing activities | (6,743) |  |  | (4,779) | \nCash flows from financing activities |  |  | \nTaxes paid related to net share settlement of equity awards | (1,009) |  |  | (925) | \nRepurchases of Class A common stock | (9,365) |  |  | (9,506) | \n |  |  | \nPrincipal payments on finance leases | (264) |  |  | (233) | \nOther financing activities | 122 |  |  | 4 | \nNet cash used in financing activities | (10,516) |  |  | (10,660) | \nEffect of exchange rate changes on cash, cash equivalents, and restricted cash | 85 |  |  | (149) | \nNet decrease in cash, cash equivalents, and restricted cash | (3,176) |  |  | (1,512) | \nCash, cash equivalents, and restricted cash at beginning of the period | 15,596 |  |  | 16,865 | \nCash, cash equivalents, and restricted cash at end of the period | $ | 12,420 |  |  | $ | 15,353 | \n |  |  | \nReconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets |  |  | \nCash and cash equivalents | $ | 11,551 |  |  | $ | 14,886 | \nRestricted cash, included in prepaid expenses and other current assets | 224 |  |  | 294 | \nRestricted cash, included in other assets | 645 |  |  | 173 | \nTotal cash, cash equivalents, and restricted cash | $ | 12,420 |  |  | $ | 15,353 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2023 |  | 2022\nSupplemental cash flow data |  |  | \nCash paid for income taxes, net | $ | 405 |  |  | $ | 502 | \nCash paid for interest, net of amounts capitalized | $ | 182 |  |  | $ | \u2014 | \nNon-cash investing and financing activities: |  |  | \nProperty and equipment in accounts payable and accrued expenses and other current liabilities | $ | 4,466 |  |  | $ | 3,709 | \nAcquisition of businesses in accrued expenses and other current liabilities and other liabilities | $ | 263 |  |  | $ | 73 | \nSettlement of convertible notes in exchange of equity securities in other current assets | $ | \u2014 |  |  | $ | 131 | \nOther current assets through financing arrangement in accrued expenses and other current liabilities | $ | 11 |  |  | $ | 659 | \nRepurchases of Class A common stock in accrued expenses and other current liabilities | $ | 86 |  |  | $ | 221 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nAdvertising | $ | 28,101 |  |  | $ | 26,998 |  |  |  |  | \nOther revenue | 205 |  |  | 215 |  |  |  |  | \nFamily of Apps | 28,306 |  |  | 27,213 |  |  |  |  | \nReality Labs | 339 |  |  | 695 |  |  |  |  | \nTotal revenue | $ | 28,645 |  |  | $ | 27,908 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nUnited States and Canada(1) | $ | 11,449 |  |  | $ | 11,780 |  |  |  |  | \nEurope(2) | 6,759 |  |  | 6,638 |  |  |  |  | \nAsia-Pacific | 7,292 |  |  | 6,722 |  |  |  |  | \nRest of World(2) | 3,145 |  |  | 2,768 |  |  |  |  | \nTotal revenue | $ | 28,645 |  |  | $ | 27,908 |  |  |  |  |   |  |  |  |  | \n | Three Months Ended March 31, 2023\nResearch and development | $ | 324 | \nMarketing and sales | 5 | \nGeneral and administrative | 194 | \nTotal(1) | $ | 523 |   |  |  |  |  | \n | Severance Liabilities\nBalance as of January 1, 2023 | $ | \u2014 | \nSeverance and other personnel costs | 462 | \nCash payments | (9) | \nBalance as of March 31, 2023 | $ | 453 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | 2022 |  | Three Months Ended March 31, 2023 |  | Plan to Date\n | Facilities Consolidation |  | Severance and Other Personnel Costs |  | Data Center Assets |  | Total |  | Facilities Consolidation |  | Severance and Other Personnel Costs |  | Data Center Assets(1) |  | Total |  | Total\nCost of revenue | $ | 154 |  |  | $ | \u2014 |  |  | $ | 1,341 |  |  | $ | 1,495 |  |  | $ | 58 |  |  | $ | \u2014 |  |  | $ | (168) |  |  | $ | (110) |  |  | $ | 1,385 | \nResearch and development | 1,311 |  |  | 408 |  |  | \u2014 |  |  | 1,719 |  |  | 484 |  |  | (4) |  |  | \u2014 |  |  | 480 |  |  | 2,199 | \nMarketing and sales | 404 |  |  | 234 |  |  | \u2014 |  |  | 638 |  |  | 136 |  |  | (2) |  |  | \u2014 |  |  | 134 |  |  | 772 | \nGeneral and administrative | 426 |  |  | 333 |  |  | \u2014 |  |  | 759 |  |  | 129 |  |  | (12) |  |  | \u2014 |  |  | 117 |  |  | 876 | \nTotal | $ | 2,295 |  |  | $ | 975 |  |  | $ | 1,341 |  |  | $ | 4,611 |  |  | $ | 807 |  |  | $ | (18) |  |  | $ | (168) |  |  | $ | 621 |  |  | $ | 5,232 |   |  |  |  |  | \n | Severance Liabilities\nBalance as of January 1, 2022 | $ | \u2014 | \nSeverance and other personnel costs | 975 | \nCash payments | (203) | \nBalance as of December 31, 2022 | 772 | \nAdjustments and foreign exchange | (27) | \nCash payments | (675) | \nBalance as of March 31, 2023 | $ | 70 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \n | Class A |  | Class B |  | Class A |  | Class B |  |  |  |  |  |  |  | \nBasic EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 4,905 |  |  | $ | 804 |  |  | $ | 6,334 |  |  | $ | 1,131 |  |  |  |  |  |  |  |  | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,223 |  |  | 364 |  |  | 2,312 |  |  | 413 |  |  |  |  |  |  |  |  | \nBasic EPS | $ | 2.21 |  |  | $ | 2.21 |  |  | $ | 2.74 |  |  | $ | 2.74 |  |  |  |  |  |  |  |  | \nDiluted EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 4,905 |  |  | $ | 804 |  |  | $ | 6,334 |  |  | $ | 1,131 |  |  |  |  |  |  |  |  | \nReallocation of net income as a result of conversion of Class B to Class\u00a0A common stock | 804 |  |  | \u2014 |  |  | 1,131 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nReallocation of net income to Class B common stock | \u2014 |  |  | (3) |  |  | \u2014 |  |  | (7) |  |  |  |  |  |  |  |  | \nNet income for diluted EPS | $ | 5,709 |  |  | $ | 801 |  |  | $ | 7,465 |  |  | $ | 1,124 |  |  |  |  |  |  |  |  | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,223 |  |  | 364 |  |  | 2,312 |  |  | 413 |  |  |  |  |  |  |  |  | \nConversion of Class B to Class\u00a0A common stock | 364 |  |  | \u2014 |  |  | 413 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nWeighted-average effect of dilutive RSUs | 9 |  |  | \u2014 |  |  | 17 |  |  | \u2014 |  |  |  |  |  |  |  |  | \nShares used in computation of diluted earnings per share | 2,596 |  |  | 364 |  |  | 2,742 |  |  | 413 |  |  |  |  |  |  |  |  | \nDiluted EPS | $ | 2.20 |  |  | $ | 2.20 |  |  | $ | 2.72 |  |  | $ | 2.72 |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using |  | \nDescription |  | March 31, 2023 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3) |  | \nCash |  | $ | 5,680 |  |  |  |  |  |  |  |  | \nCash equivalents: |  |  |  |  |  |  |  |  |  | \nMoney market funds |  | 5,384 |  |  | $ | 5,384 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | \nU.S. government and agency securities |  | 50 |  |  | 50 |  |  | \u2014 |  |  | \u2014 |  |  | \n |  |  |  |  |  |  |  |  |  | \nTime deposits |  | 424 |  |  | \u2014 |  |  | 424 |  |  | \u2014 |  |  | \nCorporate debt securities |  | 13 |  |  | \u2014 |  |  | 13 |  |  | \u2014 |  |  | \nTotal cash and cash equivalents |  | 11,551 |  |  | 5,434 |  |  | 437 |  |  | \u2014 |  |  | \nMarketable securities: |  |  |  |  |  |  |  |  |  | \nU.S. government securities |  | 8,706 |  |  | 8,706 |  |  | \u2014 |  |  | \u2014 |  |  | \nU.S. government agency securities |  | 4,997 |  |  | 4,997 |  |  | \u2014 |  |  | \u2014 |  |  | \nCorporate debt securities |  | 12,185 |  |  | \u2014 |  |  | 12,185 |  |  | \u2014 |  |  | \n |  |  |  |  |  |  |  |  |  | \nTotal marketable securities |  | 25,888 |  |  | 13,703 |  |  | 12,185 |  |  | \u2014 |  |  | \nRestricted cash equivalents |  | 579 |  |  | 579 |  |  | \u2014 |  |  | \u2014 |  |  | \nOther assets |  | 93 |  |  | \u2014 |  |  | \u2014 |  |  | 93 |  |  | \nTotal |  | $ | 38,111 |  |  | $ | 19,716 |  |  | $ | 12,622 |  |  | $ | 93 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | December 31, 2022 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3)\nCash |  | $ | 6,176 |  |  |  |  |  |  | \nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | 8,305 |  |  | $ | 8,305 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities |  | 16 |  |  | 16 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nTime deposits |  | 156 |  |  | \u2014 |  |  | 156 |  |  | \u2014 | \nCorporate debt securities |  | 28 |  |  | \u2014 |  |  | 28 |  |  | \u2014 | \nTotal cash and cash equivalents |  | 14,681 |  |  | 8,321 |  |  | 184 |  |  | \u2014 | \nMarketable securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 8,708 |  |  | 8,708 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 4,989 |  |  | 4,989 |  |  | \u2014 |  |  | \u2014 | \nCorporate debt securities |  | 12,335 |  |  | \u2014 |  |  | 12,335 |  |  | \u2014 | \nMarketable equity securities |  | 25 |  |  | 25 |  |  | \u2014 |  |  | \u2014 | \nTotal marketable securities |  | 26,057 |  |  | 13,722 |  |  | 12,335 |  |  | \u2014 | \nRestricted cash equivalents |  | 583 |  |  | 583 |  |  | \u2014 |  |  | \u2014 | \nOther assets |  | 157 |  |  | \u2014 |  |  | \u2014 |  |  | 157 | \nTotal |  | $ | 41,478 |  |  | $ | 22,626 |  |  | $ | 12,519 |  |  | $ | 157 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023\n | Less than 12 months |  | 12 months or greater |  | Total\n | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses\nU.S. government securities | $ | 2,338 |  |  | $ | (59) |  |  | $ | 6,061 |  |  | $ | (311) |  |  | $ | 8,399 |  |  | $ | (370) | \nU.S. government agency securities | 130 |  |  | (2) |  |  | 4,769 |  |  | (260) |  |  | 4,899 |  |  | (262) | \nCorporate debt securities | 1,685 |  |  | (25) |  |  | 10,194 |  |  | (735) |  |  | 11,879 |  |  | (760) | \nTotal | $ | 4,153 |  |  | $ | (86) |  |  | $ | 21,024 |  |  | $ | (1,306) |  |  | $ | 25,177 |  |  | $ | (1,392) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | December 31, 2022\n | Less than 12 months |  | 12 months or greater |  | Total\n | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses\nU.S. government securities | $ | 5,008 |  |  | $ | (234) |  |  | $ | 3,499 |  |  | $ | (247) |  |  | $ | 8,507 |  |  | $ | (481) | \nU.S. government agency securities | 524 |  |  | (17) |  |  | 4,415 |  |  | (308) |  |  | 4,939 |  |  | (325) | \nCorporate debt securities | 4,555 |  |  | (249) |  |  | 7,256 |  |  | (634) |  |  | 11,811 |  |  | (883) | \nTotal | $ | 10,087 |  |  | $ | (500) |  |  | $ | 15,170 |  |  | $ | (1,189) |  |  | $ | 25,257 |  |  | $ | (1,689) |   |  |  |  |  | \n | March 31, 2023\nDue within one year | $ | 5,163 | \nDue after one year to five years | 20,725 | \nTotal | $ | 25,888 |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nNon-marketable equity securities under measurement alternative: |  |  | \nInitial cost | $ | 6,388 |  |  | $ | 6,388 | \nCumulative upward adjustments | 293 |  |  | 293 | \nCumulative impairment/downward adjustments | (532) |  |  | (497) | \nCarrying value | 6,149 |  |  | 6,184 | \nNon-marketable equity securities under equity method | 18 |  |  | 17 | \nTotal | $ | 6,167 |  |  | $ | 6,201 |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nLand | $ | 1,874 |  |  | $ | 1,874 | \nServers and network assets | 37,282 |  |  | 34,330 | \nBuildings | 30,882 |  |  | 27,720 | \nLeasehold improvements | 6,654 |  |  | 6,522 | \nEquipment and other | 5,831 |  |  | 5,642 | \nFinance lease right-of-use assets | 3,573 |  |  | 3,353 | \nConstruction in progress | 25,039 |  |  | 25,052 | \nProperty and equipment, gross | 111,135 |  |  | 104,493 | \nLess: Accumulated depreciation | (26,979) |  |  | (24,975) | \nProperty and equipment, net | $ | 84,156 |  |  | $ | 79,518 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nFinance lease cost: |  |  |  |  |  |  | \nAmortization of right-of-use assets | $ | 104 |  |  | $ | 98 |  |  |  |  | \nInterest | 5 |  |  | 4 |  |  |  |  | \nOperating lease cost | 557 |  |  | 411 |  |  |  |  | \nVariable lease cost and other, net | 124 |  |  | 90 |  |  |  |  | \nTotal lease cost | $ | 790 |  |  | $ | 603 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nWeighted-average remaining lease term: |  |  | \nFinance leases | 14.3years |  | 14.4years\nOperating leases | 12.2years |  | 12.5years\nWeighted-average discount rate: |  |  | \nFinance leases | 3.2 | % |  | 3.1 | %\nOperating leases | 3.3 | % |  | 3.2 | %  |  |  |  |  |  |  |  |  |  |  | \n | Operating Leases |  | Finance Leases\nThe remainder of 2023 | $ | 1,362 |  |  | $ | 115 | \n2024 | 2,208 |  |  | 60 | \n2025 | 2,049 |  |  | 60 | \n2026 | 1,859 |  |  | 56 | \n2027 | 1,834 |  |  | 54 | \nThereafter | 12,729 |  |  | 491 | \nTotal undiscounted cash flows | 22,041 |  |  | 836 | \nLess: Imputed interest | (4,391) |  |  | (149) | \nPresent value of lease liabilities(1) | $ | 17,650 |  |  | $ | 687 | \n |  |  | \nLease liabilities, current | $ | 1,479 |  |  | $ | 114 | \nLease liabilities, non-current | 16,171 |  |  | 573 | \nPresent value of lease liabilities(1) | $ | 17,650 |  |  | $ | 687 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2023 |  | 2022\nCash paid for amounts included in the measurement of lease liabilities: |  |  | \nOperating cash flows for operating leases | $ | 478 |  |  | $ | 389 | \nOperating cash flows for finance leases | $ | 5 |  |  | $ | 4 | \nFinancing cash flows for finance leases | $ | 264 |  |  | $ | 233 | \nLease liabilities arising from obtaining right-of-use assets: |  |  | \nOperating leases | $ | 1,282 |  |  | $ | 539 | \nFinance leases | $ | 70 |  |  | $ | 52 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total\nGoodwill at December 31, 2022 | $ | 19,250 |  |  | $ | 1,056 |  |  | $ | 20,306 | \nAcquisitions | \u2014 |  |  | 343 |  |  | 343 | \nGoodwill at March 31, 2023 | $ | 19,250 |  |  | $ | 1,399 |  |  | $ | 20,649 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | March 31, 2023 |  | December 31, 2022\n | Weighted-Average Remaining Useful Lives(in years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount\nAcquired technology | 5.0 |  | $ | 513 |  |  | $ | (154) |  |  | $ | 359 |  |  | $ | 507 |  |  | $ | (144) |  |  | $ | 363 | \nAcquired patents | 2.8 |  | 365 |  |  | (284) |  |  | 81 |  |  | 380 |  |  | (289) |  |  | 91 | \nOther | 1.9 |  | 60 |  |  | (25) |  |  | 35 |  |  | 86 |  |  | (25) |  |  | 61 | \nTotal finite-lived assets |  |  | 938 |  |  | (463) |  |  | 475 |  |  | 973 |  |  | (458) |  |  | 515 | \nTotal indefinite-lived assets | N/A |  | 474 |  |  | \u2014 |  |  | 474 |  |  | 382 |  |  | \u2014 |  |  | 382 | \nTotal intangible assets |  |  | $ | 1,412 |  |  | $ | (463) |  |  | $ | 949 |  |  | $ | 1,355 |  |  | $ | (458) |  |  | $ | 897 |   |  |  |  |  | \nThe remainder of 2023 | $ | 132 | \n2024 | 132 | \n2025 | 86 | \n2026 | 41 | \n2027 | 24 | \nThereafter | 60 | \nTotal | $ | 475 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturity |  | Stated Interest Rate |  | Effective Interest Rate |  | March 31, 2023 |  | December 31, 2022\n2027 Notes | 2027 |  | 3.50% |  | 3.63% |  | $ | 2,750 |  |  | $ | 2,750 | \n2032 Notes | 2032 |  | 3.85% |  | 3.92% |  | 3,000 |  |  | 3,000 | \n2052 Notes | 2052 |  | 4.45% |  | 4.51% |  | 2,750 |  |  | 2,750 | \n2062 Notes | 2062 |  | 4.65% |  | 4.71% |  | 1,500 |  |  | 1,500 | \nTotal face amount of long-term debt |  |  |  |  |  |  | 10,000 |  |  | 10,000 | \nUnamortized discount and issuance costs, net |  |  |  |  |  |  | (75) |  | (77)\nLong-term debt |  |  |  |  |  |  | $ | 9,925 |  |  | $ | 9,923 |   |  |  |  |  | \nRemainder of 2023 through 2026 | $ | \u2014 | \n2027 | 2,750 | \nThereafter | 7,250 | \nTotal outstanding debt | $ | 10,000 |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nLegal-related accruals(1) | $ | 5,474 |  |  | $ | 4,795 | \nAccrued compensation and benefits | 3,392 |  |  | 4,591 | \nAccrued property and equipment | 2,561 |  |  | 2,921 | \nAccrued taxes | 3,589 |  |  | 2,339 | \nOther current liabilities | 4,329 |  |  | 4,906 | \nAccrued expenses and other current liabilities | $ | 19,345 |  |  | $ | 19,552 |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nIncome tax payable | $ | 6,946 |  |  | $ | 6,645 | \n |  |  | \nOther non-current liabilities | 1,273 |  |  | 1,119 | \nOther liabilities | $ | 8,219 |  |  | $ | 7,764 |   |  |  |  |  | \nThe remainder of 2023 | $ | 10,745 | \n2024 | 2,222 | \n2025 | 1,500 | \n2026 | 264 | \n2027 | 210 | \nThereafter | 2,536 | \nTotal | $ | 17,477 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2023 |  | 2022\nCost of revenue | $ | 160 |  |  | $ | 160 | \nResearch and development | 2,449 |  |  | 1,941 | \nMarketing and sales | 219 |  |  | 216 | \nGeneral and administrative | 223 |  |  | 181 | \nTotal share-based compensation expense | $ | 3,051 |  |  | $ | 2,498 |   |  |  |  |  |  |  |  |  |  |  | \n | Number of Shares |  | Weighted-Average Grant Date Fair Value Per Share\n | (in thousands) |  | \nUnvested at December 31, 2022 | 127,110 |  |  | $ | 216.93 | \nGranted | 105,156 |  |  | $ | 196.27 | \nVested | (13,612) |  |  | $ | 211.80 | \nForfeited | (3,262) |  |  | $ | 229.43 | \nUnvested at March 31, 2023 | 215,392 |  |  | $ | 206.98 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nRevenue: |  |  |  |  |  |  | \nFamily of Apps | $ | 28,306 |  |  | $ | 27,213 |  |  |  |  | \nReality Labs | 339 |  |  | 695 |  |  |  |  | \nTotal revenue | $ | 28,645 |  |  | $ | 27,908 |  |  |  |  | \n |  |  |  |  |  |  | \nIncome (loss) from operations: |  |  |  |  |  |  | \nFamily of Apps | $ | 11,219 |  |  | $ | 11,484 |  |  |  |  | \nReality Labs | (3,992) |  |  | (2,960) |  |  |  |  | \nTotal income from operations | $ | 7,227 |  |  | $ | 8,524 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nUnited States | $ | 80,214 |  |  | $ | 76,334 | \nRest of the world(1) | 16,841 |  |  | 15,857 | \nTotal long-lived assets | $ | 97,055 |  |  | $ | 92,191 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total |  |  |  |  |  | \n | Three Months Ended March 31, |  | % change |  | Three Months Ended March 31, |  | % change |  | Three Months Ended March 31, |  | % change |  |  |  | \n | 2023 |  | 2022 |  |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages) |  |  |  |  |  | \nRevenue | $ | 28,306 |  |  | $ | 27,213 |  |  | 4% |  | $ | 339 |  |  | $ | 695 |  |  | (51)% |  | $ | 28,645 |  |  | $ | 27,908 |  |  | 3% |  |  |  |  |  | \nCosts and expenses | $ | 17,087 |  |  | $ | 15,729 |  |  | 9% |  | $ | 4,331 |  |  | $ | 3,655 |  |  | 18% |  | $ | 21,418 |  |  | $ | 19,384 |  |  | 10% |  |  |  |  |  | \nIncome (loss) from operations | $ | 11,219 |  |  | $ | 11,484 |  |  | (2)% |  | $ | (3,992) |  |  | $ | (2,960) |  |  | (35)% |  | $ | 7,227 |  |  | $ | 8,524 |  |  | (15)% |  |  |  |  |  | \nOperating margin | 40 | % |  | 42 | % |  |  |  | (1,178) | % |  | (426) | % |  |  |  | 25 | % |  | 31 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, 2023\n | Severance and Other Personnel Costs(1) |  | Facilities Consolidation |  | Data Center Assets(2) |  | Total\nCost of revenue | $ | \u2014 |  |  | $ | 58 |  |  | $ | (168) |  |  | $ | (110) | \nResearch and development | 320 |  |  | 484 |  |  | \u2014 |  |  | 804 | \nMarketing and sales | 3 |  |  | 136 |  |  | \u2014 |  |  | 139 | \nGeneral and administrative | 182 |  |  | 129 |  |  | \u2014 |  |  | 311 | \nTotal | $ | 505 |  |  | $ | 807 |  |  | $ | (168) |  |  | $ | 1,144 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDAP/MAP: | 79% | 79% | 78% | 79% | 79% | 79% | 79% | 79% | 79%  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPP: | $7.75 | $8.36 | $8.18 | $9.39 | $7.72 | $7.91 | $7.53 | $8.63 | $7.59\n |  |  |  |  |  |  |  |  | \n |  |  | Ad Revenue |  | Non-Ad Revenue |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | Ad Revenue |  | Non-Ad Revenue |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nRevenue | $ | 28,645 |  |  | $ | 27,908 |  |  |  |  | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 6,108 |  |  | 6,005 |  |  |  |  | \nResearch and development | 9,381 |  |  | 7,707 |  |  |  |  | \nMarketing and sales | 3,044 |  |  | 3,312 |  |  |  |  | \nGeneral and administrative | 2,885 |  |  | 2,360 |  |  |  |  | \nTotal costs and expenses | 21,418 |  |  | 19,384 |  |  |  |  | \nIncome from operations | 7,227 |  |  | 8,524 |  |  |  |  | \nInterest and other income, net | 80 |  |  | 384 |  |  |  |  | \nIncome before provision for income taxes | 7,307 |  |  | 8,908 |  |  |  |  | \nProvision for income taxes | 1,598 |  |  | 1,443 |  |  |  |  | \nNet income | $ | 5,709 |  |  | $ | 7,465 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nRevenue | 100 | % |  | 100 | % |  |  |  | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 21 |  |  | 22 |  |  |  |  | \nResearch and development | 33 |  |  | 28 |  |  |  |  | \nMarketing and sales | 11 |  |  | 12 |  |  |  |  | \nGeneral and administrative | 10 |  |  | 8 |  |  |  |  | \nTotal costs and expenses | 75 |  |  | 69 |  |  |  |  | \nIncome from operations | 25 |  |  | 31 |  |  |  |  | \nInterest and other income, net | \u2014 |  |  | 1 |  |  |  |  | \nIncome before provision for income taxes | 26 |  |  | 32 |  |  |  |  | \nProvision for income taxes | 6 |  |  | 5 |  |  |  |  | \nNet income | 20 | % |  | 27 | % |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nAdvertising | $ | 28,101 |  |  | $ | 26,998 |  |  | 4 | % |  |  |  |  |  | \nOther revenue | 205 |  |  | 215 |  |  | (5) | % |  |  |  |  |  | \nFamily of Apps | 28,306 |  |  | 27,213 |  |  | 4 | % |  |  |  |  |  | \nReality Labs | 339 |  |  | 695 |  |  | (51) | % |  |  |  |  |  | \nTotal revenue | $ | 28,645 |  |  | $ | 27,908 |  |  | 3 | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nCost of revenue | $ | 6,108 |  |  | $ | 6,005 |  |  | 2 | % |  |  |  |  |  | \nPercentage of revenue | 21 | % |  | 22 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nResearch and development | $ | 9,381 |  |  | $ | 7,707 |  |  | 22 | % |  |  |  |  |  | \nPercentage of revenue | 33 | % |  | 28 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nMarketing and sales | $ | 3,044 |  |  | $ | 3,312 |  |  | (8) | % |  |  |  |  |  | \nPercentage of revenue | 11 | % |  | 12 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nGeneral and administrative | $ | 2,885 |  |  | $ | 2,360 |  |  | 22 | % |  |  |  |  |  | \nPercentage of revenue | 10 | % |  | 8 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nFamily of Apps | $ | 11,219 |  |  | $ | 11,484 |  |  | (2) | % |  |  |  |  |  | \nReality Labs | (3,992) |  |  | (2,960) |  |  | (35) | % |  |  |  |  |  | \nTotal income from operations | $ | 7,227 |  |  | $ | 8,524 |  |  | (15) | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\n |  |  |  |  |  |  |  |  |  |  | \nInterest income | $ | 193 |  |  | $ | 81 |  |  | 138 | % |  |  |  |  |  | \nInterest expense | (55) |  |  | (5) |  |  | NM |  |  |  |  |  | \nForeign currency exchange gains (losses), net | (63) |  |  | 54 |  |  | (217) | % |  |  |  |  |  | \nOther income, net | 5 |  |  | 254 |  |  | (98) | % |  |  |  |  |  | \nInterest and other income, net | $ | 80 |  |  | $ | 384 |  |  | (79) | % |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | % change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nProvision for income taxes | $ | 1,598 |  |  | $ | 1,443 |  |  | 11 | % |  |  |  |  |  | \nEffective tax rate | 22 | % |  | 16 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2023 |  | 2022\nNet cash provided by operating activities | $ | 13,998 |  |  | $ | 14,076 | \nNet cash used in investing activities | $ | (6,743) |  |  | $ | (4,779) | \nNet cash used in financing activities | $ | (10,516) |  |  | $ | (10,660) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total Number of Shares Purchased(1) |  | Average Price Paid Per Share(2) |  | Total Number of Shares Purchased as Part of Publicly Announced Programs(1) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(1)\n | (in thousands) |  |  |  | (in thousands) |  | (in millions)\nJanuary 1 - 31, 2023 | 23,677 |  |  | $ | 136.60 |  |  | 23,677 |  |  | $ | 47,634 | \nFebruary 1 - 28, 2023 | 18,216 |  |  | $ | 176.57 |  |  | 18,216 |  |  | $ | 44,417 | \nMarch 1 - 31, 2023 | 14,279 |  |  | $ | 188.46 |  |  | 14,279 |  |  | $ | 41,726 | \n | 56,172 |  |  |  |  | 56,172 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nExhibitNumber |  |  |  | Incorporated by Reference |  | FiledHerewith\n | Exhibit Description |  | Form |  | File No. |  | Exhibit |  | Filing\u00a0Date | \n |  |  |  |  |  |  |  |  |  |  |  | \n10.1 |  | 2012 Equity Incentive Plan forms of award agreements (Additional Forms). |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n10.2 |  | Bonus Plan, effective January 1, 2023. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n10.3 |  | Offer Letter, dated March 14, 2022, between Registrant and Andrew Bosworth. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n10.4 |  | Offer Letter, dated November 1, 2022, between Registrant and Susan Li. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n10.5 |  | Director Compensation Policy, as amended. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n31.1 |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n31.2 |  | Certification ofSusan Li, Chief Financial Officer, pursuant to Rule\u00a013a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.1# |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.2# |  | Certification ofSusan Li, Chief Financial Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.INS |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.LAB |  | Inline XBRL Taxonomy Extension Labels Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n104 |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |  |  |  |  |  |  |  |  |  | X  |  |  |  |  |  |  |  | \n |  | META PLATFORMS, INC.\n | \nDate: April 26, 2023 |  | /s/ SUSAN LI\n |  | Susan LiChief Financial Officer(Principal Financial Officer)\n | \nDate: April 26, 2023 |  | /s/ SUSAN J.S. TAYLOR\n |  | Susan J.S. TaylorChief Accounting Officer(Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Meta, in 2023 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  | \nDelaware | 20-1665019\n(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number)  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class | Trading symbol(s) | Name of each exchange on which registered\nClass A Common Stock, $0.000006 par value | META | The Nasdaq Stock Market LLC  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer |  | \u2612 | Accelerated\u00a0filer |  | \u2610\nNon-accelerated filer |  | \u2610 | Smaller\u00a0reporting\u00a0company |  | \u2610\n |  |  | Emerging growth company |  | \u2610\n |  |  |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |  | \u2610  |  |  |  |  |  |  |  |  |  |  | \nClass | Number of Shares Outstanding\nClass\u00a0A Common Stock | $0.000006 par value | 2,222,582,542 |  | shares outstanding as of July 21, 2023\nClass B Common Stock | $0.000006 par value | 350,578,831 |  | shares outstanding as of July 21, 2023  |  |  |  |  |  |  |  | \n |  | Page\n | \nNote About Forward-Looking Statements | 3\n | \nLimitations of Key Metrics and Other Data | 4\n | \nPART I\u2014FINANCIAL INFORMATION | 7\n |  | \nItem 1. | Financial Statements (unaudited) | 7\n |  | \n | Condensed Consolidated Balance Sheets\u2014June 30, 2023 and December\u00a031, 2022 | 7\n |  | \n | Condensed Consolidated Statements of Income\u2014for the threeand sixmonths endedJune 30, 2023 and 2022 | 8\n |  | \n | Condensed Consolidated Statements of Comprehensive Income\u2014for the threeand sixmonths endedJune 30, 2023 and 2022 | 9\n |  | \n | Condensed Consolidated Statements of Stockholders' Equity\u2014for the threeand sixmonths endedJune 30, 2023 and 2022 | 10\n |  | \n | Condensed Consolidated Statements of Cash Flows\u2014for thesixmonths endedJune 30, 2023 and 2022 | 11\n |  | \n | Notes to Condensed Consolidated Financial Statements | 13\n |  | \nItem 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 32\n |  | \nItem 3. | Quantitative and Qualitative Disclosures About Market Risk | 52\n |  | \nItem 4. | Controls and Procedures | 52\n | \nPART II\u2014OTHER INFORMATION | 53\n |  | \nItem 1. | Legal Proceedings | 53\n |  | \nItem\u00a01A. | Risk Factors | 57\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 91\n |  | \nItem5. | Other Information | 92\n | \nItem 6. | Exhibits | 93\n | \nSIGNATURES | 94  |  |  |  |  |  |  |  |  |  |  | \n | June 30,2023 |  | December 31,2022\nAssets |  |  | \nCurrent assets: |  |  | \nCash and cash equivalents | $ | 28,785 |  |  | $ | 14,681 | \nMarketable securities | 24,661 |  |  | 26,057 | \nAccounts receivable, net | 12,511 |  |  | 13,466 | \nPrepaid expenses and other current assets | 3,603 |  |  | 5,345 | \nTotal current assets | 69,560 |  |  | 59,549 | \nNon-marketable equity securities | 6,208 |  |  | 6,201 | \nProperty and equipment, net | 87,949 |  |  | 79,518 | \nOperating lease right-of-use assets | 12,955 |  |  | 12,673 | \nIntangible assets, net | 856 |  |  | 897 | \nGoodwill | 20,659 |  |  | 20,306 | \nOther assets | 8,501 |  |  | 6,583 | \nTotal assets | $ | 206,688 |  |  | $ | 185,727 | \n |  |  | \nLiabilities and stockholders' equity |  |  | \nCurrent liabilities: |  |  | \nAccounts payable | $ | 3,093 |  |  | $ | 4,990 | \nPartners payable | 772 |  |  | 1,117 | \nOperating lease liabilities, current | 1,396 |  |  | 1,367 | \nAccrued expenses and other current liabilities | 24,660 |  |  | 19,552 | \nTotal current liabilities | 29,921 |  |  | 27,026 | \nOperating lease liabilities, non-current | 16,440 |  |  | 15,301 | \nLong-term debt | 18,382 |  |  | 9,923 | \nOther liabilities | 7,912 |  |  | 7,764 | \nTotal liabilities | 72,655 |  |  | 60,014 | \nCommitments and contingencies |  |  | \nStockholders' equity: |  |  | \nCommon stock, $0.000006par value;5,000million Class A shares authorized,2,222million and2,247million shares issued and outstanding, as of June\u00a030, 2023 and December\u00a031, 2022, respectively;4,141million Class B shares authorized,351million and367million shares issued and outstanding, as of June\u00a030, 2023 and December\u00a031, 2022, respectively | \u2014 |  |  | \u2014 | \nAdditional paid-in capital | 69,159 |  |  | 64,444 | \nAccumulated other comprehensive loss | (3,106) |  |  | (3,530) | \nRetained earnings | 67,980 |  |  | 64,799 | \nTotal stockholders' equity | 134,033 |  |  | 125,713 | \nTotal liabilities and stockholders' equity | $ | 206,688 |  |  | $ | 185,727 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue | $ | 31,999 |  |  | $ | 28,822 |  |  | $ | 60,645 |  |  | $ | 56,729 | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 5,945 |  |  | 5,192 |  |  | 12,054 |  |  | 11,197 | \nResearch and development | 9,344 |  |  | 8,690 |  |  | 18,725 |  |  | 16,397 | \nMarketing and sales | 3,154 |  |  | 3,595 |  |  | 6,198 |  |  | 6,907 | \nGeneral and administrative | 4,164 |  |  | 2,987 |  |  | 7,049 |  |  | 5,347 | \nTotal costs and expenses | 22,607 |  |  | 20,464 |  |  | 44,026 |  |  | 39,848 | \nIncome from operations | 9,392 |  |  | 8,358 |  |  | 16,619 |  |  | 16,881 | \nInterest and other income (expense), net | (99) |  |  | (172) |  |  | (19) |  |  | 213 | \nIncome before provision for income taxes | 9,293 |  |  | 8,186 |  |  | 16,600 |  |  | 17,094 | \nProvision for income taxes | 1,505 |  |  | 1,499 |  |  | 3,102 |  |  | 2,942 | \nNet income | $ | 7,788 |  |  | $ | 6,687 |  |  | $ | 13,498 |  |  | $ | 14,152 | \nEarnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | $ | 3.03 |  |  | $ | 2.47 |  |  | $ | 5.24 |  |  | $ | 5.21 | \nDiluted | $ | 2.98 |  |  | $ | 2.46 |  |  | $ | 5.18 |  |  | $ | 5.19 | \nWeighted-average shares used to compute earnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | 2,568 |  |  | 2,704 |  |  | 2,577 |  |  | 2,714 | \nDiluted | 2,612 |  |  | 2,713 |  |  | 2,604 |  |  | 2,729 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet income | $ | 7,788 |  |  | $ | 6,687 |  |  | $ | 13,498 |  |  | $ | 14,152 | \nOther comprehensive income (loss): |  |  |  |  |  |  | \nChange in foreign currency translation adjustment, net of tax | (37) |  |  | (1,076) |  |  | 211 |  |  | (1,435) | \nChange in unrealized gain (loss) on available-for-sale investments and other, net of tax | (88) |  |  | (339) |  |  | 213 |  |  | (1,283) | \nComprehensive income | $ | 7,663 |  |  | $ | 5,272 |  |  | $ | 13,922 |  |  | $ | 11,434 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2023 |  | Three Months Ended June 30, 2022\n | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity |  | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par  Value |  |  | Shares |  | Par  Value | \nBalances at beginning of period | 2,566 |  |  | $ | \u2014 |  |  | $ | 66,535 |  |  | $ | (2,981) |  |  | $ | 61,241 |  |  | $ | 124,795 |  |  | 2,714 |  |  | $ | \u2014 |  |  | $ | 57,512 |  |  | $ | (1,996) |  |  | $ | 67,712 |  |  | $ | 123,228 | \nIssuance of common stock | 18 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 14 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (7) |  |  | \u2014 |  |  | (1,436) |  |  | \u2014 |  |  | (256) |  |  | (1,692) |  |  | (5) |  |  | \u2014 |  |  | (934) |  |  | \u2014 |  |  | (68) |  |  | (1,002) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 4,060 |  |  | \u2014 |  |  | \u2014 |  |  | 4,060 |  |  | \u2014 |  |  | \u2014 |  |  | 3,351 |  |  | \u2014 |  |  | \u2014 |  |  | 3,351 | \nShare repurchases | (4) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (793) |  |  | (793) |  |  | (26) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (5,082) |  |  | (5,082) | \nOther comprehensive loss | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (125) |  |  | \u2014 |  |  | (125) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,415) |  |  | \u2014 |  |  | (1,415) | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 7,788 |  |  | 7,788 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 6,687 |  |  | 6,687 | \nBalances at end of period | 2,573 |  |  | $ | \u2014 |  |  | $ | 69,159 |  |  | $ | (3,106) |  |  | $ | 67,980 |  |  | $ | 134,033 |  |  | 2,697 |  |  | $ | \u2014 |  |  | $ | 59,929 |  |  | $ | (3,411) |  |  | $ | 69,249 |  |  | $ | 125,767 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30, 2023 |  | Six Months Ended June 30, 2022\n | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Income (Loss) |  | Retained Earnings |  | Total Stockholders' Equity |  | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par  Value |  |  | Shares |  | Par  Value | \nBalances at beginning of period | 2,614 |  |  | $ | \u2014 |  |  | $ | 64,444 |  |  | $ | (3,530) |  |  | $ | 64,799 |  |  | $ | 125,713 |  |  | 2,741 |  |  | $ | \u2014 |  |  | $ | 55,811 |  |  | $ | (693) |  |  | $ | 69,761 |  |  | $ | 124,879 | \nIssuance of common stock | 32 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 25 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (13) |  |  | \u2014 |  |  | (2,396) |  |  | \u2014 |  |  | (305) |  |  | (2,701) |  |  | (9) |  |  | \u2014 |  |  | (1,732) |  |  | \u2014 |  |  | (195) |  |  | (1,927) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 7,111 |  |  | \u2014 |  |  | \u2014 |  |  | 7,111 |  |  | \u2014 |  |  | \u2014 |  |  | 5,850 |  |  | \u2014 |  |  | \u2014 |  |  | 5,850 | \nShare repurchases | (60) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (10,012) |  |  | (10,012) |  |  | (60) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (14,469) |  |  | (14,469) | \nOther comprehensive income (loss) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 424 |  |  | \u2014 |  |  | 424 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (2,718) |  |  | \u2014 |  |  | (2,718) | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 13,498 |  |  | 13,498 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 14,152 |  |  | 14,152 | \nBalances at end of period | 2,573 |  |  | $ | \u2014 |  |  | $ | 69,159 |  |  | $ | (3,106) |  |  | $ | 67,980 |  |  | $ | 134,033 |  |  | 2,697 |  |  | $ | \u2014 |  |  | $ | 59,929 |  |  | $ | (3,411) |  |  | $ | 69,249 |  |  | $ | 125,767 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2023 |  | 2022\nCash flows from operating activities |  |  | \nNet income | $ | 13,498 |  |  | $ | 14,152 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nDepreciation and amortization | 5,147 |  |  | 4,135 | \nShare-based compensation | 7,111 |  |  | 5,850 | \nDeferred income taxes | (1,757) |  |  | (1,016) | \nImpairment charges for facilities consolidation | 1,002 |  |  | \u2014 | \n |  |  | \n |  |  | \nOther | 204 |  |  | (33) | \nChanges in assets and liabilities: |  |  | \nAccounts receivable | 1,122 |  |  | 2,035 | \nPrepaid expenses and other current assets | 767 |  |  | 138 | \nOther assets | 67 |  |  | (132) | \nAccounts payable | (1,155) |  |  | (645) | \nPartners payable | (356) |  |  | (33) | \nAccrued expenses and other current liabilities | 5,624 |  |  | 1,943 | \nOther liabilities | 33 |  |  | (122) | \nNet cash provided by operating activities | 31,307 |  |  | 26,272 | \nCash flows from investing activities |  |  | \nPurchases of property and equipment | (13,058) |  |  | (13,013) | \nProceeds relating to property and equipment | 101 |  |  | 170 | \nPurchases of marketable debt securities | (803) |  |  | (6,288) | \n |  |  | \nMaturities and sales of marketable debt securities | 2,351 |  |  | 8,626 | \n |  |  | \nAcquisitions of businesses and intangible assets | (527) |  |  | (1,216) | \nOther investing activities | (10) |  |  | (17) | \nNet cash used in investing activities | (11,946) |  |  | (11,738) | \nCash flows from financing activities |  |  | \nTaxes paid related to net share settlement of equity awards | (2,701) |  |  | (1,927) | \nRepurchases of Class A common stock | (10,263) |  |  | (14,739) | \nProceeds from issuance of long-term debt, net | 8,455 |  |  | \u2014 | \nPrincipal payments on finance leases | (484) |  |  | (452) | \nOther financing activities | (231) |  |  | (105) | \nNet cash used in financing activities | (5,224) |  |  | (17,223) | \nEffect of exchange rate changes on cash, cash equivalents, and restricted cash | 71 |  |  | (698) | \nNet increase (decrease) in cash, cash equivalents, and restricted cash | 14,208 |  |  | (3,387) | \nCash, cash equivalents, and restricted cash at beginning of the period | 15,596 |  |  | 16,865 | \nCash, cash equivalents, and restricted cash at end of the period | $ | 29,804 |  |  | $ | 13,478 | \n |  |  | \nReconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets |  |  | \nCash and cash equivalents | $ | 28,785 |  |  | $ | 12,681 | \nRestricted cash, included in prepaid expenses and other current assets | 165 |  |  | 228 | \nRestricted cash, included in other assets | 854 |  |  | 569 | \nTotal cash, cash equivalents, and restricted cash | $ | 29,804 |  |  | $ | 13,478 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2023 |  | 2022\nSupplemental cash flow data |  |  | \nCash paid for income taxes, net | $ | 1,507 |  |  | $ | 2,641 | \nCash paid for interest, net of amounts capitalized | $ | 182 |  |  | $ | \u2014 | \nNon-cash investing and financing activities: |  |  | \nProperty and equipment in accounts payable and accrued expenses and other current liabilities | $ | 3,845 |  |  | $ | 4,543 | \nAcquisition of businesses in accrued expenses and other current liabilities and other liabilities | $ | 217 |  |  | $ | 43 | \nSettlement of convertible notes in exchange of equity securities in other current assets | $ | \u2014 |  |  | $ | 131 | \nOther current assets through financing arrangement in accrued expenses and other current liabilities | $ | 14 |  |  | $ | 214 | \nRepurchases of Class A common stock in accrued expenses and other current liabilities | $ | \u2014 |  |  | $ | 70 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nAdvertising | $ | 31,498 |  |  | $ | 28,152 |  |  | $ | 59,599 |  |  | $ | 55,150 | \nOther revenue | 225 |  |  | 218 |  |  | 430 |  |  | 433 | \nFamily of Apps | 31,723 |  |  | 28,370 |  |  | 60,029 |  |  | 55,583 | \nReality Labs | 276 |  |  | 452 |  |  | 616 |  |  | 1,146 | \nTotal revenue | $ | 31,999 |  |  | $ | 28,822 |  |  | $ | 60,645 |  |  | $ | 56,729 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nUnited States and Canada(1) | $ | 12,404 |  |  | $ | 12,186 |  |  | $ | 23,854 |  |  | $ | 23,965 | \nEurope(2) | 7,515 |  |  | 6,650 |  |  | 14,274 |  |  | 13,288 | \nAsia-Pacific | 8,551 |  |  | 6,960 |  |  | 15,843 |  |  | 13,682 | \nRest of World(2) | 3,529 |  |  | 3,026 |  |  | 6,674 |  |  | 5,794 | \nTotal revenue | $ | 31,999 |  |  | $ | 28,822 |  |  | $ | 60,645 |  |  | $ | 56,729 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2023 |  | Six Months Ended June 30, 2023\nResearch and development | $ | 142 |  |  | $ | 466 | \nMarketing and sales | 217 |  |  | 222 | \nGeneral and administrative | 237 |  |  | 431 | \nTotal(1) | $ | 596 |  |  | $ | 1,119 |   |  |  |  |  | \n | Severance Liabilities\nBalance as of January 1, 2023 | $ | \u2014 | \nSeverance and other personnel costs | 1,017 | \nCash payments | (339) | \nBalance as of June 30, 2023 | $ | 678 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2023 |  | Six Months Ended June 30, 2023\n | Facilities Consolidation |  | Severance and Other Personnel Costs |  | Data Center Assets(1) |  | Total |  | Facilities Consolidation |  | Severance and Other Personnel Costs |  | Data Center Assets(1) |  | Total\nCost of revenue | $ | 9 |  |  | $ | \u2014 |  |  | $ | (51) |  |  | $ | (42) |  |  | $ | 67 |  |  | $ | \u2014 |  |  | $ | (220) |  |  | $ | (153) | \nResearch and development | 159 |  |  | (7) |  |  | \u2014 |  |  | 152 |  |  | 643 |  |  | (11) |  |  | \u2014 |  |  | 632 | \nMarketing and sales | 43 |  |  | 1 |  |  | \u2014 |  |  | 44 |  |  | 179 |  |  | (1) |  |  | \u2014 |  |  | 178 | \nGeneral and administrative | 36 |  |  | (6) |  |  | \u2014 |  |  | 30 |  |  | 165 |  |  | (18) |  |  | \u2014 |  |  | 147 | \nTotal | $ | 247 |  |  | $ | (12) |  |  | $ | (51) |  |  | $ | 184 |  |  | $ | 1,054 |  |  | $ | (30) |  |  | $ | (220) |  |  | $ | 804 |   |  |  |  |  | \n | Severance Liabilities\nBalance as of January 1, 2022 | $ | \u2014 | \nSeverance and other personnel costs | 975 | \nCash payments | (203) | \nBalance as of December 31, 2022 | 772 | \nAdjustments and foreign exchange | (38) | \nCash payments | (727) | \nBalance as of June 30, 2023 | $ | 7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n | Class A |  | Class B |  | Class A |  | Class B |  | Class A |  | Class B |  | Class A |  | Class B\nBasic EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 6,725 |  |  | $ | 1,063 |  |  | $ | 5,673 |  |  | $ | 1,014 |  |  | $ | 11,627 |  |  | $ | 1,871 |  |  | $ | 12,009 |  |  | $ | 2,143 | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,217 |  |  | 351 |  |  | 2,294 |  |  | 410 |  |  | 2,220 |  |  | 357 |  |  | 2,303 |  |  | 411 | \nBasic EPS | $ | 3.03 |  |  | $ | 3.03 |  |  | $ | 2.47 |  |  | $ | 2.47 |  |  | $ | 5.24 |  |  | $ | 5.24 |  |  | $ | 5.21 |  |  | $ | 5.21 | \nDiluted EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 6,725 |  |  | $ | 1,063 |  |  | $ | 5,673 |  |  | $ | 1,014 |  |  | $ | 11,627 |  |  | $ | 1,871 |  |  | $ | 12,009 |  |  | $ | 2,143 | \nReallocation of net income as a result of conversion of Class B to Class\u00a0A common stock | 1,063 |  |  | \u2014 |  |  | 1,014 |  |  | \u2014 |  |  | 1,871 |  |  | \u2014 |  |  | 2,143 |  |  | \u2014 | \nReallocation of net income to Class B common stock | \u2014 |  |  | (18) |  |  | \u2014 |  |  | (4) |  |  | \u2014 |  |  | (20) |  |  | \u2014 |  |  | (11) | \nNet income for diluted EPS | $ | 7,788 |  |  | $ | 1,045 |  |  | $ | 6,687 |  |  | $ | 1,010 |  |  | $ | 13,498 |  |  | $ | 1,851 |  |  | $ | 14,152 |  |  | $ | 2,132 | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,217 |  |  | 351 |  |  | 2,294 |  |  | 410 |  |  | 2,220 |  |  | 357 |  |  | 2,303 |  |  | 411 | \nConversion of Class B to Class\u00a0A common stock | 351 |  |  | \u2014 |  |  | 410 |  |  | \u2014 |  |  | 357 |  |  | \u2014 |  |  | 411 |  |  | \u2014 | \nWeighted-average effect of dilutive RSUs | 44 |  |  | \u2014 |  |  | 9 |  |  | \u2014 |  |  | 27 |  |  | \u2014 |  |  | 15 |  |  | \u2014 | \nShares used in computation of diluted earnings per share | 2,612 |  |  | 351 |  |  | 2,713 |  |  | 410 |  |  | 2,604 |  |  | 357 |  |  | 2,729 |  |  | 411 | \nDiluted EPS | $ | 2.98 |  |  | $ | 2.98 |  |  | $ | 2.46 |  |  | $ | 2.46 |  |  | $ | 5.18 |  |  | $ | 5.18 |  |  | $ | 5.19 |  |  | $ | 5.19 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | June 30, 2023 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3)\nCash |  | $ | 6,122 |  |  |  |  |  |  | \nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | 21,055 |  |  | $ | 21,055 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities |  | 946 |  |  | 946 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nTime deposits |  | 514 |  |  | \u2014 |  |  | 514 |  |  | \u2014 | \nCorporate debt securities |  | 148 |  |  | \u2014 |  |  | 148 |  |  | \u2014 | \nTotal cash and cash equivalents |  | 28,785 |  |  | 22,001 |  |  | 662 |  |  | \u2014 | \nMarketable securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 8,497 |  |  | 8,497 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 4,504 |  |  | 4,504 |  |  | \u2014 |  |  | \u2014 | \nCorporate debt securities |  | 11,660 |  |  | \u2014 |  |  | 11,660 |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nTotal marketable securities |  | 24,661 |  |  | 13,001 |  |  | 11,660 |  |  | \u2014 | \nRestricted cash equivalents |  | 837 |  |  | 837 |  |  | \u2014 |  |  | \u2014 | \nOther assets |  | 94 |  |  | \u2014 |  |  | \u2014 |  |  | 94 | \nTotal |  | $ | 54,377 |  |  | $ | 35,839 |  |  | $ | 12,322 |  |  | $ | 94 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | December 31, 2022 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3)\nCash |  | $ | 6,176 |  |  |  |  |  |  | \nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | 8,305 |  |  | $ | 8,305 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities |  | 16 |  |  | 16 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nTime deposits |  | 156 |  |  | \u2014 |  |  | 156 |  |  | \u2014 | \nCorporate debt securities |  | 28 |  |  | \u2014 |  |  | 28 |  |  | \u2014 | \nTotal cash and cash equivalents |  | 14,681 |  |  | 8,321 |  |  | 184 |  |  | \u2014 | \nMarketable securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 8,708 |  |  | 8,708 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 4,989 |  |  | 4,989 |  |  | \u2014 |  |  | \u2014 | \nCorporate debt securities |  | 12,335 |  |  | \u2014 |  |  | 12,335 |  |  | \u2014 | \nMarketable equity securities |  | 25 |  |  | 25 |  |  | \u2014 |  |  | \u2014 | \nTotal marketable securities |  | 26,057 |  |  | 13,722 |  |  | 12,335 |  |  | \u2014 | \nRestricted cash equivalents |  | 583 |  |  | 583 |  |  | \u2014 |  |  | \u2014 | \nOther assets |  | 157 |  |  | \u2014 |  |  | \u2014 |  |  | 157 | \nTotal |  | $ | 41,478 |  |  | $ | 22,626 |  |  | $ | 12,519 |  |  | $ | 157 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023\n | Less than 12 months |  | 12 months or greater |  | Total\n | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses\nU.S. government securities | $ | 2,183 |  |  | $ | (88) |  |  | $ | 5,949 |  |  | $ | (349) |  |  | $ | 8,132 |  |  | $ | (437) | \nU.S. government agency securities | 141 |  |  | (4) |  |  | 4,206 |  |  | (263) |  |  | 4,347 |  |  | (267) | \nCorporate debt securities | 1,259 |  |  | (25) |  |  | 9,901 |  |  | (743) |  |  | 11,160 |  |  | (768) | \nTotal | $ | 3,583 |  |  | $ | (117) |  |  | $ | 20,056 |  |  | $ | (1,355) |  |  | $ | 23,639 |  |  | $ | (1,472) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | December 31, 2022\n | Less than 12 months |  | 12 months or greater |  | Total\n | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses\nU.S. government securities | $ | 5,008 |  |  | $ | (234) |  |  | $ | 3,499 |  |  | $ | (247) |  |  | $ | 8,507 |  |  | $ | (481) | \nU.S. government agency securities | 524 |  |  | (17) |  |  | 4,415 |  |  | (308) |  |  | 4,939 |  |  | (325) | \nCorporate debt securities | 4,555 |  |  | (249) |  |  | 7,256 |  |  | (634) |  |  | 11,811 |  |  | (883) | \nTotal | $ | 10,087 |  |  | $ | (500) |  |  | $ | 15,170 |  |  | $ | (1,189) |  |  | $ | 25,257 |  |  | $ | (1,689) |   |  |  |  |  | \n | June 30, 2023\nDue within one year | $ | 5,703 | \nDue after one year to five years | 18,958 | \nTotal | $ | 24,661 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nNon-marketable equity securities under measurement alternative: |  |  | \nInitial cost | $ | 6,389 |  |  | $ | 6,388 | \nCumulative upward adjustments | 293 |  |  | 293 | \nCumulative impairment/downward adjustments | (533) |  |  | (497) | \nCarrying value | 6,149 |  |  | 6,184 | \nNon-marketable equity securities under equity method | 59 |  |  | 17 | \nTotal | $ | 6,208 |  |  | $ | 6,201 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nLand | $ | 1,875 |  |  | $ | 1,874 | \nServers and network assets | 40,824 |  |  | 34,330 | \nBuildings | 32,446 |  |  | 27,720 | \nLeasehold improvements | 6,661 |  |  | 6,522 | \nEquipment and other | 6,449 |  |  | 5,642 | \nFinance lease right-of-use assets | 3,804 |  |  | 3,353 | \nConstruction in progress | 24,843 |  |  | 25,052 | \nProperty and equipment, gross | 116,902 |  |  | 104,493 | \nLess: Accumulated depreciation | (28,953) |  |  | (24,975) | \nProperty and equipment, net | $ | 87,949 |  |  | $ | 79,518 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nFinance lease cost: |  |  |  |  |  |  | \nAmortization of right-of-use assets | $ | 80 |  |  | $ | 95 |  |  | $ | 184 |  |  | $ | 193 | \nInterest | 5 |  |  | 4 |  |  | 10 |  |  | 8 | \nOperating lease cost | 516 |  |  | 435 |  |  | 1,073 |  |  | 846 | \nVariable lease cost and other, net | 112 |  |  | 86 |  |  | 236 |  |  | 176 | \nTotal lease cost | $ | 713 |  |  | $ | 620 |  |  | $ | 1,503 |  |  | $ | 1,223 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nWeighted-average remaining lease term: |  |  | \nFinance leases | 14.1years |  | 14.4years\nOperating leases | 12.3years |  | 12.5years\nWeighted-average discount rate: |  |  | \nFinance leases | 3.2 | % |  | 3.1 | %\nOperating leases | 3.4 | % |  | 3.2 | %  |  |  |  |  |  |  |  |  |  |  | \n | Operating Leases |  | Finance Leases\nThe remainder of 2023 | $ | 848 |  |  | $ | 168 | \n2024 | 2,232 |  |  | 60 | \n2025 | 2,002 |  |  | 61 | \n2026 | 1,948 |  |  | 59 | \n2027 | 1,933 |  |  | 57 | \nThereafter | 13,362 |  |  | 504 | \nTotal undiscounted cash flows | 22,325 |  |  | 909 | \nLess: Imputed interest | (4,489) |  |  | (149) | \nPresent value of lease liabilities(1) | $ | 17,836 |  |  | $ | 760 | \n |  |  | \nLease liabilities, current | $ | 1,396 |  |  | $ | 181 | \nLease liabilities, non-current | 16,440 |  |  | 579 | \nPresent value of lease liabilities(1) | $ | 17,836 |  |  | $ | 760 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2023 |  | 2022\nCash paid for amounts included in the measurement of lease liabilities: |  |  | \nOperating cash flows for operating leases | $ | 994 |  |  | $ | 779 | \nOperating cash flows for finance leases | $ | 10 |  |  | $ | 8 | \nFinancing cash flows for finance leases | $ | 484 |  |  | $ | 452 | \nLease liabilities arising from obtaining right-of-use assets: |  |  | \nOperating leases | $ | 1,868 |  |  | $ | 3,073 | \nFinance leases | $ | 338 |  |  | $ | 103 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total\nGoodwill at December 31, 2022 | $ | 19,250 |  |  | $ | 1,056 |  |  | $ | 20,306 | \nAcquisitions | \u2014 |  |  | 357 |  |  | 357 | \nAdjustments | (4) |  |  | \u2014 |  |  | (4) | \nGoodwill at June 30, 2023 | $ | 19,246 |  |  | $ | 1,413 |  |  | $ | 20,659 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | June 30, 2023 |  | December 31, 2022\n | Weighted-Average Remaining Useful Lives(in years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount\nAcquired technology | 5.0 |  | $ | 464 |  |  | $ | (131) |  |  | $ | 333 |  |  | $ | 507 |  |  | $ | (144) |  |  | $ | 363 | \nAcquired patents | 2.7 |  | 347 |  |  | (276) |  |  | 71 |  |  | 380 |  |  | (289) |  |  | 91 | \nOther | 1.8 |  | 44 |  |  | (17) |  |  | 27 |  |  | 86 |  |  | (25) |  |  | 61 | \nTotal finite-lived assets |  |  | 855 |  |  | (424) |  |  | 431 |  |  | 973 |  |  | (458) |  |  | 515 | \nTotal indefinite-lived assets | N/A |  | 425 |  |  | \u2014 |  |  | 425 |  |  | 382 |  |  | \u2014 |  |  | 382 | \nTotal intangible assets |  |  | $ | 1,280 |  |  | $ | (424) |  |  | $ | 856 |  |  | $ | 1,355 |  |  | $ | (458) |  |  | $ | 897 |   |  |  |  |  | \nThe remainder of 2023 | $ | 82 | \n2024 | 131 | \n2025 | 91 | \n2026 | 43 | \n2027 | 24 | \nThereafter | 60 | \nTotal | $ | 431 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturity |  | Stated Interest Rate |  | Effective Interest Rate |  | June 30, 2023 |  | December 31, 2022\nAugust 2022 debt: |  |  |  |  |  |  |  |  | \n2027 Notes | 2027 |  | 3.50% |  | 3.63% |  | $ | 2,750 |  |  | $ | 2,750 | \n2032 Notes | 2032 |  | 3.85% |  | 3.92% |  | 3,000 |  |  | 3,000 | \n2052 Notes | 2052 |  | 4.45% |  | 4.51% |  | 2,750 |  |  | 2,750 | \n2062 Notes | 2062 |  | 4.65% |  | 4.71% |  | 1,500 |  |  | 1,500 | \n |  |  |  |  |  |  |  |  | \nMay 2023 debt: |  |  |  |  |  |  |  |  | \n2028 Notes | 2028 |  | 4.60% |  | 4.68% |  | 1,500 |  |  | \n2030 Notes | 2030 |  | 4.80% |  | 4.90% |  | 1,000 |  |  | \n2033 Notes | 2033 |  | 4.95% |  | 5.00% |  | 1,750 |  |  | \n2053 Notes | 2053 |  | 5.60% |  | 5.64% |  | 2,500 |  |  | \n2063 Notes | 2063 |  | 5.75% |  | 5.79% |  | 1,750 |  |  | \nTotal face amount of long-term debt |  |  |  |  |  |  | 18,500 |  |  | 10,000 | \nUnamortized discount and issuance costs, net |  |  |  |  |  |  | (118) |  | (77)\nLong-term debt |  |  |  |  |  |  | $ | 18,382 |  |  | $ | 9,923 |   |  |  |  |  | \nRemainder of 2023 through 2026 | $ | \u2014 | \n2027 | 2,750 | \nThereafter | 15,750 | \nTotal outstanding debt | $ | 18,500 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nLegal-related accruals(1) | $ | 7,456 |  |  | $ | 4,795 | \nAccrued compensation and benefits | 4,338 |  |  | 4,591 | \nAccrued property and equipment | 2,306 |  |  | 2,921 | \nAccrued taxes | 5,837 |  |  | 2,339 | \nOther current liabilities | 4,723 |  |  | 4,906 | \nAccrued expenses and other current liabilities | $ | 24,660 |  |  | $ | 19,552 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nIncome tax payable | $ | 6,570 |  |  | $ | 6,645 | \n |  |  | \nOther non-current liabilities | 1,342 |  |  | 1,119 | \nOther liabilities | $ | 7,912 |  |  | $ | 7,764 |   |  |  |  |  | \nThe remainder of 2023 | $ | 12,346 | \n2024 | 2,836 | \n2025 | 1,414 | \n2026 | 301 | \n2027 | 213 | \nThereafter | 2,573 | \nTotal | $ | 19,683 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nCost of revenue | $ | 193 |  |  | $ | 213 |  |  | $ | 352 |  |  | $ | 373 | \nResearch and development | 3,305 |  |  | 2,606 |  |  | 5,754 |  |  | 4,547 | \nMarketing and sales | 289 |  |  | 289 |  |  | 509 |  |  | 506 | \nGeneral and administrative | 273 |  |  | 243 |  |  | 496 |  |  | 424 | \nTotal share-based compensation expense | $ | 4,060 |  |  | $ | 3,351 |  |  | $ | 7,111 |  |  | $ | 5,850 |   |  |  |  |  |  |  |  |  |  |  | \n | Number of Shares |  | Weighted-Average Grant Date Fair Value Per Share\n | (in thousands) |  | \nUnvested at December 31, 2022 | 127,110 |  |  | $ | 216.93 | \nGranted | 107,550 |  |  | $ | 197.24 | \nVested | (31,987) |  |  | $ | 210.65 | \nForfeited | (19,704) |  |  | $ | 210.36 | \nUnvested at June 30, 2023 | 182,969 |  |  | $ | 207.16 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue: |  |  |  |  |  |  | \nFamily of Apps | $ | 31,723 |  |  | $ | 28,370 |  |  | $ | 60,029 |  |  | $ | 55,583 | \nReality Labs | 276 |  |  | 452 |  |  | 616 |  |  | 1,146 | \nTotal revenue | $ | 31,999 |  |  | $ | 28,822 |  |  | $ | 60,645 |  |  | $ | 56,729 | \n |  |  |  |  |  |  | \nIncome (loss) from operations: |  |  |  |  |  |  | \nFamily of Apps | $ | 13,131 |  |  | $ | 11,164 |  |  | $ | 24,351 |  |  | $ | 22,647 | \nReality Labs | (3,739) |  |  | (2,806) |  |  | (7,732) |  |  | (5,766) | \nTotal income from operations | $ | 9,392 |  |  | $ | 8,358 |  |  | $ | 16,619 |  |  | $ | 16,881 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nUnited States | $ | 83,711 |  |  | $ | 76,334 | \nRest of the world(1) | 17,193 |  |  | 15,857 | \nTotal long-lived assets | $ | 100,904 |  |  | $ | 92,191 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total |  |  |  |  |  | \n | Three Months Ended June 30, |  | % change |  | Three Months Ended June 30, |  | % change |  | Three Months Ended June 30, |  | % change |  |  |  | \n | 2023 |  | 2022 |  |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages) |  |  |  |  |  | \nRevenue | $ | 31,723 |  | $ | 28,370 |  | 12% |  | $ | 276 |  | $ | 452 |  | (39)% |  | $ | 31,999 |  | $ | 28,822 |  | 11% |  |  |  |  |  | \nCosts and expenses | $ | 18,592 |  | $ | 17,206 |  | 8% |  | $ | 4,015 |  | $ | 3,258 |  | 23% |  | $ | 22,607 |  | $ | 20,464 |  | 10% |  |  |  |  |  | \nIncome (loss) from operations | $ | 13,131 |  | $ | 11,164 |  | 18% |  | $ | (3,739) |  | $ | (2,806) |  | (33)% |  | $ | 9,392 |  | $ | 8,358 |  | 12% |  |  |  |  |  | \nOperating margin | 41 | % |  | 39 | % |  |  |  | (1,355) | % |  | (621) | % |  |  |  | 29 | % |  | 29 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, 2023\n | Facilities Consolidation |  | Severance and Other Personnel Costs |  | Data Center Assets |  | Total\nCost of revenue | $ | 9 |  |  | $ | \u2014 |  |  | $ | (51) |  |  | $ | (42) | \nResearch and development | 159 |  |  | 136 |  |  | \u2014 |  |  | 295 | \nMarketing and sales | 43 |  |  | 218 |  |  | \u2014 |  |  | 261 | \nGeneral and administrative | 36 |  |  | 230 |  |  | \u2014 |  |  | 266 | \nTotal | $ | 247 |  |  | $ | 584 |  |  | $ | (51) |  |  | $ | 780 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPP: | $8.36 | $8.18 | $9.39 | $7.72 | $7.91 | $7.53 | $8.63 | $7.59 | $8.32\n |  |  |  |  |  |  |  |  | \n |  |  | Ad Revenue |  | Non-Ad Revenue |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | Ad Revenue |  | Non-Ad Revenue |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue | $ | 31,999 |  |  | $ | 28,822 |  |  | $ | 60,645 |  |  | $ | 56,729 | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 5,945 |  |  | 5,192 |  |  | 12,054 |  |  | 11,197 | \nResearch and development | 9,344 |  |  | 8,690 |  |  | 18,725 |  |  | 16,397 | \nMarketing and sales | 3,154 |  |  | 3,595 |  |  | 6,198 |  |  | 6,907 | \nGeneral and administrative | 4,164 |  |  | 2,987 |  |  | 7,049 |  |  | 5,347 | \nTotal costs and expenses | 22,607 |  |  | 20,464 |  |  | 44,026 |  |  | 39,848 | \nIncome from operations | 9,392 |  |  | 8,358 |  |  | 16,619 |  |  | 16,881 | \nInterest and other income (expense), net | (99) |  |  | (172) |  |  | (19) |  |  | 213 | \nIncome before provision for income taxes | 9,293 |  |  | 8,186 |  |  | 16,600 |  |  | 17,094 | \nProvision for income taxes | 1,505 |  |  | 1,499 |  |  | 3,102 |  |  | 2,942 | \nNet income | $ | 7,788 |  |  | $ | 6,687 |  |  | $ | 13,498 |  |  | $ | 14,152 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue | 100 | % |  | 100 | % |  | 100 | % |  | 100 | %\nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 19 |  |  | 18 |  |  | 20 |  |  | 20 | \nResearch and development | 29 |  |  | 30 |  |  | 31 |  |  | 29 | \nMarketing and sales | 10 |  |  | 12 |  |  | 10 |  |  | 12 | \nGeneral and administrative | 13 |  |  | 10 |  |  | 12 |  |  | 9 | \nTotal costs and expenses | 71 |  |  | 71 |  |  | 73 |  |  | 70 | \nIncome from operations | 29 |  |  | 29 |  |  | 27 |  |  | 30 | \nInterest and other income (expense), net | \u2014 |  |  | (1) |  |  | \u2014 |  |  | \u2014 | \nIncome before provision for income taxes | 29 |  |  | 28 |  |  | 27 |  |  | 30 | \nProvision for income taxes | 5 |  |  | 5 |  |  | 5 |  |  | 5 | \nNet income | 24 | % |  | 23 | % |  | 22 | % |  | 25 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nAdvertising | $ | 31,498 |  |  | $ | 28,152 |  |  | 12 | % |  | $ | 59,599 |  |  | $ | 55,150 |  |  | 8 | %\nOther revenue | 225 |  |  | 218 |  |  | 3 | % |  | 430 |  |  | 433 |  |  | (1) | %\nFamily of Apps | 31,723 |  |  | 28,370 |  |  | 12 | % |  | 60,029 |  |  | 55,583 |  |  | 8 | %\nReality Labs | 276 |  |  | 452 |  |  | (39) | % |  | 616 |  |  | 1,146 |  |  | (46) | %\nTotal revenue | $ | 31,999 |  |  | $ | 28,822 |  |  | 11 | % |  | $ | 60,645 |  |  | $ | 56,729 |  |  | 7 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nCost of revenue | $ | 5,945 |  |  | $ | 5,192 |  |  | 15 | % |  | $ | 12,054 |  |  | $ | 11,197 |  |  | 8 | %\nPercentage of revenue | 19 | % |  | 18 | % |  |  |  | 20 | % |  | 20 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nResearch and development | $ | 9,344 |  |  | $ | 8,690 |  |  | 8 | % |  | $ | 18,725 |  |  | $ | 16,397 |  |  | 14 | %\nPercentage of revenue | 29 | % |  | 30 | % |  |  |  | 31 | % |  | 29 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nMarketing and sales | $ | 3,154 |  |  | $ | 3,595 |  |  | (12) | % |  | $ | 6,198 |  |  | $ | 6,907 |  |  | (10) | %\nPercentage of revenue | 10 | % |  | 12 | % |  |  |  | 10 | % |  | 12 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nGeneral and administrative | $ | 4,164 |  |  | $ | 2,987 |  |  | 39 | % |  | $ | 7,049 |  |  | $ | 5,347 |  |  | 32 | %\nPercentage of revenue | 13 | % |  | 10 | % |  |  |  | 12 | % |  | 9 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nFamily of Apps | $ | 13,131 |  |  | $ | 11,164 |  |  | 18 | % |  | $ | 24,351 |  |  | $ | 22,647 |  |  | 8 | %\nReality Labs | (3,739) |  |  | (2,806) |  |  | (33) | % |  | (7,732) |  |  | (5,766) |  |  | (34) | %\nTotal income from operations | $ | 9,392 |  |  | $ | 8,358 |  |  | 12 | % |  | $ | 16,619 |  |  | $ | 16,881 |  |  | (2) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\n |  |  |  |  |  |  |  |  |  |  | \nInterest income | $ | 323 |  |  | $ | 96 |  |  | 236 | % |  | $ | 517 |  |  | $ | 177 |  |  | 192 | %\nInterest expense | (116) |  |  | (5) |  |  | NM |  | (172) |  |  | (10) |  |  | NM\nForeign currency exchange gains (losses), net | (145) |  |  | (60) |  |  | (142) | % |  | (207) |  |  | (6) |  |  | NM\nOther income (expense), net | (161) |  |  | (203) |  |  | 21 | % |  | (157) |  |  | 52 |  |  | NM\nInterest and other income (expense), net | $ | (99) |  |  | $ | (172) |  |  | 42 | % |  | $ | (19) |  |  | $ | 213 |  |  | (109) | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nProvision for income taxes | $ | 1,505 |  |  | $ | 1,499 |  |  | \u2014 | % |  | $ | 3,102 |  |  | $ | 2,942 |  |  | 5 | %\nEffective tax rate | 16 | % |  | 18 | % |  |  |  | 19 | % |  | 17 | % |  |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2023 |  | 2022\nNet cash provided by operating activities | $ | 31,307 |  |  | $ | 26,272 | \nNet cash used in investing activities | $ | (11,946) |  |  | $ | (11,738) | \nNet cash used in financing activities | $ | (5,224) |  |  | $ | (17,223) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total Number of Shares Purchased |  | Average Price Paid Per Share(2) |  | Total Number of Shares Purchased as Part of Publicly Announced Programs(1) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(1)\n | (in thousands) |  |  |  | (in thousands) |  | (in millions)\nApril 1 - 30, 2023 | 3,788 |  |  | $ | 214.16 |  |  | 3,788 |  |  | $ | 40,915 | \nMay 1 - 31, 2023 | \u2014 |  |  | $ | \u2014 |  |  | \u2014 |  |  | $ | 40,915 | \nJune 1 - 30, 2023 | \u2014 |  |  | $ | \u2014 |  |  | \u2014 |  |  | $ | 40,915 | \n | 3,788 |  |  |  |  | 3,788 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nExhibitNumber |  |  |  | Incorporated by Reference |  | FiledHerewith\n | Exhibit Description |  | Form |  | File No. |  | Exhibit |  | Filing\u00a0Date | \n |  |  |  |  |  |  |  |  |  |  |  | \n4.1 |  | Second Supplemental Indenture, dated as of May 3, 2023, by and between Meta Platforms, Inc. and U.S. Bank Trust Company, National Association, as trustee, including forms of global notes representing the 4.600% Senior Notes due 2028, 4.800% Senior Notes due 2030, 4.950% Senior Notes due 2033, 5.600% Senior Notes due 2053 and 5.750% Senior Notes due 2063. |  | 8-K |  | 001-35551 |  | 4.1 |  | May 3, 2023 |  | \n31.1 |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n31.2 |  | Certification of Susan Li, Chief Financial Officer, pursuant to Rule\u00a013a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.1# |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.2# |  | Certification of Susan Li, Chief Financial Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.INS |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.LAB |  | Inline XBRL Taxonomy Extension Labels Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n104 |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |  |  |  |  |  |  |  |  |  | X  |  |  |  |  |  |  |  | \n |  | META PLATFORMS, INC.\n | \nDate: July 26, 2023 |  | /s/ SUSAN LI\n |  | Susan LiChief Financial Officer(Principal Financial Officer)\n | \nDate: July 26, 2023 |  | /s/ AARON ANDERSON\n |  | Aaron AndersonChief Accounting Officer(Principal Accounting Officer)"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Meta, in 2023 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  |  |  |  | \nDelaware | 20-1665019\n(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number)  |  |  |  |  |  |  |  |  |  |  | \nTitle of each class | Trading symbol(s) | Name of each exchange on which registered\nClass A Common Stock, $0.000006 par value | META | The Nasdaq Stock Market LLC  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer |  | \u2612 | Accelerated\u00a0filer |  | \u2610\nNon-accelerated filer |  | \u2610 | Smaller\u00a0reporting\u00a0company |  | \u2610\n |  |  | Emerging growth company |  | \u2610\n |  |  |  |  | \nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |  | \u2610  |  |  |  |  |  |  |  |  |  |  | \nClass | Number of Shares Outstanding\nClass\u00a0A Common Stock | $0.000006 par value | 2,219,607,026 |  | shares outstanding as of October 20, 2023\nClass B Common Stock | $0.000006 par value | 350,255,706 |  | shares outstanding as of October 20, 2023  |  |  |  |  |  |  |  | \n |  | Page\n | \nNote About Forward-Looking Statements | 3\n | \nLimitations of Key Metrics and Other Data | 4\n | \nPART I\u2014FINANCIAL INFORMATION | 7\n |  | \nItem 1. | Financial Statements (unaudited) | 7\n |  | \n | Condensed Consolidated Balance Sheets\u2014September30, 2023 and December\u00a031, 2022 | 7\n |  | \n | Condensed Consolidated Statements of Income\u2014for the three andninemonths endedSeptember30, 2023 and 2022 | 8\n |  | \n | Condensed Consolidated Statements of Comprehensive Income\u2014for the three andninemonths endedSeptember30, 2023 and 2022 | 9\n |  | \n | Condensed Consolidated Statements of Stockholders' Equity\u2014for the three andninemonths endedSeptember30, 2023 and 2022 | 10\n |  | \n | Condensed Consolidated Statements of Cash Flows\u2014for theninemonths endedSeptember30, 2023 and 2022 | 11\n |  | \n | Notes to Condensed Consolidated Financial Statements | 13\n |  | \nItem 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 33\n |  | \nItem 3. | Quantitative and Qualitative Disclosures About Market Risk | 53\n |  | \nItem 4. | Controls and Procedures | 53\n | \nPART II\u2014OTHER INFORMATION | 54\n |  | \nItem 1. | Legal Proceedings | 54\n |  | \nItem\u00a01A. | Risk Factors | 58\n |  | \nItem 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 92\n |  | \nItem 5. | Other Information | 93\n | \nItem 6. | Exhibits | 94\n | \nSIGNATURES | 95  |  |  |  |  |  |  |  |  |  |  | \n | September 30,2023 |  | December 31,2022\nAssets |  |  | \nCurrent assets: |  |  | \nCash and cash equivalents | $ | 36,890 |  |  | $ | 14,681 | \nMarketable securities | 24,233 |  |  | 26,057 | \nAccounts receivable, net | 12,944 |  |  | 13,466 | \nPrepaid expenses and other current assets | 4,311 |  |  | 5,345 | \nTotal current assets | 78,378 |  |  | 59,549 | \nNon-marketable equity securities | 6,142 |  |  | 6,201 | \nProperty and equipment, net | 91,772 |  |  | 79,518 | \nOperating lease right-of-use assets | 13,033 |  |  | 12,673 | \nIntangible assets, net | 813 |  |  | 897 | \nGoodwill | 20,668 |  |  | 20,306 | \nOther assets | 5,468 |  |  | 6,583 | \nTotal assets | $ | 216,274 |  |  | $ | 185,727 | \n |  |  | \nLiabilities and stockholders' equity |  |  | \nCurrent liabilities: |  |  | \nAccounts payable | $ | 4,372 |  |  | $ | 4,990 | \nPartners payable | 770 |  |  | 1,117 | \nOperating lease liabilities, current | 1,460 |  |  | 1,367 | \nAccrued expenses and other current liabilities | 23,929 |  |  | 19,552 | \nTotal current liabilities | 30,531 |  |  | 27,026 | \nOperating lease liabilities, non-current | 16,374 |  |  | 15,301 | \nLong-term debt | 18,383 |  |  | 9,923 | \nOther liabilities | 8,113 |  |  | 7,764 | \nTotal liabilities | 73,401 |  |  | 60,014 | \nCommitments and contingencies |  |  | \nStockholders' equity: |  |  | \nCommon stock, $0.000006par value;5,000million Class A shares authorized,2,221million and2,247million shares issued and outstanding, as of September\u00a030, 2023 and December\u00a031, 2022, respectively;4,141million Class B shares authorized,350million and367million shares issued and outstanding, as of September\u00a030, 2023 and December\u00a031, 2022, respectively | \u2014 |  |  | \u2014 | \nAdditional paid-in capital | 71,224 |  |  | 64,444 | \nAccumulated other comprehensive loss | (3,556) |  |  | (3,530) | \nRetained earnings | 75,205 |  |  | 64,799 | \nTotal stockholders' equity | 142,873 |  |  | 125,713 | \nTotal liabilities and stockholders' equity | $ | 216,274 |  |  | $ | 185,727 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue | $ | 34,146 |  |  | $ | 27,714 |  |  | $ | 94,791 |  |  | $ | 84,444 | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 6,210 |  |  | 5,716 |  |  | 18,264 |  |  | 16,913 | \nResearch and development | 9,241 |  |  | 9,170 |  |  | 27,966 |  |  | 25,567 | \nMarketing and sales | 2,877 |  |  | 3,780 |  |  | 9,075 |  |  | 10,688 | \nGeneral and administrative | 2,070 |  |  | 3,384 |  |  | 9,119 |  |  | 8,731 | \nTotal costs and expenses | 20,398 |  |  | 22,050 |  |  | 64,424 |  |  | 61,899 | \nIncome from operations | 13,748 |  |  | 5,664 |  |  | 30,367 |  |  | 22,545 | \nInterest and other income (expense), net | 272 |  |  | (88) |  |  | 254 |  |  | 125 | \nIncome before provision for income taxes | 14,020 |  |  | 5,576 |  |  | 30,621 |  |  | 22,670 | \nProvision for income taxes | 2,437 |  |  | 1,181 |  |  | 5,540 |  |  | 4,123 | \nNet income | $ | 11,583 |  |  | $ | 4,395 |  |  | $ | 25,081 |  |  | $ | 18,547 | \nEarnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | $ | 4.50 |  |  | $ | 1.64 |  |  | $ | 9.73 |  |  | $ | 6.86 | \nDiluted | $ | 4.39 |  |  | $ | 1.64 |  |  | $ | 9.56 |  |  | $ | 6.82 | \nWeighted-average shares used to compute earnings per share attributable to Class A and Class B common stockholders: |  |  |  |  |  |  | \nBasic | 2,576 |  |  | 2,682 |  |  | 2,577 |  |  | 2,703 | \nDiluted | 2,641 |  |  | 2,687 |  |  | 2,623 |  |  | 2,718 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet income | $ | 11,583 |  |  | $ | 4,395 |  |  | $ | 25,081 |  |  | $ | 18,547 | \nOther comprehensive income (loss): |  |  |  |  |  |  | \nChange in foreign currency translation adjustment, net of tax | (533) |  |  | (1,037) |  |  | (322) |  |  | (2,472) | \nChange in unrealized gain (loss) on available-for-sale investments and other, net of tax | 83 |  |  | (606) |  |  | 296 |  |  | (1,889) | \nComprehensive income | $ | 11,133 |  |  | $ | 2,752 |  |  | $ | 25,055 |  |  | $ | 14,186 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, 2023 |  | Three Months Ended September 30, 2022\n | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity |  | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par Value |  |  | Shares |  | Par Value | \nBalances at beginning of period | 2,573 |  |  | $ | \u2014 |  |  | $ | 69,159 |  |  | $ | (3,106) |  |  | $ | 67,980 |  |  | $ | 134,033 |  |  | 2,697 |  |  | $ | \u2014 |  |  | $ | 59,929 |  |  | $ | (3,411) |  |  | $ | 69,249 |  |  | $ | 125,767 | \nIssuance of common stock | 17 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 14 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (7) |  |  | \u2014 |  |  | (1,427) |  |  | \u2014 |  |  | (660) |  |  | (2,087) |  |  | (5) |  |  | \u2014 |  |  | (971) |  |  | \u2014 |  |  | (40) |  |  | (1,011) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 3,492 |  |  | \u2014 |  |  | \u2014 |  |  | 3,492 |  |  | \u2014 |  |  | \u2014 |  |  | 3,134 |  |  | \u2014 |  |  | \u2014 |  |  | 3,134 | \nShare repurchases | (12) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (3,698) |  |  | (3,698) |  |  | (41) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (6,548) |  |  | (6,548) | \nOther comprehensive loss | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (450) |  |  | \u2014 |  |  | (450) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (1,643) |  |  | \u2014 |  |  | (1,643) | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 11,583 |  |  | 11,583 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 4,395 |  |  | 4,395 | \nBalances at end of period | 2,571 |  |  | $ | \u2014 |  |  | $ | 71,224 |  |  | $ | (3,556) |  |  | $ | 75,205 |  |  | $ | 142,873 |  |  | 2,665 |  |  | $ | \u2014 |  |  | $ | 62,092 |  |  | $ | (5,054) |  |  | $ | 67,056 |  |  | $ | 124,094 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30, 2023 |  | Nine Months Ended September 30, 2022\n | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity |  | Class A and Class B Common Stock |  | Additional Paid-In Capital |  | Accumulated Other Comprehensive Loss |  | Retained Earnings |  | Total Stockholders' Equity\n | Shares |  | Par Value |  |  | Shares |  | Par Value | \nBalances at beginning of period | 2,614 |  |  | $ | \u2014 |  |  | $ | 64,444 |  |  | $ | (3,530) |  |  | $ | 64,799 |  |  | $ | 125,713 |  |  | 2,741 |  |  | $ | \u2014 |  |  | $ | 55,811 |  |  | $ | (693) |  |  | $ | 69,761 |  |  | $ | 124,879 | \nIssuance of common stock | 49 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 39 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nShares withheld related to net share settlement | (20) |  |  | \u2014 |  |  | (3,823) |  |  | \u2014 |  |  | (966) |  |  | (4,789) |  |  | (14) |  |  | \u2014 |  |  | (2,703) |  |  | \u2014 |  |  | (235) |  |  | (2,938) | \nShare-based compensation | \u2014 |  |  | \u2014 |  |  | 10,603 |  |  | \u2014 |  |  | \u2014 |  |  | 10,603 |  |  | \u2014 |  |  | \u2014 |  |  | 8,984 |  |  | \u2014 |  |  | \u2014 |  |  | 8,984 | \nShare repurchases | (72) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (13,709) |  |  | (13,709) |  |  | (101) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (21,017) |  |  | (21,017) | \nOther comprehensive loss | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (26) |  |  | \u2014 |  |  | (26) |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | (4,361) |  |  | \u2014 |  |  | (4,361) | \nNet income | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 25,081 |  |  | 25,081 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 18,547 |  |  | 18,547 | \nBalances at end of period | 2,571 |  |  | $ | \u2014 |  |  | $ | 71,224 |  |  | $ | (3,556) |  |  | $ | 75,205 |  |  | $ | 142,873 |  |  | 2,665 |  |  | $ | \u2014 |  |  | $ | 62,092 |  |  | $ | (5,054) |  |  | $ | 67,056 |  |  | $ | 124,094 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2023 |  | 2022\nCash flows from operating activities |  |  | \nNet income | $ | 25,081 |  |  | $ | 18,547 | \nAdjustments to reconcile net income to net cash provided by operating activities: |  |  | \nDepreciation and amortization | 8,006 |  |  | 6,310 | \nShare-based compensation | 10,603 |  |  | 8,984 | \nDeferred income taxes | 1,292 |  |  | (2,113) | \nImpairment charges for facilities consolidation, net | 1,342 |  |  | 413 | \n |  |  | \n |  |  | \nOther | 278 |  |  | 71 | \nChanges in assets and liabilities: |  |  | \nAccounts receivable | 444 |  |  | 1,930 | \nPrepaid expenses and other current assets | (141) |  |  | (693) | \nOther assets | 31 |  |  | (160) | \nAccounts payable | (543) |  |  | (666) | \nPartners payable | (347) |  |  | (12) | \nAccrued expenses and other current liabilities | 5,702 |  |  | 2,942 | \nOther liabilities | (39) |  |  | 411 | \nNet cash provided by operating activities | 51,709 |  |  | 35,964 | \nCash flows from investing activities |  |  | \nPurchases of property and equipment | (19,601) |  |  | (22,388) | \nProceeds relating to property and equipment | 148 |  |  | 190 | \nPurchases of marketable debt securities | (1,810) |  |  | (8,885) | \n |  |  | \nMaturities and sales of marketable debt securities | 3,825 |  |  | 10,895 | \n |  |  | \nAcquisitions of businesses and intangible assets | (565) |  |  | (1,250) | \nOther investing activities | (20) |  |  | (1) | \nNet cash used in investing activities | (18,023) |  |  | (21,439) | \nCash flows from financing activities |  |  | \nTaxes paid related to net share settlement of equity awards | (4,789) |  |  | (2,938) | \nRepurchases of Class A common stock | (13,832) |  |  | (21,093) | \nProceeds from issuance of long-term debt, net | 8,455 |  |  | 9,921 | \nPrincipal payments on finance leases | (751) |  |  | (615) | \nOther financing activities | (182) |  |  | (351) | \nNet cash used in financing activities | (11,099) |  |  | (15,076) | \nEffect of exchange rate changes on cash, cash equivalents, and restricted cash | (283) |  |  | (1,063) | \nNet increase (decrease) in cash, cash equivalents, and restricted cash | 22,304 |  |  | (1,614) | \nCash, cash equivalents, and restricted cash at beginning of the period | 15,596 |  |  | 16,865 | \nCash, cash equivalents, and restricted cash at end of the period | $ | 37,900 |  |  | $ | 15,251 | \n |  |  | \nReconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets |  |  | \nCash and cash equivalents | $ | 36,890 |  |  | $ | 14,308 | \nRestricted cash, included in prepaid expenses and other current assets | 152 |  |  | 232 | \nRestricted cash, included in other assets | 858 |  |  | 711 | \nTotal cash, cash equivalents, and restricted cash | $ | 37,900 |  |  | $ | 15,251 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2023 |  | 2022\nSupplemental cash flow data |  |  | \nCash paid for income taxes, net | $ | 2,016 |  |  | $ | 4,647 | \nCash paid for interest, net of amounts capitalized | $ | 302 |  |  | $ | \u2014 | \nNon-cash investing and financing activities: |  |  | \nProperty and equipment in accounts payable and accrued expenses and other current liabilities | $ | 4,506 |  |  | $ | 4,130 | \nAcquisition of businesses in accrued expenses and other current liabilities and other liabilities | $ | 182 |  |  | $ | 294 | \n |  |  | \n |  |  | \nRepurchases of Class A common stock in accrued expenses and other current liabilities | $ | 122 |  |  | $ | 265 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nAdvertising | $ | 33,643 |  |  | $ | 27,237 |  |  | $ | 93,242 |  |  | $ | 82,387 | \nOther revenue | 293 |  |  | 192 |  |  | 724 |  |  | 624 | \nFamily of Apps | 33,936 |  |  | 27,429 |  |  | 93,966 |  |  | 83,011 | \nReality Labs | 210 |  |  | 285 |  |  | 825 |  |  | 1,433 | \nTotal revenue | $ | 34,146 |  |  | $ | 27,714 |  |  | $ | 94,791 |  |  | $ | 84,444 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nUnited States and Canada(1) | $ | 12,908 |  |  | $ | 11,966 |  |  | $ | 36,761 |  |  | $ | 35,931 | \nEurope(2) | 7,578 |  |  | 5,996 |  |  | 21,852 |  |  | 19,284 | \nAsia-Pacific | 9,790 |  |  | 6,797 |  |  | 25,634 |  |  | 20,480 | \nRest of World(2) | 3,870 |  |  | 2,955 |  |  | 10,544 |  |  | 8,749 | \nTotal revenue | $ | 34,146 |  |  | $ | 27,714 |  |  | $ | 94,791 |  |  | $ | 84,444 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, 2023 |  | Nine Months Ended September 30, 2023\nResearch and development | $ | (72) |  |  | $ | 394 | \nMarketing and sales | 69 |  |  | 291 | \nGeneral and administrative | 39 |  |  | 470 | \nTotal(1) | $ | 36 |  |  | $ | 1,155 |   |  |  |  |  | \n | Severance Liabilities\nBalance as of January 1, 2023 | $ | \u2014 | \nSeverance and other personnel costs | 1,056 | \nCash payments | (944) | \nBalance as of September 30, 2023 | $ | 112 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, 2023 |  | Nine Months Ended September 30, 2023\n | Facilities Consolidation |  | Severance and Other Personnel Costs |  | Data Center Assets(1) |  | Total |  | Facilities Consolidation |  | Severance and Other Personnel Costs |  | Data Center Assets(1) |  | Total\nCost of revenue | $ | 25 |  |  | $ | \u2014 |  |  | $ | (12) |  |  | $ | 13 |  |  | $ | 92 |  |  | $ | \u2014 |  |  | $ | (232) |  |  | $ | (140) | \nResearch and development | 228 |  |  | 2 |  |  | \u2014 |  |  | 230 |  |  | 871 |  |  | (9) |  |  | \u2014 |  |  | 862 | \nMarketing and sales | 54 |  |  | 1 |  |  | \u2014 |  |  | 55 |  |  | 233 |  |  | (1) |  |  | \u2014 |  |  | 232 | \nGeneral and administrative | 45 |  |  | 1 |  |  | \u2014 |  |  | 46 |  |  | 210 |  |  | (16) |  |  | \u2014 |  |  | 194 | \nTotal | $ | 352 |  |  | $ | 4 |  |  | $ | (12) |  |  | $ | 344 |  |  | $ | 1,406 |  |  | $ | (26) |  |  | $ | (232) |  |  | $ | 1,148 |   |  |  |  |  | \n | Severance Liabilities\nBalance as of January 1, 2022 | $ | \u2014 | \nSeverance and other personnel costs | 975 | \nCash payments | (203) | \nBalance as of December 31, 2022 | 772 | \nAdjustments and foreign exchange | (35) | \nCash payments | (737) | \nBalance as of September 30, 2023 | $ | \u2014 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\n | Class A |  | Class B |  | Class A |  | Class B |  | Class A |  | Class B |  | Class A |  | Class B\nBasic EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 10,007 |  |  | $ | 1,576 |  |  | $ | 3,729 |  |  | $ | 666 |  |  | $ | 21,626 |  |  | $ | 3,455 |  |  | $ | 15,736 |  |  | $ | 2,811 | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,226 |  |  | 350 |  |  | 2,276 |  |  | 406 |  |  | 2,222 |  |  | 355 |  |  | 2,293 |  |  | 410 | \nBasic EPS | $ | 4.50 |  |  | $ | 4.50 |  |  | $ | 1.64 |  |  | $ | 1.64 |  |  | $ | 9.73 |  |  | $ | 9.73 |  |  | $ | 6.86 |  |  | $ | 6.86 | \nDiluted EPS: |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNumerator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nNet income | $ | 10,007 |  |  | $ | 1,576 |  |  | $ | 3,729 |  |  | $ | 666 |  |  | $ | 21,626 |  |  | $ | 3,455 |  |  | $ | 15,736 |  |  | $ | 2,811 | \nReallocation of net income as a result of conversion of Class B to Class\u00a0A common stock | 1,576 |  |  | \u2014 |  |  | 666 |  |  | \u2014 |  |  | 3,455 |  |  | \u2014 |  |  | 2,811 |  |  | \u2014 | \nReallocation of net income to Class B common stock | \u2014 |  |  | (38) |  |  | \u2014 |  |  | (1) |  |  | \u2014 |  |  | (60) |  |  | \u2014 |  |  | (16) | \nNet income for diluted EPS | $ | 11,583 |  |  | $ | 1,538 |  |  | $ | 4,395 |  |  | $ | 665 |  |  | $ | 25,081 |  |  | $ | 3,395 |  |  | $ | 18,547 |  |  | $ | 2,795 | \nDenominator |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nShares used in computation of basic earnings per share | 2,226 |  |  | 350 |  |  | 2,276 |  |  | 406 |  |  | 2,222 |  |  | 355 |  |  | 2,293 |  |  | 410 | \nConversion of Class B to Class\u00a0A common stock | 350 |  |  | \u2014 |  |  | 406 |  |  | \u2014 |  |  | 355 |  |  | \u2014 |  |  | 410 |  |  | \u2014 | \nWeighted-average effect of dilutive RSUs | 65 |  |  | \u2014 |  |  | 5 |  |  | \u2014 |  |  | 46 |  |  | \u2014 |  |  | 15 |  |  | \u2014 | \nShares used in computation of diluted earnings per share | 2,641 |  |  | 350 |  |  | 2,687 |  |  | 406 |  |  | 2,623 |  |  | 355 |  |  | 2,718 |  |  | 410 | \nDiluted EPS | $ | 4.39 |  |  | $ | 4.39 |  |  | $ | 1.64 |  |  | $ | 1.64 |  |  | $ | 9.56 |  |  | $ | 9.56 |  |  | $ | 6.82 |  |  | $ | 6.82 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | September 30, 2023 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3)\nCash |  | $ | 5,333 |  |  |  |  |  |  | \nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | 29,639 |  |  | $ | 29,639 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities |  | 1,445 |  |  | 1,445 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nTime deposits |  | 350 |  |  | \u2014 |  |  | 350 |  |  | \u2014 | \nCorporate debt securities |  | 123 |  |  | \u2014 |  |  | 123 |  |  | \u2014 | \nTotal cash and cash equivalents |  | 36,890 |  |  | 31,084 |  |  | 473 |  |  | \u2014 | \nMarketable securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 8,741 |  |  | 8,741 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 4,028 |  |  | 4,028 |  |  | \u2014 |  |  | \u2014 | \nCorporate debt securities |  | 11,464 |  |  | \u2014 |  |  | 11,464 |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nTotal marketable securities |  | 24,233 |  |  | 12,769 |  |  | 11,464 |  |  | \u2014 | \nRestricted cash equivalents |  | 836 |  |  | 836 |  |  | \u2014 |  |  | \u2014 | \nOther assets |  | 96 |  |  | \u2014 |  |  | \u2014 |  |  | 96 | \nTotal |  | $ | 62,055 |  |  | $ | 44,689 |  |  | $ | 11,937 |  |  | $ | 96 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Fair Value Measurement at Reporting Date Using\nDescription |  | December 31, 2022 |  | Quoted\u00a0Prices in Active Markets for Identical\u00a0Assets(Level 1) |  | Significant Other Observable Inputs(Level 2) |  | Significant Unobservable Inputs(Level 3)\nCash |  | $ | 6,176 |  |  |  |  |  |  | \nCash equivalents: |  |  |  |  |  |  |  | \nMoney market funds |  | 8,305 |  |  | $ | 8,305 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nU.S. government and agency securities |  | 16 |  |  | 16 |  |  | \u2014 |  |  | \u2014 | \n |  |  |  |  |  |  |  | \nTime deposits |  | 156 |  |  | \u2014 |  |  | 156 |  |  | \u2014 | \nCorporate debt securities |  | 28 |  |  | \u2014 |  |  | 28 |  |  | \u2014 | \nTotal cash and cash equivalents |  | 14,681 |  |  | 8,321 |  |  | 184 |  |  | \u2014 | \nMarketable securities: |  |  |  |  |  |  |  | \nU.S. government securities |  | 8,708 |  |  | 8,708 |  |  | \u2014 |  |  | \u2014 | \nU.S. government agency securities |  | 4,989 |  |  | 4,989 |  |  | \u2014 |  |  | \u2014 | \nCorporate debt securities |  | 12,335 |  |  | \u2014 |  |  | 12,335 |  |  | \u2014 | \nMarketable equity securities |  | 25 |  |  | 25 |  |  | \u2014 |  |  | \u2014 | \nTotal marketable securities |  | 26,057 |  |  | 13,722 |  |  | 12,335 |  |  | \u2014 | \nRestricted cash equivalents |  | 583 |  |  | 583 |  |  | \u2014 |  |  | \u2014 | \nOther assets |  | 157 |  |  | \u2014 |  |  | \u2014 |  |  | 157 | \nTotal |  | $ | 41,478 |  |  | $ | 22,626 |  |  | $ | 12,519 |  |  | $ | 157 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023\n | Less than 12 months |  | 12 months or greater |  | Total\n | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses\nU.S. government securities | $ | 567 |  |  | $ | (7) |  |  | $ | 7,235 |  |  | $ | (424) |  |  | $ | 7,802 |  |  | $ | (431) | \nU.S. government agency securities | 252 |  |  | (1) |  |  | 3,673 |  |  | (230) |  |  | 3,925 |  |  | (231) | \nCorporate debt securities | 660 |  |  | (10) |  |  | 10,196 |  |  | (715) |  |  | 10,856 |  |  | (725) | \nTotal | $ | 1,479 |  |  | $ | (18) |  |  | $ | 21,104 |  |  | $ | (1,369) |  |  | $ | 22,583 |  |  | $ | (1,387) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | December 31, 2022\n | Less than 12 months |  | 12 months or greater |  | Total\n | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses\nU.S. government securities | $ | 5,008 |  |  | $ | (234) |  |  | $ | 3,499 |  |  | $ | (247) |  |  | $ | 8,507 |  |  | $ | (481) | \nU.S. government agency securities | 524 |  |  | (17) |  |  | 4,415 |  |  | (308) |  |  | 4,939 |  |  | (325) | \nCorporate debt securities | 4,555 |  |  | (249) |  |  | 7,256 |  |  | (634) |  |  | 11,811 |  |  | (883) | \nTotal | $ | 10,087 |  |  | $ | (500) |  |  | $ | 15,170 |  |  | $ | (1,189) |  |  | $ | 25,257 |  |  | $ | (1,689) |   |  |  |  |  | \n | September 30, 2023\nDue within one year | $ | 7,167 | \nDue after one year to five years | 17,066 | \nTotal | $ | 24,233 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nNon-marketable equity securities under measurement alternative: |  |  | \nInitial cost | $ | 6,389 |  |  | $ | 6,388 | \nCumulative upward adjustments | 293 |  |  | 293 | \nCumulative impairment/downward adjustments | (599) |  |  | (497) | \nCarrying value | 6,083 |  |  | 6,184 | \nNon-marketable equity securities under equity method | 59 |  |  | 17 | \nTotal | $ | 6,142 |  |  | $ | 6,201 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nLand | $ | 1,900 |  |  | $ | 1,874 | \nServers and network assets | 44,662 |  |  | 34,330 | \nBuildings | 35,422 |  |  | 27,720 | \nLeasehold improvements | 6,841 |  |  | 6,522 | \nEquipment and other | 7,056 |  |  | 5,642 | \nFinance lease right-of-use assets | 3,794 |  |  | 3,353 | \nConstruction in progress | 22,945 |  |  | 25,052 | \nProperty and equipment, gross | 122,620 |  |  | 104,493 | \nLess: Accumulated depreciation | (30,848) |  |  | (24,975) | \nProperty and equipment, net | $ | 91,772 |  |  | $ | 79,518 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nFinance lease cost: |  |  |  |  |  |  | \nAmortization of right-of-use assets | $ | 80 |  |  | $ | 92 |  |  | $ | 264 |  |  | $ | 285 | \nInterest | 5 |  |  | 4 |  |  | 15 |  |  | 12 | \nOperating lease cost | 487 |  |  | 480 |  |  | 1,560 |  |  | 1,326 | \nVariable lease cost and other, net | 163 |  |  | 87 |  |  | 399 |  |  | 263 | \nTotal lease cost | $ | 735 |  |  | $ | 663 |  |  | $ | 2,238 |  |  | $ | 1,886 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nWeighted-average remaining lease term: |  |  | \nFinance leases | 13.9years |  | 14.4years\nOperating leases | 11.9years |  | 12.5years\nWeighted-average discount rate: |  |  | \nFinance leases | 3.3 | % |  | 3.1 | %\nOperating leases | 3.5 | % |  | 3.2 | %  |  |  |  |  |  |  |  |  |  |  | \n | Operating Leases |  | Finance Leases\nThe remainder of 2023 | $ | 387 |  |  | $ | 61 | \n2024 | 2,291 |  |  | 60 | \n2025 | 2,073 |  |  | 61 | \n2026 | 2,021 |  |  | 60 | \n2027 | 2,007 |  |  | 57 | \nThereafter | 13,562 |  |  | 505 | \nTotal undiscounted cash flows | 22,341 |  |  | 804 | \nLess: Imputed interest | (4,507) |  |  | (145) | \nPresent value of lease liabilities(1) | $ | 17,834 |  |  | $ | 659 | \n |  |  | \nLease liabilities, current | $ | 1,460 |  |  | $ | 85 | \nLease liabilities, non-current | 16,374 |  |  | 574 | \nPresent value of lease liabilities(1) | $ | 17,834 |  |  | $ | 659 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2023 |  | 2022\nCash paid for amounts included in the measurement of lease liabilities: |  |  | \nOperating cash flows for operating leases(1) | $ | 1,685 |  |  | $ | 1,197 | \nOperating cash flows for finance leases | $ | 15 |  |  | $ | 11 | \nFinancing cash flows for finance leases | $ | 751 |  |  | $ | 615 | \nLease liabilities arising from obtaining right-of-use assets: |  |  | \nOperating leases | $ | 3,042 |  |  | $ | 3,565 | \nFinance leases | $ | 460 |  |  | $ | 114 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total\nGoodwill at December 31, 2022 | $ | 19,250 |  |  | $ | 1,056 |  |  | $ | 20,306 | \nAcquisitions | \u2014 |  |  | 357 |  |  | 357 | \nAdjustments | (4) |  |  | 9 |  |  | 5 | \nGoodwill at September 30, 2023 | $ | 19,246 |  |  | $ | 1,422 |  |  | $ | 20,668 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | September 30, 2023 |  | December 31, 2022\n | Weighted-Average Remaining Useful Lives(in years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount\nAcquired technology | 4.8 |  | $ | 466 |  |  | $ | (155) |  |  | $ | 311 |  |  | $ | 507 |  |  | $ | (144) |  |  | $ | 363 | \nAcquired patents | 2.5 |  | 321 |  |  | (259) |  |  | 62 |  |  | 380 |  |  | (289) |  |  | 91 | \nOther | 2.4 |  | 27 |  |  | (12) |  |  | 15 |  |  | 86 |  |  | (25) |  |  | 61 | \nTotal finite-lived assets |  |  | 814 |  |  | (426) |  |  | 388 |  |  | 973 |  |  | (458) |  |  | 515 | \nTotal indefinite-lived assets | N/A |  | 425 |  |  | \u2014 |  |  | 425 |  |  | 382 |  |  | \u2014 |  |  | 382 | \nTotal intangible assets |  |  | $ | 1,239 |  |  | $ | (426) |  |  | $ | 813 |  |  | $ | 1,355 |  |  | $ | (458) |  |  | $ | 897 |   |  |  |  |  | \nThe remainder of 2023 | $ | 37 | \n2024 | 131 | \n2025 | 93 | \n2026 | 43 | \n2027 | 24 | \nThereafter | 60 | \nTotal | $ | 388 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturity |  | Stated Interest Rate |  | Effective Interest Rate |  | September 30, 2023 |  | December 31, 2022\nAugust 2022 debt: |  |  |  |  |  |  |  |  | \n2027 Notes | 2027 |  | 3.50% |  | 3.63% |  | $ | 2,750 |  |  | $ | 2,750 | \n2032 Notes | 2032 |  | 3.85% |  | 3.92% |  | 3,000 |  |  | 3,000 | \n2052 Notes | 2052 |  | 4.45% |  | 4.51% |  | 2,750 |  |  | 2,750 | \n2062 Notes | 2062 |  | 4.65% |  | 4.71% |  | 1,500 |  |  | 1,500 | \n |  |  |  |  |  |  |  |  | \nMay 2023 debt: |  |  |  |  |  |  |  |  | \n2028 Notes | 2028 |  | 4.60% |  | 4.68% |  | 1,500 |  |  | \n2030 Notes | 2030 |  | 4.80% |  | 4.90% |  | 1,000 |  |  | \n2033 Notes | 2033 |  | 4.95% |  | 5.00% |  | 1,750 |  |  | \n2053 Notes | 2053 |  | 5.60% |  | 5.64% |  | 2,500 |  |  | \n2063 Notes | 2063 |  | 5.75% |  | 5.79% |  | 1,750 |  |  | \nTotal face amount of long-term debt |  |  |  |  |  |  | 18,500 |  |  | 10,000 | \nUnamortized discount and issuance costs, net |  |  |  |  |  |  | (117) |  | (77)\nLong-term debt |  |  |  |  |  |  | $ | 18,383 |  |  | $ | 9,923 |   |  |  |  |  | \nRemainder of 2023 through 2026 | $ | \u2014 | \n2027 | 2,750 | \nThereafter | 15,750 | \nTotal outstanding debt | $ | 18,500 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nLegal-related accruals(1) | $ | 7,119 |  |  | $ | 4,795 | \nAccrued compensation and benefits | 4,968 |  |  | 4,591 | \nAccrued property and equipment | 2,303 |  |  | 2,921 | \nAccrued taxes(2) | 4,608 |  |  | 2,339 | \nOther current liabilities | 4,931 |  |  | 4,906 | \nAccrued expenses and other current liabilities | $ | 23,929 |  |  | $ | 19,552 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nIncome tax payable, non-current | $ | 6,832 |  |  | $ | 6,645 | \n |  |  | \nOther non-current liabilities | 1,281 |  |  | 1,119 | \nOther liabilities | $ | 8,113 |  |  | $ | 7,764 |   |  |  |  |  | \nThe remainder of 2023 | $ | 8,724 | \n2024 | 8,966 | \n2025 | 1,521 | \n2026 | 319 | \n2027 | 214 | \nThereafter | 2,596 | \nTotal | $ | 22,340 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nCost of revenue | $ | 183 |  |  | $ | 209 |  |  | $ | 536 |  |  | $ | 582 | \nResearch and development | 2,881 |  |  | 2,447 |  |  | 8,635 |  |  | 6,995 | \nMarketing and sales | 219 |  |  | 260 |  |  | 727 |  |  | 766 | \nGeneral and administrative | 209 |  |  | 218 |  |  | 705 |  |  | 641 | \nTotal share-based compensation expense | $ | 3,492 |  |  | $ | 3,134 |  |  | $ | 10,603 |  |  | $ | 8,984 |   |  |  |  |  |  |  |  |  |  |  | \n | Number of Shares |  | Weighted-Average Grant Date Fair Value Per Share\n | (in thousands) |  | \nUnvested at December 31, 2022 | 127,110 |  |  | $ | 216.93 | \nGranted | 108,735 |  |  | $ | 198.34 | \nVested | (49,079) |  |  | $ | 210.58 | \nForfeited | (22,063) |  |  | $ | 210.81 | \nUnvested at September 30, 2023 | 164,703 |  |  | $ | 207.37 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue: |  |  |  |  |  |  | \nFamily of Apps | $ | 33,936 |  |  | $ | 27,429 |  |  | $ | 93,966 |  |  | $ | 83,011 | \nReality Labs | 210 |  |  | 285 |  |  | 825 |  |  | 1,433 | \nTotal revenue | $ | 34,146 |  |  | $ | 27,714 |  |  | $ | 94,791 |  |  | $ | 84,444 | \n |  |  |  |  |  |  | \nIncome (loss) from operations: |  |  |  |  |  |  | \nFamily of Apps | $ | 17,490 |  |  | $ | 9,336 |  |  | $ | 41,841 |  |  | $ | 31,983 | \nReality Labs | (3,742) |  |  | (3,672) |  |  | (11,474) |  |  | (9,438) | \nTotal income from operations | $ | 13,748 |  |  | $ | 5,664 |  |  | $ | 30,367 |  |  | $ | 22,545 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nUnited States | $ | 87,932 |  |  | $ | 76,334 | \nRest of the world(1) | 16,873 |  |  | 15,857 | \nTotal long-lived assets | $ | 104,805 |  |  | $ | 92,191 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Family of Apps |  | Reality Labs |  | Total |  |  |  |  |  | \n | Three Months Ended September 30, |  | % change |  | Three Months Ended September 30, |  | % change |  | Three Months Ended September 30, |  | % change |  |  |  | \n | 2023 |  | 2022 |  |  | 2023 |  | 2022 |  |  | 2023 |  | 2022 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages) |  |  |  |  |  | \nRevenue | $ | 33,936 |  | $ | 27,429 |  | 24% |  | $ | 210 |  | $ | 285 |  | (26)% |  | $ | 34,146 |  | $ | 27,714 |  | 23% |  |  |  |  |  | \nCosts and expenses | $ | 16,446 |  | $ | 18,093 |  | (9)% |  | $ | 3,952 |  | $ | 3,957 |  | \u2014% |  | $ | 20,398 |  | $ | 22,050 |  | (7)% |  |  |  |  |  | \nIncome (loss) from operations | $ | 17,490 |  | $ | 9,336 |  | 87% |  | $ | (3,742) |  | $ | (3,672) |  | (2)% |  | $ | 13,748 |  | $ | 5,664 |  | 143% |  |  |  |  |  | \nOperating margin | 52 | % |  | 34 | % |  |  |  | (1,782) | % |  | (1,288) | % |  |  |  | 40 | % |  | 20 | % |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, 2023\n | Facilities Consolidation |  | Severance and Other Personnel Costs |  | Data Center Assets |  | Total\nCost of revenue | $ | 25 |  |  | $ | \u2014 |  |  | $ | (12) |  |  | $ | 13 | \nResearch and development | 228 |  |  | (70) |  |  | \u2014 |  |  | 158 | \nMarketing and sales | 54 |  |  | 69 |  |  | \u2014 |  |  | 123 | \nGeneral and administrative | 45 |  |  | 41 |  |  | \u2014 |  |  | 86 | \nTotal | $ | 352 |  |  | $ | 40 |  |  | $ | (12) |  |  | $ | 380 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nARPP: | $8.18 | $9.39 | $7.72 | $7.91 | $7.53 | $8.63 | $7.59 | $8.32 | $8.71\n |  |  |  |  |  |  |  |  | \n |  |  | Ad Revenue |  | Non-Ad Revenue |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  | Ad Revenue |  | Non-Ad Revenue |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue | $ | 34,146 |  |  | $ | 27,714 |  |  | $ | 94,791 |  |  | $ | 84,444 | \nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 6,210 |  |  | 5,716 |  |  | 18,264 |  |  | 16,913 | \nResearch and development | 9,241 |  |  | 9,170 |  |  | 27,966 |  |  | 25,567 | \nMarketing and sales | 2,877 |  |  | 3,780 |  |  | 9,075 |  |  | 10,688 | \nGeneral and administrative | 2,070 |  |  | 3,384 |  |  | 9,119 |  |  | 8,731 | \nTotal costs and expenses | 20,398 |  |  | 22,050 |  |  | 64,424 |  |  | 61,899 | \nIncome from operations | 13,748 |  |  | 5,664 |  |  | 30,367 |  |  | 22,545 | \nInterest and other income (expense), net | 272 |  |  | (88) |  |  | 254 |  |  | 125 | \nIncome before provision for income taxes | 14,020 |  |  | 5,576 |  |  | 30,621 |  |  | 22,670 | \nProvision for income taxes | 2,437 |  |  | 1,181 |  |  | 5,540 |  |  | 4,123 | \nNet income | $ | 11,583 |  |  | $ | 4,395 |  |  | $ | 25,081 |  |  | $ | 18,547 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue | 100 | % |  | 100 | % |  | 100 | % |  | 100 | %\nCosts and expenses: |  |  |  |  |  |  | \nCost of revenue | 18 |  |  | 21 |  |  | 19 |  |  | 20 | \nResearch and development | 27 |  |  | 33 |  |  | 30 |  |  | 30 | \nMarketing and sales | 8 |  |  | 14 |  |  | 10 |  |  | 13 | \nGeneral and administrative | 6 |  |  | 12 |  |  | 10 |  |  | 10 | \nTotal costs and expenses | 60 |  |  | 80 |  |  | 68 |  |  | 73 | \nIncome from operations | 40 |  |  | 20 |  |  | 32 |  |  | 27 | \nInterest and other income (expense), net | 1 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nIncome before provision for income taxes | 41 |  |  | 20 |  |  | 32 |  |  | 27 | \nProvision for income taxes | 7 |  |  | 4 |  |  | 6 |  |  | 5 | \nNet income | 34 | % |  | 16 | % |  | 26 | % |  | 22 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nAdvertising | $ | 33,643 |  |  | $ | 27,237 |  |  | 24 | % |  | $ | 93,242 |  |  | $ | 82,387 |  |  | 13 | %\nOther revenue | 293 |  |  | 192 |  |  | 53 | % |  | 724 |  |  | 624 |  |  | 16 | %\nFamily of Apps | 33,936 |  |  | 27,429 |  |  | 24 | % |  | 93,966 |  |  | 83,011 |  |  | 13 | %\nReality Labs | 210 |  |  | 285 |  |  | (26) | % |  | 825 |  |  | 1,433 |  |  | (42) | %\nTotal revenue | $ | 34,146 |  |  | $ | 27,714 |  |  | 23 | % |  | $ | 94,791 |  |  | $ | 84,444 |  |  | 12 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nCost of revenue | $ | 6,210 |  | $ | 5,716 |  | 9 | % |  | $ | 18,264 |  | $ | 16,913 |  | 8 | %\nPercentage of revenue | 18 | % |  | 21 | % |  |  |  | 19 | % |  | 20 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nResearch and development | $ | 9,241 |  | $ | 9,170 |  | 1 | % |  | $ | 27,966 |  | $ | 25,567 |  | 9 | %\nPercentage of revenue | 27 | % |  | 33 | % |  |  |  | 30 | % |  | 30 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nMarketing and sales | $ | 2,877 |  | $ | 3,780 |  | (24) | % |  | $ | 9,075 |  | $ | 10,688 |  | (15) | %\nPercentage of revenue | 8 | % |  | 14 | % |  |  |  | 10 | % |  | 13 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nGeneral and administrative | $ | 2,070 |  | $ | 3,384 |  | (39) | % |  | $ | 9,119 |  | $ | 8,731 |  | 4 | %\nPercentage of revenue | 6 | % |  | 12 | % |  |  |  | 10 | % |  | 10 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nFamily of Apps | $ | 17,490 |  |  | $ | 9,336 |  |  | 87 | % |  | $ | 41,841 |  |  | $ | 31,983 |  |  | 31 | %\nReality Labs | (3,742) |  |  | (3,672) |  |  | (2) | % |  | (11,474) |  |  | (9,438) |  |  | (22) | %\nTotal income from operations | $ | 13,748 |  |  | $ | 5,664 |  |  | 143 | % |  | $ | 30,367 |  |  | $ | 22,545 |  |  | 35 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\n |  |  |  |  |  |  |  |  |  |  | \nInterest income | $ | 534 |  |  | $ | 142 |  |  | 276 | % |  | $ | 1,051 |  |  | $ | 319 |  |  | 229 | %\nInterest expense | (139) |  |  | (65) |  |  | (114) | % |  | (310) |  |  | (75) |  |  | (313) | %\nForeign currency exchange gains (losses), net | (98) |  |  | (131) |  |  | 25 | % |  | (305) |  |  | (138) |  |  | (121) | %\nOther income (expense), net | (25) |  |  | (34) |  |  | 26 | % |  | (182) |  |  | 19 |  |  | NM\nInterest and other income (expense), net | $ | 272 |  |  | $ | (88) |  |  | 409 | % |  | $ | 254 |  |  | $ | 125 |  |  | 103 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months Ended September 30, |  | \n | 2023 |  | 2022 |  | % change |  | 2023 |  | 2022 |  | % change\n |  |  |  |  |  |  |  |  |  |  | \n | (in millions, except percentages)\nProvision for income taxes | $ | 2,437 |  | $ | 1,181 |  | 106 | % |  | $ | 5,540 |  | $ | 4,123 |  | 34 | %\nEffective tax rate | 17 | % |  | 21 | % |  |  |  | 18 | % |  | 18 | % |  |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2023 |  | 2022\nNet cash provided by operating activities | $ | 51,709 |  |  | $ | 35,964 | \nNet cash used in investing activities | $ | (18,023) |  |  | $ | (21,439) | \nNet cash used in financing activities | $ | (11,099) |  |  | $ | (15,076) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Total Number of Shares Purchased |  | Average Price Paid per Share(2) |  | Total Number of Shares Purchased as Part of Publicly Announced Programs(1) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs(1)\n | (in thousands) |  |  |  | (in thousands) |  | (in millions)\nJuly 1 - 31, 2023 | \u2014 |  |  | $ | \u2014 |  |  | \u2014 |  |  | $ | 40,915 | \nAugust 1 - 31, 2023 | 80 |  |  | $ | 274.95 |  |  | 80 |  |  | $ | 40,893 | \nSeptember 1 - 30, 2023 | 12,317 |  |  | $ | 297.95 |  |  | 12,317 |  |  | $ | 37,223 | \nTotal | 12,397 |  |  |  |  | 12,397 |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nExhibitNumber |  |  |  | Incorporated by Reference |  | FiledHerewith\n | Exhibit Description |  | Form |  | File No. |  | Exhibit |  | Filing\u00a0Date | \n |  |  |  |  |  |  |  |  |  |  |  | \n10.1+ |  | Amended and Restated Bonus Plan, effective January 1, 2023. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n31.1 |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n31.2 |  | Certification of Susan Li, Chief Financial Officer, pursuant to Rule\u00a013a-14(a)/15d-14(a), as adopted pursuant to Section\u00a0302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.1# |  | Certification of Mark Zuckerberg, Chief Executive Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n32.2# |  | Certification of Susan Li, Chief Financial Officer, pursuant to 18 U.S.C. Section\u00a01350, as adopted pursuant to Section\u00a0906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.INS |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.LAB |  | Inline XBRL Taxonomy Extension Labels Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  | \n101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |  |  |  |  |  |  | X\n |  |  |  |  |  |  |  |  |  |  |  | \n104 |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |  |  |  |  |  |  |  |  |  | X  |  |  |  |  |  |  |  | \n |  | META PLATFORMS, INC.\n | \nDate: October 25, 2023 |  | /s/ SUSAN LI\n |  | Susan LiChief Financial Officer(Principal Financial Officer)\n | \nDate: October 25, 2023 |  | /s/ AARON ANDERSON\n |  | Aaron AndersonChief Accounting Officer(Principal Accounting Officer)"}]}
